Innovation,Alternative Names,Category,Disease,Indication,Stage,trial_completion_date,TargetPop,is_on_fda,dates_fda,records_fda,time_to_regulatory_approval,time_approval_to_first_launch,time_launch_to_20lmic,time_to_market,expected_date_of_regulatory_approval,expected_date_of_first_launch,expected_date_of_market,Readiness,LeadOrg,Impact Score,Country,Impact Potential,Disease Burden,Epidemiological impact,Alignment with goals,Cost-effectiveness,Budget Impact,Resource optimization,Introduction Readiness,Financing,Policy,Uptake/Delivery,Probability of technical and regulatory success,Procurement model,Regulatory approvals,Policy readiness,Social context,Guidelines and training,Policy implemented,Advance launch and planning/timeline,Demand forecasting and generation,Potential supply chain,Delivery model,source_file
ARCHITECT HIV Ag/Ab Combo,AltName A,Device,hiv,hiv,Phase 3,2009-11-01,"Sex: ALL; Healthy Volunteers: Yes; Criteria: Normal Healthy Population:

Inclusion Criteria:

* Apparently healthy individual at the time of enrollment as affirmed by the subject

Exclusion Criteria:

* HIV infection as affirmed by the subject

...",No,2009-12-31,FDA-67390,2.62,0.32,5.0,7.94,2012-06-14,2012-10-09,2017-10-10,1,GSK,86,Senegal,42.0,36,12,9,90,42,63,36,2,2,0,True,True,False,True,True,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ARCHITECT HIV Ag/Ab Combo,Molecule Z,Device,hiv,hiv,Phase 3,2009-11-01,"Sex: ALL; Healthy Volunteers: Yes; Criteria: Normal Healthy Population:

Inclusion Criteria:

* Apparently healthy individual at the time of enrollment as affirmed by the subject

Exclusion Criteria:

* HIV infection as affirmed by the subject

...",No,2010-03-30,FDA-68245,2.62,0.32,5.0,7.94,2012-06-14,2012-10-09,2017-10-10,20,Novartis,12,Kenya,49.83333333333334,69,89,86,9,44,2,45,1,4,0,False,True,True,True,True,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
α1 Proteinase Inhibitor,AltName A,Biological,hiv,hiv,Phase 3,2014-07-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. HIV-1 patients must have confirmed HIV-1 disease, diagnosed using the standard criteria and be on antiretroviral therapy. Uninfected volunteers will be age and gender matched.
...",No,2014-12-21,FDA-90332,2.62,0.32,5.0,7.94,2017-02-11,2017-06-08,2022-06-09,90,GSK,71,Kenya,35.0,30,12,56,81,27,4,64,0,3,4,False,False,False,True,False,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada,AltName B,Drug,hiv,hiv,Phase 2,2013-03-01,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Male who has sex with other men (MSM) by self-report
* At least 18 years of age
* HIV-negative serostatus on baseline rapid oral HIV antibody test, and no signs or symptoms cons...",Yes,2013-06-30,FDA-75634,4.41,0.98,21.0,26.39,2017-07-28,2018-07-21,2039-07-21,74,Gilead,69,South Africa,29.33333333333333,53,46,11,16,8,42,73,1,4,3,True,False,True,True,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
collection of follow-up sample based on PRISM HIV O Plus result,TradeName X,Device,hiv,hiv,Phase 3,2008-08-01,"Sex: ALL; Age: >17 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Healthy donors that have consented to study...",No,2009-07-28,FDA-39584,2.62,0.32,5.0,7.94,2011-03-15,2011-07-10,2016-07-10,15,Pfizer,73,South Africa,45.33333333333334,40,37,42,66,57,30,73,1,4,3,True,False,True,True,True,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
HAART regimen,GenName Y,Drug,hiv,hiv,Phase 4,2013-05-01,"Sex: ALL; Age: >8 Years; Criteria: Step 1 Inclusion Criteria:

* Age greater than or equal to 8 to less than 25 years of age, at study entry
* Documentation of HIV-1 infection defined as positive results from two samples collected at d...",No,2014-03-17,FDA-86647,0.56,0.15,3.5,4.21,2013-11-21,2014-01-15,2017-07-16,8,J&J,50,South Africa,65.66666666666667,59,72,80,24,59,100,45,1,2,2,False,True,False,False,False,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
3TC or FTC monotherapy,Comp Beta,Drug,hiv,hiv,Phase 4,2013-05-01,"Sex: ALL; Age: >8 Years; Criteria: Step 1 Inclusion Criteria:

* Age greater than or equal to 8 to less than 25 years of age, at study entry
* Documentation of HIV-1 infection defined as positive results from two samples collected at d...",Yes,2014-04-29,FDA-24834,0.56,0.15,3.5,4.21,2013-11-21,2014-01-15,2017-07-16,24,J&J,81,Senegal,71.83333333333333,84,5,85,98,67,92,18,0,1,1,False,False,False,False,True,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
alpha-1-Proteinase Inhibitor,Product Alpha,Biological,hiv,hiv,Phase 3,2007-02-01,"Sex: MALE; Age: >30 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. HIV-1 patients must have confirmed HIV-1 disease, diagnosed using the standard criteria and be on antiretroviral therapy. Patients with inherited alpha-1 proteinase inhibitor d...",Yes,2007-04-05,FDA-94169,2.62,0.32,5.0,7.94,2009-09-14,2010-01-09,2015-01-10,76,Bayer,98,South Africa,29.66666666666667,16,35,19,7,44,57,36,0,2,2,False,False,True,False,False,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Darunavir/Ritonavir (DRV/r),AltName B,Drug,hiv,hiv,Phase 3,2013-09-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Occupational injury and non-occupational exposure with documented human immunodeficiency virus (HIV) exposure, or potential for HIV exposure
* Indication for HIV postexposure pr...",Yes,2014-03-04,FDA-81197,2.62,0.32,5.0,7.94,2016-05-11,2016-09-05,2021-09-06,6,Gilead,94,Senegal,35.16666666666666,25,42,48,65,15,16,36,0,3,1,False,False,False,True,True,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir in fixed combination with Ritonavir,Molecule Z,Drug,hiv,hiv,Phase 3,2013-09-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Occupational injury and non-occupational exposure with documented human immunodeficiency virus (HIV) exposure, or potential for HIV exposure
* Indication for HIV postexposure pr...",No,2014-02-16,FDA-12876,2.62,0.32,5.0,7.94,2016-05-11,2016-09-05,2021-09-06,6,AstraZeneca,3,Overall,37.83333333333334,19,45,53,90,6,14,64,1,3,3,False,True,True,True,True,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Zidovudine,AltName B,Drug,hiv,hiv,Phase 3,2013-09-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Occupational injury and non-occupational exposure with documented human immunodeficiency virus (HIV) exposure, or potential for HIV exposure
* Indication for HIV postexposure pr...",Yes,2014-05-03,FDA-84709,2.62,0.32,5.0,7.94,2016-05-11,2016-09-05,2021-09-06,13,AstraZeneca,49,South Africa,52.83333333333334,47,22,56,16,99,77,45,1,3,1,True,False,False,True,False,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
NRTIs,Product Alpha,Drug,hiv,hiv,Phase 3,2013-09-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Occupational injury and non-occupational exposure with documented human immunodeficiency virus (HIV) exposure, or potential for HIV exposure
* Indication for HIV postexposure pr...",Yes,2014-05-10,FDA-14093,2.62,0.32,5.0,7.94,2016-05-11,2016-09-05,2021-09-06,54,Novartis,46,South Africa,66.33333333333333,62,76,33,57,97,73,55,1,1,4,True,False,False,False,False,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,AltName A,Drug,hiv,hiv,Phase 3,2013-09-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Occupational injury and non-occupational exposure with documented human immunodeficiency virus (HIV) exposure, or potential for HIV exposure
* Indication for HIV postexposure pr...",Yes,2014-05-25,FDA-58281,2.62,0.32,5.0,7.94,2016-05-11,2016-09-05,2021-09-06,76,Sanofi,58,South Africa,65.66666666666667,73,98,38,98,67,20,27,0,2,1,False,False,False,False,False,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir 400 mg/ritonavir 100 mg,GenName Y,Drug,hiv,hiv,Phase 4,2011-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. HIV-1 infection
2. The absence of exclusionary resistance mutations on a genotypic resistance assay
3. Antiretroviral (ARV) drug-naïve
4. Screening HIV-1 RNA \>1000 copies/mL
5...",Yes,2011-11-28,FDA-95893,0.56,0.15,3.5,4.21,2011-07-24,2011-09-17,2015-03-18,82,AstraZeneca,80,South Africa,48.83333333333334,29,78,31,40,22,93,55,2,2,2,True,True,True,True,False,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,Product Alpha,Drug,hiv,hiv,Phase 4,2011-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. HIV-1 infection
2. The absence of exclusionary resistance mutations on a genotypic resistance assay
3. Antiretroviral (ARV) drug-naïve
4. Screening HIV-1 RNA \>1000 copies/mL
5...",Yes,2011-10-28,FDA-53313,0.56,0.15,3.5,4.21,2011-07-24,2011-09-17,2015-03-18,74,Novartis,48,Overall,49.5,24,5,44,89,57,78,55,1,2,3,False,True,False,False,False,True,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ZDV+3TC+LPV/r,GenName Y,Drug,hiv,hiv,Phase 4,2017-09-29,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* Documentation of HIV-1 infection defined as positive results from two samples collected at different time points, using protocol-specified tests
* Meets WHO classification for s...",Yes,2018-02-11,FDA-46812,0.56,0.15,3.5,4.21,2018-04-21,2018-06-15,2021-12-14,18,Gilead,18,Kenya,62.0,85,55,94,26,96,16,45,2,2,1,True,True,False,True,True,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Extended-Release Naltrexone,GenName Y,Drug,hiv,hiv,Phase 2,2016-07-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Meets DSM-IV criteria for opioid dependence
2. Age \> 18 years
3. Confirmed HIV infection, either through positive HIV antibody or detectable HIV-1 RNA level.
4. Within the Con...",Yes,2016-10-20,FDA-66091,4.41,0.98,21.0,26.39,2020-11-27,2021-11-20,2042-11-20,27,AstraZeneca,29,Senegal,43.16666666666666,32,47,20,97,21,42,64,1,5,1,True,False,True,True,True,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
darunavir with ritonavir and fixed-dose viread+emtricitabine daily,Comp Beta,Drug,hiv,hiv,Phase 4,2016-12-01,"Sex: ALL; Age: >21 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Willing to sign consent form
* Naïve to ART (remote ART use \>5 years will be considered on a case by case basis)
* No known GI or cardiovascular disease
* Between the ages of 1...",Yes,2017-05-31,FDA-39535,0.56,0.15,3.5,4.21,2017-06-23,2017-08-17,2021-02-15,97,Gilead,91,Senegal,33.83333333333334,34,28,54,55,6,26,45,2,2,1,True,True,False,True,True,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
50 mg/m2 aldoxorubicin,TradeName X,Drug,hiv,hiv,Phase 2,2016-04-25,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Age ≥18 years of age; male or female.
2. HIV (confirmed by ELISA and western blot) with histologically confirmed KS.
3. Willing to undergo serial tumor biopsies.
4. Capable of ...",No,2017-01-17,FDA-89665,4.41,0.98,21.0,26.39,2020-09-21,2021-09-14,2042-09-14,17,J&J,76,Overall,52.66666666666666,36,82,0,98,64,36,45,1,3,1,False,True,True,True,True,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
100 mg/m2 aldoxorubicin,AltName A,Drug,hiv,hiv,Phase 2,2016-04-25,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Age ≥18 years of age; male or female.
2. HIV (confirmed by ELISA and western blot) with histologically confirmed KS.
3. Willing to undergo serial tumor biopsies.
4. Capable of ...",Yes,2016-12-09,FDA-23987,4.41,0.98,21.0,26.39,2020-09-21,2021-09-14,2042-09-14,99,GSK,47,Senegal,45.0,24,55,99,13,52,27,73,1,4,3,True,False,False,True,True,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
150 mg/m2 aldoxorubicin,AltName B,Drug,hiv,hiv,Phase 2,2016-04-25,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Age ≥18 years of age; male or female.
2. HIV (confirmed by ELISA and western blot) with histologically confirmed KS.
3. Willing to undergo serial tumor biopsies.
4. Capable of ...",No,2016-12-02,FDA-66818,4.41,0.98,21.0,26.39,2020-09-21,2021-09-14,2042-09-14,8,Bayer,8,Overall,30.33333333333333,67,48,43,12,9,3,45,1,3,1,True,False,False,True,True,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
lopinavir/ritonavir (LPV/r),Comp Beta,Drug,hiv,hiv,Phase 3,2010-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants must provide written, voluntary informed consent to participate in the study.
* Participants must be naive to antiretroviral treatment with HIV RNA greater than or ...",No,2011-09-23,FDA-57488,2.62,0.32,5.0,7.94,2013-05-14,2013-09-08,2018-09-09,42,GSK,87,Senegal,45.83333333333334,71,8,22,34,91,49,55,2,3,1,True,True,False,True,False,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
emtricitabine/tenofovir disoproxil fumarate (FTC/TDF),TradeName X,Drug,hiv,hiv,Phase 3,2010-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants must provide written, voluntary informed consent to participate in the study.
* Participants must be naive to antiretroviral treatment with HIV RNA greater than or ...",Yes,2010-11-30,FDA-73757,2.62,0.32,5.0,7.94,2013-05-14,2013-09-08,2018-09-09,26,Bayer,39,Senegal,44.33333333333334,15,48,31,37,97,38,45,1,2,2,False,True,True,False,False,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
raltegravir (RAL),TradeName X,Drug,hiv,hiv,Phase 3,2010-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants must provide written, voluntary informed consent to participate in the study.
* Participants must be naive to antiretroviral treatment with HIV RNA greater than or ...",No,2011-04-04,FDA-38559,2.62,0.32,5.0,7.94,2013-05-14,2013-09-08,2018-09-09,81,Merck,99,Kenya,22.16666666666667,3,38,49,8,28,7,55,2,3,1,True,True,False,True,True,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Recommendation and Counseling for Alcohol Pharmacotherapy,AltName A,Drug,hiv,hiv,Phase 4,2023-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* At least 18 years or older;
* Receiving HIV care at the UAB, UW or UCSD clinics and not anticipating changing clinics over the next 12 months;
* AUDIT-C score \> 3 women or \> 4...",No,2024-06-22,FDA-68427,0.56,0.15,3.5,4.21,2024-05-23,2024-07-17,2028-01-16,85,Sanofi,52,Senegal,47.5,8,69,42,70,34,62,82,1,5,3,True,False,True,True,True,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Quadrivalent Live Attenuated Influenza Vaccine,AltName A,Biological,hiv,hiv,Phase 2,2016-12-01,"Sex: ALL; Age: >2 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Age 2-25
* Only supposed to get one dose of vaccine for upcoming influenza season
* No viral respiratory symptoms at time of immunization
* HIV-infected group: must have:

  * H...",No,2017-08-03,FDA-52837,4.41,0.98,21.0,26.39,2021-04-29,2022-04-22,2043-04-22,23,Merck,81,Senegal,52.66666666666666,26,64,87,79,38,22,45,1,2,2,False,True,False,False,False,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Pegylated Interferon Alpha 2b (PEGINTRON),AltName B,Drug,hiv,hiv,Phase 2,2017-05-31,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

To be eligible for study participation, a volunteer must satisfy all of the following inclusion criteria:

1. Age greater than or equal to 18 years.
2. Documentation of human im...",Yes,2018-04-04,FDA-55851,4.41,0.98,21.0,26.39,2021-10-27,2022-10-20,2043-10-20,25,Pfizer,75,Senegal,43.0,41,22,57,37,37,64,45,1,2,2,True,False,True,True,False,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Telmisartan,AltName A,Drug,hiv,hiv,Phase 2,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV positive men and women 18 years and older
* HIV-1 infection as documented by ELISA and confirmed by Western blot or plasma HIV-1 RNA \>2000 on two occasions
* Documented cen...",No,2012-05-01,FDA-90412,4.41,0.98,21.0,26.39,2015-10-28,2016-10-20,2037-10-20,28,Merck,60,South Africa,42.16666666666666,27,63,39,22,65,37,27,0,2,1,False,False,True,False,False,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
extended-release exenatide,AltName A,Drug,hiv,hiv,Phase 4,2014-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Age ≥ 18 years
* Body mass index ≥ 25 kg/m2
* Glycosylated hemoglobin (A1C) value ≥ 6.5% OR having a fasting blood glucose ≥ 126 mg/dL
* On stable antiretroviral therapy for ≥ 1...",No,2015-03-27,FDA-70146,0.56,0.15,3.5,4.21,2015-06-23,2015-08-17,2019-02-15,38,Bayer,66,Kenya,22.66666666666667,50,13,16,27,14,16,27,1,1,1,False,True,True,False,False,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz),AltName A,Drug,hiv,hiv,Phase 4,2011-11-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* HIV-1 positive by licensed diagnostic test with presumed duration of infection \> 6 months from date of randomisation.
* Aged \> 16 years of age (or minimum age as determined by...",Yes,2012-05-22,FDA-46542,0.56,0.15,3.5,4.21,2012-05-23,2012-07-17,2016-01-16,1,Sanofi,37,Senegal,29.83333333333333,60,19,26,9,37,28,36,1,2,1,False,True,True,True,False,False,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV),GenName Y,Drug,hiv,hiv,Phase 4,2011-11-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* HIV-1 positive by licensed diagnostic test with presumed duration of infection \> 6 months from date of randomisation.
* Aged \> 16 years of age (or minimum age as determined by...",Yes,2012-10-04,FDA-19985,0.56,0.15,3.5,4.21,2012-05-23,2012-07-17,2016-01-16,87,Sanofi,1,Overall,43.16666666666666,38,28,61,26,55,51,64,2,2,3,True,True,True,True,False,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC),AltName B,Drug,hiv,hiv,Phase 4,2011-11-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* HIV-1 positive by licensed diagnostic test with presumed duration of infection \> 6 months from date of randomisation.
* Aged \> 16 years of age (or minimum age as determined by...",Yes,2012-02-22,FDA-59103,0.56,0.15,3.5,4.21,2012-05-23,2012-07-17,2016-01-16,51,Sanofi,37,Senegal,67.5,75,89,100,50,20,71,64,1,5,1,True,False,True,True,True,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ALVAC-HIV vCP1521 + AIDSVAX,AltName A,Biological,hiv,hiv,Phase 3,2009-06-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Possession of the 13-digit Thai National ID card
* 18-30 years of age (inclusive), male or female
* For women, a negative urine pregnancy test on the day of enrollment, as well ...",Yes,2009-09-29,FDA-31266,2.62,0.32,5.0,7.94,2012-01-13,2012-05-09,2017-05-10,52,Gilead,63,South Africa,42.83333333333334,32,76,48,50,4,47,45,1,3,1,True,False,False,False,True,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
BIC/F/TAF 50Mg-200Mg-25Mg Tablet,Comp Beta,Drug,hiv,hiv,Phase 4,2024-08-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* At least 18 years old on day of signing informed consent
* Positive for human immunodeficiency virus (HIV)
* Received a previous renal transplant
* Must have controlled HIV infe...",Yes,2025-05-27,FDA-85887,0.56,0.15,3.5,4.21,2025-03-20,2025-05-14,2028-11-12,30,Bayer,24,South Africa,63.16666666666666,44,82,94,39,82,38,27,0,2,1,False,False,False,True,False,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Cabotegravir Injectable Suspension,TradeName X,Drug,hiv,hiv,Phase 3,2022-08-23,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Sub-study specific Inclusion Criteria:

* Capable of giving sub-study specific informed consent.
* Eligible participants must have been on CAB LA + RPV LA regimen for a minimum of...",No,2022-10-07,FDA-67309,2.62,0.32,5.0,7.94,2025-04-05,2025-07-31,2030-08-01,34,Novartis,85,Overall,41.33333333333334,77,45,7,85,1,33,55,2,2,2,True,True,True,False,False,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rilpivirine Injectable Suspension,AltName A,Drug,hiv,hiv,Phase 3,2022-08-23,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Sub-study specific Inclusion Criteria:

* Capable of giving sub-study specific informed consent.
* Eligible participants must have been on CAB LA + RPV LA regimen for a minimum of...",No,2023-03-18,FDA-98208,2.62,0.32,5.0,7.94,2025-04-05,2025-07-31,2030-08-01,75,Sanofi,58,Senegal,33.83333333333334,17,77,38,4,49,18,82,2,3,4,True,True,True,True,False,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ixazomib 1 MG,AltName A,Drug,hiv,hiv,Phase 2,2019-08-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* The following laboratory values obtained \<=14 days prior to registration.
* ANC ≥ LLN (lower limit of normal) and ≤ULN (upper limit of normal), Hgb ≥ LLN and ≤ULN, PLT ≥ LLN an...",No,2020-05-10,FDA-44162,4.41,0.98,21.0,26.39,2024-01-15,2025-01-07,2046-01-07,27,Merck,30,Kenya,45.33333333333334,43,60,82,26,30,31,55,1,3,2,True,False,True,False,False,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ixazomib 2 MG,AltName B,Drug,hiv,hiv,Phase 2,2019-08-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* The following laboratory values obtained \<=14 days prior to registration.
* ANC ≥ LLN (lower limit of normal) and ≤ULN (upper limit of normal), Hgb ≥ LLN and ≤ULN, PLT ≥ LLN an...",No,2019-12-29,FDA-62859,4.41,0.98,21.0,26.39,2024-01-15,2025-01-07,2046-01-07,77,Gilead,8,South Africa,53.5,51,65,78,71,37,19,64,2,1,4,True,True,True,False,False,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ixazomib 3 MG,Molecule Z,Drug,hiv,hiv,Phase 2,2019-08-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* The following laboratory values obtained \<=14 days prior to registration.
* ANC ≥ LLN (lower limit of normal) and ≤ULN (upper limit of normal), Hgb ≥ LLN and ≤ULN, PLT ≥ LLN an...",No,2019-11-30,FDA-35210,4.41,0.98,21.0,26.39,2024-01-15,2025-01-07,2046-01-07,40,Novartis,82,South Africa,54.0,58,94,63,35,56,18,45,1,3,1,True,False,False,False,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ixazomib 4 MG,Comp Beta,Drug,hiv,hiv,Phase 2,2019-08-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* The following laboratory values obtained \<=14 days prior to registration.
* ANC ≥ LLN (lower limit of normal) and ≤ULN (upper limit of normal), Hgb ≥ LLN and ≤ULN, PLT ≥ LLN an...",No,2020-04-13,FDA-46086,4.41,0.98,21.0,26.39,2024-01-15,2025-01-07,2046-01-07,65,Novartis,80,South Africa,54.16666666666666,66,63,51,90,42,13,27,1,0,2,False,True,False,False,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Crofelemer,Comp Beta,Drug,hiv,hiv,Phase 3,2012-10-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male or female ≥ 18 years old
* History of HIV-1 infection
* On an antiretroviral therapeutic regimen for treatment of HIV-1 disease and associated conditions (including prophyl...",No,2013-06-11,FDA-27512,2.62,0.32,5.0,7.94,2015-06-14,2015-10-09,2020-10-09,77,Novartis,17,Senegal,41.83333333333334,55,22,20,83,58,13,45,0,2,3,False,False,False,False,True,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
M72/AS01E Mycobacterium tuberculosis vaccine,Molecule Z,Biological,hiv,hiv,Phase 2,2022-08-12,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Participant with documented human immunodeficiency virus (HIV) infection who fulfill all of the following:

  * Has reactive anti-HIV antibody at screening
  * On antiretroviral...",No,2023-07-26,FDA-46456,4.41,0.98,21.0,26.39,2027-01-08,2028-01-01,2048-12-31,42,GSK,38,South Africa,57.83333333333334,51,91,39,34,71,61,73,0,4,4,False,False,True,False,True,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PENNVAX-GP,AltName A,Biological,hiv,hiv,Phase 2,2021-05-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Willing and able to provide written informed consent
2. Male or female, age ≥ 18 and ≤ 65 years
3. HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or c...",No,2021-10-09,FDA-23198,4.41,0.98,21.0,26.39,2025-10-13,2026-10-06,2047-10-06,16,Bayer,60,Senegal,39.66666666666666,27,52,48,43,50,18,55,1,2,3,False,True,False,True,False,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
INO-6145,AltName B,Biological,hiv,hiv,Phase 2,2021-05-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Willing and able to provide written informed consent
2. Male or female, age ≥ 18 and ≤ 65 years
3. HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or c...",No,2021-07-22,FDA-15317,4.41,0.98,21.0,26.39,2025-10-13,2026-10-06,2047-10-06,92,GSK,36,Overall,62.16666666666666,95,74,64,80,17,43,45,2,3,0,True,True,False,True,True,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
INO-9012,Molecule Z,Biological,hiv,hiv,Phase 2,2021-05-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Willing and able to provide written informed consent
2. Male or female, age ≥ 18 and ≤ 65 years
3. HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or c...",No,2021-08-11,FDA-73171,4.41,0.98,21.0,26.39,2025-10-13,2026-10-06,2047-10-06,94,Gilead,75,Senegal,58.5,43,51,25,84,50,98,45,1,3,1,True,False,True,True,True,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
CELLECTRA® 2000,AltName B,Device,hiv,hiv,Phase 2,2021-05-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Willing and able to provide written informed consent
2. Male or female, age ≥ 18 and ≤ 65 years
3. HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or c...",Yes,2021-11-06,FDA-20933,4.41,0.98,21.0,26.39,2025-10-13,2026-10-06,2047-10-06,55,GSK,9,Kenya,57.16666666666666,49,57,98,32,22,85,36,0,2,2,False,False,False,False,True,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Etravirine,Comp Beta,Drug,hiv,hiv,Phase 2,2012-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male or female patients, aged 18 years or above
* Patients with documented HIV-1 infection
* On current HAART regimen for at least 12 weeks continuous duration at screening, and...",Yes,2013-01-15,FDA-70551,4.41,0.98,21.0,26.39,2017-02-27,2018-02-20,2039-02-20,10,Novartis,21,Overall,33.0,9,47,6,92,42,2,55,2,2,2,True,True,False,True,False,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,Molecule Z,Drug,hiv,hiv,Phase 2,2012-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male or female patients, aged 18 years or above
* Patients with documented HIV-1 infection
* On current HAART regimen for at least 12 weeks continuous duration at screening, and...",No,2013-06-11,FDA-97108,4.41,0.98,21.0,26.39,2017-02-27,2018-02-20,2039-02-20,90,J&J,22,Kenya,31.83333333333333,0,0,34,54,54,49,64,0,3,4,False,False,False,True,True,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Darunavir,Comp Beta,Drug,hiv,hiv,Phase 2,2012-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male or female patients, aged 18 years or above
* Patients with documented HIV-1 infection
* On current HAART regimen for at least 12 weeks continuous duration at screening, and...",No,2013-05-17,FDA-23333,4.41,0.98,21.0,26.39,2017-02-27,2018-02-20,2039-02-20,79,J&J,36,South Africa,49.83333333333334,59,11,2,80,78,69,55,2,3,1,True,True,False,False,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
omega 3 fatty acids,AltName A,Drug,hiv,hiv,Phase 3,2015-06-01,"Sex: ALL; Age: >20 Years; Criteria: Inclusion Criteria:

* Seropositive HIV patients from 20 to 55 years old
* On clinical score A1, A2, B1 or B2
* Patients who received highly active antiretroviral therapy for at least 3 months.

Exclu...",No,2015-12-23,FDA-11890,2.62,0.32,5.0,7.94,2018-01-12,2018-05-09,2023-05-10,14,J&J,86,Overall,66.0,52,59,62,55,70,98,73,1,4,3,False,True,True,True,True,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"Doravirine, Tenofovir, Lamivudine",AltName A,Drug,hiv,hiv,Phase 3,2023-09-07,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Is HIV-1 positive as determined by a positive result on an enzyme-immunoassay, has screening plasma HIV-1 RNA (determined by the central laboratory) ≥1000 copies/mL within 45 da...",Yes,2024-05-27,FDA-34261,2.62,0.32,5.0,7.94,2026-04-20,2026-08-15,2031-08-16,75,Merck,27,Senegal,55.83333333333334,86,73,66,41,8,61,45,1,3,1,False,True,True,False,True,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ATRIPLA™,TradeName X,Drug,hiv,hiv,Phase 3,2023-09-07,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Is HIV-1 positive as determined by a positive result on an enzyme-immunoassay, has screening plasma HIV-1 RNA (determined by the central laboratory) ≥1000 copies/mL within 45 da...",No,2024-04-05,FDA-15275,2.62,0.32,5.0,7.94,2026-04-20,2026-08-15,2031-08-16,77,Merck,7,Overall,52.33333333333334,55,73,10,71,36,69,36,1,1,2,True,False,False,True,False,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
LIPO-5,TradeName X,Biological,hiv,hiv,Phase 2,2016-03-01,"Sex: ALL; Age: >21 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Written and signed informed consent
* Subject at low risk to contract HIV i.e.

  * no history of injecting drug use in the previous ten years;
  * no gonorrhea or syphilis in t...",No,2016-12-13,FDA-63903,4.41,0.98,21.0,26.39,2020-07-28,2021-07-21,2042-07-21,40,GSK,99,Senegal,47.5,66,10,58,0,51,100,64,2,4,1,True,True,False,True,True,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
MVA HIV-B (MVATG17401),Product Alpha,Biological,hiv,hiv,Phase 2,2016-03-01,"Sex: ALL; Age: >21 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Written and signed informed consent
* Subject at low risk to contract HIV i.e.

  * no history of injecting drug use in the previous ten years;
  * no gonorrhea or syphilis in t...",No,2016-07-13,FDA-42423,4.41,0.98,21.0,26.39,2020-07-28,2021-07-21,2042-07-21,86,AstraZeneca,65,South Africa,44.33333333333334,52,78,9,28,56,43,55,2,3,1,True,True,False,True,True,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots",TradeName X,Biological,hiv,hiv,Phase 2,2016-03-01,"Sex: ALL; Age: >21 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Written and signed informed consent
* Subject at low risk to contract HIV i.e.

  * no history of injecting drug use in the previous ten years;
  * no gonorrhea or syphilis in t...",No,2017-02-19,FDA-36931,4.41,0.98,21.0,26.39,2020-07-28,2021-07-21,2042-07-21,67,AstraZeneca,29,Kenya,50.83333333333334,19,26,6,94,66,94,27,1,1,1,False,True,False,True,False,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Doxepin,Molecule Z,Drug,hiv,hiv,Phase 4,2010-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Insomnia
* HIV Seropositive
* Stable HIV Disease

Exclusion Criteria:

* Other psychiatric illnesses
* Unstable HIV disease...",Yes,2011-01-12,FDA-10555,0.56,0.15,3.5,4.21,2011-02-21,2011-04-17,2014-10-16,65,GSK,88,Overall,56.83333333333334,30,67,93,60,70,21,27,0,1,2,False,False,True,False,False,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Temazepam,TradeName X,Drug,hiv,hiv,Phase 4,2010-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Insomnia
* HIV Seropositive
* Stable HIV Disease

Exclusion Criteria:

* Other psychiatric illnesses
* Unstable HIV disease...",Yes,2010-12-29,FDA-41152,0.56,0.15,3.5,4.21,2011-02-21,2011-04-17,2014-10-16,5,Novartis,86,South Africa,53.83333333333334,4,56,88,77,73,25,36,0,4,0,False,False,True,True,True,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir + Ritonavir,Product Alpha,Drug,hiv,hiv,Phase 3,2009-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* On continued antiretroviral (ARV) treatment, with no discontinuation periods, for the previous 6 months (24 weeks).
* Absence of evidence or suspected virologic failure on antir...",Yes,2009-06-21,FDA-75153,2.62,0.32,5.0,7.94,2011-12-13,2012-04-08,2017-04-09,1,GSK,30,Kenya,51.0,90,81,6,57,67,5,45,0,2,3,False,False,False,True,False,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ALVAC-HIV,GenName Y,Biological,hiv,hiv,Phase 2,2018-08-07,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Age of 18 to 40 years
* Access to a participating HVTN CRS and willingness to be followed for the planned duration of the study
* Ability and willingness to provide informed con...",No,2019-02-23,FDA-22143,4.41,0.98,21.0,26.39,2023-01-03,2023-12-27,2044-12-26,8,Bayer,57,Kenya,42.0,0,18,1,65,74,94,73,2,3,3,True,True,True,False,False,True,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Bivalent Subtype C gp120/MF59®,GenName Y,Biological,hiv,hiv,Phase 2,2018-08-07,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Age of 18 to 40 years
* Access to a participating HVTN CRS and willingness to be followed for the planned duration of the study
* Ability and willingness to provide informed con...",No,2019-02-24,FDA-69578,4.41,0.98,21.0,26.39,2023-01-03,2023-12-27,2044-12-26,49,GSK,42,Senegal,53.66666666666666,100,25,90,69,32,6,64,1,3,3,False,True,True,True,False,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Cyclophosphamide,AltName B,Drug,hiv,hiv,Phase 2,2018-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male or female, 18 years of age or older with documented HIV diagnosis.
* Must be willing to comply with study-mandated evaluations; including discontinuation of current antiret...",Yes,2019-03-06,FDA-97103,4.41,0.98,21.0,26.39,2022-10-28,2023-10-21,2044-10-20,98,J&J,45,Senegal,46.83333333333334,62,28,17,71,30,73,45,0,2,3,False,False,True,False,False,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PRO 140,GenName Y,Drug,hiv,hiv,Phase 3,2022-07-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria: Potential subjects are required to meet all of the following criteria for enrollment into the study.

1. Subjects who have completed 24 weeks of treatment in PRO 140\_CD 02 or CD02...",Yes,2022-12-29,FDA-35728,2.62,0.32,5.0,7.94,2025-02-20,2025-06-17,2030-06-18,74,GSK,62,Overall,34.83333333333334,35,61,0,7,68,38,55,1,4,1,False,True,True,False,True,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Zidovudine,AltName A,Drug,hiv,hiv,Phase 4,2008-08-01,"Sex: ALL; Age: >14 Years; Criteria: * INCLUSION CRITERIA:

Uniformed SANDF personnel or family members of SANDF personnel who are registered as eligible for health services from the SAMHS.

HIV positive as diagnosed and/or confirmed in ...",Yes,2008-12-22,FDA-17466,0.56,0.15,3.5,4.21,2009-02-21,2009-04-17,2012-10-16,34,Merck,93,South Africa,47.5,4,81,43,38,21,98,55,1,2,3,False,True,True,True,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Stavudine,Molecule Z,Drug,hiv,hiv,Phase 4,2008-08-01,"Sex: ALL; Age: >14 Years; Criteria: * INCLUSION CRITERIA:

Uniformed SANDF personnel or family members of SANDF personnel who are registered as eligible for health services from the SAMHS.

HIV positive as diagnosed and/or confirmed in ...",Yes,2009-01-18,FDA-82938,0.56,0.15,3.5,4.21,2009-02-21,2009-04-17,2012-10-16,20,Bayer,17,Senegal,30.16666666666667,42,64,8,61,6,0,55,1,4,1,True,False,True,True,False,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Didanosine,TradeName X,Drug,hiv,hiv,Phase 4,2008-08-01,"Sex: ALL; Age: >14 Years; Criteria: * INCLUSION CRITERIA:

Uniformed SANDF personnel or family members of SANDF personnel who are registered as eligible for health services from the SAMHS.

HIV positive as diagnosed and/or confirmed in ...",Yes,2009-06-19,FDA-22865,0.56,0.15,3.5,4.21,2009-02-21,2009-04-17,2012-10-16,19,Bayer,26,Kenya,36.16666666666666,72,15,5,49,10,66,55,1,4,1,True,False,True,False,True,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine,Molecule Z,Drug,hiv,hiv,Phase 4,2008-08-01,"Sex: ALL; Age: >14 Years; Criteria: * INCLUSION CRITERIA:

Uniformed SANDF personnel or family members of SANDF personnel who are registered as eligible for health services from the SAMHS.

HIV positive as diagnosed and/or confirmed in ...",No,2008-11-22,FDA-35122,0.56,0.15,3.5,4.21,2009-02-21,2009-04-17,2012-10-16,19,Pfizer,99,Senegal,51.66666666666666,68,91,3,6,61,81,55,1,3,2,True,False,True,False,True,False,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,Product Alpha,Drug,hiv,hiv,Phase 4,2008-08-01,"Sex: ALL; Age: >14 Years; Criteria: * INCLUSION CRITERIA:

Uniformed SANDF personnel or family members of SANDF personnel who are registered as eligible for health services from the SAMHS.

HIV positive as diagnosed and/or confirmed in ...",Yes,2009-03-26,FDA-79015,0.56,0.15,3.5,4.21,2009-02-21,2009-04-17,2012-10-16,93,AstraZeneca,21,Senegal,43.5,45,8,65,36,31,76,27,0,2,1,False,False,False,False,True,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir/Ritonavir,Comp Beta,Drug,hiv,hiv,Phase 4,2008-08-01,"Sex: ALL; Age: >14 Years; Criteria: * INCLUSION CRITERIA:

Uniformed SANDF personnel or family members of SANDF personnel who are registered as eligible for health services from the SAMHS.

HIV positive as diagnosed and/or confirmed in ...",Yes,2008-11-22,FDA-57445,0.56,0.15,3.5,4.21,2009-02-21,2009-04-17,2012-10-16,12,Novartis,56,Kenya,59.83333333333334,97,44,37,69,40,72,73,2,2,4,True,True,True,True,False,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lovaza,Product Alpha,Drug,hiv,hiv,Phase 4,2010-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-infected men and women at least 18 years of age
* On stable HAART for previous three months and without anticipated changes in their HAART regimen throughout the duration of...",No,2011-09-09,FDA-88718,0.56,0.15,3.5,4.21,2011-04-23,2011-06-17,2014-12-16,11,Novartis,4,South Africa,52.16666666666666,81,92,13,55,39,33,91,2,4,4,True,True,True,True,False,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Recombinant Lactoferrin,AltName A,Drug,hiv,hiv,Phase 2,2018-01-01,"Sex: ALL; Age: >40 Years; Criteria: Inclusion Criteria:

1. HIV-positive participants receiving Antiretroviral Therapy (ART) for \>1 year
2. HIV RNA level \<200 copies/mL for at least 6 months (≥2 separate values)
3. Age \>40 years

Exc...",Yes,2018-08-29,FDA-43088,4.41,0.98,21.0,26.39,2022-05-30,2023-05-23,2044-05-22,75,Gilead,26,South Africa,59.66666666666666,56,93,42,15,95,57,55,2,3,1,True,True,True,False,True,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
E/C/F/TAF,AltName A,Drug,hiv,hiv,Phase 3,2025-06-18,"Sex: ALL; Age: >2 Years; Criteria: Key Inclusion Criteria:

* Cohort 1

  * 12 years to \< 18 years of age at baseline
  * Weight greater than or equal to 35 kg (77 lbs)
  * Plasma HIV-1 ribonucleic acid (RNA) levels of ≥ 1,000 copies/...",No,2025-10-07,FDA-20324,2.62,0.32,5.0,7.94,2028-01-30,2028-05-26,2033-05-27,82,AstraZeneca,75,Senegal,37.66666666666666,16,81,66,38,8,17,73,2,4,2,True,True,True,False,True,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
E/C/F/TAF (Low Dose),AltName A,Drug,hiv,hiv,Phase 3,2025-06-18,"Sex: ALL; Age: >2 Years; Criteria: Key Inclusion Criteria:

* Cohort 1

  * 12 years to \< 18 years of age at baseline
  * Weight greater than or equal to 35 kg (77 lbs)
  * Plasma HIV-1 ribonucleic acid (RNA) levels of ≥ 1,000 copies/...",Yes,2025-12-09,FDA-10587,2.62,0.32,5.0,7.94,2028-01-30,2028-05-26,2033-05-27,58,GSK,45,Kenya,59.5,55,29,21,93,88,71,55,0,3,3,False,False,True,False,True,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rilpivirine,Product Alpha,Drug,hiv,hiv,Phase 2,2017-03-09,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria: Women who meet all of the following criteria will be eligible for inclusion in the study:

* Women, 18- 45 years (inclusive) of age at Enrollment
* Female at birth
* Willing and ab...",Yes,2017-05-26,FDA-59746,4.41,0.98,21.0,26.39,2021-08-05,2022-07-29,2043-07-29,59,Pfizer,70,Senegal,49.66666666666666,4,30,94,83,42,45,45,2,2,1,True,True,True,False,False,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Aerosol Interferon-Gamma,Molecule Z,Drug,hiv,hiv,Phase 2,2007-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Positive acid-fast bacillus (AFB) smear within 14 days prior to randomization
* Cluster of Differentiation 4 greater than 200 if HIV positive
* Ability to sign consent
* Bilater...",No,2008-05-31,FDA-59284,4.41,0.98,21.0,26.39,2011-12-28,2012-12-20,2033-12-20,26,J&J,91,Kenya,58.83333333333334,54,82,18,82,80,37,73,2,4,2,True,True,True,True,False,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Subcutaneous interferon-gamma,AltName B,Drug,hiv,hiv,Phase 2,2007-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Positive acid-fast bacillus (AFB) smear within 14 days prior to randomization
* Cluster of Differentiation 4 greater than 200 if HIV positive
* Ability to sign consent
* Bilater...",Yes,2007-11-09,FDA-80187,4.41,0.98,21.0,26.39,2011-12-28,2012-12-20,2033-12-20,16,Gilead,29,Overall,62.5,15,64,98,4,97,97,55,1,2,3,False,True,False,True,False,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Cannabis,AltName B,Drug,hiv,hiv,Phase 2,2022-05-31,"Sex: FEMALE; Age: >40 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. current cannabis use (within 6 months) based on self-report
2. able to perform study procedures, including ability to ambulate independently
3. adequate hearing and vision
4. f...",Yes,2023-03-05,FDA-22195,4.41,0.98,21.0,26.39,2026-10-27,2027-10-20,2048-10-19,39,GSK,51,Kenya,70.0,76,100,85,67,84,8,45,1,3,1,False,True,True,True,True,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Oral Methamphetamine,Product Alpha,Drug,hiv,hiv,Phase 4,2023-01-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Willing and able to provide written informed consent
2. Male or female, age ≥ 18 and ≤ 65 years
3. HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or c...",Yes,2023-05-24,FDA-60744,0.56,0.15,3.5,4.21,2023-08-03,2023-09-27,2027-03-28,71,Gilead,86,South Africa,68.0,24,91,61,84,55,93,55,1,1,4,False,True,False,False,False,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
EVG,AltName B,Drug,hiv,hiv,Phase 3,2017-11-03,"Sex: ALL; Age: >4 Weeks; Criteria: Key Inclusion Criteria:

Individuals must meet all of the following inclusion criteria to be eligible for participation in this study. Individuals with screening results that do not meet eligibility c...",Yes,2018-09-16,FDA-56380,2.62,0.32,5.0,7.94,2020-06-16,2020-10-11,2025-10-12,54,Merck,38,Senegal,59.16666666666666,80,71,53,50,32,69,55,2,2,2,True,True,False,False,True,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Background regimen,AltName A,Drug,hiv,hiv,Phase 3,2017-11-03,"Sex: ALL; Age: >4 Weeks; Criteria: Key Inclusion Criteria:

Individuals must meet all of the following inclusion criteria to be eligible for participation in this study. Individuals with screening results that do not meet eligibility c...",Yes,2018-06-24,FDA-11788,2.62,0.32,5.0,7.94,2020-06-16,2020-10-11,2025-10-12,93,Sanofi,9,South Africa,61.0,9,99,97,57,50,54,73,2,4,2,True,True,False,True,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Recombinant Interleukin-2,Molecule Z,Drug,hiv,hiv,Phase 2,2020-08-20,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Written informed consent signed and dated by study participant.
2. Male or female, at least 18 years of age and not older than 65 years of age.
3. HIV-1 infection, documented b...",Yes,2021-03-06,FDA-66268,4.41,0.98,21.0,26.39,2025-01-16,2026-01-09,2047-01-09,2,Gilead,25,South Africa,48.0,28,22,63,60,40,75,27,0,1,2,False,False,False,True,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Edoxaban 30mg daily,Molecule Z,Drug,hiv,hiv,Phase 2,2018-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

* HIV infection (verified by previous positive antibody or detectable HIV RNA level)
* Age ≥18 years
* Receiving continuous ART for ≥2 years (regimen changes \>3 months prior to en...",Yes,2019-05-10,FDA-34212,4.41,0.98,21.0,26.39,2023-01-28,2024-01-21,2045-01-20,92,Merck,57,Overall,57.16666666666666,38,45,90,60,50,60,45,2,0,3,True,True,False,False,False,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Comparator: MK0518 monotherapy,Comp Beta,Drug,hiv,hiv,Phase 2,2010-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient must be HIV positive who must have received less than 7 days total of any antiretroviral therapy (HIV related therapy)

Extension Studies:

* First extension: Patient co...",Yes,2011-01-05,FDA-22584,4.41,0.98,21.0,26.39,2014-11-27,2015-11-20,2036-11-19,86,Merck,51,South Africa,39.66666666666666,39,53,21,24,21,80,27,0,3,0,False,False,True,True,True,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Comparator: MK0518 combination therapy,Product Alpha,Drug,hiv,hiv,Phase 2,2010-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient must be HIV positive who must have received less than 7 days total of any antiretroviral therapy (HIV related therapy)

Extension Studies:

* First extension: Patient co...",No,2011-04-30,FDA-80902,4.41,0.98,21.0,26.39,2014-11-27,2015-11-20,2036-11-19,62,Pfizer,14,Senegal,21.33333333333333,27,17,5,32,47,0,45,0,4,1,False,False,True,True,True,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Comparator: efavirenz,AltName A,Drug,hiv,hiv,Phase 2,2010-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient must be HIV positive who must have received less than 7 days total of any antiretroviral therapy (HIV related therapy)

Extension Studies:

* First extension: Patient co...",Yes,2010-10-28,FDA-13855,4.41,0.98,21.0,26.39,2014-11-27,2015-11-20,2036-11-19,72,Bayer,2,South Africa,48.83333333333334,69,4,60,32,40,88,45,0,2,3,False,False,False,True,False,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Comparator: tenofovir,Comp Beta,Drug,hiv,hiv,Phase 2,2010-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient must be HIV positive who must have received less than 7 days total of any antiretroviral therapy (HIV related therapy)

Extension Studies:

* First extension: Patient co...",No,2010-09-12,FDA-78732,4.41,0.98,21.0,26.39,2014-11-27,2015-11-20,2036-11-19,43,J&J,61,Kenya,57.16666666666666,73,60,68,49,40,53,55,1,2,3,True,False,False,True,False,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Comparator: lamivudine,TradeName X,Drug,hiv,hiv,Phase 2,2010-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient must be HIV positive who must have received less than 7 days total of any antiretroviral therapy (HIV related therapy)

Extension Studies:

* First extension: Patient co...",No,2011-04-13,FDA-82606,4.41,0.98,21.0,26.39,2014-11-27,2015-11-20,2036-11-19,32,Merck,89,Overall,69.16666666666667,100,100,69,65,12,69,73,1,4,3,True,False,True,True,True,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir disoproxil,AltName A,Drug,hiv,hiv,Phase 3,2014-10-01,"Sex: ALL; Age: >20 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Report injection drug use in the 6 months before screening
* Possess a Thai National Identification Card
* Laboratory values as follows within 2 weeks before enrollment:
* HIV o...",Yes,2015-03-07,FDA-96701,2.62,0.32,5.0,7.94,2017-05-14,2017-09-08,2022-09-09,38,AstraZeneca,15,Senegal,56.5,58,29,45,84,86,37,27,1,0,2,False,True,False,False,False,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DNA + HIV-rAd5 vaccine,Comp Beta,Biological,hiv,hiv,Phase 2,2014-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* At least 3 years of ART without interruption (less than one month cumulative)
* ART regimen unchanged in the 3 months prior to screening
* One HIV plasma viral...",Yes,2014-07-25,FDA-56593,4.41,0.98,21.0,26.39,2018-10-28,2019-10-21,2040-10-20,27,Bayer,3,Senegal,42.16666666666666,17,24,65,66,67,14,55,1,3,2,True,False,False,False,True,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ART intensification (raltegravir),GenName Y,Drug,hiv,hiv,Phase 2,2014-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* At least 3 years of ART without interruption (less than one month cumulative)
* ART regimen unchanged in the 3 months prior to screening
* One HIV plasma viral...",Yes,2014-07-25,FDA-62345,4.41,0.98,21.0,26.39,2018-10-28,2019-10-21,2040-10-20,32,GSK,40,Kenya,52.33333333333334,67,61,89,48,1,48,55,1,3,2,True,False,True,False,True,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ART intensification (maraviroc),Molecule Z,Drug,hiv,hiv,Phase 2,2014-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* At least 3 years of ART without interruption (less than one month cumulative)
* ART regimen unchanged in the 3 months prior to screening
* One HIV plasma viral...",No,2015-01-30,FDA-49049,4.41,0.98,21.0,26.39,2018-10-28,2019-10-21,2040-10-20,75,GSK,15,Overall,58.0,71,79,100,12,69,17,45,0,3,2,False,False,False,True,True,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ad26.Mos.HIV,TradeName X,Biological,hiv,hiv,Phase 2,2018-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Confirmed human immunodeficiency virus (HIV)-1 infected and started antiretroviral therapy (ART) during acute infection (Fiebig stages I, II, III or IV) as part of trial RV254
*...",Yes,2019-01-06,FDA-10473,4.41,0.98,21.0,26.39,2023-01-28,2024-01-21,2045-01-20,85,Sanofi,66,Overall,57.16666666666666,44,54,61,48,66,70,45,1,2,2,True,False,False,True,False,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
MVA-Mosaic,GenName Y,Biological,hiv,hiv,Phase 2,2018-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Confirmed human immunodeficiency virus (HIV)-1 infected and started antiretroviral therapy (ART) during acute infection (Fiebig stages I, II, III or IV) as part of trial RV254
*...",No,2018-12-08,FDA-72043,4.41,0.98,21.0,26.39,2023-01-28,2024-01-21,2045-01-20,37,AstraZeneca,14,Overall,49.16666666666666,21,69,64,37,60,44,27,1,0,2,True,False,False,False,False,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Temazepam,Comp Beta,Drug,hiv,hiv,Phase 4,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. males or females age 18-69;
2. females must utilize an approved form of birth control during the study;
3. have at least a 3 month history of insomnia as defined in the DSM-IV ...",No,2026-11-16,FDA-40996,0.56,0.15,3.5,4.21,,,,59,J&J,1,Overall,56.33333333333334,74,45,59,58,93,9,64,2,4,1,True,True,True,True,False,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Antiretroviral therapy (ART),TradeName X,Drug,hiv,hiv,Phase 4,2015-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult Human
* Able to provide written informed consent
* HIV antibody positive
* HIV viral load positive
* HIV treatment naive
* Hepatitis C antibody positive
* Hepatitis C vira...",Yes,2015-10-05,FDA-70491,0.56,0.15,3.5,4.21,2015-10-22,2015-12-16,2019-06-16,24,Pfizer,94,Kenya,55.83333333333334,68,23,64,54,94,32,45,1,2,2,False,True,False,True,True,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
raltegravir,Molecule Z,Drug,hiv,hiv,Phase 4,2015-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult Human
* Able to provide written informed consent
* HIV antibody positive
* HIV viral load positive
* HIV treatment naive
* Hepatitis C antibody positive
* Hepatitis C vira...",Yes,2015-11-10,FDA-25786,0.56,0.15,3.5,4.21,2015-10-22,2015-12-16,2019-06-16,29,Merck,33,South Africa,43.5,88,80,25,31,17,20,36,2,2,0,True,True,False,False,True,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine and tenofovir disoproxil fumarate,Molecule Z,Drug,hiv,hiv,Phase 4,2015-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult Human
* Able to provide written informed consent
* HIV antibody positive
* HIV viral load positive
* HIV treatment naive
* Hepatitis C antibody positive
* Hepatitis C vira...",No,2015-12-06,FDA-73037,0.56,0.15,3.5,4.21,2015-10-22,2015-12-16,2019-06-16,1,AstraZeneca,10,Senegal,62.0,61,81,66,76,25,63,45,1,2,2,True,False,False,True,False,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"darunavir (DRV, TMC114)",GenName Y,Drug,hiv,hiv,Phase 3,2011-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients with documented HIV-1 infection
* Patients currently receiving HAART for at least 24 weeks
* Plasma viral load \< 50 copies/mL for at least 24 weeks prior to screening ...",Yes,2011-02-18,FDA-34518,2.62,0.32,5.0,7.94,2013-08-14,2013-12-09,2018-12-10,1,Gilead,14,Overall,52.66666666666666,65,2,86,41,30,92,36,1,3,0,False,True,True,False,True,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"darunavir (DRV, TMC114)",Product Alpha,Drug,hiv,hiv,Phase 3,2011-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients with documented HIV-1 infection
* Patients currently receiving HAART for at least 24 weeks
* Plasma viral load \< 50 copies/mL for at least 24 weeks prior to screening ...",No,2011-05-22,FDA-15975,2.62,0.32,5.0,7.94,2013-08-14,2013-12-09,2018-12-10,19,Merck,59,Senegal,66.5,31,38,96,71,86,77,45,0,1,4,False,False,False,False,False,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Disulfiram,Comp Beta,Drug,hiv,hiv,Phase 2,2014-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Age 18 or older
* HIV plasma viral load \<50 copies/ml for at least 3 years with at least one measurement per year and most recent viral load within 3 months o...",Yes,2014-12-29,FDA-93402,4.41,0.98,21.0,26.39,2018-09-27,2019-09-20,2040-09-19,74,GSK,90,Overall,60.0,83,65,39,73,41,59,45,0,4,1,False,False,False,True,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
3BNC117,Comp Beta,Drug,hiv,hiv,Phase 2,2020-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adults age 18-65 years with documented HIV-1 infection
* CD4+ T-cell count \>500 cells/mm3 at screening
* On ART for a minimum of 24 months and HIV-1 RNA plasma level of \< 50 c...",Yes,2021-07-16,FDA-37765,4.41,0.98,21.0,26.39,2025-05-29,2026-05-22,2047-05-22,41,Novartis,56,Senegal,46.66666666666666,12,34,50,49,35,100,45,1,3,1,False,True,True,True,False,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Romidepsin,Product Alpha,Drug,hiv,hiv,Phase 2,2020-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adults age 18-65 years with documented HIV-1 infection
* CD4+ T-cell count \>500 cells/mm3 at screening
* On ART for a minimum of 24 months and HIV-1 RNA plasma level of \< 50 c...",Yes,2021-08-18,FDA-41385,4.41,0.98,21.0,26.39,2025-05-29,2026-05-22,2047-05-22,93,J&J,28,South Africa,58.0,0,57,82,63,59,87,36,1,3,0,False,True,False,True,True,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Highly active antiretroviral therapy (HAART),TradeName X,Drug,hiv,hiv,Phase 4,2012-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented acute or recent HIV infection (infected in the past 12 months) as defined in the study protocol
* Antiretroviral naive. Participants who have taken antiretrovirals fo...",No,2012-11-20,FDA-19293,0.56,0.15,3.5,4.21,2012-11-21,2013-01-15,2016-07-16,94,Novartis,21,South Africa,62.66666666666666,79,76,41,22,60,98,27,1,2,0,True,False,False,False,True,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,Comp Beta,Drug,hiv,hiv,Phase 3,2022-11-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients in the switch arm who have completed the 24-week follow-up of RALAM (NCT02284035) study and remain virologically suppressed (viral load \<50 copies/mL) on dual therapy ...",Yes,2023-09-02,FDA-42028,2.62,0.32,5.0,7.94,2025-07-13,2025-11-07,2030-11-08,74,Merck,49,Overall,43.5,16,24,74,12,88,47,9,0,0,1,False,False,False,False,False,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine,Product Alpha,Drug,hiv,hiv,Phase 3,2022-11-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients in the switch arm who have completed the 24-week follow-up of RALAM (NCT02284035) study and remain virologically suppressed (viral load \<50 copies/mL) on dual therapy ...",No,2023-02-15,FDA-10844,2.62,0.32,5.0,7.94,2025-07-13,2025-11-07,2030-11-08,61,GSK,5,Kenya,48.83333333333334,54,77,35,20,72,35,18,0,2,0,False,False,True,True,False,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Engerix-B 20 mcg,Comp Beta,Biological,hiv,hiv,Phase 4,2009-06-01,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria:

* Documented HIV+
* Age 12 to \< 25 years
* History of no or one hepatitis B vaccination
* Not pregnant.
* Females engaging in sexual intercourse must be willing to practice an ap...",Yes,2009-12-29,FDA-10619,0.56,0.15,3.5,4.21,2009-12-22,2010-02-15,2013-08-16,89,Sanofi,88,Overall,40.16666666666666,69,5,53,73,39,2,36,1,2,1,False,True,False,False,True,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Engerix-B 40 mcg,Comp Beta,Biological,hiv,hiv,Phase 4,2009-06-01,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria:

* Documented HIV+
* Age 12 to \< 25 years
* History of no or one hepatitis B vaccination
* Not pregnant.
* Females engaging in sexual intercourse must be willing to practice an ap...",Yes,2010-04-17,FDA-17380,0.56,0.15,3.5,4.21,2009-12-22,2010-02-15,2013-08-16,86,GSK,49,Senegal,73.16666666666667,99,90,29,94,44,83,64,1,4,2,False,True,True,True,True,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg,Product Alpha,Biological,hiv,hiv,Phase 4,2009-06-01,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria:

* Documented HIV+
* Age 12 to \< 25 years
* History of no or one hepatitis B vaccination
* Not pregnant.
* Females engaging in sexual intercourse must be willing to practice an ap...",No,2010-05-22,FDA-27436,0.56,0.15,3.5,4.21,2009-12-22,2010-02-15,2013-08-16,97,GSK,83,Kenya,52.16666666666666,79,10,23,62,50,89,64,2,4,1,True,True,True,False,True,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Comparator: MK0518,AltName B,Drug,hiv,hiv,Phase 2,2009-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient must be HIV positive with Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) values that are within ranges required by the study
* Patient must be currently on an...",Yes,2010-01-19,FDA-23282,4.41,0.98,21.0,26.39,2013-11-27,2014-11-20,2035-11-20,51,Gilead,35,Senegal,62.16666666666666,54,56,100,40,76,47,64,0,4,3,False,False,True,True,False,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
MK0518,AltName B,Drug,hiv,hiv,Phase 2,2009-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient must be HIV positive with Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) values that are within ranges required by the study
* Patient must be currently on an...",Yes,2009-10-28,FDA-20260,4.41,0.98,21.0,26.39,2013-11-27,2014-11-20,2035-11-20,74,Gilead,4,Senegal,59.5,27,83,40,90,68,49,36,1,1,2,True,False,False,False,False,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
MK0518,GenName Y,Drug,hiv,hiv,Phase 2,2009-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient must be HIV positive with Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) values that are within ranges required by the study
* Patient must be currently on an...",Yes,2009-10-25,FDA-36622,4.41,0.98,21.0,26.39,2013-11-27,2014-11-20,2035-11-20,14,Sanofi,58,South Africa,58.66666666666666,21,18,74,93,84,62,45,0,2,3,False,False,True,True,False,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Darunavir,AltName A,Drug,hiv,hiv,Phase 3,2015-03-18,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* receiving HAART for at least 48 weeks
* Have at least 2 documented plasma HIV-1 RNA \<50 copies/mL, and no HIV-1 RNA \>=50 copies/mL in the 48 weeks prior to t...",No,2015-12-05,FDA-43918,2.62,0.32,5.0,7.94,2017-10-29,2018-02-23,2023-02-24,26,Gilead,9,Senegal,45.5,11,44,67,89,14,48,64,1,3,3,True,False,True,False,True,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,AltName B,Drug,hiv,hiv,Phase 3,2015-03-18,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* receiving HAART for at least 48 weeks
* Have at least 2 documented plasma HIV-1 RNA \<50 copies/mL, and no HIV-1 RNA \>=50 copies/mL in the 48 weeks prior to t...",No,2015-06-06,FDA-72126,2.62,0.32,5.0,7.94,2017-10-29,2018-02-23,2023-02-24,64,Sanofi,96,Senegal,55.33333333333334,72,91,76,29,2,62,18,0,1,1,False,False,False,False,True,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
tocilizumab,GenName Y,Drug,hiv,hiv,Phase 2,2017-09-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

4.1.1 Men and women age 18-60 years.

4.1.2 Ability and willingness to communicate in English or Spanish

4.1.3 Ability and willingness of subject to provide informed consent.

4.1...",No,2018-02-22,FDA-90586,4.41,0.98,21.0,26.39,2022-02-07,2023-01-31,2044-01-31,28,Novartis,95,Overall,53.0,80,49,76,66,20,27,55,1,3,2,False,True,False,True,False,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir,GenName Y,Drug,hiv,hiv,Phase 3,2015-05-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria for HIV Infected Partner:

* Positive HIV test within 60 days of study entry
* CD4 count between 350 and 550 cells/mm3 within 30 days of study entry
* If pregnant or breastfeeding, ...",Yes,2015-09-09,FDA-12264,2.62,0.32,5.0,7.94,2017-12-12,2018-04-08,2023-04-09,27,Novartis,27,Overall,52.66666666666666,92,9,47,99,69,0,36,0,3,1,False,False,True,True,False,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Didanosine,Comp Beta,Drug,hiv,hiv,Phase 3,2015-05-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria for HIV Infected Partner:

* Positive HIV test within 60 days of study entry
* CD4 count between 350 and 550 cells/mm3 within 30 days of study entry
* If pregnant or breastfeeding, ...",Yes,2016-01-12,FDA-59901,2.62,0.32,5.0,7.94,2017-12-12,2018-04-08,2023-04-09,89,Bayer,83,Overall,56.66666666666666,67,93,61,75,22,22,55,1,4,1,False,True,True,False,True,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,Comp Beta,Drug,hiv,hiv,Phase 3,2015-05-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria for HIV Infected Partner:

* Positive HIV test within 60 days of study entry
* CD4 count between 350 and 550 cells/mm3 within 30 days of study entry
* If pregnant or breastfeeding, ...",Yes,2015-09-12,FDA-45543,2.62,0.32,5.0,7.94,2017-12-12,2018-04-08,2023-04-09,28,AstraZeneca,29,Kenya,63.66666666666666,3,96,17,84,95,87,55,1,2,3,True,False,True,False,True,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine/Tenofovir disoproxil fumarate,AltName B,Drug,hiv,hiv,Phase 3,2015-05-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria for HIV Infected Partner:

* Positive HIV test within 60 days of study entry
* CD4 count between 350 and 550 cells/mm3 within 30 days of study entry
* If pregnant or breastfeeding, ...",No,2015-06-08,FDA-50515,2.62,0.32,5.0,7.94,2017-12-12,2018-04-08,2023-04-09,18,Bayer,55,Senegal,67.0,76,35,93,82,82,34,45,1,3,1,True,False,True,False,False,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine,AltName A,Drug,hiv,hiv,Phase 3,2015-05-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria for HIV Infected Partner:

* Positive HIV test within 60 days of study entry
* CD4 count between 350 and 550 cells/mm3 within 30 days of study entry
* If pregnant or breastfeeding, ...",No,2016-04-11,FDA-49096,2.62,0.32,5.0,7.94,2017-12-12,2018-04-08,2023-04-09,52,AstraZeneca,93,Senegal,66.16666666666667,86,85,90,30,94,12,55,1,3,2,True,False,True,False,True,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir/Ritonavir,AltName B,Drug,hiv,hiv,Phase 3,2015-05-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria for HIV Infected Partner:

* Positive HIV test within 60 days of study entry
* CD4 count between 350 and 550 cells/mm3 within 30 days of study entry
* If pregnant or breastfeeding, ...",Yes,2015-09-16,FDA-24049,2.62,0.32,5.0,7.94,2017-12-12,2018-04-08,2023-04-09,86,GSK,24,South Africa,48.16666666666666,85,59,37,42,37,29,82,2,4,3,True,True,True,True,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Nevirapine,AltName B,Drug,hiv,hiv,Phase 3,2015-05-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria for HIV Infected Partner:

* Positive HIV test within 60 days of study entry
* CD4 count between 350 and 550 cells/mm3 within 30 days of study entry
* If pregnant or breastfeeding, ...",Yes,2015-06-20,FDA-92092,2.62,0.32,5.0,7.94,2017-12-12,2018-04-08,2023-04-09,100,GSK,23,Overall,67.33333333333333,88,80,80,7,100,49,55,2,1,3,True,True,True,False,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Stavudine,AltName B,Drug,hiv,hiv,Phase 3,2015-05-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria for HIV Infected Partner:

* Positive HIV test within 60 days of study entry
* CD4 count between 350 and 550 cells/mm3 within 30 days of study entry
* If pregnant or breastfeeding, ...",Yes,2015-08-13,FDA-56474,2.62,0.32,5.0,7.94,2017-12-12,2018-04-08,2023-04-09,99,Sanofi,63,Senegal,72.5,49,56,81,98,74,77,45,1,3,1,True,False,False,False,True,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir disoproxil fumarate,Comp Beta,Drug,hiv,hiv,Phase 3,2015-05-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria for HIV Infected Partner:

* Positive HIV test within 60 days of study entry
* CD4 count between 350 and 550 cells/mm3 within 30 days of study entry
* If pregnant or breastfeeding, ...",Yes,2015-07-05,FDA-16133,2.62,0.32,5.0,7.94,2017-12-12,2018-04-08,2023-04-09,61,Merck,80,Kenya,58.16666666666666,5,50,82,71,46,95,55,1,3,2,True,False,True,False,True,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Zidovudine/Lamivudine,TradeName X,Drug,hiv,hiv,Phase 3,2015-05-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria for HIV Infected Partner:

* Positive HIV test within 60 days of study entry
* CD4 count between 350 and 550 cells/mm3 within 30 days of study entry
* If pregnant or breastfeeding, ...",No,2015-08-18,FDA-90045,2.62,0.32,5.0,7.94,2017-12-12,2018-04-08,2023-04-09,70,Sanofi,10,Overall,45.5,79,26,4,12,61,91,73,1,3,4,False,True,True,False,True,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,AltName A,Drug,hiv,hiv,Phase 2,2015-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* For participants in the men's component of the study, born male. For participants in the women's component of the study, born female.
* 18 years or older at the time of screenin...",Yes,2016-02-04,FDA-76109,4.41,0.98,21.0,26.39,2020-03-29,2021-03-22,2042-03-22,54,Sanofi,52,Senegal,24.66666666666667,21,53,20,4,24,26,45,0,2,3,False,False,True,False,False,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine,AltName B,Drug,hiv,hiv,Phase 2,2015-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* For participants in the men's component of the study, born male. For participants in the women's component of the study, born female.
* 18 years or older at the time of screenin...",No,2016-01-09,FDA-14386,4.41,0.98,21.0,26.39,2020-03-29,2021-03-22,2042-03-22,61,J&J,62,Overall,41.0,31,29,53,41,11,81,55,1,3,2,True,False,True,True,False,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir disoproxil fumarate,AltName A,Drug,hiv,hiv,Phase 2,2015-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* For participants in the men's component of the study, born male. For participants in the women's component of the study, born female.
* 18 years or older at the time of screenin...",No,2016-01-15,FDA-65361,4.41,0.98,21.0,26.39,2020-03-29,2021-03-22,2042-03-22,29,GSK,17,Senegal,45.16666666666666,43,55,22,40,52,59,55,1,3,2,False,True,True,True,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"Raltegravir, tenofovir/emtricitabine",Molecule Z,Drug,hiv,hiv,Phase 4,2013-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Age ≥18 years, and
2. HIV infection, and
3. Antiretroviral-naïve, and
4. CD4+ T cell count \>350 cells/mm3, and
5. ""Controllers"": antiretroviral untreated with 50-1000 copies/m...",No,2014-09-23,FDA-72846,0.56,0.15,3.5,4.21,2014-04-23,2014-06-17,2017-12-16,32,GSK,27,Senegal,50.0,100,70,41,8,2,79,82,2,3,4,True,True,False,True,True,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Escitalopram,Molecule Z,Drug,hiv,hiv,Phase 4,2009-04-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Diagnosis of major depression based on DSM-IV criteria;
* age 18-70 years;
* Greater than 15 on MADRS for severity of depression;
* HIV seropositive;
* no new antiviral medicati...",No,2009-10-27,FDA-28432,0.56,0.15,3.5,4.21,2009-10-22,2009-12-16,2013-06-16,20,Pfizer,99,Senegal,42.0,38,21,48,30,25,90,36,2,1,1,True,True,False,False,False,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada,TradeName X,Drug,hiv,hiv,Phase 4,2017-01-25,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* HIV-negative man who reports receptive anal sex with another man in the last 6 months aged 18-49 years
* Male to female transgender women who are not currently taking hormonal t...",No,2018-01-10,FDA-85331,0.56,0.15,3.5,4.21,2017-08-17,2017-10-11,2021-04-11,79,AstraZeneca,53,Kenya,47.66666666666666,74,69,51,16,62,14,55,1,3,2,True,False,True,True,True,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Gel lubricant,GenName Y,Device,hiv,hiv,Phase 4,2017-01-25,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* HIV-negative man who reports receptive anal sex with another man in the last 6 months aged 18-49 years
* Male to female transgender women who are not currently taking hormonal t...",No,2017-08-28,FDA-68287,0.56,0.15,3.5,4.21,2017-08-17,2017-10-11,2021-04-11,46,AstraZeneca,23,Overall,44.5,89,20,18,76,54,10,45,1,3,1,True,False,False,False,True,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir & Lopinavir/ritonavir,GenName Y,Drug,hiv,hiv,Phase 2,2012-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented HIV Infection
* Genotypic resistance without major resistance mutations within 30 days
* Antiretroviral drug-naïve
* Screening HIV-1 RNA ≥5000
* Women of reproductive...",Yes,2012-09-26,FDA-64859,4.41,0.98,21.0,26.39,2016-05-29,2017-05-22,2038-05-22,90,Sanofi,38,Kenya,43.5,51,70,21,69,26,24,73,1,3,4,True,False,True,False,True,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir and emtricitabine/tenofovir,AltName B,Drug,hiv,hiv,Phase 2,2012-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented HIV Infection
* Genotypic resistance without major resistance mutations within 30 days
* Antiretroviral drug-naïve
* Screening HIV-1 RNA ≥5000
* Women of reproductive...",Yes,2012-09-21,FDA-33573,4.41,0.98,21.0,26.39,2016-05-29,2017-05-22,2038-05-22,91,Bayer,80,Overall,65.5,51,10,92,78,78,84,55,2,2,2,True,True,True,False,False,False,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PF-00232798,TradeName X,Drug,hiv,hiv,Phase 2,2008-09-01,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Asymptomatic HIV-1 infected male patients between the ages of 18 and 55 years inclusive.
* Patients with CCR5 tropic virus as determined by the Monogram PhenoSense Entry assay.
...",No,2009-08-11,FDA-57133,4.41,0.98,21.0,26.39,2013-01-28,2014-01-21,2035-01-21,30,GSK,86,Senegal,49.66666666666666,35,89,5,48,23,98,55,1,2,3,True,False,True,False,True,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PF-00232798,AltName A,Drug,hiv,hiv,Phase 2,2008-09-01,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Asymptomatic HIV-1 infected male patients between the ages of 18 and 55 years inclusive.
* Patients with CCR5 tropic virus as determined by the Monogram PhenoSense Entry assay.
...",No,2009-04-03,FDA-80288,4.41,0.98,21.0,26.39,2013-01-28,2014-01-21,2035-01-21,71,GSK,85,Overall,33.83333333333334,43,14,90,18,33,5,64,1,5,1,True,False,True,True,True,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
PF-00232798,TradeName X,Drug,hiv,hiv,Phase 2,2008-09-01,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Asymptomatic HIV-1 infected male patients between the ages of 18 and 55 years inclusive.
* Patients with CCR5 tropic virus as determined by the Monogram PhenoSense Entry assay.
...",Yes,2009-03-12,FDA-47682,4.41,0.98,21.0,26.39,2013-01-28,2014-01-21,2035-01-21,49,J&J,52,Senegal,52.33333333333334,15,57,24,82,65,71,55,2,3,1,True,True,True,True,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
PF-00232798,AltName B,Drug,hiv,hiv,Phase 2,2008-09-01,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Asymptomatic HIV-1 infected male patients between the ages of 18 and 55 years inclusive.
* Patients with CCR5 tropic virus as determined by the Monogram PhenoSense Entry assay.
...",No,2009-05-23,FDA-55113,4.41,0.98,21.0,26.39,2013-01-28,2014-01-21,2035-01-21,5,Bayer,1,Overall,35.5,27,38,20,1,74,53,64,1,2,4,True,False,True,False,False,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PF-00232798,AltName B,Drug,hiv,hiv,Phase 2,2008-09-01,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Asymptomatic HIV-1 infected male patients between the ages of 18 and 55 years inclusive.
* Patients with CCR5 tropic virus as determined by the Monogram PhenoSense Entry assay.
...",No,2008-11-26,FDA-98462,4.41,0.98,21.0,26.39,2013-01-28,2014-01-21,2035-01-21,92,GSK,62,Kenya,42.83333333333334,83,72,30,43,29,0,45,1,2,2,True,False,True,False,True,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PF-00232798,Product Alpha,Drug,hiv,hiv,Phase 2,2008-09-01,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Asymptomatic HIV-1 infected male patients between the ages of 18 and 55 years inclusive.
* Patients with CCR5 tropic virus as determined by the Monogram PhenoSense Entry assay.
...",No,2009-02-23,FDA-98421,4.41,0.98,21.0,26.39,2013-01-28,2014-01-21,2035-01-21,11,AstraZeneca,2,Overall,67.16666666666667,94,37,51,93,61,67,73,1,4,3,True,False,False,True,True,True,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atorvastatin,Comp Beta,Drug,hiv,hiv,Phase 2,2008-06-19,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:
* Adults 18 years of age or older.
* Human Immunodeficiency Virus -1 (HIV-1) infection, as documented by a licensed Enzyme-Linked Immunosorbent Assay (ELISA) test kit and confirm...",No,2008-11-28,FDA-51244,4.41,0.98,21.0,26.39,2012-11-15,2013-11-08,2034-11-08,17,Pfizer,19,Kenya,45.16666666666666,43,1,52,57,28,90,45,1,2,2,False,True,False,True,True,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
chloroquine phosphate,Molecule Z,Drug,hiv,hiv,Phase 3,2009-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected adults
* CD4 count \> 250 cells/mm3
* Not presently receiving HIV antiretroviral therapy (\> 6 months or naïve)
* Viral load \> 3000 RNA copies/mL (3.5 log)
* No ...",No,2009-12-27,FDA-87807,2.62,0.32,5.0,7.94,2012-01-13,2012-05-09,2017-05-10,7,GSK,81,South Africa,56.0,94,16,84,39,97,6,55,1,3,2,True,False,False,True,True,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,TradeName X,Drug,hiv,hiv,Phase 4,2019-11-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Written informed consent (IC) obtained.
* HIV-positive adult (age over 18) subjects currently on stable ART, with no changes in the ART regimens during the past 6 months.
* Curr...",No,2020-10-14,FDA-35744,0.56,0.15,3.5,4.21,2020-06-21,2020-08-15,2024-02-14,26,Merck,80,South Africa,72.33333333333333,84,40,65,99,68,78,36,2,1,1,True,True,False,False,True,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir 400Mg Tab,Product Alpha,Drug,hiv,hiv,Phase 4,2018-09-24,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. The ability to understand and sign a written informed consent form prior to participation in any screening procedures and must be willing to comply with all trial requirements....",Yes,2019-01-07,FDA-20246,0.56,0.15,3.5,4.21,2019-04-16,2019-06-10,2022-12-09,68,Bayer,53,South Africa,42.33333333333334,32,41,17,52,80,32,36,0,2,2,False,False,True,True,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine 150Mg Tablet,TradeName X,Drug,hiv,hiv,Phase 4,2018-09-24,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. The ability to understand and sign a written informed consent form prior to participation in any screening procedures and must be willing to comply with all trial requirements....",No,2019-04-08,FDA-27342,0.56,0.15,3.5,4.21,2019-04-16,2019-06-10,2022-12-09,86,Gilead,9,Kenya,70.16666666666667,86,69,78,68,84,36,45,1,1,3,True,False,False,False,True,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,Product Alpha,Drug,hiv,hiv,Phase 4,2010-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry. HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or...",No,2011-06-05,FDA-34377,0.56,0.15,3.5,4.21,2011-01-21,2011-03-17,2014-09-15,27,Novartis,29,Senegal,29.16666666666667,14,53,73,8,21,6,64,2,3,2,True,True,True,True,False,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Comparator: raltegravir,Product Alpha,Drug,hiv,hiv,Phase 3,2009-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient is at least 18 years of age
* Patient is human immunodeficiency virus (HIV) positive
* Patient has documented Human Immunodeficiency Virus (HIV) RiboNucleic Acid (RNA) \...",Yes,2009-10-30,FDA-97992,2.62,0.32,5.0,7.94,2011-11-13,2012-03-09,2017-03-10,93,Merck,55,South Africa,24.83333333333333,0,23,13,27,35,51,64,0,4,3,False,False,True,True,True,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Comparator: lopinavir (+) ritonavir,Molecule Z,Drug,hiv,hiv,Phase 3,2009-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient is at least 18 years of age
* Patient is human immunodeficiency virus (HIV) positive
* Patient has documented Human Immunodeficiency Virus (HIV) RiboNucleic Acid (RNA) \...",Yes,2010-02-24,FDA-47108,2.62,0.32,5.0,7.94,2011-11-13,2012-03-09,2017-03-10,56,Novartis,85,Overall,46.5,53,4,40,12,86,84,55,1,4,1,True,False,True,True,True,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Naltrexone,Product Alpha,Drug,hiv,hiv,Phase 3,2016-07-01,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria: (must meet all of following):

* Hazardous drinking, on average, during the preceding 4 weeks. Defined as binge drinking (4 or more drinks per occasion at least twice monthly) and/...",Yes,2016-09-07,FDA-32956,2.62,0.32,5.0,7.94,2019-02-12,2019-06-09,2024-06-09,9,AstraZeneca,44,South Africa,53.66666666666666,54,93,11,14,100,50,73,1,4,3,False,True,True,True,False,True,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
HIV therapy,AltName A,Drug,hiv,hiv,Phase 4,2013-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Over 18 years of age.
* R5 HIV infection on screening tropism test.
* Viral load \>1,000 copies/mL.
* Never previously treated with anti-HIV medicines.

Exclusion Criteria:

* P...",No,2014-02-22,FDA-23420,0.56,0.15,3.5,4.21,2014-01-21,2014-03-17,2017-09-15,9,Gilead,12,South Africa,45.5,3,42,86,58,73,11,64,1,2,4,False,True,True,False,False,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Fluzone®,GenName Y,Biological,hiv,hiv,Phase 4,2011-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. A confirmed diagnosis of HIV-1 infection as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry or any measurable HIV RNA v...",Yes,2012-02-24,FDA-13132,0.56,0.15,3.5,4.21,2011-10-22,2011-12-16,2015-06-16,28,Sanofi,83,Kenya,35.5,74,50,21,58,7,3,73,1,3,4,False,True,True,True,False,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Fluzone®,Molecule Z,Biological,hiv,hiv,Phase 4,2011-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. A confirmed diagnosis of HIV-1 infection as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry or any measurable HIV RNA v...",Yes,2011-07-15,FDA-31542,0.56,0.15,3.5,4.21,2011-10-22,2011-12-16,2015-06-16,20,Pfizer,35,Overall,56.33333333333334,33,31,76,75,62,61,64,2,2,3,True,True,False,False,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Vicriviroc maleate,Comp Beta,Drug,hiv,hiv,Phase 2,2010-10-21,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Successful completion of ACTG Protocol A5211, or favorable response in A5211 but discontinued due to tropism shift, or screened for A5211 and met inclusion/exclusion criteria bu...",Yes,2011-04-06,FDA-23931,4.41,0.98,21.0,26.39,2015-03-19,2016-03-11,2037-03-11,16,Merck,95,Senegal,62.0,64,93,75,76,32,32,55,1,2,3,True,False,True,False,False,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir Film-coated Tablet,AltName A,Drug,hiv,hiv,Phase 2,2013-12-11,"Sex: ALL; Age: >2 Years; Criteria: Inclusion Criteria:

* HIV positive
* Weight of at least 7 kg
* HIV RNA ≥1000 copies/mL within 45 days before study treatment
* Participants of reproductive potential and sexually active agree to rema...",Yes,2014-10-31,FDA-86330,4.41,0.98,21.0,26.39,2018-05-09,2019-05-02,2040-05-01,16,Sanofi,47,Senegal,39.0,53,2,14,52,36,77,55,2,2,2,True,True,True,False,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir Chewable Tablet,GenName Y,Drug,hiv,hiv,Phase 2,2013-12-11,"Sex: ALL; Age: >2 Years; Criteria: Inclusion Criteria:

* HIV positive
* Weight of at least 7 kg
* HIV RNA ≥1000 copies/mL within 45 days before study treatment
* Participants of reproductive potential and sexually active agree to rema...",Yes,2014-09-24,FDA-71591,4.41,0.98,21.0,26.39,2018-05-09,2019-05-02,2040-05-01,13,Novartis,77,Kenya,77.33333333333333,90,42,81,88,96,67,27,0,1,2,False,False,False,True,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Other Anti-Retroviral Therapy,AltName A,Drug,hiv,hiv,Phase 2,2013-12-11,"Sex: ALL; Age: >2 Years; Criteria: Inclusion Criteria:

* HIV positive
* Weight of at least 7 kg
* HIV RNA ≥1000 copies/mL within 45 days before study treatment
* Participants of reproductive potential and sexually active agree to rema...",Yes,2014-12-01,FDA-29694,4.41,0.98,21.0,26.39,2018-05-09,2019-05-02,2040-05-01,48,Merck,60,Kenya,67.66666666666667,96,100,70,17,39,84,55,2,3,1,True,True,True,True,False,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,Product Alpha,Drug,hiv,hiv,Phase 4,2018-10-23,"Sex: MALE; Age: >20 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Japanese male in good health
* Body mass index (BMI) between 18.5 and 32.0 kg/m\^2
* Nonsmoker and has not used nicotine-containing products for over 3 months at the time of scr...",No,2019-05-12,FDA-60494,0.56,0.15,3.5,4.21,2019-05-15,2019-07-09,2023-01-07,0,Merck,82,Kenya,32.33333333333334,15,55,28,58,12,26,55,2,2,2,True,True,True,False,True,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Alendronate,AltName B,Drug,hiv,hiv,Phase 2,2017-01-01,"Sex: ALL; Age: >11 Years; Criteria: Inclusion Criteria (Version 2.0 of protocol):

* Documentation of HIV-1 infection
* HIV-infection acquired before puberty
* For participants receiving antiretroviral therapy, must have been on the sam...",No,2017-08-03,FDA-90514,4.41,0.98,21.0,26.39,2021-05-30,2022-05-23,2043-05-23,17,J&J,73,Kenya,63.0,87,44,77,34,88,48,55,1,3,2,True,False,True,True,False,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Highly active antiretroviral therapy (HAART),Molecule Z,Drug,hiv,hiv,Phase 4,2016-08-31,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Women age ≥ 18 years or who had attained the minimum age of independent consent, as defined by the local Institutional Review Board (IRB), and were willing and able to provide w...",Yes,2017-05-25,FDA-86047,0.56,0.15,3.5,4.21,2017-03-23,2017-05-17,2020-11-15,46,Gilead,3,South Africa,63.66666666666666,74,83,15,42,80,88,64,2,2,3,True,True,True,False,True,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine/tenofovir (FTC/TDF (Truvada®)),AltName B,Drug,hiv,hiv,Phase 2,2016-11-01,"Sex: MALE; Age: >15 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Willing and able to provide written informed consent;
* Male gender at birth;
* Age 15 years and 0 days through 17 years and 364 days, inclusive, at the time of signed informed ...",No,2017-01-30,FDA-36390,4.41,0.98,21.0,26.39,2021-03-30,2022-03-23,2043-03-23,26,Bayer,37,Senegal,29.66666666666667,74,17,3,47,5,32,55,1,2,3,False,True,False,False,True,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir (DTG),Product Alpha,Drug,hiv,hiv,Phase 2,2021-12-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability and willingness of participant or legal guardian/representative to provide informed consent.
* Weight ≥40 kg and a body mass index (BMI) of greater than 18.5 kg/m\^2.
* ...",No,2022-12-02,FDA-71515,4.41,0.98,21.0,26.39,2026-05-25,2027-05-18,2048-05-17,6,Gilead,88,South Africa,29.33333333333333,26,46,3,24,53,24,45,1,4,0,True,False,True,True,False,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Isoniazid (INH),Comp Beta,Drug,hiv,hiv,Phase 2,2021-12-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability and willingness of participant or legal guardian/representative to provide informed consent.
* Weight ≥40 kg and a body mass index (BMI) of greater than 18.5 kg/m\^2.
* ...",Yes,2022-12-01,FDA-87802,4.41,0.98,21.0,26.39,2026-05-25,2027-05-18,2048-05-17,90,Novartis,11,Kenya,52.0,54,64,0,39,88,67,45,1,2,2,True,False,False,True,False,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rifapentine (RPT),Product Alpha,Drug,hiv,hiv,Phase 2,2021-12-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability and willingness of participant or legal guardian/representative to provide informed consent.
* Weight ≥40 kg and a body mass index (BMI) of greater than 18.5 kg/m\^2.
* ...",Yes,2022-10-26,FDA-81321,4.41,0.98,21.0,26.39,2026-05-25,2027-05-18,2048-05-17,53,Merck,9,South Africa,68.0,76,8,36,92,98,98,45,2,2,1,True,True,False,True,True,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Antiretroviral Therapy (ART),Comp Beta,Drug,hiv,hiv,Phase 2,2021-12-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability and willingness of participant or legal guardian/representative to provide informed consent.
* Weight ≥40 kg and a body mass index (BMI) of greater than 18.5 kg/m\^2.
* ...",No,2022-11-17,FDA-76911,4.41,0.98,21.0,26.39,2026-05-25,2027-05-18,2048-05-17,1,Gilead,27,Senegal,52.66666666666666,43,70,81,38,24,60,45,1,2,2,True,False,True,False,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
All licensed antiretroviral medications,TradeName X,Drug,hiv,hiv,Phase 4,2022-07-27,"Sex: ALL; Age: >18 Years; Criteria: INCLUSION CRITERIA:

* Signed informed consent
* HIV infection documented by a plasma HIV RNA viral load, rapid HIV test or any licensed\* ELISA test; and confirmed by another test using a different m...",No,2023-04-14,FDA-31648,0.56,0.15,3.5,4.21,2023-02-16,2023-04-12,2026-10-11,21,Novartis,28,Kenya,53.33333333333334,26,97,73,22,36,66,64,2,3,2,True,True,True,False,True,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DOR/ISL,Molecule Z,Drug,hiv,hiv,Phase 3,2025-02-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Is HIV-1 positive with plasma Human Immunodeficiency Virus 1 (HIV-1) RNA \<50 copies/mL at screening.
* Has been receiving BIC/FTC/TAF therapy with documented viral suppression ...",Yes,2025-04-20,FDA-23944,2.62,0.32,5.0,7.94,2027-10-11,2028-02-05,2033-02-05,76,Pfizer,70,Senegal,54.0,44,94,21,67,85,13,36,0,2,2,False,False,True,False,False,False,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
BIC/FTC/TAF,Comp Beta,Drug,hiv,hiv,Phase 3,2025-02-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Is HIV-1 positive with plasma Human Immunodeficiency Virus 1 (HIV-1) RNA \<50 copies/mL at screening.
* Has been receiving BIC/FTC/TAF therapy with documented viral suppression ...",Yes,2026-02-05,FDA-16878,2.62,0.32,5.0,7.94,2027-10-11,2028-02-05,2033-02-05,80,Bayer,79,Kenya,62.5,75,54,78,29,96,43,55,1,3,2,True,False,False,True,True,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Aspirin 325mg,Molecule Z,Drug,hiv,hiv,Phase 2,2010-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. HIV-infected (by positive HIV Ab or detectable HIV RNA level)
2. No ART for at least previous 3 months
3. Ready to start or re-start ART (regimen pre-chosen by patient and prov...",Yes,2010-07-25,FDA-59399,4.41,0.98,21.0,26.39,2014-10-28,2015-10-21,2036-10-20,43,Bayer,2,Senegal,67.33333333333333,29,97,36,80,62,100,36,1,0,3,True,False,False,False,False,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Antiretroviral therapy (ART),GenName Y,Drug,hiv,hiv,Phase 2,2010-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. HIV-infected (by positive HIV Ab or detectable HIV RNA level)
2. No ART for at least previous 3 months
3. Ready to start or re-start ART (regimen pre-chosen by patient and prov...",Yes,2010-08-25,FDA-19660,4.41,0.98,21.0,26.39,2014-10-28,2015-10-21,2036-10-20,39,Novartis,80,Kenya,71.83333333333333,94,64,54,75,75,69,73,1,4,3,False,True,True,True,True,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine/tenofovir (FTC/TDF (Truvada®)),GenName Y,Drug,hiv,hiv,Phase 2,2015-11-01,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Willing and able to provide written informed consent;
* Male gender at birth;
* Age 18 years and 0 days through 22 years and 364 days, inclusive, at the time of signed informed ...",Yes,2016-01-31,FDA-36071,4.41,0.98,21.0,26.39,2020-03-29,2021-03-22,2042-03-22,94,J&J,74,Overall,35.83333333333334,61,3,6,63,58,24,45,1,2,2,False,True,False,True,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
HIV vaccine 732461,AltName A,Biological,hiv,hiv,Phase 2,2008-06-13,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* A male or female between and including 18-40 years at the time of first vaccination.
* Written informed consent obtained from the subject prior to any study procedure.
* Subject...",Yes,2009-05-16,FDA-42085,4.41,0.98,21.0,26.39,2012-11-09,2013-11-02,2034-11-02,28,Bayer,30,South Africa,66.5,73,48,37,82,61,98,27,1,1,1,False,True,True,False,False,False,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir,AltName A,Drug,hiv,hiv,Phase 3,2023-12-07,"Sex: ALL; Age: >28 Days; Criteria: Inclusion Criteria:

ALL PATIENTS:

* Children ≥28 days and \<18 years weighing ≥3kg with confirmed HIV-1 infection
* Parents/carers and children, where applicable, give informed written consent
* Gir...",No,2024-02-24,FDA-35301,2.62,0.32,5.0,7.94,2026-07-20,2026-11-14,2031-11-15,30,Pfizer,48,Kenya,68.33333333333333,13,60,100,67,91,79,55,0,3,3,False,False,True,True,True,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Standard of Care,Molecule Z,Drug,hiv,hiv,Phase 3,2023-12-07,"Sex: ALL; Age: >28 Days; Criteria: Inclusion Criteria:

ALL PATIENTS:

* Children ≥28 days and \<18 years weighing ≥3kg with confirmed HIV-1 infection
* Parents/carers and children, where applicable, give informed written consent
* Gir...",No,2024-08-01,FDA-93988,2.62,0.32,5.0,7.94,2026-07-20,2026-11-14,2031-11-15,12,Sanofi,19,South Africa,37.0,53,38,43,41,36,11,27,1,2,0,False,True,True,True,False,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DOR/ISL,AltName B,Drug,hiv,hiv,Phase 3,2024-08-26,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Is human immunodeficiency virus (HIV-1) positive
* Has been receiving continuous, stable oral 2-drug or 3-drug combination (± pharmacokinetic (PK) booster) with documented viral...",Yes,2025-07-18,FDA-71303,2.62,0.32,5.0,7.94,2027-04-09,2027-08-04,2032-08-04,15,Sanofi,34,South Africa,59.66666666666666,63,95,10,81,43,66,45,1,2,2,True,False,False,True,True,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ART,AltName A,Drug,hiv,hiv,Phase 3,2024-08-26,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Is human immunodeficiency virus (HIV-1) positive
* Has been receiving continuous, stable oral 2-drug or 3-drug combination (± pharmacokinetic (PK) booster) with documented viral...",No,2024-12-11,FDA-52151,2.62,0.32,5.0,7.94,2027-04-09,2027-08-04,2032-08-04,45,Pfizer,15,Overall,50.33333333333334,28,25,78,33,51,87,27,0,1,2,False,False,False,False,False,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Enfuvirtide,GenName Y,Drug,hiv,hiv,Phase 4,2009-12-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Individuals at least 16 years of age infected with HIV-1
* CD4 lymphocyte count less than equal to (\<=) 100 cells per cubic millimeter (cells/mm\^3) and HIV-1 ribonucleic acid ...",Yes,2010-06-25,FDA-24945,0.56,0.15,3.5,4.21,2010-06-23,2010-08-17,2014-02-15,76,J&J,82,Overall,30.33333333333333,73,26,47,5,9,22,64,2,3,2,True,True,False,True,True,False,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
tenofovir disoproxil fumarate,Comp Beta,Drug,hiv,hiv,Phase 2,2009-08-01,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Healthy biologic male (male at birth)
* 18-60 years of age
* HIV-1 negative by licensed, commercially available, FDA-approved whole blood rapid enzyme immunoassay (EIA) at scree...",No,2009-11-29,FDA-43180,4.41,0.98,21.0,26.39,2013-12-28,2014-12-21,2035-12-21,62,Bayer,74,Senegal,40.66666666666666,98,63,24,19,25,15,55,1,2,3,True,False,False,True,False,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Reformulated Raltegravir,AltName B,Drug,hiv,hiv,Phase 3,2016-12-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 positive
* Naïve to antiretroviral therapy including investigational antiretroviral agents
* Not of reproductive potential or, if of reproductive potential agrees to 1) tr...",Yes,2017-05-03,FDA-62472,2.62,0.32,5.0,7.94,2019-08-02,2019-11-27,2024-11-27,9,AstraZeneca,95,Overall,57.33333333333334,37,79,49,52,70,57,64,2,2,3,True,True,False,True,False,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,GenName Y,Drug,hiv,hiv,Phase 3,2016-12-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 positive
* Naïve to antiretroviral therapy including investigational antiretroviral agents
* Not of reproductive potential or, if of reproductive potential agrees to 1) tr...",No,2017-12-19,FDA-74975,2.62,0.32,5.0,7.94,2019-08-02,2019-11-27,2024-11-27,55,Pfizer,28,South Africa,47.16666666666666,84,60,37,13,37,52,36,1,1,2,True,False,False,False,True,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
TRUVADA™,TradeName X,Drug,hiv,hiv,Phase 3,2016-12-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 positive
* Naïve to antiretroviral therapy including investigational antiretroviral agents
* Not of reproductive potential or, if of reproductive potential agrees to 1) tr...",No,2017-12-01,FDA-76391,2.62,0.32,5.0,7.94,2019-08-02,2019-11-27,2024-11-27,1,AstraZeneca,36,Senegal,46.5,9,48,39,78,9,96,64,1,4,2,True,False,False,True,True,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
MK0518 (raltegravir),Product Alpha,Drug,hiv,hiv,Phase 3,2009-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient is at least 18 years of age
* Patient is Human Immunodeficiency Virus (HIV) positive
* Patient has documented Human Immunodeficiency Virus (HIV) RiboNucleic Acid (RNA) \...",Yes,2009-11-19,FDA-64189,2.62,0.32,5.0,7.94,2011-11-13,2012-03-09,2017-03-10,40,GSK,48,South Africa,69.16666666666667,95,70,27,78,88,57,27,0,1,2,False,False,False,False,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Comparator: KALETRA™ (lopinavir (+) ritonavir ),Comp Beta,Drug,hiv,hiv,Phase 3,2009-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient is at least 18 years of age
* Patient is Human Immunodeficiency Virus (HIV) positive
* Patient has documented Human Immunodeficiency Virus (HIV) RiboNucleic Acid (RNA) \...",No,2010-02-24,FDA-71359,2.62,0.32,5.0,7.94,2011-11-13,2012-03-09,2017-03-10,35,AstraZeneca,21,Kenya,9.5,4,4,2,4,4,39,55,1,3,2,True,False,True,True,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ABX464,Comp Beta,Drug,hiv,hiv,Phase 2,2018-01-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients infected with HIV;
* Patients with HIV plasma viral load ≤ 50 copies mL-1 during the 6 months prior to screening with a maximum of 2 blips during this period;
* Patient...",Yes,2018-06-27,FDA-69625,4.41,0.98,21.0,26.39,2022-06-09,2023-06-02,2044-06-01,20,Bayer,48,Senegal,56.33333333333334,52,41,48,81,88,28,27,1,1,1,True,False,False,False,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Proleukin,Molecule Z,Drug,hiv,hiv,Phase 3,2007-01-01,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

Subjects are eligible for this study if they have been on greater than or equal to 2 ART for greater than or equal to 4 months prior to randomization, with no change in the type...",Yes,2007-05-10,FDA-83269,2.62,0.32,5.0,7.94,2009-08-14,2009-12-09,2014-12-10,59,Merck,11,Overall,39.5,21,23,34,20,64,75,45,0,2,3,False,False,False,False,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,Comp Beta,Drug,hiv,hiv,Phase 4,2008-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Stable Renal Function defined as ≤20% (25% for normal renal function) difference between 2 measurements of serum creatinine obtained on 2 occasions separated by at least 2 weeks...",Yes,2009-10-24,FDA-34070,0.56,0.15,3.5,4.21,2009-05-24,2009-07-18,2013-01-16,1,Pfizer,17,South Africa,39.83333333333334,66,39,44,7,47,36,55,2,3,1,True,True,False,False,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,Product Alpha,Drug,hiv,hiv,Phase 4,2008-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Stable Renal Function defined as ≤20% (25% for normal renal function) difference between 2 measurements of serum creatinine obtained on 2 occasions separated by at least 2 weeks...",No,2009-04-12,FDA-51719,0.56,0.15,3.5,4.21,2009-05-24,2009-07-18,2013-01-16,55,Merck,43,Overall,31.16666666666667,53,55,5,12,19,43,45,1,3,1,False,True,True,False,True,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,AltName B,Drug,hiv,hiv,Phase 4,2008-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Stable Renal Function defined as ≤20% (25% for normal renal function) difference between 2 measurements of serum creatinine obtained on 2 occasions separated by at least 2 weeks...",No,2008-12-03,FDA-42330,0.56,0.15,3.5,4.21,2009-05-24,2009-07-18,2013-01-16,84,Sanofi,58,Senegal,30.33333333333333,4,28,14,29,61,46,55,1,3,2,False,True,True,False,True,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Saquinavir,TradeName X,Drug,hiv,hiv,Phase 4,2008-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Stable Renal Function defined as ≤20% (25% for normal renal function) difference between 2 measurements of serum creatinine obtained on 2 occasions separated by at least 2 weeks...",No,2009-05-03,FDA-89605,0.56,0.15,3.5,4.21,2009-05-24,2009-07-18,2013-01-16,73,Merck,89,Kenya,53.33333333333334,46,17,30,93,46,88,18,2,0,0,True,True,False,False,False,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,Product Alpha,Drug,hiv,hiv,Phase 4,2008-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Stable Renal Function defined as ≤20% (25% for normal renal function) difference between 2 measurements of serum creatinine obtained on 2 occasions separated by at least 2 weeks...",Yes,2009-04-27,FDA-87175,0.56,0.15,3.5,4.21,2009-05-24,2009-07-18,2013-01-16,18,Novartis,100,Kenya,45.66666666666666,64,36,9,26,91,48,73,1,3,4,True,False,True,True,False,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,GenName Y,Drug,hiv,hiv,Phase 4,2008-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Stable Renal Function defined as ≤20% (25% for normal renal function) difference between 2 measurements of serum creatinine obtained on 2 occasions separated by at least 2 weeks...",Yes,2009-10-07,FDA-89608,0.56,0.15,3.5,4.21,2009-05-24,2009-07-18,2013-01-16,94,AstraZeneca,44,Senegal,51.83333333333334,99,61,26,7,26,92,36,0,2,2,False,False,True,False,False,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Saquinavir,GenName Y,Drug,hiv,hiv,Phase 4,2008-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Stable Renal Function defined as ≤20% (25% for normal renal function) difference between 2 measurements of serum creatinine obtained on 2 occasions separated by at least 2 weeks...",Yes,2009-02-02,FDA-50848,0.56,0.15,3.5,4.21,2009-05-24,2009-07-18,2013-01-16,98,Novartis,30,South Africa,54.0,47,45,80,50,10,92,64,1,3,3,True,False,False,True,False,True,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,AltName B,Drug,hiv,hiv,Phase 4,2008-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Stable Renal Function defined as ≤20% (25% for normal renal function) difference between 2 measurements of serum creatinine obtained on 2 occasions separated by at least 2 weeks...",No,2009-06-11,FDA-16900,0.56,0.15,3.5,4.21,2009-05-24,2009-07-18,2013-01-16,76,AstraZeneca,3,Senegal,42.5,1,24,79,81,64,6,36,1,2,1,True,False,False,False,True,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,Product Alpha,Drug,hiv,hiv,Phase 4,2008-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Stable Renal Function defined as ≤20% (25% for normal renal function) difference between 2 measurements of serum creatinine obtained on 2 occasions separated by at least 2 weeks...",No,2009-10-05,FDA-51675,0.56,0.15,3.5,4.21,2009-05-24,2009-07-18,2013-01-16,7,GSK,42,South Africa,42.66666666666666,30,32,63,26,37,68,36,1,2,1,False,True,True,True,False,False,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Saquinavir,GenName Y,Drug,hiv,hiv,Phase 4,2008-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Stable Renal Function defined as ≤20% (25% for normal renal function) difference between 2 measurements of serum creatinine obtained on 2 occasions separated by at least 2 weeks...",No,2009-10-14,FDA-54443,0.56,0.15,3.5,4.21,2009-05-24,2009-07-18,2013-01-16,3,Merck,55,Overall,46.33333333333334,2,26,96,36,22,96,45,0,3,2,False,False,False,True,True,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,Comp Beta,Drug,hiv,hiv,Phase 4,2008-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Stable Renal Function defined as ≤20% (25% for normal renal function) difference between 2 measurements of serum creatinine obtained on 2 occasions separated by at least 2 weeks...",Yes,2009-08-10,FDA-93816,0.56,0.15,3.5,4.21,2009-05-24,2009-07-18,2013-01-16,97,Bayer,14,Senegal,58.16666666666666,10,83,4,84,94,74,45,0,3,2,False,False,True,True,False,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,Product Alpha,Drug,hiv,hiv,Phase 4,2008-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Stable Renal Function defined as ≤20% (25% for normal renal function) difference between 2 measurements of serum creatinine obtained on 2 occasions separated by at least 2 weeks...",Yes,2009-03-11,FDA-86564,0.56,0.15,3.5,4.21,2009-05-24,2009-07-18,2013-01-16,60,Gilead,85,Overall,48.16666666666666,4,87,13,29,68,88,45,2,1,2,True,True,False,False,True,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,Product Alpha,Drug,hiv,hiv,Phase 4,2008-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Stable Renal Function defined as ≤20% (25% for normal renal function) difference between 2 measurements of serum creatinine obtained on 2 occasions separated by at least 2 weeks...",No,2009-06-26,FDA-75577,0.56,0.15,3.5,4.21,2009-05-24,2009-07-18,2013-01-16,16,Sanofi,43,Overall,54.83333333333334,52,8,24,90,100,55,55,2,1,3,True,True,False,False,False,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,TradeName X,Drug,hiv,hiv,Phase 3,2010-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects with limited or no approved treatment options available to them due to resistance or intolerance;
* Subjects must be failing to achieve adequate virologic suppression o...",Yes,2011-05-28,FDA-32133,2.62,0.32,5.0,7.94,2013-04-14,2013-08-09,2018-08-10,37,GSK,6,Overall,31.16666666666667,62,5,30,35,11,44,64,1,3,3,False,True,True,False,True,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,Comp Beta,Drug,hiv,hiv,Phase 4,2019-03-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. 18 years old
2. Hepatitis C-infected without plans to undergo hepatitis C treatment for duration of the study
3. Human immunodeficiency virus (HIV) infected
4. Currently receiv...",No,2019-07-10,FDA-21158,0.56,0.15,3.5,4.21,2019-10-17,2019-12-11,2023-06-11,19,Bayer,82,South Africa,58.0,97,6,79,16,69,81,64,2,2,3,True,True,False,True,False,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg,AltName A,Drug,hiv,hiv,Phase 3,2011-03-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* citizen of Botswana 18-39 years old
* sexually active
* HIV uninfected
* Hepatitis B and C uninfected
* Calculated creatinine clearance \>= 60 mL/min
* hemoglobin \>= 8 gm/dL
* ...",No,2011-06-04,FDA-30531,2.62,0.32,5.0,7.94,2013-10-12,2014-02-06,2019-02-07,61,Novartis,90,Senegal,42.83333333333334,45,28,4,97,18,65,36,1,1,2,True,False,False,False,False,False,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"HPV vaccine for strains -6, -11, -16, and -18",TradeName X,Biological,hiv,hiv,Phase 2,2011-02-01,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

* Young women age 16 years and 0 days to 23 years and 364 days
* HIV-infection after the age of 9 years as documented by a positive result on any of the following licensed tests: ...",No,2011-03-14,FDA-27118,4.41,0.98,21.0,26.39,2015-06-30,2016-06-22,2037-06-22,17,Merck,24,Senegal,50.5,86,21,21,37,62,76,64,1,5,1,True,False,True,True,True,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ART,Comp Beta,Drug,hiv,hiv,Phase 2,2021-12-03,"Sex: ALL; Age: >96 Weeks; Criteria: Inclusion Criteria for PK Step\*:

* On ART for at least 96 weeks
* Greater than or equal to 96 weeks and less than 5 years of age at enrollment
* HIV RNA less than 40 copies/mL for at least 24 weeks ...",No,2022-07-31,FDA-77953,4.41,0.98,21.0,26.39,2026-05-01,2027-04-24,2048-04-23,27,Pfizer,29,Overall,36.33333333333334,55,22,72,5,9,55,45,1,3,1,True,False,True,True,False,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
VRC01LS,Product Alpha,Biological,hiv,hiv,Phase 2,2021-12-03,"Sex: ALL; Age: >96 Weeks; Criteria: Inclusion Criteria for PK Step\*:

* On ART for at least 96 weeks
* Greater than or equal to 96 weeks and less than 5 years of age at enrollment
* HIV RNA less than 40 copies/mL for at least 24 weeks ...",No,2022-04-17,FDA-28777,4.41,0.98,21.0,26.39,2026-05-01,2027-04-24,2048-04-23,69,Pfizer,90,South Africa,35.5,41,69,46,8,16,33,64,1,2,4,True,False,True,False,True,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
10-1074,GenName Y,Biological,hiv,hiv,Phase 2,2021-12-03,"Sex: ALL; Age: >96 Weeks; Criteria: Inclusion Criteria for PK Step\*:

* On ART for at least 96 weeks
* Greater than or equal to 96 weeks and less than 5 years of age at enrollment
* HIV RNA less than 40 copies/mL for at least 24 weeks ...",No,2022-09-06,FDA-37213,4.41,0.98,21.0,26.39,2026-05-01,2027-04-24,2048-04-23,6,GSK,22,South Africa,37.0,57,83,12,9,40,21,45,1,3,1,True,False,True,True,True,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir (ATV) 300 mg,Molecule Z,Drug,hiv,hiv,Phase 2,2012-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

\- Documented HIV-1 infection

* Failing on a stable ART (anti retroviral therapy) with HIV-1 plasma viral load above 500 HIV-1 RNA copies/ml
* Presence of at least 1 documented N...",Yes,2013-02-14,FDA-74875,4.41,0.98,21.0,26.39,2016-08-28,2017-08-21,2038-08-21,87,Bayer,13,Overall,51.0,74,50,77,33,10,62,36,2,0,2,True,True,False,False,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir (ATV) 400 mg,GenName Y,Drug,hiv,hiv,Phase 2,2012-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

\- Documented HIV-1 infection

* Failing on a stable ART (anti retroviral therapy) with HIV-1 plasma viral load above 500 HIV-1 RNA copies/ml
* Presence of at least 1 documented N...",Yes,2012-12-16,FDA-60378,4.41,0.98,21.0,26.39,2016-08-28,2017-08-21,2038-08-21,28,Bayer,63,South Africa,64.66666666666667,21,96,72,2,100,97,9,0,0,1,False,False,False,False,False,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir (rtv) 100 mg,AltName B,Drug,hiv,hiv,Phase 2,2012-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

\- Documented HIV-1 infection

* Failing on a stable ART (anti retroviral therapy) with HIV-1 plasma viral load above 500 HIV-1 RNA copies/ml
* Presence of at least 1 documented N...",No,2013-03-22,FDA-43913,4.41,0.98,21.0,26.39,2016-08-28,2017-08-21,2038-08-21,79,J&J,94,Overall,66.5,63,100,22,64,87,63,73,2,5,1,True,True,True,True,True,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs),AltName A,Drug,hiv,hiv,Phase 2,2012-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

\- Documented HIV-1 infection

* Failing on a stable ART (anti retroviral therapy) with HIV-1 plasma viral load above 500 HIV-1 RNA copies/ml
* Presence of at least 1 documented N...",No,2012-08-20,FDA-19132,4.41,0.98,21.0,26.39,2016-08-28,2017-08-21,2038-08-21,88,Pfizer,3,Senegal,49.83333333333334,70,81,57,2,41,48,64,1,4,2,True,False,True,True,False,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Etravirine (ETR) 200 mg,Product Alpha,Drug,hiv,hiv,Phase 2,2012-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

\- Documented HIV-1 infection

* Failing on a stable ART (anti retroviral therapy) with HIV-1 plasma viral load above 500 HIV-1 RNA copies/ml
* Presence of at least 1 documented N...",Yes,2012-08-18,FDA-55758,4.41,0.98,21.0,26.39,2016-08-28,2017-08-21,2038-08-21,96,J&J,61,Senegal,50.83333333333334,68,79,57,42,13,46,55,1,2,3,False,True,True,False,False,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir disoproxil fumarate (TDF) 300 mg,Comp Beta,Drug,hiv,hiv,Phase 2,2012-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

\- Documented HIV-1 infection

* Failing on a stable ART (anti retroviral therapy) with HIV-1 plasma viral load above 500 HIV-1 RNA copies/ml
* Presence of at least 1 documented N...",No,2012-11-17,FDA-34300,4.41,0.98,21.0,26.39,2016-08-28,2017-08-21,2038-08-21,90,Gilead,42,Senegal,46.16666666666666,56,28,62,93,5,33,55,2,2,2,True,True,False,True,False,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
atazanavir,AltName B,Drug,hiv,hiv,Phase 4,2015-12-01,"Sex: ALL; Age: >19 Years; Criteria: Inclusion Criteria:

1. HIV infected adults at least 19 years of age
2. Willing and able to provide informed consent to study participation
3. Currently receiving a regimen including atazanavir 300mg/...",No,2016-07-09,FDA-63546,0.56,0.15,3.5,4.21,2016-06-22,2016-08-16,2020-02-15,66,Sanofi,72,South Africa,52.33333333333334,56,81,38,9,59,71,64,2,4,1,True,True,False,True,True,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
atazanavir/ritonavir,AltName A,Drug,hiv,hiv,Phase 4,2015-12-01,"Sex: ALL; Age: >19 Years; Criteria: Inclusion Criteria:

1. HIV infected adults at least 19 years of age
2. Willing and able to provide informed consent to study participation
3. Currently receiving a regimen including atazanavir 300mg/...",Yes,2016-08-16,FDA-71514,0.56,0.15,3.5,4.21,2016-06-22,2016-08-16,2020-02-15,5,J&J,59,Kenya,61.33333333333334,91,62,53,43,83,36,9,0,1,0,False,False,False,False,True,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
emtricitabine/tenofovir,Product Alpha,Drug,hiv,hiv,Phase 4,2008-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

* Males as females at least 18 years old. (A female is eligible to enter and participate in this study if she is of: non child-bearing potential, child bearing potential with a ne...",No,2008-05-11,FDA-27419,0.56,0.15,3.5,4.21,2008-10-22,2008-12-16,2012-06-16,51,J&J,4,Senegal,60.16666666666666,87,89,73,1,69,42,45,0,4,1,False,False,True,False,True,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
abacavir/lamivudine,Product Alpha,Drug,hiv,hiv,Phase 4,2008-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

* Males as females at least 18 years old. (A female is eligible to enter and participate in this study if she is of: non child-bearing potential, child bearing potential with a ne...",No,2009-01-08,FDA-15951,0.56,0.15,3.5,4.21,2008-10-22,2008-12-16,2012-06-16,43,Bayer,29,Overall,34.16666666666666,26,18,52,94,3,12,73,2,4,2,True,True,True,True,True,False,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Dipyridamole,AltName A,Drug,hiv,hiv,Phase 2,2017-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a li...",No,2018-07-06,FDA-10365,4.41,0.98,21.0,26.39,2022-03-30,2023-03-23,2044-03-22,58,Novartis,1,Overall,30.16666666666667,75,24,9,29,36,8,55,1,2,3,False,True,False,True,True,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Teropavimab,Comp Beta,Drug,hiv,hiv,Phase 2,2029-12-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* On stable oral antiretroviral therapy (ART) consisting of no more than 2 drug classes (with the exception of pharmacologic boosters cobicistat or ritonavir) for ≥ 1 year pri...",No,2030-03-21,FDA-95831,4.41,0.98,21.0,26.39,2034-04-29,2035-04-22,2056-04-21,48,Merck,67,Kenya,53.33333333333334,100,1,27,85,84,23,45,2,2,1,True,True,True,False,False,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Zinlirvimab,Product Alpha,Drug,hiv,hiv,Phase 2,2029-12-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* On stable oral antiretroviral therapy (ART) consisting of no more than 2 drug classes (with the exception of pharmacologic boosters cobicistat or ritonavir) for ≥ 1 year pri...",Yes,2030-07-03,FDA-42564,4.41,0.98,21.0,26.39,2034-04-29,2035-04-22,2056-04-21,88,J&J,66,Senegal,28.5,3,70,2,16,72,8,64,2,2,3,True,True,False,True,False,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lenacapavir Tablet,AltName A,Drug,hiv,hiv,Phase 2,2029-12-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* On stable oral antiretroviral therapy (ART) consisting of no more than 2 drug classes (with the exception of pharmacologic boosters cobicistat or ritonavir) for ≥ 1 year pri...",Yes,2030-07-18,FDA-49395,4.41,0.98,21.0,26.39,2034-04-29,2035-04-22,2056-04-21,45,J&J,91,Kenya,59.66666666666666,2,32,89,90,80,65,36,1,2,1,True,False,False,False,True,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lenacapavir Injection,TradeName X,Drug,hiv,hiv,Phase 2,2029-12-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* On stable oral antiretroviral therapy (ART) consisting of no more than 2 drug classes (with the exception of pharmacologic boosters cobicistat or ritonavir) for ≥ 1 year pri...",No,2030-07-08,FDA-39801,4.41,0.98,21.0,26.39,2034-04-29,2035-04-22,2056-04-21,25,Merck,66,South Africa,54.16666666666666,7,56,51,53,79,79,82,2,4,3,True,True,True,True,True,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Antiretroviral Therapy,GenName Y,Drug,hiv,hiv,Phase 2,2029-12-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* On stable oral antiretroviral therapy (ART) consisting of no more than 2 drug classes (with the exception of pharmacologic boosters cobicistat or ritonavir) for ≥ 1 year pri...",Yes,2030-11-10,FDA-29555,4.41,0.98,21.0,26.39,2034-04-29,2035-04-22,2056-04-21,27,Novartis,3,Senegal,60.33333333333334,46,74,44,87,80,31,55,1,2,3,False,True,False,True,False,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Zoledronic acid,TradeName X,Drug,hiv,hiv,Phase 2,2017-04-13,"Sex: ALL; Age: >30 Years; Criteria: Inclusion Criteria:

1. HIV-1 infection, as documented by any licensed serologic test and confirmed by a western blot or by a positive plasma HIV-1 RNA performed by any laboratory that has a Clinical ...",Yes,2017-07-07,FDA-49523,4.41,0.98,21.0,26.39,2021-09-09,2022-09-02,2043-09-02,73,Gilead,81,Overall,53.66666666666666,70,16,9,67,79,81,45,1,3,1,True,False,False,False,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
COBI,Product Alpha,Drug,hiv,hiv,Phase 3,2015-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult ≥ 18 years males or non-pregnant females
* Ability to understand and sign a written informed consent form
* General medical condition that does not interfere with the asse...",No,2015-11-11,FDA-95349,2.62,0.32,5.0,7.94,2018-05-14,2018-09-08,2023-09-09,40,Pfizer,81,South Africa,50.83333333333334,86,4,80,60,14,61,55,1,3,2,True,False,True,False,False,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
DRV,Comp Beta,Drug,hiv,hiv,Phase 3,2015-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult ≥ 18 years males or non-pregnant females
* Ability to understand and sign a written informed consent form
* General medical condition that does not interfere with the asse...",Yes,2016-07-19,FDA-74694,2.62,0.32,5.0,7.94,2018-05-14,2018-09-08,2023-09-09,68,GSK,19,Senegal,53.0,30,77,91,36,27,57,55,2,3,1,True,True,True,False,False,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
NRTIs,TradeName X,Drug,hiv,hiv,Phase 3,2015-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult ≥ 18 years males or non-pregnant females
* Ability to understand and sign a written informed consent form
* General medical condition that does not interfere with the asse...",Yes,2016-09-03,FDA-98439,2.62,0.32,5.0,7.94,2018-05-14,2018-09-08,2023-09-09,96,Pfizer,28,Senegal,74.66666666666667,83,80,86,27,83,89,45,0,3,2,False,False,True,False,True,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Atripla (r),Molecule Z,Drug,hiv,hiv,Phase 4,2016-04-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Willingness to start efavirenz-based ART as soon as possible and within no more than 3 days following randomization.
* CD4+ cell count \<50 cells/mm\^3 obtaine...",No,2016-11-14,FDA-88400,0.56,0.15,3.5,4.21,2016-10-22,2016-12-16,2020-06-16,89,Pfizer,84,Overall,31.33333333333333,19,21,19,82,32,15,27,1,1,1,True,False,False,False,False,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,AltName B,Drug,hiv,hiv,Phase 4,2016-04-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Willingness to start efavirenz-based ART as soon as possible and within no more than 3 days following randomization.
* CD4+ cell count \<50 cells/mm\^3 obtaine...",No,2016-10-31,FDA-34298,0.56,0.15,3.5,4.21,2016-10-22,2016-12-16,2020-06-16,82,Pfizer,89,Senegal,54.66666666666666,53,51,100,20,14,90,18,1,1,0,True,False,True,False,False,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada,Molecule Z,Drug,hiv,hiv,Phase 4,2016-04-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Willingness to start efavirenz-based ART as soon as possible and within no more than 3 days following randomization.
* CD4+ cell count \<50 cells/mm\^3 obtaine...",No,2017-02-15,FDA-39736,0.56,0.15,3.5,4.21,2016-10-22,2016-12-16,2020-06-16,63,Merck,50,South Africa,57.16666666666666,27,37,90,37,64,88,45,2,1,2,True,True,False,False,False,False,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rifampin/isoniazid/pyrazinamide/ethambutol FDC,Molecule Z,Drug,hiv,hiv,Phase 4,2016-04-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Willingness to start efavirenz-based ART as soon as possible and within no more than 3 days following randomization.
* CD4+ cell count \<50 cells/mm\^3 obtaine...",Yes,2016-12-03,FDA-69394,0.56,0.15,3.5,4.21,2016-10-22,2016-12-16,2020-06-16,70,Pfizer,67,South Africa,56.83333333333334,93,38,43,100,56,11,82,2,4,3,True,True,True,True,False,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Rifampin/isoniazid FDC,GenName Y,Drug,hiv,hiv,Phase 4,2016-04-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Willingness to start efavirenz-based ART as soon as possible and within no more than 3 days following randomization.
* CD4+ cell count \<50 cells/mm\^3 obtaine...",No,2016-09-03,FDA-28193,0.56,0.15,3.5,4.21,2016-10-22,2016-12-16,2020-06-16,23,AstraZeneca,26,Kenya,41.83333333333334,22,70,39,7,62,51,45,2,2,1,True,True,False,False,False,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Isoniazid,TradeName X,Drug,hiv,hiv,Phase 4,2016-04-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Willingness to start efavirenz-based ART as soon as possible and within no more than 3 days following randomization.
* CD4+ cell count \<50 cells/mm\^3 obtaine...",Yes,2016-09-01,FDA-84625,0.56,0.15,3.5,4.21,2016-10-22,2016-12-16,2020-06-16,41,Sanofi,23,Senegal,49.5,79,37,32,86,32,31,18,0,2,0,False,False,False,False,True,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
raltegravir,AltName A,Drug,hiv,hiv,Phase 3,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

The major single criterion for inclusion into the study will be the presence of confirmed acute/early HIV-1 infection, as defined by one of the three following criteria:

1. Posit...",Yes,2015-08-27,FDA-10956,2.62,0.32,5.0,7.94,2017-04-14,2017-08-09,2022-08-10,98,Novartis,0,Kenya,61.66666666666666,43,82,40,34,98,73,36,0,3,1,False,False,True,False,False,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
maraviroc,Molecule Z,Drug,hiv,hiv,Phase 3,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

The major single criterion for inclusion into the study will be the presence of confirmed acute/early HIV-1 infection, as defined by one of the three following criteria:

1. Posit...",No,2014-10-04,FDA-25010,2.62,0.32,5.0,7.94,2017-04-14,2017-08-09,2022-08-10,98,Sanofi,29,Kenya,60.5,63,66,89,49,8,88,27,0,2,1,False,False,False,False,False,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
emtricitabine 200mg /tenofovir 300mg,TradeName X,Drug,hiv,hiv,Phase 3,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

The major single criterion for inclusion into the study will be the presence of confirmed acute/early HIV-1 infection, as defined by one of the three following criteria:

1. Posit...",No,2015-02-08,FDA-33144,2.62,0.32,5.0,7.94,2017-04-14,2017-08-09,2022-08-10,26,Bayer,14,Senegal,66.33333333333333,94,45,84,11,77,87,64,2,2,3,True,True,False,False,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
lopinavir 400 mg/ritonavir 100mg,GenName Y,Drug,hiv,hiv,Phase 3,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

The major single criterion for inclusion into the study will be the presence of confirmed acute/early HIV-1 infection, as defined by one of the three following criteria:

1. Posit...",Yes,2014-12-08,FDA-41124,2.62,0.32,5.0,7.94,2017-04-14,2017-08-09,2022-08-10,27,Bayer,45,Overall,47.0,86,33,21,61,54,27,73,1,4,3,False,True,True,True,False,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
dolutegravir,TradeName X,Drug,hiv,hiv,Phase 3,2017-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 Infection
* HIV-1 RNA \<50 copies/mL on all measurements within 48 weeks prior to study entry while on any DHHS recommended or alternative three-drug antiretroviral regime...",Yes,2018-07-07,FDA-91464,2.62,0.32,5.0,7.94,2020-04-14,2020-08-09,2025-08-10,76,Novartis,24,Overall,52.66666666666666,28,81,42,87,63,15,64,1,4,2,True,False,True,False,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
lamivudine,AltName B,Drug,hiv,hiv,Phase 3,2017-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 Infection
* HIV-1 RNA \<50 copies/mL on all measurements within 48 weeks prior to study entry while on any DHHS recommended or alternative three-drug antiretroviral regime...",Yes,2018-02-14,FDA-47112,2.62,0.32,5.0,7.94,2020-04-14,2020-08-09,2025-08-10,46,GSK,39,Overall,50.83333333333334,75,5,37,54,34,100,73,2,3,3,True,True,True,False,False,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Continue current antiretroviral regimen,AltName A,Drug,hiv,hiv,Phase 3,2017-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 Infection
* HIV-1 RNA \<50 copies/mL on all measurements within 48 weeks prior to study entry while on any DHHS recommended or alternative three-drug antiretroviral regime...",Yes,2018-03-30,FDA-64374,2.62,0.32,5.0,7.94,2020-04-14,2020-08-09,2025-08-10,24,Sanofi,65,Kenya,57.33333333333334,73,26,67,80,89,9,55,1,2,3,True,False,True,False,False,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ritonavir,GenName Y,Drug,hiv,hiv,Phase 2,2008-10-01,"Sex: ALL; Age: >2 Years; Criteria: * Inclusion Criteria:
* Male or females 2 to 18 years of age
* A female is eligible to enter and participate in this study if she is of:
* a. non-childbearing potential (i.e., physiologically incapabl...",No,2009-07-12,FDA-88414,4.41,0.98,21.0,26.39,2013-02-27,2014-02-20,2035-02-20,0,Gilead,27,Senegal,42.16666666666666,84,5,20,53,51,40,55,0,5,1,False,False,True,True,True,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
fosamprenavir,Product Alpha,Drug,hiv,hiv,Phase 2,2008-10-01,"Sex: ALL; Age: >2 Years; Criteria: * Inclusion Criteria:
* Male or females 2 to 18 years of age
* A female is eligible to enter and participate in this study if she is of:
* a. non-childbearing potential (i.e., physiologically incapabl...",No,2009-08-24,FDA-15214,4.41,0.98,21.0,26.39,2013-02-27,2014-02-20,2035-02-20,18,GSK,98,Kenya,29.5,3,10,6,3,91,64,73,1,5,2,False,True,True,True,True,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Comparator: raltegravir,Molecule Z,Drug,hiv,hiv,Phase 3,2011-02-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Patient is HIV positive
* Patient agrees to use (or have their partner use) birth control as defined by the study doctor

Exclusion Criteria:

* If female, pregnant or breastfee...",No,2011-05-24,FDA-51783,2.62,0.32,5.0,7.94,2013-09-14,2014-01-09,2019-01-10,10,GSK,77,Kenya,49.0,21,87,82,40,13,51,64,0,5,2,False,False,True,True,True,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Metformin,Product Alpha,Drug,hiv,hiv,Phase 4,2014-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Age 18-70 years
* Fasting insulin \>12 μU/mL and/or serum glucose between 140-200 mg/dl after 75 g 2hr oral glucose tolerance test
* Central fat deposition or Peripheral fat atr...",No,2015-01-19,FDA-52200,0.56,0.15,3.5,4.21,2015-05-24,2015-07-18,2019-01-16,90,GSK,73,Senegal,39.33333333333334,49,7,41,31,15,93,55,0,3,3,False,False,False,True,True,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Pioglitazone,Product Alpha,Drug,hiv,hiv,Phase 4,2014-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Age 18-70 years
* Fasting insulin \>12 μU/mL and/or serum glucose between 140-200 mg/dl after 75 g 2hr oral glucose tolerance test
* Central fat deposition or Peripheral fat atr...",Yes,2015-02-09,FDA-17837,0.56,0.15,3.5,4.21,2015-05-24,2015-07-18,2019-01-16,12,GSK,21,South Africa,37.83333333333334,59,67,31,35,18,17,45,1,3,1,True,False,False,True,True,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF),Molecule Z,Drug,hiv,hiv,Phase 4,2011-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult (greater than or equal to 18 years) males or non-pregnant, non-lactating females
* HIV-1 infected subjects currently receiving a ritonavir-boosted protease inhibitor and f...",No,2011-11-01,FDA-43853,0.56,0.15,3.5,4.21,2011-10-22,2011-12-16,2015-06-16,76,Pfizer,43,Overall,23.5,11,35,22,38,28,7,45,1,2,2,False,True,False,False,False,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
abacavir (ABC)/lamivudine (3TC),AltName B,Drug,hiv,hiv,Phase 4,2011-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult (greater than or equal to 18 years) males or non-pregnant, non-lactating females
* HIV-1 infected subjects currently receiving a ritonavir-boosted protease inhibitor and f...",No,2012-01-12,FDA-55683,0.56,0.15,3.5,4.21,2011-10-22,2011-12-16,2015-06-16,32,GSK,95,South Africa,55.66666666666666,95,95,40,3,30,71,64,1,3,3,False,True,True,False,False,True,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Pentamidine,AltName B,Drug,hiv,hiv,Phase 3,2015-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients diagnosed with Visceral Leishmaniosis (VL) during the recruitment period that are EITHER treated for VL relapse and have a documented negative test of cure (TOC), OR ar...",Yes,2016-05-17,FDA-36316,2.62,0.32,5.0,7.94,2018-06-14,2018-10-09,2023-10-10,2,Bayer,67,Overall,50.0,70,7,48,45,97,33,55,0,4,2,False,False,True,True,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Atorvastatin,AltName A,Drug,hiv,hiv,Phase 4,2017-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Chronic HIV-1 infected individuals presently on HAART with no change in drug combination for at least 3 months at time of enrollment
2. Plasma viral load \<200 copies / ml for ...",Yes,2018-02-24,FDA-49363,0.56,0.15,3.5,4.21,2018-04-23,2018-06-17,2021-12-16,59,GSK,1,South Africa,50.5,85,82,47,11,20,58,36,1,1,2,True,False,False,True,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
daily TDF/FTC,AltName A,Drug,hiv,hiv,Phase 3,2014-02-01,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Male sex (at birth)
* HIV uninfected
* Age having reached the local age of consent
* High risk for HIV infection including any of the following: 1) No condom use during anal int...",No,2014-06-21,FDA-58088,2.62,0.32,5.0,7.94,2016-09-14,2017-01-09,2022-01-10,80,GSK,17,Senegal,53.33333333333334,63,61,53,84,14,45,36,1,2,1,False,True,True,False,False,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atripla or Stribild,Molecule Z,Drug,hiv,hiv,Phase 4,2021-06-30,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Adult men who have sex with men, and transgender women
* Unaware of HIV status at enrollment in follow-up cohort
* High risk for HIV infection
* Willing to test for HIV
* No pri...",Yes,2021-11-23,FDA-15428,0.56,0.15,3.5,4.21,2022-01-20,2022-03-16,2025-09-14,64,Bayer,88,Kenya,49.33333333333334,32,5,15,99,94,51,45,0,2,3,False,False,False,True,False,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine/tenofovir disoproxil fumarate,Comp Beta,Drug,hiv,hiv,Phase 3,2013-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected
* No evidence of any exclusionary mutations defined as any major NRTI or PI resistance-associated mutation on any genotype or evidence of significant NRTI or PI r...",Yes,2014-02-01,FDA-16466,2.62,0.32,5.0,7.94,2016-01-13,2016-05-09,2021-05-10,83,Novartis,40,Kenya,46.5,20,7,83,10,71,88,27,0,2,1,False,False,False,True,True,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,Product Alpha,Drug,hiv,hiv,Phase 3,2013-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected
* No evidence of any exclusionary mutations defined as any major NRTI or PI resistance-associated mutation on any genotype or evidence of significant NRTI or PI r...",No,2014-01-21,FDA-24019,2.62,0.32,5.0,7.94,2016-01-13,2016-05-09,2021-05-10,56,AstraZeneca,56,Senegal,48.16666666666666,33,78,91,6,3,78,45,1,3,1,True,False,True,True,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Darunavir,Product Alpha,Drug,hiv,hiv,Phase 3,2013-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected
* No evidence of any exclusionary mutations defined as any major NRTI or PI resistance-associated mutation on any genotype or evidence of significant NRTI or PI r...",No,2013-12-27,FDA-15996,2.62,0.32,5.0,7.94,2016-01-13,2016-05-09,2021-05-10,56,Merck,65,Kenya,62.83333333333334,78,14,98,80,16,91,55,2,1,3,True,True,True,False,False,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,Product Alpha,Drug,hiv,hiv,Phase 3,2013-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected
* No evidence of any exclusionary mutations defined as any major NRTI or PI resistance-associated mutation on any genotype or evidence of significant NRTI or PI r...",Yes,2013-12-06,FDA-80551,2.62,0.32,5.0,7.94,2016-01-13,2016-05-09,2021-05-10,98,Bayer,71,Kenya,52.66666666666666,13,99,35,75,36,58,73,1,4,3,True,False,True,True,False,True,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir,Comp Beta,Drug,hiv,hiv,Phase 3,2013-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected
* No evidence of any exclusionary mutations defined as any major NRTI or PI resistance-associated mutation on any genotype or evidence of significant NRTI or PI r...",Yes,2013-09-28,FDA-23088,2.62,0.32,5.0,7.94,2016-01-13,2016-05-09,2021-05-10,43,Sanofi,98,Overall,49.83333333333334,75,6,21,72,77,48,55,1,1,4,False,True,False,True,False,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Arm A: ABC+3TC+NNRTI,GenName Y,Drug,hiv,hiv,Phase 4,2012-06-01,"Sex: ALL; Age: >3 Months; Criteria: For initial randomisation to CDM vs LCM, and to ART induction strategy:

Inclusion Criteria:

1. Children should have an adult carer in the household who is either:

   * participating in the DART tri...",Yes,2012-10-31,FDA-47583,0.56,0.15,3.5,4.21,2012-12-22,2013-02-15,2016-08-16,35,Bayer,83,Overall,42.5,33,64,25,54,39,40,45,1,3,1,False,True,False,True,True,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance,Product Alpha,Drug,hiv,hiv,Phase 4,2012-06-01,"Sex: ALL; Age: >3 Months; Criteria: For initial randomisation to CDM vs LCM, and to ART induction strategy:

Inclusion Criteria:

1. Children should have an adult carer in the household who is either:

   * participating in the DART tri...",Yes,2012-07-11,FDA-36182,0.56,0.15,3.5,4.21,2012-12-22,2013-02-15,2016-08-16,59,Merck,63,South Africa,43.33333333333334,87,3,62,54,42,12,64,2,3,2,True,True,True,False,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance,AltName A,Drug,hiv,hiv,Phase 4,2012-06-01,"Sex: ALL; Age: >3 Months; Criteria: For initial randomisation to CDM vs LCM, and to ART induction strategy:

Inclusion Criteria:

1. Children should have an adult carer in the household who is either:

   * participating in the DART tri...",No,2012-08-03,FDA-59344,0.56,0.15,3.5,4.21,2012-12-22,2013-02-15,2016-08-16,77,Novartis,99,South Africa,56.5,73,48,40,17,74,87,27,1,0,2,False,True,False,False,False,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Once-daily ABC+3TC,AltName B,Drug,hiv,hiv,Phase 4,2012-06-01,"Sex: ALL; Age: >3 Months; Criteria: For initial randomisation to CDM vs LCM, and to ART induction strategy:

Inclusion Criteria:

1. Children should have an adult carer in the household who is either:

   * participating in the DART tri...",Yes,2013-01-15,FDA-12390,0.56,0.15,3.5,4.21,2012-12-22,2013-02-15,2016-08-16,34,Novartis,58,Overall,40.0,97,68,29,13,22,11,18,0,2,0,False,False,False,False,True,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Twice-daily ABC+3TC,TradeName X,Drug,hiv,hiv,Phase 4,2012-06-01,"Sex: ALL; Age: >3 Months; Criteria: For initial randomisation to CDM vs LCM, and to ART induction strategy:

Inclusion Criteria:

1. Children should have an adult carer in the household who is either:

   * participating in the DART tri...",Yes,2013-04-11,FDA-29402,0.56,0.15,3.5,4.21,2012-12-22,2013-02-15,2016-08-16,43,Sanofi,21,Overall,45.83333333333334,70,73,40,43,47,2,27,0,2,1,False,False,False,False,True,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Continued cotrimoxazole prophylaxis,TradeName X,Drug,hiv,hiv,Phase 4,2012-06-01,"Sex: ALL; Age: >3 Months; Criteria: For initial randomisation to CDM vs LCM, and to ART induction strategy:

Inclusion Criteria:

1. Children should have an adult carer in the household who is either:

   * participating in the DART tri...",Yes,2013-03-24,FDA-91327,0.56,0.15,3.5,4.21,2012-12-22,2013-02-15,2016-08-16,84,J&J,56,South Africa,65.83333333333333,64,92,60,83,23,73,36,1,2,1,False,True,False,True,False,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Recombinant interleukin-2 (rIL-2),AltName A,Drug,hiv,hiv,Phase 3,2008-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV positive
* Have a CD4 cell count of 300 cells/mm3 or more within 45 days of study entry
* Are on combination anti-HIV therapy or are beginning anti-HIV therapy at the time o...",No,2009-05-24,FDA-87665,2.62,0.32,5.0,7.94,2011-06-15,2011-10-10,2016-10-10,86,Novartis,23,South Africa,48.83333333333334,51,15,98,69,51,9,73,2,4,2,True,True,True,True,True,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
cisplatin,Product Alpha,Drug,hiv,hiv,Phase 2,2017-04-20,"Sex: FEMALE; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Participants (who have been adequately clinically staged by standard clinical guidelines) with primary, untreated, histologically confirmed, documented invasive squamous ce...",Yes,2018-03-19,FDA-28684,4.41,0.98,21.0,26.39,2021-09-16,2022-09-09,2043-09-09,1,Novartis,70,Senegal,69.5,42,73,39,90,77,96,36,1,1,2,True,False,True,False,False,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Standard-dose Lopinavir/Ritonavir,Molecule Z,Drug,hiv,hiv,Phase 2,2017-06-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+/CD8+ T-cell count obtained within 30 days prior to study entry
* Confirmed or probable pulmonary or extrapulmonary TB (more information on the criterion c...",No,2017-09-24,FDA-30533,4.41,0.98,21.0,26.39,2021-11-24,2022-11-17,2043-11-17,32,Novartis,2,Kenya,52.5,41,86,61,8,70,49,73,2,4,2,True,True,True,True,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Double-dose Lopinavir/Ritonavir,Product Alpha,Drug,hiv,hiv,Phase 2,2017-06-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+/CD8+ T-cell count obtained within 30 days prior to study entry
* Confirmed or probable pulmonary or extrapulmonary TB (more information on the criterion c...",No,2017-11-10,FDA-43950,4.41,0.98,21.0,26.39,2021-11-24,2022-11-17,2043-11-17,16,Merck,53,Overall,51.0,35,38,3,52,97,81,64,1,3,3,False,True,False,True,True,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,Molecule Z,Drug,hiv,hiv,Phase 2,2017-06-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+/CD8+ T-cell count obtained within 30 days prior to study entry
* Confirmed or probable pulmonary or extrapulmonary TB (more information on the criterion c...",No,2017-12-01,FDA-98569,4.41,0.98,21.0,26.39,2021-11-24,2022-11-17,2043-11-17,4,J&J,25,Senegal,44.33333333333334,47,47,54,63,1,54,55,1,3,2,True,False,True,True,False,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Isoniazid,Molecule Z,Drug,hiv,hiv,Phase 2,2017-06-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+/CD8+ T-cell count obtained within 30 days prior to study entry
* Confirmed or probable pulmonary or extrapulmonary TB (more information on the criterion c...",Yes,2017-10-25,FDA-78205,4.41,0.98,21.0,26.39,2021-11-24,2022-11-17,2043-11-17,98,Merck,91,Overall,38.5,4,63,100,58,1,5,64,2,2,3,True,True,False,False,True,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Pyridoxine,Molecule Z,Drug,hiv,hiv,Phase 2,2017-06-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+/CD8+ T-cell count obtained within 30 days prior to study entry
* Confirmed or probable pulmonary or extrapulmonary TB (more information on the criterion c...",Yes,2017-12-31,FDA-52145,4.41,0.98,21.0,26.39,2021-11-24,2022-11-17,2043-11-17,31,Merck,72,Senegal,22.33333333333333,30,2,19,75,1,7,82,2,5,2,True,True,True,True,True,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Pyrazinamide,GenName Y,Drug,hiv,hiv,Phase 2,2017-06-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+/CD8+ T-cell count obtained within 30 days prior to study entry
* Confirmed or probable pulmonary or extrapulmonary TB (more information on the criterion c...",Yes,2018-03-05,FDA-14633,4.41,0.98,21.0,26.39,2021-11-24,2022-11-17,2043-11-17,43,Novartis,87,South Africa,45.33333333333334,78,7,45,49,45,48,45,0,3,2,False,False,False,True,True,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ethambutol,AltName A,Drug,hiv,hiv,Phase 2,2017-06-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+/CD8+ T-cell count obtained within 30 days prior to study entry
* Confirmed or probable pulmonary or extrapulmonary TB (more information on the criterion c...",No,2017-12-26,FDA-15686,4.41,0.98,21.0,26.39,2021-11-24,2022-11-17,2043-11-17,67,Sanofi,66,South Africa,39.66666666666666,8,17,38,34,69,72,55,1,2,3,True,False,True,False,False,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Rifabutin,AltName B,Drug,hiv,hiv,Phase 2,2017-06-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+/CD8+ T-cell count obtained within 30 days prior to study entry
* Confirmed or probable pulmonary or extrapulmonary TB (more information on the criterion c...",No,2018-06-17,FDA-46059,4.41,0.98,21.0,26.39,2021-11-24,2022-11-17,2043-11-17,21,Pfizer,100,Overall,50.0,38,30,23,53,98,58,55,1,3,2,True,False,True,False,True,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rifampin,Product Alpha,Drug,hiv,hiv,Phase 2,2017-06-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+/CD8+ T-cell count obtained within 30 days prior to study entry
* Confirmed or probable pulmonary or extrapulmonary TB (more information on the criterion c...",No,2017-12-23,FDA-33519,4.41,0.98,21.0,26.39,2021-11-24,2022-11-17,2043-11-17,66,Merck,94,Kenya,49.5,89,32,14,74,15,73,55,1,3,2,False,True,False,True,True,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
NNRTI,AltName A,Drug,hiv,hiv,Phase 3,2014-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* Be stable on the current formulation(s) of an antiretroviral regimen consisting of an NNRTI plus FTC/TDF for ≥ 6...",No,2015-11-10,FDA-90545,2.62,0.32,5.0,7.94,2017-07-14,2017-11-08,2022-11-09,69,Sanofi,79,Kenya,55.5,64,61,70,21,36,81,64,1,3,3,False,True,True,False,False,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TDF,Molecule Z,Drug,hiv,hiv,Phase 3,2014-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* Be stable on the current formulation(s) of an antiretroviral regimen consisting of an NNRTI plus FTC/TDF for ≥ 6...",Yes,2015-06-16,FDA-21858,2.62,0.32,5.0,7.94,2017-07-14,2017-11-08,2022-11-09,71,Novartis,43,Overall,70.16666666666667,97,73,88,59,13,91,36,0,2,2,False,False,True,True,False,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Stribild,AltName B,Drug,hiv,hiv,Phase 3,2014-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* Be stable on the current formulation(s) of an antiretroviral regimen consisting of an NNRTI plus FTC/TDF for ≥ 6...",Yes,2015-10-25,FDA-23303,2.62,0.32,5.0,7.94,2017-07-14,2017-11-08,2022-11-09,82,GSK,8,Senegal,63.66666666666666,10,62,85,52,84,89,55,0,2,4,False,False,False,True,True,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"efavirenz, emtricitabine, and tenofovir",AltName A,Drug,hiv,hiv,Phase 4,2013-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Diagnosis of acute HIV infection as defined by protocol.
2. The following laboratory parameters verified within 30 days of study entry:

   * Bilirubin \</= 3.0mg/dL
   * ALT/A...",No,2014-07-06,FDA-59363,0.56,0.15,3.5,4.21,2014-06-23,2014-08-17,2018-02-15,17,J&J,63,Senegal,37.0,17,92,77,12,12,12,55,1,3,2,True,False,True,True,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Cabotegravir Injectable Suspension,AltName A,Drug,hiv,hiv,Phase 4,2025-01-30,"Sex: ALL; Age: >15 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

Inclusion criteria for the Extension include:

1. Enrollment in a SEARCH Sapphire Dynamic prevention study (NCT04810650)
2. HIV negative at start of extension
3. Residing in study...",No,2026-01-28,FDA-10787,0.56,0.15,3.5,4.21,2025-08-22,2025-10-16,2029-04-16,94,GSK,52,Senegal,40.5,43,28,32,84,10,46,36,1,1,2,True,False,False,True,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Elvitegravir,Product Alpha,Drug,hiv,hiv,Phase 3,2015-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening
* Documented resistance or at least six months experience prior to screening with two or more different classes of antiret...",Yes,2016-01-13,FDA-69020,2.62,0.32,5.0,7.94,2017-11-12,2018-03-09,2023-03-10,38,Merck,99,Overall,66.0,70,85,28,52,86,75,36,0,3,1,False,False,False,False,True,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,AltName B,Drug,hiv,hiv,Phase 3,2015-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening
* Documented resistance or at least six months experience prior to screening with two or more different classes of antiret...",No,2015-08-01,FDA-11947,2.62,0.32,5.0,7.94,2017-11-12,2018-03-09,2023-03-10,15,Sanofi,12,South Africa,61.83333333333334,28,95,21,98,70,59,55,2,3,1,True,True,False,True,True,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Background regimen,TradeName X,Drug,hiv,hiv,Phase 3,2015-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening
* Documented resistance or at least six months experience prior to screening with two or more different classes of antiret...",No,2015-08-24,FDA-32517,2.62,0.32,5.0,7.94,2017-11-12,2018-03-09,2023-03-10,26,Novartis,11,Senegal,44.33333333333334,30,97,67,13,14,45,64,2,2,3,True,True,False,False,True,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
zidovudine 300mg and lamivudine 150mg as Combivir,AltName A,Drug,hiv,hiv,Phase 4,2010-07-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Documented physician-diagnosed HIV-infection (HIV+ antibody or plasma HIV-RNA+); HIV-negative volunteers must have a negative HIV-ELISA.
* Age 18 to 55 years;
* Either antiretro...",Yes,2011-06-20,FDA-72723,0.56,0.15,3.5,4.21,2011-01-21,2011-03-17,2014-09-15,92,Gilead,93,South Africa,43.16666666666666,21,50,28,8,74,78,64,2,4,1,True,True,True,False,True,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
EVG/COBI/FTC/TDF,Product Alpha,Drug,hiv,hiv,Phase 3,2018-01-29,"Sex: ALL; Age: >12 Years; Criteria: Key Inclusion Criteria:

* 12 years to \< 18 years of age at baseline
* Able to give written assent prior to any screening evaluations
* Parent or guardian able to give written informed consent prior ...",No,2018-11-21,FDA-70673,2.62,0.32,5.0,7.94,2020-09-11,2021-01-06,2026-01-07,76,Gilead,48,Kenya,35.66666666666666,79,18,38,2,58,19,55,0,3,3,False,False,True,True,True,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"Single Dose Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)",TradeName X,Drug,hiv,hiv,Phase 4,2016-04-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* \> Age of 18 at time of first visit.
* HIV uninfected on the basis of a negative HIV Rapid Test
* Willing and able to provide written informed consent.
* Willing and able to pro...",Yes,2017-03-25,FDA-46074,0.56,0.15,3.5,4.21,2016-10-22,2016-12-16,2020-06-16,99,J&J,15,Overall,39.0,44,48,47,66,22,7,36,0,3,1,False,False,False,True,False,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
E/C/F/TDF,GenName Y,Drug,hiv,hiv,Phase 3,2015-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Cohort 1 (treatment-naive)

* Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening
* Screening genotype report must show sensitivity to FTC and TDF
* No prior use of any approve...",No,2015-12-11,FDA-14977,2.62,0.32,5.0,7.94,2017-09-14,2018-01-09,2023-01-10,97,Bayer,52,Overall,55.5,94,51,53,54,37,44,36,1,1,2,True,False,True,False,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
COBI,GenName Y,Drug,hiv,hiv,Phase 3,2015-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Cohort 1 (treatment-naive)

* Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening
* Screening genotype report must show sensitivity to FTC and TDF
* No prior use of any approve...",Yes,2015-11-06,FDA-14804,2.62,0.32,5.0,7.94,2017-09-14,2018-01-09,2023-01-10,91,GSK,62,Senegal,51.16666666666666,47,58,37,47,34,84,73,1,4,3,True,False,True,True,False,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ATV,AltName B,Drug,hiv,hiv,Phase 3,2015-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Cohort 1 (treatment-naive)

* Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening
* Screening genotype report must show sensitivity to FTC and TDF
* No prior use of any approve...",No,2015-12-23,FDA-83592,2.62,0.32,5.0,7.94,2017-09-14,2018-01-09,2023-01-10,91,Merck,35,Senegal,41.5,78,4,38,40,85,4,64,1,4,2,True,False,False,True,True,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DRV,Product Alpha,Drug,hiv,hiv,Phase 3,2015-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Cohort 1 (treatment-naive)

* Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening
* Screening genotype report must show sensitivity to FTC and TDF
* No prior use of any approve...",No,2015-07-16,FDA-90354,2.62,0.32,5.0,7.94,2017-09-14,2018-01-09,2023-01-10,88,J&J,7,Kenya,58.33333333333334,25,94,31,78,48,74,45,1,2,2,False,True,True,False,False,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
NRTI,Comp Beta,Drug,hiv,hiv,Phase 3,2015-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Cohort 1 (treatment-naive)

* Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening
* Screening genotype report must show sensitivity to FTC and TDF
* No prior use of any approve...",No,2015-11-04,FDA-27764,2.62,0.32,5.0,7.94,2017-09-14,2018-01-09,2023-01-10,100,Novartis,49,Overall,47.5,7,43,48,1,94,92,55,1,3,2,True,False,False,True,False,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Fixed dose combination zidovudine/lamivudine/abacavir,AltName B,Drug,hiv,hiv,Phase 4,2007-09-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* HIV Infection is documented by rapid HIV test or any licensed enzyme-linked immunosorbent assay (ELISA) test kit and confirmed with a different sample.
* Men or women admitted t...",Yes,2008-06-29,FDA-49034,0.56,0.15,3.5,4.21,2008-03-23,2008-05-17,2011-11-16,95,Sanofi,74,Senegal,55.5,99,85,2,41,56,50,64,1,4,2,True,False,True,True,True,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Interferon-alpha,Product Alpha,Drug,hiv,hiv,Phase 2,2009-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Must have tested positive for HIV.
* Must have two or more warts inside the mouth.
* Must be receiving a standard course of anti-retroviral therapy (HAART).

Exclusion Criteria:...",No,2009-12-01,FDA-18331,4.41,0.98,21.0,26.39,2014-02-27,2015-02-20,2036-02-20,88,Novartis,22,Overall,49.5,40,24,26,99,67,41,45,1,1,3,True,False,False,False,False,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
(FDC) ELV/COBI/FTC/TDF,Molecule Z,Drug,hiv,hiv,Phase 3,2017-02-01,"Sex: ALL; Age: >18 Years; Criteria: Acute HIV infection is defined as:

1. A positive 4th generation HIV Ag/Ab Combination Assay and HIV RNA (NAAT or viral load) and one of the following within 30 days of study entry:

   * a negative H...",No,2017-12-16,FDA-93409,2.62,0.32,5.0,7.94,2019-09-15,2020-01-10,2025-01-10,32,Pfizer,24,South Africa,27.0,41,8,70,12,14,17,55,1,2,3,True,False,False,False,True,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Darunavir,AltName A,Drug,hiv,hiv,Phase 4,2013-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Documentation of Acute HIV Infection as defined above.
2. Men and women age ≥18 years.
3. Participants will be ART naïve, defined as ≤14 days of antiretroviral treatment at any...",No,2014-02-20,FDA-77086,0.56,0.15,3.5,4.21,2014-05-24,2014-07-18,2018-01-16,36,Bayer,57,South Africa,36.83333333333334,38,18,92,33,12,28,82,2,4,3,True,True,False,True,True,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,AltName B,Drug,hiv,hiv,Phase 4,2013-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Documentation of Acute HIV Infection as defined above.
2. Men and women age ≥18 years.
3. Participants will be ART naïve, defined as ≤14 days of antiretroviral treatment at any...",No,2014-03-21,FDA-21287,0.56,0.15,3.5,4.21,2014-05-24,2014-07-18,2018-01-16,45,Gilead,54,Kenya,27.66666666666667,62,43,6,23,11,21,36,2,2,0,True,True,False,False,False,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Etravirine,Product Alpha,Drug,hiv,hiv,Phase 4,2013-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Documentation of Acute HIV Infection as defined above.
2. Men and women age ≥18 years.
3. Participants will be ART naïve, defined as ≤14 days of antiretroviral treatment at any...",No,2014-06-10,FDA-38132,0.56,0.15,3.5,4.21,2014-05-24,2014-07-18,2018-01-16,91,Sanofi,45,Senegal,59.0,70,62,30,33,68,91,55,1,3,2,True,False,False,True,True,False,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Losartan,Molecule Z,Drug,hiv,hiv,Phase 2,2019-07-16,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: HIV infected participants:

1. Inclusion Criteria:

   Participants must meet all of the following inclusion criteria to participate in this study:
   * HIV-1 infected.

     -≥ 18 years of age.
   * ...",Yes,2020-04-18,FDA-39730,4.41,0.98,21.0,26.39,2023-12-12,2024-12-04,2045-12-04,54,Gilead,81,South Africa,57.16666666666666,48,63,49,92,20,71,27,1,1,1,False,True,True,False,False,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
minocycline,AltName B,Drug,hiv,hiv,Phase 2,2009-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV infection prior to study entry
* Naïve to any antiretroviral regimen and ineligible to receive antiretroviral therapy by cluster of differentiation 4 (CD4) criteria in Ugand...",Yes,2010-03-15,FDA-71476,4.41,0.98,21.0,26.39,2014-04-29,2015-04-22,2036-04-21,84,J&J,85,Senegal,38.5,55,10,4,41,68,53,36,1,2,1,True,False,True,False,False,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir; valproic acid,Molecule Z,Drug,hiv,hiv,Phase 2,2008-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Men and women age ≥18 years.
* Ability and willingness of subject or legal guardian/representative to give written informed consent.
* Karnofsky performance st...",Yes,2009-04-16,FDA-16760,4.41,0.98,21.0,26.39,2013-01-28,2014-01-21,2035-01-21,7,Gilead,3,Overall,56.0,56,8,98,4,78,92,55,1,3,2,True,False,True,True,False,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada/Raltegravir,AltName A,Drug,hiv,hiv,Phase 3,2013-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. is male or female aged 18 years or above
2. has a documented HIV-1 infection
3. has signed the Informed Consent Form voluntarily
4. is willing to comply with the protocol requi...",No,2013-08-03,FDA-18765,2.62,0.32,5.0,7.94,2016-01-13,2016-05-09,2021-05-10,85,Sanofi,41,Kenya,53.66666666666666,16,34,57,39,91,85,55,1,3,2,True,False,True,True,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Stribild,GenName Y,Drug,hiv,hiv,Phase 3,2013-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* Virologically stable on the current first antiretroviral regimen consisting only of raltegravir twice daily plus...",Yes,2013-11-05,FDA-76306,2.62,0.32,5.0,7.94,2016-02-12,2016-06-08,2021-06-09,72,Pfizer,55,South Africa,38.0,98,81,2,4,24,19,64,1,2,4,True,False,True,False,True,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PI,GenName Y,Drug,hiv,hiv,Phase 3,2014-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* Be on a stable antiretroviral regimen consisting of a ritonavir boosted PI plus FTC/TDF continuously for ≥ 6 con...",No,2015-10-02,FDA-79962,2.62,0.32,5.0,7.94,2017-07-14,2017-11-08,2022-11-09,66,Merck,10,Overall,48.0,52,60,9,67,6,94,45,2,2,1,True,True,True,False,False,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
RTV,TradeName X,Drug,hiv,hiv,Phase 3,2014-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* Be on a stable antiretroviral regimen consisting of a ritonavir boosted PI plus FTC/TDF continuously for ≥ 6 con...",Yes,2015-10-30,FDA-24539,2.62,0.32,5.0,7.94,2017-07-14,2017-11-08,2022-11-09,2,AstraZeneca,79,South Africa,50.33333333333334,23,15,93,47,43,81,45,1,3,1,False,True,True,False,True,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TDF,GenName Y,Drug,hiv,hiv,Phase 3,2014-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* Be on a stable antiretroviral regimen consisting of a ritonavir boosted PI plus FTC/TDF continuously for ≥ 6 con...",Yes,2015-08-23,FDA-56054,2.62,0.32,5.0,7.94,2017-07-14,2017-11-08,2022-11-09,44,Sanofi,44,Kenya,52.33333333333334,89,72,56,33,17,47,55,1,2,3,True,False,True,False,False,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Stribild,Product Alpha,Drug,hiv,hiv,Phase 3,2014-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* Be on a stable antiretroviral regimen consisting of a ritonavir boosted PI plus FTC/TDF continuously for ≥ 6 con...",No,2015-03-12,FDA-22849,2.62,0.32,5.0,7.94,2017-07-14,2017-11-08,2022-11-09,50,GSK,70,Senegal,46.83333333333334,77,35,64,81,20,4,36,1,2,1,False,True,False,False,False,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
D/C/F/TAF,Comp Beta,Drug,hiv,hiv,Phase 2,2014-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult (≥ 18 years) males or non-pregnant females
* Ability to understand and sign a written informed consent form
* General medical condition which does not interfere with the a...",No,2014-08-11,FDA-54642,4.41,0.98,21.0,26.39,2018-06-30,2019-06-23,2040-06-22,40,J&J,78,Overall,66.0,13,91,72,67,95,58,55,2,3,1,True,True,False,False,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DRV,Product Alpha,Drug,hiv,hiv,Phase 2,2014-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult (≥ 18 years) males or non-pregnant females
* Ability to understand and sign a written informed consent form
* General medical condition which does not interfere with the a...",Yes,2014-12-24,FDA-67347,4.41,0.98,21.0,26.39,2018-06-30,2019-06-23,2040-06-22,38,Merck,6,Overall,63.66666666666666,56,99,48,27,58,94,45,1,2,2,False,True,False,True,False,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
COBI,GenName Y,Drug,hiv,hiv,Phase 2,2014-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult (≥ 18 years) males or non-pregnant females
* Ability to understand and sign a written informed consent form
* General medical condition which does not interfere with the a...",Yes,2014-04-25,FDA-70533,4.41,0.98,21.0,26.39,2018-06-30,2019-06-23,2040-06-22,3,Gilead,89,Overall,65.0,50,63,80,89,98,10,55,1,4,1,False,True,True,True,True,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TDF,Product Alpha,Drug,hiv,hiv,Phase 2,2014-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult (≥ 18 years) males or non-pregnant females
* Ability to understand and sign a written informed consent form
* General medical condition which does not interfere with the a...",No,2014-11-04,FDA-79105,4.41,0.98,21.0,26.39,2018-06-30,2019-06-23,2040-06-22,79,Merck,27,Overall,64.83333333333333,100,77,52,50,26,84,55,1,4,1,True,False,True,True,True,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
CYD Dengue Vaccine,Product Alpha,Biological,hiv,hiv,Phase 2,2023-01-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Aged 18 to 50 years on the day of first study vaccination (study product administration) (""18 to 50"" means from the day of the 18th birthday to the day before the 51th birthday)...",No,2023-11-11,FDA-71207,4.41,0.98,21.0,26.39,2027-06-17,2028-06-09,2049-06-09,31,Gilead,89,Senegal,47.16666666666666,23,53,56,25,49,77,36,0,2,2,False,False,False,True,False,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
E/C/F/TDF,TradeName X,Drug,hiv,hiv,Phase 2,2016-08-22,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* Plasma HIV 1 RNA levels ≥ 5,000 copies/mL
* No prior use of any approved or experimental anti-HIV drug for a...",Yes,2017-02-23,FDA-44650,4.41,0.98,21.0,26.39,2021-01-18,2022-01-11,2043-01-11,70,J&J,41,South Africa,23.5,19,31,0,55,27,9,45,0,3,2,False,False,True,False,False,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
E/C/F/TAF,Molecule Z,Drug,hiv,hiv,Phase 2,2016-08-22,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* Plasma HIV 1 RNA levels ≥ 5,000 copies/mL
* No prior use of any approved or experimental anti-HIV drug for a...",Yes,2017-07-02,FDA-46881,4.41,0.98,21.0,26.39,2021-01-18,2022-01-11,2043-01-11,70,Sanofi,47,South Africa,40.16666666666666,0,30,51,68,15,77,55,1,3,2,True,False,True,True,False,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Zidovudine (ZDV),GenName Y,Drug,hiv,hiv,Phase 3,2016-09-30,"Sex: ALL; Criteria: Antepartum Component Inclusion Criteria:

* Confirmed HIV-1 infection, defined as documented positive results from two samples collected at different time points prior to study entry. More information...",Yes,2016-12-02,FDA-11479,2.62,0.32,5.0,7.94,2019-05-14,2019-09-08,2024-09-08,45,J&J,100,Overall,47.33333333333334,81,17,24,53,41,68,45,1,3,1,False,True,True,True,False,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Nevirapine (NVP): Antepartum Mothers,GenName Y,Drug,hiv,hiv,Phase 3,2016-09-30,"Sex: ALL; Criteria: Antepartum Component Inclusion Criteria:

* Confirmed HIV-1 infection, defined as documented positive results from two samples collected at different time points prior to study entry. More information...",No,2016-11-27,FDA-64737,2.62,0.32,5.0,7.94,2019-05-14,2019-09-08,2024-09-08,61,Sanofi,49,South Africa,35.5,46,6,48,9,91,13,73,2,4,2,True,True,True,True,True,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail,TradeName X,Drug,hiv,hiv,Phase 3,2016-09-30,"Sex: ALL; Criteria: Antepartum Component Inclusion Criteria:

* Confirmed HIV-1 infection, defined as documented positive results from two samples collected at different time points prior to study entry. More information...",No,2017-04-08,FDA-12788,2.62,0.32,5.0,7.94,2019-05-14,2019-09-08,2024-09-08,0,AstraZeneca,33,Overall,64.0,90,90,60,7,65,72,36,1,1,2,False,True,True,False,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine-Zidovudine (3TC-ZDV),Molecule Z,Drug,hiv,hiv,Phase 3,2016-09-30,"Sex: ALL; Criteria: Antepartum Component Inclusion Criteria:

* Confirmed HIV-1 infection, defined as documented positive results from two samples collected at different time points prior to study entry. More information...",Yes,2017-03-01,FDA-82628,2.62,0.32,5.0,7.94,2019-05-14,2019-09-08,2024-09-08,47,Merck,19,South Africa,44.16666666666666,12,85,39,64,57,8,73,1,5,2,True,False,True,True,True,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir-ritonavir (LPV-RTV),AltName B,Drug,hiv,hiv,Phase 3,2016-09-30,"Sex: ALL; Criteria: Antepartum Component Inclusion Criteria:

* Confirmed HIV-1 infection, defined as documented positive results from two samples collected at different time points prior to study entry. More information...",No,2017-02-04,FDA-41141,2.62,0.32,5.0,7.94,2019-05-14,2019-09-08,2024-09-08,95,Gilead,4,South Africa,59.0,73,48,68,39,86,40,45,2,1,2,True,True,False,False,True,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]),Molecule Z,Drug,hiv,hiv,Phase 3,2016-09-30,"Sex: ALL; Criteria: Antepartum Component Inclusion Criteria:

* Confirmed HIV-1 infection, defined as documented positive results from two samples collected at different time points prior to study entry. More information...",No,2017-02-12,FDA-29970,2.62,0.32,5.0,7.94,2019-05-14,2019-09-08,2024-09-08,58,Merck,49,South Africa,49.0,11,68,13,62,81,59,45,1,2,2,True,False,False,False,True,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Nevirapine (NVP): Infant short-course,AltName A,Drug,hiv,hiv,Phase 3,2016-09-30,"Sex: ALL; Criteria: Antepartum Component Inclusion Criteria:

* Confirmed HIV-1 infection, defined as documented positive results from two samples collected at different time points prior to study entry. More information...",No,2017-04-29,FDA-49344,2.62,0.32,5.0,7.94,2019-05-14,2019-09-08,2024-09-08,63,Novartis,66,Kenya,63.5,53,10,95,91,46,86,45,0,2,3,False,False,True,False,True,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Nevirapine (NVP): Infant extended,Product Alpha,Drug,hiv,hiv,Phase 3,2016-09-30,"Sex: ALL; Criteria: Antepartum Component Inclusion Criteria:

* Confirmed HIV-1 infection, defined as documented positive results from two samples collected at different time points prior to study entry. More information...",No,2017-09-20,FDA-60956,2.62,0.32,5.0,7.94,2019-05-14,2019-09-08,2024-09-08,87,AstraZeneca,94,South Africa,63.66666666666666,30,26,52,97,78,99,45,1,3,1,False,True,False,True,True,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada (tenofovir/emtricitabine),AltName B,Drug,hiv,hiv,Phase 4,2010-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Age \> 18 years
2. Diagnosis of HIV infection.
3. Naive to antiretroviral therapy OR no use of antiretrovirals for ≥ 6 months.

Exclusion Criteria:

1. Blinded drug treatment.
...",No,2011-01-11,FDA-39253,0.56,0.15,3.5,4.21,2010-09-21,2010-11-15,2014-05-16,88,Sanofi,36,Senegal,34.5,2,49,43,38,23,52,55,1,3,2,True,False,False,True,True,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Kaletra (lopinavir/ritonavir),AltName B,Drug,hiv,hiv,Phase 4,2010-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Age \> 18 years
2. Diagnosis of HIV infection.
3. Naive to antiretroviral therapy OR no use of antiretrovirals for ≥ 6 months.

Exclusion Criteria:

1. Blinded drug treatment.
...",No,2010-05-06,FDA-35727,0.56,0.15,3.5,4.21,2010-09-21,2010-11-15,2014-05-16,69,Bayer,77,Kenya,74.66666666666667,63,84,87,45,90,79,64,1,4,2,False,True,True,True,False,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Inspra /Eplerenone,Comp Beta,Drug,hiv,hiv,Phase 2,2017-09-11,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

  1. Increased waist circumference on the basis of National Cholesterol Education Program guidelines (\> 102 cm in men and \> 88 cm in women)
  2. Hepatic steatosis established ...",No,2018-05-02,FDA-86845,4.41,0.98,21.0,26.39,2022-02-07,2023-01-31,2044-01-31,29,Gilead,24,Senegal,64.83333333333333,86,74,100,58,7,64,55,1,2,3,True,False,False,True,False,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
E/C/F/TDF,Product Alpha,Drug,hiv,hiv,Phase 3,2018-09-06,"Sex: FEMALE; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Female (at birth), age ≥ 18 years
* Ability to understand and sign a written informed consent form
* Plasma HIV-1 RNA levels ≥ 500 copies/mL
* No prior use of any approved o...",No,2019-05-17,FDA-63800,2.62,0.32,5.0,7.94,2021-04-19,2021-08-14,2026-08-15,53,Pfizer,2,Overall,46.0,57,37,11,44,75,52,64,1,3,3,True,False,True,False,False,True,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ATV,GenName Y,Drug,hiv,hiv,Phase 3,2018-09-06,"Sex: FEMALE; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Female (at birth), age ≥ 18 years
* Ability to understand and sign a written informed consent form
* Plasma HIV-1 RNA levels ≥ 500 copies/mL
* No prior use of any approved o...",No,2019-01-11,FDA-32730,2.62,0.32,5.0,7.94,2021-04-19,2021-08-14,2026-08-15,17,Sanofi,31,South Africa,54.5,58,42,13,76,87,51,18,1,0,1,True,False,False,False,False,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
RTV,Comp Beta,Drug,hiv,hiv,Phase 3,2018-09-06,"Sex: FEMALE; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Female (at birth), age ≥ 18 years
* Ability to understand and sign a written informed consent form
* Plasma HIV-1 RNA levels ≥ 500 copies/mL
* No prior use of any approved o...",Yes,2019-02-03,FDA-75952,2.62,0.32,5.0,7.94,2021-04-19,2021-08-14,2026-08-15,7,Novartis,95,Senegal,41.83333333333334,97,27,80,29,3,15,45,2,1,2,True,True,True,False,False,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TDF,TradeName X,Drug,hiv,hiv,Phase 3,2018-09-06,"Sex: FEMALE; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Female (at birth), age ≥ 18 years
* Ability to understand and sign a written informed consent form
* Plasma HIV-1 RNA levels ≥ 500 copies/mL
* No prior use of any approved o...",Yes,2018-11-04,FDA-34243,2.62,0.32,5.0,7.94,2021-04-19,2021-08-14,2026-08-15,57,Merck,16,South Africa,58.5,67,75,73,46,62,28,64,1,3,3,True,False,False,True,True,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
E/C/F/TAF,AltName A,Drug,hiv,hiv,Phase 3,2018-09-06,"Sex: FEMALE; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Female (at birth), age ≥ 18 years
* Ability to understand and sign a written informed consent form
* Plasma HIV-1 RNA levels ≥ 500 copies/mL
* No prior use of any approved o...",No,2018-11-05,FDA-79989,2.62,0.32,5.0,7.94,2021-04-19,2021-08-14,2026-08-15,97,Merck,63,South Africa,59.16666666666666,86,34,57,73,27,78,64,2,4,1,True,True,True,True,True,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Panobinostat,GenName Y,Drug,hiv,hiv,Phase 2,2023-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability and willingness to provide informed consent
* HIV-1 infection prior to entry
* Receiving suppressive ART therapy for a minimum of 24 consecutive months prior to screenin...",Yes,2024-10-24,FDA-52021,4.41,0.98,21.0,26.39,2028-04-28,2029-04-21,2050-04-21,74,J&J,59,South Africa,54.16666666666666,23,25,79,28,75,95,36,0,2,2,False,False,False,False,True,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Pegylated Interferon-alpha2a,Comp Beta,Drug,hiv,hiv,Phase 2,2023-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability and willingness to provide informed consent
* HIV-1 infection prior to entry
* Receiving suppressive ART therapy for a minimum of 24 consecutive months prior to screenin...",No,2024-07-08,FDA-44048,4.41,0.98,21.0,26.39,2028-04-28,2029-04-21,2050-04-21,23,J&J,75,Kenya,50.33333333333334,45,52,56,8,89,52,55,1,4,1,True,False,False,True,True,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Rifaximin,AltName B,Drug,hiv,hiv,Phase 2,2018-02-28,"Sex: ALL; Age: >18 Years; Criteria: * PARTICIPANT INCLUSION CRITERIA:

Patients who have agreed in the course of other research studies to have their records reviewed will have the following elements evaluated from their existing record...",No,2018-09-28,FDA-95663,4.41,0.98,21.0,26.39,2022-07-27,2023-07-20,2044-07-19,38,Gilead,57,Kenya,40.33333333333334,56,37,68,10,6,65,64,1,5,1,True,False,True,True,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Valganciclovir,Comp Beta,Drug,hiv,hiv,Phase 4,2008-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Infection with HIV \>1 year in duration.
* Age \>18
* Cytomegalovirus (CMV) antibody positive.
* All Cluster of Differentiation 4 (CD4)+ T cell counts in the last year and at sc...",No,2009-06-28,FDA-99309,0.56,0.15,3.5,4.21,2009-05-24,2009-07-18,2013-01-16,94,GSK,56,Overall,50.5,17,82,65,29,12,98,45,1,1,3,True,False,False,False,False,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Vitamin D,Product Alpha,Drug,hiv,hiv,Phase 2,2010-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV infected
* HIV-RNA \< 400 copies/ml at study entry and for 12 wks. prior
* 25-hydroxyvitamin D level \<20
* On a stable anti-retroviral (ARV) regimen for at least 12 weeks p...",Yes,2011-06-03,FDA-93925,4.41,0.98,21.0,26.39,2015-02-27,2016-02-20,2037-02-19,61,Novartis,78,Kenya,49.5,58,44,85,42,47,21,55,0,3,3,False,False,True,True,False,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada,TradeName X,Drug,hiv,hiv,Phase 4,2015-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients must be at least 18 years of age
* HIV uninfected on the basis of a negative HIV rapid test, EIA or Western blot, and without any signs or symptoms of acute HIV infecti...",No,2015-11-26,FDA-61877,0.56,0.15,3.5,4.21,2016-02-21,2016-04-16,2019-10-16,22,Merck,32,South Africa,40.33333333333334,71,59,20,15,45,32,45,2,1,2,True,True,False,False,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,Comp Beta,Drug,hiv,hiv,Phase 4,2015-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients must be at least 18 years of age
* HIV uninfected on the basis of a negative HIV rapid test, EIA or Western blot, and without any signs or symptoms of acute HIV infecti...",No,2016-03-19,FDA-18552,0.56,0.15,3.5,4.21,2016-02-21,2016-04-16,2019-10-16,87,Gilead,1,Kenya,36.83333333333334,32,36,6,30,86,31,73,1,3,4,False,True,False,True,True,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Aspirin,Comp Beta,Drug,hiv,hiv,Phase 2,2019-10-16,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

EC Arm

1. Age greater than or equal to 18 years.
2. Documented HIV-1 infection confirmed by enzyme-linked immunosorbent assay (ELISA) and Western blot tests (will not be repeat...",No,2020-08-01,FDA-95646,4.41,0.98,21.0,26.39,2024-03-13,2025-03-06,2046-03-06,90,AstraZeneca,34,Kenya,47.5,56,92,33,60,37,7,27,1,1,1,True,False,False,True,False,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atorvastatin,AltName A,Drug,hiv,hiv,Phase 2,2019-10-16,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

EC Arm

1. Age greater than or equal to 18 years.
2. Documented HIV-1 infection confirmed by enzyme-linked immunosorbent assay (ELISA) and Western blot tests (will not be repeat...",Yes,2020-06-04,FDA-28202,4.41,0.98,21.0,26.39,2024-03-13,2025-03-06,2046-03-06,15,Novartis,0,Senegal,48.16666666666666,61,86,15,52,42,33,55,0,3,3,False,False,True,False,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Cervarix,AltName B,Biological,hiv,hiv,Phase 2,2011-07-18,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that they can and will comply with the requirements of the protocol
* A female between, and including, 18 and 25 years of age at the time ...",No,2011-08-21,FDA-84026,4.41,0.98,21.0,26.39,2015-12-14,2016-12-06,2037-12-06,4,Pfizer,16,Kenya,51.16666666666666,56,35,76,75,8,57,55,0,3,3,False,False,False,True,False,True,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"Mesalamine (5-aminosalicylic acid, Apriso)",GenName Y,Drug,hiv,hiv,Phase 4,2012-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry.
2. Stable antiretroviral therapy for at least 6 mo...",No,2013-03-30,FDA-86554,0.56,0.15,3.5,4.21,2013-06-23,2013-08-17,2017-02-15,21,GSK,59,Kenya,61.16666666666666,99,90,32,52,49,45,64,2,3,2,True,True,False,True,True,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
SOF,TradeName X,Drug,hiv,hiv,Phase 3,2014-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Willing and able to provide written informed consent
* Male or female, age ≥ 18 years with chronic HCV and HIV-1 infection
* HCV RNA \> 1 x 10\^4 IU/mL at screening
* Infection ...",No,2014-05-27,FDA-72927,2.62,0.32,5.0,7.94,2016-09-14,2017-01-09,2022-01-10,77,GSK,33,South Africa,42.83333333333334,15,51,8,24,67,92,45,1,3,1,True,False,True,True,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
RBV,AltName A,Drug,hiv,hiv,Phase 3,2014-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Willing and able to provide written informed consent
* Male or female, age ≥ 18 years with chronic HCV and HIV-1 infection
* HCV RNA \> 1 x 10\^4 IU/mL at screening
* Infection ...",No,2014-05-14,FDA-91478,2.62,0.32,5.0,7.94,2016-09-14,2017-01-09,2022-01-10,78,J&J,77,Senegal,61.66666666666666,71,17,24,99,98,61,55,1,4,1,False,True,False,True,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK2838232,AltName B,Drug,hiv,hiv,Phase 2,2018-04-23,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Between 18 and 55 years of age inclusive, at the time of signing the informed consent.
* Healthy (other than HIV infection) male or female as determined by the investigator or m...",Yes,2018-12-11,FDA-62647,4.41,0.98,21.0,26.39,2022-09-19,2023-09-12,2044-09-11,50,Gilead,68,Kenya,43.33333333333334,86,78,15,2,45,34,45,1,4,0,False,True,True,True,True,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Cobicistat,AltName B,Drug,hiv,hiv,Phase 2,2018-04-23,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Between 18 and 55 years of age inclusive, at the time of signing the informed consent.
* Healthy (other than HIV infection) male or female as determined by the investigator or m...",Yes,2018-07-27,FDA-61236,4.41,0.98,21.0,26.39,2022-09-19,2023-09-12,2044-09-11,28,J&J,3,Kenya,44.83333333333334,1,91,35,2,47,93,82,2,4,3,True,True,True,True,True,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Serostim® 4 mg,TradeName X,Drug,hiv,hiv,Phase 3,2005-09-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Have written laboratory documentation of an HIV infection by one of the following methods:

   * Detectable viral load measured by polymerase chain reaction (PCR) amplification...",No,2006-03-23,FDA-83266,2.62,0.32,5.0,7.94,2008-05-11,2008-09-05,2013-09-06,92,Pfizer,55,Overall,47.16666666666666,29,43,84,84,37,6,64,0,3,4,False,False,False,True,True,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Serostim® 2 mg,Comp Beta,Drug,hiv,hiv,Phase 3,2005-09-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Have written laboratory documentation of an HIV infection by one of the following methods:

   * Detectable viral load measured by polymerase chain reaction (PCR) amplification...",Yes,2006-04-19,FDA-39807,2.62,0.32,5.0,7.94,2008-05-11,2008-09-05,2013-09-06,46,GSK,0,Overall,66.5,99,40,52,95,67,46,27,0,2,1,False,False,False,False,True,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK2248761 100 mg once daily,GenName Y,Drug,hiv,hiv,Phase 2,2011-07-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected adults greater than or equal to 18 years of age. Females are eligible to enter and participate in the study if she is (1) non-childbearing potential, (2) child be...",Yes,2012-06-11,FDA-44556,4.41,0.98,21.0,26.39,2015-12-15,2016-12-07,2037-12-07,53,Sanofi,1,Senegal,47.33333333333334,55,48,60,58,29,34,55,1,2,3,False,True,True,False,False,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK2248761 200 mg once daily,Comp Beta,Drug,hiv,hiv,Phase 2,2011-07-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected adults greater than or equal to 18 years of age. Females are eligible to enter and participate in the study if she is (1) non-childbearing potential, (2) child be...",No,2011-09-26,FDA-51455,4.41,0.98,21.0,26.39,2015-12-15,2016-12-07,2037-12-07,37,Novartis,91,South Africa,40.5,72,55,52,9,0,55,82,2,4,3,True,True,True,False,True,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Etravirine,AltName B,Drug,hiv,hiv,Phase 2,2011-07-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected adults greater than or equal to 18 years of age. Females are eligible to enter and participate in the study if she is (1) non-childbearing potential, (2) child be...",No,2012-03-22,FDA-57550,4.41,0.98,21.0,26.39,2015-12-15,2016-12-07,2037-12-07,18,GSK,86,Kenya,67.16666666666667,70,77,97,25,83,51,82,2,3,4,True,True,False,True,True,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
raltegravir,Product Alpha,Drug,hiv,hiv,Phase 3,2009-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients must meet all of the following inclusion criteria to be eligible for participation in this study.

  1. Subject is ≥ 18 years of age and able to understand and willing ...",No,2010-06-10,FDA-46761,2.62,0.32,5.0,7.94,2012-04-14,2012-08-09,2017-08-10,74,GSK,54,Kenya,62.5,35,75,80,84,17,84,36,0,2,2,False,False,False,False,False,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
raltegravir,AltName B,Drug,hiv,hiv,Phase 4,2014-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Stable antiretroviral therapy for at least 12 months
2. All plasma HIV RNA levels within the past year must be below level of detection (\< 50 copies RNA/mL), although isolated...",No,2014-05-03,FDA-70827,0.56,0.15,3.5,4.21,2014-08-24,2014-10-18,2018-04-18,81,Merck,92,Kenya,44.16666666666666,89,72,1,32,68,3,64,0,5,2,False,False,True,True,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
HEPLISAV-B,GenName Y,Biological,hiv,hiv,Phase 3,2024-08-13,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria, Groups A and B

* HIV-1 infection
* On current HIV-1 antiretroviral therapy (ART)
* CD4+ T-cell count ≥100 cells/mm\^3
* HIV-1 RNA \<1000 copies/mL

Inclusion Criteria, Group A onl...",No,2025-06-04,FDA-96795,2.62,0.32,5.0,7.94,2027-03-27,2027-07-22,2032-07-22,29,J&J,0,South Africa,60.33333333333334,51,97,38,63,96,17,36,1,2,1,True,False,False,False,True,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ENGERIX-B,Comp Beta,Biological,hiv,hiv,Phase 3,2024-08-13,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria, Groups A and B

* HIV-1 infection
* On current HIV-1 antiretroviral therapy (ART)
* CD4+ T-cell count ≥100 cells/mm\^3
* HIV-1 RNA \<1000 copies/mL

Inclusion Criteria, Group A onl...",Yes,2024-10-12,FDA-37288,2.62,0.32,5.0,7.94,2027-03-27,2027-07-22,2032-07-22,82,Merck,48,Senegal,41.5,33,70,24,48,66,8,18,0,1,1,False,False,False,True,False,False,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Peptide T,Product Alpha,Drug,hiv,hiv,Phase 2,1996-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients must have:

  1. Cognitive dysfunction on neuropsychological testing.
  2. HIV antibody positivity.
  3. Expected survival of 6 months.
  4. EITHER no use of an antiret...",Yes,1996-09-06,FDA-55982,4.41,0.98,21.0,26.39,2000-12-28,2001-12-21,2022-12-21,42,AstraZeneca,10,Overall,42.66666666666666,15,33,88,75,17,28,55,1,4,1,False,True,True,True,True,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Elvucitabine,AltName B,Drug,hiv,hiv,Phase 2,2009-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

A participant must meet the following criteria at Screening to be enrolled in this study:

1. Are male or female. Sexually active men with partners of childbearing potential must ...",No,2009-05-09,FDA-40325,4.41,0.98,21.0,26.39,2013-08-28,2014-08-21,2035-08-21,29,GSK,14,Kenya,46.66666666666666,20,32,83,56,5,84,64,1,3,3,False,True,True,True,False,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine,AltName B,Drug,hiv,hiv,Phase 2,2009-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

A participant must meet the following criteria at Screening to be enrolled in this study:

1. Are male or female. Sexually active men with partners of childbearing potential must ...",Yes,2010-02-12,FDA-84573,4.41,0.98,21.0,26.39,2013-08-28,2014-08-21,2035-08-21,28,J&J,54,Kenya,38.83333333333334,46,2,15,37,45,88,64,2,3,2,True,True,False,True,False,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir,TradeName X,Drug,hiv,hiv,Phase 2,2009-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

A participant must meet the following criteria at Screening to be enrolled in this study:

1. Are male or female. Sexually active men with partners of childbearing potential must ...",No,2009-08-25,FDA-44252,4.41,0.98,21.0,26.39,2013-08-28,2014-08-21,2035-08-21,88,AstraZeneca,5,Senegal,42.5,6,23,33,80,26,87,64,2,3,2,True,True,True,True,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,Comp Beta,Drug,hiv,hiv,Phase 2,2009-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

A participant must meet the following criteria at Screening to be enrolled in this study:

1. Are male or female. Sexually active men with partners of childbearing potential must ...",No,2009-09-22,FDA-78721,4.41,0.98,21.0,26.39,2013-08-28,2014-08-21,2035-08-21,2,GSK,33,Kenya,62.16666666666666,95,59,45,76,95,3,64,1,3,3,True,False,True,False,True,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
tenofovir DF 300 mg QD,GenName Y,Drug,hiv,hiv,Phase 4,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

1. Signed informed consent in accordance with Good Clinical Practice (GCP) and local regulatory requirements prior to trial participation
2. HIV-1- infected males or females great...",No,2026-09-23,FDA-45569,0.56,0.15,3.5,4.21,,,,5,Merck,27,South Africa,39.0,26,82,35,26,6,59,27,0,1,2,False,False,False,False,True,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
tenofovir DF 300 mg QD,GenName Y,Drug,hiv,hiv,Phase 4,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

1. Signed informed consent in accordance with Good Clinical Practice (GCP) and local regulatory requirements prior to trial participation
2. HIV-1- infected males or females great...",Yes,2026-01-04,FDA-77478,0.56,0.15,3.5,4.21,,,,42,Gilead,88,Kenya,44.0,70,28,66,60,26,14,45,1,2,2,True,False,False,False,True,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
emtricitabine 200 mg QD,TradeName X,Drug,hiv,hiv,Phase 4,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

1. Signed informed consent in accordance with Good Clinical Practice (GCP) and local regulatory requirements prior to trial participation
2. HIV-1- infected males or females great...",No,2026-01-08,FDA-74285,0.56,0.15,3.5,4.21,,,,0,Novartis,57,Senegal,58.66666666666666,96,33,77,71,7,68,73,2,2,4,True,True,True,False,True,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
emtricitabine 200 mg QD,AltName B,Drug,hiv,hiv,Phase 4,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

1. Signed informed consent in accordance with Good Clinical Practice (GCP) and local regulatory requirements prior to trial participation
2. HIV-1- infected males or females great...",Yes,2026-02-20,FDA-48816,0.56,0.15,3.5,4.21,,,,6,GSK,91,South Africa,41.5,18,96,8,81,36,10,55,0,3,3,False,False,True,False,False,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Nevirapine 200 mg BID,Product Alpha,Drug,hiv,hiv,Phase 4,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

1. Signed informed consent in accordance with Good Clinical Practice (GCP) and local regulatory requirements prior to trial participation
2. HIV-1- infected males or females great...",No,2026-10-09,FDA-85439,0.56,0.15,3.5,4.21,,,,76,Sanofi,10,South Africa,48.16666666666666,51,17,69,91,39,22,45,2,2,1,True,True,False,True,False,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir 300 mg,AltName A,Drug,hiv,hiv,Phase 4,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

1. Signed informed consent in accordance with Good Clinical Practice (GCP) and local regulatory requirements prior to trial participation
2. HIV-1- infected males or females great...",No,2026-11-17,FDA-18616,0.56,0.15,3.5,4.21,,,,58,AstraZeneca,38,Overall,62.16666666666666,54,85,36,68,46,84,73,2,3,3,True,True,True,False,True,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir 100 mg,AltName B,Drug,hiv,hiv,Phase 4,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

1. Signed informed consent in accordance with Good Clinical Practice (GCP) and local regulatory requirements prior to trial participation
2. HIV-1- infected males or females great...",No,2026-05-05,FDA-86737,0.56,0.15,3.5,4.21,,,,27,Gilead,53,Kenya,49.5,41,32,91,12,65,56,55,2,1,3,True,True,True,False,False,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Bevacizumab,TradeName X,Biological,hiv,hiv,Phase 2,2010-03-15,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

Age greater than or equal to 18 years.

Kaposi's sarcoma pathologically confirmed by Center for Cancer Research (CCR) pathology.

Eastern Cooperative Oncology Group (ECOG) perfo...",No,2010-09-14,FDA-80620,4.41,0.98,21.0,26.39,2014-08-11,2015-08-04,2036-08-03,97,Novartis,14,Senegal,53.66666666666666,35,72,92,55,62,6,9,0,1,0,False,False,True,False,False,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Oral Lenacapavir (LEN),Molecule Z,Drug,hiv,hiv,Phase 3,2028-05-01,"Sex: ALL; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Key Inclusion Criteria:

Incidence Phase

* CGM, TGW, TGM, and GNB who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV infection.
* HIV-1 status unknown...",Yes,2028-07-02,FDA-54829,2.62,0.32,5.0,7.94,2030-12-13,2031-04-09,2036-04-09,0,AstraZeneca,63,South Africa,42.5,57,38,76,23,4,57,55,0,3,3,False,False,True,True,False,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
F/TDF,Product Alpha,Drug,hiv,hiv,Phase 3,2028-05-01,"Sex: ALL; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Key Inclusion Criteria:

Incidence Phase

* CGM, TGW, TGM, and GNB who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV infection.
* HIV-1 status unknown...",No,2028-12-10,FDA-96623,2.62,0.32,5.0,7.94,2030-12-13,2031-04-09,2036-04-09,76,Pfizer,72,Senegal,57.83333333333334,35,63,28,98,27,96,64,1,2,4,True,False,False,False,True,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Sub-cutaneous (SC) Lenacapavir (LEN),Comp Beta,Drug,hiv,hiv,Phase 3,2028-05-01,"Sex: ALL; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Key Inclusion Criteria:

Incidence Phase

* CGM, TGW, TGM, and GNB who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV infection.
* HIV-1 status unknown...",Yes,2028-07-20,FDA-18629,2.62,0.32,5.0,7.94,2030-12-13,2031-04-09,2036-04-09,53,AstraZeneca,35,South Africa,67.5,18,98,100,53,71,65,36,1,2,1,True,False,False,True,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
PTM F/TDF,Comp Beta,Drug,hiv,hiv,Phase 3,2028-05-01,"Sex: ALL; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Key Inclusion Criteria:

Incidence Phase

* CGM, TGW, TGM, and GNB who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV infection.
* HIV-1 status unknown...",No,2028-07-05,FDA-71528,2.62,0.32,5.0,7.94,2030-12-13,2031-04-09,2036-04-09,50,Pfizer,54,Senegal,41.0,14,85,33,29,56,29,55,0,2,4,False,False,False,False,True,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PTM Oral LEN,AltName A,Drug,hiv,hiv,Phase 3,2028-05-01,"Sex: ALL; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Key Inclusion Criteria:

Incidence Phase

* CGM, TGW, TGM, and GNB who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV infection.
* HIV-1 status unknown...",Yes,2028-07-15,FDA-68778,2.62,0.32,5.0,7.94,2030-12-13,2031-04-09,2036-04-09,21,Sanofi,15,South Africa,44.83333333333334,28,22,12,62,66,79,64,2,2,3,True,True,True,False,False,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
F/TAF (for US participants only),TradeName X,Drug,hiv,hiv,Phase 3,2028-05-01,"Sex: ALL; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Key Inclusion Criteria:

Incidence Phase

* CGM, TGW, TGM, and GNB who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV infection.
* HIV-1 status unknown...",Yes,2028-12-19,FDA-99239,2.62,0.32,5.0,7.94,2030-12-13,2031-04-09,2036-04-09,50,GSK,8,South Africa,47.5,38,2,69,53,64,59,64,2,3,2,True,True,False,False,True,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"tenofovir + emtricitabine, lopinavir/ritonavir",Comp Beta,Drug,hiv,hiv,Phase 2,2011-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients must be at least 18 years of age
* Able to understand and provide consent
* High-Risk Exposure Characteristic
* (one or more of the below, unprotected or with failed co...",Yes,2012-02-21,FDA-64533,4.41,0.98,21.0,26.39,2015-12-28,2016-12-20,2037-12-20,36,Gilead,44,Overall,69.0,94,74,40,98,88,20,55,2,2,2,True,True,False,False,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
BMS-663068 400 mg,TradeName X,Drug,hiv,hiv,Phase 2,2017-05-12,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Plasma HIV-1 RNA ≥ 1000 copies/ml at Screening
* Treatment experience with antiretroviral therapies (excluding integrase inhibitors)
* Screening PHENOSENSE Entry indicating BMS-...",No,2017-06-11,FDA-61623,4.41,0.98,21.0,26.39,2021-10-08,2022-10-01,2043-10-01,52,Pfizer,24,Senegal,49.0,36,72,18,7,87,74,55,1,3,2,True,False,True,True,False,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
BMS-663068 800 mg,Molecule Z,Drug,hiv,hiv,Phase 2,2017-05-12,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Plasma HIV-1 RNA ≥ 1000 copies/ml at Screening
* Treatment experience with antiretroviral therapies (excluding integrase inhibitors)
* Screening PHENOSENSE Entry indicating BMS-...",Yes,2017-11-14,FDA-30940,4.41,0.98,21.0,26.39,2021-10-08,2022-10-01,2043-10-01,84,Novartis,33,Kenya,41.83333333333334,0,21,68,81,50,31,64,1,3,3,False,True,True,True,False,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
BMS-663068 600 mg,TradeName X,Drug,hiv,hiv,Phase 2,2017-05-12,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Plasma HIV-1 RNA ≥ 1000 copies/ml at Screening
* Treatment experience with antiretroviral therapies (excluding integrase inhibitors)
* Screening PHENOSENSE Entry indicating BMS-...",Yes,2017-11-19,FDA-22810,4.41,0.98,21.0,26.39,2021-10-08,2022-10-01,2043-10-01,53,Novartis,97,South Africa,38.0,48,8,95,68,6,3,27,0,0,3,False,False,False,False,False,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
BMS-663068 1200 mg,Product Alpha,Drug,hiv,hiv,Phase 2,2017-05-12,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Plasma HIV-1 RNA ≥ 1000 copies/ml at Screening
* Treatment experience with antiretroviral therapies (excluding integrase inhibitors)
* Screening PHENOSENSE Entry indicating BMS-...",Yes,2017-07-03,FDA-73783,4.41,0.98,21.0,26.39,2021-10-08,2022-10-01,2043-10-01,67,GSK,92,Overall,59.16666666666666,100,14,42,62,87,50,64,1,4,2,True,False,True,True,True,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir 400 mg,TradeName X,Drug,hiv,hiv,Phase 2,2017-05-12,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Plasma HIV-1 RNA ≥ 1000 copies/ml at Screening
* Treatment experience with antiretroviral therapies (excluding integrase inhibitors)
* Screening PHENOSENSE Entry indicating BMS-...",No,2018-03-19,FDA-55622,4.41,0.98,21.0,26.39,2021-10-08,2022-10-01,2043-10-01,95,J&J,65,Kenya,61.16666666666666,17,60,89,77,68,56,73,2,4,2,True,True,True,False,True,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir 300 mg,Molecule Z,Drug,hiv,hiv,Phase 2,2017-05-12,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Plasma HIV-1 RNA ≥ 1000 copies/ml at Screening
* Treatment experience with antiretroviral therapies (excluding integrase inhibitors)
* Screening PHENOSENSE Entry indicating BMS-...",No,2017-09-15,FDA-13757,4.41,0.98,21.0,26.39,2021-10-08,2022-10-01,2043-10-01,90,AstraZeneca,54,Kenya,70.0,90,79,46,91,56,58,27,1,2,0,False,True,True,False,False,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir 100 mg,Molecule Z,Drug,hiv,hiv,Phase 2,2017-05-12,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Plasma HIV-1 RNA ≥ 1000 copies/ml at Screening
* Treatment experience with antiretroviral therapies (excluding integrase inhibitors)
* Screening PHENOSENSE Entry indicating BMS-...",Yes,2017-08-21,FDA-75823,4.41,0.98,21.0,26.39,2021-10-08,2022-10-01,2043-10-01,17,Bayer,87,Kenya,55.83333333333334,61,23,69,46,64,72,64,0,5,2,False,False,True,True,True,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir 300 mg,AltName B,Drug,hiv,hiv,Phase 2,2017-05-12,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Plasma HIV-1 RNA ≥ 1000 copies/ml at Screening
* Treatment experience with antiretroviral therapies (excluding integrase inhibitors)
* Screening PHENOSENSE Entry indicating BMS-...",No,2018-01-05,FDA-46906,4.41,0.98,21.0,26.39,2021-10-08,2022-10-01,2043-10-01,51,Novartis,11,South Africa,56.0,40,12,93,55,82,54,45,1,3,1,True,False,False,False,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DTG 50 mg,AltName B,Drug,hiv,hiv,Phase 3,2020-03-06,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subject or the subject's legal representative is willing and able to understand and provide signed and dated written informed consent prior to Screening
* Adult subject (at leas...",No,2021-01-16,FDA-59842,2.62,0.32,5.0,7.94,2022-10-18,2023-02-12,2028-02-13,69,GSK,27,South Africa,54.0,16,56,80,98,15,59,55,2,2,2,True,True,True,False,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
EFV 600 mg,AltName B,Drug,hiv,hiv,Phase 3,2020-03-06,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subject or the subject's legal representative is willing and able to understand and provide signed and dated written informed consent prior to Screening
* Adult subject (at leas...",Yes,2020-09-22,FDA-14304,2.62,0.32,5.0,7.94,2022-10-18,2023-02-12,2028-02-13,62,Novartis,29,Overall,66.16666666666667,51,91,100,78,67,10,64,1,3,3,False,True,False,True,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Clopidogrel,GenName Y,Drug,hiv,hiv,Phase 2,2016-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: HIV infected participants:

Inclusion Criteria:

* HIV-1 infection
* Currently on continuous ART for ≥48 weeks prior to study entry. NOTE: This is defined as continuous active therapy with no treatmen...",No,2017-08-07,FDA-89396,4.41,0.98,21.0,26.39,2021-03-30,2022-03-23,2043-03-23,57,Pfizer,79,Overall,62.5,94,39,80,45,17,100,45,1,1,3,True,False,False,True,False,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Aspirin,Product Alpha,Drug,hiv,hiv,Phase 2,2016-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: HIV infected participants:

Inclusion Criteria:

* HIV-1 infection
* Currently on continuous ART for ≥48 weeks prior to study entry. NOTE: This is defined as continuous active therapy with no treatmen...",No,2017-08-17,FDA-58009,4.41,0.98,21.0,26.39,2021-03-30,2022-03-23,2043-03-23,100,GSK,25,South Africa,41.16666666666666,23,11,16,48,51,98,27,0,2,1,False,False,False,True,False,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Inactivated Influenza H1N1 vaccine,Product Alpha,Biological,hiv,hiv,Phase 2,2010-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Human immunodeficiency virus (HIV) infection defined as documented by an enzyme-linked immunosorbent assay (ELISA) and confirmed with a Western blot at any time prior to study e...",Yes,2011-01-03,FDA-18446,4.41,0.98,21.0,26.39,2015-03-30,2016-03-22,2037-03-22,25,Merck,90,Kenya,45.5,44,40,80,39,18,52,36,0,3,1,False,False,True,False,True,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Topiramate,Molecule Z,Drug,hiv,hiv,Phase 2,2014-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Seropositive for HIV
* Age 18-70
* Report average of at least twice weekly heavy drinking
* Willing to reduce drinking to non-hazardous levels
* Verbal Intelligence Quotient (Ve...",Yes,2014-06-20,FDA-54401,4.41,0.98,21.0,26.39,2018-05-30,2019-05-23,2040-05-22,22,Sanofi,41,Overall,68.83333333333333,65,70,51,42,95,90,36,0,2,2,False,False,False,False,True,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Busulfan,AltName B,Drug,hiv,hiv,Phase 2,2017-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Prior to any study-related procedures, signed informed consent indicating that they understand the purpose, risks and procedures required for the study and are willing to partic...",No,2018-03-15,FDA-48266,4.41,0.98,21.0,26.39,2022-03-30,2023-03-23,2044-03-22,48,Merck,83,Overall,57.0,76,47,35,90,5,89,55,1,3,2,True,False,True,False,True,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Cal-1 modified HSPC,GenName Y,Biological,hiv,hiv,Phase 2,2017-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Prior to any study-related procedures, signed informed consent indicating that they understand the purpose, risks and procedures required for the study and are willing to partic...",Yes,2018-07-17,FDA-68735,4.41,0.98,21.0,26.39,2022-03-30,2023-03-23,2044-03-22,98,J&J,4,Senegal,28.83333333333333,6,26,32,13,19,77,45,0,3,2,False,False,False,True,True,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Cal-1 modified CD4+ T lymphocytes,GenName Y,Biological,hiv,hiv,Phase 2,2017-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Prior to any study-related procedures, signed informed consent indicating that they understand the purpose, risks and procedures required for the study and are willing to partic...",No,2018-06-28,FDA-31149,4.41,0.98,21.0,26.39,2022-03-30,2023-03-23,2044-03-22,90,GSK,77,Senegal,62.33333333333334,84,50,38,56,78,68,45,1,2,2,True,False,True,False,False,False,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
fosamprenavir/ritonavir,GenName Y,Drug,hiv,hiv,Phase 4,2010-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* fasting triglycerides \>= 200 mg/dL but \<1,200 mg/dL
* fasting LDL \<= 160 mg/dL
* participation in a lipid-lowering diet and exercise program for at least 28 days
* treatment ...",Yes,2010-12-15,FDA-19034,0.56,0.15,3.5,4.21,2011-05-24,2011-07-18,2015-01-16,56,Sanofi,10,Overall,50.33333333333334,11,13,78,36,70,94,45,1,3,1,True,False,True,False,True,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir + Lamivudine FDC,Product Alpha,Drug,hiv,hiv,Phase 3,2020-10-20,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Eligible participants must be able to understand and comply with protocol requirements, instructions, and restrictions.
* Eligible participants must be likely to complete the st...",No,2021-05-30,FDA-21178,2.62,0.32,5.0,7.94,2023-06-03,2023-09-28,2028-09-28,11,GSK,11,Senegal,44.66666666666666,53,9,59,47,84,16,45,0,2,3,False,False,True,False,False,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
744 Tablet,GenName Y,Drug,hiv,hiv,Phase 2,2016-02-23,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Non-reactive HIV test at screening or enrollment.
* Males 18 to 65 years old at the time of signing the informed consent.
* At risk of acquiring HIV, defined as having at least ...",Yes,2016-07-28,FDA-52088,4.41,0.98,21.0,26.39,2020-07-21,2021-07-14,2042-07-14,23,Gilead,84,Senegal,30.5,4,21,12,58,1,87,27,1,0,2,True,False,False,False,False,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
744 LA Injection,Product Alpha,Drug,hiv,hiv,Phase 2,2016-02-23,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Non-reactive HIV test at screening or enrollment.
* Males 18 to 65 years old at the time of signing the informed consent.
* At risk of acquiring HIV, defined as having at least ...",No,2016-05-02,FDA-12828,4.41,0.98,21.0,26.39,2020-07-21,2021-07-14,2042-07-14,80,J&J,10,Senegal,77.0,84,74,58,90,57,99,64,1,2,4,True,False,False,False,True,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
BMS-955176,Molecule Z,Drug,hiv,hiv,Phase 2,2014-11-29,"Sex: ALL; Age: >18 Years; Criteria: For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

* Age 18-55 years inclusive
* Men and women: (Parts A and C); men only (Par...",Yes,2015-07-01,FDA-92514,4.41,0.98,21.0,26.39,2019-04-27,2020-04-19,2041-04-19,72,Merck,64,Senegal,67.16666666666667,45,81,97,98,9,73,36,1,3,0,False,True,False,True,True,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir,Product Alpha,Drug,hiv,hiv,Phase 2,2014-11-29,"Sex: ALL; Age: >18 Years; Criteria: For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

* Age 18-55 years inclusive
* Men and women: (Parts A and C); men only (Par...",Yes,2015-01-18,FDA-16863,4.41,0.98,21.0,26.39,2019-04-27,2020-04-19,2041-04-19,90,GSK,22,Overall,50.0,34,62,19,79,23,83,73,2,4,2,True,True,True,False,True,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,Product Alpha,Drug,hiv,hiv,Phase 2,2014-11-29,"Sex: ALL; Age: >18 Years; Criteria: For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

* Age 18-55 years inclusive
* Men and women: (Parts A and C); men only (Par...",Yes,2015-05-06,FDA-67640,4.41,0.98,21.0,26.39,2019-04-27,2020-04-19,2041-04-19,45,AstraZeneca,22,South Africa,29.16666666666667,0,1,61,77,27,9,64,2,3,2,True,True,True,True,True,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir,AltName B,Drug,hiv,hiv,Phase 2,2014-11-29,"Sex: ALL; Age: >18 Years; Criteria: For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

* Age 18-55 years inclusive
* Men and women: (Parts A and C); men only (Par...",No,2015-06-17,FDA-80020,4.41,0.98,21.0,26.39,2019-04-27,2020-04-19,2041-04-19,12,Sanofi,58,South Africa,43.83333333333334,20,64,9,56,38,76,45,0,3,2,False,False,False,True,True,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine,Comp Beta,Drug,hiv,hiv,Phase 2,2014-11-29,"Sex: ALL; Age: >18 Years; Criteria: For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

* Age 18-55 years inclusive
* Men and women: (Parts A and C); men only (Par...",Yes,2015-08-25,FDA-18004,4.41,0.98,21.0,26.39,2019-04-27,2020-04-19,2041-04-19,5,AstraZeneca,64,Senegal,48.5,27,11,100,8,97,48,36,1,1,2,False,True,False,False,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK3810109A,Molecule Z,Biological,hiv,hiv,Phase 2,2023-09-21,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participant must be 18 to 65 years of age inclusive, at the time of signing the informed consent.
* Participants must have HIV-1 infection within 45 days of the Screening Visit:...",No,2024-04-19,FDA-17890,4.41,0.98,21.0,26.39,2028-02-17,2029-02-09,2050-02-09,28,AstraZeneca,89,South Africa,30.83333333333333,56,32,19,20,20,38,55,2,2,2,True,True,False,True,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir+lamivudine SOC regimen,TradeName X,Biological,hiv,hiv,Phase 2,2023-09-21,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participant must be 18 to 65 years of age inclusive, at the time of signing the informed consent.
* Participants must have HIV-1 infection within 45 days of the Screening Visit:...",Yes,2023-12-31,FDA-71136,4.41,0.98,21.0,26.39,2028-02-17,2029-02-09,2050-02-09,96,GSK,97,South Africa,55.5,16,88,82,49,29,69,64,1,3,3,False,True,True,False,True,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK Biologicals' HPV vaccine 580299,Comp Beta,Biological,hiv,hiv,Phase 4,2017-04-19,"Sex: FEMALE; Age: >15 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that they and/or their parent(s)/legally acceptable representative(s) (LAR) can and will comply with the requirements of the protocol.
* A...",No,2018-01-19,FDA-96956,0.56,0.15,3.5,4.21,2017-11-09,2018-01-03,2021-07-04,57,Merck,35,South Africa,59.5,58,74,20,80,84,41,73,2,4,2,True,True,True,True,False,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)",Molecule Z,Biological,hiv,hiv,Phase 4,2017-04-19,"Sex: FEMALE; Age: >15 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that they and/or their parent(s)/legally acceptable representative(s) (LAR) can and will comply with the requirements of the protocol.
* A...",Yes,2018-01-22,FDA-45262,0.56,0.15,3.5,4.21,2017-11-09,2018-01-03,2021-07-04,87,Gilead,55,South Africa,67.33333333333333,89,29,72,97,27,90,64,1,3,3,False,True,False,False,True,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Bupropion,TradeName X,Drug,hiv,hiv,Phase 4,2021-11-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* VHA patient
* HIV positive serostatus
* currently smoking 7 cigarettes per week
* willing to complete study procedures. Exclusion criteria are:

Exclusion Criteria:

* current h...",No,2022-10-11,FDA-74199,0.56,0.15,3.5,4.21,2022-06-02,2022-07-27,2026-01-25,5,Pfizer,73,Overall,25.33333333333333,12,48,27,3,8,54,27,0,2,1,False,False,False,True,True,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Varenicline,Comp Beta,Drug,hiv,hiv,Phase 4,2021-11-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* VHA patient
* HIV positive serostatus
* currently smoking 7 cigarettes per week
* willing to complete study procedures. Exclusion criteria are:

Exclusion Criteria:

* current h...",Yes,2022-04-24,FDA-39204,0.56,0.15,3.5,4.21,2022-06-02,2022-07-27,2026-01-25,77,Pfizer,97,Kenya,30.83333333333333,13,31,24,4,64,49,55,1,1,4,True,False,True,False,False,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Nicotine Replacement Therapy,AltName A,Drug,hiv,hiv,Phase 4,2021-11-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* VHA patient
* HIV positive serostatus
* currently smoking 7 cigarettes per week
* willing to complete study procedures. Exclusion criteria are:

Exclusion Criteria:

* current h...",No,2022-02-25,FDA-91231,0.56,0.15,3.5,4.21,2022-06-02,2022-07-27,2026-01-25,25,Pfizer,46,Overall,45.5,51,79,28,49,22,44,55,1,3,2,False,True,True,True,False,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Vitamin D supplementation-,Product Alpha,Drug,hiv,hiv,Phase 3,2016-08-01,"Sex: ALL; Age: >8 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Ages 8-25
* Documented HIV-1 infection
* On stable antiretroviral therapy for \> 3 months
* Cumulative antiretroviral therapy of at least 6 months
* 25(OH)D level \< 30 ng/ml at...",No,2017-04-22,FDA-86329,2.62,0.32,5.0,7.94,2019-03-15,2019-07-10,2024-07-10,72,Sanofi,3,Senegal,50.83333333333334,9,81,23,64,41,87,73,2,3,3,True,True,True,True,False,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
VRC01,AltName B,Biological,hiv,hiv,Phase 2,2017-08-04,"Sex: ALL; Age: >20 Years; Criteria: Inclusion Criteria:

* Able and willing to provide written informed consent or, in the case of illiteracy, witnessed verbal informed consent with documentation of a thumbprint in lieu of a signature.
...",Yes,2018-01-12,FDA-21106,4.41,0.98,21.0,26.39,2021-12-31,2022-12-24,2043-12-24,39,Merck,56,Kenya,57.83333333333334,91,60,44,26,42,84,45,0,3,2,False,False,True,True,True,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS),GenName Y,Drug,hiv,hiv,Phase 3,2016-05-26,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Intrauterine pregnancy confirmed by ultrasound
2. Estimated gestational age between 12-28 weeks
3. Confirmed to be HIV-infected by Uganda country standard rapid HIV test
4. 16 ...",No,2016-08-30,FDA-99113,2.62,0.32,5.0,7.94,2019-01-07,2019-05-04,2024-05-04,60,AstraZeneca,13,South Africa,70.5,90,90,83,52,46,62,27,1,1,1,True,False,False,False,True,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Darunavir,Comp Beta,Drug,hiv,hiv,Phase 2,2011-02-01,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

* Participants with a documented HIV 1 infection (by any of the local standard diagnostic methods, such as HIV PCR-DNA, ELISA or western blot (WB) test for HIV antibodies, etc.)
*...",No,2011-05-19,FDA-92965,4.41,0.98,21.0,26.39,2015-06-30,2016-06-22,2037-06-22,52,Gilead,59,Kenya,50.66666666666666,67,22,22,69,26,98,55,2,4,0,True,True,True,False,True,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,Molecule Z,Drug,hiv,hiv,Phase 2,2011-02-01,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

* Participants with a documented HIV 1 infection (by any of the local standard diagnostic methods, such as HIV PCR-DNA, ELISA or western blot (WB) test for HIV antibodies, etc.)
*...",No,2012-01-01,FDA-31551,4.41,0.98,21.0,26.39,2015-06-30,2016-06-22,2037-06-22,65,Bayer,13,Senegal,63.16666666666666,67,86,26,61,51,88,36,1,2,1,True,False,False,True,False,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"etravirine (ETR, TMC125)",Molecule Z,Drug,hiv,hiv,Phase 2,2011-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented HIV-1 infection
* In the judgement of the investigator, it is appropriate to initiate ARV therapy based on the patients medical condition and taking into account appl...",Yes,2011-05-14,FDA-91029,4.41,0.98,21.0,26.39,2015-05-30,2016-05-22,2037-05-22,55,Merck,70,South Africa,46.5,36,45,62,24,83,29,36,1,2,1,True,False,False,True,True,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
efavirenz (EFV),Product Alpha,Drug,hiv,hiv,Phase 2,2011-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented HIV-1 infection
* In the judgement of the investigator, it is appropriate to initiate ARV therapy based on the patients medical condition and taking into account appl...",Yes,2011-10-18,FDA-54463,4.41,0.98,21.0,26.39,2015-05-30,2016-05-22,2037-05-22,72,Novartis,40,Overall,57.83333333333334,51,26,89,56,93,32,27,1,1,1,True,False,True,False,False,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Pharmacotherapy for opioid use disorder,AltName B,Drug,hiv,hiv,Phase 4,2022-04-06,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* 18 years or older
* HIV infected
* Hospitalized at narcology hospital
* History of injection drug use
* Current diagnosis of opioid use disorder
* Provision of information for 2...",No,2022-06-25,FDA-12675,0.56,0.15,3.5,4.21,2022-10-27,2022-12-21,2026-06-21,83,GSK,68,Kenya,41.66666666666666,24,33,72,8,35,78,55,1,3,2,False,True,True,False,False,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Cholecalciferol (Vit D3),GenName Y,Drug,hiv,hiv,Phase 2,2011-01-01,"Sex: ALL; Age: >5 Years; Criteria: Inclusion Criteria:

1. HIV seropositive diagnosed with standard techniques
2. Age for perinatally-acquired HIV/AIDS Group (PA subjects): 5.0 to 24.9 y
3. Age for non-perinatally-acquired HIV/AIDS Gro...",No,2011-06-14,FDA-26143,4.41,0.98,21.0,26.39,2015-05-30,2016-05-22,2037-05-22,44,J&J,79,South Africa,37.83333333333334,13,34,33,45,12,90,55,1,4,1,False,True,False,True,True,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Nevirapine,Molecule Z,Drug,hiv,hiv,Phase 3,2011-11-01,"Sex: ALL; Criteria: Note: As of 08/10/07, the arm assignments for current and new participants have changed. Please see the above description for this trial for more information.

Inclusion Criteria for Mothers:

* 18 ye...",No,2012-02-17,FDA-55287,2.62,0.32,5.0,7.94,2014-06-14,2014-10-09,2019-10-10,80,Pfizer,32,South Africa,67.0,56,47,94,96,94,15,64,0,4,3,False,False,True,True,True,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line),AltName B,Drug,hiv,hiv,Phase 3,2015-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient over the age of 18 years at pre-inclusion and monitored under outpatient conditions
* Documented HIV-1 infection regardless of clinical stage and CD4 lymphocyte count
* ...",No,2016-01-06,FDA-84161,2.62,0.32,5.0,7.94,2018-07-14,2018-11-08,2023-11-09,38,Bayer,14,Senegal,71.0,99,54,81,64,92,36,45,1,3,1,True,False,True,True,True,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line),Comp Beta,Drug,hiv,hiv,Phase 3,2015-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient over the age of 18 years at pre-inclusion and monitored under outpatient conditions
* Documented HIV-1 infection regardless of clinical stage and CD4 lymphocyte count
* ...",Yes,2016-06-02,FDA-25690,2.62,0.32,5.0,7.94,2018-07-14,2018-11-08,2023-11-09,33,Pfizer,94,Kenya,60.16666666666666,97,75,82,93,14,0,36,1,3,0,False,True,False,True,True,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation),AltName B,Drug,hiv,hiv,Phase 3,2015-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient over the age of 18 years at pre-inclusion and monitored under outpatient conditions
* Documented HIV-1 infection regardless of clinical stage and CD4 lymphocyte count
* ...",Yes,2016-05-04,FDA-35340,2.62,0.32,5.0,7.94,2018-07-14,2018-11-08,2023-11-09,52,AstraZeneca,30,Kenya,45.0,69,8,53,38,55,47,36,1,3,0,False,True,False,True,True,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir,AltName B,Drug,hiv,hiv,Phase 2,2010-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Human Immunodeficiency Virus (HIV)-1 positive status
* HIV ribonucleic acid (RNA) level \>=5000 copies/mL
* Antiretroviral treatment-naive
* Absolute Cluster of Differentiation ...",No,2010-12-10,FDA-17002,4.41,0.98,21.0,26.39,2014-09-27,2015-09-20,2036-09-19,32,Pfizer,18,Overall,45.66666666666666,61,58,58,26,51,20,73,1,4,3,True,False,True,True,True,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,Comp Beta,Drug,hiv,hiv,Phase 2,2010-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Human Immunodeficiency Virus (HIV)-1 positive status
* HIV ribonucleic acid (RNA) level \>=5000 copies/mL
* Antiretroviral treatment-naive
* Absolute Cluster of Differentiation ...",No,2010-10-14,FDA-86430,4.41,0.98,21.0,26.39,2014-09-27,2015-09-20,2036-09-19,17,Bayer,69,Kenya,43.66666666666666,13,54,13,51,45,86,36,1,1,2,False,True,False,True,False,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir,Product Alpha,Drug,hiv,hiv,Phase 2,2010-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Human Immunodeficiency Virus (HIV)-1 positive status
* HIV ribonucleic acid (RNA) level \>=5000 copies/mL
* Antiretroviral treatment-naive
* Absolute Cluster of Differentiation ...",Yes,2010-07-30,FDA-35588,4.41,0.98,21.0,26.39,2014-09-27,2015-09-20,2036-09-19,77,Merck,7,Kenya,47.66666666666666,59,32,78,38,27,52,64,2,3,2,True,True,True,True,False,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,AltName B,Drug,hiv,hiv,Phase 2,2010-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Human Immunodeficiency Virus (HIV)-1 positive status
* HIV ribonucleic acid (RNA) level \>=5000 copies/mL
* Antiretroviral treatment-naive
* Absolute Cluster of Differentiation ...",No,2010-07-04,FDA-86360,4.41,0.98,21.0,26.39,2014-09-27,2015-09-20,2036-09-19,48,GSK,30,Overall,55.0,57,78,45,46,14,90,45,1,1,3,False,True,False,False,True,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir/Emtricitabine,Comp Beta,Drug,hiv,hiv,Phase 2,2010-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Human Immunodeficiency Virus (HIV)-1 positive status
* HIV ribonucleic acid (RNA) level \>=5000 copies/mL
* Antiretroviral treatment-naive
* Absolute Cluster of Differentiation ...",Yes,2010-11-26,FDA-29664,4.41,0.98,21.0,26.39,2014-09-27,2015-09-20,2036-09-19,37,J&J,77,South Africa,58.33333333333334,72,92,29,71,28,58,55,1,4,1,False,True,True,True,True,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
TAF,GenName Y,Drug,hiv,hiv,Phase 3,2017-07-31,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Currently taking a failing ARV regimen
* Pla...",No,2018-02-17,FDA-80336,2.62,0.32,5.0,7.94,2020-03-13,2020-07-08,2025-07-09,59,GSK,80,Senegal,58.5,90,82,50,1,95,33,45,0,3,2,False,False,True,True,False,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
E/C/F/TAF,Comp Beta,Drug,hiv,hiv,Phase 3,2017-07-31,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Currently taking a failing ARV regimen
* Pla...",Yes,2017-12-09,FDA-65096,2.62,0.32,5.0,7.94,2020-03-13,2020-07-08,2025-07-09,27,Sanofi,66,Senegal,45.16666666666666,41,51,97,31,42,9,55,0,3,3,False,False,False,True,True,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Current failing ARV regimen,GenName Y,Drug,hiv,hiv,Phase 3,2017-07-31,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Currently taking a failing ARV regimen
* Pla...",Yes,2017-09-28,FDA-91636,2.62,0.32,5.0,7.94,2020-03-13,2020-07-08,2025-07-09,14,GSK,18,South Africa,70.0,88,42,73,53,69,95,55,1,2,3,True,False,False,True,True,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ATV,AltName B,Drug,hiv,hiv,Phase 3,2017-07-31,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Currently taking a failing ARV regimen
* Pla...",No,2018-04-09,FDA-87835,2.62,0.32,5.0,7.94,2020-03-13,2020-07-08,2025-07-09,79,Bayer,60,Overall,57.66666666666666,61,52,77,76,8,72,64,2,3,2,True,True,False,True,False,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Comparator: Raltegravir 400 mg b.i.d.,Molecule Z,Drug,hiv,hiv,Phase 3,2011-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient is male or female 18 years of age or older
* Patient is HIV positive
* Patient is naïve to antiretroviral therapy (ART) or has received less than 7 days total of any ART...",No,2012-02-03,FDA-83894,2.62,0.32,5.0,7.94,2013-12-12,2014-04-08,2019-04-09,74,AstraZeneca,22,South Africa,55.33333333333334,66,5,49,88,39,85,64,1,3,3,False,True,True,False,True,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Experimental: Raltegravir 800 mg q.d.,Comp Beta,Drug,hiv,hiv,Phase 3,2011-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient is male or female 18 years of age or older
* Patient is HIV positive
* Patient is naïve to antiretroviral therapy (ART) or has received less than 7 days total of any ART...",No,2012-03-22,FDA-17729,2.62,0.32,5.0,7.94,2013-12-12,2014-04-08,2019-04-09,57,Gilead,15,Senegal,54.16666666666666,88,57,42,72,62,4,9,0,0,1,False,False,False,False,False,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
TRUVADA™,TradeName X,Drug,hiv,hiv,Phase 3,2011-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient is male or female 18 years of age or older
* Patient is HIV positive
* Patient is naïve to antiretroviral therapy (ART) or has received less than 7 days total of any ART...",No,2011-09-25,FDA-91892,2.62,0.32,5.0,7.94,2013-12-12,2014-04-08,2019-04-09,70,GSK,51,Overall,59.66666666666666,70,78,45,89,45,31,45,1,2,2,True,False,False,True,False,False,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
BCG,TradeName X,Biological,hiv,hiv,Phase 2,,"Sex: ALL; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Healthy neonate
* Maternal HIV
* \> 36 weeks gestation
* Birth weight \> 2.4kg
* Remaining in area 4 months

Exclusion Criteria:

* Complications during pregnancy and delivery
*...",No,2026-08-21,FDA-82190,4.41,0.98,21.0,26.39,,,,17,J&J,9,Overall,45.66666666666666,66,48,97,37,9,17,45,1,3,1,True,False,False,False,True,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein),GenName Y,Drug,hiv,hiv,Phase 2,2021-05-27,"Sex: ALL; Age: >50 Years; Criteria: Inclusion Criteria:

* Provides signed and dated informed consent form
* Is willing to comply with all study procedures and availability for the duration of the study
* Is at least 50 years of age or ...",No,2022-03-16,FDA-67820,4.41,0.98,21.0,26.39,2025-10-23,2026-10-16,2047-10-16,59,Gilead,62,South Africa,62.16666666666666,98,82,48,60,53,32,18,1,1,0,False,True,False,False,False,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Saline Solution,AltName B,Drug,hiv,hiv,Phase 2,2021-05-27,"Sex: ALL; Age: >50 Years; Criteria: Inclusion Criteria:

* Provides signed and dated informed consent form
* Is willing to comply with all study procedures and availability for the duration of the study
* Is at least 50 years of age or ...",Yes,2022-02-24,FDA-94224,4.41,0.98,21.0,26.39,2025-10-23,2026-10-16,2047-10-16,71,Bayer,16,Kenya,41.33333333333334,10,6,34,91,58,49,45,1,3,1,True,False,True,True,False,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Remune and ALVAC,GenName Y,Biological,hiv,hiv,Phase 2,2010-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented HIV infection (by serology)
* HIV RNA level below 50 copies/ml for at least two years
* Receiving at least 2 antiretroviral agents including at least 1 protease inhib...",Yes,2011-07-18,FDA-16489,4.41,0.98,21.0,26.39,2015-03-30,2016-03-22,2037-03-22,83,Bayer,69,South Africa,25.33333333333333,28,0,76,24,23,1,45,0,3,2,False,False,True,False,True,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
maraviroc (Selzentry),Comp Beta,Drug,hiv,hiv,Phase 2,2013-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection as documented by ELISA and confirmed by either Western blot, HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA by RT-PCR or bDNA at any time prior to study entry.
*...",No,2014-01-23,FDA-84473,4.41,0.98,21.0,26.39,2017-12-28,2018-12-21,2039-12-21,64,Pfizer,15,Senegal,38.66666666666666,39,6,35,30,48,74,55,0,4,2,False,False,False,True,True,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"Disulfiram, (National Drug Code) NDC 0378-4141-01",AltName B,Drug,hiv,hiv,Phase 2,2019-04-09,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Age 18-65 years with documented HIV-1 infection (antibody positive or detectable plasma HIV-1 RNA)
* Receiving combination ART with plasma HIV RNA \<50 copies/mL for \>3 years
*...",No,2019-11-21,FDA-33921,4.41,0.98,21.0,26.39,2023-09-05,2024-08-28,2045-08-28,7,Sanofi,93,South Africa,40.5,60,49,11,45,0,78,36,2,2,0,True,True,False,False,False,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"Vorinostat, NDC 00006-0568-40",Molecule Z,Drug,hiv,hiv,Phase 2,2019-04-09,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Age 18-65 years with documented HIV-1 infection (antibody positive or detectable plasma HIV-1 RNA)
* Receiving combination ART with plasma HIV RNA \<50 copies/mL for \>3 years
*...",Yes,2019-10-27,FDA-96705,4.41,0.98,21.0,26.39,2023-09-05,2024-08-28,2045-08-28,16,Pfizer,6,South Africa,42.66666666666666,6,58,41,98,10,43,27,1,1,1,True,False,False,True,False,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Darunavir,AltName A,Drug,hiv,hiv,Phase 3,2016-08-11,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Pregnant females (18-26 weeks of gestation)
* documented HIV-1 infection
* Receiving darunavir/ritonavir, darunavir/cobicistat, etravirine, or rilpivirine at the time of study e...",No,2016-10-09,FDA-57023,2.62,0.32,5.0,7.94,2019-03-25,2019-07-20,2024-07-20,50,Bayer,90,Kenya,39.66666666666666,41,38,10,5,95,49,45,0,1,4,False,False,False,False,False,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,GenName Y,Drug,hiv,hiv,Phase 3,2016-08-11,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Pregnant females (18-26 weeks of gestation)
* documented HIV-1 infection
* Receiving darunavir/ritonavir, darunavir/cobicistat, etravirine, or rilpivirine at the time of study e...",No,2017-05-01,FDA-38845,2.62,0.32,5.0,7.94,2019-03-25,2019-07-20,2024-07-20,22,Pfizer,93,Overall,63.16666666666666,46,91,81,62,90,9,55,1,4,1,True,False,False,True,True,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Etravirine,TradeName X,Drug,hiv,hiv,Phase 3,2016-08-11,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Pregnant females (18-26 weeks of gestation)
* documented HIV-1 infection
* Receiving darunavir/ritonavir, darunavir/cobicistat, etravirine, or rilpivirine at the time of study e...",Yes,2016-11-14,FDA-93260,2.62,0.32,5.0,7.94,2019-03-25,2019-07-20,2024-07-20,69,Pfizer,16,Senegal,40.33333333333334,28,71,4,43,48,48,27,0,2,1,False,False,True,False,False,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rilpivirine,Product Alpha,Drug,hiv,hiv,Phase 3,2016-08-11,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Pregnant females (18-26 weeks of gestation)
* documented HIV-1 infection
* Receiving darunavir/ritonavir, darunavir/cobicistat, etravirine, or rilpivirine at the time of study e...",No,2017-05-18,FDA-39131,2.62,0.32,5.0,7.94,2019-03-25,2019-07-20,2024-07-20,62,Merck,24,South Africa,40.16666666666666,1,42,55,50,3,90,73,2,3,3,True,True,True,False,False,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Darunavir/Cobicistat (FDC),Molecule Z,Drug,hiv,hiv,Phase 3,2016-08-11,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Pregnant females (18-26 weeks of gestation)
* documented HIV-1 infection
* Receiving darunavir/ritonavir, darunavir/cobicistat, etravirine, or rilpivirine at the time of study e...",No,2017-05-06,FDA-55120,2.62,0.32,5.0,7.94,2019-03-25,2019-07-20,2024-07-20,52,Merck,38,Senegal,57.0,13,94,79,54,68,34,36,1,1,2,True,False,True,False,False,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Mycophenolate Mofetil 500Mg Tab,TradeName X,Drug,hiv,hiv,Phase 2,2019-08-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Confirmed HIV infection, by two different positive antibody tests and/or detectable plasma HIV RNA on two different dates
2. ≥18 and ≤65 years of age
3. Continuous ART during t...",Yes,2019-09-30,FDA-27944,4.41,0.98,21.0,26.39,2024-01-27,2025-01-19,2046-01-19,55,Bayer,49,Overall,34.33333333333334,34,0,14,86,47,25,36,1,0,3,True,False,False,False,False,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Abacavir sulfate,TradeName X,Drug,hiv,hiv,Phase 3,2013-01-01,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria for Infants:

NOTE: Per Letter of Amendment dated 04/04/07, Part B of this study is no longer recruiting participants. Per Letter of Amendment dated 09/16/08 Arm 1 of this study is ...",Yes,2013-10-11,FDA-72531,2.62,0.32,5.0,7.94,2015-08-15,2015-12-10,2020-12-10,72,GSK,24,Senegal,62.16666666666666,64,90,44,51,28,96,45,2,2,1,True,True,False,False,True,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Didanosine,TradeName X,Drug,hiv,hiv,Phase 3,2013-01-01,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria for Infants:

NOTE: Per Letter of Amendment dated 04/04/07, Part B of this study is no longer recruiting participants. Per Letter of Amendment dated 09/16/08 Arm 1 of this study is ...",No,2013-11-26,FDA-21652,2.62,0.32,5.0,7.94,2015-08-15,2015-12-10,2020-12-10,87,GSK,69,Kenya,49.16666666666666,13,78,44,5,93,62,45,1,3,1,True,False,False,True,True,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,TradeName X,Drug,hiv,hiv,Phase 3,2013-01-01,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria for Infants:

NOTE: Per Letter of Amendment dated 04/04/07, Part B of this study is no longer recruiting participants. Per Letter of Amendment dated 09/16/08 Arm 1 of this study is ...",No,2013-11-28,FDA-62401,2.62,0.32,5.0,7.94,2015-08-15,2015-12-10,2020-12-10,18,Pfizer,36,Senegal,52.33333333333334,17,20,45,100,93,39,82,2,4,3,True,True,True,True,True,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine,GenName Y,Drug,hiv,hiv,Phase 3,2013-01-01,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria for Infants:

NOTE: Per Letter of Amendment dated 04/04/07, Part B of this study is no longer recruiting participants. Per Letter of Amendment dated 09/16/08 Arm 1 of this study is ...",Yes,2013-08-24,FDA-30379,2.62,0.32,5.0,7.94,2015-08-15,2015-12-10,2020-12-10,76,Novartis,42,Senegal,68.16666666666667,95,14,87,96,23,94,64,1,3,3,False,True,False,False,True,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir/Ritonavir,AltName A,Drug,hiv,hiv,Phase 3,2013-01-01,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria for Infants:

NOTE: Per Letter of Amendment dated 04/04/07, Part B of this study is no longer recruiting participants. Per Letter of Amendment dated 09/16/08 Arm 1 of this study is ...",Yes,2013-04-30,FDA-54605,2.62,0.32,5.0,7.94,2015-08-15,2015-12-10,2020-12-10,50,Sanofi,25,Overall,58.83333333333334,28,49,100,65,93,18,64,1,3,3,False,True,True,True,True,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Nevirapine,GenName Y,Drug,hiv,hiv,Phase 3,2013-01-01,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria for Infants:

NOTE: Per Letter of Amendment dated 04/04/07, Part B of this study is no longer recruiting participants. Per Letter of Amendment dated 09/16/08 Arm 1 of this study is ...",Yes,2013-07-11,FDA-11106,2.62,0.32,5.0,7.94,2015-08-15,2015-12-10,2020-12-10,41,Gilead,62,Overall,48.0,26,65,73,9,53,62,45,0,3,2,False,False,False,False,True,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Zidovudine,Product Alpha,Drug,hiv,hiv,Phase 3,2013-01-01,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria for Infants:

NOTE: Per Letter of Amendment dated 04/04/07, Part B of this study is no longer recruiting participants. Per Letter of Amendment dated 09/16/08 Arm 1 of this study is ...",No,2013-11-15,FDA-26456,2.62,0.32,5.0,7.94,2015-08-15,2015-12-10,2020-12-10,69,Gilead,30,Kenya,57.16666666666666,79,24,81,57,61,41,45,0,3,2,False,False,False,True,True,False,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir Sulphate,Comp Beta,Drug,hiv,hiv,Phase 3,2018-01-22,"Sex: ALL; Age: >3 Months; Criteria: For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Key Inclusion Criteria:

* Confirmed HIV-1 infection diagnosed by protocol criteria
* Screening H...",Yes,2018-11-02,FDA-35178,2.62,0.32,5.0,7.94,2020-09-04,2020-12-30,2025-12-31,8,Merck,71,Senegal,49.5,15,78,99,27,35,43,45,0,4,1,False,False,False,True,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,Molecule Z,Drug,hiv,hiv,Phase 3,2018-01-22,"Sex: ALL; Age: >3 Months; Criteria: For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Key Inclusion Criteria:

* Confirmed HIV-1 infection diagnosed by protocol criteria
* Screening H...",No,2018-09-08,FDA-54135,2.62,0.32,5.0,7.94,2020-09-04,2020-12-30,2025-12-31,5,Novartis,19,South Africa,68.16666666666667,75,59,89,25,79,82,73,2,3,3,True,True,True,True,False,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Etravirine (Intelence),AltName A,Drug,hiv,hiv,Phase 2,2014-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection as documented by any licensed ELISA test and confirmed by Western Blot or other confirmatory test at any time prior to study entry. Acceptable alternative confir...",No,2014-06-27,FDA-70434,4.41,0.98,21.0,26.39,2018-09-27,2019-09-20,2040-09-19,94,Merck,65,Senegal,35.33333333333334,13,69,85,14,19,12,64,1,4,2,True,False,True,False,True,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada,TradeName X,Drug,hiv,hiv,Phase 2,2014-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection as documented by any licensed ELISA test and confirmed by Western Blot or other confirmatory test at any time prior to study entry. Acceptable alternative confir...",Yes,2015-02-09,FDA-66740,4.41,0.98,21.0,26.39,2018-09-27,2019-09-20,2040-09-19,95,Novartis,1,South Africa,42.66666666666666,3,22,99,40,59,33,36,1,2,1,True,False,False,True,False,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
E/C/F/TAF,TradeName X,Drug,hiv,hiv,Phase 3,2018-07-18,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

Cohort 1 (treatment-experienced switch)

* Must not have a history of known resistance to elvitegravir (EVG), tenofovir disoproxil fumarate (TDF), or emtricitabine (FTC)
* Pla...",No,2019-05-24,FDA-99333,2.62,0.32,5.0,7.94,2021-02-28,2021-06-25,2026-06-26,61,Bayer,7,Overall,49.16666666666666,56,16,57,80,36,50,36,0,1,3,False,False,False,False,False,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Daily Oral PrEP,TradeName X,Drug,hiv,hiv,Phase 4,2019-06-14,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Female at birth and identifies as female gender
* Age 18 years or older
* Able to understand and provide consent in English or Spanish
* HIV negative by 4th generation test (Ag/...",No,2020-02-09,FDA-49531,0.56,0.15,3.5,4.21,2020-01-04,2020-02-28,2023-08-29,25,Novartis,38,Overall,29.66666666666667,9,46,38,43,7,35,36,0,3,1,False,False,False,False,True,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
CABENUVA,Comp Beta,Drug,hiv,hiv,Phase 4,2024-01-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria

* Adults (greater than or equal to \[\>=\]18 years old) at the time of signing the informed consent.
* HIV-1 infected and have been prescribed CABNEUVA per the United States Prescr...",Yes,2024-05-24,FDA-28125,0.56,0.15,3.5,4.21,2024-08-22,2024-10-16,2028-04-16,63,J&J,86,Overall,53.66666666666666,76,97,57,28,64,0,27,0,2,1,False,False,False,False,True,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Stribild,TradeName X,Drug,hiv,hiv,Phase 3,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Plasma HIV-1 RNA levels ≥ 5,000 copies/mL
* No p...",No,2015-01-18,FDA-48086,2.62,0.32,5.0,7.94,2017-04-14,2017-08-09,2022-08-10,14,Sanofi,90,Overall,33.66666666666666,28,0,29,41,80,24,55,1,3,2,False,True,False,True,True,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atripla,AltName A,Drug,hiv,hiv,Phase 3,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Plasma HIV-1 RNA levels ≥ 5,000 copies/mL
* No p...",No,2015-02-21,FDA-31794,2.62,0.32,5.0,7.94,2017-04-14,2017-08-09,2022-08-10,46,Merck,59,Senegal,47.33333333333334,56,33,67,45,29,54,73,2,5,1,True,True,True,True,True,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Stribild,Molecule Z,Drug,hiv,hiv,Phase 3,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Plasma HIV-1 RNA levels ≥ 5,000 copies/mL at scr...",No,2015-07-09,FDA-16829,2.62,0.32,5.0,7.94,2017-04-14,2017-08-09,2022-08-10,94,Pfizer,39,Overall,58.83333333333334,22,94,88,51,72,26,36,1,0,3,False,True,False,False,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ATV,Molecule Z,Drug,hiv,hiv,Phase 3,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Plasma HIV-1 RNA levels ≥ 5,000 copies/mL at scr...",Yes,2015-04-22,FDA-38963,2.62,0.32,5.0,7.94,2017-04-14,2017-08-09,2022-08-10,39,Bayer,40,Overall,56.66666666666666,46,89,48,75,76,6,45,2,3,0,True,True,False,False,True,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,GenName Y,Drug,hiv,hiv,Phase 3,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Plasma HIV-1 RNA levels ≥ 5,000 copies/mL at scr...",No,2015-04-11,FDA-18160,2.62,0.32,5.0,7.94,2017-04-14,2017-08-09,2022-08-10,96,Novartis,91,Overall,50.83333333333334,84,58,82,49,24,8,45,1,2,2,False,True,False,True,False,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TDF,Comp Beta,Drug,hiv,hiv,Phase 3,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Plasma HIV-1 RNA levels ≥ 5,000 copies/mL at scr...",Yes,2015-07-06,FDA-20693,2.62,0.32,5.0,7.94,2017-04-14,2017-08-09,2022-08-10,43,Merck,10,Senegal,41.66666666666666,49,66,11,84,37,3,64,2,5,0,True,True,True,True,True,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Stribild,AltName B,Drug,hiv,hiv,Phase 2,2013-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Plasma HIV-1 RNA levels ≥ 5,000 copies/mL
* No prior use of any approved or experimental anti-HIV drug
* Normal electrocardiogram (ECG)
* Adequate renal function: estimated glom...",No,2014-03-10,FDA-73384,4.41,0.98,21.0,26.39,2018-01-28,2019-01-21,2040-01-21,85,GSK,66,Kenya,37.0,77,36,30,32,21,26,45,1,3,1,False,True,True,True,True,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Atripla,Product Alpha,Drug,hiv,hiv,Phase 2,2013-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Plasma HIV-1 RNA levels ≥ 5,000 copies/mL
* No prior use of any approved or experimental anti-HIV drug
* Normal electrocardiogram (ECG)
* Adequate renal function: estimated glom...",No,2014-06-04,FDA-99111,4.41,0.98,21.0,26.39,2018-01-28,2019-01-21,2040-01-21,81,GSK,86,Senegal,39.0,7,88,25,51,61,2,64,2,3,2,True,True,False,False,True,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Cabotegravir Tablets,GenName Y,Drug,hiv,hiv,Phase 3,2023-04-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants aged 18 years or older (or \>=19 where required by local regulatory agencies), at the time of signing the informed consent.
* A female participant is eligible to pa...",No,2024-01-06,FDA-28454,2.62,0.32,5.0,7.94,2025-11-28,2026-03-25,2031-03-26,2,Pfizer,79,Senegal,61.5,74,77,2,73,96,47,55,1,3,2,False,True,False,True,True,False,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Cabotegravir Injectable Suspension (CAB LA),AltName B,Drug,hiv,hiv,Phase 3,2023-04-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants aged 18 years or older (or \>=19 where required by local regulatory agencies), at the time of signing the informed consent.
* A female participant is eligible to pa...",Yes,2023-06-12,FDA-81454,2.62,0.32,5.0,7.94,2025-11-28,2026-03-25,2031-03-26,9,Novartis,28,Kenya,46.0,67,31,47,14,74,43,45,1,2,2,False,True,False,False,True,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rilpivirine Tablets,AltName B,Drug,hiv,hiv,Phase 3,2023-04-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants aged 18 years or older (or \>=19 where required by local regulatory agencies), at the time of signing the informed consent.
* A female participant is eligible to pa...",No,2023-06-08,FDA-69095,2.62,0.32,5.0,7.94,2025-11-28,2026-03-25,2031-03-26,56,Gilead,36,Overall,48.0,62,34,41,74,43,34,64,2,3,2,True,True,True,True,False,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rilpivirine Injectable Suspension (RPV LA),AltName B,Drug,hiv,hiv,Phase 3,2023-04-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants aged 18 years or older (or \>=19 where required by local regulatory agencies), at the time of signing the informed consent.
* A female participant is eligible to pa...",Yes,2023-07-14,FDA-60052,2.62,0.32,5.0,7.94,2025-11-28,2026-03-25,2031-03-26,67,AstraZeneca,70,Senegal,39.83333333333334,76,8,29,77,47,2,36,2,0,2,True,True,False,False,False,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
BIKTARVY Tablets (BIK),Product Alpha,Drug,hiv,hiv,Phase 3,2023-04-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants aged 18 years or older (or \>=19 where required by local regulatory agencies), at the time of signing the informed consent.
* A female participant is eligible to pa...",No,2024-01-27,FDA-57228,2.62,0.32,5.0,7.94,2025-11-28,2026-03-25,2031-03-26,90,Pfizer,91,Kenya,41.83333333333334,17,8,74,20,63,69,55,2,2,2,True,True,False,False,False,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lisinopril,Product Alpha,Drug,hiv,hiv,Phase 4,2014-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria include:

* Stable HAART with maintenance of plasma HIV RNA levels below level of detection (\< 40-75 copies/mL) for ≥ 12 months
* \> 90% adherence to HAART within preceding 30 days...",Yes,2015-09-21,FDA-73753,0.56,0.15,3.5,4.21,2015-06-23,2015-08-17,2019-02-15,80,Bayer,63,Overall,38.83333333333334,26,8,66,4,34,95,45,1,1,3,False,True,True,False,False,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Isoniazid (INH),AltName B,Drug,hiv,hiv,Phase 3,2009-05-01,"Sex: ALL; Age: >91 Days; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Mother is HIV-infected. Hard copy documentation of the mother's HIV infection is unnecessary if a positive DNA PCR from her infant is available.
* Received Bacille Calmette-Guer...",No,2010-01-31,FDA-91501,2.62,0.32,5.0,7.94,2011-12-13,2012-04-08,2017-04-09,81,J&J,1,South Africa,67.66666666666667,68,15,91,80,93,59,55,2,2,2,True,True,False,False,True,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Trimethoprim/Sulfamethoxazole (TMP/SMX),TradeName X,Drug,hiv,hiv,Phase 3,2009-05-01,"Sex: ALL; Age: >91 Days; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Mother is HIV-infected. Hard copy documentation of the mother's HIV infection is unnecessary if a positive DNA PCR from her infant is available.
* Received Bacille Calmette-Guer...",No,2010-04-18,FDA-76388,2.62,0.32,5.0,7.94,2011-12-13,2012-04-08,2017-04-09,56,AstraZeneca,13,Overall,53.66666666666666,69,97,28,25,46,57,45,1,3,1,True,False,True,True,False,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Combination Antiretroviral Therapy (cART),Comp Beta,Drug,hiv,hiv,Phase 2,2023-03-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria

1. Aged ≥18 to ≤60 years old
2. Able to give informed written consent including consent to long-term follow-up
3. Should be enrolled within a maximum of 4 weeks of a diagnosis of p...",Yes,2023-06-10,FDA-40487,4.41,0.98,21.0,26.39,2027-08-27,2028-08-19,2049-08-19,77,Merck,42,Kenya,48.66666666666666,56,30,65,98,6,37,64,1,3,3,False,True,False,True,False,True,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,Molecule Z,Drug,hiv,hiv,Phase 2,2023-03-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria

1. Aged ≥18 to ≤60 years old
2. Able to give informed written consent including consent to long-term follow-up
3. Should be enrolled within a maximum of 4 weeks of a diagnosis of p...",Yes,2024-01-16,FDA-73720,4.41,0.98,21.0,26.39,2027-08-27,2028-08-19,2049-08-19,85,Gilead,33,Kenya,58.66666666666666,39,93,14,91,59,56,27,1,1,1,True,False,False,False,True,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Vorinostat,GenName Y,Drug,hiv,hiv,Phase 2,2023-03-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria

1. Aged ≥18 to ≤60 years old
2. Able to give informed written consent including consent to long-term follow-up
3. Should be enrolled within a maximum of 4 weeks of a diagnosis of p...",No,2023-06-09,FDA-27290,4.41,0.98,21.0,26.39,2027-08-27,2028-08-19,2049-08-19,23,AstraZeneca,73,Overall,70.66666666666667,16,96,76,47,90,99,64,1,4,2,True,False,False,True,True,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ChAdV63.HIVconsv (ChAd),Comp Beta,Biological,hiv,hiv,Phase 2,2023-03-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria

1. Aged ≥18 to ≤60 years old
2. Able to give informed written consent including consent to long-term follow-up
3. Should be enrolled within a maximum of 4 weeks of a diagnosis of p...",Yes,2024-02-02,FDA-65589,4.41,0.98,21.0,26.39,2027-08-27,2028-08-19,2049-08-19,81,GSK,98,Senegal,51.83333333333334,73,9,58,44,92,35,55,0,4,2,False,False,True,True,False,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
MVA.HIVconsv (MVA),Product Alpha,Biological,hiv,hiv,Phase 2,2023-03-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria

1. Aged ≥18 to ≤60 years old
2. Able to give informed written consent including consent to long-term follow-up
3. Should be enrolled within a maximum of 4 weeks of a diagnosis of p...",No,2023-07-17,FDA-78163,4.41,0.98,21.0,26.39,2027-08-27,2028-08-19,2049-08-19,40,J&J,88,South Africa,48.83333333333334,71,73,94,23,23,9,55,1,3,2,True,False,False,True,False,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
E/C/F/TAF,AltName B,Drug,hiv,hiv,Phase 3,2020-04-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Currently receiving antiretroviral therapy c...",No,2020-08-21,FDA-74540,2.62,0.32,5.0,7.94,2022-11-13,2023-03-10,2028-03-10,58,Bayer,40,Kenya,60.0,98,80,92,9,37,44,73,1,5,2,False,True,True,True,True,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
E/C/F/TDF,AltName A,Drug,hiv,hiv,Phase 3,2020-04-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Currently receiving antiretroviral therapy c...",No,2020-12-19,FDA-10354,2.62,0.32,5.0,7.94,2022-11-13,2023-03-10,2028-03-10,85,J&J,42,Overall,51.0,85,18,81,67,33,22,27,0,1,2,False,False,True,False,False,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
EFV/FTC/TDF,TradeName X,Drug,hiv,hiv,Phase 3,2020-04-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Currently receiving antiretroviral therapy c...",Yes,2020-09-22,FDA-96200,2.62,0.32,5.0,7.94,2022-11-13,2023-03-10,2028-03-10,30,Bayer,32,South Africa,32.5,43,37,13,4,80,18,55,1,3,2,False,True,False,True,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
RTV,AltName B,Drug,hiv,hiv,Phase 3,2020-04-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Currently receiving antiretroviral therapy c...",No,2021-01-10,FDA-68737,2.62,0.32,5.0,7.94,2022-11-13,2023-03-10,2028-03-10,25,Sanofi,20,Kenya,33.16666666666666,33,45,13,23,66,19,73,2,3,3,True,True,True,True,False,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ATV,Comp Beta,Drug,hiv,hiv,Phase 3,2020-04-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Currently receiving antiretroviral therapy c...",No,2020-10-25,FDA-92276,2.62,0.32,5.0,7.94,2022-11-13,2023-03-10,2028-03-10,65,Pfizer,80,Overall,57.5,72,76,85,0,100,12,27,1,1,1,False,True,False,False,True,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TDF,AltName B,Drug,hiv,hiv,Phase 3,2020-04-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Currently receiving antiretroviral therapy c...",No,2020-07-07,FDA-80465,2.62,0.32,5.0,7.94,2022-11-13,2023-03-10,2028-03-10,49,Gilead,59,Overall,47.16666666666666,46,34,89,15,9,90,64,1,3,3,False,True,True,False,True,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
COBI,Product Alpha,Drug,hiv,hiv,Phase 3,2020-04-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Currently receiving antiretroviral therapy c...",Yes,2020-05-10,FDA-28643,2.62,0.32,5.0,7.94,2022-11-13,2023-03-10,2028-03-10,44,AstraZeneca,94,Kenya,48.0,42,10,43,23,81,89,36,2,1,1,True,True,False,False,False,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ALVAC-HIV (vCP2438),AltName B,Biological,hiv,hiv,Phase 2,2020-07-30,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

General and Demographic Criteria:

* Age of 18 to 40 years
* Access to a participating HVTN clinical research site (CRS) and willingness to be followed for the planned duration of...",Yes,2020-10-22,FDA-51262,4.41,0.98,21.0,26.39,2024-12-26,2025-12-19,2046-12-19,78,AstraZeneca,89,Senegal,46.33333333333334,96,31,23,88,8,32,45,1,3,1,False,True,True,False,False,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Bivalent subtype C gp120/MF59,TradeName X,Biological,hiv,hiv,Phase 2,2020-07-30,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

General and Demographic Criteria:

* Age of 18 to 40 years
* Access to a participating HVTN clinical research site (CRS) and willingness to be followed for the planned duration of...",Yes,2021-06-09,FDA-90026,4.41,0.98,21.0,26.39,2024-12-26,2025-12-19,2046-12-19,14,Gilead,3,Overall,62.33333333333334,100,21,97,5,64,87,36,1,2,1,True,False,False,False,True,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Bivalent subtype C gp120/AS01(B),AltName A,Biological,hiv,hiv,Phase 2,2020-07-30,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

General and Demographic Criteria:

* Age of 18 to 40 years
* Access to a participating HVTN clinical research site (CRS) and willingness to be followed for the planned duration of...",No,2021-04-04,FDA-58494,4.41,0.98,21.0,26.39,2024-12-26,2025-12-19,2046-12-19,81,Bayer,55,Overall,46.33333333333334,39,100,67,14,54,4,73,1,4,3,True,False,True,True,False,True,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Cabotegravir Oral Tablet,AltName B,Drug,hiv,hiv,Phase 3,2025-03-31,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* MSM and TGW, 18 years or older at the time of screening (male at birth)
* Willing to provide informed consent for the study
* At high risk for sexually acquiring HIV infection b...",Yes,2025-07-25,FDA-59177,2.62,0.32,5.0,7.94,2027-11-12,2028-03-08,2033-03-09,1,Novartis,82,Kenya,59.66666666666666,92,40,42,79,52,53,45,0,2,3,False,False,True,False,False,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
TDF/FTC tablets,AltName B,Drug,hiv,hiv,Phase 3,2025-03-31,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* MSM and TGW, 18 years or older at the time of screening (male at birth)
* Willing to provide informed consent for the study
* At high risk for sexually acquiring HIV infection b...",Yes,2026-03-24,FDA-41082,2.62,0.32,5.0,7.94,2027-11-12,2028-03-08,2033-03-09,56,Sanofi,16,Kenya,64.0,52,49,78,92,53,60,64,2,3,2,True,True,True,False,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
CAB LA,TradeName X,Drug,hiv,hiv,Phase 3,2025-03-31,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* MSM and TGW, 18 years or older at the time of screening (male at birth)
* Willing to provide informed consent for the study
* At high risk for sexually acquiring HIV infection b...",No,2025-07-08,FDA-62095,2.62,0.32,5.0,7.94,2027-11-12,2028-03-08,2033-03-09,34,AstraZeneca,95,Kenya,43.0,46,25,14,96,65,12,64,2,2,3,True,True,False,True,True,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
E/C/F/TAF,TradeName X,Drug,hiv,hiv,Phase 3,2016-07-09,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* History of at least two prior antiretroviral regimens, and history of resistance to at least two different c...",No,2017-05-17,FDA-19943,2.62,0.32,5.0,7.94,2019-02-20,2019-06-17,2024-06-17,46,Novartis,29,Kenya,54.83333333333334,79,8,79,51,71,41,64,0,3,4,False,False,True,True,False,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
DRV,GenName Y,Drug,hiv,hiv,Phase 3,2016-07-09,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* History of at least two prior antiretroviral regimens, and history of resistance to at least two different c...",Yes,2017-06-18,FDA-49893,2.62,0.32,5.0,7.94,2019-02-20,2019-06-17,2024-06-17,54,J&J,49,Senegal,63.66666666666666,70,82,76,65,0,89,55,1,4,1,True,False,True,True,True,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Baseline DRV- containing ARV regimen,Product Alpha,Drug,hiv,hiv,Phase 3,2016-07-09,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* History of at least two prior antiretroviral regimens, and history of resistance to at least two different c...",Yes,2016-12-11,FDA-93771,2.62,0.32,5.0,7.94,2019-02-20,2019-06-17,2024-06-17,25,GSK,61,South Africa,57.33333333333334,6,17,95,89,40,97,64,1,3,3,True,False,True,False,True,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
CAB OLI,Product Alpha,Drug,hiv,hiv,Phase 3,2023-03-13,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants aged 18 years or older at the time of signing the informed consent.
* HIV-1 infected and must be suppressed on a guideline recommended active Highly active antiretr...",No,2023-05-01,FDA-51683,2.62,0.32,5.0,7.94,2025-10-24,2026-02-18,2031-02-19,19,Sanofi,19,Senegal,36.83333333333334,29,38,32,11,63,48,64,2,2,3,True,True,False,False,True,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
CAB LA,AltName A,Drug,hiv,hiv,Phase 3,2023-03-13,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants aged 18 years or older at the time of signing the informed consent.
* HIV-1 infected and must be suppressed on a guideline recommended active Highly active antiretr...",Yes,2023-06-09,FDA-41154,2.62,0.32,5.0,7.94,2025-10-24,2026-02-18,2031-02-19,95,AstraZeneca,87,South Africa,63.5,47,55,11,97,75,96,55,0,4,2,False,False,True,True,False,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
RPV OLI,AltName A,Drug,hiv,hiv,Phase 3,2023-03-13,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants aged 18 years or older at the time of signing the informed consent.
* HIV-1 infected and must be suppressed on a guideline recommended active Highly active antiretr...",No,2023-08-30,FDA-54832,2.62,0.32,5.0,7.94,2025-10-24,2026-02-18,2031-02-19,29,GSK,88,Overall,48.0,32,0,71,85,23,77,55,0,3,3,False,False,True,False,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
RPV LA,TradeName X,Drug,hiv,hiv,Phase 3,2023-03-13,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants aged 18 years or older at the time of signing the informed consent.
* HIV-1 infected and must be suppressed on a guideline recommended active Highly active antiretr...",No,2023-09-23,FDA-77030,2.62,0.32,5.0,7.94,2025-10-24,2026-02-18,2031-02-19,46,Bayer,27,Kenya,47.66666666666666,93,49,0,56,22,66,73,2,3,3,True,True,False,True,True,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ritonavir,AltName A,Drug,hiv,hiv,Phase 4,2012-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 RNA of 1000 copies/mL or more
* No previous treatment with antiretroviral drugs for more than 10 days
* Demonstrated sensitivity \[Fold Change (FC) = lower Clinical Cut Of...",No,2012-09-04,FDA-41432,0.56,0.15,3.5,4.21,2013-01-21,2013-03-17,2016-09-15,65,GSK,5,Overall,46.33333333333334,27,21,10,85,58,77,55,0,3,3,False,False,True,False,True,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ritonavir,Comp Beta,Drug,hiv,hiv,Phase 4,2012-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 RNA of 1000 copies/mL or more
* No previous treatment with antiretroviral drugs for more than 10 days
* Demonstrated sensitivity \[Fold Change (FC) = lower Clinical Cut Of...",Yes,2012-08-15,FDA-67231,0.56,0.15,3.5,4.21,2013-01-21,2013-03-17,2016-09-15,92,J&J,29,Kenya,51.0,21,59,85,60,2,79,36,1,1,2,True,False,True,False,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
darunavir,AltName B,Drug,hiv,hiv,Phase 4,2012-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 RNA of 1000 copies/mL or more
* No previous treatment with antiretroviral drugs for more than 10 days
* Demonstrated sensitivity \[Fold Change (FC) = lower Clinical Cut Of...",Yes,2013-01-01,FDA-22219,0.56,0.15,3.5,4.21,2013-01-21,2013-03-17,2016-09-15,45,GSK,39,South Africa,36.33333333333334,88,8,54,21,4,43,73,1,3,4,True,False,False,True,False,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
emtricitabine [FTC]/tenofovir [TDF],GenName Y,Drug,hiv,hiv,Phase 4,2012-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 RNA of 1000 copies/mL or more
* No previous treatment with antiretroviral drugs for more than 10 days
* Demonstrated sensitivity \[Fold Change (FC) = lower Clinical Cut Of...",No,2013-06-09,FDA-12216,0.56,0.15,3.5,4.21,2013-01-21,2013-03-17,2016-09-15,31,J&J,12,Kenya,37.66666666666666,28,2,38,59,11,88,64,2,3,2,True,True,True,False,True,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
emtricitabine [FTC]/tenofovir [TDF],Product Alpha,Drug,hiv,hiv,Phase 4,2012-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 RNA of 1000 copies/mL or more
* No previous treatment with antiretroviral drugs for more than 10 days
* Demonstrated sensitivity \[Fold Change (FC) = lower Clinical Cut Of...",No,2012-12-31,FDA-98731,0.56,0.15,3.5,4.21,2013-01-21,2013-03-17,2016-09-15,47,AstraZeneca,93,Kenya,55.5,93,92,86,21,18,23,55,2,3,1,True,True,True,False,True,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
atazanavir,TradeName X,Drug,hiv,hiv,Phase 4,2012-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 RNA of 1000 copies/mL or more
* No previous treatment with antiretroviral drugs for more than 10 days
* Demonstrated sensitivity \[Fold Change (FC) = lower Clinical Cut Of...",Yes,2013-05-20,FDA-63830,0.56,0.15,3.5,4.21,2013-01-21,2013-03-17,2016-09-15,15,GSK,15,Kenya,47.83333333333334,0,87,93,1,74,32,36,0,1,3,False,False,False,True,False,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TAF,AltName A,Drug,hiv,hiv,Phase 4,2018-05-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Cohort 1(a \& b) Inclusion Criteria:

* Age 18 or older at the time of signed informed consent
* Not currently taking commercial Truvada for PrEP or any other investigational, oral medication for the ...",No,2018-06-23,FDA-58008,0.56,0.15,3.5,4.21,2018-11-21,2019-01-15,2022-07-16,12,Merck,76,Overall,60.33333333333334,22,18,78,97,64,83,45,1,2,2,True,False,False,True,False,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir,Product Alpha,Drug,hiv,hiv,Phase 3,2008-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV infection
* HIV-1 RNA \< 500 copies/ml
* Fasting LDL cholesterol \>130 mg/dl OR fasting triglycerides \>200 mg/dl
* CD4 count \>100 cells/mm
* Stable antiretroviral regimen ...",No,2009-03-08,FDA-14419,2.62,0.32,5.0,7.94,2011-01-13,2011-05-10,2016-05-10,12,Novartis,32,Overall,49.66666666666666,22,68,42,34,76,56,45,2,2,1,True,True,False,True,False,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
current antiretroviral regimen,Molecule Z,Drug,hiv,hiv,Phase 3,2008-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV infection
* HIV-1 RNA \< 500 copies/ml
* Fasting LDL cholesterol \>130 mg/dl OR fasting triglycerides \>200 mg/dl
* CD4 count \>100 cells/mm
* Stable antiretroviral regimen ...",No,2009-02-28,FDA-38411,2.62,0.32,5.0,7.94,2011-01-13,2011-05-10,2016-05-10,78,Merck,82,Senegal,34.16666666666666,5,53,55,2,56,34,45,2,0,3,True,True,False,False,False,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Darunavir(DRV),AltName A,Drug,hiv,hiv,Phase 2,2011-04-01,Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria: - Human immunodeficiency virus-1 (HIV-1) infected participants on their first-line treatment with highly active antiretroviral therapy (HAART) (combination of 2 or 3 nucleoside rev...,No,2012-03-14,FDA-67637,4.41,0.98,21.0,26.39,2015-08-28,2016-08-20,2037-08-20,48,Pfizer,97,Overall,67.16666666666667,79,58,71,94,57,44,64,1,5,1,True,False,True,True,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,Product Alpha,Drug,hiv,hiv,Phase 2,2011-04-01,Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria: - Human immunodeficiency virus-1 (HIV-1) infected participants on their first-line treatment with highly active antiretroviral therapy (HAART) (combination of 2 or 3 nucleoside rev...,No,2011-08-14,FDA-40237,4.41,0.98,21.0,26.39,2015-08-28,2016-08-20,2037-08-20,95,Merck,75,Overall,48.0,71,43,53,76,27,18,64,2,3,2,True,True,True,False,True,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
2 nucleoside reverse transcriptase inhibitors (NRTIs),Molecule Z,Drug,hiv,hiv,Phase 2,2011-04-01,Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria: - Human immunodeficiency virus-1 (HIV-1) infected participants on their first-line treatment with highly active antiretroviral therapy (HAART) (combination of 2 or 3 nucleoside rev...,No,2011-10-05,FDA-50569,4.41,0.98,21.0,26.39,2015-08-28,2016-08-20,2037-08-20,26,J&J,80,Overall,38.5,46,82,38,39,26,0,45,2,2,1,True,True,False,True,False,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TAF,Comp Beta,Drug,hiv,hiv,Phase 2,2016-08-16,"Sex: ALL; Age: >14 Years; Criteria: INCLUSION

* Age greater than or equal to 14 years
* Documented HIV-1 infection (written documentation of positive standard ELISA or rapid HIV-1/HIV-2 antibody test with confirmatory Western Blot, or ...",Yes,2017-01-18,FDA-89842,4.41,0.98,21.0,26.39,2021-01-12,2022-01-05,2043-01-05,79,Sanofi,61,Overall,50.16666666666666,14,36,65,75,74,37,55,1,2,3,True,False,False,False,False,True,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Nelfinavir,Comp Beta,Drug,hiv,hiv,Phase 4,2014-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV Positive
* No previous antiviral therapy
* 18 to 70 years of age

Exclusion Criteria:

* Patients with opportunistic infections or AIDS.
* Active intravenous drug users.
* P...",No,2015-06-21,FDA-53235,0.56,0.15,3.5,4.21,2015-04-23,2015-06-17,2018-12-16,33,Pfizer,70,Senegal,48.66666666666666,37,80,73,39,8,55,27,1,1,1,False,True,True,False,False,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,AltName A,Drug,hiv,hiv,Phase 4,2014-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV Positive
* No previous antiviral therapy
* 18 to 70 years of age

Exclusion Criteria:

* Patients with opportunistic infections or AIDS.
* Active intravenous drug users.
* P...",No,2014-11-12,FDA-38557,0.56,0.15,3.5,4.21,2015-04-23,2015-06-17,2018-12-16,66,GSK,75,Kenya,30.66666666666667,14,4,97,22,22,25,55,1,3,2,False,True,True,True,False,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,AltName A,Drug,hiv,hiv,Phase 4,2021-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV infected patients, age \>18 years, meet Vietnam guideline to begin ART (CD4 count \< 350 cells/mm3 and/or WHO stage III or IV disease)
* Hepatitis C infection as documented ...",No,2021-11-02,FDA-24819,0.56,0.15,3.5,4.21,2021-12-22,2022-02-15,2025-08-16,12,Sanofi,31,South Africa,46.5,57,43,81,41,16,41,55,1,3,2,False,True,True,True,False,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,AltName A,Drug,hiv,hiv,Phase 4,2021-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV infected patients, age \>18 years, meet Vietnam guideline to begin ART (CD4 count \< 350 cells/mm3 and/or WHO stage III or IV disease)
* Hepatitis C infection as documented ...",Yes,2021-07-04,FDA-94617,0.56,0.15,3.5,4.21,2021-12-22,2022-02-15,2025-08-16,53,Novartis,89,South Africa,68.83333333333333,74,92,88,49,38,72,55,1,4,1,True,False,True,True,False,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Nitazoxanide (NTZ),AltName B,Drug,hiv,hiv,Phase 2,2012-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Documentation of hepatitis C virus (HCV) genotype 1 infection prior to entry
* Chronic HCV infection for at least 180 days
* CD4+ cell count greater than 200 c...",No,2012-05-21,FDA-27675,4.41,0.98,21.0,26.39,2016-05-29,2017-05-22,2038-05-22,43,Pfizer,5,Overall,66.33333333333333,97,82,89,81,1,48,18,0,1,1,False,False,True,False,False,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Pegylated interferon alfa-2a (PEG),Product Alpha,Drug,hiv,hiv,Phase 2,2012-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Documentation of hepatitis C virus (HCV) genotype 1 infection prior to entry
* Chronic HCV infection for at least 180 days
* CD4+ cell count greater than 200 c...",Yes,2012-08-06,FDA-34901,4.41,0.98,21.0,26.39,2016-05-29,2017-05-22,2038-05-22,62,Pfizer,39,Kenya,51.16666666666666,22,50,40,59,63,73,55,1,3,2,True,False,True,False,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ribavirin (RBV),TradeName X,Drug,hiv,hiv,Phase 2,2012-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Documentation of hepatitis C virus (HCV) genotype 1 infection prior to entry
* Chronic HCV infection for at least 180 days
* CD4+ cell count greater than 200 c...",No,2012-12-19,FDA-14521,4.41,0.98,21.0,26.39,2016-05-29,2017-05-22,2038-05-22,79,Pfizer,72,Kenya,54.16666666666666,45,89,39,56,15,81,55,2,2,2,True,True,True,False,False,False,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
pregabalin,Molecule Z,Drug,hiv,hiv,Phase 3,2008-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participation in the preceding A0081066 double-blind trial met the entry criteria for that trial and completed A0081066 study through visit 7

Exclusion Criteria:

* Experienced...",Yes,2008-12-21,FDA-94403,2.62,0.32,5.0,7.94,2010-09-14,2011-01-09,2016-01-10,25,Merck,6,Senegal,49.33333333333334,19,98,21,88,56,14,45,1,1,3,True,False,False,True,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Enfuvirtide,AltName A,Drug,hiv,hiv,Phase 2,,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria

Patients may be eligible for this study if they:

* Are 3 through 16 years of age and have the consent of parent or guardian.
* Have a viral load of at least 5000 copies/ml.
* Have...",Yes,2026-03-02,FDA-93098,4.41,0.98,21.0,26.39,,,,93,Novartis,56,Senegal,40.5,67,20,44,74,0,38,64,0,3,4,False,False,True,True,False,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
nevirapine bid,AltName A,Drug,hiv,hiv,Phase 3,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

Inclusion Criteria:

1. Signed informed consent in accordance with Good Clinical Practice (GCP) and local regulatory requirements prior to trial participation
2. HIV-1-infected ma...",Yes,2026-03-05,FDA-42672,2.62,0.32,5.0,7.94,,,,100,Bayer,45,Kenya,36.5,59,79,40,1,2,38,45,2,1,2,True,True,False,False,False,False,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
nevirapine qd,AltName B,Drug,hiv,hiv,Phase 3,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

Inclusion Criteria:

1. Signed informed consent in accordance with Good Clinical Practice (GCP) and local regulatory requirements prior to trial participation
2. HIV-1-infected ma...",Yes,2026-08-24,FDA-60149,2.62,0.32,5.0,7.94,,,,17,Gilead,74,Overall,58.5,92,36,44,72,14,93,36,1,1,2,False,True,False,False,False,False,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
atazanavir,Molecule Z,Drug,hiv,hiv,Phase 3,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

Inclusion Criteria:

1. Signed informed consent in accordance with Good Clinical Practice (GCP) and local regulatory requirements prior to trial participation
2. HIV-1-infected ma...",Yes,2026-11-29,FDA-11170,2.62,0.32,5.0,7.94,,,,31,Bayer,3,Overall,26.66666666666667,38,14,20,7,18,63,55,1,3,2,True,False,True,True,True,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Delstrigo,AltName B,Drug,hiv,hiv,Phase 4,2022-07-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects attending emergency room due to potential HIV exposition of either sex:
* Aged 18 years or more.
* Who have been exposed to non-occupational HIV and who meet the prereq...",No,2023-01-17,FDA-63442,0.56,0.15,3.5,4.21,2023-02-17,2023-04-13,2026-10-12,70,AstraZeneca,11,Kenya,59.66666666666666,24,92,69,98,11,64,45,2,2,1,True,True,False,False,True,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Etravirine (ETR),Product Alpha,Drug,hiv,hiv,Phase 2,2008-08-01,"Sex: ALL; Criteria: Inclusion Criteria:

* Participants who were previously randomized to an etravirine (ETR) treatment arm and have completed at least 48 weeks of treatment with ETR
* Participants who will be able to co...",No,2009-02-25,FDA-79711,4.41,0.98,21.0,26.39,2012-12-28,2013-12-21,2034-12-21,25,Pfizer,93,Kenya,27.66666666666667,30,42,29,8,3,54,73,2,3,3,True,True,False,True,True,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Nucleotide reverse transcriptase inhibitors (NRTIs),AltName B,Drug,hiv,hiv,Phase 2,2008-08-01,"Sex: ALL; Criteria: Inclusion Criteria:

* Participants who were previously randomized to an etravirine (ETR) treatment arm and have completed at least 48 weeks of treatment with ETR
* Participants who will be able to co...",No,2008-10-13,FDA-42958,4.41,0.98,21.0,26.39,2012-12-28,2013-12-21,2034-12-21,96,J&J,86,Kenya,54.16666666666666,42,23,65,85,89,21,45,0,2,3,False,False,True,False,True,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Protease inhibitors (PIs),Product Alpha,Drug,hiv,hiv,Phase 2,2008-08-01,"Sex: ALL; Criteria: Inclusion Criteria:

* Participants who were previously randomized to an etravirine (ETR) treatment arm and have completed at least 48 weeks of treatment with ETR
* Participants who will be able to co...",No,2008-12-01,FDA-84344,4.41,0.98,21.0,26.39,2012-12-28,2013-12-21,2034-12-21,11,J&J,46,South Africa,61.0,57,95,42,29,64,79,55,1,3,2,True,False,False,True,False,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Enfuvirtide (ENF),Comp Beta,Drug,hiv,hiv,Phase 2,2008-08-01,"Sex: ALL; Criteria: Inclusion Criteria:

* Participants who were previously randomized to an etravirine (ETR) treatment arm and have completed at least 48 weeks of treatment with ETR
* Participants who will be able to co...",Yes,2008-11-24,FDA-65305,4.41,0.98,21.0,26.39,2012-12-28,2013-12-21,2034-12-21,55,GSK,24,Kenya,59.66666666666666,94,89,49,80,26,20,45,1,1,3,False,True,False,True,False,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir,Molecule Z,Drug,hiv,hiv,Phase 4,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Key inclusion criteria:

* Males and females, 18 to 65 years of age, with HIV infection and a body mass index of 18.0 to 35.0 kg/m\^2
* HIV-infected participants receiving a treatment regimen containi...",No,2011-07-01,FDA-86682,0.56,0.15,3.5,4.21,2011-12-22,2012-02-15,2015-08-16,65,J&J,28,South Africa,54.16666666666666,98,33,33,56,61,44,55,1,3,2,False,True,False,True,True,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir,TradeName X,Drug,hiv,hiv,Phase 4,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Key inclusion criteria:

* Males and females, 18 to 65 years of age, with HIV infection and a body mass index of 18.0 to 35.0 kg/m\^2
* HIV-infected participants receiving a treatment regimen containi...",Yes,2011-10-14,FDA-68055,0.56,0.15,3.5,4.21,2011-12-22,2012-02-15,2015-08-16,0,Gilead,21,Kenya,47.5,80,11,61,38,62,33,64,2,3,2,True,True,True,False,True,False,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,Molecule Z,Drug,hiv,hiv,Phase 4,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Key inclusion criteria:

* Males and females, 18 to 65 years of age, with HIV infection and a body mass index of 18.0 to 35.0 kg/m\^2
* HIV-infected participants receiving a treatment regimen containi...",No,2012-03-14,FDA-14513,0.56,0.15,3.5,4.21,2011-12-22,2012-02-15,2015-08-16,87,AstraZeneca,61,Overall,45.16666666666666,40,15,75,30,24,87,64,1,2,4,True,False,False,False,True,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,Product Alpha,Drug,hiv,hiv,Phase 4,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Key inclusion criteria:

* Males and females, 18 to 65 years of age, with HIV infection and a body mass index of 18.0 to 35.0 kg/m\^2
* HIV-infected participants receiving a treatment regimen containi...",Yes,2012-02-12,FDA-89710,0.56,0.15,3.5,4.21,2011-12-22,2012-02-15,2015-08-16,28,Sanofi,14,Overall,39.66666666666666,66,54,14,31,68,5,64,2,4,1,True,True,True,True,True,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir (TDF),AltName B,Drug,hiv,hiv,Phase 4,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Key inclusion criteria:

* Males and females, 18 to 65 years of age, with HIV infection and a body mass index of 18.0 to 35.0 kg/m\^2
* HIV-infected participants receiving a treatment regimen containi...",Yes,2012-04-06,FDA-87150,0.56,0.15,3.5,4.21,2011-12-22,2012-02-15,2015-08-16,28,Merck,84,South Africa,50.33333333333334,17,55,100,89,2,39,36,0,2,2,False,False,False,False,False,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir (TDF),Comp Beta,Drug,hiv,hiv,Phase 4,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Key inclusion criteria:

* Males and females, 18 to 65 years of age, with HIV infection and a body mass index of 18.0 to 35.0 kg/m\^2
* HIV-infected participants receiving a treatment regimen containi...",Yes,2011-09-22,FDA-68539,0.56,0.15,3.5,4.21,2011-12-22,2012-02-15,2015-08-16,8,Bayer,72,Kenya,52.0,40,38,31,53,62,88,27,0,1,2,False,False,False,True,False,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Nucleoside Reverse Transcriptase Inhibitor (NRTI),Product Alpha,Drug,hiv,hiv,Phase 4,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Key inclusion criteria:

* Males and females, 18 to 65 years of age, with HIV infection and a body mass index of 18.0 to 35.0 kg/m\^2
* HIV-infected participants receiving a treatment regimen containi...",Yes,2012-05-17,FDA-60364,0.56,0.15,3.5,4.21,2011-12-22,2012-02-15,2015-08-16,61,Gilead,37,Senegal,56.5,84,93,36,54,72,0,82,2,4,3,True,True,True,True,True,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Nucleoside Reverse Transcriptase Inhibitor (NRTI),AltName A,Drug,hiv,hiv,Phase 4,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Key inclusion criteria:

* Males and females, 18 to 65 years of age, with HIV infection and a body mass index of 18.0 to 35.0 kg/m\^2
* HIV-infected participants receiving a treatment regimen containi...",Yes,2012-05-16,FDA-95235,0.56,0.15,3.5,4.21,2011-12-22,2012-02-15,2015-08-16,48,J&J,88,Overall,75.16666666666667,88,90,54,73,46,100,36,0,1,3,False,False,False,True,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Famotidine (FAM),Product Alpha,Drug,hiv,hiv,Phase 4,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Key inclusion criteria:

* Males and females, 18 to 65 years of age, with HIV infection and a body mass index of 18.0 to 35.0 kg/m\^2
* HIV-infected participants receiving a treatment regimen containi...",No,2011-10-02,FDA-36760,0.56,0.15,3.5,4.21,2011-12-22,2012-02-15,2015-08-16,16,Merck,75,Kenya,32.66666666666666,64,5,11,3,74,39,64,2,2,3,True,True,True,False,False,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Famotidine (FAM),Comp Beta,Drug,hiv,hiv,Phase 4,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Key inclusion criteria:

* Males and females, 18 to 65 years of age, with HIV infection and a body mass index of 18.0 to 35.0 kg/m\^2
* HIV-infected participants receiving a treatment regimen containi...",Yes,2011-10-24,FDA-44730,0.56,0.15,3.5,4.21,2011-12-22,2012-02-15,2015-08-16,73,GSK,54,South Africa,55.33333333333334,68,36,16,95,39,78,73,2,4,2,True,True,True,True,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK1265744 Tablets,Molecule Z,Drug,hiv,hiv,Phase 2,2018-07-13,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Men and women, 18 to 65 years old at the time of screening
* Willing to provide informed consent for the study
* In the last 12 months (at the time of screening):

  * No self-r...",Yes,2019-04-09,FDA-64139,4.41,0.98,21.0,26.39,2022-12-09,2023-12-02,2044-12-01,31,Novartis,8,South Africa,59.33333333333334,22,2,94,89,82,67,73,2,4,2,True,True,True,True,False,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Injectable GSK1265744,AltName B,Drug,hiv,hiv,Phase 2,2018-07-13,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Men and women, 18 to 65 years old at the time of screening
* Willing to provide informed consent for the study
* In the last 12 months (at the time of screening):

  * No self-r...",Yes,2018-10-19,FDA-69998,4.41,0.98,21.0,26.39,2022-12-09,2023-12-02,2044-12-01,81,Novartis,67,Kenya,45.33333333333334,43,65,64,11,37,52,82,2,4,3,True,True,False,True,True,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada,Molecule Z,Drug,hiv,hiv,Phase 3,2013-01-01,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Willing and able (see criterion 2) to provide written informed consent to be screened for and to participate in the trial
2. Able to answer a percentage of informed consent scr...",No,2013-12-30,FDA-24926,2.62,0.32,5.0,7.94,2015-08-15,2015-12-10,2020-12-10,44,AstraZeneca,1,South Africa,37.33333333333334,18,11,16,51,54,74,36,1,1,2,False,True,False,True,False,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC),AltName A,Drug,hiv,hiv,Phase 4,2022-08-09,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* HIV-negative person, who was assigned male at birth, who reports sex with another man in the last year, and is in good general health.
* Not currently taking PrEP and no plans t...",No,2022-10-28,FDA-83300,0.56,0.15,3.5,4.21,2023-03-01,2023-04-25,2026-10-24,77,Merck,96,Kenya,73.5,72,78,95,87,55,54,27,1,2,0,False,True,True,True,False,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
E/C/F/TAF,Molecule Z,Drug,hiv,hiv,Phase 3,2017-09-06,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at...",No,2018-03-18,FDA-80885,2.62,0.32,5.0,7.94,2020-04-19,2020-08-14,2025-08-15,38,Sanofi,99,Kenya,64.16666666666667,95,88,61,18,46,77,45,0,1,4,False,False,True,False,False,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
E/C/F/TDF,TradeName X,Drug,hiv,hiv,Phase 3,2017-09-06,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at...",Yes,2018-08-28,FDA-69584,2.62,0.32,5.0,7.94,2020-04-19,2020-08-14,2025-08-15,20,Bayer,45,South Africa,45.16666666666666,34,60,52,34,58,33,55,2,3,1,True,True,False,False,True,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Vicriviroc 30 mg,Comp Beta,Drug,hiv,hiv,Phase 2,2011-03-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult participants with documented HIV infection with no detectable C-X-C Motif Chemokine Receptor 4 (CXCR4)
* Prior therapy for ≥3 months with ≥3 classes of currently marketed ...",Yes,2011-10-13,FDA-65529,4.41,0.98,21.0,26.39,2015-08-13,2016-08-05,2037-08-05,26,Novartis,28,Kenya,40.0,29,59,27,1,88,36,45,1,2,2,False,True,False,True,False,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Vicriviroc 20 mg,TradeName X,Drug,hiv,hiv,Phase 2,2011-03-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult participants with documented HIV infection with no detectable C-X-C Motif Chemokine Receptor 4 (CXCR4)
* Prior therapy for ≥3 months with ≥3 classes of currently marketed ...",Yes,2011-12-29,FDA-27910,4.41,0.98,21.0,26.39,2015-08-13,2016-08-05,2037-08-05,57,GSK,71,Overall,30.66666666666667,53,14,40,7,13,57,27,1,1,1,False,True,False,False,False,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Background ART Regimen,TradeName X,Drug,hiv,hiv,Phase 2,2011-03-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult participants with documented HIV infection with no detectable C-X-C Motif Chemokine Receptor 4 (CXCR4)
* Prior therapy for ≥3 months with ≥3 classes of currently marketed ...",No,2011-09-27,FDA-38948,4.41,0.98,21.0,26.39,2015-08-13,2016-08-05,2037-08-05,20,Novartis,49,Kenya,54.0,84,59,60,96,11,14,64,1,3,3,False,True,True,False,True,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,Comp Beta,Drug,hiv,hiv,Phase 4,2010-12-01,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

* HIV-1 infected
* Viral load of 500 copies/mL or more
* Prior HAART for more than 7 days, but less than 40 weeks during at least one previous pregnancy for prevention of MTCT of ...",No,2011-07-03,FDA-92579,0.56,0.15,3.5,4.21,2011-06-23,2011-08-17,2015-02-15,45,Novartis,64,Senegal,49.83333333333334,56,33,87,13,83,27,55,2,3,1,True,True,True,True,False,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine/Tenofovir disoproxil fumarate,Molecule Z,Drug,hiv,hiv,Phase 4,2010-12-01,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

* HIV-1 infected
* Viral load of 500 copies/mL or more
* Prior HAART for more than 7 days, but less than 40 weeks during at least one previous pregnancy for prevention of MTCT of ...",No,2011-07-08,FDA-48644,0.56,0.15,3.5,4.21,2011-06-23,2011-08-17,2015-02-15,25,GSK,90,Overall,71.66666666666667,96,43,97,69,41,84,55,1,3,2,False,True,False,True,False,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ATV,GenName Y,Drug,hiv,hiv,Phase 2,2014-09-01,"Sex: ALL; Age: >91 Days; Criteria: Inclusion Criteria for Step I:

* Age: 91 days to 21 years of age (not including the 22nd birthday).
* A confirmed diagnosis of HIV infection defined by the current definition of the IMPAACT Virology ...",No,2015-05-17,FDA-60273,4.41,0.98,21.0,26.39,2019-01-28,2020-01-21,2041-01-20,22,Pfizer,25,Senegal,60.16666666666666,37,62,93,55,76,38,45,0,2,3,False,False,False,True,False,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,Comp Beta,Drug,hiv,hiv,Phase 2,2014-09-01,"Sex: ALL; Age: >91 Days; Criteria: Inclusion Criteria for Step I:

* Age: 91 days to 21 years of age (not including the 22nd birthday).
* A confirmed diagnosis of HIV infection defined by the current definition of the IMPAACT Virology ...",Yes,2014-12-07,FDA-54464,4.41,0.98,21.0,26.39,2019-01-28,2020-01-21,2041-01-20,18,GSK,25,South Africa,60.83333333333334,90,23,55,30,78,89,36,1,3,0,False,True,False,False,True,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
LEXIVA (GW433908),Product Alpha,Drug,hiv,hiv,Phase 2,2013-07-01,"Sex: ALL; Age: >2 Years; Criteria: Inclusion criteria:

* Males or females 2 to 18 years of age Cohorts 1A and 1B, up to one month before 6th birthday at Baseline/Day 1 Cohort 2, up to one month before 12th birthday at Baseline/Day 1 C...",Yes,2014-03-19,FDA-47239,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,22,Gilead,8,Kenya,36.66666666666666,92,42,13,20,52,1,18,0,1,1,False,False,True,False,False,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,Comp Beta,Drug,hiv,hiv,Phase 2,2013-07-01,"Sex: ALL; Age: >2 Years; Criteria: Inclusion criteria:

* Males or females 2 to 18 years of age Cohorts 1A and 1B, up to one month before 6th birthday at Baseline/Day 1 Cohort 2, up to one month before 12th birthday at Baseline/Day 1 C...",No,2014-02-12,FDA-58354,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,73,Pfizer,31,South Africa,40.33333333333334,24,58,46,66,21,27,64,0,5,2,False,False,True,True,True,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
E/C/F/TAF,Product Alpha,Drug,hiv,hiv,Phase 3,2018-10-03,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at...",No,2019-06-15,FDA-65940,2.62,0.32,5.0,7.94,2021-05-16,2021-09-10,2026-09-11,79,AstraZeneca,6,Senegal,41.33333333333334,64,52,19,81,24,8,45,0,2,3,False,False,False,False,True,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
E/C/F/TDF,GenName Y,Drug,hiv,hiv,Phase 3,2018-10-03,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at...",No,2019-02-16,FDA-55479,2.62,0.32,5.0,7.94,2021-05-16,2021-09-10,2026-09-11,6,Sanofi,92,Senegal,33.33333333333334,26,58,22,13,61,20,36,2,0,2,True,True,False,False,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)",TradeName X,Drug,hiv,hiv,Phase 3,2010-03-01,"Sex: ALL; Age: >30 Days; Criteria: Inclusion Criteria:

* Older than 30 days and younger than 18 years of age (may enroll up to the day before their 18th birthday)
* HIV infected
* Not previously on HAART or received anti-HIV drugs for...",No,2010-04-30,FDA-65129,2.62,0.32,5.0,7.94,2012-10-12,2013-02-06,2018-02-07,16,J&J,58,South Africa,37.5,18,14,67,51,59,16,45,1,3,1,True,False,False,True,True,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"NNRTIs (EFV, NVP)",Molecule Z,Drug,hiv,hiv,Phase 3,2010-03-01,"Sex: ALL; Age: >30 Days; Criteria: Inclusion Criteria:

* Older than 30 days and younger than 18 years of age (may enroll up to the day before their 18th birthday)
* HIV infected
* Not previously on HAART or received anti-HIV drugs for...",No,2010-12-05,FDA-77746,2.62,0.32,5.0,7.94,2012-10-12,2013-02-06,2018-02-07,25,Bayer,59,Kenya,40.33333333333334,29,19,42,32,76,44,64,1,3,3,False,True,True,False,True,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)",AltName A,Drug,hiv,hiv,Phase 3,2010-03-01,"Sex: ALL; Age: >30 Days; Criteria: Inclusion Criteria:

* Older than 30 days and younger than 18 years of age (may enroll up to the day before their 18th birthday)
* HIV infected
* Not previously on HAART or received anti-HIV drugs for...",No,2010-04-02,FDA-48245,2.62,0.32,5.0,7.94,2012-10-12,2013-02-06,2018-02-07,70,Bayer,65,Kenya,63.83333333333334,64,56,36,63,66,98,73,1,4,3,False,True,False,True,True,True,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,GenName Y,Drug,hiv,hiv,Phase 4,2013-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV positive
* On HAART, with plasma HIV viral load \< 50 copies/ml for previous 12 months or more
* Able to provide informed consent
* HAND diagnosis, with symptom progression ...",Yes,2014-06-07,FDA-73100,0.56,0.15,3.5,4.21,2014-04-23,2014-06-17,2017-12-16,90,Bayer,17,Overall,38.5,19,24,92,55,5,36,73,2,4,2,True,True,False,True,True,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,Product Alpha,Drug,hiv,hiv,Phase 4,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV Positive
* On HAART, with plasma viral load \< 50 copies/ml for previous 12 months or more
* Able to provide informed consent
* HAND diagnosis, with symptom progression with...",Yes,2014-10-22,FDA-33912,0.56,0.15,3.5,4.21,2015-03-24,2015-05-18,2018-11-16,31,Gilead,79,Overall,21.0,59,3,12,1,31,20,64,2,2,3,True,True,False,True,False,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DNA-HIV-PT123 vaccine,TradeName X,Biological,hiv,hiv,Phase 2,2020-02-12,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

General and Demographic Criteria

* Age of 18 to 40 years
* Access to a participating HVTN clinical research site (CRS) and willingness to be followed for the planned duration of ...",Yes,2020-06-24,FDA-82834,4.41,0.98,21.0,26.39,2024-07-10,2025-07-03,2046-07-03,73,Sanofi,71,Overall,57.83333333333334,40,33,94,93,0,87,55,2,3,1,True,True,True,False,True,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Bivalent Subtype C gp120/MF59 vaccine,Product Alpha,Biological,hiv,hiv,Phase 2,2020-02-12,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

General and Demographic Criteria

* Age of 18 to 40 years
* Access to a participating HVTN clinical research site (CRS) and willingness to be followed for the planned duration of ...",Yes,2020-07-08,FDA-31505,4.41,0.98,21.0,26.39,2024-07-10,2025-07-03,2046-07-03,64,GSK,88,Kenya,41.0,1,35,60,14,93,43,73,1,4,3,False,True,True,True,False,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Bivalent Subtype C gp120/AS01B vaccine,Product Alpha,Biological,hiv,hiv,Phase 2,2020-02-12,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

General and Demographic Criteria

* Age of 18 to 40 years
* Access to a participating HVTN clinical research site (CRS) and willingness to be followed for the planned duration of ...",No,2020-07-07,FDA-13821,4.41,0.98,21.0,26.39,2024-07-10,2025-07-03,2046-07-03,2,Bayer,12,Kenya,48.66666666666666,35,63,15,94,32,53,45,0,2,3,False,False,True,False,True,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ALVAC-HIV (vCP2438),GenName Y,Biological,hiv,hiv,Phase 2,2019-12-12,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

General and Demographic Criteria

1. Age of 18 to 40 years
2. Access to a participating HVTN CRS and willingness to be followed for the planned duration of the study
3. Ability an...",Yes,2020-11-09,FDA-32179,4.41,0.98,21.0,26.39,2024-05-09,2025-05-02,2046-05-02,100,AstraZeneca,98,Senegal,36.5,36,73,1,53,19,37,36,1,0,3,False,True,False,False,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Bivalent Subtype C gp120/MF59,TradeName X,Biological,hiv,hiv,Phase 2,2019-12-12,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

General and Demographic Criteria

1. Age of 18 to 40 years
2. Access to a participating HVTN CRS and willingness to be followed for the planned duration of the study
3. Ability an...",No,2020-07-19,FDA-50751,4.41,0.98,21.0,26.39,2024-05-09,2025-05-02,2046-05-02,76,Merck,61,Senegal,52.5,51,38,47,32,78,69,55,1,3,2,True,False,True,False,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension,Product Alpha,Biological,hiv,hiv,Phase 2,2019-12-12,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

General and Demographic Criteria

1. Age of 18 to 40 years
2. Access to a participating HVTN CRS and willingness to be followed for the planned duration of the study
3. Ability an...",No,2020-07-18,FDA-57654,4.41,0.98,21.0,26.39,2024-05-09,2025-05-02,2046-05-02,1,Pfizer,63,Senegal,63.66666666666666,62,50,100,33,89,48,45,1,2,2,False,True,False,True,True,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Bivalent Subtype C gp120,AltName B,Biological,hiv,hiv,Phase 2,2019-12-12,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

General and Demographic Criteria

1. Age of 18 to 40 years
2. Access to a participating HVTN CRS and willingness to be followed for the planned duration of the study
3. Ability an...",Yes,2020-11-03,FDA-18390,4.41,0.98,21.0,26.39,2024-05-09,2025-05-02,2046-05-02,7,J&J,17,Overall,52.83333333333334,96,24,0,54,58,85,45,1,3,1,True,False,True,False,True,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Oral Lenacapavir (LEN),Comp Beta,Drug,hiv,hiv,Phase 3,2028-01-01,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Key Inclusion Criteria:

* Incidence Phase

  * HIV-1 status unknown at initial screening and no prior human immunodeficiency virus (HIV)-1 testing within the last 3 months.
  * Sexually active (has h...",No,2028-10-11,FDA-25306,2.62,0.32,5.0,7.94,2030-08-14,2030-12-09,2035-12-10,14,J&J,6,South Africa,58.0,63,60,89,32,63,41,27,0,2,1,False,False,False,True,False,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Subcutaneous (SC) Lenacapavir (LEN),AltName B,Drug,hiv,hiv,Phase 3,2028-01-01,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Key Inclusion Criteria:

* Incidence Phase

  * HIV-1 status unknown at initial screening and no prior human immunodeficiency virus (HIV)-1 testing within the last 3 months.
  * Sexually active (has h...",No,2028-03-12,FDA-12879,2.62,0.32,5.0,7.94,2030-08-14,2030-12-09,2035-12-10,74,Novartis,37,South Africa,38.66666666666666,9,28,29,80,44,42,73,2,2,4,True,True,True,False,True,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
F/TAF,TradeName X,Drug,hiv,hiv,Phase 3,2028-01-01,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Key Inclusion Criteria:

* Incidence Phase

  * HIV-1 status unknown at initial screening and no prior human immunodeficiency virus (HIV)-1 testing within the last 3 months.
  * Sexually active (has h...",No,2028-06-03,FDA-10235,2.62,0.32,5.0,7.94,2030-08-14,2030-12-09,2035-12-10,98,Sanofi,77,Senegal,53.5,65,20,73,69,8,86,55,1,3,2,False,True,False,True,True,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
F/TDF,AltName B,Drug,hiv,hiv,Phase 3,2028-01-01,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Key Inclusion Criteria:

* Incidence Phase

  * HIV-1 status unknown at initial screening and no prior human immunodeficiency virus (HIV)-1 testing within the last 3 months.
  * Sexually active (has h...",No,2028-07-07,FDA-69916,2.62,0.32,5.0,7.94,2030-08-14,2030-12-09,2035-12-10,68,Pfizer,39,Overall,46.33333333333334,26,82,42,39,76,13,55,1,2,3,True,False,False,False,True,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PTM Oral LEN,Molecule Z,Drug,hiv,hiv,Phase 3,2028-01-01,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Key Inclusion Criteria:

* Incidence Phase

  * HIV-1 status unknown at initial screening and no prior human immunodeficiency virus (HIV)-1 testing within the last 3 months.
  * Sexually active (has h...",Yes,2028-03-18,FDA-98755,2.62,0.32,5.0,7.94,2030-08-14,2030-12-09,2035-12-10,46,Gilead,41,Overall,40.33333333333334,12,6,51,62,89,22,45,1,3,1,True,False,False,True,True,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
PTM F/TAF,AltName B,Drug,hiv,hiv,Phase 3,2028-01-01,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Key Inclusion Criteria:

* Incidence Phase

  * HIV-1 status unknown at initial screening and no prior human immunodeficiency virus (HIV)-1 testing within the last 3 months.
  * Sexually active (has h...",No,2028-05-13,FDA-30493,2.62,0.32,5.0,7.94,2030-08-14,2030-12-09,2035-12-10,85,Pfizer,18,Overall,48.83333333333334,90,33,33,27,74,36,64,0,3,4,False,False,True,False,True,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PTM F/TDF,Molecule Z,Drug,hiv,hiv,Phase 3,2028-01-01,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Key Inclusion Criteria:

* Incidence Phase

  * HIV-1 status unknown at initial screening and no prior human immunodeficiency virus (HIV)-1 testing within the last 3 months.
  * Sexually active (has h...",No,2028-10-29,FDA-33690,2.62,0.32,5.0,7.94,2030-08-14,2030-12-09,2035-12-10,98,AstraZeneca,18,Senegal,36.5,6,48,48,68,11,38,27,1,1,1,True,False,False,False,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
emtricitabine/tenofovir disoproxil fumarate,Molecule Z,Drug,hiv,hiv,Phase 4,2013-05-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Adult (at least 18 years of age)employees of HFH
* History of occupational exposure to bodily fluids
* Negative HIV test
* The ability to understand a written informed consent f...",Yes,2013-09-15,FDA-53892,0.56,0.15,3.5,4.21,2013-11-21,2014-01-15,2017-07-16,89,Pfizer,92,Overall,53.83333333333334,60,27,52,54,37,93,27,1,1,1,True,False,False,False,False,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine/tenofovir disoproxil fumarate,GenName Y,Drug,hiv,hiv,Phase 2,2012-08-01,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Willing to provide adequate locator information
* Sexually active, defined as having vaginal intercourse at least once in the 3 months prior to screening
* Agree to not particip...",No,2012-12-24,FDA-89579,4.41,0.98,21.0,26.39,2016-12-28,2017-12-21,2038-12-21,99,Merck,92,South Africa,49.5,34,89,15,38,24,97,73,2,3,3,True,True,True,True,False,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir disoproxil fumarate,Molecule Z,Drug,hiv,hiv,Phase 2,2012-08-01,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Willing to provide adequate locator information
* Sexually active, defined as having vaginal intercourse at least once in the 3 months prior to screening
* Agree to not particip...",Yes,2012-09-02,FDA-79872,4.41,0.98,21.0,26.39,2016-12-28,2017-12-21,2038-12-21,60,Pfizer,11,Kenya,48.33333333333334,31,2,33,100,58,66,45,1,1,3,False,True,False,False,False,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir 1% vaginal gel,Molecule Z,Drug,hiv,hiv,Phase 2,2012-08-01,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Willing to provide adequate locator information
* Sexually active, defined as having vaginal intercourse at least once in the 3 months prior to screening
* Agree to not particip...",No,2013-02-22,FDA-70857,4.41,0.98,21.0,26.39,2016-12-28,2017-12-21,2038-12-21,89,Gilead,46,Overall,46.0,18,31,14,60,80,73,45,2,2,1,True,True,False,False,True,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Dapivirine Vaginal Ring,TradeName X,Drug,hiv,hiv,Phase 2,2015-04-01,"Sex: FEMALE; Age: >45 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Age 45 through 65 years (inclusive) at Screening, verified per site SOPs
2. Per participant report, postmenopausal at Screening, defined as amenorrhoeic for the past 12 months ...",Yes,2015-11-08,FDA-53346,4.41,0.98,21.0,26.39,2019-08-28,2020-08-20,2041-08-20,60,Pfizer,30,Senegal,38.16666666666666,30,31,39,51,46,32,55,2,4,0,True,True,True,True,False,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Kaletra + Current Dual NRTI Backbone,GenName Y,Drug,hiv,hiv,Phase 4,2009-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV Infection documented CD4+ count within the last 30 days (or drawn with screening labs)
* Currently on a stable 3-drug HAART regimen including 2 NRTIs for \> 6 month viral lo...",No,2010-01-23,FDA-18875,0.56,0.15,3.5,4.21,2010-06-23,2010-08-17,2014-02-15,90,Pfizer,20,South Africa,40.16666666666666,2,53,18,94,20,54,73,2,5,1,True,True,True,True,True,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Current Regimen,AltName A,Drug,hiv,hiv,Phase 4,2009-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV Infection documented CD4+ count within the last 30 days (or drawn with screening labs)
* Currently on a stable 3-drug HAART regimen including 2 NRTIs for \> 6 month viral lo...",No,2010-07-18,FDA-39765,0.56,0.15,3.5,4.21,2010-06-23,2010-08-17,2014-02-15,40,Sanofi,14,Kenya,51.0,89,45,2,75,24,71,36,1,2,1,False,True,True,False,False,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK1349572 (Cohort I),GenName Y,Drug,hiv,hiv,Phase 2,2015-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected male or female adults at least 18 years of age with a plasma HIV-1 RNA \> 1,000 copies/mL at study entry. Women capable of becoming pregnant must use appropriate ...",No,2015-05-24,FDA-96939,4.41,0.98,21.0,26.39,2019-05-30,2020-05-22,2041-05-22,73,AstraZeneca,57,Kenya,57.5,10,61,83,1,95,95,55,1,4,1,False,True,True,True,True,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK1349572 (Cohort II),GenName Y,Drug,hiv,hiv,Phase 2,2015-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected male or female adults at least 18 years of age with a plasma HIV-1 RNA \> 1,000 copies/mL at study entry. Women capable of becoming pregnant must use appropriate ...",No,2015-06-13,FDA-23019,4.41,0.98,21.0,26.39,2019-05-30,2020-05-22,2041-05-22,80,Merck,100,South Africa,62.5,42,66,40,79,82,66,45,1,3,1,False,True,True,False,True,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Nitazoxanide With Pegylated Interferon And Ribavirin,Molecule Z,Drug,hiv,hiv,Phase 2,2011-10-01,"Sex: ALL; Age: >18 Years; Criteria: * ELIGIBILITY CRITERIA:

To be eligible for participation on this protocol, a participant must satisfy all of the following conditions:

Be greater than or equal to 18 years old and have an identifiab...",Yes,2012-02-14,FDA-66931,4.41,0.98,21.0,26.39,2016-02-27,2017-02-19,2038-02-19,68,J&J,6,Overall,26.0,11,54,16,3,63,9,64,1,2,4,False,True,False,True,True,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
COBI,TradeName X,Drug,hiv,hiv,Phase 3,2015-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Plasma HIV-1 RNA levels ≥ 5,000 copies/mL at scr...",No,2015-12-31,FDA-75805,2.62,0.32,5.0,7.94,2017-11-12,2018-03-09,2023-03-10,68,Gilead,14,Kenya,29.16666666666667,13,13,21,67,40,21,18,0,0,2,False,False,False,False,False,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
RTV,TradeName X,Drug,hiv,hiv,Phase 3,2015-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Plasma HIV-1 RNA levels ≥ 5,000 copies/mL at scr...",No,2016-02-11,FDA-95286,2.62,0.32,5.0,7.94,2017-11-12,2018-03-09,2023-03-10,60,AstraZeneca,18,South Africa,37.5,77,18,4,29,78,19,64,1,4,2,False,True,True,False,True,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ATV,AltName B,Drug,hiv,hiv,Phase 3,2015-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Plasma HIV-1 RNA levels ≥ 5,000 copies/mL at scr...",Yes,2016-01-04,FDA-72804,2.62,0.32,5.0,7.94,2017-11-12,2018-03-09,2023-03-10,50,Sanofi,44,Senegal,26.33333333333333,13,12,24,7,61,41,36,1,2,1,True,False,True,False,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TDF,Product Alpha,Drug,hiv,hiv,Phase 3,2015-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Plasma HIV-1 RNA levels ≥ 5,000 copies/mL at scr...",No,2015-11-29,FDA-44603,2.62,0.32,5.0,7.94,2017-11-12,2018-03-09,2023-03-10,64,Sanofi,23,Kenya,49.16666666666666,17,68,93,0,81,36,36,0,3,1,False,False,True,False,True,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Cabotegravir (CAB) tablet,AltName B,Drug,hiv,hiv,Phase 2,2023-07-07,"Sex: MALE; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Assigned male at birth (includes MSM, TGW, and gender non-conforming people)
* At enrollment, aged below 18 years
* At enrollment, body weight ≥ 35 kg (77 lbs.)
* Willing to pro...",No,2023-10-20,FDA-51475,4.41,0.98,21.0,26.39,2027-12-03,2028-11-25,2049-11-25,28,AstraZeneca,7,South Africa,47.5,93,83,36,16,37,20,45,1,3,1,True,False,True,True,False,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
CAB LA,AltName B,Drug,hiv,hiv,Phase 2,2023-07-07,"Sex: MALE; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Assigned male at birth (includes MSM, TGW, and gender non-conforming people)
* At enrollment, aged below 18 years
* At enrollment, body weight ≥ 35 kg (77 lbs.)
* Willing to pro...",No,2024-03-23,FDA-28210,4.41,0.98,21.0,26.39,2027-12-03,2028-11-25,2049-11-25,81,Gilead,2,Kenya,36.83333333333334,38,64,42,4,20,53,55,2,2,2,True,True,False,False,True,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet,Comp Beta,Drug,hiv,hiv,Phase 2,2023-07-07,"Sex: MALE; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Assigned male at birth (includes MSM, TGW, and gender non-conforming people)
* At enrollment, aged below 18 years
* At enrollment, body weight ≥ 35 kg (77 lbs.)
* Willing to pro...",No,2023-10-17,FDA-15308,4.41,0.98,21.0,26.39,2027-12-03,2028-11-25,2049-11-25,41,Novartis,61,Overall,57.66666666666666,83,73,97,5,1,87,73,1,5,2,False,True,True,True,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
IL-2,Product Alpha,Drug,hiv,hiv,Phase 2,2011-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV infected
* CD4 count of 300 cells/mm3 or more
* Access to a HAART regimen consisting of 1 or more protease inhibitors (PIs) and 2 or more nucleoside or nucleotide reverse tr...",No,2011-05-16,FDA-63273,4.41,0.98,21.0,26.39,2015-06-30,2016-06-22,2037-06-22,75,J&J,28,South Africa,63.66666666666666,48,24,70,91,86,63,82,2,4,3,True,True,True,True,False,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ALVAC-HIV (vCP2438),Comp Beta,Biological,hiv,hiv,Phase 3,2021-11-16,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria

* Age of 18 to 35 years
* Sexually active, defined as having had sexual intercourse at least twice in the past 30 days prior to screening, and is considered by the site staff to be...",No,2022-06-13,FDA-87850,2.62,0.32,5.0,7.94,2024-06-29,2024-10-24,2029-10-25,92,Bayer,89,Senegal,34.0,25,7,44,25,10,93,45,1,3,1,True,False,False,False,True,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Bivalent Subtype C gp120/MF59,GenName Y,Biological,hiv,hiv,Phase 3,2021-11-16,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria

* Age of 18 to 35 years
* Sexually active, defined as having had sexual intercourse at least twice in the past 30 days prior to screening, and is considered by the site staff to be...",Yes,2022-07-30,FDA-69334,2.62,0.32,5.0,7.94,2024-06-29,2024-10-24,2029-10-25,61,Gilead,20,South Africa,64.0,95,48,65,51,40,85,45,1,2,2,True,False,False,False,True,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir poloxamer film coated tablet,Product Alpha,Drug,hiv,hiv,Phase 2,2017-05-18,"Sex: ALL; Age: >30 Days; Criteria: Inclusion Criteria for All Participants:

* Documentation of HIV-1 infection, defined as positive results from two samples collected at different time points. More information on this criterion can be...",No,2018-01-10,FDA-97281,4.41,0.98,21.0,26.39,2021-10-14,2022-10-07,2043-10-07,71,Merck,43,Senegal,51.33333333333334,66,68,1,12,67,94,36,1,1,2,True,False,False,False,False,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir chewable tablet,TradeName X,Drug,hiv,hiv,Phase 2,2017-05-18,"Sex: ALL; Age: >30 Days; Criteria: Inclusion Criteria for All Participants:

* Documentation of HIV-1 infection, defined as positive results from two samples collected at different time points. More information on this criterion can be...",Yes,2018-02-18,FDA-26583,4.41,0.98,21.0,26.39,2021-10-14,2022-10-07,2043-10-07,65,Gilead,44,South Africa,43.83333333333334,60,30,95,13,48,17,55,0,4,2,False,False,True,False,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir oral granules for suspension (20 mg/mL),Molecule Z,Drug,hiv,hiv,Phase 2,2017-05-18,"Sex: ALL; Age: >30 Days; Criteria: Inclusion Criteria for All Participants:

* Documentation of HIV-1 infection, defined as positive results from two samples collected at different time points. More information on this criterion can be...",Yes,2018-04-02,FDA-62489,4.41,0.98,21.0,26.39,2021-10-14,2022-10-07,2043-10-07,60,Pfizer,79,Overall,53.66666666666666,18,71,76,95,51,11,73,1,5,2,False,True,True,True,True,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir poloxamer film coated tablet,Comp Beta,Drug,hiv,hiv,Phase 2,2017-05-18,"Sex: ALL; Age: >30 Days; Criteria: Inclusion Criteria for All Participants:

* Documentation of HIV-1 infection, defined as positive results from two samples collected at different time points. More information on this criterion can be...",No,2018-02-09,FDA-35408,4.41,0.98,21.0,26.39,2021-10-14,2022-10-07,2043-10-07,75,Merck,93,Kenya,28.33333333333333,15,48,0,29,17,61,45,1,2,2,True,False,True,True,False,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
raltegravir potassium,Molecule Z,Drug,hiv,hiv,Phase 3,2011-05-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Patient must be HIV positive with HIV RNA values that are within ranges required by the study
* Patient must have documented failure of certain antiretroviral therapy
* Patient ...",No,2011-09-24,FDA-74592,2.62,0.32,5.0,7.94,2013-12-12,2014-04-08,2019-04-09,43,Bayer,35,Kenya,65.33333333333333,24,90,32,82,72,92,45,1,3,1,False,True,False,True,False,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,Molecule Z,Drug,hiv,hiv,Phase 4,2011-09-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* HIV-negative, proven by ELISA
* Age: ≥ 18 years old

Exclusion Criteria:

* Psychiatric or psychological illness that would make adherence to protocol procedures unlikely....",No,2011-12-27,FDA-89047,0.56,0.15,3.5,4.21,2012-03-23,2012-05-17,2015-11-16,14,J&J,42,Overall,54.0,97,53,22,89,50,13,36,2,2,0,True,True,True,True,False,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Over-encapsulated efavirenz,AltName A,Drug,hiv,hiv,Phase 4,2011-09-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* HIV-negative, proven by ELISA
* Age: ≥ 18 years old

Exclusion Criteria:

* Psychiatric or psychological illness that would make adherence to protocol procedures unlikely....",No,2012-03-09,FDA-61669,0.56,0.15,3.5,4.21,2012-03-23,2012-05-17,2015-11-16,35,Sanofi,48,Senegal,27.0,18,92,5,6,39,2,45,0,3,2,False,False,True,False,True,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Teduglutide,AltName A,Drug,hiv,hiv,Phase 2,2021-01-21,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

1. Men and women age 21-65 with previously diagnosed HIV disease
2. Stable anti-retroviral therapy (ART) as defined by no changes in ART regimen for \>6 months
3. HIV viral load \...",Yes,2021-06-16,FDA-18602,4.41,0.98,21.0,26.39,2025-06-19,2026-06-12,2047-06-12,15,Merck,47,Overall,59.33333333333334,91,56,33,87,4,85,27,0,0,3,False,False,False,False,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
CAB LA+RPV LA,AltName B,Drug,hiv,hiv,Phase 3,2022-03-18,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Be able to understand and comply with protocol requirements, instructions, and restrictions;
* Understand the long-term commitment to the study and be likely to complete the stu...",Yes,2022-08-07,FDA-86906,2.62,0.32,5.0,7.94,2024-10-29,2025-02-23,2030-02-24,38,Pfizer,12,South Africa,50.66666666666666,63,44,52,1,95,49,64,0,4,3,False,False,True,True,True,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
GW433908,AltName B,Drug,hiv,hiv,Phase 2,2022-03-29,"Sex: ALL; Age: >4 Weeks; Criteria: Inclusion Criteria:

* Male or female 4 weeks to \<2 years of age. Cohort 1 (6 months - \<2 years): Subjects must be \<2 years of age at the Week 2 visit therefore the maximum age at screening is 22 m...",No,2022-10-22,FDA-77029,4.41,0.98,21.0,26.39,2026-08-25,2027-08-18,2048-08-17,67,J&J,37,Senegal,56.66666666666666,64,90,39,29,88,30,18,0,1,1,False,False,False,False,False,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ritonavir,Comp Beta,Drug,hiv,hiv,Phase 2,2022-03-29,"Sex: ALL; Age: >4 Weeks; Criteria: Inclusion Criteria:

* Male or female 4 weeks to \<2 years of age. Cohort 1 (6 months - \<2 years): Subjects must be \<2 years of age at the Week 2 visit therefore the maximum age at screening is 22 m...",No,2022-11-21,FDA-76907,4.41,0.98,21.0,26.39,2026-08-25,2027-08-18,2048-08-17,35,Pfizer,6,South Africa,55.83333333333334,55,89,32,71,50,38,36,1,2,1,False,True,False,False,True,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
LDMTX,GenName Y,Drug,hiv,hiv,Phase 2,2016-12-08,"Sex: ALL; Age: >40 Years; Criteria: Inclusion Criteria:

* HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a li...",No,2017-11-05,FDA-13428,4.41,0.98,21.0,26.39,2021-05-06,2022-04-29,2043-04-29,55,Pfizer,13,Overall,75.5,72,59,89,81,98,54,73,1,4,3,True,False,True,True,False,True,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada,AltName A,Drug,hiv,hiv,Phase 2,2010-12-01,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Individual must identify as a male who has sex with other men (MSM);
* At least 18 years of age;
* HIV negative serostatus on baseline rapid oral HIV antibody test;
* Self-repor...",No,2011-08-11,FDA-37465,4.41,0.98,21.0,26.39,2015-04-29,2016-04-21,2037-04-21,98,Gilead,26,South Africa,49.33333333333334,28,42,82,88,14,42,55,0,2,4,False,False,True,False,False,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
iHIVARNA-01,AltName A,Biological,hiv,hiv,Phase 2,2018-02-12,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. ≥ 18 years of age;
2. Voluntarily signed informed consent;
3. Proven HIV-1 infection (with documented antibodies against HIV-1 and a detectable plasma HIV-1 RNA before initiati...",Yes,2018-10-27,FDA-44988,4.41,0.98,21.0,26.39,2022-07-11,2023-07-04,2044-07-03,65,GSK,13,South Africa,57.66666666666666,4,58,75,93,58,58,45,1,3,1,True,False,True,True,False,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
TriMix,GenName Y,Biological,hiv,hiv,Phase 2,2018-02-12,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. ≥ 18 years of age;
2. Voluntarily signed informed consent;
3. Proven HIV-1 infection (with documented antibodies against HIV-1 and a detectable plasma HIV-1 RNA before initiati...",Yes,2018-12-07,FDA-75600,4.41,0.98,21.0,26.39,2022-07-11,2023-07-04,2044-07-03,47,AstraZeneca,36,Senegal,62.66666666666666,34,94,47,33,69,99,45,1,1,3,True,False,False,False,False,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Oral CAB,AltName A,Drug,hiv,hiv,Phase 3,2026-10-17,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Born female
* 18-45 years at the time of screening
* Willing and able to provide informed consent
* Willing and able to undergo all required study procedures
* Non-reactive HIV ...",No,2027-02-08,FDA-52670,2.62,0.32,5.0,7.94,2029-05-30,2029-09-24,2034-09-25,11,Merck,98,South Africa,53.0,53,57,79,69,8,52,55,0,5,1,False,False,True,True,True,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Oral TDF/FTC,AltName A,Drug,hiv,hiv,Phase 3,2026-10-17,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Born female
* 18-45 years at the time of screening
* Willing and able to provide informed consent
* Willing and able to undergo all required study procedures
* Non-reactive HIV ...",Yes,2027-03-31,FDA-29316,2.62,0.32,5.0,7.94,2029-05-30,2029-09-24,2034-09-25,13,Bayer,51,South Africa,56.83333333333334,88,80,23,42,9,99,27,1,0,2,False,True,False,False,False,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
CAB LA,Comp Beta,Drug,hiv,hiv,Phase 3,2026-10-17,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Born female
* 18-45 years at the time of screening
* Willing and able to provide informed consent
* Willing and able to undergo all required study procedures
* Non-reactive HIV ...",Yes,2027-03-09,FDA-97271,2.62,0.32,5.0,7.94,2029-05-30,2029-09-24,2034-09-25,35,Pfizer,57,Senegal,38.5,58,23,44,57,41,8,36,1,1,2,False,True,True,False,False,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Biktarvy,TradeName X,Drug,hiv,hiv,Phase 3,2021-09-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Patients with HIV on abacavir/lamivudine/dolutegravir STR regimens for at least 1 year fulfilling the following inclusion criteria:

1. age ≥ 45 years for men and ≥ 55 years for w...",No,2022-07-18,FDA-62858,2.62,0.32,5.0,7.94,2024-04-28,2024-08-23,2029-08-24,55,Sanofi,0,Overall,56.33333333333334,66,48,50,92,17,65,36,1,2,1,False,True,False,False,True,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
60 µg dose hepatitis B vaccine,GenName Y,Biological,hiv,hiv,Phase 4,2018-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-infected
* Aged between 18 and 70 years
* Serologically negative for hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) at enrollment
* Willing ...",No,2018-10-28,FDA-45555,0.56,0.15,3.5,4.21,2019-01-21,2019-03-17,2022-09-15,9,AstraZeneca,14,Kenya,57.5,34,55,60,83,66,47,64,1,4,2,False,True,True,False,True,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
20 µg dose hepatitis B vaccine,TradeName X,Biological,hiv,hiv,Phase 4,2018-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-infected
* Aged between 18 and 70 years
* Serologically negative for hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) at enrollment
* Willing ...",Yes,2019-03-09,FDA-84763,0.56,0.15,3.5,4.21,2019-01-21,2019-03-17,2022-09-15,90,Pfizer,34,Kenya,52.5,62,28,57,73,88,7,55,0,4,2,False,False,True,True,True,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Pravastatin,AltName B,Drug,hiv,hiv,Phase 2,2021-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* HIV RNA below the lower limit of assay detection within 12 months of study entry
* 1\) Documented coronary heart disease (CHD): nonfatal MI, unrecognized MI, u...",No,2021-12-04,FDA-66643,4.41,0.98,21.0,26.39,2025-10-28,2026-10-21,2047-10-21,13,Merck,89,Kenya,71.83333333333333,58,97,61,47,84,84,55,2,1,3,True,True,False,True,False,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Rosuvastatin,AltName A,Drug,hiv,hiv,Phase 2,2021-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* HIV RNA below the lower limit of assay detection within 12 months of study entry
* 1\) Documented coronary heart disease (CHD): nonfatal MI, unrecognized MI, u...",Yes,2021-10-17,FDA-82896,4.41,0.98,21.0,26.39,2025-10-28,2026-10-21,2047-10-21,36,Pfizer,62,Senegal,44.83333333333334,58,28,75,57,29,22,36,1,1,2,True,False,False,False,False,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir,AltName A,Drug,hiv,hiv,Phase 3,2016-06-01,"Sex: ALL; Age: >45 Years; Criteria: Inclusion Criteria:

* Age ≥ 45 years
* Stable non-atazanavir-containing regimen consisting of co-formulated tenofovir/emtricitabine as the NRTIs plus a third agent for 3 months or longer. The third a...",Yes,2017-03-02,FDA-91225,2.62,0.32,5.0,7.94,2019-01-13,2019-05-10,2024-05-10,48,Sanofi,79,South Africa,62.66666666666666,92,43,74,51,58,58,18,0,1,1,False,False,False,False,False,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tipranavir,Product Alpha,Drug,hiv,hiv,Phase 3,,"Sex: ALL; Age: >18 Years; Criteria: INCLUSION CRITERIA

1. Ability and willingness to give written informed consent in accordance with institutional and federal guidelines and to comply with the investigational nature of the study and t...",Yes,2026-05-13,FDA-37549,2.62,0.32,5.0,7.94,,,,28,Bayer,82,Senegal,46.5,73,52,15,50,41,48,45,2,1,2,True,True,False,False,False,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
dolutegravir,Molecule Z,Drug,hiv,hiv,Phase 3,2015-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Screening plasma HIV-1 RNA ≥500 copies/mL
* ART-experienced, INI-experienced, DTG naïve
* Experienced virological failure on raltegravir (RAL) or elvitegravir (ELV) regimen
* Th...",No,2016-02-15,FDA-92252,2.62,0.32,5.0,7.94,2017-12-12,2018-04-08,2023-04-09,15,Gilead,83,Senegal,51.16666666666666,10,66,98,32,33,68,55,2,2,2,True,True,False,False,True,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir/ritonavir,Molecule Z,Drug,hiv,hiv,Phase 4,2011-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. HIV infection
2. Age \> or = 18 years old.
3. Signed informed consent.
4. Clinical lipoatrophy of at least moderate severity and in at least two different areas of the followin...",No,2012-05-17,FDA-89319,0.56,0.15,3.5,4.21,2012-06-22,2012-08-16,2016-02-15,52,Pfizer,79,Senegal,48.5,37,0,91,12,92,59,27,0,2,1,False,False,False,False,False,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,Molecule Z,Drug,hiv,hiv,Phase 4,2011-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. HIV infection
2. Age \> or = 18 years old.
3. Signed informed consent.
4. Clinical lipoatrophy of at least moderate severity and in at least two different areas of the followin...",Yes,2012-11-18,FDA-89590,0.56,0.15,3.5,4.21,2012-06-22,2012-08-16,2016-02-15,1,AstraZeneca,84,Kenya,58.16666666666666,66,99,29,59,43,53,64,0,3,4,False,False,False,True,True,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
boceprevir,AltName A,Drug,hiv,hiv,Phase 3,2015-06-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* For inclusion in the study, subjects must have a qualifying regimen defined as peginterferon alfa-2a plus ribavirin or peginterferon alfa-2b plus ribavirin for a minimum of 12 w...",No,2015-08-29,FDA-87296,2.62,0.32,5.0,7.94,2018-02-10,2018-06-07,2023-06-08,57,AstraZeneca,3,South Africa,48.16666666666666,18,64,65,36,51,55,45,1,2,2,False,True,True,False,False,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ribavirin,AltName B,Drug,hiv,hiv,Phase 3,2015-06-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* For inclusion in the study, subjects must have a qualifying regimen defined as peginterferon alfa-2a plus ribavirin or peginterferon alfa-2b plus ribavirin for a minimum of 12 w...",Yes,2015-09-12,FDA-83383,2.62,0.32,5.0,7.94,2018-02-10,2018-06-07,2023-06-08,97,AstraZeneca,87,Overall,43.33333333333334,45,29,99,15,8,64,73,2,3,3,True,True,False,True,True,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Peginterferon alfa-2a,Comp Beta,Drug,hiv,hiv,Phase 3,2015-06-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* For inclusion in the study, subjects must have a qualifying regimen defined as peginterferon alfa-2a plus ribavirin or peginterferon alfa-2b plus ribavirin for a minimum of 12 w...",No,2016-01-30,FDA-80210,2.62,0.32,5.0,7.94,2018-02-10,2018-06-07,2023-06-08,65,GSK,19,Kenya,65.0,95,40,88,77,33,57,55,2,2,2,True,True,False,True,False,False,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Peginterferon alfa-2b,GenName Y,Drug,hiv,hiv,Phase 3,2015-06-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* For inclusion in the study, subjects must have a qualifying regimen defined as peginterferon alfa-2a plus ribavirin or peginterferon alfa-2b plus ribavirin for a minimum of 12 w...",Yes,2016-03-06,FDA-24454,2.62,0.32,5.0,7.94,2018-02-10,2018-06-07,2023-06-08,75,Gilead,69,South Africa,61.0,68,86,41,94,36,41,55,2,2,2,True,True,False,True,False,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
TMC310911 75 mg twice daily,AltName B,Drug,hiv,hiv,Phase 2,2011-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented human immunodeficiency virus type 1 (HIV-1) infection for at least 6 months prior to the screening date
* Participant who has not been treated with a therapeutic HIV ...",Yes,2011-08-16,FDA-21552,4.41,0.98,21.0,26.39,2015-06-30,2016-06-22,2037-06-22,88,AstraZeneca,33,Overall,59.16666666666666,21,50,100,9,93,82,36,0,2,2,False,False,True,False,False,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
TMC310911 150 mg twice daily,Molecule Z,Drug,hiv,hiv,Phase 2,2011-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented human immunodeficiency virus type 1 (HIV-1) infection for at least 6 months prior to the screening date
* Participant who has not been treated with a therapeutic HIV ...",No,2011-03-03,FDA-45766,4.41,0.98,21.0,26.39,2015-06-30,2016-06-22,2037-06-22,43,J&J,97,Kenya,33.0,7,28,43,84,33,3,36,0,2,2,False,False,False,True,False,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
TMC310911 300 mg twice daily,Product Alpha,Drug,hiv,hiv,Phase 2,2011-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented human immunodeficiency virus type 1 (HIV-1) infection for at least 6 months prior to the screening date
* Participant who has not been treated with a therapeutic HIV ...",Yes,2011-06-01,FDA-59999,4.41,0.98,21.0,26.39,2015-06-30,2016-06-22,2037-06-22,7,Pfizer,77,South Africa,50.16666666666666,69,35,28,8,72,89,27,1,2,0,False,True,True,False,False,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
TMC310911 300 mg once daily,Product Alpha,Drug,hiv,hiv,Phase 2,2011-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented human immunodeficiency virus type 1 (HIV-1) infection for at least 6 months prior to the screening date
* Participant who has not been treated with a therapeutic HIV ...",Yes,2011-08-31,FDA-79850,4.41,0.98,21.0,26.39,2015-06-30,2016-06-22,2037-06-22,35,GSK,8,Overall,62.83333333333334,69,30,86,92,57,43,18,1,1,0,False,True,False,False,False,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir 100 mg twice daily,Molecule Z,Drug,hiv,hiv,Phase 2,2011-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented human immunodeficiency virus type 1 (HIV-1) infection for at least 6 months prior to the screening date
* Participant who has not been treated with a therapeutic HIV ...",No,2011-09-24,FDA-80162,4.41,0.98,21.0,26.39,2015-06-30,2016-06-22,2037-06-22,65,Bayer,82,South Africa,61.66666666666666,39,84,32,67,51,97,45,1,2,2,True,False,False,False,False,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir 100 mg once daily,Comp Beta,Drug,hiv,hiv,Phase 2,2011-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented human immunodeficiency virus type 1 (HIV-1) infection for at least 6 months prior to the screening date
* Participant who has not been treated with a therapeutic HIV ...",No,2011-11-01,FDA-13009,4.41,0.98,21.0,26.39,2015-06-30,2016-06-22,2037-06-22,38,AstraZeneca,62,Senegal,66.16666666666667,67,91,32,62,97,48,73,1,4,3,True,False,True,True,False,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Armodafinil,Molecule Z,Drug,hiv,hiv,Phase 4,2010-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Ages 18-75
2. HIV+
3. Clinically significant fatigue (score of 4.5+ on Fatigue Severity Scale, plus impairment on 1+ categories of Role Function Scale)
4. Fatigue duration for ...",Yes,2011-03-12,FDA-93830,0.56,0.15,3.5,4.21,2011-03-24,2011-05-18,2014-11-16,55,Pfizer,8,Senegal,40.33333333333334,98,4,13,41,20,66,55,1,2,3,False,True,False,True,False,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Pegylated interferon alfa-2a + Ribavirin,GenName Y,Drug,hiv,hiv,Phase 4,2013-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Newly acquired HCV infection of 6 months or less duration
* Detectable HCV RNA at study entry
* HIV infection, any CD4 count

Exclusion Criteria:

* Pregnant or intent to become...",Yes,2014-10-31,FDA-96198,0.56,0.15,3.5,4.21,2014-06-23,2014-08-17,2018-02-15,86,AstraZeneca,89,Kenya,46.16666666666666,13,55,18,100,27,64,55,1,2,3,False,True,False,True,False,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Biktarvy 50Mg-200Mg-25Mg Tablet,AltName A,Drug,hiv,hiv,Phase 4,2023-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Adult (age\>18 years);
2. positive rapid HIV test;
3. ability to provide informed consent;
4. HIV RNA \> 200 copies/ml;
5. creatinine clearance \> 30 mg/dl as measured by serum...",Yes,2024-11-25,FDA-17116,0.56,0.15,3.5,4.21,2024-07-22,2024-09-15,2028-03-16,55,Pfizer,11,Kenya,44.83333333333334,27,12,60,38,50,82,45,0,2,3,False,False,False,False,True,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK1349572,TradeName X,Drug,hiv,hiv,Phase 2,2016-12-22,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected male or female adults at least 18 years of age. Women capable of becoming pregnant must use appropriate contraception during the study (as defined by the protocol...",No,2017-12-10,FDA-75894,4.41,0.98,21.0,26.39,2021-05-20,2022-05-13,2043-05-13,34,Gilead,62,Senegal,34.66666666666666,32,10,63,27,38,38,36,0,1,3,False,False,False,False,False,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
efavirenz,Molecule Z,Drug,hiv,hiv,Phase 2,2016-12-22,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected male or female adults at least 18 years of age. Women capable of becoming pregnant must use appropriate contraception during the study (as defined by the protocol...",No,2017-08-03,FDA-51746,4.41,0.98,21.0,26.39,2021-05-20,2022-05-13,2043-05-13,11,J&J,32,Senegal,42.83333333333334,9,67,94,34,6,47,64,1,4,2,False,True,True,True,False,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Boosted Atazanavir,Molecule Z,Drug,hiv,hiv,Phase 4,2016-11-23,"Sex: ALL; Age: >6 Years; Criteria: Inclusion Criteria:

* HIV positive children with elevated lipid levels
* on stable HAART for at least 3 months (defined to be on the same regimen with viral load \< 1000 for 6 months prior to baselin...",No,2017-10-28,FDA-29606,0.56,0.15,3.5,4.21,2017-06-15,2017-08-09,2021-02-07,7,Merck,62,Overall,55.16666666666666,78,80,26,30,24,93,64,1,3,3,False,True,True,False,True,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Sofosbuvir,TradeName X,Drug,hiv,hiv,Phase 3,2014-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Age ≥ 18 years with HIV-1 and chronic HCV genotype 1, 2, 3, or 4 co-infection
* HCV RNA \> 10,000 IU/mL at screening
* HCV treatment history:

  * Treatment-naive for HCV genoty...",Yes,2014-08-03,FDA-86715,2.62,0.32,5.0,7.94,2017-02-11,2017-06-08,2022-06-09,19,J&J,61,Overall,40.5,67,10,16,37,55,58,64,1,2,4,True,False,True,True,False,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
RBV,GenName Y,Drug,hiv,hiv,Phase 3,2014-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Age ≥ 18 years with HIV-1 and chronic HCV genotype 1, 2, 3, or 4 co-infection
* HCV RNA \> 10,000 IU/mL at screening
* HCV treatment history:

  * Treatment-naive for HCV genoty...",No,2015-05-03,FDA-75662,2.62,0.32,5.0,7.94,2017-02-11,2017-06-08,2022-06-09,16,Novartis,80,Kenya,50.5,83,6,65,96,28,25,55,0,2,4,False,False,True,False,False,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,Product Alpha,Drug,hiv,hiv,Phase 3,2017-08-02,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Pregnant women with confirmed HIV-1 infection (positive Western blot or plasma HIV-1 RNA \>1,000 copies/ml)
* Gestational age higher than 28 weeks
* Age equal or higher than 15 ...",No,2018-07-08,FDA-66003,2.62,0.32,5.0,7.94,2020-03-15,2020-07-10,2025-07-11,3,Gilead,25,Kenya,23.5,59,5,41,17,11,8,55,2,4,0,True,True,False,True,True,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir/Ritonavir,Comp Beta,Drug,hiv,hiv,Phase 3,2017-08-02,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Pregnant women with confirmed HIV-1 infection (positive Western blot or plasma HIV-1 RNA \>1,000 copies/ml)
* Gestational age higher than 28 weeks
* Age equal or higher than 15 ...",Yes,2018-07-08,FDA-77033,2.62,0.32,5.0,7.94,2020-03-15,2020-07-10,2025-07-11,10,J&J,5,Overall,60.66666666666666,91,57,12,53,88,63,55,2,2,2,True,True,False,True,False,False,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ibudilast,GenName Y,Drug,hiv,hiv,Phase 2,2017-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. 18 years of age or older;
2. meet DSM-IV-TR criteria for MA dependence (SCID verified);
3. a MA-positive urine drug screen at one or more visit during the two week lead-in peri...",Yes,2018-11-25,FDA-43606,4.41,0.98,21.0,26.39,2022-05-29,2023-05-22,2044-05-21,19,Sanofi,73,Overall,70.83333333333333,55,76,74,84,45,91,73,2,4,2,True,True,True,True,False,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
D/C/F/TAF,GenName Y,Drug,hiv,hiv,Phase 3,2020-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Currently being treated with a stable antiretroviral (ARV) regimen consisting of a boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir...",No,2021-05-01,FDA-45855,2.62,0.32,5.0,7.94,2023-05-15,2023-09-09,2028-09-09,94,J&J,83,Senegal,47.16666666666666,19,72,83,28,1,80,18,1,1,0,True,False,False,False,False,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Boosted Protease Inhibitor (bPI),AltName B,Drug,hiv,hiv,Phase 3,2020-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Currently being treated with a stable antiretroviral (ARV) regimen consisting of a boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir...",Yes,2021-08-05,FDA-66232,2.62,0.32,5.0,7.94,2023-05-15,2023-09-09,2028-09-09,74,Sanofi,74,Kenya,76.33333333333333,90,64,100,48,97,59,64,1,3,3,False,True,True,False,True,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TDF,Molecule Z,Drug,hiv,hiv,Phase 3,2020-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Currently being treated with a stable antiretroviral (ARV) regimen consisting of a boosted protease inhibitor (limited to darunavir \[DRV\] or atazanavir with low-dose ritonavir...",No,2021-07-19,FDA-61966,2.62,0.32,5.0,7.94,2023-05-15,2023-09-09,2028-09-09,51,Gilead,65,Overall,42.0,79,11,5,46,75,36,45,2,2,1,True,True,True,False,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Oral cabotegravir (CAB),Product Alpha,Drug,hiv,hiv,Phase 2,2023-01-10,"Sex: FEMALE; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Assigned female at birth
* At enrollment, below 18 years of age
* At enrollment, body weight ≥ 35 kg (77 lbs.)
* Willing and able to provide informed assent/consent for the stud...",No,2023-11-06,FDA-54654,4.41,0.98,21.0,26.39,2027-06-08,2028-05-31,2049-05-31,39,Sanofi,74,Kenya,35.33333333333334,27,38,7,50,61,29,9,0,1,0,False,False,False,False,False,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
CAB LA,Product Alpha,Drug,hiv,hiv,Phase 2,2023-01-10,"Sex: FEMALE; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Assigned female at birth
* At enrollment, below 18 years of age
* At enrollment, body weight ≥ 35 kg (77 lbs.)
* Willing and able to provide informed assent/consent for the stud...",No,2023-09-15,FDA-71326,4.41,0.98,21.0,26.39,2027-06-08,2028-05-31,2049-05-31,21,Bayer,12,Overall,52.5,73,70,98,50,18,6,55,1,2,3,True,False,False,False,False,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC),Product Alpha,Drug,hiv,hiv,Phase 2,2023-01-10,"Sex: FEMALE; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Assigned female at birth
* At enrollment, below 18 years of age
* At enrollment, body weight ≥ 35 kg (77 lbs.)
* Willing and able to provide informed assent/consent for the stud...",Yes,2023-12-12,FDA-96723,4.41,0.98,21.0,26.39,2027-06-08,2028-05-31,2049-05-31,56,Bayer,51,Overall,53.33333333333334,36,72,82,78,52,0,36,0,4,0,False,False,True,True,True,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine/ tenofovir disoproxil fumarate,GenName Y,Drug,hiv,hiv,Phase 2,2011-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria for Step 1:

* Recently infected with HIV
* No prior antiretroviral therapy (ART)
* CD4 count of 350 cells/mm3 or more AND a CD4% of 14% or more within 21 days prior to study entry
...",No,2011-08-29,FDA-67018,4.41,0.98,21.0,26.39,2015-09-27,2016-09-19,2037-09-19,3,AstraZeneca,49,Kenya,32.5,8,14,16,89,38,30,36,1,2,1,True,False,False,True,True,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir/Ritonavir,Molecule Z,Drug,hiv,hiv,Phase 2,2011-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria for Step 1:

* Recently infected with HIV
* No prior antiretroviral therapy (ART)
* CD4 count of 350 cells/mm3 or more AND a CD4% of 14% or more within 21 days prior to study entry
...",No,2011-12-10,FDA-59194,4.41,0.98,21.0,26.39,2015-09-27,2016-09-19,2037-09-19,38,Merck,8,Overall,58.16666666666666,4,62,86,26,74,97,45,0,2,3,False,False,False,True,False,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,Product Alpha,Drug,hiv,hiv,Phase 3,2020-04-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Age ≥18 years old
2. Documented HIV infection
3. Stable 3-drug antiretroviral treatment including PI/r/c or NNRTI for at least 6 months.
4. Plasma HIV-1 RNA load \<50 copies/mL...",Yes,2021-03-18,FDA-29180,2.62,0.32,5.0,7.94,2022-12-12,2023-04-08,2028-04-08,60,Novartis,71,South Africa,63.5,46,59,75,99,50,52,45,0,3,2,False,False,True,True,True,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Current ART,TradeName X,Drug,hiv,hiv,Phase 3,2020-04-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Age ≥18 years old
2. Documented HIV infection
3. Stable 3-drug antiretroviral treatment including PI/r/c or NNRTI for at least 6 months.
4. Plasma HIV-1 RNA load \<50 copies/mL...",No,2021-01-22,FDA-91662,2.62,0.32,5.0,7.94,2022-12-12,2023-04-08,2028-04-08,92,GSK,42,Kenya,50.66666666666666,70,45,34,45,93,17,27,2,0,1,True,True,False,False,False,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor),Molecule Z,Drug,hiv,hiv,Phase 4,2013-04-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Males and Females ages 18 years to 60 years inclusive
* HIV positive (no anticipated antiretroviral therapy adjustments/changes)
* CD4 count greater than or equal to 50 cells/ml...",Yes,2013-12-27,FDA-56587,0.56,0.15,3.5,4.21,2013-10-22,2013-12-16,2017-06-16,23,Gilead,48,South Africa,41.83333333333334,0,77,85,47,39,3,27,1,1,1,False,True,True,False,False,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor),GenName Y,Drug,hiv,hiv,Phase 4,2013-04-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Males and Females ages 18 years to 60 years inclusive
* HIV positive (no anticipated antiretroviral therapy adjustments/changes)
* CD4 count greater than or equal to 50 cells/ml...",Yes,2013-09-06,FDA-76799,0.56,0.15,3.5,4.21,2013-10-22,2013-12-16,2017-06-16,83,Pfizer,41,Kenya,43.5,1,87,72,26,71,4,55,2,2,2,True,True,False,False,True,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)],Comp Beta,Drug,hiv,hiv,Phase 4,2013-04-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Males and Females ages 18 years to 60 years inclusive
* HIV positive (no anticipated antiretroviral therapy adjustments/changes)
* CD4 count greater than or equal to 50 cells/ml...",No,2014-01-15,FDA-18251,0.56,0.15,3.5,4.21,2013-10-22,2013-12-16,2017-06-16,63,Gilead,38,Kenya,63.33333333333334,67,78,64,71,63,37,36,0,3,1,False,False,False,True,False,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
CAB LA,TradeName X,Drug,hiv,hiv,Phase 2,2023-01-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Aged 18 years or older (or \>=19 where required by local regulatory agencies), at the time of signing the informed consent.
* A female participant is eligible to participate if ...",No,2023-04-05,FDA-33617,4.41,0.98,21.0,26.39,2027-06-28,2028-06-20,2049-06-20,7,Bayer,20,Kenya,53.66666666666666,72,63,8,87,40,52,27,0,2,1,False,False,True,False,False,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
RPV LA,Product Alpha,Drug,hiv,hiv,Phase 2,2023-01-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Aged 18 years or older (or \>=19 where required by local regulatory agencies), at the time of signing the informed consent.
* A female participant is eligible to participate if ...",No,2023-06-17,FDA-74272,4.41,0.98,21.0,26.39,2027-06-28,2028-06-20,2049-06-20,94,Pfizer,50,Senegal,42.0,66,45,91,11,35,4,55,2,1,3,True,True,False,True,False,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
RPV,AltName B,Drug,hiv,hiv,Phase 2,2023-01-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Aged 18 years or older (or \>=19 where required by local regulatory agencies), at the time of signing the informed consent.
* A female participant is eligible to participate if ...",Yes,2023-12-10,FDA-95138,4.41,0.98,21.0,26.39,2027-06-28,2028-06-20,2049-06-20,28,Novartis,57,Kenya,50.16666666666666,60,77,81,11,38,34,36,1,2,1,False,True,False,False,False,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DTG,Molecule Z,Drug,hiv,hiv,Phase 2,2023-01-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Aged 18 years or older (or \>=19 where required by local regulatory agencies), at the time of signing the informed consent.
* A female participant is eligible to participate if ...",No,2024-01-04,FDA-25849,4.41,0.98,21.0,26.39,2027-06-28,2028-06-20,2049-06-20,84,Sanofi,15,Senegal,38.33333333333334,34,13,67,57,18,41,27,0,1,2,False,False,True,False,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP,TradeName X,Drug,hiv,hiv,Phase 2,2011-09-01,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Willing and able to independently provide written informed consent;
* Of male gender at birth;
* Between the ages of 18 years and 0 days through 22 years and 364 days at the tim...",Yes,2012-07-18,FDA-65299,4.41,0.98,21.0,26.39,2016-01-28,2017-01-20,2038-01-20,6,Sanofi,98,Senegal,45.16666666666666,5,51,67,46,27,75,82,1,4,4,False,True,False,True,True,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK's investigational vaccine 692342,Comp Beta,Biological,hiv,hiv,Phase 2,2015-06-04,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
* A male or female between, and including, 18 and 59 years of age at ...",No,2016-01-14,FDA-49815,4.41,0.98,21.0,26.39,2019-10-31,2020-10-23,2041-10-23,43,J&J,71,Overall,36.66666666666666,83,2,2,12,35,86,55,2,1,3,True,True,False,True,False,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Physiological saline,Molecule Z,Biological,hiv,hiv,Phase 2,2015-06-04,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
* A male or female between, and including, 18 and 59 years of age at ...",No,2016-01-22,FDA-64942,4.41,0.98,21.0,26.39,2019-10-31,2020-10-23,2041-10-23,53,Gilead,89,South Africa,50.83333333333334,25,8,78,43,67,84,64,1,4,2,True,False,True,False,True,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"TMC125, Darunavir; Ritonavir",TradeName X,Drug,hiv,hiv,Phase 3,2008-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented HIV-1 positive
* History of drug resistance or antiretroviral failure while receiving each of three drug classes: Nucleoside Reverse Transcriptase Inhibitors (NRTIs),...",Yes,2009-05-09,FDA-53175,2.62,0.32,5.0,7.94,2011-05-15,2011-09-09,2016-09-09,91,Novartis,66,Kenya,54.16666666666666,7,22,98,11,95,92,82,2,4,3,True,True,True,False,True,True,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Switch to Maraviroc + Raltegravir or Dolutegravir,Comp Beta,Drug,hiv,hiv,Phase 3,2018-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Age between 18 and 75 years
* CD4 count nadir ≥ 250 cells/mm3
* HIV RNA ≤ 50 copies/ml for ≥ 12 months while taking any ART regimen

  o One virologic blip ≤ 4...",Yes,2019-07-12,FDA-16535,2.62,0.32,5.0,7.94,2021-07-14,2021-11-08,2026-11-09,75,AstraZeneca,60,Kenya,40.83333333333334,47,68,37,0,47,46,36,0,2,2,False,False,True,False,True,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Modafinil,TradeName X,Drug,hiv,hiv,Phase 4,2010-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Ages 18-75
2. HIV+
3. Clinically significant fatigue (score of 4.5+ on Fatigue Severity Scale, plus impairment on 1+ categories of Role Function Scale)
4. Fatigue duration for ...",Yes,2011-03-29,FDA-41736,0.56,0.15,3.5,4.21,2011-05-24,2011-07-18,2015-01-16,22,J&J,96,Overall,39.16666666666666,18,14,95,45,17,46,64,2,3,2,True,True,False,True,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Vitamin D3,TradeName X,Drug,hiv,hiv,Phase 2,2016-02-01,"Sex: FEMALE; Age: >40 Years; Criteria: Inclusion Criteria:

* HIV+ African American and Latina postmenopausal women, aged 40-70, who meet the standard definition of menopause:

If 50 years old or older then amenorrhea for \> 1year. If age ...",Yes,2017-01-08,FDA-52929,4.41,0.98,21.0,26.39,2020-06-29,2021-06-22,2042-06-22,77,J&J,13,South Africa,47.5,40,59,61,0,32,93,55,2,3,1,True,True,False,True,False,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Vitamin Supplements,Molecule Z,Drug,hiv,hiv,Phase 2,2016-02-01,"Sex: FEMALE; Age: >40 Years; Criteria: Inclusion Criteria:

* HIV+ African American and Latina postmenopausal women, aged 40-70, who meet the standard definition of menopause:

If 50 years old or older then amenorrhea for \> 1year. If age ...",Yes,2016-06-12,FDA-90689,4.41,0.98,21.0,26.39,2020-06-29,2021-06-22,2042-06-22,56,GSK,80,South Africa,47.16666666666666,73,89,64,0,12,45,36,0,1,3,False,False,False,False,False,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK2248761 100 mg once daily,AltName B,Drug,hiv,hiv,Phase 2,2011-07-04,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected adults greater than or equal to 18 years of age. A female is eligible to enter and participate in the study if she is (1) Non-childbearing potential, (2) Child-be...",Yes,2012-06-23,FDA-76340,4.41,0.98,21.0,26.39,2015-11-30,2016-11-22,2037-11-22,76,Pfizer,67,Kenya,55.16666666666666,0,43,86,72,51,79,27,0,2,1,False,False,False,True,True,False,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK2248761 200 mg once daily,AltName A,Drug,hiv,hiv,Phase 2,2011-07-04,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected adults greater than or equal to 18 years of age. A female is eligible to enter and participate in the study if she is (1) Non-childbearing potential, (2) Child-be...",No,2012-03-28,FDA-49045,4.41,0.98,21.0,26.39,2015-11-30,2016-11-22,2037-11-22,27,Merck,31,Kenya,35.16666666666666,21,4,71,12,80,23,45,1,3,1,True,False,True,True,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz 600 mg once daily,Molecule Z,Drug,hiv,hiv,Phase 2,2011-07-04,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected adults greater than or equal to 18 years of age. A female is eligible to enter and participate in the study if she is (1) Non-childbearing potential, (2) Child-be...",No,2011-09-05,FDA-17923,4.41,0.98,21.0,26.39,2015-11-30,2016-11-22,2037-11-22,93,GSK,92,Overall,57.5,46,85,35,96,5,78,45,2,0,3,True,True,False,False,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
RotaTeq,AltName B,Biological,hiv,hiv,Phase 2,2014-01-01,"Sex: ALL; Age: >2 Weeks; Healthy Volunteers: Yes; Criteria: Inclusion Criteria for All Vaccinations:

* Participant was born to an HIV-1-infected mother whose HIV-1 diagnosis was determined by two different tests performed on the same or separate maternal samp...",No,2014-10-17,FDA-83938,4.41,0.98,21.0,26.39,2018-05-30,2019-05-23,2040-05-22,95,AstraZeneca,43,Overall,16.83333333333333,11,23,38,6,5,18,27,1,0,2,False,True,False,False,False,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Evolocumab,Molecule Z,Drug,hiv,hiv,Phase 3,2020-01-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male or female ≥ 18 years of age
* Known HIV infection with stable HIV therapy for ≥ 6 months
* Cluster of differentiation 4 (CD4) ≥ 250 cells/mm\^3 for ≥ 6 months
* HIV viral l...",No,2021-01-01,FDA-81513,2.62,0.32,5.0,7.94,2022-09-09,2023-01-04,2028-01-05,72,GSK,43,Overall,57.16666666666666,60,78,100,72,7,26,55,1,3,2,True,False,True,True,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,TradeName X,Drug,hiv,hiv,Phase 4,2010-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Stable antiretroviral therapy for at least 12 months
* Screening CD4+ T cell count \< 350 cells/mm3
* All available CD4+ T cell counts in the last year and at screening \< 350 c...",Yes,2010-09-25,FDA-74771,0.56,0.15,3.5,4.21,2010-09-21,2010-11-15,2014-05-16,29,Sanofi,27,Senegal,60.5,47,94,58,14,54,96,36,2,1,1,True,True,False,False,False,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DTG + 3TC,Product Alpha,Drug,hiv,hiv,Phase 3,2022-05-03,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participant must be able to understand and comply with protocol requirements, instructions, and restrictions;
* Participant must be likely to complete the study as planned;
* Pa...",Yes,2022-12-10,FDA-98750,2.62,0.32,5.0,7.94,2024-12-14,2025-04-10,2030-04-11,82,J&J,23,South Africa,69.5,38,62,96,78,48,95,73,1,5,2,False,True,True,True,True,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
TAF based regimen (TBR),GenName Y,Drug,hiv,hiv,Phase 3,2022-05-03,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participant must be able to understand and comply with protocol requirements, instructions, and restrictions;
* Participant must be likely to complete the study as planned;
* Pa...",Yes,2023-03-20,FDA-45672,2.62,0.32,5.0,7.94,2024-12-14,2025-04-10,2030-04-11,51,Novartis,74,Senegal,49.16666666666666,43,67,90,8,27,60,55,2,2,2,True,True,False,False,True,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,AltName B,Drug,hiv,hiv,Phase 2,2023-06-30,"Sex: ALL; Age: >2 Years; Criteria: Inclusion Criteria:

* Subjects who are 2-18 years of age, treatment experienced for 6 months or longer with at least 2 ARV drug classes, with HIV-1 RNA ≥1,000 copies/mL

Exclusion Criteria:

* X4- or...",No,2023-08-30,FDA-55362,4.41,0.98,21.0,26.39,2027-11-26,2028-11-18,2049-11-18,45,Novartis,43,Senegal,52.16666666666666,95,5,14,74,82,43,36,0,2,2,False,False,False,True,False,False,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
EVG,GenName Y,Drug,hiv,hiv,Phase 2,2015-03-01,"Sex: ALL; Criteria: Inclusion Criteria:

* Completion of a prior EVG+RTV treatment study without treatment-limiting toxicity.
* Males and females of childbearing potential must agree to utilize effective contraception me...",Yes,2015-06-10,FDA-64060,4.41,0.98,21.0,26.39,2019-07-28,2020-07-20,2041-07-20,43,Merck,0,Kenya,68.33333333333333,91,74,79,71,71,24,55,0,4,2,False,False,True,True,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
RTV,AltName B,Drug,hiv,hiv,Phase 2,2015-03-01,"Sex: ALL; Criteria: Inclusion Criteria:

* Completion of a prior EVG+RTV treatment study without treatment-limiting toxicity.
* Males and females of childbearing potential must agree to utilize effective contraception me...",No,2015-10-31,FDA-93127,4.41,0.98,21.0,26.39,2019-07-28,2020-07-20,2041-07-20,60,Pfizer,1,South Africa,35.5,67,34,27,26,10,49,55,1,3,2,False,True,True,True,False,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ARV regimen,AltName B,Drug,hiv,hiv,Phase 2,2015-03-01,"Sex: ALL; Criteria: Inclusion Criteria:

* Completion of a prior EVG+RTV treatment study without treatment-limiting toxicity.
* Males and females of childbearing potential must agree to utilize effective contraception me...",No,2015-11-20,FDA-91356,4.41,0.98,21.0,26.39,2019-07-28,2020-07-20,2041-07-20,94,AstraZeneca,100,Overall,56.66666666666666,87,61,3,51,67,71,45,2,1,2,True,True,False,False,False,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK3640254,Comp Beta,Drug,hiv,hiv,Phase 2,2023-05-29,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants must be 18 years of age inclusive, at the time of signing the informed consent.
* Treatment-naive, defined as no anti-retrovirals (ARVs) (in combination or monother...",Yes,2024-04-03,FDA-20495,4.41,0.98,21.0,26.39,2027-10-25,2028-10-17,2049-10-17,73,Novartis,58,Senegal,52.5,48,35,33,53,96,50,55,1,4,1,False,True,True,True,True,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ABC/3TC,Molecule Z,Drug,hiv,hiv,Phase 2,2023-05-29,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants must be 18 years of age inclusive, at the time of signing the informed consent.
* Treatment-naive, defined as no anti-retrovirals (ARVs) (in combination or monother...",No,2024-03-04,FDA-13275,4.41,0.98,21.0,26.39,2027-10-25,2028-10-17,2049-10-17,77,Pfizer,59,Senegal,53.0,31,77,98,0,85,27,45,0,2,3,False,False,True,False,True,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TAF,AltName A,Drug,hiv,hiv,Phase 2,2023-05-29,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants must be 18 years of age inclusive, at the time of signing the informed consent.
* Treatment-naive, defined as no anti-retrovirals (ARVs) (in combination or monother...",No,2023-10-11,FDA-67223,4.41,0.98,21.0,26.39,2027-10-25,2028-10-17,2049-10-17,75,Novartis,90,Kenya,50.0,77,73,30,24,80,16,64,2,4,1,True,True,True,False,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir,Product Alpha,Drug,hiv,hiv,Phase 2,2023-05-29,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants must be 18 years of age inclusive, at the time of signing the informed consent.
* Treatment-naive, defined as no anti-retrovirals (ARVs) (in combination or monother...",No,2024-05-07,FDA-59876,4.41,0.98,21.0,26.39,2027-10-25,2028-10-17,2049-10-17,40,Pfizer,61,Overall,66.16666666666667,61,79,84,22,89,62,55,2,2,2,True,True,True,False,True,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir/abacavir/lamivudine FDC,Comp Beta,Drug,hiv,hiv,Phase 3,2022-08-18,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected females (gender at birth) \>=18 years of age
* Women capable of becoming pregnant must use appropriate contraception during the study (as defined by the protocol)...",No,2023-05-17,FDA-28456,2.62,0.32,5.0,7.94,2025-03-31,2025-07-26,2030-07-27,89,Pfizer,59,Kenya,39.66666666666666,55,39,16,65,5,58,36,1,1,2,False,True,False,False,False,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir,Comp Beta,Drug,hiv,hiv,Phase 3,2022-08-18,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected females (gender at birth) \>=18 years of age
* Women capable of becoming pregnant must use appropriate contraception during the study (as defined by the protocol)...",No,2023-06-09,FDA-17870,2.62,0.32,5.0,7.94,2025-03-31,2025-07-26,2030-07-27,77,Pfizer,25,Senegal,50.83333333333334,59,46,78,56,25,41,64,1,4,2,False,True,True,True,True,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,Product Alpha,Drug,hiv,hiv,Phase 3,2022-08-18,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected females (gender at birth) \>=18 years of age
* Women capable of becoming pregnant must use appropriate contraception during the study (as defined by the protocol)...",No,2022-12-20,FDA-52844,2.62,0.32,5.0,7.94,2025-03-31,2025-07-26,2030-07-27,51,Novartis,72,South Africa,62.83333333333334,71,67,88,43,44,64,55,0,4,2,False,False,True,False,True,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir/emtricitabine FDC,AltName A,Drug,hiv,hiv,Phase 3,2022-08-18,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected females (gender at birth) \>=18 years of age
* Women capable of becoming pregnant must use appropriate contraception during the study (as defined by the protocol)...",No,2023-06-11,FDA-94478,2.62,0.32,5.0,7.94,2025-03-31,2025-07-26,2030-07-27,27,Merck,99,Kenya,72.33333333333333,70,62,59,92,53,98,36,0,1,3,False,False,False,True,False,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir,TradeName X,Drug,hiv,hiv,Phase 3,2015-12-03,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Screening plasma HIV-1 RNA ≥1000 c/mL
* Antiretroviral-naïve (≤ 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection)
* Ability to und...",Yes,2016-06-06,FDA-29983,2.62,0.32,5.0,7.94,2018-07-16,2018-11-10,2023-11-11,47,Sanofi,90,Kenya,48.83333333333334,6,62,30,90,85,20,45,1,2,2,True,False,True,False,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atripla,TradeName X,Drug,hiv,hiv,Phase 3,2015-12-03,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Screening plasma HIV-1 RNA ≥1000 c/mL
* Antiretroviral-naïve (≤ 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection)
* Ability to und...",No,2016-06-18,FDA-55803,2.62,0.32,5.0,7.94,2018-07-16,2018-11-10,2023-11-11,57,J&J,51,South Africa,62.83333333333334,3,48,97,99,30,100,36,1,2,1,True,False,True,False,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Abacavir/Lamivudine,AltName A,Drug,hiv,hiv,Phase 3,2015-12-03,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Screening plasma HIV-1 RNA ≥1000 c/mL
* Antiretroviral-naïve (≤ 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection)
* Ability to und...",Yes,2016-06-01,FDA-33704,2.62,0.32,5.0,7.94,2018-07-16,2018-11-10,2023-11-11,68,Sanofi,45,Overall,34.66666666666666,40,33,30,67,25,13,55,1,3,2,True,False,False,False,True,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir and truvada,Product Alpha,Drug,hiv,hiv,Phase 4,2013-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients must be HIV-1 positive and naïve to HIV therapy.
* Patients must plan to participate and be available for the trial for the 96-week study period.
* Patients followed at...",Yes,2013-09-30,FDA-21854,0.56,0.15,3.5,4.21,2013-07-24,2013-09-17,2017-03-18,49,AstraZeneca,13,Senegal,44.66666666666666,49,7,51,50,47,64,64,1,3,3,False,True,True,True,False,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"Atazanavir, Norvir and Truvada",GenName Y,Drug,hiv,hiv,Phase 4,2013-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients must be HIV-1 positive and naïve to HIV therapy.
* Patients must plan to participate and be available for the trial for the 96-week study period.
* Patients followed at...",Yes,2013-06-07,FDA-66981,0.56,0.15,3.5,4.21,2013-07-24,2013-09-17,2017-03-18,85,Bayer,54,Senegal,81.83333333333333,66,94,75,80,89,87,36,0,3,1,False,False,False,True,True,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
TMC278 25 mg,Product Alpha,Drug,hiv,hiv,Phase 2,2011-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented human immunodeficiency virus type 1 (HIV-1) infection
* Never been treated with an antiretroviral (ARV) treatment or therapeutic HIV vaccine, or received less than or...",No,2012-03-15,FDA-88957,4.41,0.98,21.0,26.39,2016-04-28,2017-04-21,2038-04-21,48,Gilead,69,Kenya,58.83333333333334,63,6,88,95,36,65,36,1,1,2,False,True,False,False,False,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
TMC278 75 mg,TradeName X,Drug,hiv,hiv,Phase 2,2011-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented human immunodeficiency virus type 1 (HIV-1) infection
* Never been treated with an antiretroviral (ARV) treatment or therapeutic HIV vaccine, or received less than or...",Yes,2012-04-29,FDA-35612,4.41,0.98,21.0,26.39,2016-04-28,2017-04-21,2038-04-21,86,Pfizer,49,Senegal,67.16666666666667,71,66,95,93,26,52,55,1,3,2,False,True,True,False,False,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
TMC278 150 mg,Comp Beta,Drug,hiv,hiv,Phase 2,2011-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented human immunodeficiency virus type 1 (HIV-1) infection
* Never been treated with an antiretroviral (ARV) treatment or therapeutic HIV vaccine, or received less than or...",Yes,2012-11-12,FDA-85422,4.41,0.98,21.0,26.39,2016-04-28,2017-04-21,2038-04-21,79,J&J,27,Senegal,51.0,12,81,83,58,49,23,55,2,2,2,True,True,True,False,False,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,Product Alpha,Drug,hiv,hiv,Phase 2,2011-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented human immunodeficiency virus type 1 (HIV-1) infection
* Never been treated with an antiretroviral (ARV) treatment or therapeutic HIV vaccine, or received less than or...",Yes,2012-03-17,FDA-33774,4.41,0.98,21.0,26.39,2016-04-28,2017-04-21,2038-04-21,43,Merck,84,South Africa,60.5,49,99,59,19,82,55,55,0,4,2,False,False,True,True,True,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Non-nucleoside reverse transcriptase inhibitor (NRTIs),Molecule Z,Drug,hiv,hiv,Phase 2,2011-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented human immunodeficiency virus type 1 (HIV-1) infection
* Never been treated with an antiretroviral (ARV) treatment or therapeutic HIV vaccine, or received less than or...",No,2012-06-08,FDA-39778,4.41,0.98,21.0,26.39,2016-04-28,2017-04-21,2038-04-21,43,AstraZeneca,41,Kenya,42.16666666666666,70,38,3,41,29,72,64,2,3,2,True,True,True,True,True,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir + ritonavir + tenofovir + nucleoside,TradeName X,Drug,hiv,hiv,Phase 3,2009-03-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Virologic failure to 2 or more highly active antiretroviral therapy (HAART) regimens that, in total, have included at least one drug from all approved classes protease inhibitor...",No,2009-10-30,FDA-51944,2.62,0.32,5.0,7.94,2011-10-13,2012-02-07,2017-02-07,92,J&J,24,Senegal,34.66666666666666,39,18,68,20,5,58,45,0,3,2,False,False,True,False,True,False,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir + saquinavir + tenofovir + nucleoside,Product Alpha,Drug,hiv,hiv,Phase 3,2009-03-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Virologic failure to 2 or more highly active antiretroviral therapy (HAART) regimens that, in total, have included at least one drug from all approved classes protease inhibitor...",Yes,2009-10-28,FDA-41110,2.62,0.32,5.0,7.94,2011-10-13,2012-02-07,2017-02-07,32,Pfizer,72,South Africa,60.5,14,53,89,60,50,97,45,0,3,2,False,False,True,False,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir/ritonavir + tenofovir + nucleoside,Molecule Z,Drug,hiv,hiv,Phase 3,2009-03-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Virologic failure to 2 or more highly active antiretroviral therapy (HAART) regimens that, in total, have included at least one drug from all approved classes protease inhibitor...",Yes,2009-12-08,FDA-42994,2.62,0.32,5.0,7.94,2011-10-13,2012-02-07,2017-02-07,1,Bayer,9,Overall,69.16666666666667,84,84,63,41,54,89,36,0,1,3,False,False,False,True,False,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Letermovir Oral Tablet,GenName Y,Drug,hiv,hiv,Phase 2,2023-11-30,"Sex: ALL; Age: >40 Years; Criteria: Inclusion Criteria:

1. HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a l...",No,2024-08-23,FDA-12481,4.41,0.98,21.0,26.39,2028-04-27,2029-04-20,2050-04-20,76,Sanofi,35,Overall,57.5,97,56,4,10,93,85,55,0,3,3,False,False,True,False,True,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir DF,AltName B,Drug,hiv,hiv,Phase 3,2013-12-01,"Sex: ALL; Age: >12 Years; Criteria: Major Inclusion Criteria:

* Weight ≥ 35 kg
* Documented laboratory diagnosis of HIV infection
* Plasma HIV-1 RNA ≥ 1000 copies/mL
* Prior antiretroviral treatment experience with at least 2 antiretro...",No,2014-02-08,FDA-35845,2.62,0.32,5.0,7.94,2016-07-14,2016-11-08,2021-11-09,99,GSK,31,Kenya,35.83333333333334,17,66,41,1,15,75,55,1,3,2,False,True,True,False,True,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
1% tenofovir gel,Molecule Z,Drug,hiv,hiv,Phase 3,2015-12-01,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Age 18 years and older
* Women who previously participated in an ARV prevention study
* Currently utilizing or agreeing to attend designated public sector family planning servic...",Yes,2016-11-04,FDA-38068,2.62,0.32,5.0,7.94,2018-07-14,2018-11-08,2023-11-09,4,AstraZeneca,54,Overall,41.83333333333334,8,66,28,45,88,16,45,2,2,1,True,True,True,True,False,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
MK-0518,Product Alpha,Drug,hiv,hiv,Phase 3,2012-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participant is a male or female at least 18 years of age
* Participant is HIV positive
* Participant is naïve to antiretroviral therapy (ART) and has not received any ART

Exclu...",No,2012-06-10,FDA-11337,2.62,0.32,5.0,7.94,2014-09-14,2015-01-09,2020-01-10,78,J&J,61,Senegal,44.33333333333334,26,5,71,37,92,35,55,0,3,3,False,False,True,False,False,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Comparator: efavirenz,Molecule Z,Drug,hiv,hiv,Phase 3,2012-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participant is a male or female at least 18 years of age
* Participant is HIV positive
* Participant is naïve to antiretroviral therapy (ART) and has not received any ART

Exclu...",Yes,2012-05-31,FDA-21496,2.62,0.32,5.0,7.94,2014-09-14,2015-01-09,2020-01-10,43,Merck,71,South Africa,39.33333333333334,22,56,41,79,36,2,55,2,3,1,True,True,False,True,False,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Comparator: Truvada,Molecule Z,Drug,hiv,hiv,Phase 3,2012-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participant is a male or female at least 18 years of age
* Participant is HIV positive
* Participant is naïve to antiretroviral therapy (ART) and has not received any ART

Exclu...",Yes,2012-06-30,FDA-26675,2.62,0.32,5.0,7.94,2014-09-14,2015-01-09,2020-01-10,18,AstraZeneca,7,Overall,48.33333333333334,22,41,100,97,2,28,45,2,2,1,True,True,True,False,False,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK's candidate Mycobacterium tuberculosis vaccine 692342,GenName Y,Biological,hiv,hiv,Phase 2,2009-05-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects who the Investigator believes that they can and will comply with the requirements of the protocol.
* A male or female between, and including, 18 and 50 years of age at ...",Yes,2009-06-30,FDA-85123,4.41,0.98,21.0,26.39,2013-10-23,2014-10-16,2035-10-16,100,J&J,60,Kenya,37.83333333333334,9,66,51,0,87,14,36,1,1,2,True,False,True,False,False,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
V114,GenName Y,Biological,hiv,hiv,Phase 3,2021-05-03,"Sex: ALL; Age: >6 Years; Criteria: Inclusion Criteria:

* Male or female between the ages of 6 and 17 years (inclusive) infected with HIV and has a Cluster of Differentiation 4+ (CD4+) T-cell count ≥200 cells/µL and plasma HIV ribonucl...",Yes,2021-10-08,FDA-44034,2.62,0.32,5.0,7.94,2023-12-15,2024-04-10,2029-04-11,80,Sanofi,72,South Africa,44.16666666666666,73,13,16,0,77,86,73,2,3,3,True,True,False,True,True,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Prevnar 13™,AltName B,Biological,hiv,hiv,Phase 3,2021-05-03,"Sex: ALL; Age: >6 Years; Criteria: Inclusion Criteria:

* Male or female between the ages of 6 and 17 years (inclusive) infected with HIV and has a Cluster of Differentiation 4+ (CD4+) T-cell count ≥200 cells/µL and plasma HIV ribonucl...",No,2022-02-10,FDA-59752,2.62,0.32,5.0,7.94,2023-12-15,2024-04-10,2029-04-11,90,Merck,23,Senegal,43.16666666666666,6,79,28,47,59,40,55,1,2,3,False,True,True,False,False,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PNEUMOVAX™23,GenName Y,Biological,hiv,hiv,Phase 3,2021-05-03,"Sex: ALL; Age: >6 Years; Criteria: Inclusion Criteria:

* Male or female between the ages of 6 and 17 years (inclusive) infected with HIV and has a Cluster of Differentiation 4+ (CD4+) T-cell count ≥200 cells/µL and plasma HIV ribonucl...",Yes,2021-09-30,FDA-82972,2.62,0.32,5.0,7.94,2023-12-15,2024-04-10,2029-04-11,33,AstraZeneca,53,Kenya,50.33333333333334,31,85,32,65,61,28,45,1,2,2,False,True,False,True,False,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ruxolitinib,Molecule Z,Drug,hiv,hiv,Phase 2,2018-04-04,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+ T cell count greater than 350 cells/mm\^3 within 45 days prior to study entry
* Documented virologic suppression defined as HIV-1 RNA level below the limi...",Yes,2018-06-28,FDA-94000,4.41,0.98,21.0,26.39,2022-08-31,2023-08-24,2044-08-23,93,Sanofi,45,South Africa,37.33333333333334,68,21,63,23,47,2,36,2,2,0,True,True,True,True,False,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
dolutegravir 50 mg OAD,GenName Y,Drug,hiv,hiv,Phase 3,2016-12-26,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected adults greater than or equal to 18 years of age. Females are eligible to enter and participate in the study if she is (1) non-childbearing potential, (2) child be...",Yes,2017-10-11,FDA-93508,2.62,0.32,5.0,7.94,2019-08-09,2019-12-04,2024-12-04,62,Merck,4,Senegal,63.83333333333334,87,99,44,67,42,44,82,1,4,4,False,True,False,True,True,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
darunavir 800mg OAD,AltName A,Drug,hiv,hiv,Phase 3,2016-12-26,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected adults greater than or equal to 18 years of age. Females are eligible to enter and participate in the study if she is (1) non-childbearing potential, (2) child be...",Yes,2017-11-26,FDA-11959,2.62,0.32,5.0,7.94,2019-08-09,2019-12-04,2024-12-04,43,Merck,68,Senegal,46.33333333333334,52,47,17,83,39,40,64,2,2,3,True,True,False,True,False,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ritonavir 100mg OAD,AltName B,Drug,hiv,hiv,Phase 3,2016-12-26,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected adults greater than or equal to 18 years of age. Females are eligible to enter and participate in the study if she is (1) non-childbearing potential, (2) child be...",No,2017-07-31,FDA-86739,2.62,0.32,5.0,7.94,2019-08-09,2019-12-04,2024-12-04,9,Pfizer,79,Kenya,29.0,0,23,11,0,73,67,27,0,1,2,False,False,False,False,False,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ibalizumab,AltName A,Drug,hiv,hiv,Phase 3,2018-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

(Cohort 1)

* Currently receiving ibalizumab via other TaiMed-sponsored or investigator-Sponsored protocol
* Are capable of understanding and have voluntarily signed the informed ...",Yes,2019-05-21,FDA-96548,2.62,0.32,5.0,7.94,2021-06-14,2021-10-09,2026-10-10,11,AstraZeneca,77,Senegal,59.66666666666666,75,98,4,99,62,20,73,2,4,2,True,True,True,True,True,False,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Optimized Background Regimen,GenName Y,Drug,hiv,hiv,Phase 3,2018-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

(Cohort 1)

* Currently receiving ibalizumab via other TaiMed-sponsored or investigator-Sponsored protocol
* Are capable of understanding and have voluntarily signed the informed ...",Yes,2019-05-11,FDA-97264,2.62,0.32,5.0,7.94,2021-06-14,2021-10-09,2026-10-10,83,AstraZeneca,75,South Africa,44.66666666666666,16,49,91,11,41,60,45,0,3,2,False,False,False,True,True,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Doravirine,AltName A,Drug,hiv,hiv,Phase 2,2016-03-21,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 positive
* No previous use of antiretroviral therapy (ART)
* No signs of active pulmonary disease within 45 days before the start of study treatment
* Clinically stable wi...",Yes,2016-10-15,FDA-33935,4.41,0.98,21.0,26.39,2020-08-17,2021-08-10,2042-08-10,55,Pfizer,49,Kenya,76.5,78,38,97,99,100,47,27,1,2,0,False,True,True,False,False,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,Product Alpha,Drug,hiv,hiv,Phase 2,2016-03-21,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 positive
* No previous use of antiretroviral therapy (ART)
* No signs of active pulmonary disease within 45 days before the start of study treatment
* Clinically stable wi...",Yes,2017-02-16,FDA-22173,4.41,0.98,21.0,26.39,2020-08-17,2021-08-10,2042-08-10,24,AstraZeneca,86,Kenya,54.5,84,80,47,15,67,34,27,1,1,1,False,True,False,False,True,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
TRUVADA®,Molecule Z,Drug,hiv,hiv,Phase 2,2016-03-21,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 positive
* No previous use of antiretroviral therapy (ART)
* No signs of active pulmonary disease within 45 days before the start of study treatment
* Clinically stable wi...",No,2016-10-02,FDA-56761,4.41,0.98,21.0,26.39,2020-08-17,2021-08-10,2042-08-10,63,Sanofi,78,Kenya,53.16666666666666,62,45,67,14,62,69,55,0,4,2,False,False,True,True,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
BMS-663068,TradeName X,Drug,hiv,hiv,Phase 2,2010-06-25,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Clade B HIV-1 infected subjects meeting following criteria at screening:

  * Plasma HIV RNA ≥ 5,000 copies/mL
  * CD4+ lymphocyte ≥ 200 cells/µL
  * Antiretroviral naive or exp...",Yes,2010-08-28,FDA-23952,4.41,0.98,21.0,26.39,2014-11-21,2015-11-14,2036-11-13,22,Novartis,49,South Africa,36.33333333333334,62,25,10,56,61,4,64,1,3,3,True,False,False,True,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,AltName B,Drug,hiv,hiv,Phase 2,2010-06-25,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Clade B HIV-1 infected subjects meeting following criteria at screening:

  * Plasma HIV RNA ≥ 5,000 copies/mL
  * CD4+ lymphocyte ≥ 200 cells/µL
  * Antiretroviral naive or exp...",No,2010-10-03,FDA-15902,4.41,0.98,21.0,26.39,2014-11-21,2015-11-14,2036-11-13,62,GSK,93,Kenya,62.0,95,80,43,20,69,65,55,1,3,2,False,True,True,False,True,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PRO 140 (humanized monoclonal antibody to CCR5),Molecule Z,Drug,hiv,hiv,Phase 2,2008-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Males \& females, age ≥ 18 years (or minimum adult age as determined by local regulatory authorities)
2. Screening plasma HIV-1 RNA ≥ 5,000 copies/mL
3. CD4+ lymphocyte cell co...",No,2009-11-01,FDA-67527,4.41,0.98,21.0,26.39,2013-03-30,2014-03-23,2035-03-23,80,Bayer,17,South Africa,59.16666666666666,32,62,87,63,67,44,45,0,4,1,False,False,True,True,True,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine,TradeName X,Drug,hiv,hiv,Phase 3,2011-02-01,"Sex: FEMALE; Age: >13 Years; Criteria: Inclusion Criteria for All Participants:

* HIV infected
* CD4 count less than 200 cells/mm\^3 within 90 days prior to study entry
* Plasma HIV-1 RNA using standard Roche Amplicor HIV-1 Monitor Assay ...",Yes,2011-08-31,FDA-76695,2.62,0.32,5.0,7.94,2013-09-14,2014-01-09,2019-01-10,0,Novartis,63,South Africa,44.66666666666666,78,1,80,72,6,31,55,0,3,3,False,False,True,False,False,True,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine/Tenofovir disoproxil fumarate,GenName Y,Drug,hiv,hiv,Phase 3,2011-02-01,"Sex: FEMALE; Age: >13 Years; Criteria: Inclusion Criteria for All Participants:

* HIV infected
* CD4 count less than 200 cells/mm\^3 within 90 days prior to study entry
* Plasma HIV-1 RNA using standard Roche Amplicor HIV-1 Monitor Assay ...",No,2011-04-06,FDA-96395,2.62,0.32,5.0,7.94,2013-09-14,2014-01-09,2019-01-10,12,Novartis,62,Overall,35.83333333333334,16,39,14,17,84,45,55,0,3,3,False,False,True,True,False,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir/Ritonavir,GenName Y,Drug,hiv,hiv,Phase 3,2011-02-01,"Sex: FEMALE; Age: >13 Years; Criteria: Inclusion Criteria for All Participants:

* HIV infected
* CD4 count less than 200 cells/mm\^3 within 90 days prior to study entry
* Plasma HIV-1 RNA using standard Roche Amplicor HIV-1 Monitor Assay ...",No,2011-08-03,FDA-78429,2.62,0.32,5.0,7.94,2013-09-14,2014-01-09,2019-01-10,6,Bayer,6,Overall,56.5,7,97,54,66,86,29,27,0,2,1,False,False,False,False,True,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Nevirapine,AltName B,Drug,hiv,hiv,Phase 3,2011-02-01,"Sex: FEMALE; Age: >13 Years; Criteria: Inclusion Criteria for All Participants:

* HIV infected
* CD4 count less than 200 cells/mm\^3 within 90 days prior to study entry
* Plasma HIV-1 RNA using standard Roche Amplicor HIV-1 Monitor Assay ...",Yes,2011-06-04,FDA-39176,2.62,0.32,5.0,7.94,2013-09-14,2014-01-09,2019-01-10,28,Novartis,7,South Africa,50.33333333333334,2,77,43,45,92,43,45,1,3,1,True,False,True,False,False,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir disoproxil fumarate,Molecule Z,Drug,hiv,hiv,Phase 3,2011-02-01,"Sex: FEMALE; Age: >13 Years; Criteria: Inclusion Criteria for All Participants:

* HIV infected
* CD4 count less than 200 cells/mm\^3 within 90 days prior to study entry
* Plasma HIV-1 RNA using standard Roche Amplicor HIV-1 Monitor Assay ...",No,2011-10-19,FDA-78844,2.62,0.32,5.0,7.94,2013-09-14,2014-01-09,2019-01-10,96,Pfizer,68,South Africa,50.16666666666666,40,31,21,27,90,92,45,0,3,2,False,False,False,True,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
vorapaxar,Comp Beta,Drug,hiv,hiv,Phase 2,2018-01-01,"Sex: ALL; Age: >40 Years; Criteria: Inclusion Criteria:

1. HIV-1 positive by licensed diagnostic test
2. aged ≥40 years
3. plasma HIV RNA \<50 copies/mL for at least 24 weeks
4. screening CD4+ cell count \> 50 cells/mm3
5. treated for ...",Yes,2018-12-16,FDA-37661,4.41,0.98,21.0,26.39,2022-05-30,2023-05-23,2044-05-22,18,Merck,70,Senegal,46.33333333333334,19,39,91,12,83,34,55,2,1,3,True,True,False,False,False,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir (DTG),Product Alpha,Drug,hiv,hiv,Phase 3,2022-08-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Must be an HIV 1 infected adult \>=18 years of age (or older, if required by local regulations) at the time of signing the informed consent
* An eligible female participant shou...",No,2023-07-29,FDA-69645,2.62,0.32,5.0,7.94,2025-03-28,2025-07-23,2030-07-24,9,GSK,40,Overall,51.5,91,86,6,80,36,10,27,1,1,1,False,True,False,False,True,False,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine (3TC),Comp Beta,Drug,hiv,hiv,Phase 3,2022-08-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Must be an HIV 1 infected adult \>=18 years of age (or older, if required by local regulations) at the time of signing the informed consent
* An eligible female participant shou...",No,2023-07-10,FDA-72372,2.62,0.32,5.0,7.94,2025-03-28,2025-07-23,2030-07-24,18,Merck,60,Kenya,56.0,21,83,13,52,75,92,36,1,1,2,True,False,True,False,False,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC),TradeName X,Drug,hiv,hiv,Phase 3,2022-08-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Must be an HIV 1 infected adult \>=18 years of age (or older, if required by local regulations) at the time of signing the informed consent
* An eligible female participant shou...",Yes,2023-03-24,FDA-36638,2.62,0.32,5.0,7.94,2025-03-28,2025-07-23,2030-07-24,89,GSK,17,Senegal,60.33333333333334,36,57,71,96,57,45,45,1,2,2,True,False,True,False,False,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Half-boosted Fosamprenavir,AltName B,Drug,hiv,hiv,Phase 3,2008-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

* Subjects with HIV-1 infection.
* Are willing and able to understand and provide written consent prior to participation in this study.

Exclusion criteria:

* Are pregnant or bre...",No,2008-07-12,FDA-56130,2.62,0.32,5.0,7.94,2011-01-13,2011-05-10,2016-05-10,0,Gilead,98,South Africa,46.33333333333334,70,33,19,39,27,90,55,1,2,3,False,True,True,False,False,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Full Boosted Fosamprenavir,Product Alpha,Drug,hiv,hiv,Phase 3,2008-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

* Subjects with HIV-1 infection.
* Are willing and able to understand and provide written consent prior to participation in this study.

Exclusion criteria:

* Are pregnant or bre...",Yes,2009-01-11,FDA-53750,2.62,0.32,5.0,7.94,2011-01-13,2011-05-10,2016-05-10,4,Gilead,60,Senegal,37.66666666666666,13,50,97,45,1,20,36,1,2,1,False,True,False,True,False,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK1265744 30mg,AltName A,Drug,hiv,hiv,Phase 2,2009-08-13,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

A subject will be eligible for inclusion in this study only if all of the following criteria apply:

* Male or female between 18 and 65 years of age inclusive, at the time of sign...",Yes,2010-08-03,FDA-79225,4.41,0.98,21.0,26.39,2014-01-09,2015-01-02,2036-01-02,17,J&J,29,Kenya,41.66666666666666,54,38,16,8,56,78,64,2,4,1,True,True,False,True,True,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK1265744 5mg,GenName Y,Drug,hiv,hiv,Phase 2,2009-08-13,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

A subject will be eligible for inclusion in this study only if all of the following criteria apply:

* Male or female between 18 and 65 years of age inclusive, at the time of sign...",No,2010-01-16,FDA-52864,4.41,0.98,21.0,26.39,2014-01-09,2015-01-02,2036-01-02,18,Merck,26,South Africa,66.0,21,77,70,59,98,71,45,1,3,1,True,False,False,True,True,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
raltegravir potassium,AltName B,Drug,hiv,hiv,Phase 3,2011-05-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Patient must be HIV positive with HIV RNA values that are within ranges required by the study
* Patient must have documented failure of certain antiretroviral therapy
* Patient ...",No,2011-12-29,FDA-74611,2.62,0.32,5.0,7.94,2013-12-12,2014-04-08,2019-04-09,20,Novartis,86,Senegal,48.33333333333334,12,36,47,44,79,72,73,0,5,3,False,False,True,True,True,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK1349572 (dolutegravir),Molecule Z,Drug,hiv,hiv,Phase 3,2016-12-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Screening plasma HIV-1 RNA ≥1000 c/mL
* Antiretroviral-naïve (≤ 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection)
* Ability to und...",Yes,2017-02-10,FDA-31476,2.62,0.32,5.0,7.94,2019-08-10,2019-12-05,2024-12-05,23,Pfizer,49,Overall,29.66666666666667,9,22,56,22,42,27,27,0,2,1,False,False,False,True,True,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
raltegravir,Molecule Z,Drug,hiv,hiv,Phase 3,2016-12-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Screening plasma HIV-1 RNA ≥1000 c/mL
* Antiretroviral-naïve (≤ 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection)
* Ability to und...",No,2017-12-03,FDA-31556,2.62,0.32,5.0,7.94,2019-08-10,2019-12-05,2024-12-05,83,Gilead,54,Senegal,56.16666666666666,48,22,10,65,99,93,64,1,3,3,True,False,True,True,True,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Boceprevir,GenName Y,Drug,hiv,hiv,Phase 2,2016-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Documented recent HCV genotype 1 infection (≤26 weeks old at the time of the baseline visit) according to definition mentioned below.
2. Plan to start a Standard Of Care therap...",No,2016-09-21,FDA-56670,4.41,0.98,21.0,26.39,2020-05-29,2021-05-22,2042-05-22,26,GSK,82,Senegal,42.83333333333334,45,24,62,20,81,25,36,2,1,1,True,True,False,False,False,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Levonorgestrel and Ethinyl Estradiol,AltName A,Drug,hiv,hiv,Phase 4,2016-11-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV positive
* Female
* Age 18-45
* Using any of the following medication regimens: no ARV medication, entry inhibitors, nucleoside reverse transcriptase inhibitors (NRTIs), int...",No,2017-06-13,FDA-30165,0.56,0.15,3.5,4.21,2017-05-24,2017-07-18,2021-01-16,72,Gilead,94,Kenya,36.5,10,84,2,37,52,34,55,1,4,1,False,True,False,True,True,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,GenName Y,Drug,hiv,hiv,Phase 4,2012-12-01,"Sex: ALL; Age: >60 Years; Criteria: Inclusion Criteria:

1. HIV-1 infected males or females
2. 60 years of age or greater\*
3. signed informed consent
4. willing to switch therapy as per study protocol
5. no previous exposure to raltegr...",Yes,2013-04-30,FDA-92421,0.56,0.15,3.5,4.21,2013-06-23,2013-08-17,2017-02-15,67,Sanofi,73,South Africa,45.66666666666666,3,76,30,94,54,17,64,2,4,1,True,True,True,True,True,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir,Product Alpha,Drug,hiv,hiv,Phase 4,2012-12-01,"Sex: ALL; Age: >60 Years; Criteria: Inclusion Criteria:

1. HIV-1 infected males or females
2. 60 years of age or greater\*
3. signed informed consent
4. willing to switch therapy as per study protocol
5. no previous exposure to raltegr...",Yes,2013-03-03,FDA-54176,0.56,0.15,3.5,4.21,2013-06-23,2013-08-17,2017-02-15,18,J&J,5,Overall,39.16666666666666,6,67,21,20,21,100,45,0,3,2,False,False,True,False,True,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine,AltName A,Drug,hiv,hiv,Phase 4,2012-12-01,"Sex: ALL; Age: >60 Years; Criteria: Inclusion Criteria:

1. HIV-1 infected males or females
2. 60 years of age or greater\*
3. signed informed consent
4. willing to switch therapy as per study protocol
5. no previous exposure to raltegr...",No,2013-10-23,FDA-81257,0.56,0.15,3.5,4.21,2013-06-23,2013-08-17,2017-02-15,95,J&J,41,South Africa,32.16666666666666,20,70,55,25,21,2,45,1,3,1,True,False,True,False,True,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
atazanavir/raltegravir,AltName A,Drug,hiv,hiv,Phase 4,2012-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Treatment with a stable antiretroviral regiment containing boosted atazanavir, tenofovir and emtricitabine at screen and for at least 90 days prior to screenin...",No,2012-04-15,FDA-52436,0.56,0.15,3.5,4.21,2012-09-21,2012-11-15,2016-05-16,87,Sanofi,89,Kenya,77.83333333333333,81,82,87,71,67,79,55,1,2,3,True,False,False,True,False,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
atazanavir/raltegravir,Comp Beta,Drug,hiv,hiv,Phase 4,2012-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Treatment with a stable antiretroviral regiment containing boosted atazanavir, tenofovir and emtricitabine at screen and for at least 90 days prior to screenin...",No,2013-02-02,FDA-47446,0.56,0.15,3.5,4.21,2012-09-21,2012-11-15,2016-05-16,2,Sanofi,80,Senegal,40.33333333333334,45,48,27,56,58,8,73,2,4,2,True,True,True,False,True,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
atazanavir/tenofovir/emtricitabine,AltName A,Drug,hiv,hiv,Phase 4,2012-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Treatment with a stable antiretroviral regiment containing boosted atazanavir, tenofovir and emtricitabine at screen and for at least 90 days prior to screenin...",No,2012-08-14,FDA-67519,0.56,0.15,3.5,4.21,2012-09-21,2012-11-15,2016-05-16,23,J&J,22,Senegal,59.83333333333334,85,81,14,72,30,77,45,0,4,1,False,False,True,True,True,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir/Ritonavir (LPV/r),AltName B,Drug,hiv,hiv,Phase 3,2013-01-01,"Sex: ALL; Age: >2 Months; Healthy Volunteers: Yes; Criteria: Inclusion criteria:

1. Age 2 months to \< 11 years
2. Confirmed HIV diagnosis. i. Children \> 18 months: Documentation of HIV status must come from two assays. Assays include DNA PCR, HIV RNA, Wester...",Yes,2013-07-11,FDA-16029,2.62,0.32,5.0,7.94,2015-08-15,2015-12-10,2020-12-10,45,Merck,7,Senegal,55.16666666666666,96,25,34,33,57,86,45,1,2,2,False,True,False,True,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Nevirapine (NVP),Product Alpha,Drug,hiv,hiv,Phase 3,2013-01-01,"Sex: ALL; Age: >2 Months; Healthy Volunteers: Yes; Criteria: Inclusion criteria:

1. Age 2 months to \< 11 years
2. Confirmed HIV diagnosis. i. Children \> 18 months: Documentation of HIV status must come from two assays. Assays include DNA PCR, HIV RNA, Wester...",No,2013-05-30,FDA-61375,2.62,0.32,5.0,7.94,2015-08-15,2015-12-10,2020-12-10,94,Sanofi,26,South Africa,73.83333333333333,89,76,97,49,87,45,55,0,3,3,False,False,True,False,True,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz (EFV),AltName A,Drug,hiv,hiv,Phase 3,2013-01-01,"Sex: ALL; Age: >2 Months; Healthy Volunteers: Yes; Criteria: Inclusion criteria:

1. Age 2 months to \< 11 years
2. Confirmed HIV diagnosis. i. Children \> 18 months: Documentation of HIV status must come from two assays. Assays include DNA PCR, HIV RNA, Wester...",Yes,2013-04-29,FDA-83660,2.62,0.32,5.0,7.94,2015-08-15,2015-12-10,2020-12-10,59,Gilead,11,Kenya,42.66666666666666,42,41,100,12,45,16,64,1,4,2,True,False,True,True,False,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
2 nucleoside reverse transcriptase inhibitor (NRTI),Molecule Z,Drug,hiv,hiv,Phase 3,2013-01-01,"Sex: ALL; Age: >2 Months; Healthy Volunteers: Yes; Criteria: Inclusion criteria:

1. Age 2 months to \< 11 years
2. Confirmed HIV diagnosis. i. Children \> 18 months: Documentation of HIV status must come from two assays. Assays include DNA PCR, HIV RNA, Wester...",No,2013-04-06,FDA-31970,2.62,0.32,5.0,7.94,2015-08-15,2015-12-10,2020-12-10,79,Pfizer,93,Kenya,46.0,85,38,17,17,59,60,45,0,4,1,False,False,True,True,False,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Enfuvirtide,AltName B,Drug,hiv,hiv,Phase 3,2013-04-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Triple-class drug experience or resistance. More information on this criterion can be found in the protocol.
* Currently on a failing PI-containing regimen tha...",Yes,2013-07-20,FDA-29415,2.62,0.32,5.0,7.94,2015-11-13,2016-03-09,2021-03-10,27,GSK,18,Overall,27.5,26,10,26,16,27,60,45,0,2,3,False,False,True,False,False,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,Product Alpha,Drug,hiv,hiv,Phase 3,2013-04-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Triple-class drug experience or resistance. More information on this criterion can be found in the protocol.
* Currently on a failing PI-containing regimen tha...",Yes,2014-03-05,FDA-98566,2.62,0.32,5.0,7.94,2015-11-13,2016-03-09,2021-03-10,87,GSK,53,Overall,51.83333333333334,52,12,82,66,42,57,64,2,3,2,True,True,True,False,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Darunavir,AltName B,Drug,hiv,hiv,Phase 3,2013-04-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Triple-class drug experience or resistance. More information on this criterion can be found in the protocol.
* Currently on a failing PI-containing regimen tha...",No,2013-08-12,FDA-31570,2.62,0.32,5.0,7.94,2015-11-13,2016-03-09,2021-03-10,61,Bayer,16,Overall,23.83333333333333,34,1,1,37,57,13,27,0,1,2,False,False,False,False,False,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tipranavir,GenName Y,Drug,hiv,hiv,Phase 3,2013-04-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Triple-class drug experience or resistance. More information on this criterion can be found in the protocol.
* Currently on a failing PI-containing regimen tha...",Yes,2013-08-20,FDA-27956,2.62,0.32,5.0,7.94,2015-11-13,2016-03-09,2021-03-10,86,AstraZeneca,78,Overall,48.66666666666666,37,76,50,40,39,50,27,1,2,0,False,True,False,False,False,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Etravirine,Comp Beta,Drug,hiv,hiv,Phase 3,2013-04-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Triple-class drug experience or resistance. More information on this criterion can be found in the protocol.
* Currently on a failing PI-containing regimen tha...",Yes,2014-03-20,FDA-13630,2.62,0.32,5.0,7.94,2015-11-13,2016-03-09,2021-03-10,28,Bayer,38,Senegal,37.0,22,91,27,38,18,26,64,0,4,3,False,False,False,True,True,True,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,Product Alpha,Drug,hiv,hiv,Phase 3,2013-04-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Triple-class drug experience or resistance. More information on this criterion can be found in the protocol.
* Currently on a failing PI-containing regimen tha...",Yes,2013-09-12,FDA-47033,2.62,0.32,5.0,7.94,2015-11-13,2016-03-09,2021-03-10,1,Sanofi,20,Overall,62.83333333333334,69,12,73,75,62,86,36,1,2,1,True,False,False,False,True,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
TDF-FTC,AltName B,Drug,hiv,hiv,Phase 4,2023-09-30,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Documented HIV-negative according to two fingerpick rapid tests (per routine antenatal care protocol in this setting), confirmed with a 4th generation antigen HIV test at study...",Yes,2024-03-21,FDA-64687,0.56,0.15,3.5,4.21,2024-04-21,2024-06-15,2027-12-15,81,Merck,21,Overall,66.66666666666667,97,33,94,66,10,100,27,1,2,0,False,True,False,True,True,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir alafenamide,GenName Y,Drug,hiv,hiv,Phase 3,2023-09-01,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. \>18 years old
2. confirmed HIV-negative (confirmed with a 4th generation antigen HIV test) at time of study entry
3. intend on giving birth in the MOU facility
4. confirmed to...",Yes,2024-01-07,FDA-54919,2.62,0.32,5.0,7.94,2026-04-14,2026-08-09,2031-08-10,71,Merck,43,Senegal,67.5,78,74,85,28,50,90,27,1,2,0,True,False,False,False,True,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir Disoproxil Fumarate,Product Alpha,Drug,hiv,hiv,Phase 3,2023-09-01,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. \>18 years old
2. confirmed HIV-negative (confirmed with a 4th generation antigen HIV test) at time of study entry
3. intend on giving birth in the MOU facility
4. confirmed to...",No,2024-02-16,FDA-31627,2.62,0.32,5.0,7.94,2026-04-14,2026-08-09,2031-08-10,4,J&J,3,Overall,40.66666666666666,49,40,67,56,28,4,64,2,3,2,True,True,False,True,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
V116,Product Alpha,Biological,hiv,hiv,Phase 3,2024-01-25,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Is infected with HIV
* Is receiving combination anti-retroviral therapy (ART) for ≥6 weeks before study entry with no intended changes to combination ART therapy for 3 months af...",Yes,2024-03-21,FDA-11161,2.62,0.32,5.0,7.94,2026-09-07,2027-01-02,2032-01-03,54,Gilead,58,Senegal,51.0,32,35,24,47,93,75,64,2,2,3,True,True,False,True,False,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PCV15,TradeName X,Biological,hiv,hiv,Phase 3,2024-01-25,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Is infected with HIV
* Is receiving combination anti-retroviral therapy (ART) for ≥6 weeks before study entry with no intended changes to combination ART therapy for 3 months af...",No,2024-08-19,FDA-40643,2.62,0.32,5.0,7.94,2026-09-07,2027-01-02,2032-01-03,91,GSK,9,Senegal,58.16666666666666,79,68,23,38,70,71,45,1,2,2,False,True,True,False,False,False,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
PPSV23,TradeName X,Biological,hiv,hiv,Phase 3,2024-01-25,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Is infected with HIV
* Is receiving combination anti-retroviral therapy (ART) for ≥6 weeks before study entry with no intended changes to combination ART therapy for 3 months af...",Yes,2024-11-15,FDA-18612,2.62,0.32,5.0,7.94,2026-09-07,2027-01-02,2032-01-03,35,GSK,74,Overall,55.83333333333334,95,93,27,7,57,56,73,2,4,2,True,True,False,True,True,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
PCV15 - Part B,Product Alpha,Biological,hiv,hiv,Phase 3,2024-01-25,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Is infected with HIV
* Is receiving combination anti-retroviral therapy (ART) for ≥6 weeks before study entry with no intended changes to combination ART therapy for 3 months af...",No,2024-12-18,FDA-13662,2.62,0.32,5.0,7.94,2026-09-07,2027-01-02,2032-01-03,11,Pfizer,30,Senegal,74.5,86,95,98,17,55,96,55,1,2,3,False,True,True,False,False,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,AltName B,Drug,hiv,hiv,Phase 2,2015-12-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented HIV-1 infection in female patients, age ≥18 years
* Patients receiving antiretroviral therapy consisting of at least 2 antiretroviral agents other than protease inhib...",Yes,2016-03-02,FDA-10091,4.41,0.98,21.0,26.39,2020-04-28,2021-04-21,2042-04-21,79,AstraZeneca,89,Kenya,24.66666666666667,4,11,63,35,0,35,36,1,2,1,True,False,False,False,False,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz (EFV),GenName Y,Drug,hiv,hiv,Phase 3,2014-12-01,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

* HIV-infected child 3 to 5 years of age at time of screening for this trial if enrolled from outside or any age if enrolled from control arm of Neverest II.
* Reliable history or...",No,2015-05-15,FDA-40706,2.62,0.32,5.0,7.94,2017-07-14,2017-11-08,2022-11-09,90,Gilead,48,South Africa,38.66666666666666,58,49,23,33,15,54,64,0,4,3,False,False,True,True,True,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir/ritonavir (LPV/r),AltName A,Drug,hiv,hiv,Phase 3,2014-12-01,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

* HIV-infected child 3 to 5 years of age at time of screening for this trial if enrolled from outside or any age if enrolled from control arm of Neverest II.
* Reliable history or...",No,2015-06-15,FDA-83997,2.62,0.32,5.0,7.94,2017-07-14,2017-11-08,2022-11-09,27,Gilead,31,Senegal,40.0,36,57,16,38,3,90,45,0,3,2,False,False,True,False,True,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Stavudine (D4T),TradeName X,Drug,hiv,hiv,Phase 3,2014-12-01,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

* HIV-infected child 3 to 5 years of age at time of screening for this trial if enrolled from outside or any age if enrolled from control arm of Neverest II.
* Reliable history or...",No,2015-03-14,FDA-15315,2.62,0.32,5.0,7.94,2017-07-14,2017-11-08,2022-11-09,47,Pfizer,62,South Africa,56.33333333333334,88,38,80,22,68,42,64,2,2,3,True,True,True,True,False,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Abacavir (ABC),Comp Beta,Drug,hiv,hiv,Phase 3,2014-12-01,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

* HIV-infected child 3 to 5 years of age at time of screening for this trial if enrolled from outside or any age if enrolled from control arm of Neverest II.
* Reliable history or...",Yes,2015-02-09,FDA-95950,2.62,0.32,5.0,7.94,2017-07-14,2017-11-08,2022-11-09,11,Novartis,62,South Africa,44.33333333333334,46,32,51,25,16,96,45,2,3,0,True,True,True,True,True,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Trizivir,TradeName X,Drug,hiv,hiv,Phase 2,2010-09-01,"Sex: ALL; Healthy Volunteers: Yes; Criteria: Inclusion Criteria for Mothers:

* HIV-infected
* At least at 26th week of pregnancy (treatment group) or 18th week of pregnancy (observational group) but not beyond the 34th week of pregnancy
* Able ...",Yes,2011-03-26,FDA-34668,4.41,0.98,21.0,26.39,2015-01-28,2016-01-21,2037-01-20,3,Sanofi,9,Overall,65.33333333333333,96,7,79,32,83,95,64,1,3,3,True,False,True,True,True,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine/Zidovudine,Comp Beta,Drug,hiv,hiv,Phase 2,2010-09-01,"Sex: ALL; Healthy Volunteers: Yes; Criteria: Inclusion Criteria for Mothers:

* HIV-infected
* At least at 26th week of pregnancy (treatment group) or 18th week of pregnancy (observational group) but not beyond the 34th week of pregnancy
* Able ...",Yes,2011-04-09,FDA-23905,4.41,0.98,21.0,26.39,2015-01-28,2016-01-21,2037-01-20,6,J&J,62,Kenya,61.5,16,86,32,76,62,97,73,2,2,4,True,True,True,False,True,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir/Ritonavir,TradeName X,Drug,hiv,hiv,Phase 2,2010-09-01,"Sex: ALL; Healthy Volunteers: Yes; Criteria: Inclusion Criteria for Mothers:

* HIV-infected
* At least at 26th week of pregnancy (treatment group) or 18th week of pregnancy (observational group) but not beyond the 34th week of pregnancy
* Able ...",Yes,2011-08-25,FDA-73695,4.41,0.98,21.0,26.39,2015-01-28,2016-01-21,2037-01-20,22,Pfizer,76,Kenya,76.0,65,99,53,76,78,85,45,0,3,2,False,False,False,True,False,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Nevirapine,Comp Beta,Drug,hiv,hiv,Phase 2,2010-09-01,"Sex: ALL; Healthy Volunteers: Yes; Criteria: Inclusion Criteria for Mothers:

* HIV-infected
* At least at 26th week of pregnancy (treatment group) or 18th week of pregnancy (observational group) but not beyond the 34th week of pregnancy
* Able ...",No,2011-01-04,FDA-71388,4.41,0.98,21.0,26.39,2015-01-28,2016-01-21,2037-01-20,25,GSK,27,Senegal,34.33333333333334,5,0,31,84,45,41,45,0,4,1,False,False,False,True,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
dolutegravir,TradeName X,Drug,hiv,hiv,Phase 4,2019-09-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* No ARVs in the last 6 months (from date of screening)
* No documented or suspected resistance to integrase inhibitors (dolutegravir, elvitegravir, raltegravir, or bictegravir).
...",No,2019-10-16,FDA-68554,0.56,0.15,3.5,4.21,2020-04-02,2020-05-27,2023-11-26,85,Sanofi,21,South Africa,64.33333333333333,75,86,23,83,81,38,36,0,2,2,False,False,False,True,False,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Triumeq,Comp Beta,Drug,hiv,hiv,Phase 4,2019-09-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* No ARVs in the last 6 months (from date of screening)
* No documented or suspected resistance to integrase inhibitors (dolutegravir, elvitegravir, raltegravir, or bictegravir).
...",No,2020-07-27,FDA-48472,0.56,0.15,3.5,4.21,2020-04-02,2020-05-27,2023-11-26,83,Merck,84,Kenya,22.5,2,5,15,87,18,8,55,1,3,2,False,True,True,True,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada,AltName A,Drug,hiv,hiv,Phase 4,2019-09-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* No ARVs in the last 6 months (from date of screening)
* No documented or suspected resistance to integrase inhibitors (dolutegravir, elvitegravir, raltegravir, or bictegravir).
...",Yes,2019-11-11,FDA-87009,0.56,0.15,3.5,4.21,2020-04-02,2020-05-27,2023-11-26,96,Merck,12,Kenya,40.83333333333334,44,12,24,54,46,65,45,1,3,1,True,False,True,True,True,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lubiprostone,AltName A,Drug,hiv,hiv,Phase 2,2016-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by West...",Yes,2016-04-16,FDA-53917,4.41,0.98,21.0,26.39,2020-06-29,2021-06-22,2042-06-22,55,Pfizer,83,Kenya,48.5,87,6,83,15,96,4,27,0,2,1,False,False,True,False,False,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
PRO 140,GenName Y,Drug,hiv,hiv,Phase 2,2015-02-02,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Males and females, age ≥18 years
2. Exclusive CCR5-tropic virus at Screening Visit as determined by Trofile™ DNA Assay
3. On stable antiretroviral therapy for last 12 months
4....",Yes,2015-12-28,FDA-97061,4.41,0.98,21.0,26.39,2019-07-01,2020-06-23,2041-06-23,65,J&J,15,Kenya,33.16666666666666,6,2,70,2,84,35,55,1,3,2,False,True,True,True,False,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Pegylated interferon alpha-2a,Product Alpha,Drug,hiv,hiv,Phase 4,2015-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Confirmed HIV infection (anti-HIV1/2 antibody positive).
* Chronic HCV infection (anti-HCV positive, HCV-RNA detectable for \>6 months).
* HCV-GT 1 infection.
* Age ≥18 years an...",Yes,2015-10-12,FDA-84447,0.56,0.15,3.5,4.21,2015-12-22,2016-02-15,2019-08-16,51,Novartis,94,Senegal,51.5,59,93,11,44,73,29,55,1,3,2,True,False,True,False,False,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ribavirin,TradeName X,Drug,hiv,hiv,Phase 4,2015-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Confirmed HIV infection (anti-HIV1/2 antibody positive).
* Chronic HCV infection (anti-HCV positive, HCV-RNA detectable for \>6 months).
* HCV-GT 1 infection.
* Age ≥18 years an...",No,2015-09-03,FDA-75369,0.56,0.15,3.5,4.21,2015-12-22,2016-02-15,2019-08-16,87,Bayer,100,Kenya,56.83333333333334,41,43,92,81,43,41,27,1,2,0,True,False,True,True,False,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Boceprevir,Comp Beta,Drug,hiv,hiv,Phase 4,2015-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Confirmed HIV infection (anti-HIV1/2 antibody positive).
* Chronic HCV infection (anti-HCV positive, HCV-RNA detectable for \>6 months).
* HCV-GT 1 infection.
* Age ≥18 years an...",No,2016-05-14,FDA-38304,0.56,0.15,3.5,4.21,2015-12-22,2016-02-15,2019-08-16,13,Merck,30,Kenya,67.83333333333333,31,81,86,37,85,87,73,2,3,3,True,True,False,True,True,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ritonavir,AltName A,Drug,hiv,hiv,Phase 2,2010-03-01,"Sex: ALL; Age: >4 Months; Criteria: Inclusion Criteria:

* infants and children, 4 months to \<6 years;
* confirmed HIV-1 infection;
* patients for whom saquinavir/ritonavir together with \>=2 background ARVs is considered appropriate.
...",Yes,2010-08-27,FDA-86733,4.41,0.98,21.0,26.39,2014-07-28,2015-07-21,2036-07-20,14,Pfizer,69,South Africa,49.83333333333334,54,47,62,68,19,49,36,1,1,2,False,True,False,False,False,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
saquinavir [Invirase],Molecule Z,Drug,hiv,hiv,Phase 2,2010-03-01,"Sex: ALL; Age: >4 Months; Criteria: Inclusion Criteria:

* infants and children, 4 months to \<6 years;
* confirmed HIV-1 infection;
* patients for whom saquinavir/ritonavir together with \>=2 background ARVs is considered appropriate.
...",Yes,2010-06-19,FDA-97785,4.41,0.98,21.0,26.39,2014-07-28,2015-07-21,2036-07-20,64,Pfizer,73,South Africa,72.66666666666667,87,53,66,79,84,67,64,1,3,3,True,False,False,False,True,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Standard of Care (SOC) Oral ART,Comp Beta,Drug,hiv,hiv,Phase 3,2026-08-30,"Sex: ALL; Age: >18 Years; Criteria: Step 1 Inclusion Criteria

HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by ...",Yes,2027-08-30,FDA-12331,2.62,0.32,5.0,7.94,2029-04-12,2029-08-07,2034-08-08,80,GSK,78,Overall,64.16666666666667,93,28,86,69,68,41,45,1,2,2,True,False,False,False,True,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Oral RPV,Molecule Z,Drug,hiv,hiv,Phase 3,2026-08-30,"Sex: ALL; Age: >18 Years; Criteria: Step 1 Inclusion Criteria

HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by ...",No,2027-08-16,FDA-90217,2.62,0.32,5.0,7.94,2029-04-12,2029-08-07,2034-08-08,31,AstraZeneca,21,South Africa,49.66666666666666,41,56,45,76,22,58,73,2,3,3,True,True,True,True,True,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Oral CAB,Comp Beta,Drug,hiv,hiv,Phase 3,2026-08-30,"Sex: ALL; Age: >18 Years; Criteria: Step 1 Inclusion Criteria

HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by ...",No,2027-02-18,FDA-83150,2.62,0.32,5.0,7.94,2029-04-12,2029-08-07,2034-08-08,81,Pfizer,5,Overall,54.83333333333334,62,17,69,80,1,100,45,0,2,3,False,False,False,True,True,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
RPV-LA Loading Dose,Comp Beta,Drug,hiv,hiv,Phase 3,2026-08-30,"Sex: ALL; Age: >18 Years; Criteria: Step 1 Inclusion Criteria

HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by ...",No,2027-04-07,FDA-20582,2.62,0.32,5.0,7.94,2029-04-12,2029-08-07,2034-08-08,68,Merck,76,Kenya,54.33333333333334,56,84,19,100,41,26,45,1,3,1,False,True,True,True,False,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
CAB-LA Loading Dose,AltName B,Drug,hiv,hiv,Phase 3,2026-08-30,"Sex: ALL; Age: >18 Years; Criteria: Step 1 Inclusion Criteria

HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by ...",No,2027-05-08,FDA-72636,2.62,0.32,5.0,7.94,2029-04-12,2029-08-07,2034-08-08,36,Bayer,51,Kenya,48.33333333333334,46,16,73,69,36,50,36,1,2,1,True,False,True,False,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
RPV-LA Maintenance Dose,GenName Y,Drug,hiv,hiv,Phase 3,2026-08-30,"Sex: ALL; Age: >18 Years; Criteria: Step 1 Inclusion Criteria

HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by ...",No,2027-03-08,FDA-54509,2.62,0.32,5.0,7.94,2029-04-12,2029-08-07,2034-08-08,0,GSK,3,South Africa,65.66666666666667,64,31,84,35,96,84,55,2,1,3,True,True,True,False,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
CAB-LA Maintenance Dose,TradeName X,Drug,hiv,hiv,Phase 3,2026-08-30,"Sex: ALL; Age: >18 Years; Criteria: Step 1 Inclusion Criteria

HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by ...",Yes,2027-05-25,FDA-29243,2.62,0.32,5.0,7.94,2029-04-12,2029-08-07,2034-08-08,59,Sanofi,13,Senegal,45.16666666666666,1,69,63,56,19,63,45,0,3,2,False,False,True,True,False,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs),GenName Y,Drug,hiv,hiv,Phase 3,2008-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects were human immunodeficiency virus type 1 (HIV-1) positive, antiretroviral-experienced adults at least 18 years of age currently receiving an antiretroviral regimen whic...",No,2009-04-20,FDA-23687,2.62,0.32,5.0,7.94,2011-06-15,2011-10-10,2016-10-10,44,Merck,77,Overall,69.16666666666667,84,82,65,67,95,22,64,1,3,3,False,True,False,True,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs),Comp Beta,Drug,hiv,hiv,Phase 3,2008-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects were human immunodeficiency virus type 1 (HIV-1) positive, antiretroviral-experienced adults at least 18 years of age currently receiving an antiretroviral regimen whic...",Yes,2008-12-02,FDA-99882,2.62,0.32,5.0,7.94,2011-06-15,2011-10-10,2016-10-10,34,AstraZeneca,39,Kenya,47.0,39,38,68,28,63,46,45,0,2,3,False,False,True,False,False,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lovaza,TradeName X,Drug,hiv,hiv,Phase 4,2015-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-infected men and women at least 18 years of age,
* On stable HAART for the previous two months and without anticipated changes in their HAART regimen throughout the duration...",Yes,2015-11-04,FDA-87118,0.56,0.15,3.5,4.21,2016-02-21,2016-04-16,2019-10-16,46,Merck,49,South Africa,88.83333333333333,83,90,85,99,100,76,64,1,4,2,False,True,True,False,True,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DTG/3TC FDC,GenName Y,Drug,hiv,hiv,Phase 3,2022-09-09,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Eligible participants must be able to understand and comply with protocol requirements, instructions, and restrictions; participant must be likely to complete the study as plann...",Yes,2023-02-13,FDA-32323,2.62,0.32,5.0,7.94,2025-04-22,2025-08-17,2030-08-18,37,GSK,14,South Africa,34.5,18,45,21,0,100,23,55,2,2,2,True,True,False,True,False,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
CAR,TradeName X,Drug,hiv,hiv,Phase 3,2022-09-09,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Eligible participants must be able to understand and comply with protocol requirements, instructions, and restrictions; participant must be likely to complete the study as plann...",No,2022-12-02,FDA-97423,2.62,0.32,5.0,7.94,2025-04-22,2025-08-17,2030-08-18,31,Pfizer,51,Senegal,55.5,50,79,34,69,51,50,45,1,2,2,False,True,True,True,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Depot medroxyprogesterone acetate (DMPA),Product Alpha,Drug,hiv,hiv,Phase 4,2019-10-23,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Female
* Age 18-45 years
* Normal menses (22-35 day intervals) for at least 3 cycles
* Intact uterus and cervix
* Interested in to DMPA, Eng-Implant or Lng-IUD or ParaGuard
* Wi...",Yes,2020-08-22,FDA-15020,0.56,0.15,3.5,4.21,2020-05-14,2020-07-08,2024-01-07,100,Gilead,75,Kenya,35.33333333333334,15,19,14,58,32,74,55,2,1,3,True,True,False,False,True,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Etonogestrel implant (Eng-Implant),GenName Y,Device,hiv,hiv,Phase 4,2019-10-23,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Female
* Age 18-45 years
* Normal menses (22-35 day intervals) for at least 3 cycles
* Intact uterus and cervix
* Interested in to DMPA, Eng-Implant or Lng-IUD or ParaGuard
* Wi...",Yes,2020-06-05,FDA-53575,0.56,0.15,3.5,4.21,2020-05-14,2020-07-08,2024-01-07,99,Gilead,79,Kenya,54.16666666666666,11,22,21,77,94,100,36,1,2,1,False,True,True,True,False,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Levonorgestrel intrauterine device (Lng-IUD),AltName B,Device,hiv,hiv,Phase 4,2019-10-23,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Female
* Age 18-45 years
* Normal menses (22-35 day intervals) for at least 3 cycles
* Intact uterus and cervix
* Interested in to DMPA, Eng-Implant or Lng-IUD or ParaGuard
* Wi...",Yes,2020-08-18,FDA-36112,0.56,0.15,3.5,4.21,2020-05-14,2020-07-08,2024-01-07,82,Bayer,43,South Africa,60.0,70,10,84,68,68,60,9,0,1,0,False,False,False,True,False,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ParaGard® T 380A Intrauterine Copper Contraceptive,AltName B,Device,hiv,hiv,Phase 4,2019-10-23,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Female
* Age 18-45 years
* Normal menses (22-35 day intervals) for at least 3 cycles
* Intact uterus and cervix
* Interested in to DMPA, Eng-Implant or Lng-IUD or ParaGuard
* Wi...",Yes,2020-07-24,FDA-78016,0.56,0.15,3.5,4.21,2020-05-14,2020-07-08,2024-01-07,11,Sanofi,56,Kenya,54.33333333333334,85,56,75,13,41,56,45,1,3,1,False,True,False,False,True,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
TRUVADA + Raltegravir,AltName A,Drug,hiv,hiv,Phase 4,2010-08-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* HIV uninfected on the basis of a negative HIV Rapid Test, EIA or Western blot, and a negative HIV-1 RNA assay
* Possible non-occupational exposure to HIV-1, recent enough to per...",Yes,2011-01-14,FDA-94885,0.56,0.15,3.5,4.21,2011-02-21,2011-04-17,2014-10-16,42,Pfizer,73,Overall,47.0,19,97,58,1,23,84,64,0,3,4,False,False,True,False,False,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Pioglitazone,Product Alpha,Drug,hiv,hiv,Phase 2,,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

  1. Men and women, 18 years of age or greater.
  2. Confirmed HIV infection by ELISA and Western blot.
  3. No changes in antiretroviral regimen within the prior 3 months. Indi...",Yes,2026-02-05,FDA-91017,4.41,0.98,21.0,26.39,,,,74,Novartis,98,Kenya,49.0,48,29,67,29,40,81,45,0,2,3,False,False,True,False,False,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Dihydroartemisinin-piperaquine,GenName Y,Drug,hiv,hiv,Phase 4,2022-04-11,"Sex: ALL; Age: >3 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

All participants:

* Agreement to come to clinic for all follow-up PK and safety evaluations
* Provision of informed consent.

HIV-infected participants:

* Residency within 30km ...",Yes,2022-08-19,FDA-96468,0.56,0.15,3.5,4.21,2022-11-01,2022-12-26,2026-06-26,98,J&J,68,Kenya,49.5,16,31,53,85,62,50,55,1,3,2,False,True,True,True,False,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
valacyclovir,GenName Y,Drug,hiv,hiv,Phase 4,2011-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Age 18 years or older
* Documented HIV-1 seropositive
* Not on HIV-1 antiretroviral therapy nor planning to initiate antiretroviral therapy during the study period
* Detectable ...",Yes,2011-04-11,FDA-37951,0.56,0.15,3.5,4.21,2011-09-21,2011-11-15,2015-05-16,34,Sanofi,34,South Africa,33.16666666666666,12,14,78,4,50,41,55,2,1,3,True,True,False,False,False,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
acyclovir,Molecule Z,Drug,hiv,hiv,Phase 4,2011-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Age 18 years or older
* Documented HIV-1 seropositive
* Not on HIV-1 antiretroviral therapy nor planning to initiate antiretroviral therapy during the study period
* Detectable ...",No,2011-10-28,FDA-32055,0.56,0.15,3.5,4.21,2011-09-21,2011-11-15,2015-05-16,71,Bayer,6,Overall,55.16666666666666,34,44,54,95,13,91,64,1,3,3,True,False,False,True,False,True,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir,Comp Beta,Drug,hiv,hiv,Phase 4,2017-02-20,"Sex: ALL; Age: >6 Years; Criteria: Inclusion Criteria:

* Confirmed HIV-1 infection diagnosed by protocol criteria
* Male or female children, ≥ 6 years to \<17 years 6 months of age at the time of first treatment
* Antiretroviral-naïve...",Yes,2017-07-30,FDA-34315,0.56,0.15,3.5,4.21,2017-09-12,2017-11-06,2021-05-07,75,J&J,93,Overall,37.16666666666666,83,56,1,4,19,60,55,1,2,3,False,True,False,False,True,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,TradeName X,Drug,hiv,hiv,Phase 4,2017-02-20,"Sex: ALL; Age: >6 Years; Criteria: Inclusion Criteria:

* Confirmed HIV-1 infection diagnosed by protocol criteria
* Male or female children, ≥ 6 years to \<17 years 6 months of age at the time of first treatment
* Antiretroviral-naïve...",Yes,2017-05-07,FDA-83739,0.56,0.15,3.5,4.21,2017-09-12,2017-11-06,2021-05-07,46,Merck,31,South Africa,57.0,35,82,77,59,4,85,55,1,2,3,False,True,False,True,True,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Reyataz + Norvir + Truvada,GenName Y,Drug,hiv,hiv,Phase 4,2012-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subject is an adult (greater than or equal to 18 years) with documented HIV-1 infection
* Subject is a male or female of non-childbearing potential (physiologically incapable of...",Yes,2013-06-21,FDA-12282,0.56,0.15,3.5,4.21,2013-06-23,2013-08-17,2017-02-15,7,GSK,39,Senegal,62.5,50,89,72,98,10,56,36,1,1,2,False,True,False,False,False,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Reyataz + Epzicom,Comp Beta,Drug,hiv,hiv,Phase 4,2012-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subject is an adult (greater than or equal to 18 years) with documented HIV-1 infection
* Subject is a male or female of non-childbearing potential (physiologically incapable of...",No,2013-01-11,FDA-45801,0.56,0.15,3.5,4.21,2013-06-23,2013-08-17,2017-02-15,93,Sanofi,97,Overall,40.16666666666666,53,94,64,13,17,0,55,1,3,2,True,False,True,False,True,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Didanosine (ddI),GenName Y,Drug,hiv,hiv,Phase 2,2009-01-01,"Sex: ALL; Age: >90 Days; Criteria: Inclusion Criteria:

* HIV infected
* Antiretroviral naive OR have received no more than 56 days of drugs to prevent mother-to-child transmission of HIV OR have received less than 7 total days of anti...",Yes,2009-05-06,FDA-77083,4.41,0.98,21.0,26.39,2013-05-30,2014-05-23,2035-05-23,50,GSK,41,Kenya,43.83333333333334,19,92,33,13,98,8,45,0,3,2,False,False,False,True,False,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz (EFV),TradeName X,Drug,hiv,hiv,Phase 2,2009-01-01,"Sex: ALL; Age: >90 Days; Criteria: Inclusion Criteria:

* HIV infected
* Antiretroviral naive OR have received no more than 56 days of drugs to prevent mother-to-child transmission of HIV OR have received less than 7 total days of anti...",Yes,2009-11-10,FDA-91532,4.41,0.98,21.0,26.39,2013-05-30,2014-05-23,2035-05-23,77,Sanofi,20,Overall,39.16666666666666,45,38,72,51,5,24,45,1,2,2,True,False,True,False,False,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine (FTC),TradeName X,Drug,hiv,hiv,Phase 2,2009-01-01,"Sex: ALL; Age: >90 Days; Criteria: Inclusion Criteria:

* HIV infected
* Antiretroviral naive OR have received no more than 56 days of drugs to prevent mother-to-child transmission of HIV OR have received less than 7 total days of anti...",No,2009-06-22,FDA-42314,4.41,0.98,21.0,26.39,2013-05-30,2014-05-23,2035-05-23,68,Merck,17,South Africa,51.66666666666666,18,74,25,51,86,56,18,0,1,1,False,False,False,False,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ibalizumab,AltName B,Biological,hiv,hiv,Phase 3,2016-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Are capable of understanding and have voluntarily signed the informed consent document
* Have documented HIV-1 infection by official, signed, written history (e.g., laboratory r...",Yes,2017-05-31,FDA-20418,2.62,0.32,5.0,7.94,2019-07-15,2019-11-09,2024-11-09,61,Novartis,76,South Africa,53.16666666666666,77,66,3,66,92,15,55,1,3,2,True,False,True,False,True,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Optimized Background Regimen (OBR),AltName B,Drug,hiv,hiv,Phase 3,2016-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Are capable of understanding and have voluntarily signed the informed consent document
* Have documented HIV-1 infection by official, signed, written history (e.g., laboratory r...",Yes,2017-02-08,FDA-26695,2.62,0.32,5.0,7.94,2019-07-15,2019-11-09,2024-11-09,51,Sanofi,98,South Africa,27.0,6,56,8,42,44,6,27,1,1,1,True,False,False,False,False,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Twice-daily combination Darunavir and ritonavir,Molecule Z,Drug,hiv,hiv,Phase 4,2015-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. ART-experienced, HIV-1 infected subjects ≥18 years of age.
2. A female subject is eligible to enter and participate in the study if she:

   1. is of non-childbearing potential...",No,2015-09-23,FDA-59567,0.56,0.15,3.5,4.21,2015-10-22,2015-12-16,2019-06-16,68,Sanofi,65,Kenya,36.33333333333334,12,70,15,77,24,20,64,2,3,2,True,True,False,True,False,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Once-daily combination Darunavir and ritonavir,Product Alpha,Drug,hiv,hiv,Phase 4,2015-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. ART-experienced, HIV-1 infected subjects ≥18 years of age.
2. A female subject is eligible to enter and participate in the study if she:

   1. is of non-childbearing potential...",No,2015-09-18,FDA-73085,0.56,0.15,3.5,4.21,2015-10-22,2015-12-16,2019-06-16,56,J&J,79,South Africa,61.33333333333334,68,70,5,55,96,74,82,2,5,2,True,True,True,True,True,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada,GenName Y,Drug,hiv,hiv,Phase 2,2017-03-06,"Sex: ALL; Age: >15 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Age 15 to 19 years (inclusive) at screening, verified per study site standard operating procedures (SOPs)
* Able and willing to provide written informed consent/assent (age depe...",No,2017-10-12,FDA-96826,4.41,0.98,21.0,26.39,2021-08-02,2022-07-26,2043-07-26,0,Gilead,35,South Africa,33.33333333333334,25,6,38,92,21,18,73,1,3,4,True,False,True,True,True,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Zaleplon,Comp Beta,Drug,hiv,hiv,Phase 2,2015-02-04,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Male or female subjects aged 18-65 years with a diagnosis of asymptomatic seropositive HIV
2. Principal diagnosis of Major Depressive Disorder or Dysthymic Disorder in accordan...",Yes,2015-12-09,FDA-38229,4.41,0.98,21.0,26.39,2019-07-03,2020-06-25,2041-06-25,36,AstraZeneca,8,Overall,57.33333333333334,98,71,65,11,79,20,36,1,2,1,True,False,False,True,True,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir,Molecule Z,Drug,hiv,hiv,Phase 4,2012-05-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Age of 18 at time of first visit.
2. HIV uninfected on the basis of a negative HIV Rapid Test
3. Possible non-occupational exposure to HIV-1, recent enough to permit receiving ...",No,2013-03-19,FDA-77793,0.56,0.15,3.5,4.21,2012-11-21,2013-01-15,2016-07-16,15,Novartis,67,South Africa,56.33333333333334,41,16,61,93,98,29,55,2,1,3,True,True,True,False,False,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
DTG 50 mg,Comp Beta,Drug,hiv,hiv,Phase 3,2023-05-25,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants must have been able to understand and comply with protocol requirements, instructions, and restrictions.
* Participants must have been likely to complete the study ...",Yes,2024-05-19,FDA-82839,2.62,0.32,5.0,7.94,2026-01-05,2026-05-02,2031-05-03,1,GSK,29,Overall,54.0,20,6,50,100,79,69,55,2,2,2,True,True,False,False,True,False,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
RPV 25 mg,AltName B,Drug,hiv,hiv,Phase 3,2023-05-25,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants must have been able to understand and comply with protocol requirements, instructions, and restrictions.
* Participants must have been likely to complete the study ...",Yes,2023-09-18,FDA-73784,2.62,0.32,5.0,7.94,2026-01-05,2026-05-02,2031-05-03,68,Merck,57,Senegal,63.0,45,18,98,86,73,58,36,1,2,1,True,False,True,False,False,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
CAR,TradeName X,Drug,hiv,hiv,Phase 3,2023-05-25,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants must have been able to understand and comply with protocol requirements, instructions, and restrictions.
* Participants must have been likely to complete the study ...",No,2023-07-18,FDA-40429,2.62,0.32,5.0,7.94,2026-01-05,2026-05-02,2031-05-03,49,GSK,12,Senegal,47.66666666666666,18,46,77,11,98,36,45,1,2,2,True,False,False,False,False,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
DTG 50 mg,AltName B,Drug,hiv,hiv,Phase 3,2023-05-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants must have been able to understand and comply with protocol requirements, instructions, and restrictions.
* Participants must have been likely to complete the study ...",No,2024-04-16,FDA-54601,2.62,0.32,5.0,7.94,2026-01-10,2026-05-07,2031-05-08,95,Merck,66,South Africa,47.33333333333334,25,21,76,54,18,90,64,1,3,3,True,False,True,True,True,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
RPV 25 mg,Molecule Z,Drug,hiv,hiv,Phase 3,2023-05-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants must have been able to understand and comply with protocol requirements, instructions, and restrictions.
* Participants must have been likely to complete the study ...",No,2024-01-26,FDA-23975,2.62,0.32,5.0,7.94,2026-01-10,2026-05-07,2031-05-08,52,GSK,9,South Africa,47.66666666666666,10,78,17,67,91,23,27,0,1,2,False,False,True,False,False,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
CAR,Product Alpha,Drug,hiv,hiv,Phase 3,2023-05-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants must have been able to understand and comply with protocol requirements, instructions, and restrictions.
* Participants must have been likely to complete the study ...",Yes,2024-02-22,FDA-17942,2.62,0.32,5.0,7.94,2026-01-10,2026-05-07,2031-05-08,19,Gilead,19,Overall,63.83333333333334,92,58,26,41,92,74,36,2,1,1,True,True,False,True,False,False,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF),Comp Beta,Drug,hiv,hiv,Phase 2,2024-02-24,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: PK Component (Groups 1 and 2) Inclusion Criteria:

* At study entry, pregnant or recently delivered, in one of the following two enrollment windows:

  * Group 1: Gestational age of 14 to 24 weeks.
  ...",Yes,2024-07-07,FDA-80253,4.41,0.98,21.0,26.39,2028-07-22,2029-07-15,2050-07-15,58,Bayer,25,South Africa,54.5,61,86,35,42,59,44,45,0,3,2,False,False,False,True,False,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rosiglitazone,AltName B,Drug,hiv,hiv,Phase 2,2008-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Lipoatrophy
* Thymidine sparing ARV for at least 24 weeks
* Prior thymidine NRTIs for at least 12 months

Exclusion Criteria:

* Diabetes
* Heart failure
* Liver disease
* Hormo...",No,2009-01-29,FDA-83470,4.41,0.98,21.0,26.39,2013-04-29,2014-04-22,2035-04-22,85,Sanofi,35,South Africa,49.66666666666666,34,99,50,45,54,16,55,1,3,2,True,False,False,True,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir (DTG),TradeName X,Drug,hiv,hiv,Phase 3,2022-06-29,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Must be an HIV 1 infected adult \>=18 years of age (or older, if required by local regulations) at the time of signing the informed consent
* An eligible female participant shou...",Yes,2023-06-01,FDA-44449,2.62,0.32,5.0,7.94,2025-02-09,2025-06-06,2030-06-07,22,Novartis,60,Overall,62.5,31,92,20,83,72,77,18,0,1,1,False,False,True,False,False,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine (3TC),TradeName X,Drug,hiv,hiv,Phase 3,2022-06-29,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Must be an HIV 1 infected adult \>=18 years of age (or older, if required by local regulations) at the time of signing the informed consent
* An eligible female participant shou...",Yes,2023-05-22,FDA-35460,2.62,0.32,5.0,7.94,2025-02-09,2025-06-06,2030-06-07,57,Pfizer,12,Senegal,54.5,59,39,4,70,58,97,55,1,2,3,False,True,True,False,False,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC),AltName B,Drug,hiv,hiv,Phase 3,2022-06-29,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Must be an HIV 1 infected adult \>=18 years of age (or older, if required by local regulations) at the time of signing the informed consent
* An eligible female participant shou...",No,2023-05-10,FDA-34873,2.62,0.32,5.0,7.94,2025-02-09,2025-06-06,2030-06-07,94,Novartis,90,Overall,54.66666666666666,50,78,24,74,14,88,64,2,3,2,True,True,True,True,False,False,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Daily dosing,AltName B,Drug,hiv,hiv,Phase 2,2014-12-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Literacy in one of the study languages (Thai, Xhosa, and/or English)
* Able to provide written informed consent
* Able to provide weekly telephonic updates
* Within 70 days of e...",Yes,2015-02-04,FDA-28512,4.41,0.98,21.0,26.39,2019-04-29,2020-04-21,2041-04-21,97,Novartis,47,Kenya,56.33333333333334,82,14,53,92,51,46,45,1,3,1,True,False,False,True,True,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Time-driven dosing,Comp Beta,Drug,hiv,hiv,Phase 2,2014-12-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Literacy in one of the study languages (Thai, Xhosa, and/or English)
* Able to provide written informed consent
* Able to provide weekly telephonic updates
* Within 70 days of e...",No,2015-08-29,FDA-59275,4.41,0.98,21.0,26.39,2019-04-29,2020-04-21,2041-04-21,78,Sanofi,14,South Africa,56.66666666666666,71,47,55,88,47,32,73,2,3,3,True,True,True,False,True,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Event-driven dosing,Molecule Z,Drug,hiv,hiv,Phase 2,2014-12-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Literacy in one of the study languages (Thai, Xhosa, and/or English)
* Able to provide written informed consent
* Able to provide weekly telephonic updates
* Within 70 days of e...",Yes,2015-01-10,FDA-38163,4.41,0.98,21.0,26.39,2019-04-29,2020-04-21,2041-04-21,56,Novartis,5,Overall,38.66666666666666,34,84,28,20,17,49,73,1,5,2,False,True,True,True,True,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
PRO 140 350mg weekly subcutaneous (SC) injection.,AltName B,Drug,hiv,hiv,Phase 2,2022-07-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Subjects who have completed 12 weeks of treatment in PRO 140\_CD01 study without experiencing virologic failure.
2. Both male and female patients and their partners of childbea...",Yes,2022-10-09,FDA-72061,4.41,0.98,21.0,26.39,2026-12-11,2027-12-04,2048-12-03,80,Pfizer,72,Kenya,40.16666666666666,1,100,32,38,2,68,36,0,1,3,False,False,False,True,False,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC),Product Alpha,Drug,hiv,hiv,Phase 2,2013-07-01,"Sex: ALL; Age: >3 Months; Criteria: Inclusion Criteria:

* HIV-1 infected; \>=3 months of age to \<=6 years of age (at time of treatment); screening plasma viral load \>=1000 copies/mL

Exclusion Criteria:

* Genotypic or phenotypic res...",Yes,2014-04-02,FDA-25053,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,50,Sanofi,72,Kenya,73.66666666666667,67,98,29,97,64,87,55,1,3,2,False,True,True,False,False,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Vicriviroc,AltName A,Drug,hiv,hiv,Phase 2,2010-08-01,"Sex: ALL; Age: >2 Years; Criteria: Inclusion Criteria:

* Confirmed HIV infection
* Treatment experienced subjects: Children or adolescents on an unchanged therapeutic regimen for at least 12 weeks and experiencing virologic failure OR...",No,2011-04-07,FDA-11672,4.41,0.98,21.0,26.39,2014-12-28,2015-12-21,2036-12-20,84,Pfizer,84,South Africa,63.83333333333334,41,34,84,91,52,81,55,2,2,2,True,True,True,False,False,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Darunavir (DRV),Molecule Z,Drug,hiv,hiv,Phase 3,2011-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients with documented human immunodeficiency virus - Type 1 (HIV-1) infection
* Patients with a viral load greater than 1,000 HIV-1 ribonucleic acid (RNA) copies/mL
* Stable ...",No,2012-09-28,FDA-54227,2.62,0.32,5.0,7.94,2014-05-14,2014-09-08,2019-09-09,31,Gilead,32,Kenya,76.33333333333333,97,35,67,91,80,88,73,1,5,2,False,True,True,True,True,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir (rtv),Comp Beta,Drug,hiv,hiv,Phase 3,2011-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients with documented human immunodeficiency virus - Type 1 (HIV-1) infection
* Patients with a viral load greater than 1,000 HIV-1 ribonucleic acid (RNA) copies/mL
* Stable ...",No,2012-05-16,FDA-70756,2.62,0.32,5.0,7.94,2014-05-14,2014-09-08,2019-09-09,85,Bayer,78,Kenya,74.0,81,56,92,91,50,74,55,1,4,1,True,False,True,False,True,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Chloroquine,Comp Beta,Drug,hiv,hiv,Phase 2,2013-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected
* Certain specified laboratory values obtained within 30 days prior to study entry. More information on this criterion can be found in the study protocol.
* Docum...",No,2013-07-27,FDA-68068,4.41,0.98,21.0,26.39,2017-09-27,2018-09-20,2039-09-20,80,J&J,46,Kenya,52.83333333333334,9,34,51,35,90,98,55,2,1,3,True,True,False,False,False,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PRO 140,Comp Beta,Drug,hiv,hiv,Phase 2,2008-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Males \& females, age ≥ 18 years (or minimum adult age as determined by local regulatory authorities)
2. Screening plasma HIV-1 RNA ≥ 5,000 copies/mL
3. CD4+ T-lymphocyte cell ...",No,2008-11-25,FDA-67278,4.41,0.98,21.0,26.39,2012-12-28,2013-12-21,2034-12-21,24,GSK,76,Overall,43.0,92,48,30,56,22,10,64,0,4,3,False,False,True,False,True,True,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PRO 140,TradeName X,Drug,hiv,hiv,Phase 2,2008-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Males \& females, age ≥ 18 years (or minimum adult age as determined by local regulatory authorities)
2. Screening plasma HIV-1 RNA ≥ 5,000 copies/mL
3. CD4+ T-lymphocyte cell ...",No,2009-02-27,FDA-50230,4.41,0.98,21.0,26.39,2012-12-28,2013-12-21,2034-12-21,30,GSK,83,Senegal,51.33333333333334,82,41,5,30,87,63,45,1,1,3,False,True,False,False,False,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Romidepsin,Product Alpha,Drug,hiv,hiv,Phase 2,2018-04-16,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria: Cohorts 1, 2, \& 3

* HIV-1 infection, documented by any licensed rapid HIV test or HIV E/CIA test kit at any time prior to study entry \& confirmed by a licensed Western blot or a...",No,2019-01-28,FDA-62216,4.41,0.98,21.0,26.39,2022-09-12,2023-09-05,2044-09-04,25,Bayer,67,Kenya,63.66666666666666,5,84,95,64,73,61,55,2,2,2,True,True,True,False,False,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520),AltName B,Biological,hiv,hiv,Phase 2,2008-05-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Demonstrates good general health
* Human Immunodeficiency Virus (HIV), Hepatitis B surface Antigen (HBsAg), and Hepatitis C (HCV) seronegative
* Low risk of acquiring HIV infect...",Yes,2008-12-19,FDA-90416,4.41,0.98,21.0,26.39,2012-09-27,2013-09-20,2034-09-20,56,Pfizer,53,South Africa,44.66666666666666,7,65,32,90,55,19,45,1,1,3,True,False,False,False,True,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520),GenName Y,Biological,hiv,hiv,Phase 2,2008-05-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Demonstrates good general health
* Human Immunodeficiency Virus (HIV), Hepatitis B surface Antigen (HBsAg), and Hepatitis C (HCV) seronegative
* Low risk of acquiring HIV infect...",No,2008-10-09,FDA-96175,4.41,0.98,21.0,26.39,2012-09-27,2013-09-20,2034-09-20,40,Sanofi,61,South Africa,29.16666666666667,21,49,38,41,19,7,36,0,2,2,False,False,True,False,False,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520),TradeName X,Biological,hiv,hiv,Phase 2,2008-05-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Demonstrates good general health
* Human Immunodeficiency Virus (HIV), Hepatitis B surface Antigen (HBsAg), and Hepatitis C (HCV) seronegative
* Low risk of acquiring HIV infect...",Yes,2009-01-08,FDA-12798,4.41,0.98,21.0,26.39,2012-09-27,2013-09-20,2034-09-20,95,J&J,58,South Africa,46.66666666666666,6,91,45,38,3,97,55,1,3,2,False,True,True,True,False,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Colchicine,AltName B,Drug,hiv,hiv,Phase 2,2020-09-01,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* Patients of either gender who are 21 years of age (no upper age limit), HIV positive and taking stable ART (no change in ART regimen in last 3 months),
* HIV viral load \<100 co...",Yes,2020-11-05,FDA-52942,4.41,0.98,21.0,26.39,2025-01-28,2026-01-21,2047-01-21,26,Bayer,67,Overall,63.83333333333334,55,97,47,37,59,88,64,1,2,4,True,False,True,True,False,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,AltName A,Drug,hiv,hiv,Phase 2,2022-05-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participant is able to understand and provide informed consent.
* Documented HIV infection (by any licensed enzyme-linked immunosorbent assay \[ELISA\] and confirmation by Weste...",No,2023-02-01,FDA-61429,4.41,0.98,21.0,26.39,2026-10-06,2027-09-29,2048-09-28,27,AstraZeneca,72,South Africa,42.33333333333334,61,29,22,82,0,60,36,1,1,2,True,False,False,False,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ibalizumab,AltName A,Drug,hiv,hiv,Phase 2,2011-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Are capable of understanding and have voluntarily signed the informed consent document
2. Have documented HIV-1 infection by official, signed, written history (eg, laboratory r...",No,2011-08-10,FDA-77991,4.41,0.98,21.0,26.39,2015-08-28,2016-08-20,2037-08-20,68,AstraZeneca,4,South Africa,59.66666666666666,84,57,100,6,88,23,27,0,0,3,False,False,False,False,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ibalizumab,TradeName X,Drug,hiv,hiv,Phase 2,2011-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Are capable of understanding and have voluntarily signed the informed consent document
2. Have documented HIV-1 infection by official, signed, written history (eg, laboratory r...",No,2012-01-29,FDA-19153,4.41,0.98,21.0,26.39,2015-08-28,2016-08-20,2037-08-20,75,Pfizer,92,Senegal,19.66666666666667,51,18,2,0,28,19,64,1,3,3,True,False,True,False,True,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir,AltName B,Drug,hiv,hiv,Phase 3,2014-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected adults at least 18 years of age. Females are eligible to enter and participate in the study if she is (1) of non-childbearing potential or (2) of childbearing pot...",No,2014-12-23,FDA-35078,2.62,0.32,5.0,7.94,2016-12-12,2017-04-08,2022-04-09,39,Gilead,21,Senegal,54.83333333333334,14,76,26,58,67,88,45,0,3,2,False,False,False,True,True,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,Product Alpha,Drug,hiv,hiv,Phase 4,2014-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. provision of written, informed consent
2. HIV-infected adults at least 18 years of age
3. receiving stable ART including TDF and a r/PI for the previous 6 months
4. no prior PI...",No,2015-02-10,FDA-93430,0.56,0.15,3.5,4.21,2014-10-22,2014-12-16,2018-06-16,14,Merck,79,Overall,46.5,77,80,11,47,13,51,45,1,2,2,True,False,True,False,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Glecaprevir/Pibrentasvir (G/P),GenName Y,Drug,hiv,hiv,Phase 2,2023-08-22,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

* Acute HCV infection (or reinfection) within 24 weeks prior to entry
* Detectable HCV RNA at the screening visit

Exclusion Criteria

* Any HCV treatment during the current acute ...",No,2024-03-01,FDA-98339,4.41,0.98,21.0,26.39,2028-01-18,2029-01-10,2050-01-10,91,J&J,43,Kenya,60.0,62,92,40,3,98,65,36,0,1,3,False,False,False,False,False,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine",Comp Beta,Biological,hiv,hiv,Phase 2,2017-12-12,"Sex: MALE; Age: >13 Years; Criteria: DISEASE CHARACTERISTICS:

* Men with a history of at least one male sexual partner

  * ""Men"" is defined as those documented ""male"" at birth (including male-to-female transgendered persons)
* HIV-1 in...",Yes,2018-11-28,FDA-88593,4.41,0.98,21.0,26.39,2022-05-10,2023-05-03,2044-05-02,12,Sanofi,75,Kenya,51.83333333333334,15,31,54,90,93,28,64,0,3,4,False,False,True,False,True,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir,Molecule Z,Drug,hiv,hiv,Phase 3,2016-02-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Subjects must provide written informed consent
* Currently receiving atazanavir (unboosted or boosted with 100 mg ritonavir QD)and/or tenofovir-emtricitabine at time of screenin...",Yes,2016-09-03,FDA-51286,2.62,0.32,5.0,7.94,2018-09-14,2019-01-09,2024-01-10,3,J&J,50,South Africa,42.16666666666666,37,76,9,41,4,86,45,1,2,2,False,True,False,False,True,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir/Ritonavir,AltName B,Drug,hiv,hiv,Phase 3,2016-02-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Subjects must provide written informed consent
* Currently receiving atazanavir (unboosted or boosted with 100 mg ritonavir QD)and/or tenofovir-emtricitabine at time of screenin...",Yes,2016-12-31,FDA-82088,2.62,0.32,5.0,7.94,2018-09-14,2019-01-09,2024-01-10,93,Novartis,10,Overall,60.66666666666666,49,38,87,93,83,14,36,1,3,0,True,False,True,True,False,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir/Emtricitabine,GenName Y,Drug,hiv,hiv,Phase 3,2016-02-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Subjects must provide written informed consent
* Currently receiving atazanavir (unboosted or boosted with 100 mg ritonavir QD)and/or tenofovir-emtricitabine at time of screenin...",Yes,2016-06-01,FDA-38630,2.62,0.32,5.0,7.94,2018-09-14,2019-01-09,2024-01-10,3,Sanofi,53,Overall,53.0,11,57,27,46,95,82,64,1,5,1,False,True,True,True,True,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir/ritonavir,Molecule Z,Drug,hiv,hiv,Phase 3,2016-02-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Subjects must provide written informed consent
* Currently receiving atazanavir (unboosted or boosted with 100 mg ritonavir QD)and/or tenofovir-emtricitabine at time of screenin...",Yes,2017-01-12,FDA-57862,2.62,0.32,5.0,7.94,2018-09-14,2019-01-09,2024-01-10,98,Pfizer,83,Overall,53.16666666666666,91,28,73,13,100,14,45,1,2,2,False,True,False,True,False,False,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine/zidovudine,AltName A,Drug,hiv,hiv,Phase 4,2018-12-11,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

* Naive to antiretroviral therapy (ART) or have received ART with short course zidovudine (maximum of 8 weeks) for prevention of mother-to-child transmission in previous pregnanci...",Yes,2019-09-30,FDA-97833,0.56,0.15,3.5,4.21,2019-07-03,2019-08-27,2023-02-25,81,Gilead,32,Kenya,64.33333333333333,36,79,56,96,45,74,36,0,2,2,False,False,False,True,False,False,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,GenName Y,Drug,hiv,hiv,Phase 4,2018-12-11,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

* Naive to antiretroviral therapy (ART) or have received ART with short course zidovudine (maximum of 8 weeks) for prevention of mother-to-child transmission in previous pregnanci...",Yes,2019-10-31,FDA-58530,0.56,0.15,3.5,4.21,2019-07-03,2019-08-27,2023-02-25,76,Pfizer,88,Overall,63.83333333333334,98,62,68,17,74,64,18,0,2,0,False,False,False,True,True,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,Comp Beta,Drug,hiv,hiv,Phase 4,2018-12-11,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

* Naive to antiretroviral therapy (ART) or have received ART with short course zidovudine (maximum of 8 weeks) for prevention of mother-to-child transmission in previous pregnanci...",No,2019-09-27,FDA-78216,0.56,0.15,3.5,4.21,2019-07-03,2019-08-27,2023-02-25,25,Bayer,90,Senegal,66.0,83,69,95,55,17,77,73,2,3,3,True,True,False,True,True,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
BMS-955176,Product Alpha,Drug,hiv,hiv,Phase 2,2017-08-21,"Sex: ALL; Age: >18 Years; Criteria: For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

* Men and non-pregnant women, at least 18 years of age
* Antiretroviral tre...",No,2018-02-06,FDA-12373,4.41,0.98,21.0,26.39,2022-01-17,2023-01-10,2044-01-10,66,J&J,85,Overall,48.33333333333334,23,52,94,27,70,24,36,1,1,2,False,True,False,True,False,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
EFV,Product Alpha,Drug,hiv,hiv,Phase 2,2017-08-21,"Sex: ALL; Age: >18 Years; Criteria: For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

* Men and non-pregnant women, at least 18 years of age
* Antiretroviral tre...",Yes,2017-12-10,FDA-82147,4.41,0.98,21.0,26.39,2022-01-17,2023-01-10,2044-01-10,75,Sanofi,49,South Africa,34.66666666666666,8,99,4,36,33,28,55,1,2,3,False,True,True,False,False,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
TDF/FTC,TradeName X,Drug,hiv,hiv,Phase 2,2017-08-21,"Sex: ALL; Age: >18 Years; Criteria: For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

* Men and non-pregnant women, at least 18 years of age
* Antiretroviral tre...",Yes,2017-11-17,FDA-81850,4.41,0.98,21.0,26.39,2022-01-17,2023-01-10,2044-01-10,59,AstraZeneca,73,South Africa,30.5,19,4,21,12,44,83,36,1,2,1,True,False,False,True,False,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
IMVAMUNE (MVA-BN),AltName B,Biological,hiv,hiv,Phase 2,2009-10-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: * Genders eligible for Study: Both
* Age: between 18 and 55 years
* Healthy volunteers are accepted

Inclusion Criteria:

* Subjects tested positive for HIV-1 infection (HIV-infected subjects).
* Subj...",No,2010-03-16,FDA-64722,4.41,0.98,21.0,26.39,2014-02-27,2015-02-20,2036-02-20,93,Novartis,74,Kenya,57.5,72,98,66,23,79,7,73,0,5,3,False,False,True,True,True,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine,Comp Beta,Drug,hiv,hiv,Phase 2,2016-12-01,"Sex: ALL; Age: >2 Months; Criteria: Inclusion Criteria for All Participants:\>\>

* age \>=6 months to \< 36 months (decreased to 2 months in protocol version 4.0)\>\>
* HIV infected\>\>
* Viral load greater than 5,000 copies/ml within ...",No,2017-04-12,FDA-10384,4.41,0.98,21.0,26.39,2021-04-29,2022-04-22,2043-04-22,34,Gilead,10,Senegal,48.33333333333334,33,45,8,98,99,7,55,0,2,4,False,False,False,False,True,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir/ritonavir,AltName B,Drug,hiv,hiv,Phase 2,2016-12-01,"Sex: ALL; Age: >2 Months; Criteria: Inclusion Criteria for All Participants:\>\>

* age \>=6 months to \< 36 months (decreased to 2 months in protocol version 4.0)\>\>
* HIV infected\>\>
* Viral load greater than 5,000 copies/ml within ...",Yes,2017-02-13,FDA-16356,4.41,0.98,21.0,26.39,2021-04-29,2022-04-22,2043-04-22,66,Bayer,26,Senegal,61.16666666666666,77,56,26,82,86,40,73,2,4,2,True,True,True,False,True,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Nevirapine,Product Alpha,Drug,hiv,hiv,Phase 2,2016-12-01,"Sex: ALL; Age: >2 Months; Criteria: Inclusion Criteria for All Participants:\>\>

* age \>=6 months to \< 36 months (decreased to 2 months in protocol version 4.0)\>\>
* HIV infected\>\>
* Viral load greater than 5,000 copies/ml within ...",No,2017-08-12,FDA-46429,4.41,0.98,21.0,26.39,2021-04-29,2022-04-22,2043-04-22,53,Bayer,74,Kenya,37.33333333333334,94,4,16,43,56,11,82,2,4,3,True,True,True,True,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Zidovudine,AltName B,Drug,hiv,hiv,Phase 2,2016-12-01,"Sex: ALL; Age: >2 Months; Criteria: Inclusion Criteria for All Participants:\>\>

* age \>=6 months to \< 36 months (decreased to 2 months in protocol version 4.0)\>\>
* HIV infected\>\>
* Viral load greater than 5,000 copies/ml within ...",No,2017-09-15,FDA-62181,4.41,0.98,21.0,26.39,2021-04-29,2022-04-22,2043-04-22,40,Gilead,16,Kenya,46.66666666666666,100,38,11,42,33,56,55,2,3,1,True,True,False,True,True,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir/ritonavir,Molecule Z,Drug,hiv,hiv,Phase 3,2013-12-01,"Sex: ALL; Age: >4 Weeks; Criteria: Inclusion Criteria:

* Weight equal to or greater than 3 kg, but less than 25 kg, at the time of enrollment
* Confirmed diagnosis of HIV-1 infection
* Lopinavir/ritonavir (LPV/r)-treatment naïve and L...",Yes,2014-04-16,FDA-78486,2.62,0.32,5.0,7.94,2016-07-14,2016-11-08,2021-11-09,81,J&J,48,Overall,57.33333333333334,64,22,85,79,2,92,55,0,4,2,False,False,False,True,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Enfuvirtide,GenName Y,Drug,hiv,hiv,Phase 4,2008-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected adults \>=18 years of age;
* currently on antiretroviral (ARV) therapy;
* previously treated with 2 or 3 different antiretroviral classes;
* HIV-1 Ribonucleic aci...",No,2008-10-23,FDA-73111,0.56,0.15,3.5,4.21,2008-10-22,2008-12-16,2012-06-16,30,AstraZeneca,6,South Africa,45.83333333333334,92,4,7,67,12,93,27,0,2,1,False,False,False,True,False,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Highly active antiretroviral treatment (HAART),GenName Y,Drug,hiv,hiv,Phase 4,2008-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected adults \>=18 years of age;
* currently on antiretroviral (ARV) therapy;
* previously treated with 2 or 3 different antiretroviral classes;
* HIV-1 Ribonucleic aci...",Yes,2008-07-11,FDA-19449,0.56,0.15,3.5,4.21,2008-10-22,2008-12-16,2012-06-16,10,AstraZeneca,31,South Africa,44.83333333333334,36,1,74,73,74,11,55,1,2,3,True,False,False,False,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
SoC + iTab,AltName A,Device,hiv,hiv,Phase 4,2018-07-11,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Man or transgender M to F who has sex with men.
* Age 18 years or older.
* Subjects must have substantial ongoing risk of acquisition of HIV as evident by one or more of the fol...",No,2018-11-09,FDA-30509,0.56,0.15,3.5,4.21,2019-01-31,2019-03-27,2022-09-25,0,J&J,47,Overall,41.16666666666666,66,85,34,30,3,29,18,1,1,0,True,False,False,True,False,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"Didanosine, enteric-coated",AltName A,Drug,hiv,hiv,Phase 2,2009-11-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria for Mothers:

* HIV infected
* Pregnant with a viable fetus
* Between 28 and 38 weeks of pregnancy
* CD4 count greater than 250 cells/mm3 within 30 days prior to study entry
* Able ...",No,2010-08-24,FDA-91952,4.41,0.98,21.0,26.39,2014-03-30,2015-03-23,2036-03-22,26,Novartis,19,South Africa,55.0,53,84,42,39,35,77,73,2,4,2,True,True,True,True,False,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir/ritonavir,Molecule Z,Drug,hiv,hiv,Phase 2,2009-11-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria for Mothers:

* HIV infected
* Pregnant with a viable fetus
* Between 28 and 38 weeks of pregnancy
* CD4 count greater than 250 cells/mm3 within 30 days prior to study entry
* Able ...",Yes,2010-05-29,FDA-98368,4.41,0.98,21.0,26.39,2014-03-30,2015-03-23,2036-03-22,91,GSK,40,Kenya,81.0,72,65,77,100,73,99,64,0,3,4,False,False,True,False,True,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Nevirapine,Molecule Z,Drug,hiv,hiv,Phase 2,2009-11-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria for Mothers:

* HIV infected
* Pregnant with a viable fetus
* Between 28 and 38 weeks of pregnancy
* CD4 count greater than 250 cells/mm3 within 30 days prior to study entry
* Able ...",Yes,2010-09-09,FDA-75476,4.41,0.98,21.0,26.39,2014-03-30,2015-03-23,2036-03-22,53,Gilead,61,Kenya,56.0,82,91,35,29,74,25,55,1,5,0,True,False,True,True,True,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Zidovudine,AltName A,Drug,hiv,hiv,Phase 2,2009-11-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria for Mothers:

* HIV infected
* Pregnant with a viable fetus
* Between 28 and 38 weeks of pregnancy
* CD4 count greater than 250 cells/mm3 within 30 days prior to study entry
* Able ...",Yes,2010-01-26,FDA-69808,4.41,0.98,21.0,26.39,2014-03-30,2015-03-23,2036-03-22,63,Pfizer,11,Overall,50.66666666666666,7,32,9,87,76,93,18,0,2,0,False,False,True,True,False,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,AltName A,Drug,hiv,hiv,Phase 4,2017-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male or female
* Documented HIV-infection
* Age ≥ 18 years
* Willing to comply with the protocol requirements
* On stable antiretroviral therapy (ART) for ≥ 6 months at screenin...",Yes,2018-02-15,FDA-36633,0.56,0.15,3.5,4.21,2018-01-21,2018-03-17,2021-09-15,14,AstraZeneca,95,Senegal,50.16666666666666,89,86,7,18,26,75,36,1,2,1,False,True,True,False,False,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Continuation of own regimen,AltName A,Drug,hiv,hiv,Phase 4,2017-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male or female
* Documented HIV-infection
* Age ≥ 18 years
* Willing to comply with the protocol requirements
* On stable antiretroviral therapy (ART) for ≥ 6 months at screenin...",Yes,2017-10-06,FDA-79167,0.56,0.15,3.5,4.21,2018-01-21,2018-03-17,2021-09-15,43,Pfizer,39,South Africa,45.16666666666666,15,71,2,25,73,85,18,0,1,1,False,False,False,False,False,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada,Product Alpha,Drug,hiv,hiv,Phase 4,2018-10-25,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

Young women who meet all of the following criteria are eligible for inclusion in this study:

* Female at birth
* Age 16-25 years
* Per participant report, sexually active, define...",Yes,2019-06-21,FDA-72562,0.56,0.15,3.5,4.21,2019-05-17,2019-07-11,2023-01-09,80,Pfizer,67,Kenya,70.0,2,87,70,93,86,82,55,1,3,2,False,True,True,False,True,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Minocycline,Product Alpha,Drug,hiv,hiv,Phase 2,2010-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV infected
* Currently on a stable ART regimen for at least 16 consecutive weeks prior to study entry. Participants whose regimens have changed with respect to dose or formula...",Yes,2010-12-05,FDA-37293,4.41,0.98,21.0,26.39,2014-05-30,2015-05-23,2036-05-22,72,J&J,78,Overall,66.16666666666667,62,37,84,73,62,79,27,0,2,1,False,False,True,False,False,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
darunavir,GenName Y,Drug,hiv,hiv,Phase 3,2008-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented HIV infection
* Plasma HIV-RNA \>= 1000 copies/mL
* Must be able to comply with protocol requirements

Exclusion Criteria:

* No prior use of PREZISTA (darunavir), TM...",No,2009-07-12,FDA-49924,2.62,0.32,5.0,7.94,2011-07-15,2011-11-09,2016-11-09,59,Novartis,7,Kenya,65.66666666666667,95,74,84,31,69,41,73,2,3,3,True,True,True,True,False,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ritonavir,Comp Beta,Drug,hiv,hiv,Phase 3,2008-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented HIV infection
* Plasma HIV-RNA \>= 1000 copies/mL
* Must be able to comply with protocol requirements

Exclusion Criteria:

* No prior use of PREZISTA (darunavir), TM...",No,2009-04-14,FDA-31131,2.62,0.32,5.0,7.94,2011-07-15,2011-11-09,2016-11-09,38,GSK,81,South Africa,60.33333333333334,70,6,99,84,7,96,64,1,4,2,False,True,True,True,True,False,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK3640254,Comp Beta,Drug,hiv,hiv,Phase 2,2023-05-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Treatment-naive, defined as no anti-retrovirals (ARVs) (in combination or monotherapy) received after a known diagnosis of HIV-1 infection.
* Documented HIV infection and Screen...",Yes,2023-09-06,FDA-72746,4.41,0.98,21.0,26.39,2027-10-07,2028-09-29,2049-09-29,20,Bayer,42,Overall,34.16666666666666,52,4,59,65,23,2,36,1,0,3,True,False,False,False,False,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir,Molecule Z,Drug,hiv,hiv,Phase 2,2023-05-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Treatment-naive, defined as no anti-retrovirals (ARVs) (in combination or monotherapy) received after a known diagnosis of HIV-1 infection.
* Documented HIV infection and Screen...",Yes,2023-07-26,FDA-28405,4.41,0.98,21.0,26.39,2027-10-07,2028-09-29,2049-09-29,53,J&J,37,Kenya,50.83333333333334,50,62,44,27,95,27,82,2,5,2,True,True,True,True,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine capsules,GenName Y,Drug,hiv,hiv,Phase 2,2023-05-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Treatment-naive, defined as no anti-retrovirals (ARVs) (in combination or monotherapy) received after a known diagnosis of HIV-1 infection.
* Documented HIV infection and Screen...",No,2023-11-10,FDA-14231,4.41,0.98,21.0,26.39,2027-10-07,2028-09-29,2049-09-29,1,Pfizer,11,South Africa,52.5,30,22,43,82,63,75,36,0,3,1,False,False,False,True,True,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine tablets,GenName Y,Drug,hiv,hiv,Phase 2,2023-05-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Treatment-naive, defined as no anti-retrovirals (ARVs) (in combination or monotherapy) received after a known diagnosis of HIV-1 infection.
* Documented HIV infection and Screen...",No,2023-06-10,FDA-93865,4.41,0.98,21.0,26.39,2027-10-07,2028-09-29,2049-09-29,80,GSK,42,South Africa,47.16666666666666,46,56,45,22,50,64,27,0,2,1,False,False,False,True,False,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
GW873140,TradeName X,Drug,hiv,hiv,Phase 3,2007-09-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-infected.
* Screening viral load at least 5000copies/mL.
* R5-tropic only virus at screening.
* Total prior antiretroviral experience of at least 3 months and documented res...",No,2007-12-10,FDA-45706,2.62,0.32,5.0,7.94,2010-04-24,2010-08-19,2015-08-20,56,Sanofi,16,Kenya,35.66666666666666,9,37,46,29,90,3,45,2,2,1,True,True,False,False,False,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
maraviroc,Molecule Z,Drug,hiv,hiv,Phase 3,2010-06-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Subjects must be failing to achieve adequate virologic suppression on their current regimen and have HIV-1 RNA greater than or equal to 1000 copies/ml, at screening
* Have only ...",Yes,2010-10-18,FDA-23366,2.62,0.32,5.0,7.94,2013-01-12,2013-05-09,2018-05-10,49,Bayer,35,Overall,30.66666666666667,15,36,3,86,6,38,45,1,2,2,True,False,True,False,False,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"Nevirapine, FTC, and Tenofovir",GenName Y,Drug,hiv,hiv,Phase 4,2008-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. HIV-1 infection, as documented by any licensed ELISA test kit, and confirmed by Western blot, positive HIV-1 blood culture, positive HIV serum antigen, or plasma viremia at any...",Yes,2008-10-18,FDA-25230,0.56,0.15,3.5,4.21,2009-01-21,2009-03-17,2012-09-15,0,Pfizer,73,Senegal,51.83333333333334,20,38,91,18,53,91,45,1,2,2,True,False,True,False,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine,Molecule Z,Drug,hiv,hiv,Phase 4,2016-03-11,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Between 18 and 65 years of age inclusive, at the time of signing the informed consent.
* Healthy as determined by the investigator or medically qualified designee based on a med...",No,2016-06-18,FDA-46676,0.56,0.15,3.5,4.21,2016-10-01,2016-11-25,2020-05-26,93,Pfizer,26,Kenya,54.0,15,45,86,13,79,86,27,0,1,2,False,False,False,False,False,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Sorbitol,AltName B,Drug,hiv,hiv,Phase 4,2016-03-11,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Between 18 and 65 years of age inclusive, at the time of signing the informed consent.
* Healthy as determined by the investigator or medically qualified designee based on a med...",Yes,2016-08-04,FDA-66111,0.56,0.15,3.5,4.21,2016-10-01,2016-11-25,2020-05-26,55,Pfizer,71,Kenya,57.33333333333334,91,64,57,29,19,84,73,2,4,2,True,True,True,False,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK1349572,Comp Beta,Drug,hiv,hiv,Phase 2,2008-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male or female \>/18 and \</ 65 years of age.
* A female subject is eligible to participate if she is of non-childbearing potential defined as pre-menopausal females with a docu...",No,2009-04-03,FDA-33921,4.41,0.98,21.0,26.39,2012-12-28,2013-12-21,2034-12-21,69,AstraZeneca,19,Overall,59.0,33,79,85,60,40,57,45,2,3,0,True,True,False,True,True,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
FDA Approved Antiretroviral Therapy (see list below),Product Alpha,Drug,hiv,hiv,Phase 3,2012-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV infected- confirmed by ELISA or 2 prior viral loads \>2000
* 18 years or older
* Under consideration to initiate or change their HAART regimens (based on current consensus t...",No,2012-08-08,FDA-64167,2.62,0.32,5.0,7.94,2015-01-13,2015-05-10,2020-05-10,83,GSK,0,Overall,39.33333333333334,8,84,14,35,15,80,64,1,4,2,True,False,True,True,True,False,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DNA plasmid vaccine,AltName B,Biological,hiv,hiv,Phase 2,2017-10-06,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* HIV-1 and -2 negative
* Good general health
* Fully circumcised
* Experienced one or both of the following HIV risk criteria in the 6 months before study entry:

  1. Unprotecte...",No,2018-03-18,FDA-85892,4.41,0.98,21.0,26.39,2022-03-04,2023-02-25,2044-02-25,5,Bayer,55,Senegal,69.16666666666667,90,76,88,17,65,79,55,1,3,2,False,True,False,True,True,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Recombinant adenoviral serotype 5 (rAD5) vector vaccine,Comp Beta,Biological,hiv,hiv,Phase 2,2017-10-06,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* HIV-1 and -2 negative
* Good general health
* Fully circumcised
* Experienced one or both of the following HIV risk criteria in the 6 months before study entry:

  1. Unprotecte...",No,2018-02-10,FDA-26835,4.41,0.98,21.0,26.39,2022-03-04,2023-02-25,2044-02-25,83,J&J,26,South Africa,38.33333333333334,71,13,20,23,35,68,73,2,3,3,True,True,True,True,False,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Buprenorphine/Naloxone,Product Alpha,Drug,hiv,hiv,Phase 3,2012-07-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* HIV-uninfected within 28 days of enrollment
* Meets DSM-IV criteria for opiate dependence
* Positive urine test for opiates
* Injected opiates at least 12 times in the 28 days p...",Yes,2012-08-05,FDA-12318,2.62,0.32,5.0,7.94,2015-02-12,2015-06-09,2020-06-09,92,GSK,93,Overall,58.33333333333334,82,19,35,97,21,96,55,1,3,2,False,True,False,False,True,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,AltName A,Drug,hiv,hiv,Phase 4,2013-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

To qualify for this study, participants will need to have:

1. At least 18 years of age
2. Documented HIV-1 infection
3. CD4+ count \<350 cells/mm3 at the time of enrollment or CD...",Yes,2014-03-17,FDA-47550,0.56,0.15,3.5,4.21,2013-11-21,2014-01-15,2017-07-16,52,Gilead,7,South Africa,62.0,84,75,36,24,92,61,27,1,1,1,True,False,False,False,True,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,Product Alpha,Drug,hiv,hiv,Phase 4,2013-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

To qualify for this study, participants will need to have:

1. At least 18 years of age
2. Documented HIV-1 infection
3. CD4+ count \<350 cells/mm3 at the time of enrollment or CD...",No,2013-06-18,FDA-20262,0.56,0.15,3.5,4.21,2013-11-21,2014-01-15,2017-07-16,37,GSK,76,South Africa,40.83333333333334,91,13,42,73,5,21,73,2,4,2,True,True,True,True,True,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir/emtricitabine,AltName B,Drug,hiv,hiv,Phase 4,2013-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection, documented by (1) any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by ...",No,2014-01-01,FDA-29246,0.56,0.15,3.5,4.21,2013-10-22,2013-12-16,2017-06-16,61,J&J,11,Overall,32.0,11,2,85,31,43,20,55,1,3,2,False,True,False,True,True,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir/emtricitabine/efavirenz,AltName B,Drug,hiv,hiv,Phase 4,2013-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection, documented by (1) any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by ...",No,2013-10-19,FDA-31103,0.56,0.15,3.5,4.21,2013-10-22,2013-12-16,2017-06-16,76,Merck,62,Overall,38.16666666666666,76,2,19,21,99,12,36,0,3,1,False,False,True,True,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,TradeName X,Drug,hiv,hiv,Phase 4,2013-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection, documented by (1) any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by ...",Yes,2013-12-20,FDA-86436,0.56,0.15,3.5,4.21,2013-10-22,2013-12-16,2017-06-16,22,Sanofi,43,South Africa,50.33333333333334,67,23,57,43,90,22,64,1,2,4,True,False,False,False,True,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
acyclovir,TradeName X,Drug,hiv,hiv,Phase 4,2010-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 seropositive
* Not on HIV-1 antiretroviral therapy nor planning to initiate antiretroviral therapy during the study period
* CD4 cell count \>250 cell/µL
* Not otherwise e...",No,2011-11-23,FDA-50697,0.56,0.15,3.5,4.21,2011-06-23,2011-08-17,2015-02-15,82,J&J,3,Kenya,52.5,12,35,99,51,28,90,36,0,2,2,False,False,False,False,True,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
valacyclovir,AltName B,Drug,hiv,hiv,Phase 4,2010-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 seropositive
* Not on HIV-1 antiretroviral therapy nor planning to initiate antiretroviral therapy during the study period
* CD4 cell count \>250 cell/µL
* Not otherwise e...",No,2011-09-28,FDA-88152,0.56,0.15,3.5,4.21,2011-06-23,2011-08-17,2015-02-15,85,Bayer,62,Overall,50.0,79,31,16,97,22,55,45,2,1,2,True,True,False,False,True,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir 50mg od,Comp Beta,Drug,hiv,hiv,Phase 3,2018-12-06,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Able to provide informed consent
* Willing to participate,
* Women age 18 years and above
* Pregnant
* Untreated HIV infection in late pregnancy at ≥28 - 36 weeks gestation

Exc...",No,2019-11-12,FDA-83151,2.62,0.32,5.0,7.94,2021-07-19,2021-11-13,2026-11-14,36,Bayer,17,Overall,56.16666666666666,58,75,92,21,66,25,55,0,2,4,False,False,False,True,False,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Standard of Care,GenName Y,Drug,hiv,hiv,Phase 3,2018-12-06,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Able to provide informed consent
* Willing to participate,
* Women age 18 years and above
* Pregnant
* Untreated HIV infection in late pregnancy at ≥28 - 36 weeks gestation

Exc...",Yes,2019-03-11,FDA-42203,2.62,0.32,5.0,7.94,2021-07-19,2021-11-13,2026-11-14,5,J&J,71,Senegal,35.0,12,29,87,25,55,2,55,1,2,3,True,False,False,False,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Oral Cabotegravir (CAB),GenName Y,Drug,hiv,hiv,Phase 2,2025-04-22,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria: Cohort 1 Step 1, Cohort 2 Step 3, and Cohort 2 Step 5

All the following criteria must be met for inclusion of any adolescent participant in Step 1 of Cohort 1, or in Step 3 of Coh...",No,2025-12-11,FDA-74985,4.41,0.98,21.0,26.39,2029-09-18,2030-09-11,2051-09-11,99,Novartis,82,Kenya,35.83333333333334,44,30,27,69,12,33,64,2,3,2,True,True,False,True,False,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Oral Rilpivirine (RPV),GenName Y,Drug,hiv,hiv,Phase 2,2025-04-22,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria: Cohort 1 Step 1, Cohort 2 Step 3, and Cohort 2 Step 5

All the following criteria must be met for inclusion of any adolescent participant in Step 1 of Cohort 1, or in Step 3 of Coh...",No,2025-08-11,FDA-38092,4.41,0.98,21.0,26.39,2029-09-18,2030-09-11,2051-09-11,34,Sanofi,19,Overall,55.66666666666666,40,30,63,64,78,59,55,2,2,2,True,True,False,False,False,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Long-Acting Injectable Cabotegravir (CAB LA),TradeName X,Drug,hiv,hiv,Phase 2,2025-04-22,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria: Cohort 1 Step 1, Cohort 2 Step 3, and Cohort 2 Step 5

All the following criteria must be met for inclusion of any adolescent participant in Step 1 of Cohort 1, or in Step 3 of Coh...",Yes,2025-06-26,FDA-42861,4.41,0.98,21.0,26.39,2029-09-18,2030-09-11,2051-09-11,84,Pfizer,68,South Africa,52.66666666666666,33,44,76,81,36,46,45,0,3,2,False,False,True,False,True,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Long-Acting Injectable Rilpivirine (RPV LA),TradeName X,Drug,hiv,hiv,Phase 2,2025-04-22,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria: Cohort 1 Step 1, Cohort 2 Step 3, and Cohort 2 Step 5

All the following criteria must be met for inclusion of any adolescent participant in Step 1 of Cohort 1, or in Step 3 of Coh...",Yes,2026-03-10,FDA-49112,4.41,0.98,21.0,26.39,2029-09-18,2030-09-11,2051-09-11,92,Sanofi,75,Overall,58.16666666666666,26,72,75,63,90,23,36,1,1,2,True,False,False,False,False,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Combination Antiretroviral Therapy (cART),TradeName X,Drug,hiv,hiv,Phase 2,2025-04-22,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria: Cohort 1 Step 1, Cohort 2 Step 3, and Cohort 2 Step 5

All the following criteria must be met for inclusion of any adolescent participant in Step 1 of Cohort 1, or in Step 3 of Coh...",Yes,2025-09-17,FDA-93537,4.41,0.98,21.0,26.39,2029-09-18,2030-09-11,2051-09-11,74,Novartis,74,Overall,45.16666666666666,82,24,23,22,24,96,45,0,2,3,False,False,True,True,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ad26.ZEBOV,Comp Beta,Biological,hiv,hiv,Phase 2,2019-02-12,"Sex: ALL; Age: >4 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

Criteria for healthy adults and elderly participants:

* Participant must be healthy in the investigator's clinical judgment on the basis of clinical laboratory tests, medical his...",Yes,2019-04-26,FDA-87783,4.41,0.98,21.0,26.39,2023-07-11,2024-07-03,2045-07-03,16,AstraZeneca,69,Senegal,34.0,69,5,37,10,79,4,55,1,3,2,True,False,False,True,True,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
MVA-BN-Filo,AltName A,Biological,hiv,hiv,Phase 2,2019-02-12,"Sex: ALL; Age: >4 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

Criteria for healthy adults and elderly participants:

* Participant must be healthy in the investigator's clinical judgment on the basis of clinical laboratory tests, medical his...",No,2019-09-16,FDA-94210,4.41,0.98,21.0,26.39,2023-07-11,2024-07-03,2045-07-03,25,Novartis,41,Overall,37.83333333333334,23,41,26,47,37,53,45,0,4,1,False,False,True,True,False,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs),Product Alpha,Drug,hiv,hiv,Phase 3,2008-07-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria

* Subjects were human immunodeficiency virus type 1 (HIV-1) positive, antiretroviral naïve adults at least 18 years of age with \< 7 days of prior antiretroviral therapy.
* Subject...",Yes,2009-03-08,FDA-83967,2.62,0.32,5.0,7.94,2011-02-12,2011-06-09,2016-06-09,55,Merck,6,Kenya,59.66666666666666,27,53,87,10,86,95,64,0,4,3,False,False,True,True,True,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs),Molecule Z,Drug,hiv,hiv,Phase 3,2008-07-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria

* Subjects were human immunodeficiency virus type 1 (HIV-1) positive, antiretroviral naïve adults at least 18 years of age with \< 7 days of prior antiretroviral therapy.
* Subject...",No,2008-10-20,FDA-33600,2.62,0.32,5.0,7.94,2011-02-12,2011-06-09,2016-06-09,87,Bayer,88,Kenya,65.0,32,51,99,78,71,59,55,2,2,2,True,True,True,False,False,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs),Molecule Z,Drug,hiv,hiv,Phase 3,2008-07-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria

* Subjects were human immunodeficiency virus type 1 (HIV-1) positive, antiretroviral naïve adults at least 18 years of age with \< 7 days of prior antiretroviral therapy.
* Subject...",Yes,2008-09-09,FDA-87311,2.62,0.32,5.0,7.94,2011-02-12,2011-06-09,2016-06-09,86,GSK,77,Senegal,33.33333333333334,34,9,10,73,67,7,45,2,2,1,True,True,False,True,False,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs),AltName A,Drug,hiv,hiv,Phase 3,2008-07-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria

* Subjects were human immunodeficiency virus type 1 (HIV-1) positive, antiretroviral naïve adults at least 18 years of age with \< 7 days of prior antiretroviral therapy.
* Subject...",No,2009-05-06,FDA-41786,2.62,0.32,5.0,7.94,2011-02-12,2011-06-09,2016-06-09,99,Merck,96,Overall,51.33333333333334,39,24,59,65,58,63,64,1,5,1,False,True,True,True,True,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
LPV/r,TradeName X,Drug,hiv,hiv,Phase 4,2007-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Age greater or equal to 18 years
* Diagnosis of HIV infection as previously established by HIV Enzyme-Linked Immunosorbent Assay (ELISA) test and confirmed by Western blot analy...",Yes,2007-06-13,FDA-84590,0.56,0.15,3.5,4.21,2007-07-24,2007-09-17,2011-03-18,87,Bayer,7,Overall,48.16666666666666,81,42,13,24,43,86,64,2,3,2,True,True,False,True,True,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,TradeName X,Drug,hiv,hiv,Phase 4,2014-04-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. HIV-1 infection
2. All available CD4+ T cell counts within the last 12 months of screening below 350 cells/mm3 (minimum of 3 values obtained \> 30 days apart).
3. HIV treatment...",Yes,2014-08-30,FDA-93262,0.56,0.15,3.5,4.21,2014-11-01,2014-12-26,2018-06-26,27,Novartis,61,Senegal,60.66666666666666,53,68,96,39,32,76,64,2,3,2,True,True,False,True,True,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ganciclovir,Comp Beta,Drug,hiv,hiv,Phase 3,1995-03-01,Sex: ALL; Age: >18 Years; Criteria: inclusion criteria: Males and females eligible for the CRRT must have been age 18 years or older and have had AIDS and CMV retinitis. They must have had active CMV despite a minimum of 28 days of prev...,Yes,1995-08-25,FDA-97734,2.62,0.32,5.0,7.94,1997-10-12,1998-02-06,2003-02-07,82,J&J,29,Senegal,31.0,59,13,19,73,1,21,45,0,4,1,False,False,True,True,True,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Foscarnet,TradeName X,Drug,hiv,hiv,Phase 3,1995-03-01,Sex: ALL; Age: >18 Years; Criteria: inclusion criteria: Males and females eligible for the CRRT must have been age 18 years or older and have had AIDS and CMV retinitis. They must have had active CMV despite a minimum of 28 days of prev...,Yes,1995-05-18,FDA-88069,2.62,0.32,5.0,7.94,1997-10-12,1998-02-06,2003-02-07,15,Merck,16,Kenya,40.5,70,29,75,17,18,34,45,1,4,0,False,True,True,False,True,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Quadrivalent HPV Vaccine,Product Alpha,Biological,hiv,hiv,Phase 3,2016-01-01,"Sex: ALL; Age: >27 Years; Criteria: Inclusion Criteria:

* HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a li...",Yes,2016-02-14,FDA-91032,2.62,0.32,5.0,7.94,2018-08-14,2018-12-09,2023-12-10,65,Pfizer,67,Senegal,61.66666666666666,62,34,35,73,67,99,27,1,0,2,False,True,False,False,False,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose),AltName B,Biological,hiv,hiv,Phase 2,2009-09-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Healthy, HIV seronegative adults at high risk of acquiring HIV infection
* Cannot have previously received an investigational vaccine

Exclusion Criteria:

* In a monogamous rel...",No,2010-01-28,FDA-76010,4.41,0.98,21.0,26.39,2014-01-28,2015-01-21,2036-01-21,1,Sanofi,56,South Africa,29.16666666666667,18,19,12,61,15,50,45,2,1,2,True,True,False,False,False,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir (MK-0518),GenName Y,Drug,hiv,hiv,Phase 2,2017-07-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male, or non-pregnant, non-breastfeeding female
* No previous history of virological failure
* No previous exposure to non-nucleoside reverse transcriptase inhibitors or integra...",Yes,2017-09-13,FDA-15390,4.41,0.98,21.0,26.39,2021-12-06,2022-11-29,2043-11-29,20,GSK,89,Kenya,61.83333333333334,35,95,41,20,95,85,36,1,2,1,True,False,True,False,False,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Nevirapine,Product Alpha,Drug,hiv,hiv,Phase 2,2017-07-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male, or non-pregnant, non-breastfeeding female
* No previous history of virological failure
* No previous exposure to non-nucleoside reverse transcriptase inhibitors or integra...",Yes,2018-03-17,FDA-69218,4.41,0.98,21.0,26.39,2021-12-06,2022-11-29,2043-11-29,49,AstraZeneca,33,Overall,54.0,0,82,86,5,70,81,36,1,1,2,True,False,False,True,False,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine,Molecule Z,Drug,hiv,hiv,Phase 2,2017-07-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male, or non-pregnant, non-breastfeeding female
* No previous history of virological failure
* No previous exposure to non-nucleoside reverse transcriptase inhibitors or integra...",Yes,2017-10-09,FDA-42630,4.41,0.98,21.0,26.39,2021-12-06,2022-11-29,2043-11-29,89,J&J,44,Overall,58.5,42,28,40,67,90,84,36,1,0,3,True,False,False,False,False,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir,Product Alpha,Drug,hiv,hiv,Phase 2,2017-07-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male, or non-pregnant, non-breastfeeding female
* No previous history of virological failure
* No previous exposure to non-nucleoside reverse transcriptase inhibitors or integra...",No,2017-08-31,FDA-48965,4.41,0.98,21.0,26.39,2021-12-06,2022-11-29,2043-11-29,51,Bayer,43,Kenya,75.66666666666667,97,70,80,95,52,60,45,1,2,2,True,False,False,False,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine,AltName A,Drug,hiv,hiv,Phase 2,2017-07-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male, or non-pregnant, non-breastfeeding female
* No previous history of virological failure
* No previous exposure to non-nucleoside reverse transcriptase inhibitors or integra...",No,2017-10-19,FDA-71176,4.41,0.98,21.0,26.39,2021-12-06,2022-11-29,2043-11-29,91,J&J,82,Senegal,54.66666666666666,70,49,7,95,37,70,27,0,2,1,False,False,False,True,False,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir,GenName Y,Drug,hiv,hiv,Phase 2,2017-07-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male, or non-pregnant, non-breastfeeding female
* No previous history of virological failure
* No previous exposure to non-nucleoside reverse transcriptase inhibitors or integra...",Yes,2017-10-25,FDA-92490,4.41,0.98,21.0,26.39,2021-12-06,2022-11-29,2043-11-29,31,Pfizer,75,Senegal,56.83333333333334,51,82,98,35,1,74,36,0,1,3,False,False,True,False,False,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,TradeName X,Drug,hiv,hiv,Phase 2,2017-07-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male, or non-pregnant, non-breastfeeding female
* No previous history of virological failure
* No previous exposure to non-nucleoside reverse transcriptase inhibitors or integra...",Yes,2018-05-05,FDA-63304,4.41,0.98,21.0,26.39,2021-12-06,2022-11-29,2043-11-29,45,Sanofi,77,South Africa,51.33333333333334,9,86,31,26,94,62,73,2,3,3,True,True,True,False,True,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir,AltName A,Drug,hiv,hiv,Phase 2,2017-07-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male, or non-pregnant, non-breastfeeding female
* No previous history of virological failure
* No previous exposure to non-nucleoside reverse transcriptase inhibitors or integra...",Yes,2017-11-29,FDA-21660,4.41,0.98,21.0,26.39,2021-12-06,2022-11-29,2043-11-29,11,Pfizer,67,Overall,61.16666666666666,57,98,71,27,69,45,55,1,3,2,False,True,True,True,False,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Darunavir,AltName A,Drug,hiv,hiv,Phase 2,2017-07-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male, or non-pregnant, non-breastfeeding female
* No previous history of virological failure
* No previous exposure to non-nucleoside reverse transcriptase inhibitors or integra...",Yes,2018-04-13,FDA-85124,4.41,0.98,21.0,26.39,2021-12-06,2022-11-29,2043-11-29,3,Pfizer,48,South Africa,35.0,65,50,25,18,25,27,45,2,2,1,True,True,True,True,False,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK2248761,AltName B,Drug,hiv,hiv,Phase 2,2009-11-28,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* Male or Female, 21 to 65 years of age.
* Female of non-childbearing potential defined as: being post-menopausal, defined as 12 months of spontaneous amenorrhea and having a seru...",Yes,2010-11-28,FDA-30141,4.41,0.98,21.0,26.39,2014-04-26,2015-04-19,2036-04-18,86,Gilead,89,Senegal,38.33333333333334,3,99,27,30,57,14,55,1,4,1,True,False,True,True,True,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir/ritonavir,Comp Beta,Drug,hiv,hiv,Phase 2,2009-11-28,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* Male or Female, 21 to 65 years of age.
* Female of non-childbearing potential defined as: being post-menopausal, defined as 12 months of spontaneous amenorrhea and having a seru...",No,2010-08-05,FDA-87065,4.41,0.98,21.0,26.39,2014-04-26,2015-04-19,2036-04-18,63,GSK,100,Senegal,41.33333333333334,31,45,74,55,21,22,55,1,4,1,False,True,True,True,False,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
HAART,TradeName X,Drug,hiv,hiv,Phase 2,2009-11-28,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* Male or Female, 21 to 65 years of age.
* Female of non-childbearing potential defined as: being post-menopausal, defined as 12 months of spontaneous amenorrhea and having a seru...",Yes,2010-04-20,FDA-68565,4.41,0.98,21.0,26.39,2014-04-26,2015-04-19,2036-04-18,42,AstraZeneca,23,Overall,52.83333333333334,13,77,49,96,66,16,36,1,2,1,True,False,True,True,False,False,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK2248761,Comp Beta,Drug,hiv,hiv,Phase 2,2009-11-28,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* Male or Female, 21 to 65 years of age.
* Female of non-childbearing potential defined as: being post-menopausal, defined as 12 months of spontaneous amenorrhea and having a seru...",Yes,2010-01-15,FDA-32212,4.41,0.98,21.0,26.39,2014-04-26,2015-04-19,2036-04-18,84,Novartis,82,Senegal,54.16666666666666,73,84,48,54,32,34,36,0,1,3,False,False,True,False,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Cabotegravir - Injectable Suspension (CAB LA),Molecule Z,Drug,hiv,hiv,Phase 3,2023-09-14,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Capable of giving signed informed consent (FLAIR and Sub-study specific informed consent)
* Eligible participants must have been on CAB LA + RPV LA regimen for a minimum of 12 m...",No,2024-02-16,FDA-92809,2.62,0.32,5.0,7.94,2026-04-27,2026-08-22,2031-08-23,26,Pfizer,76,Kenya,53.33333333333334,26,71,26,89,96,12,36,1,2,1,False,True,False,False,False,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rilpivirine - Injectable Suspension (RPV LA),AltName B,Drug,hiv,hiv,Phase 3,2023-09-14,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Capable of giving signed informed consent (FLAIR and Sub-study specific informed consent)
* Eligible participants must have been on CAB LA + RPV LA regimen for a minimum of 12 m...",No,2024-09-07,FDA-50023,2.62,0.32,5.0,7.94,2026-04-27,2026-08-22,2031-08-23,53,Sanofi,5,Kenya,65.33333333333333,5,73,93,90,94,37,45,0,3,2,False,False,True,False,True,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DTG + 3TC FDC,Molecule Z,Drug,hiv,hiv,Phase 3,2024-09-30,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria:

* HIV-1 infected adolescents \>=12 to \<18 years of age at the time of signing the informed consent form.
* Weight \>=25 kg at the time of signing the informed consent form.
* Scr...",Yes,2024-12-28,FDA-11412,2.62,0.32,5.0,7.94,2027-05-14,2027-09-08,2032-09-08,85,Bayer,4,Senegal,48.83333333333334,67,32,90,12,74,18,73,1,4,3,True,False,True,True,True,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir (DTG),TradeName X,Drug,hiv,hiv,Phase 4,2021-01-05,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection, documented by:

  * a licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by ...",No,2021-07-16,FDA-10416,0.56,0.15,3.5,4.21,2021-07-28,2021-09-21,2025-03-22,48,GSK,58,Kenya,29.33333333333333,52,5,1,38,1,79,64,2,3,2,True,True,False,True,True,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc (MVC),Comp Beta,Drug,hiv,hiv,Phase 4,2021-01-05,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection, documented by:

  * a licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by ...",No,2021-06-06,FDA-85777,0.56,0.15,3.5,4.21,2021-07-28,2021-09-21,2025-03-22,44,Merck,3,Senegal,50.66666666666666,42,19,92,89,21,41,64,2,3,2,True,True,True,True,True,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
VH4524184,AltName B,Drug,hiv,hiv,Phase 2,2024-06-12,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participant must be 18 to 65 years of age inclusive at the time of signing the informed consent.
* Participants who are overtly healthy (other than HIV infection) as determined ...",No,2024-10-29,FDA-11724,4.41,0.98,21.0,26.39,2028-11-08,2029-11-01,2050-11-01,94,Merck,64,Kenya,54.33333333333334,34,57,86,68,39,42,64,1,3,3,False,True,False,True,False,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Antiretroviral therapy,Comp Beta,Drug,hiv,hiv,Phase 2,2024-06-12,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participant must be 18 to 65 years of age inclusive at the time of signing the informed consent.
* Participants who are overtly healthy (other than HIV infection) as determined ...",No,2025-01-19,FDA-59029,4.41,0.98,21.0,26.39,2028-11-08,2029-11-01,2050-11-01,1,AstraZeneca,73,Senegal,63.33333333333334,85,35,41,86,50,83,64,1,3,3,True,False,True,True,False,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir,AltName A,Drug,hiv,hiv,Phase 3,2013-01-22,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

\- Signed Written Informed Consent.

i) Freely given informed consent must be obtained from subjects prior to clinical trial participation, including informed consent for any scree...",No,2013-04-25,FDA-75596,2.62,0.32,5.0,7.94,2015-09-05,2015-12-31,2020-12-31,27,Pfizer,50,Senegal,62.5,55,71,56,67,88,38,55,1,3,2,True,False,False,True,True,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,TradeName X,Drug,hiv,hiv,Phase 3,2013-01-22,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

\- Signed Written Informed Consent.

i) Freely given informed consent must be obtained from subjects prior to clinical trial participation, including informed consent for any scree...",Yes,2013-05-23,FDA-74051,2.62,0.32,5.0,7.94,2015-09-05,2015-12-31,2020-12-31,27,J&J,12,South Africa,57.5,76,30,80,94,60,5,27,0,1,2,False,False,False,True,False,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine,AltName A,Drug,hiv,hiv,Phase 3,2013-01-22,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

\- Signed Written Informed Consent.

i) Freely given informed consent must be obtained from subjects prior to clinical trial participation, including informed consent for any scree...",Yes,2014-01-09,FDA-13561,2.62,0.32,5.0,7.94,2015-09-05,2015-12-31,2020-12-31,61,Sanofi,54,Senegal,21.16666666666667,34,32,4,17,22,18,64,2,4,1,True,True,True,False,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir/Emtricitabine,Molecule Z,Drug,hiv,hiv,Phase 3,2013-01-22,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

\- Signed Written Informed Consent.

i) Freely given informed consent must be obtained from subjects prior to clinical trial participation, including informed consent for any scree...",Yes,2013-12-09,FDA-80113,2.62,0.32,5.0,7.94,2015-09-05,2015-12-31,2020-12-31,13,Bayer,65,Senegal,45.5,30,70,100,67,1,5,64,1,5,1,True,False,True,True,True,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Duloxetine,TradeName X,Drug,hiv,hiv,Phase 2,2010-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV infected
* HIV-associated neuropathy
* Able and willing to provide informed consent
* Successful completion of a daily baseline pain diary over 1 week immediately prior to e...",Yes,2011-03-30,FDA-13485,4.41,0.98,21.0,26.39,2015-04-29,2016-04-21,2037-04-21,34,Merck,75,Overall,52.0,16,50,35,38,87,86,64,0,4,3,False,False,True,True,True,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Methadone,Comp Beta,Drug,hiv,hiv,Phase 2,2010-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV infected
* HIV-associated neuropathy
* Able and willing to provide informed consent
* Successful completion of a daily baseline pain diary over 1 week immediately prior to e...",Yes,2011-06-19,FDA-31570,4.41,0.98,21.0,26.39,2015-04-29,2016-04-21,2037-04-21,99,Gilead,99,Senegal,41.16666666666666,6,78,28,45,59,31,36,0,2,2,False,False,False,False,False,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Interleukin 2,AltName B,Drug,hiv,hiv,Phase 2,2007-12-01,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

Age greater than or equal to 18 years.

HIV-1 infection confirmed by ELISA and Western Blot before screening.

Category A or B HIV-1 infection.

Antiretroviral treatment:

* sta...",Yes,2008-08-21,FDA-89483,4.41,0.98,21.0,26.39,2012-04-28,2013-04-21,2034-04-21,44,Merck,31,Kenya,46.66666666666666,72,63,31,4,57,53,45,0,4,1,False,False,True,True,False,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
HAART,Product Alpha,Drug,hiv,hiv,Phase 2,2007-12-01,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

Age greater than or equal to 18 years.

HIV-1 infection confirmed by ELISA and Western Blot before screening.

Category A or B HIV-1 infection.

Antiretroviral treatment:

* sta...",Yes,2008-03-16,FDA-96569,4.41,0.98,21.0,26.39,2012-04-28,2013-04-21,2034-04-21,61,Gilead,31,Kenya,48.66666666666666,2,66,71,64,30,59,27,2,1,0,True,True,False,False,True,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Treatment interruption,GenName Y,Drug,hiv,hiv,Phase 2,2007-12-01,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

Age greater than or equal to 18 years.

HIV-1 infection confirmed by ELISA and Western Blot before screening.

Category A or B HIV-1 infection.

Antiretroviral treatment:

* sta...",Yes,2008-05-23,FDA-31503,4.41,0.98,21.0,26.39,2012-04-28,2013-04-21,2034-04-21,39,Bayer,44,Overall,59.0,21,89,60,90,20,74,55,0,4,2,False,False,True,False,True,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir / ritonavir,Product Alpha,Drug,hiv,hiv,Phase 4,2013-08-01,"Sex: ALL; Age: >16 Years; Criteria: Second-Line main study identifier: NCT00931463

Inclusion Criteria:

1. HIV-1 positive by licensed diagnostic test
2. Aged 16 years or older (or minimum age as determined by local regulations or as le...",Yes,2013-11-08,FDA-84830,0.56,0.15,3.5,4.21,2014-02-21,2014-04-17,2017-10-16,35,Novartis,84,Overall,45.16666666666666,17,45,8,75,30,96,55,0,3,3,False,False,True,True,True,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
2-3N(t)RTI,Product Alpha,Drug,hiv,hiv,Phase 4,2013-08-01,"Sex: ALL; Age: >16 Years; Criteria: Second-Line main study identifier: NCT00931463

Inclusion Criteria:

1. HIV-1 positive by licensed diagnostic test
2. Aged 16 years or older (or minimum age as determined by local regulations or as le...",No,2014-05-13,FDA-48416,0.56,0.15,3.5,4.21,2014-02-21,2014-04-17,2017-10-16,2,GSK,82,South Africa,44.33333333333334,50,99,0,16,23,78,36,0,2,2,False,False,False,True,False,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
raltegravir,Product Alpha,Drug,hiv,hiv,Phase 4,2013-08-01,"Sex: ALL; Age: >16 Years; Criteria: Second-Line main study identifier: NCT00931463

Inclusion Criteria:

1. HIV-1 positive by licensed diagnostic test
2. Aged 16 years or older (or minimum age as determined by local regulations or as le...",Yes,2014-01-04,FDA-63887,0.56,0.15,3.5,4.21,2014-02-21,2014-04-17,2017-10-16,72,Bayer,14,Kenya,23.16666666666667,35,18,45,9,27,5,45,2,1,2,True,True,False,False,False,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
co-formulated 25mg TAF/ 200mg FTC,Molecule Z,Drug,hiv,hiv,Phase 3,2023-12-19,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Age ≥18 and ≤30 years old
* Willing to undergo urine pregnancy tests
* Has understood the information provided and has provided written informed consent before any study-related...",Yes,2024-02-17,FDA-10874,2.62,0.32,5.0,7.94,2026-08-01,2026-11-26,2031-11-27,45,Gilead,5,Senegal,48.16666666666666,17,64,54,78,15,61,73,2,4,2,True,True,True,False,True,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ABC/DTG/3TC FDC,GenName Y,Drug,hiv,hiv,Phase 3,2015-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Be able to understand and comply with protocol requirements, instructions, and restrictions;
* Be likely to complete the study as planned;
* Be considered appropriate candidates...",Yes,2016-02-08,FDA-26089,2.62,0.32,5.0,7.94,2018-07-14,2018-11-08,2023-11-09,71,Bayer,97,Overall,57.66666666666666,40,3,58,91,69,85,64,1,5,1,False,True,True,True,True,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ongoing cART regimen,Comp Beta,Drug,hiv,hiv,Phase 3,2015-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Be able to understand and comply with protocol requirements, instructions, and restrictions;
* Be likely to complete the study as planned;
* Be considered appropriate candidates...",Yes,2016-04-01,FDA-47218,2.62,0.32,5.0,7.94,2018-07-14,2018-11-08,2023-11-09,95,Pfizer,56,Senegal,51.0,17,42,60,56,67,64,27,1,2,0,False,True,True,False,True,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rillus®,AltName B,Drug,hiv,hiv,Phase 2,2018-12-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV patient with immunological non-responder status which defined as:
* first line antiretroviral therapy (ART) treated for minimal 6 months
* CD4+ level between 200-410 cell/μL...",No,2019-03-23,FDA-68882,4.41,0.98,21.0,26.39,2023-05-25,2024-05-17,2045-05-17,4,Novartis,49,Kenya,49.5,21,39,50,99,15,73,55,2,1,3,True,True,False,False,True,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Escitalopram,TradeName X,Drug,hiv,hiv,Phase 4,2022-03-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Men and women aged 18-70 years, of any race and ethnicity,
2. HIV-seropositive by ELISA and Western Blot assays, infected by behavioral transmission (perinatal HIV excluded),
3...",No,2022-07-31,FDA-13319,0.56,0.15,3.5,4.21,2022-10-21,2022-12-15,2026-06-15,18,Gilead,6,South Africa,58.16666666666666,16,96,94,48,66,29,82,1,4,4,True,False,False,True,True,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
tipranavir,Comp Beta,Drug,hiv,hiv,Phase 3,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Main inclusion criteria for the study are:

1. HIV-1 infected adults, men and women at least 18 years of age.
2. 3-class (nucleoside reverse transcriptase inhibitor (NRTI), non-nu...",No,2026-05-23,FDA-89365,2.62,0.32,5.0,7.94,,,,59,GSK,28,South Africa,59.16666666666666,43,37,66,37,75,97,55,0,3,3,False,False,True,False,True,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ritonavir,TradeName X,Drug,hiv,hiv,Phase 3,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Main inclusion criteria for the study are:

1. HIV-1 infected adults, men and women at least 18 years of age.
2. 3-class (nucleoside reverse transcriptase inhibitor (NRTI), non-nu...",No,2026-10-06,FDA-35008,2.62,0.32,5.0,7.94,,,,13,J&J,92,South Africa,44.5,76,31,60,4,32,64,55,2,2,2,True,True,True,False,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Optimized Background Regimen (OBR),AltName B,Drug,hiv,hiv,Phase 3,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Main inclusion criteria for the study are:

1. HIV-1 infected adults, men and women at least 18 years of age.
2. 3-class (nucleoside reverse transcriptase inhibitor (NRTI), non-nu...",Yes,2026-02-23,FDA-64874,2.62,0.32,5.0,7.94,,,,79,J&J,60,Senegal,34.0,86,28,10,5,5,70,91,1,5,4,True,False,True,True,True,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir powder,TradeName X,Drug,hiv,hiv,Phase 3,2017-09-11,"Sex: ALL; Age: >3 Months; Criteria: Key Inclusion Criteria:

* Confirmed human immunodeficiency virus (HIV)-1 infection diagnosed by a positive virologic test result on 2 separate occasions by:

  * HIV DNA polymerase chain reaction
  *...",Yes,2018-07-07,FDA-68578,2.62,0.32,5.0,7.94,2020-04-24,2020-08-19,2025-08-20,43,GSK,23,Kenya,69.83333333333333,84,98,60,76,94,7,45,2,0,3,True,True,False,False,False,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir oral solution,Product Alpha,Drug,hiv,hiv,Phase 3,2017-09-11,"Sex: ALL; Age: >3 Months; Criteria: Key Inclusion Criteria:

* Confirmed human immunodeficiency virus (HIV)-1 infection diagnosed by a positive virologic test result on 2 separate occasions by:

  * HIV DNA polymerase chain reaction
  *...",Yes,2017-11-15,FDA-79619,2.62,0.32,5.0,7.94,2020-04-24,2020-08-19,2025-08-20,25,AstraZeneca,99,South Africa,63.83333333333334,96,56,65,59,99,8,73,1,4,3,False,True,True,True,True,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir capsules,GenName Y,Drug,hiv,hiv,Phase 3,2017-09-11,"Sex: ALL; Age: >3 Months; Criteria: Key Inclusion Criteria:

* Confirmed human immunodeficiency virus (HIV)-1 infection diagnosed by a positive virologic test result on 2 separate occasions by:

  * HIV DNA polymerase chain reaction
  *...",No,2018-05-19,FDA-19399,2.62,0.32,5.0,7.94,2020-04-24,2020-08-19,2025-08-20,25,Gilead,63,South Africa,61.0,84,71,96,83,6,26,73,1,3,4,False,True,True,False,False,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir capsules,TradeName X,Drug,hiv,hiv,Phase 3,2017-09-11,"Sex: ALL; Age: >3 Months; Criteria: Key Inclusion Criteria:

* Confirmed human immunodeficiency virus (HIV)-1 infection diagnosed by a positive virologic test result on 2 separate occasions by:

  * HIV DNA polymerase chain reaction
  *...",No,2017-12-24,FDA-41740,2.62,0.32,5.0,7.94,2020-04-24,2020-08-19,2025-08-20,2,Sanofi,82,Senegal,63.83333333333334,25,89,64,45,91,69,64,0,4,3,False,False,True,True,True,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"Naltrexone, 50mg, once per day for 4 months",Molecule Z,Drug,hiv,hiv,Phase 2,2012-10-01,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Hazardous drinking: defined by the NIAAA as either of the following:

  1. binge drinking (4 or more drinks per occasion at least twice monthly), (NIAAA 2005) - OR
  2. high qua...",No,2013-09-12,FDA-74455,4.41,0.98,21.0,26.39,2017-02-27,2018-02-20,2039-02-20,26,GSK,56,Kenya,57.5,7,74,58,93,77,36,55,1,2,3,False,True,True,False,True,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Zidovudine,Molecule Z,Drug,hiv,hiv,Phase 3,2011-02-01,"Sex: ALL; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

Infants who meet all of the following criteria are eligible for the study:

* Mother known to be HIV-1-infected prior to labor or identified at the time of labor or \<48 hours pos...",Yes,2011-07-16,FDA-67592,2.62,0.32,5.0,7.94,2013-09-14,2014-01-09,2019-01-10,40,Bayer,97,Overall,19.5,60,2,3,23,3,26,55,2,3,1,True,True,True,False,False,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Nevirapine (NVP),Comp Beta,Drug,hiv,hiv,Phase 3,2011-02-01,"Sex: ALL; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

Infants who meet all of the following criteria are eligible for the study:

* Mother known to be HIV-1-infected prior to labor or identified at the time of labor or \<48 hours pos...",No,2011-11-26,FDA-89637,2.62,0.32,5.0,7.94,2013-09-14,2014-01-09,2019-01-10,21,Sanofi,31,Senegal,44.16666666666666,58,35,20,91,50,11,55,1,2,3,False,True,True,True,False,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Epivir (3TC),TradeName X,Drug,hiv,hiv,Phase 3,2011-02-01,"Sex: ALL; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

Infants who meet all of the following criteria are eligible for the study:

* Mother known to be HIV-1-infected prior to labor or identified at the time of labor or \<48 hours pos...",Yes,2011-05-28,FDA-66586,2.62,0.32,5.0,7.94,2013-09-14,2014-01-09,2019-01-10,49,J&J,26,South Africa,48.66666666666666,72,35,11,87,85,2,64,1,4,2,True,False,True,False,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Nelfinavir (NFV),GenName Y,Drug,hiv,hiv,Phase 3,2011-02-01,"Sex: ALL; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

Infants who meet all of the following criteria are eligible for the study:

* Mother known to be HIV-1-infected prior to labor or identified at the time of labor or \<48 hours pos...",No,2011-05-26,FDA-65392,2.62,0.32,5.0,7.94,2013-09-14,2014-01-09,2019-01-10,81,Pfizer,84,Senegal,42.83333333333334,23,66,18,47,10,93,45,2,1,2,True,True,False,False,False,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Herpes Zoster Vaccine GSK1437173A,Comp Beta,Biological,hiv,hiv,Phase 2,2013-05-14,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that they can and will comply with the requirements of the protocol;
* Male and female subjects at least 18 years old at the time of vacci...",Yes,2013-11-06,FDA-17020,4.41,0.98,21.0,26.39,2017-10-10,2018-10-03,2039-10-03,74,Novartis,33,Senegal,70.66666666666667,93,91,43,37,99,61,45,0,3,2,False,False,True,True,False,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
fosamprenavir (GW433908),TradeName X,Drug,hiv,hiv,Phase 3,2010-10-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* Male or non-pregnant/non-lactating females \>/=13 years of age (or \>/= 18 years of age according to local requirements).
* Received fosamprenavir through prior participation in...",Yes,2010-11-22,FDA-68936,2.62,0.32,5.0,7.94,2013-05-14,2013-09-08,2018-09-09,88,Gilead,66,South Africa,74.66666666666667,78,87,98,86,44,55,55,2,2,2,True,True,False,True,False,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ritonavir,Product Alpha,Drug,hiv,hiv,Phase 3,2010-10-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* Male or non-pregnant/non-lactating females \>/=13 years of age (or \>/= 18 years of age according to local requirements).
* Received fosamprenavir through prior participation in...",Yes,2011-03-05,FDA-85093,2.62,0.32,5.0,7.94,2013-05-14,2013-09-08,2018-09-09,10,Merck,51,South Africa,34.0,53,29,70,25,27,0,55,2,1,3,True,True,True,False,False,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
BCNU,AltName B,Drug,hiv,hiv,Phase 2,2016-06-01,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

* Diagnosis of persistent or recurrent World Health Organization (WHO) classification diffuse large B-cell lymphoma, composite lymphoma with \> 50% diffuse large B-cell lymphoma, ...",No,2017-03-28,FDA-97539,4.41,0.98,21.0,26.39,2020-10-28,2021-10-21,2042-10-21,0,AstraZeneca,88,Senegal,56.33333333333334,65,37,52,12,72,100,82,1,4,4,True,False,True,True,True,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Etoposide,AltName B,Drug,hiv,hiv,Phase 2,2016-06-01,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

* Diagnosis of persistent or recurrent World Health Organization (WHO) classification diffuse large B-cell lymphoma, composite lymphoma with \> 50% diffuse large B-cell lymphoma, ...",Yes,2016-10-09,FDA-65027,4.41,0.98,21.0,26.39,2020-10-28,2021-10-21,2042-10-21,98,Merck,69,Kenya,37.33333333333334,48,66,3,31,38,38,27,0,2,1,False,False,False,False,False,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Cytarabine,Molecule Z,Drug,hiv,hiv,Phase 2,2016-06-01,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

* Diagnosis of persistent or recurrent World Health Organization (WHO) classification diffuse large B-cell lymphoma, composite lymphoma with \> 50% diffuse large B-cell lymphoma, ...",No,2016-09-02,FDA-87546,4.41,0.98,21.0,26.39,2020-10-28,2021-10-21,2042-10-21,8,Gilead,31,Kenya,63.0,64,45,27,94,97,51,27,1,0,2,False,True,False,False,False,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Melphalan,Comp Beta,Drug,hiv,hiv,Phase 2,2016-06-01,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

* Diagnosis of persistent or recurrent World Health Organization (WHO) classification diffuse large B-cell lymphoma, composite lymphoma with \> 50% diffuse large B-cell lymphoma, ...",No,2017-01-12,FDA-21545,4.41,0.98,21.0,26.39,2020-10-28,2021-10-21,2042-10-21,46,AstraZeneca,54,South Africa,46.83333333333334,55,9,11,85,50,71,64,0,3,4,False,False,False,True,True,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada,AltName B,Drug,hiv,hiv,Phase 4,2009-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* infection with human immunodeficiency virus (HIV) with undetectable viral load
* on Combivir or trizivir
* able to exercise and sign consent

Exclusion Criteria:

* other active...",No,2010-05-04,FDA-44393,0.56,0.15,3.5,4.21,2010-01-21,2010-03-17,2013-09-15,75,J&J,22,Kenya,64.5,2,80,99,60,47,99,36,2,0,2,True,True,False,False,False,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Combivir,AltName A,Drug,hiv,hiv,Phase 4,2009-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* infection with human immunodeficiency virus (HIV) with undetectable viral load
* on Combivir or trizivir
* able to exercise and sign consent

Exclusion Criteria:

* other active...",Yes,2010-05-03,FDA-55379,0.56,0.15,3.5,4.21,2010-01-21,2010-03-17,2013-09-15,66,Bayer,71,Kenya,29.16666666666667,12,3,0,95,4,61,64,1,4,2,False,True,True,True,True,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Trizivir,GenName Y,Drug,hiv,hiv,Phase 4,2009-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* infection with human immunodeficiency virus (HIV) with undetectable viral load
* on Combivir or trizivir
* able to exercise and sign consent

Exclusion Criteria:

* other active...",No,2010-04-29,FDA-96303,0.56,0.15,3.5,4.21,2010-01-21,2010-03-17,2013-09-15,48,Merck,41,Senegal,52.33333333333334,8,16,88,56,68,78,64,1,4,2,False,True,True,True,True,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Cabotegravir Tablets,TradeName X,Drug,hiv,hiv,Phase 3,2029-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects who will be able to understand and comply with protocol requirements, instructions, and restrictions.
* Understand the long term commitment to the study and be likely t...",No,2030-09-02,FDA-63173,2.62,0.32,5.0,7.94,2032-08-13,2032-12-08,2037-12-09,76,Novartis,36,South Africa,41.66666666666666,57,10,57,69,32,25,73,1,5,2,True,False,True,True,True,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Rilpivirine Tablets,Product Alpha,Drug,hiv,hiv,Phase 3,2029-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects who will be able to understand and comply with protocol requirements, instructions, and restrictions.
* Understand the long term commitment to the study and be likely t...",No,2030-10-22,FDA-53582,2.62,0.32,5.0,7.94,2032-08-13,2032-12-08,2037-12-09,52,Pfizer,100,Overall,58.16666666666666,60,38,47,94,82,28,45,1,2,2,False,True,False,True,True,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Cabotegravir Injectable Suspension,Molecule Z,Drug,hiv,hiv,Phase 3,2029-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects who will be able to understand and comply with protocol requirements, instructions, and restrictions.
* Understand the long term commitment to the study and be likely t...",No,2030-04-24,FDA-30889,2.62,0.32,5.0,7.94,2032-08-13,2032-12-08,2037-12-09,87,Bayer,83,Kenya,27.0,46,28,2,11,22,53,55,1,3,2,False,True,False,False,True,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Rilpivirine Injectable Suspension,Molecule Z,Drug,hiv,hiv,Phase 3,2029-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects who will be able to understand and comply with protocol requirements, instructions, and restrictions.
* Understand the long term commitment to the study and be likely t...",No,2030-11-21,FDA-31327,2.62,0.32,5.0,7.94,2032-08-13,2032-12-08,2037-12-09,49,J&J,3,South Africa,41.83333333333334,58,6,6,30,53,98,64,2,2,3,True,True,False,False,True,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Once daily,Molecule Z,Drug,hiv,hiv,Phase 4,2011-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Male or female patients \>18 years of age with documented HIV-1 infection
2. Naïve to antiretroviral therapy
3. Able and willing to provide written informed consent
4. No CD4 r...",Yes,2012-01-01,FDA-49384,0.56,0.15,3.5,4.21,2011-11-21,2012-01-15,2015-07-16,22,Gilead,72,Overall,50.83333333333334,65,40,27,7,67,99,73,0,4,4,False,False,True,True,False,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
H1N1 vaccination,TradeName X,Biological,hiv,hiv,Phase 4,2010-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. A confirmed diagnosis of HIV-1 infection as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry or any measurable HIV RNA v...",No,2011-10-04,FDA-28186,0.56,0.15,3.5,4.21,2011-06-23,2011-08-17,2015-02-15,81,AstraZeneca,36,South Africa,59.33333333333334,91,66,92,11,87,9,27,0,2,1,False,False,True,False,False,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir,AltName B,Drug,hiv,hiv,Phase 2,2010-04-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry. HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or...",No,2010-10-11,FDA-29842,4.41,0.98,21.0,26.39,2014-09-23,2015-09-16,2036-09-15,87,Gilead,81,Kenya,52.0,17,36,77,94,20,68,55,1,3,2,False,True,False,True,False,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Abacavir,GenName Y,Drug,hiv,hiv,Phase 2,2010-04-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry. HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or...",No,2010-08-12,FDA-33655,4.41,0.98,21.0,26.39,2014-09-23,2015-09-16,2036-09-15,66,GSK,13,Senegal,55.0,88,12,60,51,33,86,64,2,2,3,True,True,True,True,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir/ritonavir,GenName Y,Drug,hiv,hiv,Phase 3,2013-07-01,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

1. Age \> 16 years (if \<18 years old, living independently from parents)
2. Documentation of HIV status must come from two assays. Assays include DNA PCR, HIV RNA, Western blot, ...",Yes,2014-03-21,FDA-50171,2.62,0.32,5.0,7.94,2016-02-12,2016-06-08,2021-06-09,50,Pfizer,66,Kenya,60.83333333333334,92,52,15,72,39,95,55,1,2,3,False,True,False,True,False,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,AltName B,Drug,hiv,hiv,Phase 3,2013-07-01,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

1. Age \> 16 years (if \<18 years old, living independently from parents)
2. Documentation of HIV status must come from two assays. Assays include DNA PCR, HIV RNA, Western blot, ...",Yes,2014-05-27,FDA-81849,2.62,0.32,5.0,7.94,2016-02-12,2016-06-08,2021-06-09,66,GSK,8,South Africa,49.16666666666666,54,12,56,41,79,53,36,0,3,1,False,False,True,False,False,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Zidovudine,AltName A,Drug,hiv,hiv,Phase 3,2013-07-01,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

1. Age \> 16 years (if \<18 years old, living independently from parents)
2. Documentation of HIV status must come from two assays. Assays include DNA PCR, HIV RNA, Western blot, ...",No,2014-01-30,FDA-66344,2.62,0.32,5.0,7.94,2016-02-12,2016-06-08,2021-06-09,93,Merck,62,Senegal,59.0,76,64,48,74,58,34,64,1,4,2,False,True,True,False,True,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine,TradeName X,Drug,hiv,hiv,Phase 3,2013-07-01,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

1. Age \> 16 years (if \<18 years old, living independently from parents)
2. Documentation of HIV status must come from two assays. Assays include DNA PCR, HIV RNA, Western blot, ...",Yes,2013-08-01,FDA-27173,2.62,0.32,5.0,7.94,2016-02-12,2016-06-08,2021-06-09,56,Gilead,76,Kenya,31.33333333333333,22,37,4,85,0,40,9,0,1,0,False,False,False,True,False,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir disoproxil,AltName B,Drug,hiv,hiv,Phase 4,2011-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult (≥18 years) males or non-pregnant females, non-lactating females.
* HIV-infected participants currently receiving fixed-dose abacavir/lamivudine based regimen for ≥3 month...",Yes,2012-01-20,FDA-12397,0.56,0.15,3.5,4.21,2012-06-22,2012-08-16,2016-02-15,66,GSK,34,South Africa,51.5,1,32,52,86,42,96,36,0,3,1,False,False,True,False,False,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet),Molecule Z,Drug,hiv,hiv,Phase 2,2015-05-26,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Male or transgender female \> age of 18 at Screening
2. Able and willing to provide written informed consent
3. HIV-1 uninfected at Screening and Enrollment
4. Able and willing...",Yes,2016-02-22,FDA-67842,4.41,0.98,21.0,26.39,2019-10-22,2020-10-14,2041-10-14,49,J&J,70,Overall,30.5,9,19,55,56,11,33,64,1,4,2,False,True,True,True,True,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel),AltName A,Drug,hiv,hiv,Phase 2,2015-05-26,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Male or transgender female \> age of 18 at Screening
2. Able and willing to provide written informed consent
3. HIV-1 uninfected at Screening and Enrollment
4. Able and willing...",No,2015-09-06,FDA-75286,4.41,0.98,21.0,26.39,2019-10-22,2020-10-14,2041-10-14,29,J&J,14,South Africa,47.16666666666666,6,89,50,52,53,33,82,2,3,4,True,True,True,True,False,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel),TradeName X,Drug,hiv,hiv,Phase 2,2015-05-26,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Male or transgender female \> age of 18 at Screening
2. Able and willing to provide written informed consent
3. HIV-1 uninfected at Screening and Enrollment
4. Able and willing...",No,2015-11-15,FDA-48001,4.41,0.98,21.0,26.39,2019-10-22,2020-10-14,2041-10-14,65,Novartis,11,Overall,52.33333333333334,68,4,85,9,72,76,27,0,2,1,False,False,True,False,False,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Low dose naltrexone,Product Alpha,Drug,hiv,hiv,Phase 2,2018-12-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* 18 years or older
* HIV-positive
* Chronic pain (present ≥3 mo) of moderate to severe intensity
* Heavy drinking past year (Based on NIAAA criteria: \> 14 standard drinks per we...",Yes,2019-12-10,FDA-97058,4.41,0.98,21.0,26.39,2023-05-17,2024-05-09,2045-05-09,39,Merck,57,Senegal,64.0,57,44,39,82,89,73,82,2,3,4,True,True,False,False,True,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Nalmefene,AltName A,Drug,hiv,hiv,Phase 2,2018-12-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* 18 years or older
* HIV-positive
* Chronic pain (present ≥3 mo) of moderate to severe intensity
* Heavy drinking past year (Based on NIAAA criteria: \> 14 standard drinks per we...",No,2019-05-28,FDA-37238,4.41,0.98,21.0,26.39,2023-05-17,2024-05-09,2045-05-09,17,Merck,43,South Africa,53.66666666666666,58,65,24,15,83,77,73,2,4,2,True,True,True,False,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
saquinavir [Invirase],TradeName X,Drug,hiv,hiv,Phase 3,2008-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* adult patients \>=18 years of age;
* chronic HIV-1 infection;
* treatment-naive;
* HIV-1 RNA viral load \>=10,000copies/mL;
* women of childbearing potential must have a negativ...",No,2009-03-09,FDA-62137,2.62,0.32,5.0,7.94,2011-02-12,2011-06-09,2016-06-09,33,Sanofi,84,Kenya,49.66666666666666,42,86,30,71,1,68,45,1,3,1,True,False,False,True,True,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir/ritonavir,AltName A,Drug,hiv,hiv,Phase 3,2008-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* adult patients \>=18 years of age;
* chronic HIV-1 infection;
* treatment-naive;
* HIV-1 RNA viral load \>=10,000copies/mL;
* women of childbearing potential must have a negativ...",Yes,2009-06-05,FDA-30389,2.62,0.32,5.0,7.94,2011-02-12,2011-06-09,2016-06-09,7,AstraZeneca,9,South Africa,40.0,69,26,36,29,17,63,36,0,3,1,False,False,True,False,True,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine/tenofovir disoproxil fumarate,Comp Beta,Drug,hiv,hiv,Phase 3,2008-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* adult patients \>=18 years of age;
* chronic HIV-1 infection;
* treatment-naive;
* HIV-1 RNA viral load \>=10,000copies/mL;
* women of childbearing potential must have a negativ...",Yes,2008-09-08,FDA-80900,2.62,0.32,5.0,7.94,2011-02-12,2011-06-09,2016-06-09,36,AstraZeneca,88,Overall,58.5,73,65,100,12,47,54,27,0,2,1,False,False,True,True,False,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,Molecule Z,Drug,hiv,hiv,Phase 3,2008-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* adult patients \>=18 years of age;
* chronic HIV-1 infection;
* treatment-naive;
* HIV-1 RNA viral load \>=10,000copies/mL;
* women of childbearing potential must have a negativ...",No,2009-06-27,FDA-73606,2.62,0.32,5.0,7.94,2011-02-12,2011-06-09,2016-06-09,43,J&J,17,South Africa,34.33333333333334,14,7,67,36,61,21,45,1,2,2,False,True,True,False,False,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
VH4004280,Comp Beta,Drug,hiv,hiv,Phase 2,2024-06-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants who are overtly healthy (other than HIV-1 infection).
* Screening cluster of differentiation-4 (CD4+) T-cell count greater than or equal to (≥)200 cells/microliter ...",No,2024-07-25,FDA-35381,4.41,0.98,21.0,26.39,2028-11-20,2029-11-13,2050-11-13,29,Merck,53,Senegal,49.5,79,36,45,8,58,71,36,0,3,1,False,False,True,False,True,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
VH4011499,TradeName X,Drug,hiv,hiv,Phase 2,2024-06-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants who are overtly healthy (other than HIV-1 infection).
* Screening cluster of differentiation-4 (CD4+) T-cell count greater than or equal to (≥)200 cells/microliter ...",Yes,2024-11-21,FDA-85053,4.41,0.98,21.0,26.39,2028-11-20,2029-11-13,2050-11-13,54,Gilead,42,Kenya,37.0,32,61,70,18,28,13,64,0,4,3,False,False,True,True,True,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Antiretroviral therapy,AltName A,Drug,hiv,hiv,Phase 2,2024-06-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants who are overtly healthy (other than HIV-1 infection).
* Screening cluster of differentiation-4 (CD4+) T-cell count greater than or equal to (≥)200 cells/microliter ...",No,2024-10-19,FDA-79507,4.41,0.98,21.0,26.39,2028-11-20,2029-11-13,2050-11-13,88,Gilead,4,South Africa,42.66666666666666,11,19,93,43,8,82,64,2,2,3,True,True,True,True,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Kaletra + Isentress,AltName A,Drug,hiv,hiv,Phase 4,2011-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1-infected individuals receiving HAART regimen (if on PI-based regimen, must be 1st PI-containing HAART).
* They must have been on and tolerating current HAART regimen for \...",No,2011-07-12,FDA-85736,0.56,0.15,3.5,4.21,2011-07-24,2011-09-17,2015-03-18,64,Bayer,95,Senegal,33.83333333333334,14,89,15,46,27,12,45,1,4,0,False,True,True,False,True,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Pre-study antiretroviral regimen,Molecule Z,Drug,hiv,hiv,Phase 4,2011-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1-infected individuals receiving HAART regimen (if on PI-based regimen, must be 1st PI-containing HAART).
* They must have been on and tolerating current HAART regimen for \...",No,2011-07-30,FDA-25070,0.56,0.15,3.5,4.21,2011-07-24,2011-09-17,2015-03-18,42,Merck,23,Senegal,36.5,86,27,47,16,37,6,64,1,3,3,False,True,True,True,False,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,Comp Beta,Drug,hiv,hiv,Phase 4,2010-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Documented HIV infection confirmed by western blot or HIV RNA.
2. At least 18 years of age.
3. Less than 1 week of prior antiretroviral therapy.
4. In the opinion of the invest...",No,2010-09-14,FDA-23342,0.56,0.15,3.5,4.21,2010-12-22,2011-02-15,2014-08-16,4,Novartis,3,Kenya,48.33333333333334,66,78,67,55,18,6,27,0,2,1,False,False,True,False,True,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir/Ritonavir,Product Alpha,Drug,hiv,hiv,Phase 4,2010-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Documented HIV infection confirmed by western blot or HIV RNA.
2. At least 18 years of age.
3. Less than 1 week of prior antiretroviral therapy.
4. In the opinion of the invest...",Yes,2010-09-07,FDA-53568,0.56,0.15,3.5,4.21,2010-12-22,2011-02-15,2014-08-16,0,J&J,25,South Africa,60.83333333333334,89,77,99,11,8,81,45,1,2,2,True,False,False,True,True,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada,Molecule Z,Drug,hiv,hiv,Phase 4,2010-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Documented HIV infection confirmed by western blot or HIV RNA.
2. At least 18 years of age.
3. Less than 1 week of prior antiretroviral therapy.
4. In the opinion of the invest...",No,2010-10-09,FDA-38422,0.56,0.15,3.5,4.21,2010-12-22,2011-02-15,2014-08-16,86,J&J,19,Overall,56.16666666666666,81,58,25,12,86,75,64,2,3,2,True,True,True,False,False,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
raltegravir,Comp Beta,Drug,hiv,hiv,Phase 3,2014-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Age \>18
* Fasting LDL\>130 mg/dL
* Fasting triglycerides \>250 mg/dL
* Plasma viral load below 50 copies/mL on current regimen for 6 months prior to study entry.
* No prior his...",Yes,2014-12-29,FDA-85197,2.62,0.32,5.0,7.94,2016-11-12,2017-03-09,2022-03-10,9,Bayer,47,Overall,28.66666666666667,14,5,24,24,24,81,73,1,4,3,True,False,False,True,True,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
tipranavir,Product Alpha,Drug,hiv,hiv,Phase 3,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. HIV-1 infected males or females at least 18 years of age.
2. Three-class (Nucleoside reverse transcriptase inhibitor (NRTI), Non nucleoside reverse transcriptase inhibitor (NNR...",Yes,2026-09-18,FDA-54320,2.62,0.32,5.0,7.94,,,,48,GSK,60,Kenya,35.33333333333334,9,55,48,16,78,6,55,2,3,1,True,True,True,True,False,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ritonavir,Molecule Z,Drug,hiv,hiv,Phase 3,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. HIV-1 infected males or females at least 18 years of age.
2. Three-class (Nucleoside reverse transcriptase inhibitor (NRTI), Non nucleoside reverse transcriptase inhibitor (NNR...",No,2026-09-20,FDA-51000,2.62,0.32,5.0,7.94,,,,85,Bayer,88,Overall,45.16666666666666,57,75,6,16,89,28,27,1,1,1,True,False,False,True,False,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir,Product Alpha,Drug,hiv,hiv,Phase 4,2008-06-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Age 18 to 55 years
* Negative HIV screening antibody test
* CYP3A5 expressor status, race, and sex fit an enrollment opening.

Exclusion Criteria:

* Pregnant or breast-feeding
...",Yes,2009-04-01,FDA-58412,0.56,0.15,3.5,4.21,2008-12-22,2009-02-15,2012-08-16,63,AstraZeneca,46,Overall,46.33333333333334,8,10,33,99,95,33,55,2,2,2,True,True,True,False,False,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
VH3739937,AltName B,Drug,hiv,hiv,Phase 2,2024-08-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants who are overtly healthy (other than HIV infection) as determined by the Investigator or medically qualified designee based on a medical evaluation including medical...",Yes,2025-03-16,FDA-48768,4.41,0.98,21.0,26.39,2029-01-23,2030-01-16,2051-01-16,52,Bayer,21,South Africa,49.83333333333334,76,19,80,81,9,34,27,0,3,0,False,False,True,True,False,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rilpivirine,Molecule Z,Drug,hiv,hiv,Phase 2,2023-02-23,"Sex: ALL; Age: >2 Years; Criteria: Inclusion Criteria:

* Weighing at least 10 kilogram (kg) at screening
* Have documented chronic Human Immunodeficiency Virus (HIV-1) infection
* On a stable antiretroviral (ARV) regimen for at least ...",No,2024-02-10,FDA-85669,4.41,0.98,21.0,26.39,2027-07-22,2028-07-14,2049-07-14,27,Novartis,23,Overall,67.16666666666667,79,91,49,72,61,51,55,0,4,2,False,False,False,True,True,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ARV Background Regimen,AltName A,Drug,hiv,hiv,Phase 2,2023-02-23,"Sex: ALL; Age: >2 Years; Criteria: Inclusion Criteria:

* Weighing at least 10 kilogram (kg) at screening
* Have documented chronic Human Immunodeficiency Virus (HIV-1) infection
* On a stable antiretroviral (ARV) regimen for at least ...",No,2023-09-10,FDA-12982,4.41,0.98,21.0,26.39,2027-07-22,2028-07-14,2049-07-14,27,GSK,28,Senegal,37.83333333333334,77,18,86,1,43,2,64,0,3,4,False,False,False,False,True,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
E/C/F/TAF,AltName B,Drug,hiv,hiv,Phase 3,2017-10-23,"Sex: ALL; Age: >12 Years; Criteria: Key Inclusion Criteria:

* Currently on a stable antiretroviral regimen for ≥ 6 consecutive months
* Weight ≥ 35 kg (77 lbs.)
* Plasma HIV-1 RNA levels \< 50 copies/mL for ≥ 6 months
* CD4+ cell count...",Yes,2018-09-28,FDA-44574,2.62,0.32,5.0,7.94,2020-06-05,2020-09-30,2025-10-01,16,Pfizer,43,Senegal,42.83333333333334,14,53,13,2,78,97,45,1,2,2,True,False,True,False,False,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"Pegylated Interferon-alpha 2a, 180 mcg/week sc",TradeName X,Drug,hiv,hiv,Phase 2,2011-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male or female, age ≥ 18 but \<65 years
* Able and willing to provide informed consent.
* HIV-1 infection documented by any licensed enzyme-linked immunosorbent assay (ELISA) te...",Yes,2012-01-11,FDA-84478,4.41,0.98,21.0,26.39,2015-09-27,2016-09-19,2037-09-19,77,Pfizer,87,South Africa,45.16666666666666,8,51,54,94,37,27,36,1,1,2,True,False,False,False,False,False,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"Pegylated Interferon-alpha 2a, 90 mcg/week sc",Comp Beta,Drug,hiv,hiv,Phase 2,2011-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male or female, age ≥ 18 but \<65 years
* Able and willing to provide informed consent.
* HIV-1 infection documented by any licensed enzyme-linked immunosorbent assay (ELISA) te...",Yes,2012-01-29,FDA-31939,4.41,0.98,21.0,26.39,2015-09-27,2016-09-19,2037-09-19,40,Novartis,51,Overall,64.5,89,64,11,80,87,56,55,2,3,1,True,True,True,False,True,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Entecavir with continued standard of care antiretroviral therapy,AltName A,Drug,hiv,hiv,Phase 4,2010-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability and willingness to provide written informed consent
* HIV infection, documented in patient medical record. Acceptable forms of documentation include positive HIV antibod...",Yes,2010-12-20,FDA-69055,0.56,0.15,3.5,4.21,2010-11-21,2011-01-15,2014-07-16,38,Pfizer,62,Kenya,43.0,64,14,29,95,10,46,55,2,3,1,True,True,True,False,False,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
continued standard of care with tenofovir in addition to emtricitabine or lamivudine,AltName B,Drug,hiv,hiv,Phase 4,2010-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability and willingness to provide written informed consent
* HIV infection, documented in patient medical record. Acceptable forms of documentation include positive HIV antibod...",No,2010-06-23,FDA-13913,0.56,0.15,3.5,4.21,2010-11-21,2011-01-15,2014-07-16,86,AstraZeneca,76,South Africa,52.0,98,8,94,59,29,24,36,0,2,2,False,False,False,False,True,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
lopinavir/ritonavir plus maraviroc,Product Alpha,Drug,hiv,hiv,Phase 4,2010-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* The patient has signed and dated approved informed consent form.
* There is confirmed laboratory diagnosis of HIV infection (positive ELISA HIV antibody test confirmed by Wester...",Yes,2011-03-01,FDA-76259,0.56,0.15,3.5,4.21,2011-06-23,2011-08-17,2015-02-15,5,GSK,11,South Africa,45.33333333333334,26,52,16,40,97,41,55,2,2,2,True,True,True,False,True,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir + 2 NRTIs,AltName A,Drug,hiv,hiv,Phase 4,2008-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Treatment naive HIV-1 infected subjects ( \< 10 days of treatment with any ARV).
* Subjects who have an HIV-1 RNA level ≥ 5000 c/mL at screening.
* Subjects who have a CD4 count...",Yes,2008-07-15,FDA-50705,0.56,0.15,3.5,4.21,2008-07-23,2008-09-16,2012-03-17,57,Bayer,58,Kenya,38.5,3,21,65,76,34,32,36,1,1,2,True,False,False,False,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir + Ritonavir + 2 NRTIs,Product Alpha,Drug,hiv,hiv,Phase 4,2008-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Treatment naive HIV-1 infected subjects ( \< 10 days of treatment with any ARV).
* Subjects who have an HIV-1 RNA level ≥ 5000 c/mL at screening.
* Subjects who have a CD4 count...",No,2008-05-09,FDA-56579,0.56,0.15,3.5,4.21,2008-07-23,2008-09-16,2012-03-17,83,Novartis,27,South Africa,65.66666666666667,43,83,77,54,58,79,55,1,2,3,False,True,False,True,True,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir disoproxil fumarate,TradeName X,Drug,hiv,hiv,Phase 2,2010-07-01,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* General good health
* HIV-uninfected
* Normal menstrual cycle. More information can be found in the protocol.
* Creatinine clearance greater than 70 ml/min
* Sexually active. Mo...",No,2010-09-27,FDA-84042,4.41,0.98,21.0,26.39,2014-11-27,2015-11-20,2036-11-19,74,J&J,86,South Africa,55.66666666666666,35,94,57,78,55,15,45,1,2,2,True,False,False,True,True,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir gel,TradeName X,Drug,hiv,hiv,Phase 2,2010-07-01,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* General good health
* HIV-uninfected
* Normal menstrual cycle. More information can be found in the protocol.
* Creatinine clearance greater than 70 ml/min
* Sexually active. Mo...",No,2011-03-31,FDA-27656,4.41,0.98,21.0,26.39,2014-11-27,2015-11-20,2036-11-19,85,Gilead,95,Kenya,33.16666666666666,3,24,36,76,41,19,36,1,2,1,False,True,False,False,True,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,TradeName X,Drug,hiv,hiv,Phase 4,2015-03-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV coinfected with HCV and/or HBV.
* Undetectable HIV-1 RNA for at least 3 months prior to the screening visit
* Treatment with current antiretroviral therapy (3-6 drugs exclud...",No,2015-07-27,FDA-36680,0.56,0.15,3.5,4.21,2015-10-14,2015-12-08,2019-06-08,27,Pfizer,16,Senegal,39.5,72,23,50,58,28,6,64,1,4,2,True,False,True,True,True,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
VRC01,AltName B,Biological,hiv,hiv,Phase 2,2021-03-03,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

General and Demographic Criteria

* Age of 18 to 50 years
* Access to a participating clinical research site (CRS) and willingness to be followed for the planned duration of the s...",No,2021-04-24,FDA-11617,4.41,0.98,21.0,26.39,2025-07-30,2026-07-23,2047-07-23,71,Pfizer,39,Overall,61.66666666666666,48,97,13,84,30,98,27,1,1,1,True,False,False,False,True,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz 600mg,AltName A,Drug,hiv,hiv,Phase 3,2014-08-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* HIV-1 positive by licensed diagnostic test
* aged \>16 years of age (or minimum age as determined by local regulations or as legal requirements dictate)
* 50 \< cluster of diffe...",Yes,2015-03-01,FDA-22132,2.62,0.32,5.0,7.94,2017-03-14,2017-07-09,2022-07-10,85,Merck,44,Senegal,47.66666666666666,3,91,19,32,83,58,73,2,4,2,True,True,False,True,True,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz 400mg,Comp Beta,Drug,hiv,hiv,Phase 3,2014-08-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* HIV-1 positive by licensed diagnostic test
* aged \>16 years of age (or minimum age as determined by local regulations or as legal requirements dictate)
* 50 \< cluster of diffe...",Yes,2015-02-12,FDA-53034,2.62,0.32,5.0,7.94,2017-03-14,2017-07-09,2022-07-10,100,J&J,25,South Africa,44.0,60,77,67,6,31,23,55,1,2,3,True,False,False,True,False,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PRO 140,TradeName X,Drug,hiv,hiv,Phase 3,2018-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Males and females, age ≥ 18 years
2. Exclusive CCR5-tropic virus at Screening Visit
3. Have a history of at least 3 months on current antiretroviral regimen
4. Treatment-experi...",Yes,2019-04-28,FDA-81816,2.62,0.32,5.0,7.94,2021-02-11,2021-06-08,2026-06-09,40,AstraZeneca,9,Kenya,54.83333333333334,24,72,43,72,28,90,64,1,3,3,True,False,False,True,True,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Optimized Background Regimen,Molecule Z,Drug,hiv,hiv,Phase 3,2018-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Males and females, age ≥ 18 years
2. Exclusive CCR5-tropic virus at Screening Visit
3. Have a history of at least 3 months on current antiretroviral regimen
4. Treatment-experi...",No,2018-12-05,FDA-36775,2.62,0.32,5.0,7.94,2021-02-11,2021-06-08,2026-06-09,56,J&J,96,South Africa,75.33333333333333,96,93,85,92,30,56,36,1,2,1,False,True,False,True,False,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Pneumococcal vaccine GSK1024850A,Molecule Z,Biological,hiv,hiv,Phase 3,2012-06-27,"Sex: ALL; Age: >6 Weeks; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Male or female subjects between, and including 6-10 weeks of age at the time of the first vaccination.
* Subjects for whom the investigator believes that their parent(s)/guardia...",Yes,2012-08-18,FDA-12667,2.62,0.32,5.0,7.94,2015-02-08,2015-06-05,2020-06-05,75,Bayer,94,Senegal,45.83333333333334,34,62,87,35,20,37,55,1,2,3,True,False,True,True,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tritanrix-HepB/Hib,AltName B,Biological,hiv,hiv,Phase 3,2012-06-27,"Sex: ALL; Age: >6 Weeks; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Male or female subjects between, and including 6-10 weeks of age at the time of the first vaccination.
* Subjects for whom the investigator believes that their parent(s)/guardia...",Yes,2012-08-18,FDA-82173,2.62,0.32,5.0,7.94,2015-02-08,2015-06-05,2020-06-05,31,Pfizer,22,Senegal,49.16666666666666,86,60,26,47,48,28,27,1,1,1,False,True,False,True,False,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
measles,AltName A,Biological,hiv,hiv,Phase 3,2012-06-27,"Sex: ALL; Age: >6 Weeks; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Male or female subjects between, and including 6-10 weeks of age at the time of the first vaccination.
* Subjects for whom the investigator believes that their parent(s)/guardia...",Yes,2013-02-23,FDA-99640,2.62,0.32,5.0,7.94,2015-02-08,2015-06-05,2020-06-05,54,Merck,27,Senegal,32.0,89,6,28,11,26,32,64,2,3,2,True,True,True,False,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rotarix,Molecule Z,Biological,hiv,hiv,Phase 3,2012-06-27,"Sex: ALL; Age: >6 Weeks; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Male or female subjects between, and including 6-10 weeks of age at the time of the first vaccination.
* Subjects for whom the investigator believes that their parent(s)/guardia...",Yes,2013-01-18,FDA-13676,2.62,0.32,5.0,7.94,2015-02-08,2015-06-05,2020-06-05,47,AstraZeneca,70,South Africa,48.16666666666666,52,21,88,74,53,1,45,0,2,3,False,False,False,False,True,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Local OPV,TradeName X,Biological,hiv,hiv,Phase 3,2012-06-27,"Sex: ALL; Age: >6 Weeks; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Male or female subjects between, and including 6-10 weeks of age at the time of the first vaccination.
* Subjects for whom the investigator believes that their parent(s)/guardia...",Yes,2012-11-28,FDA-39464,2.62,0.32,5.0,7.94,2015-02-08,2015-06-05,2020-06-05,29,Sanofi,99,Kenya,73.5,99,88,35,59,83,77,36,1,2,1,False,True,False,False,False,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Isoniazid (INH),AltName A,Drug,hiv,hiv,Phase 4,2017-09-06,"Sex: FEMALE; Age: >13 Years; Criteria: Inclusion Criteria:

* Documented HIV-1 infection, defined as positive results from two samples collected at different time points. All samples tested must be whole blood, serum, or plasma. More infor...",Yes,2018-03-30,FDA-18565,0.56,0.15,3.5,4.21,2018-03-29,2018-05-23,2021-11-21,36,Gilead,85,Overall,47.83333333333334,49,59,16,25,61,77,91,2,5,3,True,True,True,True,True,True,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DTG,AltName A,Drug,hiv,hiv,Phase 3,2022-02-14,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected subjects \>=18 years of age.
* A female subject may be eligible to enter and participate in the study if she:

is of non-childbearing potential defined as either ...",Yes,2023-01-16,FDA-94247,2.62,0.32,5.0,7.94,2024-09-27,2025-01-22,2030-01-23,50,Pfizer,78,Senegal,42.33333333333334,99,31,39,41,44,0,55,1,3,2,True,False,False,True,True,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
LPV/RTV,Product Alpha,Drug,hiv,hiv,Phase 3,2022-02-14,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected subjects \>=18 years of age.
* A female subject may be eligible to enter and participate in the study if she:

is of non-childbearing potential defined as either ...",No,2022-05-30,FDA-17292,2.62,0.32,5.0,7.94,2024-09-27,2025-01-22,2030-01-23,90,AstraZeneca,68,Senegal,54.83333333333334,17,91,39,10,80,92,27,1,0,2,False,True,False,False,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Two NRTIs,Comp Beta,Drug,hiv,hiv,Phase 3,2022-02-14,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected subjects \>=18 years of age.
* A female subject may be eligible to enter and participate in the study if she:

is of non-childbearing potential defined as either ...",No,2022-04-14,FDA-22405,2.62,0.32,5.0,7.94,2024-09-27,2025-01-22,2030-01-23,22,Gilead,6,Overall,52.16666666666666,95,14,40,57,69,38,73,2,3,3,True,True,True,False,False,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Abacavir/Lamivudine,AltName B,Drug,hiv,hiv,Phase 3,2009-11-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* HIV-infected. A resistance assay must be obtained if the participant has evidence of recent infection. More information on this criterion can be found in the protocol.
* Antiret...",Yes,2010-09-25,FDA-42050,2.62,0.32,5.0,7.94,2012-06-14,2012-10-09,2017-10-10,98,Novartis,21,Senegal,48.5,3,3,57,51,100,77,45,1,3,1,False,True,True,True,False,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir,Product Alpha,Drug,hiv,hiv,Phase 3,2009-11-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* HIV-infected. A resistance assay must be obtained if the participant has evidence of recent infection. More information on this criterion can be found in the protocol.
* Antiret...",No,2010-08-04,FDA-90138,2.62,0.32,5.0,7.94,2012-06-14,2012-10-09,2017-10-10,87,Novartis,72,Overall,57.16666666666666,38,8,82,22,94,99,64,1,3,3,True,False,True,True,False,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,TradeName X,Drug,hiv,hiv,Phase 3,2009-11-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* HIV-infected. A resistance assay must be obtained if the participant has evidence of recent infection. More information on this criterion can be found in the protocol.
* Antiret...",Yes,2010-08-04,FDA-48825,2.62,0.32,5.0,7.94,2012-06-14,2012-10-09,2017-10-10,7,GSK,31,Senegal,58.0,97,48,26,74,88,15,45,2,2,1,True,True,False,False,True,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine/Tenofovir disoproxil fumarate,Product Alpha,Drug,hiv,hiv,Phase 3,2009-11-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* HIV-infected. A resistance assay must be obtained if the participant has evidence of recent infection. More information on this criterion can be found in the protocol.
* Antiret...",Yes,2010-10-08,FDA-35016,2.62,0.32,5.0,7.94,2012-06-14,2012-10-09,2017-10-10,97,AstraZeneca,40,Senegal,26.5,21,20,53,40,12,13,36,0,3,1,False,False,False,False,True,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,AltName B,Drug,hiv,hiv,Phase 3,2009-11-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* HIV-infected. A resistance assay must be obtained if the participant has evidence of recent infection. More information on this criterion can be found in the protocol.
* Antiret...",Yes,2010-09-30,FDA-19064,2.62,0.32,5.0,7.94,2012-06-14,2012-10-09,2017-10-10,17,GSK,87,South Africa,71.83333333333333,88,51,81,68,85,58,36,1,2,1,False,True,True,False,False,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ABT-493 coformulated with ABT-530,GenName Y,Drug,hiv,hiv,Phase 3,2017-06-07,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Male or female, at least 18 years of age at time of Screening.
2. Screening laboratory result indicating Hepatitis C virus (HCV) genotype (GT)1-, 2-, 3-, 4-, 5-, or 6-infection...",No,2018-05-13,FDA-59740,2.62,0.32,5.0,7.94,2020-01-19,2020-05-15,2025-05-16,70,J&J,43,South Africa,20.66666666666667,48,31,13,13,5,14,36,0,2,2,False,False,True,True,False,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
raltegravir,AltName A,Drug,hiv,hiv,Phase 4,2013-08-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

1. HIV-1 positive by licensed diagnostic test
2. Aged 16 years or older (or minimum age as determined by local regulations or as legal requirements dictate)
3. Have received first...",No,2013-11-07,FDA-81062,0.56,0.15,3.5,4.21,2014-02-21,2014-04-17,2017-10-16,14,Novartis,70,South Africa,32.66666666666666,91,35,11,35,2,22,45,0,3,2,False,False,True,True,False,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
2N(t)RTI,GenName Y,Drug,hiv,hiv,Phase 4,2013-08-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

1. HIV-1 positive by licensed diagnostic test
2. Aged 16 years or older (or minimum age as determined by local regulations or as legal requirements dictate)
3. Have received first...",Yes,2014-04-23,FDA-18974,0.56,0.15,3.5,4.21,2014-02-21,2014-04-17,2017-10-16,95,AstraZeneca,80,Kenya,50.0,57,61,81,33,10,58,55,2,1,3,True,True,False,True,False,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir-boosted lopinavir,Product Alpha,Drug,hiv,hiv,Phase 4,2013-08-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

1. HIV-1 positive by licensed diagnostic test
2. Aged 16 years or older (or minimum age as determined by local regulations or as legal requirements dictate)
3. Have received first...",No,2013-09-15,FDA-42230,0.56,0.15,3.5,4.21,2014-02-21,2014-04-17,2017-10-16,33,Gilead,98,Kenya,67.16666666666667,88,2,97,75,93,48,73,1,3,4,False,True,True,True,False,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine (FTC),AltName B,Drug,hiv,hiv,Phase 3,2009-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria: Participants must have met all inclusion criteria within 28 days prior to randomization unless specified otherwise including:

* Plasma HIV-1 RNA levels greater than 10,000 c/mL us...",Yes,2009-09-08,FDA-86947,2.62,0.32,5.0,7.94,2012-01-13,2012-05-09,2017-05-10,9,Pfizer,30,Senegal,39.83333333333334,16,94,14,62,9,44,45,1,4,0,True,False,True,True,False,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir Disoproxil Fumarate (TDF),Molecule Z,Drug,hiv,hiv,Phase 3,2009-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria: Participants must have met all inclusion criteria within 28 days prior to randomization unless specified otherwise including:

* Plasma HIV-1 RNA levels greater than 10,000 c/mL us...",No,2009-09-29,FDA-10330,2.62,0.32,5.0,7.94,2012-01-13,2012-05-09,2017-05-10,3,Sanofi,52,South Africa,46.83333333333334,90,83,34,19,8,47,55,1,3,2,False,True,True,True,True,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz (EFV),GenName Y,Drug,hiv,hiv,Phase 3,2009-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria: Participants must have met all inclusion criteria within 28 days prior to randomization unless specified otherwise including:

* Plasma HIV-1 RNA levels greater than 10,000 c/mL us...",No,2009-10-31,FDA-50449,2.62,0.32,5.0,7.94,2012-01-13,2012-05-09,2017-05-10,84,Pfizer,82,Senegal,59.5,48,17,82,91,43,76,73,1,4,3,False,True,False,True,True,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TDF,Product Alpha,Drug,hiv,hiv,Phase 3,2009-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria: Participants must have met all inclusion criteria within 28 days prior to randomization unless specified otherwise including:

* Plasma HIV-1 RNA levels greater than 10,000 c/mL us...",No,2010-03-25,FDA-57842,2.62,0.32,5.0,7.94,2012-01-13,2012-05-09,2017-05-10,55,J&J,66,Overall,43.5,67,21,17,97,7,52,73,1,4,3,False,True,False,True,True,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TDF/EFV,AltName A,Drug,hiv,hiv,Phase 3,2009-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria: Participants must have met all inclusion criteria within 28 days prior to randomization unless specified otherwise including:

* Plasma HIV-1 RNA levels greater than 10,000 c/mL us...",Yes,2009-10-01,FDA-56986,2.62,0.32,5.0,7.94,2012-01-13,2012-05-09,2017-05-10,64,J&J,17,Kenya,52.83333333333334,98,89,75,19,9,27,55,0,4,2,False,False,True,True,True,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine/zidovudine,Comp Beta,Drug,hiv,hiv,Phase 3,2009-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria: Participants must have met all inclusion criteria within 28 days prior to randomization unless specified otherwise including:

* Plasma HIV-1 RNA levels greater than 10,000 c/mL us...",No,2009-10-10,FDA-88933,2.62,0.32,5.0,7.94,2012-01-13,2012-05-09,2017-05-10,35,Pfizer,39,South Africa,55.16666666666666,86,69,42,78,10,46,27,0,1,2,False,False,False,False,False,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
p24CE1/2 pDNA vaccine,AltName A,Biological,hiv,hiv,Phase 2,2021-02-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a li...",No,2021-05-13,FDA-60322,4.41,0.98,21.0,26.39,2025-07-09,2026-07-02,2047-07-02,13,GSK,33,Kenya,40.16666666666666,1,15,75,82,56,12,45,0,2,3,False,False,False,False,False,True,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine,Comp Beta,Biological,hiv,hiv,Phase 2,2021-02-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a li...",Yes,2021-11-03,FDA-32109,4.41,0.98,21.0,26.39,2025-07-09,2026-07-02,2047-07-02,99,Merck,41,South Africa,37.16666666666666,16,23,73,59,11,41,27,0,2,1,False,False,True,True,False,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Full-length p55^gag pDNA vaccine,AltName B,Biological,hiv,hiv,Phase 2,2021-02-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a li...",Yes,2021-12-04,FDA-52268,4.41,0.98,21.0,26.39,2025-07-09,2026-07-02,2047-07-02,77,J&J,49,Overall,53.83333333333334,87,28,56,65,41,46,45,0,3,2,False,False,True,True,False,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rosuvastatin,Comp Beta,Drug,hiv,hiv,Phase 4,2018-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Age ≥ 18 years
* Moderate cardiovascular disease (CVD) risk, (10-15% 10 year risk of CVD)
* HIV positive
* Stable combination anti-retroviral therapy (cART) with plasma HIV vira...",Yes,2019-10-24,FDA-55986,0.56,0.15,3.5,4.21,2019-05-24,2019-07-18,2023-01-16,18,Gilead,80,Senegal,43.0,47,83,6,18,71,33,45,2,2,1,True,True,True,True,False,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Acyclovir,GenName Y,Drug,hiv,hiv,Phase 2,2010-11-01,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

  1. Documentation of HIV-1 infection, by either two positive ELISAs or two discrepant ELISAs with a confirmatory positive Western Blot
  2. Documentation of prior HSV-2 infecti...",No,2011-05-08,FDA-83568,4.41,0.98,21.0,26.39,2015-03-30,2016-03-22,2037-03-22,99,Gilead,94,South Africa,40.66666666666666,78,57,15,25,0,69,27,0,3,0,False,False,False,True,True,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Nicoderm CQ 21Mg/24Hr Transdermal System,GenName Y,Drug,hiv,hiv,Phase 3,2024-04-30,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* diagnosed with HIV
* at least 18 years of age
* smoking at least 5 cigarettes/day
* exhaled Carbon Monoxide level greater than 5 at baseline
* willing to use transdermal nicotin...",Yes,2025-01-18,FDA-67680,2.62,0.32,5.0,7.94,2026-12-12,2027-04-08,2032-04-08,36,Pfizer,75,Overall,48.16666666666666,2,47,27,60,55,98,64,1,3,3,True,False,True,False,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
VRC01,AltName A,Biological,hiv,hiv,Phase 2,2021-02-11,"Sex: ALL; Age: >0 Weeks; Criteria: Infant Inclusion Criteria:

* Weigh at least 2500 grams
* Confirmed HIV-1 infection
* The following laboratory values at screening:

  * Cluster of differentiation 4 (CD4) lymphocyte percentage greate...",No,2022-01-30,FDA-46123,4.41,0.98,21.0,26.39,2025-07-10,2026-07-03,2047-07-03,62,J&J,37,South Africa,61.83333333333334,77,77,2,66,68,81,55,1,3,2,False,True,False,True,True,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Combination Antiretroviral Therapy (cART),TradeName X,Drug,hiv,hiv,Phase 2,2021-02-11,"Sex: ALL; Age: >0 Weeks; Criteria: Infant Inclusion Criteria:

* Weigh at least 2500 grams
* Confirmed HIV-1 infection
* The following laboratory values at screening:

  * Cluster of differentiation 4 (CD4) lymphocyte percentage greate...",No,2021-11-16,FDA-73618,4.41,0.98,21.0,26.39,2025-07-10,2026-07-03,2047-07-03,61,AstraZeneca,45,Kenya,56.33333333333334,3,55,63,61,90,66,55,0,3,3,False,False,True,False,True,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Intermitent Dosing,AltName B,Drug,hiv,hiv,Phase 4,2009-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Age 18 years or older
* CD4 count \> or = 200
* Viral load \< 50
* Treatment with a regimen containing efavirenz and tenofovir and lamivudine or emtricitabine for at least 90 da...",Yes,2010-04-15,FDA-35893,0.56,0.15,3.5,4.21,2010-06-23,2010-08-17,2014-02-15,71,Bayer,14,Kenya,52.5,59,26,44,73,27,86,36,1,1,2,False,True,False,True,False,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
E/C/F/TAF,GenName Y,Drug,hiv,hiv,Phase 3,2016-10-26,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Both Cohorts 1 and 2:

  * The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
  * HIV/HBV co-...",Yes,2017-08-23,FDA-44515,2.62,0.32,5.0,7.94,2019-06-09,2019-10-04,2024-10-04,19,AstraZeneca,55,South Africa,62.66666666666666,85,80,77,66,20,48,55,1,3,2,False,True,True,True,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Doravirine 100 Mg,Product Alpha,Drug,hiv,hiv,Phase 4,2024-10-18,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Ability and willingness of participant or legal guardian/representative to provide informed consent.

HIV-1, documented by any licensed rapid HIV test or HIV enzyme or chemilumine...",No,2024-12-20,FDA-17410,0.56,0.15,3.5,4.21,2025-05-10,2025-07-04,2029-01-02,77,GSK,39,South Africa,77.83333333333333,96,94,90,70,19,98,45,1,3,1,False,True,True,True,False,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Integrase strand transfer inhibitors,AltName B,Drug,hiv,hiv,Phase 4,2024-10-18,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Ability and willingness of participant or legal guardian/representative to provide informed consent.

HIV-1, documented by any licensed rapid HIV test or HIV enzyme or chemilumine...",No,2024-12-30,FDA-96627,0.56,0.15,3.5,4.21,2025-05-10,2025-07-04,2029-01-02,18,Sanofi,82,Senegal,60.66666666666666,92,21,100,37,18,96,18,0,0,2,False,False,False,False,False,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir alafenamide/emtricitabine,AltName A,Drug,hiv,hiv,Phase 4,2024-10-18,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Ability and willingness of participant or legal guardian/representative to provide informed consent.

HIV-1, documented by any licensed rapid HIV test or HIV enzyme or chemilumine...",Yes,2025-07-02,FDA-24944,0.56,0.15,3.5,4.21,2025-05-10,2025-07-04,2029-01-02,59,J&J,17,Kenya,43.83333333333334,73,77,14,5,26,68,45,0,4,1,False,False,False,True,True,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
tenofovir disproxil fumarate/emtricitabine,Molecule Z,Drug,hiv,hiv,Phase 4,2024-10-18,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Ability and willingness of participant or legal guardian/representative to provide informed consent.

HIV-1, documented by any licensed rapid HIV test or HIV enzyme or chemilumine...",No,2025-03-15,FDA-91857,0.56,0.15,3.5,4.21,2025-05-10,2025-07-04,2029-01-02,61,AstraZeneca,5,Overall,41.66666666666666,4,38,85,77,28,18,45,2,1,2,True,True,False,False,False,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Dapivirine (DPV) Vaginal Ring (VR),GenName Y,Drug,hiv,hiv,Phase 3,2024-05-13,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Age 18 through 40 years (inclusive) at Enrollment, verified per site standard operating procedures (SOPs).
* At Enrollment, evidence of a viable, intrauterine, singleton pregnan...",Yes,2024-11-09,FDA-47117,2.62,0.32,5.0,7.94,2026-12-25,2027-04-21,2032-04-21,24,J&J,35,South Africa,55.16666666666666,45,27,53,30,87,89,55,1,1,4,False,True,False,True,False,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada Tablet,GenName Y,Drug,hiv,hiv,Phase 3,2024-05-13,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Age 18 through 40 years (inclusive) at Enrollment, verified per site standard operating procedures (SOPs).
* At Enrollment, evidence of a viable, intrauterine, singleton pregnan...",No,2024-09-14,FDA-67924,2.62,0.32,5.0,7.94,2026-12-25,2027-04-21,2032-04-21,96,Bayer,58,Overall,28.83333333333333,21,40,55,23,20,14,36,1,2,1,True,False,True,False,True,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Fluzone High Dose Vaccine,GenName Y,Biological,hiv,hiv,Phase 2,2013-08-01,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

* Age 3 years (on or past their 3rd birthday) through 21 years of age (not yet reached their 22nd birthday) at the time of entry into the study.
* Written informed consent (and as...",Yes,2014-02-02,FDA-44042,4.41,0.98,21.0,26.39,2017-12-28,2018-12-21,2039-12-21,36,Pfizer,88,Senegal,33.66666666666666,73,22,35,1,26,45,36,1,2,1,True,False,False,True,False,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Fluzone Standard Dose Vaccine,Comp Beta,Biological,hiv,hiv,Phase 2,2013-08-01,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

* Age 3 years (on or past their 3rd birthday) through 21 years of age (not yet reached their 22nd birthday) at the time of entry into the study.
* Written informed consent (and as...",No,2014-04-02,FDA-43227,4.41,0.98,21.0,26.39,2017-12-28,2018-12-21,2039-12-21,26,J&J,27,Senegal,42.66666666666666,42,26,65,44,43,36,55,2,3,1,True,True,True,True,False,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Palifermin,GenName Y,Drug,hiv,hiv,Phase 2,2008-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV infected
* Receiving potent ART, defined as a combination of three or more antiretroviral drugs for at least 6 months prior to study entry
* CD4 count of 200 cells/mm3 or le...",Yes,2009-02-23,FDA-79420,4.41,0.98,21.0,26.39,2013-01-28,2014-01-21,2035-01-21,50,GSK,85,Kenya,41.83333333333334,74,55,41,56,4,21,73,2,3,3,True,True,True,True,True,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada,TradeName X,Drug,hiv,hiv,Phase 4,2008-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients displaying abnormal fasted triglycerides (\> 2 g/L \[2.26 mmol/L\] and less than or equal to 10 g/L \[11.29 mmol/L\]) and/or fasted low density lipoprotein cholesterol ...",No,2008-09-30,FDA-86485,0.56,0.15,3.5,4.21,2008-09-21,2008-11-15,2012-05-16,80,GSK,49,Kenya,33.0,61,12,73,10,38,4,27,2,1,0,True,True,False,False,False,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Current HAART regimen,TradeName X,Drug,hiv,hiv,Phase 4,2008-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients displaying abnormal fasted triglycerides (\> 2 g/L \[2.26 mmol/L\] and less than or equal to 10 g/L \[11.29 mmol/L\]) and/or fasted low density lipoprotein cholesterol ...",Yes,2008-04-02,FDA-63749,0.56,0.15,3.5,4.21,2008-09-21,2008-11-15,2012-05-16,66,Gilead,9,Senegal,78.66666666666667,70,86,90,83,53,90,45,1,2,2,True,False,True,True,False,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Metronidazole,Comp Beta,Drug,hiv,hiv,Phase 4,2009-08-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Female
* 18 years or older
* HIV-positive
* TV positive by either wet preparation or culture
* ability to refrain from all alcohol use for 24 hours before and after taking oral ...",No,2010-01-24,FDA-83400,0.56,0.15,3.5,4.21,2010-02-21,2010-04-17,2013-10-16,23,AstraZeneca,89,Kenya,58.33333333333334,31,97,18,83,69,52,55,1,3,2,False,True,True,False,True,False,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir 50 mg twice daily,TradeName X,Drug,hiv,hiv,Phase 3,2013-12-16,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Screening plasma HIV-1 RNA ≥1000 copies/mL
* ART-experienced, INI-experienced, DTG naïve
* Current virological failure on raltegravir (RAL) or elvitegravir (ELV) regimen
* The s...",Yes,2014-06-13,FDA-28310,2.62,0.32,5.0,7.94,2016-07-29,2016-11-23,2021-11-24,83,AstraZeneca,16,South Africa,51.5,21,88,41,16,69,74,55,1,3,2,True,False,False,False,True,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir,Product Alpha,Drug,hiv,hiv,Phase 3,2020-10-03,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Mother is able to provide written informed consent for her and her infant's participation in this study
* Mother has confirmed HIV-1 infection based on documented testing of two...",No,2020-12-09,FDA-12685,2.62,0.32,5.0,7.94,2023-05-17,2023-09-11,2028-09-11,53,Merck,71,Kenya,39.33333333333334,69,13,50,49,35,20,36,1,3,0,True,False,False,True,True,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine/tenofovir alafenamide,Molecule Z,Drug,hiv,hiv,Phase 3,2020-10-03,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Mother is able to provide written informed consent for her and her infant's participation in this study
* Mother has confirmed HIV-1 infection based on documented testing of two...",No,2021-06-23,FDA-61673,2.62,0.32,5.0,7.94,2023-05-17,2023-09-11,2028-09-11,47,Bayer,56,South Africa,52.16666666666666,87,80,82,14,48,2,27,1,1,1,False,True,False,False,True,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine/tenofovir disoproxil fumarate,AltName A,Drug,hiv,hiv,Phase 3,2020-10-03,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Mother is able to provide written informed consent for her and her infant's participation in this study
* Mother has confirmed HIV-1 infection based on documented testing of two...",No,2021-05-03,FDA-85272,2.62,0.32,5.0,7.94,2023-05-17,2023-09-11,2028-09-11,59,GSK,30,Senegal,46.0,24,56,86,17,12,81,36,0,2,2,False,False,False,False,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz/emtricitabine/tenofovir disoproxil fumarate,Comp Beta,Drug,hiv,hiv,Phase 3,2020-10-03,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Mother is able to provide written informed consent for her and her infant's participation in this study
* Mother has confirmed HIV-1 infection based on documented testing of two...",Yes,2021-06-23,FDA-71905,2.62,0.32,5.0,7.94,2023-05-17,2023-09-11,2028-09-11,9,AstraZeneca,73,South Africa,60.66666666666666,68,54,34,74,93,41,45,1,2,2,False,True,False,False,True,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir,TradeName X,Drug,hiv,hiv,Phase 4,2010-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria :\>

* HIV-1 infected\>
* CD4 count fewer than 300 cells/mm3 \>
* Viral load test result\>
* Absolute Neutrophil Count at least 750mm3 \>
* Hemoglobin at least 7.5 g/dL\>
* Platelet...",No,2010-06-16,FDA-73217,0.56,0.15,3.5,4.21,2010-11-21,2011-01-15,2014-07-16,39,Novartis,10,Kenya,67.66666666666667,32,57,94,85,99,39,64,1,3,3,True,False,False,True,True,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Didanosine (enteric-coated),GenName Y,Drug,hiv,hiv,Phase 4,2010-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria :\>

* HIV-1 infected\>
* CD4 count fewer than 300 cells/mm3 \>
* Viral load test result\>
* Absolute Neutrophil Count at least 750mm3 \>
* Hemoglobin at least 7.5 g/dL\>
* Platelet...",Yes,2011-05-01,FDA-59854,0.56,0.15,3.5,4.21,2010-11-21,2011-01-15,2014-07-16,61,Pfizer,74,Senegal,21.66666666666667,62,9,2,12,16,29,55,2,1,3,True,True,False,True,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,Molecule Z,Drug,hiv,hiv,Phase 4,2010-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria :\>

* HIV-1 infected\>
* CD4 count fewer than 300 cells/mm3 \>
* Viral load test result\>
* Absolute Neutrophil Count at least 750mm3 \>
* Hemoglobin at least 7.5 g/dL\>
* Platelet...",No,2010-08-06,FDA-60709,0.56,0.15,3.5,4.21,2010-11-21,2011-01-15,2014-07-16,12,Pfizer,35,South Africa,51.33333333333334,42,53,23,46,53,91,73,1,3,4,False,True,False,True,True,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine,Comp Beta,Drug,hiv,hiv,Phase 4,2010-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria :\>

* HIV-1 infected\>
* CD4 count fewer than 300 cells/mm3 \>
* Viral load test result\>
* Absolute Neutrophil Count at least 750mm3 \>
* Hemoglobin at least 7.5 g/dL\>
* Platelet...",Yes,2010-07-05,FDA-17513,0.56,0.15,3.5,4.21,2010-11-21,2011-01-15,2014-07-16,89,Bayer,27,Overall,45.83333333333334,70,12,52,38,3,100,55,1,3,2,False,True,False,True,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine/Tenofovir disoproxil fumarate,Comp Beta,Drug,hiv,hiv,Phase 4,2010-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria :\>

* HIV-1 infected\>
* CD4 count fewer than 300 cells/mm3 \>
* Viral load test result\>
* Absolute Neutrophil Count at least 750mm3 \>
* Hemoglobin at least 7.5 g/dL\>
* Platelet...",Yes,2010-07-15,FDA-28455,0.56,0.15,3.5,4.21,2010-11-21,2011-01-15,2014-07-16,97,Merck,42,Senegal,40.33333333333334,7,83,2,45,45,60,27,0,2,1,False,False,True,False,False,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine/Zidovudine,AltName B,Drug,hiv,hiv,Phase 4,2010-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria :\>

* HIV-1 infected\>
* CD4 count fewer than 300 cells/mm3 \>
* Viral load test result\>
* Absolute Neutrophil Count at least 750mm3 \>
* Hemoglobin at least 7.5 g/dL\>
* Platelet...",No,2011-01-27,FDA-59034,0.56,0.15,3.5,4.21,2010-11-21,2011-01-15,2014-07-16,12,Pfizer,80,Overall,78.83333333333333,30,91,79,84,97,92,55,0,3,3,False,False,True,False,False,True,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK1265744 10 mg,AltName B,Drug,hiv,hiv,Phase 2,2019-01-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected male or female subjects \>= 18 years of age
* Screening plasma HIV-1 RNA \>=1000 c/mL
* CD4+ cell count \>=200 cells/millimeter (mm)\^3
* ART-naive defined as hav...",Yes,2019-08-07,FDA-14811,4.41,0.98,21.0,26.39,2023-06-13,2024-06-05,2045-06-05,99,Bayer,96,Kenya,34.16666666666666,45,8,52,4,96,0,73,2,3,3,True,True,True,True,False,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK1265744 30 mg,Comp Beta,Drug,hiv,hiv,Phase 2,2019-01-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected male or female subjects \>= 18 years of age
* Screening plasma HIV-1 RNA \>=1000 c/mL
* CD4+ cell count \>=200 cells/millimeter (mm)\^3
* ART-naive defined as hav...",Yes,2019-02-22,FDA-29177,4.41,0.98,21.0,26.39,2023-06-13,2024-06-05,2045-06-05,2,Gilead,97,Kenya,56.33333333333334,54,49,34,70,96,35,27,1,2,0,False,True,False,False,True,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK1265744 60 mg,Comp Beta,Drug,hiv,hiv,Phase 2,2019-01-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected male or female subjects \>= 18 years of age
* Screening plasma HIV-1 RNA \>=1000 c/mL
* CD4+ cell count \>=200 cells/millimeter (mm)\^3
* ART-naive defined as hav...",Yes,2019-05-02,FDA-68889,4.41,0.98,21.0,26.39,2023-06-13,2024-06-05,2045-06-05,87,Pfizer,69,Senegal,59.83333333333334,43,99,94,23,98,2,55,1,3,2,False,True,True,False,True,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz 600 mg,Molecule Z,Drug,hiv,hiv,Phase 2,2019-01-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected male or female subjects \>= 18 years of age
* Screening plasma HIV-1 RNA \>=1000 c/mL
* CD4+ cell count \>=200 cells/millimeter (mm)\^3
* ART-naive defined as hav...",Yes,2019-05-31,FDA-96141,4.41,0.98,21.0,26.39,2023-06-13,2024-06-05,2045-06-05,33,AstraZeneca,73,Overall,37.33333333333334,43,8,38,38,35,62,45,0,2,3,False,False,False,True,True,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rilpivirine 25 mg,Comp Beta,Drug,hiv,hiv,Phase 2,2019-01-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected male or female subjects \>= 18 years of age
* Screening plasma HIV-1 RNA \>=1000 c/mL
* CD4+ cell count \>=200 cells/millimeter (mm)\^3
* ART-naive defined as hav...",No,2019-03-05,FDA-31233,4.41,0.98,21.0,26.39,2023-06-13,2024-06-05,2045-06-05,19,Merck,44,Kenya,46.83333333333334,2,65,59,93,21,41,45,1,3,1,False,True,True,True,False,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC),AltName B,Drug,hiv,hiv,Phase 2,2019-01-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected male or female subjects \>= 18 years of age
* Screening plasma HIV-1 RNA \>=1000 c/mL
* CD4+ cell count \>=200 cells/millimeter (mm)\^3
* ART-naive defined as hav...",No,2019-10-19,FDA-80826,4.41,0.98,21.0,26.39,2023-06-13,2024-06-05,2045-06-05,56,Sanofi,30,Overall,32.0,52,4,25,6,59,46,55,1,3,2,False,True,True,False,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Abacavir/lamivudine and efavirenz,Molecule Z,Drug,hiv,hiv,Phase 4,2009-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subject is at least 18 years of age.
* Subject is antiretroviral-naïve (defined as having no previous therapy with any NNRTI and 14 days of prior therapy with any other antiretr...",Yes,2010-10-05,FDA-44706,0.56,0.15,3.5,4.21,2010-06-23,2010-08-17,2014-02-15,91,Sanofi,49,Senegal,67.33333333333333,86,84,80,73,55,26,45,1,2,2,False,True,True,True,False,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir/Emtricitabine and efavirenz,Molecule Z,Drug,hiv,hiv,Phase 4,2009-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subject is at least 18 years of age.
* Subject is antiretroviral-naïve (defined as having no previous therapy with any NNRTI and 14 days of prior therapy with any other antiretr...",Yes,2010-05-30,FDA-87388,0.56,0.15,3.5,4.21,2010-06-23,2010-08-17,2014-02-15,79,Bayer,8,Senegal,58.66666666666666,96,89,49,72,8,38,18,0,1,1,False,False,False,False,False,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
LC002 standard vaccination,AltName B,Biological,hiv,hiv,Phase 2,2010-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1-infected
* On a stable HAART regimen without changes or interruptions for more than 4 consecutive days for at least 12 weeks prior to study entry. Patients must be current...",No,2011-03-10,FDA-12638,4.41,0.98,21.0,26.39,2015-01-28,2016-01-21,2037-01-20,37,AstraZeneca,30,South Africa,49.0,12,48,90,88,54,2,36,0,1,3,False,False,False,True,False,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
LC002 high-dose vaccination,AltName A,Biological,hiv,hiv,Phase 2,2010-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1-infected
* On a stable HAART regimen without changes or interruptions for more than 4 consecutive days for at least 12 weeks prior to study entry. Patients must be current...",No,2011-03-03,FDA-84998,4.41,0.98,21.0,26.39,2015-01-28,2016-01-21,2037-01-20,24,Sanofi,33,Senegal,46.83333333333334,46,29,46,85,44,31,64,0,4,3,False,False,True,False,True,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
TUTI-16 (0.03mg),GenName Y,Biological,hiv,hiv,Phase 2,2010-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Males and Females
* Age ≥18 and ≤50 years at Screening
* HIV-1 seropositive
* asymptomatic and in generally good health
* no prior anti-retroviral therapy within 6 months of scr...",Yes,2010-09-20,FDA-32181,4.41,0.98,21.0,26.39,2014-09-27,2015-09-20,2036-09-19,94,Sanofi,54,Kenya,56.16666666666666,27,93,63,77,10,67,64,1,4,2,True,False,False,True,True,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
TUTI-16 (0.1mg),Product Alpha,Biological,hiv,hiv,Phase 2,2010-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Males and Females
* Age ≥18 and ≤50 years at Screening
* HIV-1 seropositive
* asymptomatic and in generally good health
* no prior anti-retroviral therapy within 6 months of scr...",No,2010-10-16,FDA-82235,4.41,0.98,21.0,26.39,2014-09-27,2015-09-20,2036-09-19,27,Merck,14,Overall,48.5,56,51,59,13,83,29,45,2,2,1,True,True,False,True,False,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
TUTI-16 (0.6mg),GenName Y,Biological,hiv,hiv,Phase 2,2010-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Males and Females
* Age ≥18 and ≤50 years at Screening
* HIV-1 seropositive
* asymptomatic and in generally good health
* no prior anti-retroviral therapy within 6 months of scr...",Yes,2010-07-18,FDA-71301,4.41,0.98,21.0,26.39,2014-09-27,2015-09-20,2036-09-19,57,Bayer,2,South Africa,40.83333333333334,60,21,16,33,95,20,36,1,1,2,False,True,False,False,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ATV/r,Molecule Z,Drug,hiv,hiv,Phase 4,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Currently receiving Antiretroviral Therapy (ART) regimen including LPV/r or FPV/r and \> or equal to 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs). Patient must be on a ...",No,2012-04-30,FDA-95836,0.56,0.15,3.5,4.21,2011-12-22,2012-02-15,2015-08-16,25,Gilead,75,Senegal,66.0,76,90,59,93,64,14,55,1,3,2,True,False,False,True,True,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DRV/r,AltName A,Drug,hiv,hiv,Phase 4,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Currently receiving Antiretroviral Therapy (ART) regimen including LPV/r or FPV/r and \> or equal to 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs). Patient must be on a ...",No,2011-12-15,FDA-28034,0.56,0.15,3.5,4.21,2011-12-22,2012-02-15,2015-08-16,43,Sanofi,82,Overall,63.66666666666666,79,74,78,50,26,75,18,1,0,1,True,False,False,False,False,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir 50 mg,Product Alpha,Drug,hiv,hiv,Phase 2,2022-10-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

HIV positive patients over 18 years old, who have failed first-line ART regimen of tenofovir-emtricitabine/lamivudine-efavirenz, are able to attend the study clinic for one year o...",No,2023-01-14,FDA-91605,4.41,0.98,21.0,26.39,2027-03-25,2028-03-17,2049-03-17,9,Sanofi,95,Kenya,36.83333333333334,88,13,3,42,20,55,55,0,2,4,False,False,False,True,False,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Optimized Background Therapy (OBT),Molecule Z,Drug,hiv,hiv,Phase 3,2009-04-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Men or women at least 16 years of age (or minimum age as determined by local regulatory authorities)
* HIV-1 RNA viral load of greater than or equal to 5,000 copies/mL
* Stable ...",No,2010-02-08,FDA-97490,2.62,0.32,5.0,7.94,2011-11-13,2012-03-09,2017-03-10,2,Sanofi,68,Overall,68.0,56,91,51,83,90,37,45,1,3,1,False,True,True,True,False,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"maraviroc (UK-427,857)",GenName Y,Drug,hiv,hiv,Phase 3,2009-04-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Men or women at least 16 years of age (or minimum age as determined by local regulatory authorities)
* HIV-1 RNA viral load of greater than or equal to 5,000 copies/mL
* Stable ...",No,2010-02-06,FDA-76343,2.62,0.32,5.0,7.94,2011-11-13,2012-03-09,2017-03-10,51,Merck,53,Overall,60.66666666666666,76,46,47,53,66,76,45,1,2,2,True,False,False,False,True,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Optimized Background Therapy (OBT),TradeName X,Drug,hiv,hiv,Phase 3,2009-04-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Men or women at least 16 years of age (or minimum age as determined by local regulatory authorities)
* HIV-1 RNA viral load of greater than or equal to 5,000 copies/mL
* Stable ...",No,2010-02-05,FDA-63916,2.62,0.32,5.0,7.94,2011-11-13,2012-03-09,2017-03-10,55,Merck,40,South Africa,63.16666666666666,53,67,75,95,76,13,45,1,3,1,False,True,True,True,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"maraviroc (UK-427,857)",AltName A,Drug,hiv,hiv,Phase 3,2009-04-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Men or women at least 16 years of age (or minimum age as determined by local regulatory authorities)
* HIV-1 RNA viral load of greater than or equal to 5,000 copies/mL
* Stable ...",Yes,2009-05-29,FDA-35094,2.62,0.32,5.0,7.94,2011-11-13,2012-03-09,2017-03-10,5,Gilead,36,Senegal,66.0,48,41,98,97,18,94,55,2,2,2,True,True,False,False,True,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Optimized Background Therapy (OBT),AltName B,Drug,hiv,hiv,Phase 3,2009-04-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Men or women at least 16 years of age (or minimum age as determined by local regulatory authorities)
* HIV-1 RNA viral load of greater than or equal to 5,000 copies/mL
* Stable ...",Yes,2009-11-23,FDA-23105,2.62,0.32,5.0,7.94,2011-11-13,2012-03-09,2017-03-10,42,Gilead,95,Kenya,39.16666666666666,81,68,12,13,26,35,36,0,4,0,False,False,True,True,False,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Subjects do not receive study medication in this study 202094,Comp Beta,Drug,hiv,hiv,Phase 3,2018-08-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Screened and eligible but not yet randomised to either of the parent studies 201636 (SWORD-1) or 201637 (SWORD-2)
* Receiving an ART regimen which contains TDF
* Female subjects...",Yes,2019-02-13,FDA-38055,2.62,0.32,5.0,7.94,2021-03-30,2021-07-25,2026-07-26,16,Bayer,54,South Africa,69.66666666666667,24,91,62,93,90,58,27,1,1,1,True,False,True,False,False,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
pitavastatin,Product Alpha,Drug,hiv,hiv,Phase 4,2015-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* aged ≥18 years
* able to provide informed consent
* had confirmed HIV infection
* on ART including atazanavir 300 mg and ritonavir 100 mg each day in the regimens that were not ...",No,2015-10-05,FDA-98768,0.56,0.15,3.5,4.21,2015-07-24,2015-09-17,2019-03-18,81,Bayer,76,Senegal,25.0,85,10,8,19,19,9,45,2,1,2,True,True,True,False,False,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
miconazole Lauriad,TradeName X,Drug,hiv,hiv,Phase 3,2008-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients with clinical picture of oropharyngeal candidiasis
* Confirmation of oropharyngeal candidiasis by candida culture positive
* HIV-positive patients
* Patients 18 years o...",No,2008-05-24,FDA-90256,2.62,0.32,5.0,7.94,2010-08-14,2010-12-09,2015-12-10,9,Merck,48,Senegal,42.5,4,73,13,50,85,30,45,1,3,1,True,False,False,True,False,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Clotrimazole,Molecule Z,Drug,hiv,hiv,Phase 3,2008-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients with clinical picture of oropharyngeal candidiasis
* Confirmation of oropharyngeal candidiasis by candida culture positive
* HIV-positive patients
* Patients 18 years o...",Yes,2008-08-09,FDA-56364,2.62,0.32,5.0,7.94,2010-08-14,2010-12-09,2015-12-10,45,Novartis,31,Kenya,64.16666666666667,58,69,42,52,72,92,64,1,3,3,True,False,False,True,True,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Varenicline,Comp Beta,Drug,hiv,hiv,Phase 3,2021-04-01,"Sex: ALL; Age: >18 Years; Criteria: Study Inclusion Criteria:

1. Confirmed chart diagnosis of a HIV and receiving HIV treatment at the participating HIV clinic.
2. Age 18 years or older.
3. Currently self-report smoking 10 cigarettes p...",Yes,2021-06-06,FDA-54102,2.62,0.32,5.0,7.94,2023-11-13,2024-03-09,2029-03-10,63,Bayer,16,South Africa,48.5,52,3,27,65,76,68,45,0,2,3,False,False,True,False,False,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Background ARVs,AltName B,Drug,hiv,hiv,Phase 4,2007-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* adult patients, \>=18 years of age;
* seropositive for HIV-1;
* enrolled in an early access program for a new investigational PI;
* naive to Fuzeon, and the investigational PI;
...",Yes,2007-10-23,FDA-85225,0.56,0.15,3.5,4.21,2007-11-21,2008-01-15,2011-07-16,35,Gilead,68,South Africa,41.33333333333334,70,63,2,56,9,48,45,1,2,2,False,True,False,True,False,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
PI,AltName A,Drug,hiv,hiv,Phase 4,2007-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* adult patients, \>=18 years of age;
* seropositive for HIV-1;
* enrolled in an early access program for a new investigational PI;
* naive to Fuzeon, and the investigational PI;
...",No,2007-07-29,FDA-17674,0.56,0.15,3.5,4.21,2007-11-21,2008-01-15,2011-07-16,26,J&J,98,Overall,60.16666666666666,10,96,63,94,94,4,27,1,1,1,True,False,True,False,False,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
enfuvirtide [Fuzeon],GenName Y,Drug,hiv,hiv,Phase 4,2007-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* adult patients, \>=18 years of age;
* seropositive for HIV-1;
* enrolled in an early access program for a new investigational PI;
* naive to Fuzeon, and the investigational PI;
...",Yes,2007-12-07,FDA-63864,0.56,0.15,3.5,4.21,2007-11-21,2008-01-15,2011-07-16,84,Gilead,55,Senegal,55.66666666666666,70,89,92,52,0,31,27,1,2,0,False,True,False,True,False,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"Abacavir sulfate, Lamivudine, and Zidovudine",GenName Y,Drug,hiv,hiv,Phase 2,2008-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Acute HIV infection with HIV viral load of more than 50,000 copies/ml AND either negative ELISA OR Western blot with 5 bands or less within 4 weeks prior to study entry
* Hepati...",Yes,2008-03-17,FDA-91330,4.41,0.98,21.0,26.39,2012-05-29,2013-05-22,2034-05-22,37,Pfizer,53,Senegal,61.16666666666666,37,75,80,95,39,41,55,0,3,3,False,False,True,True,True,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir/Ritonavir,Comp Beta,Drug,hiv,hiv,Phase 2,2008-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Acute HIV infection with HIV viral load of more than 50,000 copies/ml AND either negative ELISA OR Western blot with 5 bands or less within 4 weeks prior to study entry
* Hepati...",Yes,2008-02-24,FDA-16082,4.41,0.98,21.0,26.39,2012-05-29,2013-05-22,2034-05-22,56,J&J,85,South Africa,70.16666666666667,97,88,53,53,91,39,64,2,3,2,True,True,False,False,True,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ATRIPLA,Comp Beta,Drug,hiv,hiv,Phase 4,2015-07-21,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adults (≥ 18 years)
* HIV-1 infection, clinical stability, and treatment with ATRIPLA ® for the past two years.
* Standard plasma viral load below the limit of detection for at ...",No,2016-05-07,FDA-74510,0.56,0.15,3.5,4.21,2016-02-10,2016-04-05,2019-10-05,26,Bayer,38,Senegal,33.16666666666666,2,20,99,45,25,8,55,1,2,3,False,True,False,False,True,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ATV,Comp Beta,Drug,hiv,hiv,Phase 3,2008-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV RNA ≥5000 c/ml

Exclusion Criteria:

* Any antiretroviral therapy within 30 days prior to screening;
* Women of Childbearing potential (WOCBP) unwilling or unable to use an ...",No,2009-08-29,FDA-44073,2.62,0.32,5.0,7.94,2011-05-15,2011-09-09,2016-09-09,76,J&J,61,Overall,47.16666666666666,17,82,1,94,17,72,36,0,2,2,False,False,True,True,False,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
RTV,Product Alpha,Drug,hiv,hiv,Phase 3,2008-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV RNA ≥5000 c/ml

Exclusion Criteria:

* Any antiretroviral therapy within 30 days prior to screening;
* Women of Childbearing potential (WOCBP) unwilling or unable to use an ...",No,2009-03-28,FDA-99219,2.62,0.32,5.0,7.94,2011-05-15,2011-09-09,2016-09-09,26,Sanofi,14,Senegal,41.83333333333334,46,16,66,16,41,66,55,0,4,2,False,False,True,True,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovi-Emtricitabine (TDF/FTC) tablet,AltName A,Drug,hiv,hiv,Phase 3,2008-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV RNA ≥5000 c/ml

Exclusion Criteria:

* Any antiretroviral therapy within 30 days prior to screening;
* Women of Childbearing potential (WOCBP) unwilling or unable to use an ...",Yes,2008-12-21,FDA-93782,2.62,0.32,5.0,7.94,2011-05-15,2011-09-09,2016-09-09,22,Novartis,82,South Africa,44.0,43,52,9,18,52,90,45,0,4,1,False,False,True,False,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
LPV,Molecule Z,Drug,hiv,hiv,Phase 3,2008-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV RNA ≥5000 c/ml

Exclusion Criteria:

* Any antiretroviral therapy within 30 days prior to screening;
* Women of Childbearing potential (WOCBP) unwilling or unable to use an ...",Yes,2009-07-11,FDA-54766,2.62,0.32,5.0,7.94,2011-05-15,2011-09-09,2016-09-09,79,Bayer,79,Senegal,51.33333333333334,69,60,24,10,61,84,73,1,4,3,True,False,True,True,True,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
VRC01,Comp Beta,Biological,hiv,hiv,Phase 2,2020-12-01,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

General and Demographic Criteria

* Age of 18 to 50 years
* Access to a participating clinical research site (CRS) and willingness to be followed for the planned duration of the s...",No,2021-04-04,FDA-56416,4.41,0.98,21.0,26.39,2025-04-29,2026-04-22,2047-04-22,89,GSK,46,Senegal,45.16666666666666,40,73,3,32,99,24,64,1,3,3,True,False,True,True,False,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
pneumococcal conjugate vaccine,TradeName X,Biological,hiv,hiv,Phase 3,2013-07-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria for HIV positive subjects:

1. At least one prior PPV ≥ 3 and \< 8 years ago, while HIV positive. There is no upper limit to the number of previously received PPVs.
2. HIV-positive ...",Yes,2013-10-24,FDA-55087,2.62,0.32,5.0,7.94,2016-02-12,2016-06-08,2021-06-09,61,Gilead,9,Senegal,33.33333333333334,13,11,16,4,57,99,55,2,1,3,True,True,False,False,True,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
pneumococcal polysaccharide vaccine,AltName B,Biological,hiv,hiv,Phase 3,2013-07-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria for HIV positive subjects:

1. At least one prior PPV ≥ 3 and \< 8 years ago, while HIV positive. There is no upper limit to the number of previously received PPVs.
2. HIV-positive ...",No,2014-04-24,FDA-38669,2.62,0.32,5.0,7.94,2016-02-12,2016-06-08,2021-06-09,17,GSK,96,South Africa,60.5,96,95,8,44,27,93,45,0,3,2,False,False,False,False,True,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Dapivirine vaginal ring,TradeName X,Device,hiv,hiv,Phase 2,2021-09-09,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Age 16 through 21 years (inclusive) at Enrollment, verified per site standard operating procedures (SOPs).
* Able and willing to provide informed consent, and if under the legal...",Yes,2022-01-24,FDA-32967,4.41,0.98,21.0,26.39,2026-02-05,2027-01-29,2048-01-29,87,AstraZeneca,44,Overall,30.83333333333333,54,66,23,13,16,13,27,0,2,1,False,False,False,False,True,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TDF,GenName Y,Drug,hiv,hiv,Phase 2,2021-09-09,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Age 16 through 21 years (inclusive) at Enrollment, verified per site standard operating procedures (SOPs).
* Able and willing to provide informed consent, and if under the legal...",No,2022-03-01,FDA-43338,4.41,0.98,21.0,26.39,2026-02-05,2027-01-29,2048-01-29,87,Novartis,95,South Africa,60.0,94,8,66,69,30,93,82,2,3,4,True,True,False,True,False,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
CAB Oral Tablets,Comp Beta,Drug,hiv,hiv,Phase 2,2023-04-20,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects screened for this study must be HIV-1 infected and \>=18 years of age.
* A female subject is eligible to enter and participate in the study if she: is of non-child-bear...",Yes,2023-05-22,FDA-83532,4.41,0.98,21.0,26.39,2027-09-16,2028-09-08,2049-09-08,76,Merck,97,South Africa,38.5,24,0,21,88,28,70,36,1,3,0,True,False,True,True,True,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
CAB LA,Molecule Z,Drug,hiv,hiv,Phase 2,2023-04-20,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects screened for this study must be HIV-1 infected and \>=18 years of age.
* A female subject is eligible to enter and participate in the study if she: is of non-child-bear...",No,2023-10-01,FDA-34962,4.41,0.98,21.0,26.39,2027-09-16,2028-09-08,2049-09-08,59,AstraZeneca,24,Senegal,52.33333333333334,61,89,53,26,33,52,64,2,2,3,True,True,False,False,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ABC/3TC Oral tablets,Molecule Z,Drug,hiv,hiv,Phase 2,2023-04-20,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects screened for this study must be HIV-1 infected and \>=18 years of age.
* A female subject is eligible to enter and participate in the study if she: is of non-child-bear...",Yes,2023-11-15,FDA-91619,4.41,0.98,21.0,26.39,2027-09-16,2028-09-08,2049-09-08,33,Pfizer,61,South Africa,65.0,83,94,43,35,48,87,36,1,1,2,False,True,False,False,True,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
RPV Oral Tablets,AltName B,Drug,hiv,hiv,Phase 2,2023-04-20,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects screened for this study must be HIV-1 infected and \>=18 years of age.
* A female subject is eligible to enter and participate in the study if she: is of non-child-bear...",No,2024-02-19,FDA-50168,4.41,0.98,21.0,26.39,2027-09-16,2028-09-08,2049-09-08,60,Sanofi,33,Senegal,29.83333333333333,77,18,11,6,11,56,45,2,3,0,True,True,False,True,True,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
RPV,Product Alpha,Drug,hiv,hiv,Phase 2,2023-04-20,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects screened for this study must be HIV-1 infected and \>=18 years of age.
* A female subject is eligible to enter and participate in the study if she: is of non-child-bear...",Yes,2023-07-19,FDA-30836,4.41,0.98,21.0,26.39,2027-09-16,2028-09-08,2049-09-08,1,Novartis,100,Kenya,37.5,1,48,17,91,29,39,36,1,3,0,True,False,True,True,True,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Nicotine Replacement Therapy,AltName B,Drug,hiv,hiv,Phase 4,2024-05-23,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Diagnosed with HIV (based on self-report).
* Be 18 years and older
* Have smoked ≥ 5 cigarettes/day in the past year
* Be interested in making a quit attempt in the next 30 days...",Yes,2024-12-26,FDA-55806,0.56,0.15,3.5,4.21,2024-12-13,2025-02-06,2028-08-07,41,Novartis,73,South Africa,54.5,42,97,8,90,61,29,55,1,3,2,True,False,True,False,True,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Kaletra + Isentress,TradeName X,Drug,hiv,hiv,Phase 2,2014-02-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented HIV-1 infection.
* Treatment naïve (defined as having never received any HIV antiretroviral agents in past).
* CD4+ T-cell count greater than or equal to 50 cells/mm3...",Yes,2015-01-18,FDA-91209,4.41,0.98,21.0,26.39,2018-07-10,2019-07-03,2040-07-02,72,Gilead,93,South Africa,54.16666666666666,75,4,65,76,64,41,27,0,1,2,False,False,True,False,False,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Atripla,AltName B,Drug,hiv,hiv,Phase 2,2014-02-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented HIV-1 infection.
* Treatment naïve (defined as having never received any HIV antiretroviral agents in past).
* CD4+ T-cell count greater than or equal to 50 cells/mm3...",Yes,2014-09-12,FDA-96028,4.41,0.98,21.0,26.39,2018-07-10,2019-07-03,2040-07-02,59,Novartis,51,Overall,46.5,70,27,14,88,58,22,55,1,2,3,True,False,False,False,False,True,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Darunavir (DRV/r),TradeName X,Drug,hiv,hiv,Phase 4,2010-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Age 18 years or older
* Treatment with a stable antiretroviral regimen containing two protease inhibitors, one additional FDA-licensed agent from another class (except NNRTIs) a...",No,2010-08-25,FDA-75658,0.56,0.15,3.5,4.21,2010-08-24,2010-10-18,2014-04-18,54,GSK,98,Senegal,45.16666666666666,18,62,48,45,37,61,45,1,2,2,True,False,False,False,True,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
continue on current dual boosted PI,AltName B,Drug,hiv,hiv,Phase 4,2010-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Age 18 years or older
* Treatment with a stable antiretroviral regimen containing two protease inhibitors, one additional FDA-licensed agent from another class (except NNRTIs) a...",No,2010-05-11,FDA-65090,0.56,0.15,3.5,4.21,2010-08-24,2010-10-18,2014-04-18,36,Gilead,87,South Africa,45.0,32,3,73,21,77,64,64,0,4,3,False,False,True,True,False,True,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir 50 mg,Molecule Z,Drug,hiv,hiv,Phase 2,2022-06-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection as documented by screening plasma HIV-1 RNA \>1000 c/mL
* ART-naïve (short-term antiretroviral use for prevention of mother-to-child transmission will be allowed...",No,2023-03-15,FDA-89421,4.41,0.98,21.0,26.39,2026-11-24,2027-11-17,2048-11-16,19,Pfizer,80,South Africa,49.33333333333334,97,41,73,48,37,0,64,0,3,4,False,False,False,True,False,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
B/FTC/TAF,TradeName X,Drug,hiv,hiv,Phase 4,2020-12-15,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Self-identified transgender woman (TW)
* HIV infection
* Undetectable HIV viral load (HIV-1 RNA \<50 copies/mL) at screening and for \>/=24 weeks prior to entry.
* Current HIV t...",Yes,2021-04-26,FDA-23399,0.56,0.15,3.5,4.21,2021-07-07,2021-08-31,2025-03-01,53,Gilead,5,Kenya,30.83333333333333,17,48,58,34,8,20,36,1,2,1,True,False,False,False,True,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Current ART,Product Alpha,Drug,hiv,hiv,Phase 4,2020-12-15,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Self-identified transgender woman (TW)
* HIV infection
* Undetectable HIV viral load (HIV-1 RNA \<50 copies/mL) at screening and for \>/=24 weeks prior to entry.
* Current HIV t...",Yes,2021-07-19,FDA-14076,0.56,0.15,3.5,4.21,2021-07-07,2021-08-31,2025-03-01,61,Novartis,41,Senegal,44.66666666666666,87,35,55,39,52,0,64,2,2,3,True,True,False,False,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Serostim,GenName Y,Biological,hiv,hiv,Phase 3,2006-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Must meet all inclusion/exclusion criteria for Serono Study 25373, have participated in Serono Study 24380, must have been assigned to Group A, must have completed all treatment...",No,2006-11-24,FDA-91404,2.62,0.32,5.0,7.94,2008-08-14,2008-12-09,2013-12-10,94,J&J,52,South Africa,47.5,14,29,86,72,61,23,64,1,3,3,False,True,True,True,True,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets,AltName B,Drug,hiv,hiv,Phase 2,2022-05-31,"Sex: ALL; Criteria: Inclusion Criteria:

* Weight 6 kg to less than 40 kg at entry
* Antiretroviral therapy (ART)-naïve at entry or has been taking a stable ART regimen for at least six consecutive months at entry

  * N...",No,2022-10-21,FDA-28830,4.41,0.98,21.0,26.39,2026-10-27,2027-10-20,2048-10-19,42,Gilead,18,Kenya,64.66666666666667,99,38,14,54,89,94,45,0,2,3,False,False,True,True,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release),Comp Beta,Drug,hiv,hiv,Phase 2,2022-05-31,"Sex: ALL; Criteria: Inclusion Criteria:

* Weight 6 kg to less than 40 kg at entry
* Antiretroviral therapy (ART)-naïve at entry or has been taking a stable ART regimen for at least six consecutive months at entry

  * N...",Yes,2023-03-17,FDA-21622,4.41,0.98,21.0,26.39,2026-10-27,2027-10-20,2048-10-19,86,J&J,99,South Africa,57.83333333333334,79,99,24,50,33,62,64,2,2,3,True,True,False,True,False,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tesamorelin,Molecule Z,Drug,hiv,hiv,Phase 3,2008-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects who have completed the 26 weeks treatment period of the TH9507-CTR-1011 study.
* Signed informed consent before any trial-related activities.

Exclusion Criteria:

* Fa...",No,2009-08-06,FDA-61138,2.62,0.32,5.0,7.94,2011-05-15,2011-09-09,2016-09-09,59,Novartis,56,Overall,50.83333333333334,49,50,32,33,70,71,64,2,4,1,True,True,True,True,True,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Asunaprevir and Daclatasvir,GenName Y,Drug,hiv,hiv,Phase 2,2016-11-01,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA

Subjects who meet the following criteria are eligible to enter the study:

1. Eighteen years of age or older at screening
2. Naive to treatment for hepatitis C or treatment exper...",No,2017-09-21,FDA-45425,4.41,0.98,21.0,26.39,2021-03-30,2022-03-23,2043-03-23,98,Sanofi,33,Senegal,56.83333333333334,83,61,7,73,52,65,64,1,4,2,False,True,True,True,True,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Asunaprevir and Daclatasvir with BMS-791325,Product Alpha,Drug,hiv,hiv,Phase 2,2016-11-01,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA

Subjects who meet the following criteria are eligible to enter the study:

1. Eighteen years of age or older at screening
2. Naive to treatment for hepatitis C or treatment exper...",Yes,2017-08-01,FDA-74206,4.41,0.98,21.0,26.39,2021-03-30,2022-03-23,2043-03-23,79,Merck,27,Overall,28.16666666666667,45,13,39,2,58,12,73,2,3,3,True,True,False,False,True,True,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Fludarabine,Molecule Z,Drug,hiv,hiv,Phase 2,2022-11-30,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* \>= 6 months to =\< 65 years
* Treatment with combination antiretroviral therapy (cART) for at least 1 month before enrollment
* Viral load \< 5000 copies/ml plasma on cART
* Di...",No,2023-03-10,FDA-24561,4.41,0.98,21.0,26.39,2027-04-28,2028-04-20,2049-04-20,70,Pfizer,3,Kenya,67.5,26,59,83,84,60,93,55,1,4,1,True,False,False,True,True,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Cyclophosphamide,Product Alpha,Drug,hiv,hiv,Phase 2,2022-11-30,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* \>= 6 months to =\< 65 years
* Treatment with combination antiretroviral therapy (cART) for at least 1 month before enrollment
* Viral load \< 5000 copies/ml plasma on cART
* Di...",No,2023-10-28,FDA-42104,4.41,0.98,21.0,26.39,2027-04-28,2028-04-20,2049-04-20,60,Gilead,81,South Africa,51.16666666666666,10,61,62,26,55,93,45,1,2,2,False,True,True,False,False,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Thiotepa,AltName B,Drug,hiv,hiv,Phase 2,2022-11-30,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* \>= 6 months to =\< 65 years
* Treatment with combination antiretroviral therapy (cART) for at least 1 month before enrollment
* Viral load \< 5000 copies/ml plasma on cART
* Di...",No,2023-01-14,FDA-36224,4.41,0.98,21.0,26.39,2027-04-28,2028-04-20,2049-04-20,26,Pfizer,43,Senegal,54.0,66,84,93,58,8,15,64,1,4,2,True,False,True,True,True,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Dilanubicel,Product Alpha,Biological,hiv,hiv,Phase 2,2022-11-30,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* \>= 6 months to =\< 65 years
* Treatment with combination antiretroviral therapy (cART) for at least 1 month before enrollment
* Viral load \< 5000 copies/ml plasma on cART
* Di...",No,2023-09-15,FDA-95575,4.41,0.98,21.0,26.39,2027-04-28,2028-04-20,2049-04-20,91,Novartis,0,South Africa,50.66666666666666,72,50,25,41,28,88,45,2,2,1,True,True,False,True,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Switch ritonavir-boosted PI,Product Alpha,Drug,hiv,hiv,Phase 4,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-positive status
* Adults (≥18 years of age)
* Stable and well-tolerated combination ART including a ritonavir-boosted protease inhibitor for the previous 6 months
* HIV RNA ...",Yes,2015-07-09,FDA-27177,0.56,0.15,3.5,4.21,2015-03-24,2015-05-18,2018-11-16,0,Gilead,53,Senegal,49.16666666666666,44,92,49,36,71,3,45,0,2,3,False,False,True,False,True,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Continue Ritonavir-boosted PI+Rosuvastatin,Product Alpha,Drug,hiv,hiv,Phase 4,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-positive status
* Adults (≥18 years of age)
* Stable and well-tolerated combination ART including a ritonavir-boosted protease inhibitor for the previous 6 months
* HIV RNA ...",No,2015-06-09,FDA-10644,0.56,0.15,3.5,4.21,2015-03-24,2015-05-18,2018-11-16,91,Pfizer,82,South Africa,72.66666666666667,66,44,84,96,74,72,55,1,2,3,False,True,True,False,True,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Grazoprevir/Elbasvir 100mg/50mg,AltName B,Drug,hiv,hiv,Phase 3,2019-01-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. HIV positive
2. Acute HCV genotype 1 or 4 infection (≤26 weeks old at the baseline visit)

Exclusion Criteria:

1. Not on cART and a CD4 \<500 at the time of screening
2. Patie...",No,2019-10-13,FDA-53750,2.62,0.32,5.0,7.94,2021-08-24,2021-12-19,2026-12-20,48,Bayer,84,Kenya,65.5,49,51,76,68,74,75,45,0,1,4,False,False,True,False,False,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r),Product Alpha,Drug,hiv,hiv,Phase 3,2010-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

* Subject is ≥ 18 years of age and has documented evidence of HIV-1 infection. (A female is eligible to enter and participate in this study if she is of: non child-bearing potenti...",No,2011-06-08,FDA-91459,2.62,0.32,5.0,7.94,2013-02-11,2013-06-08,2018-06-09,23,Gilead,99,Kenya,31.0,3,49,20,10,98,6,64,2,2,3,True,True,True,False,False,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV),Molecule Z,Drug,hiv,hiv,Phase 3,2010-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

* Subject is ≥ 18 years of age and has documented evidence of HIV-1 infection. (A female is eligible to enter and participate in this study if she is of: non child-bearing potenti...",No,2011-02-16,FDA-58021,2.62,0.32,5.0,7.94,2013-02-11,2013-06-08,2018-06-09,7,AstraZeneca,43,Senegal,47.83333333333334,1,50,38,84,78,36,45,1,3,1,True,False,False,False,True,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
lopinavir/ritonavir (Kaletra®) tablets,Comp Beta,Drug,hiv,hiv,Phase 4,2009-05-01,"Sex: FEMALE; Age: >6 Years; Criteria: Inclusion Criteria:

* Documented HIV infection
* Taking lopinavir/ritonavir (Kaletra) tablets at standard pediatric doses for greater than two weeks
* Concomitant medications and/or natural products,...",No,2010-01-09,FDA-10556,0.56,0.15,3.5,4.21,2009-11-21,2010-01-15,2013-07-16,26,Sanofi,9,Senegal,54.0,60,58,47,0,64,95,36,1,1,2,True,False,False,True,False,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Cabotegravir (CAB) tablet,GenName Y,Drug,hiv,hiv,Phase 3,2025-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria: - HIV-1 infected, ART-naive men or women aged 18 years or greater at the time of signing the informed consent. - HIV-1 infection as documented by Screening plasma HIV-1 RNA \>=1000...",Yes,2026-10-05,FDA-64797,2.62,0.32,5.0,7.94,2028-08-13,2028-12-08,2033-12-09,41,AstraZeneca,99,South Africa,69.83333333333333,45,83,96,58,62,75,36,0,4,0,False,False,True,True,True,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rilpivirine (RPV) tablet,Product Alpha,Drug,hiv,hiv,Phase 3,2025-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria: - HIV-1 infected, ART-naive men or women aged 18 years or greater at the time of signing the informed consent. - HIV-1 infection as documented by Screening plasma HIV-1 RNA \>=1000...",No,2026-02-01,FDA-11787,2.62,0.32,5.0,7.94,2028-08-13,2028-12-08,2033-12-09,40,Novartis,46,Overall,43.83333333333334,32,88,55,14,36,38,36,2,1,1,True,True,False,False,True,False,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Cabotegravir - Injectable Suspension (CAB LA),Comp Beta,Drug,hiv,hiv,Phase 3,2025-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria: - HIV-1 infected, ART-naive men or women aged 18 years or greater at the time of signing the informed consent. - HIV-1 infection as documented by Screening plasma HIV-1 RNA \>=1000...",Yes,2026-05-16,FDA-13446,2.62,0.32,5.0,7.94,2028-08-13,2028-12-08,2033-12-09,59,AstraZeneca,43,South Africa,35.0,49,47,66,6,15,27,55,0,4,2,False,False,False,True,True,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rilpivirine - Injectable Suspension (RPV LA),Comp Beta,Drug,hiv,hiv,Phase 3,2025-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria: - HIV-1 infected, ART-naive men or women aged 18 years or greater at the time of signing the informed consent. - HIV-1 infection as documented by Screening plasma HIV-1 RNA \>=1000...",No,2026-08-24,FDA-24106,2.62,0.32,5.0,7.94,2028-08-13,2028-12-08,2033-12-09,88,Novartis,75,Senegal,49.16666666666666,52,53,25,76,83,6,36,0,2,2,False,False,False,True,True,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ABC/DTG/3TC STR - Tablet,TradeName X,Drug,hiv,hiv,Phase 3,2025-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria: - HIV-1 infected, ART-naive men or women aged 18 years or greater at the time of signing the informed consent. - HIV-1 infection as documented by Screening plasma HIV-1 RNA \>=1000...",Yes,2026-10-22,FDA-64316,2.62,0.32,5.0,7.94,2028-08-13,2028-12-08,2033-12-09,93,Merck,32,South Africa,60.0,45,70,70,81,16,78,36,1,2,1,False,True,True,True,False,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DTG Tablet,Comp Beta,Drug,hiv,hiv,Phase 3,2025-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria: - HIV-1 infected, ART-naive men or women aged 18 years or greater at the time of signing the informed consent. - HIV-1 infection as documented by Screening plasma HIV-1 RNA \>=1000...",No,2026-09-01,FDA-81857,2.62,0.32,5.0,7.94,2028-08-13,2028-12-08,2033-12-09,10,AstraZeneca,68,South Africa,35.16666666666666,2,76,39,26,60,8,55,1,2,3,False,True,True,False,True,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Dapivirine (DPV) Vaginal Ring (VR)-004,Comp Beta,Drug,hiv,hiv,Phase 3,2021-11-04,"Sex: ALL; Age: >6 Weeks; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

Inclusion Criteria - Mother

Participant mothers must meet all the following criteria to be eligible for inclusion in the study:

* Age 18 years or older at Screening, as verified...",Yes,2021-12-24,FDA-35869,2.62,0.32,5.0,7.94,2024-06-17,2024-10-12,2029-10-13,9,GSK,64,South Africa,57.66666666666666,47,37,91,3,79,89,45,1,3,1,True,False,True,False,True,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada Tablet,TradeName X,Drug,hiv,hiv,Phase 3,2021-11-04,"Sex: ALL; Age: >6 Weeks; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

Inclusion Criteria - Mother

Participant mothers must meet all the following criteria to be eligible for inclusion in the study:

* Age 18 years or older at Screening, as verified...",No,2022-08-16,FDA-30525,2.62,0.32,5.0,7.94,2024-06-17,2024-10-12,2029-10-13,52,AstraZeneca,79,Overall,46.16666666666666,36,54,14,69,82,22,45,1,3,1,False,True,False,True,True,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir (MK-0518),AltName B,Drug,hiv,hiv,Phase 2,2008-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 Infection
* ART for at least 12 months prior to study entry that includes at least two NRTIs and either an NNRTI or a ritonavir-boosted PI
* No change in ART regimen for a...",Yes,2009-08-14,FDA-50382,4.41,0.98,21.0,26.39,2013-03-30,2014-03-23,2035-03-23,74,Pfizer,47,Kenya,44.0,1,47,33,91,42,50,64,2,4,1,True,True,True,False,True,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ZOSTAVAX,TradeName X,Biological,hiv,hiv,Phase 2,2012-01-03,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV infected
* Use of potent combination ART regimen within 90 days prior to entry and undetectable plasma HIV RNA level within 90-210 days prior to study entry
* CD4 cell count...",No,2012-10-12,FDA-93154,4.41,0.98,21.0,26.39,2016-05-31,2017-05-24,2038-05-24,85,Pfizer,75,South Africa,64.66666666666667,73,44,82,52,43,94,64,1,3,3,False,True,False,False,True,True,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ABT-450/r/ABT-267,GenName Y,Drug,hiv,hiv,Phase 3,2016-10-25,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Chronic HCV infection at screening defined as: positive anti-HCV antibodies (Ab) at screening and HCV RNA \> 1,000 IU/mL at screening.
* Plasma HIV-1 RNA \< 40 copies/mL during ...",Yes,2017-07-31,FDA-68992,2.62,0.32,5.0,7.94,2019-06-08,2019-10-03,2024-10-03,3,Sanofi,64,Kenya,48.5,32,47,2,67,57,86,27,1,0,2,False,True,False,False,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ABT-333,TradeName X,Drug,hiv,hiv,Phase 3,2016-10-25,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Chronic HCV infection at screening defined as: positive anti-HCV antibodies (Ab) at screening and HCV RNA \> 1,000 IU/mL at screening.
* Plasma HIV-1 RNA \< 40 copies/mL during ...",No,2017-01-22,FDA-24631,2.62,0.32,5.0,7.94,2019-06-08,2019-10-03,2024-10-03,91,Gilead,58,South Africa,40.83333333333334,21,80,31,68,13,32,55,0,3,3,False,False,False,True,True,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ribavirin,AltName A,Drug,hiv,hiv,Phase 3,2016-10-25,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Chronic HCV infection at screening defined as: positive anti-HCV antibodies (Ab) at screening and HCV RNA \> 1,000 IU/mL at screening.
* Plasma HIV-1 RNA \< 40 copies/mL during ...",Yes,2017-02-16,FDA-34323,2.62,0.32,5.0,7.94,2019-06-08,2019-10-03,2024-10-03,72,J&J,79,Kenya,64.66666666666667,68,100,51,59,37,73,73,2,2,4,True,True,True,False,False,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ledipasvir 90 mg and Sofosbuvir 400 mg,TradeName X,Drug,hiv,hiv,Phase 4,2018-07-13,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

  1. Male or female at least 18 years of age at time of screening who is determined to be eligible based on evaluation by a treating provider,
  2. Documentation of genotype 1 (...",Yes,2018-12-25,FDA-65912,0.56,0.15,3.5,4.21,2019-02-02,2019-03-29,2022-09-27,56,AstraZeneca,17,Senegal,40.16666666666666,26,7,5,70,39,94,64,1,3,3,True,False,True,True,False,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
VGX-410 (Mifepristone),AltName A,Drug,hiv,hiv,Phase 2,2007-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4 cell count \> 200
* Plasma HIV-1 RNA \> 2000 copies/mL and have not received antiretroviral therapy within the 16 weeks prior to entry
* Absolute neutrophi...",Yes,2007-12-10,FDA-67319,4.41,0.98,21.0,26.39,2012-03-29,2013-03-22,2034-03-22,48,Bayer,30,Kenya,44.0,35,17,40,80,5,87,55,0,3,3,False,False,False,False,True,True,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Doravirine (DOR),Product Alpha,Drug,hiv,hiv,Phase 2,2022-05-25,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria:

* Weight greater than or equal 35 kg at entry
* If not of legal age to provide independent informed consent: Parent or guardian was willing and able to provide written informed co...",No,2023-01-21,FDA-97323,4.41,0.98,21.0,26.39,2026-10-21,2027-10-14,2048-10-13,8,Pfizer,59,Kenya,59.66666666666666,9,18,86,91,89,65,73,1,4,3,True,False,True,True,True,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF),TradeName X,Drug,hiv,hiv,Phase 2,2022-05-25,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria:

* Weight greater than or equal 35 kg at entry
* If not of legal age to provide independent informed consent: Parent or guardian was willing and able to provide written informed co...",No,2022-11-10,FDA-53998,4.41,0.98,21.0,26.39,2026-10-21,2027-10-14,2048-10-13,43,J&J,7,Kenya,52.83333333333334,77,36,16,98,81,9,45,1,1,3,False,True,True,False,False,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Antiretroviral (ARV) medications,Comp Beta,Drug,hiv,hiv,Phase 2,2022-05-25,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria:

* Weight greater than or equal 35 kg at entry
* If not of legal age to provide independent informed consent: Parent or guardian was willing and able to provide written informed co...",Yes,2022-09-04,FDA-23473,4.41,0.98,21.0,26.39,2026-10-21,2027-10-14,2048-10-13,14,Merck,55,Overall,52.83333333333334,9,53,79,91,59,26,82,2,5,2,True,True,True,True,True,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
BMS-955176,GenName Y,Drug,hiv,hiv,Phase 2,2017-06-07,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Men and non-pregnant women, at least 18 years of age
* Antiretroviral treatment-experienced, defined as having documented evidence of having failed 1 or 2 regimens that include ...",No,2017-12-18,FDA-53078,4.41,0.98,21.0,26.39,2021-11-03,2022-10-27,2043-10-27,28,Bayer,99,Kenya,49.5,2,95,42,71,75,12,45,2,2,1,True,True,True,False,True,False,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir (ATV),AltName B,Drug,hiv,hiv,Phase 2,2017-06-07,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Men and non-pregnant women, at least 18 years of age
* Antiretroviral treatment-experienced, defined as having documented evidence of having failed 1 or 2 regimens that include ...",No,2017-10-15,FDA-51397,4.41,0.98,21.0,26.39,2021-11-03,2022-10-27,2043-10-27,58,Sanofi,75,Overall,34.66666666666666,54,2,78,37,29,8,36,1,3,0,True,False,True,False,True,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir (RTV),AltName B,Drug,hiv,hiv,Phase 2,2017-06-07,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Men and non-pregnant women, at least 18 years of age
* Antiretroviral treatment-experienced, defined as having documented evidence of having failed 1 or 2 regimens that include ...",No,2018-01-22,FDA-24917,4.41,0.98,21.0,26.39,2021-11-03,2022-10-27,2043-10-27,40,Bayer,19,Overall,56.83333333333334,74,49,7,84,65,62,55,1,3,2,True,False,False,False,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir (DTG),Comp Beta,Drug,hiv,hiv,Phase 2,2017-06-07,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Men and non-pregnant women, at least 18 years of age
* Antiretroviral treatment-experienced, defined as having documented evidence of having failed 1 or 2 regimens that include ...",Yes,2018-04-17,FDA-64752,4.41,0.98,21.0,26.39,2021-11-03,2022-10-27,2043-10-27,37,Bayer,23,Kenya,41.66666666666666,30,5,95,60,4,56,73,2,3,3,True,True,True,False,True,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir (TDF),Molecule Z,Drug,hiv,hiv,Phase 2,2017-06-07,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Men and non-pregnant women, at least 18 years of age
* Antiretroviral treatment-experienced, defined as having documented evidence of having failed 1 or 2 regimens that include ...",Yes,2018-05-08,FDA-93497,4.41,0.98,21.0,26.39,2021-11-03,2022-10-27,2043-10-27,57,Sanofi,77,South Africa,52.16666666666666,90,31,52,51,41,48,27,0,2,1,False,False,False,False,True,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir DF,AltName A,Drug,hiv,hiv,Phase 3,2017-08-16,"Sex: ALL; Age: >2 Years; Criteria: Major Inclusion Criteria:

* Documented laboratory diagnosis of HIV-1 infection
* Plasma HIV-1 RNA \< 400 copies/mL
* Currently on a stable stavudine or zidovudine -containing antiretroviral therapy r...",Yes,2018-05-15,FDA-39000,2.62,0.32,5.0,7.94,2020-03-29,2020-07-24,2025-07-25,17,AstraZeneca,86,Overall,29.33333333333333,21,27,69,39,9,11,82,2,4,3,True,True,True,True,False,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Zidovudine,AltName B,Drug,hiv,hiv,Phase 3,2017-08-16,"Sex: ALL; Age: >2 Years; Criteria: Major Inclusion Criteria:

* Documented laboratory diagnosis of HIV-1 infection
* Plasma HIV-1 RNA \< 400 copies/mL
* Currently on a stable stavudine or zidovudine -containing antiretroviral therapy r...",No,2018-01-24,FDA-69006,2.62,0.32,5.0,7.94,2020-03-29,2020-07-24,2025-07-25,62,Bayer,38,Overall,37.33333333333334,0,74,28,88,15,19,45,2,1,2,True,True,True,False,False,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Stavudine,GenName Y,Drug,hiv,hiv,Phase 3,2017-08-16,"Sex: ALL; Age: >2 Years; Criteria: Major Inclusion Criteria:

* Documented laboratory diagnosis of HIV-1 infection
* Plasma HIV-1 RNA \< 400 copies/mL
* Currently on a stable stavudine or zidovudine -containing antiretroviral therapy r...",No,2018-02-25,FDA-10072,2.62,0.32,5.0,7.94,2020-03-29,2020-07-24,2025-07-25,59,Gilead,89,South Africa,58.83333333333334,71,76,35,68,70,33,64,1,3,3,True,False,True,False,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DTG film-coated tablets,AltName B,Drug,hiv,hiv,Phase 2,2023-10-18,"Sex: ALL; Age: >4 Weeks; Criteria: Inclusion Criteria:

* Confirmed HIV-1 infection, defined as positive results from two samples collected at different time points (see protocol for more information)
* Participant belonged to one of t...",Yes,2024-08-04,FDA-40949,4.41,0.98,21.0,26.39,2028-03-15,2029-03-08,2050-03-08,58,Gilead,30,South Africa,42.33333333333334,31,22,56,37,74,34,45,0,2,3,False,False,True,False,False,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DTG granules for suspension,Molecule Z,Drug,hiv,hiv,Phase 2,2023-10-18,"Sex: ALL; Age: >4 Weeks; Criteria: Inclusion Criteria:

* Confirmed HIV-1 infection, defined as positive results from two samples collected at different time points (see protocol for more information)
* Participant belonged to one of t...",Yes,2024-01-26,FDA-95717,4.41,0.98,21.0,26.39,2028-03-15,2029-03-08,2050-03-08,54,J&J,41,Kenya,51.83333333333334,3,82,18,87,90,31,36,1,3,0,True,False,False,False,True,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DTG dispersible tablets,TradeName X,Drug,hiv,hiv,Phase 2,2023-10-18,"Sex: ALL; Age: >4 Weeks; Criteria: Inclusion Criteria:

* Confirmed HIV-1 infection, defined as positive results from two samples collected at different time points (see protocol for more information)
* Participant belonged to one of t...",Yes,2024-03-30,FDA-76909,4.41,0.98,21.0,26.39,2028-03-15,2029-03-08,2050-03-08,51,Bayer,2,Kenya,39.16666666666666,51,44,10,48,61,21,45,2,2,1,True,True,False,True,True,False,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DTG dispersible tablets,Molecule Z,Drug,hiv,hiv,Phase 2,2023-10-18,"Sex: ALL; Age: >4 Weeks; Criteria: Inclusion Criteria:

* Confirmed HIV-1 infection, defined as positive results from two samples collected at different time points (see protocol for more information)
* Participant belonged to one of t...",Yes,2024-01-30,FDA-70590,4.41,0.98,21.0,26.39,2028-03-15,2029-03-08,2050-03-08,82,AstraZeneca,83,Kenya,57.0,92,26,86,25,93,20,45,1,2,2,True,False,False,True,True,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
DTG dispersible tablets,Molecule Z,Drug,hiv,hiv,Phase 2,2023-10-18,"Sex: ALL; Age: >4 Weeks; Criteria: Inclusion Criteria:

* Confirmed HIV-1 infection, defined as positive results from two samples collected at different time points (see protocol for more information)
* Participant belonged to one of t...",Yes,2023-12-24,FDA-73653,4.41,0.98,21.0,26.39,2028-03-15,2029-03-08,2050-03-08,58,AstraZeneca,78,Overall,63.5,88,89,74,45,41,44,64,0,4,3,False,False,False,True,True,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
imiquimod,Product Alpha,Drug,hiv,hiv,Phase 3,2024-05-02,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* HIV-positive; documentation of HIV infection must be based on a federally approved, licensed HIV test performed in conjunction with screening (enzyme linked immunosorbent assay ...",No,2024-10-27,FDA-72342,2.62,0.32,5.0,7.94,2026-12-14,2027-04-10,2032-04-10,87,Bayer,65,Overall,27.5,13,9,63,11,0,69,45,1,2,2,True,False,True,False,False,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
fluorouracil,Product Alpha,Drug,hiv,hiv,Phase 3,2024-05-02,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* HIV-positive; documentation of HIV infection must be based on a federally approved, licensed HIV test performed in conjunction with screening (enzyme linked immunosorbent assay ...",No,2025-04-29,FDA-78360,2.62,0.32,5.0,7.94,2026-12-14,2027-04-10,2032-04-10,79,Gilead,4,Overall,84.66666666666667,82,89,80,100,87,70,45,1,2,2,False,True,False,True,True,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Darunavir,GenName Y,Drug,hiv,hiv,Phase 3,2016-07-01,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

1. Subjects with documented HIV-1 infection.
2. Male or female aged \> 21 years old.
3. Subjects receiving ART with 2 NRTIs + LPV/r (or ATV/r) for at least 3 months at the time of...",Yes,2017-06-04,FDA-74302,2.62,0.32,5.0,7.94,2019-02-12,2019-06-09,2024-06-09,88,Gilead,44,Overall,47.83333333333334,33,40,45,64,17,88,55,2,2,2,True,True,False,True,False,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ART with 2 NRTIs plus LPV/r (or ATV/r),AltName A,Drug,hiv,hiv,Phase 3,2016-07-01,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

1. Subjects with documented HIV-1 infection.
2. Male or female aged \> 21 years old.
3. Subjects receiving ART with 2 NRTIs + LPV/r (or ATV/r) for at least 3 months at the time of...",No,2017-06-03,FDA-35841,2.62,0.32,5.0,7.94,2019-02-12,2019-06-09,2024-06-09,84,J&J,4,Senegal,61.83333333333334,86,77,96,16,58,38,45,0,2,3,False,False,False,True,False,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Nevirapine XR,Comp Beta,Drug,hiv,hiv,Phase 3,2012-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

HIV infected subjects treated with a Viramune based regimen.

A subject that meets the following inclusion criteria will be eligible for participation in this study:

1. Signed an...",No,2012-11-20,FDA-29296,2.62,0.32,5.0,7.94,2014-08-14,2014-12-09,2019-12-10,58,J&J,59,Senegal,29.83333333333333,60,26,21,35,27,10,55,2,2,2,True,True,True,False,False,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Nevirapine XR,AltName B,Drug,hiv,hiv,Phase 3,2012-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

HIV infected subjects treated with a Viramune based regimen.

A subject that meets the following inclusion criteria will be eligible for participation in this study:

1. Signed an...",Yes,2012-07-27,FDA-65757,2.62,0.32,5.0,7.94,2014-08-14,2014-12-09,2019-12-10,46,Sanofi,28,Senegal,63.66666666666666,97,86,37,18,83,61,27,1,1,1,True,False,False,False,True,False,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Nevirapine IR,Comp Beta,Drug,hiv,hiv,Phase 3,2012-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

HIV infected subjects treated with a Viramune based regimen.

A subject that meets the following inclusion criteria will be eligible for participation in this study:

1. Signed an...",No,2012-05-26,FDA-20216,2.62,0.32,5.0,7.94,2014-08-14,2014-12-09,2019-12-10,18,Bayer,62,Kenya,40.33333333333334,19,25,42,63,0,93,36,1,2,1,True,False,True,False,False,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine/Tenofovir Disoproxil Fumarate,Product Alpha,Drug,hiv,hiv,Phase 2,2011-11-01,"Sex: FEMALE; Age: >13 Years; Criteria: Inclusion Criteria for Mothers:

* HIV-1 infected
* CD4 count 250 cells/mm3 or greater within 30 days of study entry
* The following laboratory values obtained within 30 days prior to study entry: abs...",No,2012-03-12,FDA-73364,4.41,0.98,21.0,26.39,2016-03-29,2017-03-22,2038-03-22,23,GSK,24,South Africa,16.5,39,2,15,5,5,33,73,1,5,2,False,True,True,True,True,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine/Zidovudine,Comp Beta,Drug,hiv,hiv,Phase 2,2011-11-01,"Sex: FEMALE; Age: >13 Years; Criteria: Inclusion Criteria for Mothers:

* HIV-1 infected
* CD4 count 250 cells/mm3 or greater within 30 days of study entry
* The following laboratory values obtained within 30 days prior to study entry: abs...",Yes,2012-05-10,FDA-84219,4.41,0.98,21.0,26.39,2016-03-29,2017-03-22,2038-03-22,43,Merck,24,Kenya,53.33333333333334,88,16,37,47,45,87,45,1,3,1,True,False,True,False,True,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir/Ritonavir,Comp Beta,Drug,hiv,hiv,Phase 2,2011-11-01,"Sex: FEMALE; Age: >13 Years; Criteria: Inclusion Criteria for Mothers:

* HIV-1 infected
* CD4 count 250 cells/mm3 or greater within 30 days of study entry
* The following laboratory values obtained within 30 days prior to study entry: abs...",Yes,2012-04-22,FDA-76735,4.41,0.98,21.0,26.39,2016-03-29,2017-03-22,2038-03-22,20,Pfizer,14,South Africa,45.33333333333334,49,17,52,8,86,60,36,1,2,1,False,True,True,False,False,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
single dose Nevirapine,AltName A,Drug,hiv,hiv,Phase 2,2011-11-01,"Sex: FEMALE; Age: >13 Years; Criteria: Inclusion Criteria for Mothers:

* HIV-1 infected
* CD4 count 250 cells/mm3 or greater within 30 days of study entry
* The following laboratory values obtained within 30 days prior to study entry: abs...",Yes,2012-09-11,FDA-31133,4.41,0.98,21.0,26.39,2016-03-29,2017-03-22,2038-03-22,20,Gilead,51,South Africa,74.83333333333333,85,80,62,99,82,41,45,0,2,3,False,False,True,False,True,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Aspirin,TradeName X,Drug,hiv,hiv,Phase 2,2017-02-01,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* HIV infection
* Current Antiretroviral Therapy with no change in regimen in the 12 weeks prior to study entry and no plans to change ART for the study duration
* Ability to sign...",Yes,2017-09-06,FDA-55289,4.41,0.98,21.0,26.39,2021-06-30,2022-06-23,2043-06-23,0,Merck,61,South Africa,42.16666666666666,73,27,4,7,92,50,36,0,3,1,False,False,False,True,True,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Clopidogrel,GenName Y,Drug,hiv,hiv,Phase 2,2017-02-01,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* HIV infection
* Current Antiretroviral Therapy with no change in regimen in the 12 weeks prior to study entry and no plans to change ART for the study duration
* Ability to sign...",Yes,2017-12-20,FDA-86487,4.41,0.98,21.0,26.39,2021-06-30,2022-06-23,2043-06-23,27,Bayer,90,Senegal,30.5,61,29,43,14,32,4,45,1,2,2,True,False,False,True,True,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tipranavir,GenName Y,Drug,hiv,hiv,Phase 3,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Patients meeting the following criteria will be eligible for participation in th is study:

1. Human Immunodeficiency virus 1 (HIV-1) infected males or females \>=18 years of age....",Yes,2026-04-22,FDA-92042,2.62,0.32,5.0,7.94,,,,86,Novartis,99,South Africa,58.66666666666666,60,76,49,64,9,94,55,1,4,1,False,True,True,True,False,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir(r),GenName Y,Drug,hiv,hiv,Phase 3,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Patients meeting the following criteria will be eligible for participation in th is study:

1. Human Immunodeficiency virus 1 (HIV-1) infected males or females \>=18 years of age....",Yes,2026-03-19,FDA-80403,2.62,0.32,5.0,7.94,,,,77,Sanofi,91,Kenya,55.16666666666666,92,47,43,25,75,49,36,1,2,1,True,False,False,True,True,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Comparator Protease Inhibitor (CPI),Product Alpha,Drug,hiv,hiv,Phase 3,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Patients meeting the following criteria will be eligible for participation in th is study:

1. Human Immunodeficiency virus 1 (HIV-1) infected males or females \>=18 years of age....",Yes,2026-09-15,FDA-36404,2.62,0.32,5.0,7.94,,,,65,J&J,93,Kenya,42.33333333333334,6,35,7,69,81,56,64,2,3,2,True,True,False,True,False,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,AltName B,Drug,hiv,hiv,Phase 3,2014-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Stable antiretroviral therapy for at least 12 months
2. All plasma HIV RNA levels within the past year must be below level of detection (\< 50 copies RNA/mL), although isolated...",Yes,2014-10-20,FDA-89764,2.62,0.32,5.0,7.94,2017-01-12,2017-05-09,2022-05-10,9,Bayer,85,Kenya,55.33333333333334,25,35,80,21,89,82,64,2,3,2,True,True,False,True,True,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Triomune,AltName B,Drug,hiv,hiv,Phase 4,2008-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. HIV-infected men and non-pregnant women;
2. On Triomune for at least 4 weeks;
3. 18 years or greater;
4. Residing within 15km of Kampala city center

Exclusion Criteria:

1. Un...",Yes,2009-02-05,FDA-72695,0.56,0.15,3.5,4.21,2008-09-21,2008-11-15,2012-05-16,3,Pfizer,82,Senegal,64.33333333333333,80,93,30,89,67,27,55,0,3,3,False,False,False,True,True,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Zerit/Epivir/Viramune,Comp Beta,Drug,hiv,hiv,Phase 4,2008-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. HIV-infected men and non-pregnant women;
2. On Triomune for at least 4 weeks;
3. 18 years or greater;
4. Residing within 15km of Kampala city center

Exclusion Criteria:

1. Un...",No,2008-05-16,FDA-77902,0.56,0.15,3.5,4.21,2008-09-21,2008-11-15,2012-05-16,47,Gilead,55,Senegal,61.33333333333334,6,86,72,26,89,89,64,1,4,2,False,True,False,True,True,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
TUTI-16 (1.0 mg),Comp Beta,Biological,hiv,hiv,Phase 2,2012-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Males and Females
* Age ≥ 18 and ≤ 50 years at Screening
* Body weight of 50-100 kg (inclusive) at Screening.
* HIV-1 seropositive subjects on effective ART for \> 12 months (un...",Yes,2013-04-03,FDA-62594,4.41,0.98,21.0,26.39,2016-10-28,2017-10-21,2038-10-21,60,GSK,33,Kenya,50.5,72,52,18,33,89,39,73,1,3,4,False,True,True,True,False,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
emtricitabine 200mg/tenofovir 300mg,Product Alpha,Drug,hiv,hiv,Phase 4,2016-05-01,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* At least 18 years of age
* Able to understand and provide consent in English or Spanish
* Self identified MSM, MSM/W, or Transfemale
* At least one male sex partner for anal int...",No,2016-10-29,FDA-25946,0.56,0.15,3.5,4.21,2016-11-21,2017-01-15,2020-07-16,75,Bayer,14,Kenya,47.83333333333334,18,13,70,57,81,48,36,1,2,1,True,False,True,True,False,False,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
TUTI-16 (0.2mg),Comp Beta,Biological,hiv,hiv,Phase 2,2011-04-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Males and Females
* Age ≥18 and ≤50 years at Screening
* HIV negative healthy subjects or HIV-1 seropositive subjects on effective ART for \>2 months (undetectable HIV plasma vi...",No,2012-02-07,FDA-31355,4.41,0.98,21.0,26.39,2015-08-28,2016-08-20,2037-08-20,99,J&J,51,Overall,47.66666666666666,52,27,62,59,42,44,45,2,1,2,True,True,False,False,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
TUTI-16 (1.0 mg),AltName B,Biological,hiv,hiv,Phase 2,2011-04-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Males and Females
* Age ≥18 and ≤50 years at Screening
* HIV negative healthy subjects or HIV-1 seropositive subjects on effective ART for \>2 months (undetectable HIV plasma vi...",Yes,2011-06-20,FDA-29897,4.41,0.98,21.0,26.39,2015-08-28,2016-08-20,2037-08-20,3,Sanofi,14,Overall,59.66666666666666,15,19,83,84,78,79,45,1,3,1,False,True,True,True,False,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Dapivirine Vaginal Ring-004,AltName A,Drug,hiv,hiv,Phase 3,2019-01-11,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

Women must meet all the following criteria to be eligible to enrol in the trial:

1. Previously enrolled in the IPM 027 trial
2. Available for all visits and consent to follow all...",No,2019-11-11,FDA-65561,2.62,0.32,5.0,7.94,2021-08-24,2021-12-19,2026-12-20,21,Novartis,96,Senegal,54.0,23,98,0,65,65,73,27,0,1,2,False,False,False,False,False,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Buprenorphine,Product Alpha,Drug,hiv,hiv,Phase 4,2010-09-01,"Sex: FEMALE; Age: >19 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* female,
* history of opioid dependence,
* released back to the community from a controlled environment,
* criminal justice involvement.

Exclusion Criteria:

* under age 19,
* m...",Yes,2011-04-18,FDA-74066,0.56,0.15,3.5,4.21,2011-03-24,2011-05-18,2014-11-16,49,Sanofi,55,South Africa,71.0,93,83,57,25,70,98,73,1,5,2,False,True,True,True,True,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamiduvine (Epivir),Product Alpha,Drug,hiv,hiv,Phase 4,2011-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients treated with the same regimen including 2NRTIs + ATV/r from at least 6 months
* Aged 18 years or older
* Who gave informed consent to the participation to the study
* W...",No,2011-07-13,FDA-24633,0.56,0.15,3.5,4.21,2011-11-21,2012-01-15,2015-07-16,89,AstraZeneca,68,Overall,53.16666666666666,35,24,5,67,98,90,55,1,4,1,True,False,True,True,True,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir (Reyataz),Comp Beta,Drug,hiv,hiv,Phase 4,2011-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients treated with the same regimen including 2NRTIs + ATV/r from at least 6 months
* Aged 18 years or older
* Who gave informed consent to the participation to the study
* W...",Yes,2011-11-25,FDA-91810,0.56,0.15,3.5,4.21,2011-11-21,2012-01-15,2015-07-16,84,Bayer,58,Kenya,44.0,67,94,8,6,13,76,36,1,1,2,True,False,False,True,False,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir (Norvir),TradeName X,Drug,hiv,hiv,Phase 4,2011-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients treated with the same regimen including 2NRTIs + ATV/r from at least 6 months
* Aged 18 years or older
* Who gave informed consent to the participation to the study
* W...",No,2012-01-20,FDA-55726,0.56,0.15,3.5,4.21,2011-11-21,2012-01-15,2015-07-16,26,Pfizer,25,Senegal,51.5,73,25,92,14,5,100,45,0,3,2,False,False,True,True,False,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Oral Cabotegravir (CAB),Molecule Z,Drug,hiv,hiv,Phase 2,2024-04-29,"Sex: ALL; Age: >18 Years; Criteria: Step 1 Inclusion Criteria:

* Individual with HIV-1
* On a three-drug ART regimen for at least 8 weeks that includes a boosted protease inhibitor (PI), a nonnuceloside reverse transcriptase inhibitor ...",Yes,2024-11-28,FDA-72208,4.41,0.98,21.0,26.39,2028-09-25,2029-09-18,2050-09-18,22,Pfizer,52,Senegal,61.0,69,64,91,43,64,35,9,0,0,1,False,False,False,False,False,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Nucleoside Reverse Transcriptase Inhibitors (NRTIs),Product Alpha,Drug,hiv,hiv,Phase 2,2024-04-29,"Sex: ALL; Age: >18 Years; Criteria: Step 1 Inclusion Criteria:

* Individual with HIV-1
* On a three-drug ART regimen for at least 8 weeks that includes a boosted protease inhibitor (PI), a nonnuceloside reverse transcriptase inhibitor ...",Yes,2024-11-27,FDA-68328,4.41,0.98,21.0,26.39,2028-09-25,2029-09-18,2050-09-18,68,Merck,83,South Africa,57.5,87,74,43,61,78,2,36,1,1,2,False,True,False,False,False,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Long-Acting Injectable Cabotegravir (CAB LA),AltName A,Drug,hiv,hiv,Phase 2,2024-04-29,"Sex: ALL; Age: >18 Years; Criteria: Step 1 Inclusion Criteria:

* Individual with HIV-1
* On a three-drug ART regimen for at least 8 weeks that includes a boosted protease inhibitor (PI), a nonnuceloside reverse transcriptase inhibitor ...",Yes,2024-10-31,FDA-69390,4.41,0.98,21.0,26.39,2028-09-25,2029-09-18,2050-09-18,47,GSK,85,Overall,30.66666666666667,0,40,42,55,8,39,27,1,1,1,False,True,False,False,False,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
VRC07-523LS,AltName A,Biological,hiv,hiv,Phase 2,2024-04-29,"Sex: ALL; Age: >18 Years; Criteria: Step 1 Inclusion Criteria:

* Individual with HIV-1
* On a three-drug ART regimen for at least 8 weeks that includes a boosted protease inhibitor (PI), a nonnuceloside reverse transcriptase inhibitor ...",No,2024-10-30,FDA-86000,4.41,0.98,21.0,26.39,2028-09-25,2029-09-18,2050-09-18,91,Pfizer,45,Senegal,31.0,48,52,19,59,2,6,55,1,4,1,False,True,True,True,True,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Standard of Care (SOC) ART,Comp Beta,Drug,hiv,hiv,Phase 2,2024-04-29,"Sex: ALL; Age: >18 Years; Criteria: Step 1 Inclusion Criteria:

* Individual with HIV-1
* On a three-drug ART regimen for at least 8 weeks that includes a boosted protease inhibitor (PI), a nonnuceloside reverse transcriptase inhibitor ...",No,2024-12-07,FDA-35544,4.41,0.98,21.0,26.39,2028-09-25,2029-09-18,2050-09-18,76,GSK,18,Kenya,57.83333333333334,40,61,62,68,34,82,36,1,2,1,False,True,False,False,False,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tipranavir (with low dose ritonavir),TradeName X,Drug,hiv,hiv,Phase 3,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Signed informed consent prior to trial participation.
2. Human immunodeficiency virus-1 infected males or females \>=18 years of age.
3. Screening genotypic resistance report i...",Yes,2026-09-06,FDA-87367,2.62,0.32,5.0,7.94,,,,60,J&J,44,South Africa,60.33333333333334,37,97,86,32,71,39,64,1,3,3,False,True,True,False,False,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Comparator protease inhibitor(CPI)/low dose ritonavir(r),AltName A,Drug,hiv,hiv,Phase 3,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Signed informed consent prior to trial participation.
2. Human immunodeficiency virus-1 infected males or females \>=18 years of age.
3. Screening genotypic resistance report i...",Yes,2026-01-05,FDA-64958,2.62,0.32,5.0,7.94,,,,77,Bayer,80,Senegal,54.33333333333334,13,80,19,78,74,62,73,2,3,3,True,True,True,True,False,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
nevirapine IR,Product Alpha,Drug,hiv,hiv,Phase 3,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

1. Signed informed consent in accordance with Good Clinical Practice and local regulatory requirements prior to trial participation
2. HIV-1 infected males or females \>= 18 years...",Yes,2026-03-26,FDA-12055,2.62,0.32,5.0,7.94,,,,95,Pfizer,65,Overall,59.16666666666666,95,80,6,66,34,74,73,1,4,3,False,True,True,True,True,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
nevirapine XR,Molecule Z,Drug,hiv,hiv,Phase 3,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

1. Signed informed consent in accordance with Good Clinical Practice and local regulatory requirements prior to trial participation
2. HIV-1 infected males or females \>= 18 years...",No,2026-06-17,FDA-41605,2.62,0.32,5.0,7.94,,,,12,Sanofi,82,Overall,46.5,63,47,59,0,28,82,45,1,3,1,False,True,True,True,False,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,TradeName X,Drug,hiv,hiv,Phase 2,2019-11-27,"Sex: ALL; Age: >4 Weeks; Criteria: Inclusion Criteria:

* Weight greater than or equal to 3.5 kg at entry
* Confirmation of HIV-1 infection was defined as positive results from two samples collected at different time points. All sample...",No,2020-11-13,FDA-29307,4.41,0.98,21.0,26.39,2024-04-24,2025-04-17,2046-04-17,59,GSK,58,Senegal,38.83333333333334,48,57,7,71,19,31,45,1,3,1,False,True,False,True,True,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,TradeName X,Drug,hiv,hiv,Phase 3,2011-08-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion criteria:

1. Able to give informed consent.
2. Negative HIV-1 serology.
3. At least 18 but no more than 55 years of age.
4. Body mass index \<30.
5. Estimated creatinine clearance ≥ 50 mL/m...",Yes,2012-04-10,FDA-13036,2.62,0.32,5.0,7.94,2014-03-14,2014-07-09,2019-07-10,50,GSK,74,Senegal,46.0,67,34,13,49,60,53,36,1,1,2,True,False,False,False,False,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tamoxifen,Comp Beta,Drug,hiv,hiv,Phase 2,2023-07-27,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Postmenopausal at study entry with agreement not to participate in assisted reproductive technology in the future.
* CD4+ cell count greater than 300 cells/uL ...",Yes,2024-02-12,FDA-40674,4.41,0.98,21.0,26.39,2027-12-23,2028-12-15,2049-12-15,62,J&J,64,South Africa,55.0,42,28,71,61,85,43,55,0,3,3,False,False,True,False,False,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Vorinostat,TradeName X,Drug,hiv,hiv,Phase 2,2023-07-27,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Postmenopausal at study entry with agreement not to participate in assisted reproductive technology in the future.
* CD4+ cell count greater than 300 cells/uL ...",No,2024-01-14,FDA-14459,4.41,0.98,21.0,26.39,2027-12-23,2028-12-15,2049-12-15,50,Merck,88,South Africa,77.0,29,75,87,87,89,95,36,0,3,1,False,False,True,False,True,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Antiretroviral drugs,Comp Beta,Drug,hiv,hiv,Phase 2,2023-07-27,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Postmenopausal at study entry with agreement not to participate in assisted reproductive technology in the future.
* CD4+ cell count greater than 300 cells/uL ...",No,2024-03-17,FDA-71135,4.41,0.98,21.0,26.39,2027-12-23,2028-12-15,2049-12-15,30,Gilead,58,Kenya,56.0,53,64,11,25,99,84,55,2,2,2,True,True,False,False,True,False,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Biktarvy,Product Alpha,Drug,hiv,hiv,Phase 4,2020-08-28,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

1. HIV-negative man who reports receptive anal sex with another man in the last 6 months
2. Aged 18-49 years
3. Not currently taking PrEP and no plans to initiate during study
4. ...",No,2020-11-14,FDA-79776,0.56,0.15,3.5,4.21,2021-03-20,2021-05-14,2024-11-12,36,Novartis,14,Kenya,50.16666666666666,61,34,40,10,79,77,55,2,3,1,True,True,True,True,True,False,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK3640254,Molecule Z,Drug,hiv,hiv,Phase 2,2020-02-06,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subject must be 18 to 65 years of age inclusive, at the time of signing the informed consent.
* Subjects who are healthy (other than HIV infection) as determined by the Investig...",No,2021-01-14,FDA-64272,4.41,0.98,21.0,26.39,2024-07-04,2025-06-27,2046-06-27,48,Merck,6,Kenya,64.5,93,60,60,19,97,58,55,0,3,3,False,False,True,True,True,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Naltrexone Injectable Suspension,Product Alpha,Drug,hiv,hiv,Phase 3,2019-11-08,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participant is at least 18 years old
* Participant has provided written informed consent and HIPAA for medical record abstraction
* Participant meets Diagnostic and Statistical ...",Yes,2020-01-18,FDA-74999,2.62,0.32,5.0,7.94,2022-06-21,2022-10-16,2027-10-17,42,AstraZeneca,27,South Africa,40.66666666666666,10,32,67,66,56,13,45,1,1,3,True,False,False,False,True,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Vitamin E,AltName A,Drug,hiv,hiv,Phase 2,2021-03-08,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. males and females ≥18 years with biopsy-proven NASH within 6 months prior to enrollment
2. histological diagnosis of NASH will be confirmed by an experienced liver pathologist ...",No,2021-08-06,FDA-92140,4.41,0.98,21.0,26.39,2025-08-04,2026-07-28,2047-07-28,18,Merck,2,Overall,41.83333333333334,28,10,87,43,20,63,55,1,4,1,True,False,True,True,True,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Amlodipine 5mg,AltName A,Drug,hiv,hiv,Phase 2,2023-12-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* PLWH 18-65 years of age
* ART duration ≥ 1 year, stable regimen ≥ 6 months
* HIV 1-RNA \< 1,000 copies/mL within past 12 months
* Pre-HTN (SBP 120-139 or DBP 80-89 mm Hg)
* No c...",Yes,2024-05-19,FDA-13512,4.41,0.98,21.0,26.39,2028-05-27,2029-05-20,2050-05-20,65,Sanofi,70,Kenya,46.16666666666666,21,54,64,24,73,41,45,1,1,3,True,False,False,False,False,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
AERAS-402,AltName B,Biological,hiv,hiv,Phase 2,2012-05-01,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

1. Age 21 years through 45 years (i.e., subject had not yet reached his/her 46th birthday at day of randomization).
2. Had completed the written informed consent process prior to ...",Yes,2013-03-29,FDA-67730,4.41,0.98,21.0,26.39,2016-09-27,2017-09-20,2038-09-20,79,Bayer,100,South Africa,52.16666666666666,18,94,8,15,98,80,55,1,3,2,False,True,False,False,True,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Pitavastatin,Product Alpha,Drug,hiv,hiv,Phase 3,2023-08-21,"Sex: ALL; Age: >40 Years; Criteria: Inclusion Criteria:

* Individual with HIV-1
* Combination antiretroviral therapy (ART) for at least 180 days prior to study entry
* CD4+ cell count greater than 100 cells/mm\^3
* Acceptable screening...",No,2024-05-29,FDA-30703,2.62,0.32,5.0,7.94,2026-04-03,2026-07-29,2031-07-30,28,Bayer,53,Senegal,46.66666666666666,76,30,12,100,22,40,45,1,3,1,False,True,False,False,True,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Cemiplimab,GenName Y,Biological,hiv,hiv,Phase 2,2020-08-18,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* On ART for at least 24 months
* Receiving ART with no changes of the components of ART medications within 90 days prior to study entry

  * Changes within drug...",No,2021-06-09,FDA-55223,4.41,0.98,21.0,26.39,2025-01-14,2026-01-07,2047-01-07,88,J&J,65,Senegal,59.0,24,86,64,80,44,56,36,1,2,1,False,True,True,False,False,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ritonavir-boosted atazanavir,GenName Y,Drug,hiv,hiv,Phase 4,2010-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* 18 years of age or older.
* Patient agrees to participate in the study by giving written informed consent.
* Documentation of HIV infection.
* No prior treatment with any anti-r...",Yes,2010-10-09,FDA-44108,0.56,0.15,3.5,4.21,2010-09-21,2010-11-15,2014-05-16,79,AstraZeneca,99,Overall,50.5,41,98,24,24,77,39,64,2,3,2,True,True,True,True,False,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ritonavir-boosted fosamprenavir,Product Alpha,Drug,hiv,hiv,Phase 4,2010-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* 18 years of age or older.
* Patient agrees to participate in the study by giving written informed consent.
* Documentation of HIV infection.
* No prior treatment with any anti-r...",No,2010-04-19,FDA-55438,0.56,0.15,3.5,4.21,2010-09-21,2010-11-15,2014-05-16,83,AstraZeneca,97,South Africa,34.16666666666666,2,14,12,52,36,89,55,1,3,2,True,False,True,False,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Buprenorphine/naloxone,TradeName X,Drug,hiv,hiv,Phase 4,2019-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV positive
* Current moderate or severe Diagnostic and Statistical Manual (DSM-V) opioid use disorder
* Urine drug screen positive for opioids
* Interested in receiving treatm...",Yes,2019-08-16,FDA-89460,0.56,0.15,3.5,4.21,2019-10-22,2019-12-16,2023-06-16,81,Novartis,5,Senegal,37.0,97,25,12,25,11,52,64,0,4,3,False,False,True,True,True,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Methadone Maintenance Therapy,Product Alpha,Drug,hiv,hiv,Phase 4,2019-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV positive
* Current moderate or severe Diagnostic and Statistical Manual (DSM-V) opioid use disorder
* Urine drug screen positive for opioids
* Interested in receiving treatm...",No,2019-10-08,FDA-23622,0.56,0.15,3.5,4.21,2019-10-22,2019-12-16,2023-06-16,17,AstraZeneca,46,South Africa,69.5,84,47,33,99,77,77,27,1,0,2,False,True,False,False,False,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atorvastatin,Product Alpha,Drug,hiv,hiv,Phase 2,2014-12-01,"Sex: ALL; Age: >10 Years; Criteria: Inclusion Criteria:

* A diagnosis of HIV-1 infection
* CD4 % of at least 15 at screening
* HIV-1 viral load of less than 10,000 copies/ml at screening
* On a stable antiretroviral therapy regimen for...",No,2015-04-02,FDA-87153,4.41,0.98,21.0,26.39,2019-04-29,2020-04-21,2041-04-21,88,Pfizer,32,Overall,44.0,50,3,67,23,34,87,45,2,2,1,True,True,False,True,False,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"darunavir, ritonavir, rosuvastatin",Product Alpha,Drug,hiv,hiv,Phase 2,2010-08-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Absence of HIV-1/HIV-2 infection as documented by a licensed ELISA test kit within 21 days prior to study entry.
2. Male or female subjects, aged ≥ 18 and ≤ 60 years
3. Weight ...",Yes,2011-04-02,FDA-67883,4.41,0.98,21.0,26.39,2014-12-28,2015-12-21,2036-12-20,1,GSK,54,Overall,76.0,36,77,76,83,89,95,82,1,5,3,False,True,True,True,True,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"rosuvastatin, darunavir, ritonavir",Product Alpha,Drug,hiv,hiv,Phase 2,2010-08-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Absence of HIV-1/HIV-2 infection as documented by a licensed ELISA test kit within 21 days prior to study entry.
2. Male or female subjects, aged ≥ 18 and ≤ 60 years
3. Weight ...",No,2010-09-26,FDA-53364,4.41,0.98,21.0,26.39,2014-12-28,2015-12-21,2036-12-20,73,Gilead,71,Overall,42.66666666666666,41,10,37,29,77,62,27,0,2,1,False,False,True,False,False,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"Maraviroc (UK-427,857)",AltName B,Drug,hiv,hiv,Phase 3,2011-04-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Men or women at least 16 yers of age (or minimum age as determined by local regulatory authorities)
* HIV-1 RNA viral load of greater than or equal to 5,000 copies/mL
* Stable p...",No,2012-02-19,FDA-35018,2.62,0.32,5.0,7.94,2013-11-12,2014-03-09,2019-03-10,89,Gilead,28,Senegal,62.5,80,86,10,83,46,70,45,1,1,3,True,False,False,True,False,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
optimized background therapy,Product Alpha,Drug,hiv,hiv,Phase 3,2011-04-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Men or women at least 16 yers of age (or minimum age as determined by local regulatory authorities)
* HIV-1 RNA viral load of greater than or equal to 5,000 copies/mL
* Stable p...",Yes,2011-12-17,FDA-90847,2.62,0.32,5.0,7.94,2013-11-12,2014-03-09,2019-03-10,69,Sanofi,57,South Africa,50.66666666666666,99,4,18,76,16,91,64,1,4,2,False,True,True,False,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"Maraviroc (UK-427,857)",AltName B,Drug,hiv,hiv,Phase 3,2011-04-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Men or women at least 16 yers of age (or minimum age as determined by local regulatory authorities)
* HIV-1 RNA viral load of greater than or equal to 5,000 copies/mL
* Stable p...",No,2011-09-13,FDA-68144,2.62,0.32,5.0,7.94,2013-11-12,2014-03-09,2019-03-10,95,AstraZeneca,33,Overall,56.5,79,18,56,58,47,81,55,0,4,2,False,False,True,True,False,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
optimized background therapy,Comp Beta,Drug,hiv,hiv,Phase 3,2011-04-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Men or women at least 16 yers of age (or minimum age as determined by local regulatory authorities)
* HIV-1 RNA viral load of greater than or equal to 5,000 copies/mL
* Stable p...",Yes,2011-08-31,FDA-55001,2.62,0.32,5.0,7.94,2013-11-12,2014-03-09,2019-03-10,39,Merck,53,South Africa,50.33333333333334,78,12,14,50,66,82,45,1,3,1,True,False,True,True,False,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
optimized background therapy,TradeName X,Drug,hiv,hiv,Phase 3,2011-04-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Men or women at least 16 yers of age (or minimum age as determined by local regulatory authorities)
* HIV-1 RNA viral load of greater than or equal to 5,000 copies/mL
* Stable p...",No,2012-02-22,FDA-79635,2.62,0.32,5.0,7.94,2013-11-12,2014-03-09,2019-03-10,42,GSK,4,Kenya,24.5,13,11,59,40,4,20,36,0,1,3,False,False,True,False,False,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Rituximab,Molecule Z,Biological,hiv,hiv,Phase 2,2024-01-18,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

Aggressive B-lymphocyte antigen CD20 (CD20) positive Diffuse Large B-cell lymphoma confirmed by Laboratory of Pathology, National Cancer Institute (NCI). Note: Participants with...",No,2024-05-25,FDA-81041,4.41,0.98,21.0,26.39,2028-06-15,2029-06-08,2050-06-08,38,Gilead,76,South Africa,54.83333333333334,85,43,20,42,89,50,36,1,3,0,False,True,True,False,True,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Filgrastim,Comp Beta,Biological,hiv,hiv,Phase 2,2024-01-18,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

Aggressive B-lymphocyte antigen CD20 (CD20) positive Diffuse Large B-cell lymphoma confirmed by Laboratory of Pathology, National Cancer Institute (NCI). Note: Participants with...",Yes,2024-06-11,FDA-77170,4.41,0.98,21.0,26.39,2028-06-15,2029-06-08,2050-06-08,77,Sanofi,63,Senegal,55.66666666666666,69,58,3,87,95,22,45,2,2,1,True,True,False,False,True,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
EPOCH,TradeName X,Drug,hiv,hiv,Phase 2,2024-01-18,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

Aggressive B-lymphocyte antigen CD20 (CD20) positive Diffuse Large B-cell lymphoma confirmed by Laboratory of Pathology, National Cancer Institute (NCI). Note: Participants with...",Yes,2024-11-17,FDA-92713,4.41,0.98,21.0,26.39,2028-06-15,2029-06-08,2050-06-08,39,J&J,32,South Africa,50.16666666666666,96,81,29,42,45,8,36,0,3,1,False,False,True,False,False,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"Maraviroc (UK-427,857)",Product Alpha,Drug,hiv,hiv,Phase 3,2011-04-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Men or women at least 16 years of age (or minimum age as determined by local regulatory authorities)
* HIV-1 RNA viral load of greater than or equal to 5,000 copies/mL
* Stable ...",No,2011-10-07,FDA-71352,2.62,0.32,5.0,7.94,2013-11-12,2014-03-09,2019-03-10,42,Gilead,50,Senegal,47.5,20,45,67,27,47,79,36,1,2,1,False,True,False,False,True,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Optimized Background Therapy,GenName Y,Drug,hiv,hiv,Phase 3,2011-04-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Men or women at least 16 years of age (or minimum age as determined by local regulatory authorities)
* HIV-1 RNA viral load of greater than or equal to 5,000 copies/mL
* Stable ...",No,2012-03-14,FDA-85427,2.62,0.32,5.0,7.94,2013-11-12,2014-03-09,2019-03-10,10,Merck,98,South Africa,31.66666666666667,10,35,4,63,4,74,55,1,4,1,False,True,True,True,False,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Optimized Background Therapy,GenName Y,Drug,hiv,hiv,Phase 3,2011-04-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Men or women at least 16 years of age (or minimum age as determined by local regulatory authorities)
* HIV-1 RNA viral load of greater than or equal to 5,000 copies/mL
* Stable ...",Yes,2011-09-23,FDA-42628,2.62,0.32,5.0,7.94,2013-11-12,2014-03-09,2019-03-10,52,Novartis,53,Senegal,72.83333333333333,77,75,55,80,50,100,64,1,2,4,True,False,False,False,True,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Optimized Background Therapy,Product Alpha,Drug,hiv,hiv,Phase 3,2011-04-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Men or women at least 16 years of age (or minimum age as determined by local regulatory authorities)
* HIV-1 RNA viral load of greater than or equal to 5,000 copies/mL
* Stable ...",No,2011-08-27,FDA-88740,2.62,0.32,5.0,7.94,2013-11-12,2014-03-09,2019-03-10,80,Merck,51,South Africa,60.0,35,99,14,29,87,96,55,1,3,2,True,False,True,True,True,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
BMS-663068,TradeName X,Drug,hiv,hiv,Phase 3,2026-09-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Men and non-pregnant women with chronic HIV-1 infection
* Antiretroviral-experienced with documented historical or baseline resistance, intolerability, and/or contraindications ...",No,2027-05-14,FDA-29111,2.62,0.32,5.0,7.94,2029-05-13,2029-09-07,2034-09-08,44,GSK,46,Overall,32.5,24,0,45,89,18,19,45,2,2,1,True,True,False,True,False,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
MVA85A/AERAS-485,GenName Y,Biological,hiv,hiv,Phase 2,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Has completed the written informed consent process prior to undergoing any screening evaluations.
* Either males or females aged 18-50 years (inclusive) on Study Day 0
* In gene...",Yes,2015-06-19,FDA-24512,4.41,0.98,21.0,26.39,2019-01-28,2020-01-21,2041-01-20,53,J&J,78,Kenya,44.16666666666666,51,54,60,23,9,68,36,0,3,1,False,False,True,False,True,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Cabotegravir (CAB) tablet,AltName B,Drug,hiv,hiv,Phase 3,2025-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Aged 18 years or older (or ≥19 where required by local regulatory agencies), at the time of signing the informed consent.
* Must be on uninterrupted current regimen (either the ...",Yes,2026-05-29,FDA-78205,2.62,0.32,5.0,7.94,2028-08-13,2028-12-08,2033-12-09,10,Gilead,63,Kenya,37.33333333333334,45,81,6,80,0,12,64,2,3,2,True,True,True,False,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Rilpivirine (RPV) tablet,TradeName X,Drug,hiv,hiv,Phase 3,2025-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Aged 18 years or older (or ≥19 where required by local regulatory agencies), at the time of signing the informed consent.
* Must be on uninterrupted current regimen (either the ...",Yes,2026-04-19,FDA-15070,2.62,0.32,5.0,7.94,2028-08-13,2028-12-08,2033-12-09,46,Novartis,7,Senegal,63.0,91,98,26,7,78,78,64,2,3,2,True,True,True,False,True,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Cabotegravir - Injectable Suspension (CAB LA),GenName Y,Drug,hiv,hiv,Phase 3,2025-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Aged 18 years or older (or ≥19 where required by local regulatory agencies), at the time of signing the informed consent.
* Must be on uninterrupted current regimen (either the ...",Yes,2026-11-07,FDA-64211,2.62,0.32,5.0,7.94,2028-08-13,2028-12-08,2033-12-09,75,GSK,2,Kenya,46.33333333333334,15,13,94,76,45,35,64,1,4,2,False,True,True,False,True,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Rilpivirine - Injectable Suspension (RPV LA),TradeName X,Drug,hiv,hiv,Phase 3,2025-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Aged 18 years or older (or ≥19 where required by local regulatory agencies), at the time of signing the informed consent.
* Must be on uninterrupted current regimen (either the ...",No,2026-12-04,FDA-32061,2.62,0.32,5.0,7.94,2028-08-13,2028-12-08,2033-12-09,31,J&J,59,South Africa,32.0,19,42,69,10,17,35,55,1,3,2,True,False,True,False,False,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"2 NRTIs plus an INI, NNRTI, or PI",Molecule Z,Drug,hiv,hiv,Phase 3,2025-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Aged 18 years or older (or ≥19 where required by local regulatory agencies), at the time of signing the informed consent.
* Must be on uninterrupted current regimen (either the ...",Yes,2026-10-04,FDA-26629,2.62,0.32,5.0,7.94,2028-08-13,2028-12-08,2033-12-09,18,AstraZeneca,25,Kenya,32.0,3,66,71,16,26,10,27,1,2,0,True,False,False,False,True,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,TradeName X,Drug,hiv,hiv,Phase 4,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented HIV-1 infection
* Age \>18 years
* Signed informed consent
* Receiving combination ART (cART) for at least 12 months with a stable cART regimen for a minimum of 6 mon...",No,2011-11-28,FDA-21061,0.56,0.15,3.5,4.21,2011-12-22,2012-02-15,2015-08-16,40,Novartis,9,South Africa,43.66666666666666,63,81,13,44,22,39,55,1,3,2,False,True,True,False,False,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Hyper-immune Bovine Colostrum,GenName Y,Drug,hiv,hiv,Phase 4,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented HIV-1 infection
* Age \>18 years
* Signed informed consent
* Receiving combination ART (cART) for at least 12 months with a stable cART regimen for a minimum of 6 mon...",Yes,2011-09-18,FDA-89225,0.56,0.15,3.5,4.21,2011-12-22,2012-02-15,2015-08-16,38,J&J,57,Senegal,52.16666666666666,85,76,18,66,4,64,64,2,2,3,True,True,True,False,True,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
raltegravir and hyper-immune bovine colostrum,Comp Beta,Drug,hiv,hiv,Phase 4,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented HIV-1 infection
* Age \>18 years
* Signed informed consent
* Receiving combination ART (cART) for at least 12 months with a stable cART regimen for a minimum of 6 mon...",No,2012-02-11,FDA-99335,0.56,0.15,3.5,4.21,2011-12-22,2012-02-15,2015-08-16,72,Merck,76,Overall,45.83333333333334,35,54,22,80,36,48,45,0,2,3,False,False,False,False,True,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
etonogestrel implant,Molecule Z,Drug,hiv,hiv,Phase 2,2022-10-25,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

1. Evidence of a personally signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study.
2. Participants who...",No,2023-07-07,FDA-63580,4.41,0.98,21.0,26.39,2027-03-23,2028-03-15,2049-03-15,52,GSK,27,Kenya,44.66666666666666,85,45,68,10,28,32,27,0,1,2,False,False,False,False,True,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Fludarabine and Busulfan,GenName Y,Drug,hiv,hiv,Phase 2,2018-06-01,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

1. HIV-1 infection, as documented by a rapid HIV test or any FDA-Approved HIV-1 Enzyme or Chemiluminescence Immunoassay (E/CIA) test kit and confirmed by Western Blot at any time ...",Yes,2018-08-27,FDA-69763,4.41,0.98,21.0,26.39,2022-10-28,2023-10-21,2044-10-20,19,Sanofi,86,South Africa,54.5,31,46,52,85,27,86,64,0,5,2,False,False,True,True,True,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Fludarabine and Melphalan,Product Alpha,Drug,hiv,hiv,Phase 2,2018-06-01,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

1. HIV-1 infection, as documented by a rapid HIV test or any FDA-Approved HIV-1 Enzyme or Chemiluminescence Immunoassay (E/CIA) test kit and confirmed by Western Blot at any time ...",No,2019-02-17,FDA-90221,4.41,0.98,21.0,26.39,2022-10-28,2023-10-21,2044-10-20,63,Bayer,10,Overall,37.5,63,65,4,14,50,29,27,1,1,1,False,True,False,False,False,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Busulfan and Fludarabine,AltName A,Drug,hiv,hiv,Phase 2,2018-06-01,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

1. HIV-1 infection, as documented by a rapid HIV test or any FDA-Approved HIV-1 Enzyme or Chemiluminescence Immunoassay (E/CIA) test kit and confirmed by Western Blot at any time ...",Yes,2019-04-07,FDA-54534,4.41,0.98,21.0,26.39,2022-10-28,2023-10-21,2044-10-20,27,Bayer,6,Senegal,27.16666666666667,50,31,16,39,8,19,73,1,4,3,False,True,True,False,True,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Cyclophosphamide and Total Body Irradiation,Product Alpha,Drug,hiv,hiv,Phase 2,2018-06-01,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

1. HIV-1 infection, as documented by a rapid HIV test or any FDA-Approved HIV-1 Enzyme or Chemiluminescence Immunoassay (E/CIA) test kit and confirmed by Western Blot at any time ...",Yes,2018-09-16,FDA-30130,4.41,0.98,21.0,26.39,2022-10-28,2023-10-21,2044-10-20,58,Sanofi,47,Overall,42.5,88,31,89,8,5,34,82,2,4,3,True,True,True,True,True,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK1349572,TradeName X,Drug,hiv,hiv,Phase 3,2021-02-02,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Antiretroviral therapy (ART)-experienced, Human Immunodeficiency Virus (HIV) -1 infected adults at least 18 years of age.
* Women capable of becoming pregnant must use appropria...",Yes,2022-01-22,FDA-70123,2.62,0.32,5.0,7.94,2023-09-16,2024-01-11,2029-01-11,31,AstraZeneca,74,Kenya,49.83333333333334,48,15,30,92,40,74,27,0,1,2,False,False,False,False,False,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,AltName A,Drug,hiv,hiv,Phase 3,2021-02-02,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Antiretroviral therapy (ART)-experienced, Human Immunodeficiency Virus (HIV) -1 infected adults at least 18 years of age.
* Women capable of becoming pregnant must use appropria...",Yes,2021-08-24,FDA-73938,2.62,0.32,5.0,7.94,2023-09-16,2024-01-11,2029-01-11,26,AstraZeneca,6,Overall,33.33333333333334,39,7,29,48,42,35,55,1,2,3,False,True,True,True,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Autologous HIV-1 ApB DC Vaccine,Comp Beta,Biological,hiv,hiv,Phase 2,2012-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Confirmed HIV-1 infection.
* CD4 greater than or equal to 350 cells/mL within 8 weeks prior to study entry.
* Plasma HIV-1 RNA level of 5000-100,000 copies/mL within 8 weeks pri...",No,2012-11-30,FDA-22428,4.41,0.98,21.0,26.39,2017-01-28,2018-01-21,2039-01-21,21,Gilead,13,Senegal,46.33333333333334,89,92,26,29,7,35,55,2,2,2,True,True,True,False,True,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz 600mg,Comp Beta,Drug,hiv,hiv,Phase 3,2011-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Screening plasma HIV-1 RNA viral load \>5000 copies/mL Self-identification as having any non-White/Caucasian European geographic ancestry (i.e., an individual is eligible if she/h...",No,2011-09-16,FDA-22036,2.62,0.32,5.0,7.94,2014-02-11,2014-06-08,2019-06-09,36,J&J,63,South Africa,64.0,47,79,46,87,74,51,55,0,4,2,False,False,True,False,True,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Boosted Lexiva,Comp Beta,Drug,hiv,hiv,Phase 3,2011-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Screening plasma HIV-1 RNA viral load \>5000 copies/mL Self-identification as having any non-White/Caucasian European geographic ancestry (i.e., an individual is eligible if she/h...",Yes,2012-03-13,FDA-79765,2.62,0.32,5.0,7.94,2014-02-11,2014-06-08,2019-06-09,7,Bayer,35,Overall,57.66666666666666,88,64,31,31,61,71,45,2,1,2,True,True,False,False,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
efavirenz,AltName B,Drug,hiv,hiv,Phase 4,2013-03-01,"Sex: ALL; Age: >14 Years; Criteria: Inclusion Criteria:

* HIV-infection, documented by ELISA
* Antiretroviral medication naïve (excluding mother-to-child transmission therapy)
* Age \>14 years
* Cryptococcal meningitis diagnosed by eit...",Yes,2014-01-08,FDA-56488,0.56,0.15,3.5,4.21,2013-09-21,2013-11-15,2017-05-16,34,GSK,85,South Africa,51.33333333333334,24,50,100,36,49,49,73,1,3,4,False,True,True,True,False,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
nucleoside,AltName A,Biological,hiv,hiv,Phase 4,2013-03-01,"Sex: ALL; Age: >14 Years; Criteria: Inclusion Criteria:

* HIV-infection, documented by ELISA
* Antiretroviral medication naïve (excluding mother-to-child transmission therapy)
* Age \>14 years
* Cryptococcal meningitis diagnosed by eit...",No,2013-05-27,FDA-52759,0.56,0.15,3.5,4.21,2013-09-21,2013-11-15,2017-05-16,27,Gilead,55,Kenya,67.16666666666667,99,94,63,29,91,27,36,0,3,1,False,False,True,False,True,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Atorvastatin (generic Lipitor),TradeName X,Drug,hiv,hiv,Phase 4,2017-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Chronic HIV-1 infected individuals on HAART (with no change in treatment within 4 weeks of study entry) and willing to continue therapy for the duration of the study.
2. HIV vi...",No,2017-12-24,FDA-48864,0.56,0.15,3.5,4.21,2018-04-23,2018-06-17,2021-12-16,91,Merck,61,Overall,44.66666666666666,28,47,9,34,96,54,55,1,3,2,True,False,True,True,True,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Etravirine (ETR),AltName A,Drug,hiv,hiv,Phase 2,2020-08-26,"Sex: ALL; Age: >2 Months; Criteria: Inclusion Criteria:

* Confirmed HIV-1 infection as described in the protocol
* NOTE: Children who were born at or sooner than 37 weeks gestational age must be at least 12 weeks of age and at least 46...",No,2021-06-06,FDA-56745,4.41,0.98,21.0,26.39,2025-01-22,2026-01-15,2047-01-15,13,GSK,87,Overall,35.66666666666666,68,62,17,10,38,19,64,1,3,3,True,False,False,True,True,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
peginterferon alfa-2a,TradeName X,Biological,hiv,hiv,Phase 2,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Chronic, genotype 1, hepatitis C with detectable HCV RNA
* HIV-1 infection for \>6 months
* Documentation of a liver biopsy within 1 year before the screening visit showing evid...",No,2026-07-16,FDA-45240,4.41,0.98,21.0,26.39,,,,36,Pfizer,72,Senegal,43.66666666666666,0,31,43,90,40,58,55,1,3,2,True,False,True,True,True,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ribavirin (fixed dose),AltName B,Drug,hiv,hiv,Phase 2,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Chronic, genotype 1, hepatitis C with detectable HCV RNA
* HIV-1 infection for \>6 months
* Documentation of a liver biopsy within 1 year before the screening visit showing evid...",No,2026-03-25,FDA-96527,4.41,0.98,21.0,26.39,,,,23,J&J,92,Kenya,39.16666666666666,52,7,90,26,57,3,45,1,1,3,False,True,False,False,False,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ribavirin (weight-based dose),Comp Beta,Drug,hiv,hiv,Phase 2,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Chronic, genotype 1, hepatitis C with detectable HCV RNA
* HIV-1 infection for \>6 months
* Documentation of a liver biopsy within 1 year before the screening visit showing evid...",Yes,2026-11-22,FDA-87524,4.41,0.98,21.0,26.39,,,,44,Gilead,62,Senegal,45.5,31,6,60,84,68,24,55,1,4,1,True,False,True,False,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
enfuvirtide [Fuzeon],AltName B,Drug,hiv,hiv,Phase 4,2008-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult patients, \>=18 years of age
* HIV-1 infection
* Triple class treatment-experienced, Fuzeon- and integrase-inhibitor naive
* GSS \>= 3 ; nucleosides excluded

Exclusion Cr...",No,2008-12-23,FDA-91095,0.56,0.15,3.5,4.21,2009-04-23,2009-06-17,2012-12-16,39,Novartis,25,Senegal,41.5,21,11,79,94,24,20,73,2,4,2,True,True,True,True,True,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Optimized background ARV,GenName Y,Drug,hiv,hiv,Phase 4,2008-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult patients, \>=18 years of age
* HIV-1 infection
* Triple class treatment-experienced, Fuzeon- and integrase-inhibitor naive
* GSS \>= 3 ; nucleosides excluded

Exclusion Cr...",Yes,2009-07-09,FDA-68733,0.56,0.15,3.5,4.21,2009-04-23,2009-06-17,2012-12-16,40,AstraZeneca,63,South Africa,42.0,57,0,1,97,96,1,45,1,2,2,False,True,False,True,False,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Integrase inhibitor,GenName Y,Drug,hiv,hiv,Phase 4,2008-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult patients, \>=18 years of age
* HIV-1 infection
* Triple class treatment-experienced, Fuzeon- and integrase-inhibitor naive
* GSS \>= 3 ; nucleosides excluded

Exclusion Cr...",No,2008-12-26,FDA-78151,0.56,0.15,3.5,4.21,2009-04-23,2009-06-17,2012-12-16,38,Pfizer,1,Senegal,52.16666666666666,90,40,97,17,17,52,36,0,2,2,False,False,True,False,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
enfuvirtide [Fuzeon],TradeName X,Drug,hiv,hiv,Phase 4,2008-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult patients, \>=18 years of age
* HIV-1 infection
* Triple class treatment-experienced, Fuzeon- and integrase-inhibitor naive
* GSS \>= 3 ; nucleosides excluded

Exclusion Cr...",No,2009-05-06,FDA-27113,0.56,0.15,3.5,4.21,2009-04-23,2009-06-17,2012-12-16,98,Pfizer,96,Overall,80.83333333333333,55,94,95,83,100,58,73,1,3,4,False,True,False,True,False,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Peg-interferon + ribavirin under HIV physician supervision,GenName Y,Drug,hiv,hiv,Phase 4,2018-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Evidence of chronic HCV infection for at least 6 months before study entry (at least one detectable HCV viral load, i.e. ≥17 IU/mL, with an antibody test positive at least 6 mon...",Yes,2018-06-12,FDA-60002,0.56,0.15,3.5,4.21,2018-07-24,2018-09-17,2022-03-18,43,Bayer,56,Kenya,32.66666666666666,17,28,20,80,35,16,18,0,2,0,False,False,True,False,True,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
raltegravir,AltName B,Drug,hiv,hiv,Phase 2,2011-12-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry or plasma HIV-1 RNA \> 2000 on two occasions,
* Femal...",No,2012-02-14,FDA-50615,4.41,0.98,21.0,26.39,2016-04-28,2017-04-21,2038-04-21,75,GSK,72,Senegal,58.5,100,16,11,89,48,87,64,0,3,4,False,False,True,True,False,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
tenofovir-alafenamide-emtricitabine,AltName A,Drug,hiv,hiv,Phase 4,2021-02-25,"Sex: FEMALE; Age: >40 Years; Criteria: Inclusion Criteria:

1. Biological female aged 40-60
2. Documented HIV-1 infection
3. Peri-menopausal ( as documented by history).
4. Signed Informed Consent Form and willing to comply with the protoc...",Yes,2021-10-04,FDA-68785,0.56,0.15,3.5,4.21,2021-09-17,2021-11-11,2025-05-12,53,AstraZeneca,77,Kenya,59.83333333333334,86,48,38,79,92,16,73,1,3,4,True,False,True,True,False,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
tenofovir-emtricitabine,TradeName X,Drug,hiv,hiv,Phase 4,2021-02-25,"Sex: FEMALE; Age: >40 Years; Criteria: Inclusion Criteria:

1. Biological female aged 40-60
2. Documented HIV-1 infection
3. Peri-menopausal ( as documented by history).
4. Signed Informed Consent Form and willing to comply with the protoc...",Yes,2021-07-13,FDA-47056,0.56,0.15,3.5,4.21,2021-09-17,2021-11-11,2025-05-12,93,J&J,77,Senegal,48.16666666666666,61,83,48,11,22,64,36,1,2,1,True,False,False,False,True,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Durvalumab,AltName A,Drug,hiv,hiv,Phase 2,2022-03-22,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Written informed consent
2. Age \> 18 years at time of study entry.
3. Eastern Cooperative Oncology Group (ECOG) 0-2
4. Life expectancy of \> 16 weeks
5. Adequate normal organ ...",Yes,2023-03-11,FDA-82703,4.41,0.98,21.0,26.39,2026-08-18,2027-08-11,2048-08-10,55,J&J,2,Kenya,45.0,58,54,73,23,19,43,45,0,3,2,False,False,True,True,False,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
mirtazapine,TradeName X,Drug,hiv,hiv,Phase 2,2010-03-01,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. HIV-negative by rapid test, or documentation of HIV infection with a laboratory result of a positive HIV test;
2. male gender;
3. reports having anal sex with men in the prior ...",No,2010-08-15,FDA-30938,4.41,0.98,21.0,26.39,2014-07-28,2015-07-21,2036-07-20,67,Sanofi,12,Overall,46.5,92,22,16,37,64,48,45,1,2,2,True,False,False,True,False,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
NucleomaxX,GenName Y,Drug,hiv,hiv,Phase 3,2008-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected
* Stable ART containing zidovudine or stavudine for at least 12 consecutive weeks prior to study entry
* Cumulative ART with zidovudine or stavudine for at least ...",No,2009-04-14,FDA-33775,2.62,0.32,5.0,7.94,2011-07-15,2011-11-09,2016-11-09,33,Novartis,98,South Africa,40.33333333333334,31,1,61,34,25,90,82,1,5,3,False,True,True,True,True,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Pyridostigmine tablets,AltName B,Drug,hiv,hiv,Phase 2,2009-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected subjects 18 years of age or older
* Receiving HAART for at least two years
* At least a viral load determination per year since HAART initiation, all undetectable...",Yes,2009-05-24,FDA-38338,4.41,0.98,21.0,26.39,2013-05-30,2014-05-23,2035-05-23,48,AstraZeneca,52,South Africa,45.0,28,53,13,47,93,36,45,0,3,2,False,False,False,True,True,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
tipranavir,AltName A,Drug,hiv,hiv,Phase 2,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Signed informed consent in accordance with GCP and local regulatory requirements prior to trial participation.
* HIV-1 infected men and non-pregnant women who are treatment naïv...",Yes,2026-01-08,FDA-78712,4.41,0.98,21.0,26.39,,,,58,Novartis,70,Kenya,27.33333333333333,17,32,50,31,29,5,55,1,3,2,False,True,True,False,True,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ritonavir,AltName B,Drug,hiv,hiv,Phase 2,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Signed informed consent in accordance with GCP and local regulatory requirements prior to trial participation.
* HIV-1 infected men and non-pregnant women who are treatment naïv...",Yes,2026-03-08,FDA-20667,4.41,0.98,21.0,26.39,,,,43,Bayer,30,Kenya,24.66666666666667,44,24,4,2,58,16,64,1,2,4,True,False,True,True,False,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tipranavir,Product Alpha,Drug,hiv,hiv,Phase 3,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Signed informed consent prior to trial participation.
2. HIV-1 infected male or female \>18 years of age.
3. Three-class (NRTI, NNRTI, and PI) treatment-experienced patients (a...",No,2026-03-02,FDA-26122,2.62,0.32,5.0,7.94,,,,40,Pfizer,6,Kenya,51.83333333333334,82,72,2,59,7,89,55,1,3,2,False,True,True,False,True,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Darunavir,Product Alpha,Drug,hiv,hiv,Phase 3,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Signed informed consent prior to trial participation.
2. HIV-1 infected male or female \>18 years of age.
3. Three-class (NRTI, NNRTI, and PI) treatment-experienced patients (a...",No,2026-11-10,FDA-89200,2.62,0.32,5.0,7.94,,,,56,Sanofi,69,Senegal,57.66666666666666,22,88,73,29,94,40,45,1,3,1,False,True,False,True,True,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,AltName B,Drug,hiv,hiv,Phase 3,,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Signed informed consent prior to trial participation.
2. HIV-1 infected male or female \>18 years of age.
3. Three-class (NRTI, NNRTI, and PI) treatment-experienced patients (a...",No,2026-02-15,FDA-80166,2.62,0.32,5.0,7.94,,,,58,GSK,23,Senegal,54.66666666666666,69,44,28,83,37,67,45,2,2,1,True,True,False,True,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs)",Product Alpha,Drug,hiv,hiv,Phase 4,2008-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected on HAART regimen containing 2 NRTI and boosted PI for at least 12 weeks prior to screening. Subjects may not have experienced virological failure to more than one...",Yes,2009-05-22,FDA-95822,0.56,0.15,3.5,4.21,2008-12-22,2009-02-15,2012-08-16,18,Sanofi,22,Overall,37.0,36,42,0,41,31,72,36,1,2,1,False,True,True,False,False,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs),Molecule Z,Drug,hiv,hiv,Phase 4,2008-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected on HAART regimen containing 2 NRTI and boosted PI for at least 12 weeks prior to screening. Subjects may not have experienced virological failure to more than one...",No,2008-11-30,FDA-59117,0.56,0.15,3.5,4.21,2008-12-22,2009-02-15,2012-08-16,68,AstraZeneca,80,Overall,45.5,88,47,6,31,93,8,45,0,2,3,False,False,True,False,True,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Islatravir,GenName Y,Drug,hiv,hiv,Phase 3,2024-06-11,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Confirmed HIV-uninfected based on negative HIV-1/HIV-2 test results before randomization.
* Sexually active (vaginal and/or anal sex) with a male sexual partner in the 30 days p...",No,2024-10-20,FDA-75836,2.62,0.32,5.0,7.94,2027-01-23,2027-05-20,2032-05-20,98,AstraZeneca,53,Senegal,39.5,61,44,6,78,47,1,64,2,2,3,True,True,True,False,False,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TDF,Molecule Z,Drug,hiv,hiv,Phase 3,2024-06-11,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Confirmed HIV-uninfected based on negative HIV-1/HIV-2 test results before randomization.
* Sexually active (vaginal and/or anal sex) with a male sexual partner in the 30 days p...",No,2024-12-06,FDA-35707,2.62,0.32,5.0,7.94,2027-01-23,2027-05-20,2032-05-20,15,Novartis,64,Overall,45.83333333333334,38,51,86,61,20,19,45,1,2,2,False,True,False,False,True,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
AZT/3TC/NVP (zidovudine/lamivudine/nevirapine),AltName A,Drug,hiv,hiv,Phase 3,2009-12-01,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* 6-18 months age
* HIV-1 DNA detection with confirmation (positive on two HIV-1 DNA filter paper tests)
* Mother exposed to NVP-containing PMTCT regimen during currently ended pr...",No,2010-02-16,FDA-17469,2.62,0.32,5.0,7.94,2012-07-14,2012-11-08,2017-11-09,98,Bayer,92,Kenya,70.16666666666667,65,86,82,67,47,74,27,1,0,2,False,True,False,False,False,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
d4T/3TC/NVP (stavudine/lamivudine/nevirapine),GenName Y,Drug,hiv,hiv,Phase 3,2009-12-01,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* 6-18 months age
* HIV-1 DNA detection with confirmation (positive on two HIV-1 DNA filter paper tests)
* Mother exposed to NVP-containing PMTCT regimen during currently ended pr...",Yes,2010-01-13,FDA-94479,2.62,0.32,5.0,7.94,2012-07-14,2012-11-08,2017-11-09,31,Pfizer,30,Overall,63.16666666666666,37,96,66,37,73,70,55,2,3,1,True,True,True,False,False,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
AZT/3TC/ABC (zidovudine/lamivudine/abacavir),Comp Beta,Drug,hiv,hiv,Phase 3,2009-12-01,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* 6-18 months age
* HIV-1 DNA detection with confirmation (positive on two HIV-1 DNA filter paper tests)
* Mother exposed to NVP-containing PMTCT regimen during currently ended pr...",Yes,2010-09-22,FDA-65016,2.62,0.32,5.0,7.94,2012-07-14,2012-11-08,2017-11-09,17,Gilead,58,Overall,53.33333333333334,96,40,21,58,54,51,45,1,3,1,False,True,True,True,False,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
d4T/3TC/ABC (stavudine/lamivudine/abacavir),Product Alpha,Drug,hiv,hiv,Phase 3,2009-12-01,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* 6-18 months age
* HIV-1 DNA detection with confirmation (positive on two HIV-1 DNA filter paper tests)
* Mother exposed to NVP-containing PMTCT regimen during currently ended pr...",Yes,2010-07-06,FDA-18532,2.62,0.32,5.0,7.94,2012-07-14,2012-11-08,2017-11-09,77,Sanofi,97,Overall,38.33333333333334,24,19,37,82,19,49,45,0,3,2,False,False,False,False,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir),Comp Beta,Drug,hiv,hiv,Phase 3,2009-12-01,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* 6-18 months age
* HIV-1 DNA detection with confirmation (positive on two HIV-1 DNA filter paper tests)
* Mother exposed to NVP-containing PMTCT regimen during currently ended pr...",No,2010-06-14,FDA-81015,2.62,0.32,5.0,7.94,2012-07-14,2012-11-08,2017-11-09,96,J&J,44,South Africa,50.66666666666666,76,59,49,22,80,18,55,1,2,3,True,False,True,True,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz),AltName A,Drug,hiv,hiv,Phase 3,2009-12-01,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* 6-18 months age
* HIV-1 DNA detection with confirmation (positive on two HIV-1 DNA filter paper tests)
* Mother exposed to NVP-containing PMTCT regimen during currently ended pr...",No,2010-05-16,FDA-99776,2.62,0.32,5.0,7.94,2012-07-14,2012-11-08,2017-11-09,10,Gilead,2,Senegal,47.0,77,81,27,54,18,25,45,1,3,1,False,True,False,True,True,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ABC/3TC/NVP (abacavir/lamivudine/nevirapine),TradeName X,Drug,hiv,hiv,Phase 3,2009-12-01,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* 6-18 months age
* HIV-1 DNA detection with confirmation (positive on two HIV-1 DNA filter paper tests)
* Mother exposed to NVP-containing PMTCT regimen during currently ended pr...",No,2010-06-03,FDA-68616,2.62,0.32,5.0,7.94,2012-07-14,2012-11-08,2017-11-09,16,GSK,56,Overall,46.66666666666666,0,63,65,35,67,50,55,0,4,2,False,False,True,False,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
rifabutin plus trimethoprim sulfamethoxazole,TradeName X,Drug,hiv,hiv,Phase 2,2010-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Age \> 18 years
2. HIV infection as reported by the subject's physician
3. Physician-reported SSSI within the prior 6 months.
4. S. aureus colonization at ≥ 1 body site as defi...",No,2011-07-24,FDA-73121,4.41,0.98,21.0,26.39,2015-04-29,2016-04-21,2037-04-21,91,J&J,22,Overall,68.16666666666667,56,88,76,15,99,75,45,0,3,2,False,False,False,True,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
LACTIN-V,Molecule Z,Drug,hiv,hiv,Phase 2,2023-03-31,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

1. FRESH study participant.
2. Capable of reading and writing English or isiZulu and voluntarily provide written informed consent to participate in the study and comply with all s...",Yes,2024-01-02,FDA-39058,4.41,0.98,21.0,26.39,2027-08-27,2028-08-19,2049-08-19,84,Merck,30,Senegal,26.66666666666667,29,47,18,15,26,25,36,0,3,1,False,False,True,False,False,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Bedaquiline,AltName A,Drug,hiv,hiv,Phase 2,2025-04-30,"Sex: ALL; Age: >0 Months; Criteria: Inclusion Criteria:

* Parent/legal guardian willing and able to provide written informed consent for study participation; in addition, when applicable per local Institutional Review Board (IRB)/Ethic...",Yes,2026-01-16,FDA-71973,4.41,0.98,21.0,26.39,2029-09-26,2030-09-19,2051-09-19,59,Bayer,25,South Africa,55.0,77,68,21,22,46,96,45,1,4,0,True,False,True,True,True,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rilpivirine,Product Alpha,Drug,hiv,hiv,Phase 3,2020-07-02,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Documented human immunodeficiency virus-type 1 (HIV-1) infection Patients who have been receiving first line highly active antiretroviral therapy (HAART) for at least 1 year befor...",Yes,2020-10-30,FDA-63440,2.62,0.32,5.0,7.94,2023-02-13,2023-06-10,2028-06-10,59,Bayer,44,Senegal,47.16666666666666,53,1,64,55,49,61,73,1,5,2,False,True,True,True,True,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,GenName Y,Drug,hiv,hiv,Phase 3,2020-07-02,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Documented human immunodeficiency virus-type 1 (HIV-1) infection Patients who have been receiving first line highly active antiretroviral therapy (HAART) for at least 1 year befor...",Yes,2020-10-29,FDA-11804,2.62,0.32,5.0,7.94,2023-02-13,2023-06-10,2028-06-10,42,J&J,56,Senegal,49.66666666666666,28,54,0,71,91,54,64,1,3,3,True,False,False,True,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir disoproxil fumarate,Molecule Z,Drug,hiv,hiv,Phase 3,2020-07-02,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Documented human immunodeficiency virus-type 1 (HIV-1) infection Patients who have been receiving first line highly active antiretroviral therapy (HAART) for at least 1 year befor...",Yes,2021-03-22,FDA-29139,2.62,0.32,5.0,7.94,2023-02-13,2023-06-10,2028-06-10,73,AstraZeneca,93,Kenya,50.66666666666666,92,69,6,100,30,7,45,0,4,1,False,False,False,True,True,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine,Molecule Z,Drug,hiv,hiv,Phase 3,2020-07-02,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Documented human immunodeficiency virus-type 1 (HIV-1) infection Patients who have been receiving first line highly active antiretroviral therapy (HAART) for at least 1 year befor...",No,2020-09-20,FDA-55490,2.62,0.32,5.0,7.94,2023-02-13,2023-06-10,2028-06-10,61,Sanofi,49,Senegal,57.83333333333334,100,4,36,48,88,71,45,1,2,2,True,False,True,False,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Combined short-course zidovudine/nevirapine,GenName Y,Drug,hiv,hiv,Phase 2,2006-04-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* The subject population is recruited from Mathare North Clinic in Nairobi, Kenya where voluntary HIV-1 counseling and testing is offered to pregnant women
* Pregnant women who te...",No,2006-09-24,FDA-55326,4.41,0.98,21.0,26.39,2010-08-28,2011-08-21,2032-08-20,18,Novartis,13,Kenya,44.83333333333334,96,19,5,86,8,55,27,0,1,2,False,False,False,True,False,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
HAART,Product Alpha,Drug,hiv,hiv,Phase 2,2006-04-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* The subject population is recruited from Mathare North Clinic in Nairobi, Kenya where voluntary HIV-1 counseling and testing is offered to pregnant women
* Pregnant women who te...",No,2007-03-17,FDA-87094,4.41,0.98,21.0,26.39,2010-08-28,2011-08-21,2032-08-20,5,Sanofi,3,South Africa,63.16666666666666,43,85,44,100,66,41,55,1,3,2,False,True,True,False,False,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK Biologicals HIV Vaccine 732462,GenName Y,Biological,hiv,hiv,Phase 2,2012-11-05,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

All subjects must satisfy ALL the following criteria at study entry:

* Subjects who the investigator believes can and will comply with the requirements of the protocol.
* Written...",Yes,2013-08-25,FDA-69483,4.41,0.98,21.0,26.39,2017-04-03,2018-03-27,2039-03-27,83,Pfizer,46,South Africa,57.33333333333334,52,86,17,44,49,96,64,0,4,3,False,False,True,True,True,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
everolimus,TradeName X,Drug,hiv,hiv,Phase 4,2018-01-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Solid organ (kidney, kidney/pancreas, or liver) transplant recipient
2. Male or female ≥ 18 years of age.
3. Documentation of HIV-1 infection diagnosis as evidenced by any lice...",No,2018-04-24,FDA-85119,0.56,0.15,3.5,4.21,2018-08-23,2018-10-17,2022-04-17,64,Novartis,95,Kenya,32.66666666666666,50,8,35,49,48,6,45,0,4,1,False,False,True,True,False,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Leptin,Molecule Z,Drug,hiv,hiv,Phase 2,2014-09-01,"Sex: ALL; Age: >14 Years; Criteria: Inclusion Criteria - General inclusion:

* Age \> 14 years
* HIV infection being treated with HIV-1 protease inhibitors for \>6 months currently, or previous protease inhibitor therapy of at least 2 y...",No,2015-01-12,FDA-41734,4.41,0.98,21.0,26.39,2019-01-28,2020-01-21,2041-01-20,96,Merck,45,Overall,66.0,72,87,56,15,97,69,73,2,3,3,True,True,False,True,True,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Quadrivalent meningococcal conjugate vaccine,Comp Beta,Biological,hiv,hiv,Phase 2,2013-03-01,"Sex: ALL; Age: >2 Years; Criteria: Inclusion Criteria for Steps 1, 2, and 3:

* HIV-infected
* Age greater than or equal to 2 and less than 25 years (Steps 1 and 2 only)
* CD4% documented within 120 days of study entry
* Participants o...",Yes,2013-06-04,FDA-51644,4.41,0.98,21.0,26.39,2017-07-28,2018-07-21,2039-07-21,19,J&J,73,Overall,47.0,32,36,59,15,80,60,45,1,2,2,False,True,True,True,False,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
cenicriviroc,GenName Y,Drug,hiv,hiv,Phase 2,2016-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* 4.2.1.1 Documentation of HIV-1 infection by an FDA approved test at any time prior to study entry
* On ARV medication uninterrupted for \> 1 year leading up to the screening per...",No,2016-08-08,FDA-54687,4.41,0.98,21.0,26.39,2020-10-28,2021-10-21,2042-10-21,18,AstraZeneca,82,Kenya,49.0,71,24,73,47,18,61,55,1,2,3,False,True,True,False,True,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
LDV/SOF,TradeName X,Drug,hiv,hiv,Phase 2,2016-01-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Acute, untreated, hepatitis C infection, genotype 1 or 4, with an estimated duration less than 24 weeks
* Confirmed HIV-1 infection
* CD4 T cell count \>200/μL for individua...",Yes,2016-04-26,FDA-35732,4.41,0.98,21.0,26.39,2020-05-29,2021-05-22,2042-05-22,47,Bayer,93,Senegal,30.5,23,3,46,73,9,29,45,1,2,2,True,False,False,True,False,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rosuvastatin 10 mg. daily for 96 weeks,Comp Beta,Drug,hiv,hiv,Phase 2,2014-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Clinical diagnosis of HIV Disease
* Age \> 18 years old
* Receiving a stable ARV regimen for at least the last 12 weeks prior to study entry and cumulative duration of ARV for 1...",No,2014-07-25,FDA-55721,4.41,0.98,21.0,26.39,2018-09-27,2019-09-20,2040-09-19,63,Pfizer,91,Kenya,43.83333333333334,22,1,53,99,25,63,45,1,2,2,False,True,False,True,False,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Combination antiretroviral therapy (cART),Molecule Z,Drug,hiv,hiv,Phase 2,2012-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documentation of HIV infection with a positive HIV enzyme-linked immunosorbent assay (ELISA) test and confirmatory western blot test
* Has not received any antiretroviral therap...",Yes,2013-06-22,FDA-35317,4.41,0.98,21.0,26.39,2017-04-29,2018-04-22,2039-04-22,72,Gilead,53,Kenya,41.16666666666666,19,27,68,38,92,3,36,0,3,1,False,False,True,False,True,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Pentoxifylline,AltName B,Drug,hiv,hiv,Phase 2,2012-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documentation of HIV infection with a positive HIV enzyme-linked immunosorbent assay (ELISA) test and confirmatory western blot test
* Has not received any antiretroviral therap...",Yes,2013-08-17,FDA-86000,4.41,0.98,21.0,26.39,2017-04-29,2018-04-22,2039-04-22,93,Bayer,91,Overall,51.66666666666666,60,25,14,91,57,63,36,0,2,2,False,False,True,False,False,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT),Molecule Z,Drug,hiv,hiv,Phase 2,2018-11-13,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Men and women age greater than or equal to 18 to less than or equal to 70 years at study entry.
* Body mass index (BMI) from greater than or equal to 18 to less than 38 kg/m\^2 ...",No,2019-02-08,FDA-36066,4.41,0.98,21.0,26.39,2023-04-11,2024-04-03,2045-04-03,7,GSK,35,Overall,56.5,67,100,84,69,7,12,36,1,1,2,True,False,False,False,False,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Dasabuvir (DSV),TradeName X,Drug,hiv,hiv,Phase 2,2018-11-13,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Men and women age greater than or equal to 18 to less than or equal to 70 years at study entry.
* Body mass index (BMI) from greater than or equal to 18 to less than 38 kg/m\^2 ...",Yes,2019-11-02,FDA-15913,4.41,0.98,21.0,26.39,2023-04-11,2024-04-03,2045-04-03,18,Merck,69,South Africa,54.33333333333334,30,98,62,31,68,37,64,2,2,3,True,True,True,True,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ribavirin (RBV),GenName Y,Drug,hiv,hiv,Phase 2,2018-11-13,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Men and women age greater than or equal to 18 to less than or equal to 70 years at study entry.
* Body mass index (BMI) from greater than or equal to 18 to less than 38 kg/m\^2 ...",Yes,2019-07-02,FDA-42213,4.41,0.98,21.0,26.39,2023-04-11,2024-04-03,2045-04-03,21,Gilead,31,Kenya,60.83333333333334,98,64,40,77,16,70,73,2,4,2,True,True,True,False,True,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Bupropion,Product Alpha,Drug,hiv,hiv,Phase 3,2023-07-25,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

* Chart diagnosis of HIV at recruitment clinic.
* Age 18 years and older
* Currently self-report smoking approximately 1 cigarette per day.
* Motivation to quit (score 6-8 on the A...",Yes,2023-09-24,FDA-31455,2.62,0.32,5.0,7.94,2026-03-07,2026-07-02,2031-07-03,79,Bayer,15,Kenya,38.16666666666666,5,28,39,67,74,16,64,2,2,3,True,True,False,False,False,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Intravenous Immunoglobulin,AltName A,Drug,hiv,hiv,Phase 4,2016-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented history of HIV infection.
* Age ≥ 18
* Males and females are eligible. Subjects must agree to practice birth control or abstinence. Females of child-bearing potential...",Yes,2017-04-22,FDA-34493,0.56,0.15,3.5,4.21,2017-03-24,2017-05-18,2020-11-16,12,GSK,29,South Africa,59.16666666666666,62,8,92,8,89,96,45,2,1,2,True,True,False,False,False,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Boceprevir,TradeName X,Drug,hiv,hiv,Phase 4,2013-09-01,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

To be eligible for participation on this protocol, a participant must satisfy all of the following conditions:

1. Be greater than or equal to18 years old and have an identifiab...",Yes,2014-05-25,FDA-16326,0.56,0.15,3.5,4.21,2014-03-24,2014-05-18,2017-11-16,46,GSK,0,Overall,63.16666666666666,86,51,6,81,97,58,64,1,3,3,True,False,False,True,True,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Peg-Interferon-alfa 2B,GenName Y,Drug,hiv,hiv,Phase 4,2013-09-01,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

To be eligible for participation on this protocol, a participant must satisfy all of the following conditions:

1. Be greater than or equal to18 years old and have an identifiab...",Yes,2014-07-28,FDA-33205,0.56,0.15,3.5,4.21,2014-03-24,2014-05-18,2017-11-16,41,Sanofi,15,South Africa,59.83333333333334,80,19,77,67,28,88,27,1,2,0,True,False,False,True,True,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ribavirin,TradeName X,Drug,hiv,hiv,Phase 4,2013-09-01,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

To be eligible for participation on this protocol, a participant must satisfy all of the following conditions:

1. Be greater than or equal to18 years old and have an identifiab...",Yes,2014-07-12,FDA-39619,0.56,0.15,3.5,4.21,2014-03-24,2014-05-18,2017-11-16,89,Gilead,79,South Africa,26.5,21,2,4,27,21,84,45,1,3,1,False,True,True,False,False,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc Pill,AltName B,Drug,hiv,hiv,Phase 4,2018-12-07,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria

* Healthy volunteer between the ages of 18 and 70, inclusive on the date of screening, with an intact gastrointestinal tract. Healthy is defined as no clinically relevant abnormali...",No,2019-05-06,FDA-79181,0.56,0.15,3.5,4.21,2019-06-29,2019-08-23,2023-02-21,99,Pfizer,56,Senegal,40.5,50,5,40,55,26,67,36,1,2,1,False,True,True,False,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir Pill,TradeName X,Drug,hiv,hiv,Phase 4,2018-12-07,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria

* Healthy volunteer between the ages of 18 and 70, inclusive on the date of screening, with an intact gastrointestinal tract. Healthy is defined as no clinically relevant abnormali...",No,2019-06-28,FDA-27316,0.56,0.15,3.5,4.21,2019-06-29,2019-08-23,2023-02-21,17,Pfizer,26,Kenya,52.33333333333334,2,100,76,23,48,65,45,0,2,3,False,False,False,False,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada Pill,Product Alpha,Drug,hiv,hiv,Phase 4,2018-12-07,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria

* Healthy volunteer between the ages of 18 and 70, inclusive on the date of screening, with an intact gastrointestinal tract. Healthy is defined as no clinically relevant abnormali...",Yes,2019-02-20,FDA-43260,0.56,0.15,3.5,4.21,2019-06-29,2019-08-23,2023-02-21,30,Merck,69,Senegal,46.66666666666666,24,71,59,51,21,54,55,1,3,2,True,False,True,True,True,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ad26.Mos4.HIV,GenName Y,Biological,hiv,hiv,Phase 3,2023-08-10,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Individual is either cis-gender man having sex with cis-gender men and/or transgender individuals or transgender woman having sex with cis-gender men and/or transgender individu...",Yes,2024-04-01,FDA-26599,2.62,0.32,5.0,7.94,2026-03-23,2026-07-18,2031-07-19,54,AstraZeneca,82,Overall,50.0,35,91,45,34,21,74,64,2,4,1,True,True,True,False,True,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Clade C and Mosaic gp140 HIV bivalent vaccine,GenName Y,Biological,hiv,hiv,Phase 3,2023-08-10,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Individual is either cis-gender man having sex with cis-gender men and/or transgender individuals or transgender woman having sex with cis-gender men and/or transgender individu...",Yes,2024-02-03,FDA-93806,2.62,0.32,5.0,7.94,2026-03-23,2026-07-18,2031-07-19,15,Bayer,86,Overall,52.66666666666666,96,66,33,48,24,49,45,0,2,3,False,False,True,False,False,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Omega-3 fatty acid administration,TradeName X,Drug,hiv,hiv,Phase 4,2010-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability and willingness to give informed consent
* Age ≥ 18 years
* HIV-1 infection documented at any time prior to study entry
* Fasting plasma triglyceride value between 200 a...",No,2010-08-14,FDA-35760,0.56,0.15,3.5,4.21,2010-10-22,2010-12-16,2014-06-16,57,GSK,38,Overall,58.5,33,75,66,85,6,86,45,1,2,2,False,True,False,False,False,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Benzathine Penicillin,Molecule Z,Drug,hiv,hiv,Phase 4,2023-03-20,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Subject is aged 18 years or older.
2. Subject has provided informed consent.
3. Subject has untreated primary\*, secondary\*\*, or early latent\*\*\* syphilis.

   \*Primary sy...",Yes,2023-07-01,FDA-83560,0.56,0.15,3.5,4.21,2023-10-10,2023-12-04,2027-06-04,42,Merck,42,Senegal,50.83333333333334,51,36,81,33,79,25,64,1,4,2,True,False,True,True,True,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
GS-7977/GS- 5885 FDC,AltName B,Drug,hiv,hiv,Phase 2,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

  1. Eighteen years of age or older at screening.
  2. HCV treatment-naive, as defined as no prior exposure to any IFN, RBV, or other approved or experimental HCV-specific direc...",No,2014-11-27,FDA-31817,4.41,0.98,21.0,26.39,2019-01-28,2020-01-21,2041-01-20,12,Gilead,6,South Africa,66.16666666666667,97,85,61,47,73,34,64,1,4,2,True,False,False,True,True,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
infrared photocoagulation therapy,Product Alpha,Device,hiv,hiv,Phase 3,2016-07-01,"Sex: ALL; Age: >27 Years; Criteria: DISEASE CHARACTERISTICS:

* Diagnosis of high-grade anal intraepithelial neoplasia (AIN) meeting the following:

  * AIN2 and/or AIN3 confirmed by biopsy ≥ 2 weeks to ≤ 60 days before enrollment
  * 1...",No,2016-10-26,FDA-17353,2.62,0.32,5.0,7.94,2019-02-12,2019-06-09,2024-06-09,35,Novartis,69,Overall,50.5,16,67,63,97,6,54,55,1,2,3,True,False,True,False,False,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets,TradeName X,Drug,hiv,hiv,Phase 3,2021-09-15,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV infected females participating in ING117172 on the DTG/ABC/3TC treatment arm who became pregnant with a singleton and have not met any safety or confirmed virologic withdraw...",No,2022-03-28,FDA-20543,2.62,0.32,5.0,7.94,2024-04-28,2024-08-23,2029-08-24,62,Novartis,3,South Africa,58.0,28,97,40,85,67,31,64,1,4,2,False,True,True,False,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Policosanol,Molecule Z,Drug,hiv,hiv,Phase 2,2009-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

CD4 count \> 250 Plasma HIV RNA \< 50,000 Currently receiving HAART age 18-60 total cholesterol between 200-240 or triglycerides between 150-400 or LDL cholesterol \> 160

Exclusi...",Yes,2010-06-16,FDA-23335,4.41,0.98,21.0,26.39,2014-01-28,2015-01-21,2036-01-21,16,Gilead,32,South Africa,38.0,50,29,24,32,59,34,36,0,2,2,False,False,True,False,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"Insulin, intranasal",Molecule Z,Drug,hiv,hiv,Phase 2,2020-10-16,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Must have HIV,
* Capable of providing informed consent,
* Between the ages of 18-69 years,
* Evidence of problems with memory, speed, and brain function,
* Same HIV medications ...",Yes,2020-11-19,FDA-63520,4.41,0.98,21.0,26.39,2025-03-14,2026-03-07,2047-03-07,96,AstraZeneca,36,Senegal,29.33333333333333,9,51,46,3,4,63,45,0,3,2,False,False,False,True,True,False,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Interferon-Gamma,AltName B,Drug,hiv,hiv,Phase 2,2006-04-06,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants must sign the form of informed consent and agree to follow the protocol requirements
* Women willing to participate in the study must protect against possible pregn...",No,2006-06-26,FDA-76165,4.41,0.98,21.0,26.39,2010-09-02,2011-08-26,2032-08-25,81,AstraZeneca,76,South Africa,41.33333333333334,83,22,17,48,35,43,73,1,4,3,False,True,True,True,False,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
American ginseng,Product Alpha,Drug,hiv,hiv,Phase 2,2016-09-01,"Sex: ALL; Age: >18 Years; Criteria: INCLUSION CRITERIA

1. HIV-infected men and women, ≥18 years of age
2. HIV-1 infection documented by a rapid HIV test or any licensed ELISA test kit and confirmed by a repeat ELISA, Western blot at an...",Yes,2017-03-08,FDA-68842,4.41,0.98,21.0,26.39,2021-01-28,2022-01-21,2043-01-21,40,AstraZeneca,47,South Africa,40.0,37,51,12,66,49,25,45,0,4,1,False,False,True,True,True,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
NucleomaxX,Molecule Z,Drug,hiv,hiv,Phase 2,2008-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Diagnosis of HIV lipoatrophy
* Receiving a stable stavudine- or zidovudine-containing ARV regimen
* HIV-1 RNA viral load less than 50 copies/ml

Exclusion Criteria:

* Coagulopa...",Yes,2009-05-23,FDA-51317,4.41,0.98,21.0,26.39,2013-02-27,2014-02-20,2035-02-20,53,Gilead,39,Kenya,61.66666666666666,78,85,83,36,58,30,45,0,3,2,False,False,False,False,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir Disoproxil Fumarate,GenName Y,Drug,hiv,hiv,Phase 2,2008-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Diagnosis of HIV lipoatrophy
* Receiving a stable stavudine- or zidovudine-containing ARV regimen
* HIV-1 RNA viral load less than 50 copies/ml

Exclusion Criteria:

* Coagulopa...",Yes,2009-05-29,FDA-32031,4.41,0.98,21.0,26.39,2013-02-27,2014-02-20,2035-02-20,58,Pfizer,72,Kenya,35.66666666666666,52,17,22,44,66,13,36,0,1,3,False,False,False,True,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Evolocumab,Product Alpha,Drug,hiv,hiv,Phase 2,2019-11-30,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* Participants of either gender who are \>21 years of age (no upper age limit)
* HIV (Human Immunodeficiency Virus) positive and taking stable Anti-Retroviral Therapy (ART), no ch...",Yes,2020-11-15,FDA-40007,4.41,0.98,21.0,26.39,2024-04-27,2025-04-20,2046-04-20,100,Gilead,32,Senegal,41.16666666666666,84,16,38,27,59,23,45,0,3,2,False,False,True,True,False,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Daily oral PrEP,Comp Beta,Drug,hiv,hiv,Phase 4,2023-12-10,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Men ages ≥18
* Has a female sexual partner enrolled in the Kampala Women's Bone Study
* Willing and able to provide informed consent

Exclusion Criteria:

* Has any other condit...",Yes,2024-05-13,FDA-39421,0.56,0.15,3.5,4.21,2024-07-01,2024-08-25,2028-02-24,32,Novartis,74,Overall,52.33333333333334,43,19,14,79,77,82,64,1,3,3,True,False,False,False,True,True,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Daily oral PrEP,TradeName X,Drug,hiv,hiv,Phase 4,2023-12-10,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Men ages ≥18
* Has a female sexual partner enrolled in the Kampala Women's Bone Study
* Willing and able to provide informed consent

Exclusion Criteria:

* Has any other condit...",Yes,2024-04-15,FDA-65061,0.56,0.15,3.5,4.21,2024-07-01,2024-08-25,2028-02-24,67,Merck,29,South Africa,51.33333333333334,14,38,46,68,61,81,45,2,2,1,True,True,False,True,True,False,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Peginterferon alfa-2b,Comp Beta,Drug,hiv,hiv,Phase 2,2009-04-01,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

Age greater than or equal to 18 years.

Documentation of HIV-1 infection by any licensed ELISA test and confirmed by a Western Blot.

Documentation of Hepatitis C infection by d...",Yes,2009-05-21,FDA-55086,4.41,0.98,21.0,26.39,2013-08-28,2014-08-21,2035-08-21,100,Novartis,3,South Africa,41.5,77,43,27,5,8,89,36,2,2,0,True,True,True,False,True,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ribavirin,Product Alpha,Drug,hiv,hiv,Phase 2,2009-04-01,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

Age greater than or equal to 18 years.

Documentation of HIV-1 infection by any licensed ELISA test and confirmed by a Western Blot.

Documentation of Hepatitis C infection by d...",Yes,2009-11-23,FDA-46808,4.41,0.98,21.0,26.39,2013-08-28,2014-08-21,2035-08-21,75,Pfizer,98,South Africa,59.66666666666666,64,32,95,58,39,70,82,2,5,2,True,True,True,True,True,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
DOR/3TC/TDF,Product Alpha,Drug,hiv,hiv,Phase 4,2024-03-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented HIV-1 infection by means of any one of the following:

Documentation of HIV diagnosis in the medical record by a licensed health care provider; OR HIV-1 RNA detection...",Yes,2024-05-31,FDA-80176,0.56,0.15,3.5,4.21,2024-10-21,2024-12-15,2028-06-15,40,AstraZeneca,12,Senegal,59.16666666666666,95,56,41,15,78,70,64,2,2,3,True,True,False,True,False,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Group B streptococcus vaccine,Comp Beta,Biological,hiv,hiv,Phase 2,2012-12-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Pregnant women 18-40 years of age between 24-35 weeks gestation
* Women who were HIVneg or HIVpos with WHO stage I or II disease and with CD4+ counts \> 50 cells/µL

Exclusion C...",No,2013-01-01,FDA-11564,4.41,0.98,21.0,26.39,2017-04-29,2018-04-22,2039-04-22,36,Novartis,8,Senegal,29.33333333333333,7,7,76,52,12,22,64,0,3,4,False,False,True,True,True,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Daclatasvir,TradeName X,Drug,hiv,hiv,Phase 3,2015-01-01,"Sex: ALL; Age: >18 Years; Criteria: For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Key Inclusion Criteria:

* Patients must be able to understand and agree to/comply with the presc...",Yes,2015-06-02,FDA-48332,2.62,0.32,5.0,7.94,2017-08-14,2017-12-09,2022-12-10,16,Pfizer,46,Overall,57.83333333333334,33,95,65,40,71,43,45,0,2,3,False,False,False,True,False,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Sofosbuvir,Product Alpha,Drug,hiv,hiv,Phase 3,2015-01-01,"Sex: ALL; Age: >18 Years; Criteria: For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Key Inclusion Criteria:

* Patients must be able to understand and agree to/comply with the presc...",No,2015-07-02,FDA-67344,2.62,0.32,5.0,7.94,2017-08-14,2017-12-09,2022-12-10,56,AstraZeneca,89,Kenya,31.0,10,48,65,9,13,41,45,2,2,1,True,True,False,True,False,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Double dose pegylated interferon with weight based Ribavirin,Molecule Z,Drug,hiv,hiv,Phase 2,2008-11-01,"Sex: ALL; Age: >18 Years; Criteria: INCLUSION CRITERIA

* Age greater than or equal to18 years.
* Documentation of HIV-1 infection by licensed ELISA test and confirmed by a Western Blot.
* Documentation of Hepatitis C infection by demon...",Yes,2008-12-25,FDA-40402,4.41,0.98,21.0,26.39,2013-03-30,2014-03-23,2035-03-23,55,Merck,46,South Africa,30.66666666666667,55,41,74,2,7,5,45,1,2,2,True,False,False,True,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
standard dose pegylated interferon alfa -2a and ribavirin,GenName Y,Drug,hiv,hiv,Phase 2,2008-11-01,"Sex: ALL; Age: >18 Years; Criteria: INCLUSION CRITERIA

* Age greater than or equal to18 years.
* Documentation of HIV-1 infection by licensed ELISA test and confirmed by a Western Blot.
* Documentation of Hepatitis C infection by demon...",No,2009-10-30,FDA-64212,4.41,0.98,21.0,26.39,2013-03-30,2014-03-23,2035-03-23,61,Novartis,48,Kenya,47.0,29,16,98,8,67,64,45,1,2,2,False,True,False,True,True,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Elbasvir / Grazoprevir Oral Tablet [Zepatier],GenName Y,Drug,hiv,hiv,Phase 4,2022-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Age \> or equal to 18 years old
2. Able and willing to sign informed consent
3. Chronically infected with any HCV genotype (1a, 1b, 2, 3, 4, 5, or 6), defined as any individual...",Yes,2023-04-26,FDA-73204,0.56,0.15,3.5,4.21,2023-07-23,2023-09-16,2027-03-17,12,GSK,47,Kenya,54.83333333333334,57,61,36,13,84,78,45,0,3,2,False,False,True,False,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Bedaquiline,Comp Beta,Drug,hiv,hiv,Phase 2,2021-02-04,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented pulmonary infection due to strains of MTB with (a) resistance to isoniazid (INH) and rifampin (RIF) (MDR-TB) or (b) resistance to RIF but not INH (RR-TB) from a sputu...",No,2021-12-31,FDA-95822,4.41,0.98,21.0,26.39,2025-07-03,2026-06-26,2047-06-26,20,Pfizer,98,Overall,55.66666666666666,48,73,3,75,63,72,45,1,2,2,False,True,True,False,True,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Delamanid,AltName B,Drug,hiv,hiv,Phase 2,2021-02-04,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented pulmonary infection due to strains of MTB with (a) resistance to isoniazid (INH) and rifampin (RIF) (MDR-TB) or (b) resistance to RIF but not INH (RR-TB) from a sputu...",Yes,2021-04-01,FDA-87153,4.41,0.98,21.0,26.39,2025-07-03,2026-06-26,2047-06-26,25,GSK,86,Kenya,38.66666666666666,50,41,38,12,70,21,36,2,0,2,True,True,False,False,False,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir,GenName Y,Drug,hiv,hiv,Phase 2,2021-02-04,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented pulmonary infection due to strains of MTB with (a) resistance to isoniazid (INH) and rifampin (RIF) (MDR-TB) or (b) resistance to RIF but not INH (RR-TB) from a sputu...",Yes,2021-08-25,FDA-83813,4.41,0.98,21.0,26.39,2025-07-03,2026-06-26,2047-06-26,85,J&J,50,Overall,51.83333333333334,31,58,59,1,77,85,82,2,4,3,True,True,True,False,True,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Multidrug Background Treatment (MBT) for TB,AltName B,Drug,hiv,hiv,Phase 2,2021-02-04,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented pulmonary infection due to strains of MTB with (a) resistance to isoniazid (INH) and rifampin (RIF) (MDR-TB) or (b) resistance to RIF but not INH (RR-TB) from a sputu...",No,2021-12-11,FDA-47971,4.41,0.98,21.0,26.39,2025-07-03,2026-06-26,2047-06-26,32,Merck,24,Kenya,39.83333333333334,52,34,64,0,16,73,18,1,0,1,True,False,False,False,False,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
3% SPL7013 Gel (VivaGel),Molecule Z,Drug,hiv,hiv,Phase 2,2009-03-01,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Healthy women aged 18-45 with regular menstrual cycles, free from sexually transmitted infections and using adequate contraception

Exclusion Criteria:

* Any condition, includi...",Yes,2009-04-16,FDA-44784,4.41,0.98,21.0,26.39,2013-07-28,2014-07-21,2035-07-21,32,Merck,46,South Africa,57.5,32,43,79,82,82,27,27,1,2,0,False,True,False,True,False,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rifapentine (RPT),GenName Y,Drug,hiv,hiv,Phase 3,2017-11-14,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Tuberculin skin test (TST) reactivity greater than or equal to 5 mm or a positive interferon gamma release assay (IGRA) at any time prior to study entry, OR li...",No,2018-01-01,FDA-86661,2.62,0.32,5.0,7.94,2020-06-27,2020-10-22,2025-10-23,88,Pfizer,29,South Africa,59.5,81,83,38,68,1,86,18,1,0,1,False,True,False,False,False,False,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Isoniazid (INH),GenName Y,Drug,hiv,hiv,Phase 3,2017-11-14,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Tuberculin skin test (TST) reactivity greater than or equal to 5 mm or a positive interferon gamma release assay (IGRA) at any time prior to study entry, OR li...",No,2018-10-11,FDA-81465,2.62,0.32,5.0,7.94,2020-06-27,2020-10-22,2025-10-23,19,Merck,31,Kenya,37.5,73,95,4,23,26,4,45,2,2,1,True,True,False,False,True,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Leptin,TradeName X,Drug,hiv,hiv,Phase 2,2011-06-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Age18 years and above and ability and willingness to give written informed consent
* Documented HIV-1 infection
* At least 6 months of stable cumulative antiretroviral therapy w...",Yes,2011-09-18,FDA-85957,4.41,0.98,21.0,26.39,2015-10-28,2016-10-20,2037-10-20,51,AstraZeneca,30,Overall,64.16666666666667,40,64,92,88,40,61,36,0,2,2,False,False,False,False,True,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Pioglitazone or metformin,Product Alpha,Drug,hiv,hiv,Phase 2,2011-06-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Age18 years and above and ability and willingness to give written informed consent
* Documented HIV-1 infection
* At least 6 months of stable cumulative antiretroviral therapy w...",Yes,2011-07-11,FDA-80691,4.41,0.98,21.0,26.39,2015-10-28,2016-10-20,2037-10-20,45,GSK,98,Kenya,28.33333333333333,23,46,23,62,7,9,36,1,2,1,True,False,True,False,False,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
TMC278,AltName B,Drug,hiv,hiv,Phase 3,2012-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient with documented HIV-1 infection
* Patient has never been treated with a therapeutic HIV vaccine or an ARV drug prior to screening
* Patient's HIV-1 plasma viral load at ...",No,2012-11-08,FDA-10630,2.62,0.32,5.0,7.94,2014-09-14,2015-01-09,2020-01-10,97,Novartis,94,Senegal,41.16666666666666,13,43,62,72,28,29,18,0,1,1,False,False,False,False,False,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
efavirenz,TradeName X,Drug,hiv,hiv,Phase 3,2012-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient with documented HIV-1 infection
* Patient has never been treated with a therapeutic HIV vaccine or an ARV drug prior to screening
* Patient's HIV-1 plasma viral load at ...",No,2012-06-29,FDA-74676,2.62,0.32,5.0,7.94,2014-09-14,2015-01-09,2020-01-10,80,GSK,50,Kenya,48.33333333333334,22,58,53,71,13,73,36,0,3,1,False,False,False,True,False,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Pegylated-Interferon Alfa 2b (PEG-IFN),Comp Beta,Drug,hiv,hiv,Phase 3,2015-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria (Groups A and B):

* Men and women 18 years of age or older
* Presence of chronic HCV infection, defined by presence of plasma or serum HCV RNA in a participant with HCV antibody fo...",No,2015-05-20,FDA-56937,2.62,0.32,5.0,7.94,2017-11-12,2018-03-09,2023-03-10,1,Pfizer,18,Overall,37.0,84,62,11,12,0,53,36,1,1,2,False,True,False,False,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ribavirin (RBV),AltName A,Drug,hiv,hiv,Phase 3,2015-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria (Groups A and B):

* Men and women 18 years of age or older
* Presence of chronic HCV infection, defined by presence of plasma or serum HCV RNA in a participant with HCV antibody fo...",No,2015-05-04,FDA-43458,2.62,0.32,5.0,7.94,2017-11-12,2018-03-09,2023-03-10,29,Merck,69,Kenya,54.16666666666666,72,83,16,25,36,93,64,1,3,3,False,True,True,False,True,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Boceprevir (BOC),AltName B,Drug,hiv,hiv,Phase 3,2015-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria (Groups A and B):

* Men and women 18 years of age or older
* Presence of chronic HCV infection, defined by presence of plasma or serum HCV RNA in a participant with HCV antibody fo...",No,2016-03-16,FDA-67254,2.62,0.32,5.0,7.94,2017-11-12,2018-03-09,2023-03-10,91,Novartis,53,Senegal,64.66666666666667,96,33,13,96,73,77,27,0,3,0,False,False,False,False,True,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
JULUCA 50Mg-25Mg Tablet,Comp Beta,Drug,hiv,hiv,Phase 4,2023-07-31,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Negative HIV antibody testing at screening.
2. For the ESRD requiring HD study group: ESRD requiring chronic hemodialysis for at least 6 months at an established center (not ho...",Yes,2024-03-01,FDA-46579,0.56,0.15,3.5,4.21,2024-02-20,2024-04-15,2027-10-15,78,GSK,26,Overall,46.16666666666666,55,15,15,66,67,59,64,2,3,2,True,True,False,True,False,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Aramchol,Product Alpha,Drug,hiv,hiv,Phase 2,2018-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Age at entry at least 18 years.
2. And at least one of the following risk factor for more severe liver disease: Hypertriglyceridemia based upon ATP-III guidelines, Increased LD...",No,2018-08-12,FDA-53556,4.41,0.98,21.0,26.39,2022-06-30,2023-06-23,2044-06-22,93,Gilead,72,Kenya,63.33333333333334,60,72,49,93,24,82,36,1,3,0,True,False,False,True,True,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Crofelemer 125 mg,AltName A,Drug,hiv,hiv,Phase 3,2011-07-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* History of HIV-1 infection confirmed by standard serological tests
* Stable medical regimen for treatment of HIV disease and associated conditions for at least 4 weeks prior to ...",Yes,2012-03-26,FDA-52397,2.62,0.32,5.0,7.94,2014-02-21,2014-06-18,2019-06-19,75,Sanofi,76,Overall,38.16666666666666,24,90,70,41,1,3,55,1,3,2,False,True,True,False,True,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Crofelemer 250 mg,Product Alpha,Drug,hiv,hiv,Phase 3,2011-07-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* History of HIV-1 infection confirmed by standard serological tests
* Stable medical regimen for treatment of HIV disease and associated conditions for at least 4 weeks prior to ...",Yes,2012-02-09,FDA-79125,2.62,0.32,5.0,7.94,2014-02-21,2014-06-18,2019-06-19,55,Sanofi,38,Kenya,53.16666666666666,35,37,30,62,85,70,55,2,2,2,True,True,True,False,False,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Crofelemer 500 mg,Comp Beta,Drug,hiv,hiv,Phase 3,2011-07-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* History of HIV-1 infection confirmed by standard serological tests
* Stable medical regimen for treatment of HIV disease and associated conditions for at least 4 weeks prior to ...",Yes,2011-11-09,FDA-10825,2.62,0.32,5.0,7.94,2014-02-21,2014-06-18,2019-06-19,97,Merck,92,Kenya,36.66666666666666,30,0,9,100,56,25,18,0,2,0,False,False,True,False,False,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Pomalidomide,AltName A,Drug,hiv,hiv,Phase 2,2022-05-17,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:
* Age greater than or equal to 18 Years.
* Any human immunodeficiency virus (HIV) status.
* Kaposi sarcoma pathologically confirmed by Department of Pathology, Clinical Center, N...",Yes,2023-01-13,FDA-11841,4.41,0.98,21.0,26.39,2026-10-13,2027-10-06,2048-10-05,56,Pfizer,74,South Africa,54.16666666666666,32,42,45,59,89,58,55,1,2,3,True,False,False,True,True,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir Disoproxil Fumarate (TDF),Molecule Z,Drug,hiv,hiv,Phase 3,2013-10-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria for HIV-1 uninfected partner:

* Partner within an HIV-1 discordant heterosexual relationship
* One partner meets study eligibility for HIV-1 uninfected study participant and the ot...",No,2014-09-13,FDA-95234,2.62,0.32,5.0,7.94,2016-05-14,2016-09-08,2021-09-09,67,Sanofi,92,Senegal,51.33333333333334,98,8,1,65,54,82,55,1,3,2,True,False,True,False,True,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF),Product Alpha,Drug,hiv,hiv,Phase 3,2013-10-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria for HIV-1 uninfected partner:

* Partner within an HIV-1 discordant heterosexual relationship
* One partner meets study eligibility for HIV-1 uninfected study participant and the ot...",Yes,2013-11-03,FDA-72120,2.62,0.32,5.0,7.94,2016-05-14,2016-09-08,2021-09-09,40,J&J,29,South Africa,50.16666666666666,35,23,80,80,47,36,36,0,2,2,False,False,False,False,True,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
TMC278,Product Alpha,Drug,hiv,hiv,Phase 3,2011-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient with documented HIV-1 infection
* Patient has never been treated with a therapeutic HIV vaccine or an ARV drug prior to screening
* Patient's HIV-1 plasma viral load at ...",Yes,2012-04-05,FDA-73081,2.62,0.32,5.0,7.94,2014-07-14,2014-11-08,2019-11-09,84,Novartis,4,Senegal,65.66666666666667,18,52,65,93,77,89,55,0,3,3,False,False,True,False,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,Comp Beta,Drug,hiv,hiv,Phase 3,2011-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patient with documented HIV-1 infection
* Patient has never been treated with a therapeutic HIV vaccine or an ARV drug prior to screening
* Patient's HIV-1 plasma viral load at ...",Yes,2012-02-06,FDA-93716,2.62,0.32,5.0,7.94,2014-07-14,2014-11-08,2019-11-09,58,J&J,48,Senegal,40.16666666666666,40,52,18,43,29,59,55,1,3,2,False,True,True,False,True,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rifapentine,GenName Y,Drug,hiv,hiv,Phase 2,2025-06-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Pulmonary TB (among participants with or without history of prior TB treatment) identified within 5 days prior to entry by:

  * At least one sputum specimen positive for M. tub...",No,2026-02-09,FDA-60033,4.41,0.98,21.0,26.39,2029-11-20,2030-11-13,2051-11-13,68,AstraZeneca,92,Kenya,66.16666666666667,71,87,89,92,54,4,36,0,1,3,False,False,False,False,False,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Rifampicin,AltName B,Drug,hiv,hiv,Phase 2,2025-06-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Pulmonary TB (among participants with or without history of prior TB treatment) identified within 5 days prior to entry by:

  * At least one sputum specimen positive for M. tub...",Yes,2025-09-02,FDA-42363,4.41,0.98,21.0,26.39,2029-11-20,2030-11-13,2051-11-13,62,GSK,72,Overall,47.66666666666666,42,32,97,39,4,72,36,1,2,1,True,False,False,False,True,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Isoniazid,TradeName X,Drug,hiv,hiv,Phase 2,2025-06-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Pulmonary TB (among participants with or without history of prior TB treatment) identified within 5 days prior to entry by:

  * At least one sputum specimen positive for M. tub...",No,2026-02-27,FDA-91650,4.41,0.98,21.0,26.39,2029-11-20,2030-11-13,2051-11-13,14,Merck,49,Kenya,63.0,87,46,69,61,69,46,73,1,4,3,True,False,True,True,False,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Pyrazinamide,Comp Beta,Drug,hiv,hiv,Phase 2,2025-06-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Pulmonary TB (among participants with or without history of prior TB treatment) identified within 5 days prior to entry by:

  * At least one sputum specimen positive for M. tub...",Yes,2025-10-10,FDA-41833,4.41,0.98,21.0,26.39,2029-11-20,2030-11-13,2051-11-13,46,Merck,4,Overall,46.66666666666666,87,38,66,14,74,1,64,1,3,3,False,True,True,False,True,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ethambutol,AltName A,Drug,hiv,hiv,Phase 2,2025-06-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Pulmonary TB (among participants with or without history of prior TB treatment) identified within 5 days prior to entry by:

  * At least one sputum specimen positive for M. tub...",Yes,2026-06-17,FDA-93179,4.41,0.98,21.0,26.39,2029-11-20,2030-11-13,2051-11-13,6,J&J,89,South Africa,36.66666666666666,9,61,3,29,21,97,18,0,0,2,False,False,False,False,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Clofazimine loading dose,GenName Y,Drug,hiv,hiv,Phase 2,2025-06-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Pulmonary TB (among participants with or without history of prior TB treatment) identified within 5 days prior to entry by:

  * At least one sputum specimen positive for M. tub...",Yes,2025-07-25,FDA-25781,4.41,0.98,21.0,26.39,2029-11-20,2030-11-13,2051-11-13,8,Novartis,54,Senegal,39.33333333333334,22,17,6,90,18,83,73,1,3,4,True,False,True,False,True,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Clofazimine 100 MG,AltName B,Drug,hiv,hiv,Phase 2,2025-06-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Pulmonary TB (among participants with or without history of prior TB treatment) identified within 5 days prior to entry by:

  * At least one sputum specimen positive for M. tub...",Yes,2025-09-26,FDA-47056,4.41,0.98,21.0,26.39,2029-11-20,2030-11-13,2051-11-13,52,Bayer,83,Overall,49.0,0,60,35,74,73,52,73,2,3,3,True,True,False,False,True,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Fluconazole,GenName Y,Drug,hiv,hiv,Phase 2,2017-01-12,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria - Step 1

* CM documented either by a positive CSF cryptococcal culture, a positive CSF India ink preparation, or a positive CSF cryptococcal antigen latex agglutination test within...",Yes,2017-11-24,FDA-11286,4.41,0.98,21.0,26.39,2021-06-10,2022-06-03,2043-06-03,42,J&J,97,Kenya,70.33333333333333,99,63,68,93,63,36,45,1,1,3,False,True,False,True,False,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Amphotericin B,GenName Y,Drug,hiv,hiv,Phase 2,2017-01-12,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria - Step 1

* CM documented either by a positive CSF cryptococcal culture, a positive CSF India ink preparation, or a positive CSF cryptococcal antigen latex agglutination test within...",No,2017-12-24,FDA-10470,4.41,0.98,21.0,26.39,2021-06-10,2022-06-03,2043-06-03,63,J&J,76,South Africa,78.83333333333333,72,99,87,84,76,55,45,1,2,2,False,True,False,False,True,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
SOF,GenName Y,Drug,hiv,hiv,Phase 2,2013-11-01,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* Healthy according to medical history and physical examination with exception of HCV and HIV diagnoses
* Confirmation of Chronic HCV infection
* Confirmation of Chronic HIV-1 inf...",No,2014-08-11,FDA-38757,4.41,0.98,21.0,26.39,2018-03-30,2019-03-23,2040-03-22,75,Gilead,13,Kenya,65.0,61,89,96,62,55,27,9,0,0,1,False,False,False,False,False,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
EFV/FTC/TDF,AltName A,Drug,hiv,hiv,Phase 2,2013-11-01,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* Healthy according to medical history and physical examination with exception of HCV and HIV diagnoses
* Confirmation of Chronic HCV infection
* Confirmation of Chronic HIV-1 inf...",Yes,2014-04-29,FDA-17760,4.41,0.98,21.0,26.39,2018-03-30,2019-03-23,2040-03-22,44,J&J,62,South Africa,71.33333333333333,37,91,95,56,81,68,73,2,3,3,True,True,True,False,True,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
EFV,AltName B,Drug,hiv,hiv,Phase 2,2013-11-01,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* Healthy according to medical history and physical examination with exception of HCV and HIV diagnoses
* Confirmation of Chronic HCV infection
* Confirmation of Chronic HIV-1 inf...",No,2014-01-19,FDA-48641,4.41,0.98,21.0,26.39,2018-03-30,2019-03-23,2040-03-22,53,AstraZeneca,37,Kenya,53.5,60,88,83,55,19,16,64,1,3,3,True,False,True,False,True,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ZDV/3TC,Product Alpha,Drug,hiv,hiv,Phase 2,2013-11-01,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* Healthy according to medical history and physical examination with exception of HCV and HIV diagnoses
* Confirmation of Chronic HCV infection
* Confirmation of Chronic HIV-1 inf...",No,2014-02-01,FDA-64699,4.41,0.98,21.0,26.39,2018-03-30,2019-03-23,2040-03-22,50,Sanofi,41,Kenya,53.83333333333334,44,74,7,62,58,78,73,2,3,3,True,True,True,True,False,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ATV,Comp Beta,Drug,hiv,hiv,Phase 2,2013-11-01,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* Healthy according to medical history and physical examination with exception of HCV and HIV diagnoses
* Confirmation of Chronic HCV infection
* Confirmation of Chronic HIV-1 inf...",No,2014-01-12,FDA-62281,4.41,0.98,21.0,26.39,2018-03-30,2019-03-23,2040-03-22,86,Merck,50,Kenya,61.33333333333334,28,84,33,98,34,91,55,1,2,3,False,True,False,True,False,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,Comp Beta,Drug,hiv,hiv,Phase 2,2013-11-01,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* Healthy according to medical history and physical examination with exception of HCV and HIV diagnoses
* Confirmation of Chronic HCV infection
* Confirmation of Chronic HIV-1 inf...",Yes,2014-10-28,FDA-80720,4.41,0.98,21.0,26.39,2018-03-30,2019-03-23,2040-03-22,66,J&J,70,Kenya,42.66666666666666,26,8,60,43,62,57,27,0,3,0,False,False,False,False,True,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TDF,Comp Beta,Drug,hiv,hiv,Phase 2,2013-11-01,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* Healthy according to medical history and physical examination with exception of HCV and HIV diagnoses
* Confirmation of Chronic HCV infection
* Confirmation of Chronic HIV-1 inf...",No,2014-06-29,FDA-66411,4.41,0.98,21.0,26.39,2018-03-30,2019-03-23,2040-03-22,40,Gilead,29,Overall,72.0,93,94,65,32,96,52,27,1,1,1,False,True,False,False,False,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DRV,AltName B,Drug,hiv,hiv,Phase 2,2013-11-01,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* Healthy according to medical history and physical examination with exception of HCV and HIV diagnoses
* Confirmation of Chronic HCV infection
* Confirmation of Chronic HIV-1 inf...",Yes,2014-10-01,FDA-98969,4.41,0.98,21.0,26.39,2018-03-30,2019-03-23,2040-03-22,51,Gilead,74,South Africa,75.83333333333333,94,100,49,93,74,45,73,2,4,2,True,True,True,True,True,False,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
RAL,AltName B,Drug,hiv,hiv,Phase 2,2013-11-01,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* Healthy according to medical history and physical examination with exception of HCV and HIV diagnoses
* Confirmation of Chronic HCV infection
* Confirmation of Chronic HIV-1 inf...",Yes,2014-01-09,FDA-13502,4.41,0.98,21.0,26.39,2018-03-30,2019-03-23,2040-03-22,79,J&J,65,Overall,38.83333333333334,9,6,97,22,46,53,55,0,4,2,False,False,False,True,True,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PEG,AltName B,Drug,hiv,hiv,Phase 2,2013-11-01,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* Healthy according to medical history and physical examination with exception of HCV and HIV diagnoses
* Confirmation of Chronic HCV infection
* Confirmation of Chronic HIV-1 inf...",No,2014-06-11,FDA-47125,4.41,0.98,21.0,26.39,2018-03-30,2019-03-23,2040-03-22,13,J&J,2,Overall,48.33333333333334,41,12,25,71,47,94,45,1,1,3,False,True,False,True,False,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
RBV,Product Alpha,Drug,hiv,hiv,Phase 2,2013-11-01,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* Healthy according to medical history and physical examination with exception of HCV and HIV diagnoses
* Confirmation of Chronic HCV infection
* Confirmation of Chronic HIV-1 inf...",No,2014-08-03,FDA-42343,4.41,0.98,21.0,26.39,2018-03-30,2019-03-23,2040-03-22,39,Sanofi,84,South Africa,44.5,24,70,52,23,98,0,27,1,1,1,False,True,False,False,True,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Influenza A (H1N1) 2009 monovalent vaccine,Molecule Z,Biological,hiv,hiv,Phase 2,2010-08-01,"Sex: ALL; Age: >4 Years; Criteria: Inclusion Criteria for Step I:

* HIV infected
* HIV-1 was perinatally acquired, in the opinion of the investigator
* Participants receiving antiretrovirals (ARVs) must have been receiving a stable re...",Yes,2011-01-24,FDA-33603,4.41,0.98,21.0,26.39,2014-12-28,2015-12-21,2036-12-20,94,Merck,39,Overall,60.5,23,65,58,84,35,98,36,2,0,2,True,True,False,False,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
LDV/SOF,AltName A,Drug,hiv,hiv,Phase 3,2015-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HCV RNA ≥ 10,000 IU/mL at screening
* HCV genotype 1 or 4
* HIV-1 infection
* Cirrhosis determination, a fibroscan or liver biopsy may be required
* Screening laboratory values ...",No,2016-01-03,FDA-70321,2.62,0.32,5.0,7.94,2018-07-14,2018-11-08,2023-11-09,24,Sanofi,18,Kenya,42.16666666666666,26,5,87,1,72,62,55,2,1,3,True,True,False,False,False,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
RBV,AltName B,Drug,hiv,hiv,Phase 3,2015-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HCV RNA ≥ 10,000 IU/mL at screening
* HCV genotype 1 or 4
* HIV-1 infection
* Cirrhosis determination, a fibroscan or liver biopsy may be required
* Screening laboratory values ...",Yes,2016-01-11,FDA-75868,2.62,0.32,5.0,7.94,2018-07-14,2018-11-08,2023-11-09,16,GSK,37,Senegal,45.66666666666666,8,39,26,63,79,59,36,0,2,2,False,False,False,True,False,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
standard care,Product Alpha,Drug,hiv,hiv,Phase 4,2015-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected males or females
* signed informed consent
* no previous antiretroviral treatment since HIV diagnosis
* screening CD4+ lymphocyte count \<= 350 cells/ųL
* suscept...",Yes,2016-08-10,FDA-73951,0.56,0.15,3.5,4.21,2016-04-22,2016-06-16,2019-12-16,85,Gilead,88,Senegal,41.16666666666666,17,53,67,55,4,51,73,2,3,3,True,True,True,True,True,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
novel treatment,AltName B,Drug,hiv,hiv,Phase 4,2015-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected males or females
* signed informed consent
* no previous antiretroviral treatment since HIV diagnosis
* screening CD4+ lymphocyte count \<= 350 cells/ųL
* suscept...",No,2016-05-02,FDA-29361,0.56,0.15,3.5,4.21,2016-04-22,2016-06-16,2019-12-16,81,GSK,46,South Africa,28.5,22,24,11,28,39,47,73,2,4,2,True,True,True,True,True,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)",Molecule Z,Biological,hiv,hiv,Phase 2,2009-08-01,"Sex: ALL; Age: >7 Years; Criteria: Inclusion Criteria

Children ages ≥ 7 to \< 12 years of age.

A confirmed diagnosis of HIV infection, defined as two positive assays from two different samples. The two results may be in any combinati...",Yes,2009-10-22,FDA-44074,4.41,0.98,21.0,26.39,2013-12-28,2014-12-21,2035-12-21,80,Novartis,43,Overall,53.33333333333334,70,42,29,52,76,51,82,2,4,3,True,True,False,True,True,True,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Pravastatin,Comp Beta,Drug,hiv,hiv,Phase 4,2010-09-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Healthy, HIV-negative volunteers

Exclusion Criteria:

* Currently active or chronic cardiovascular, hepatic, renal, pancreatic, gastrointestinal, neurologic, hematologic, psych...",No,2011-01-06,FDA-51783,0.56,0.15,3.5,4.21,2011-03-24,2011-05-18,2014-11-16,8,Pfizer,18,Senegal,61.83333333333334,81,16,17,78,82,97,27,0,1,2,False,False,True,False,False,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Darunavir,Comp Beta,Drug,hiv,hiv,Phase 4,2010-09-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Healthy, HIV-negative volunteers

Exclusion Criteria:

* Currently active or chronic cardiovascular, hepatic, renal, pancreatic, gastrointestinal, neurologic, hematologic, psych...",No,2011-01-07,FDA-18149,0.56,0.15,3.5,4.21,2011-03-24,2011-05-18,2014-11-16,60,Gilead,31,Overall,48.83333333333334,37,92,24,70,46,24,36,2,1,1,True,True,False,False,True,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,AltName A,Drug,hiv,hiv,Phase 4,2010-09-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Healthy, HIV-negative volunteers

Exclusion Criteria:

* Currently active or chronic cardiovascular, hepatic, renal, pancreatic, gastrointestinal, neurologic, hematologic, psych...",No,2010-11-12,FDA-24437,0.56,0.15,3.5,4.21,2011-03-24,2011-05-18,2014-11-16,22,Bayer,94,Kenya,63.33333333333334,95,90,75,19,80,21,64,0,3,4,False,False,True,True,False,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Pravastatin,Molecule Z,Drug,hiv,hiv,Phase 4,2010-09-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Healthy, HIV-negative volunteers

Exclusion Criteria:

* Currently active or chronic cardiovascular, hepatic, renal, pancreatic, gastrointestinal, neurologic, hematologic, psych...",Yes,2011-06-21,FDA-47708,0.56,0.15,3.5,4.21,2011-03-24,2011-05-18,2014-11-16,12,J&J,80,Kenya,66.0,38,77,70,55,85,71,64,2,3,2,True,True,False,False,True,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ad26.Mos4.HIV,GenName Y,Biological,hiv,hiv,Phase 2,2022-02-02,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Sexually active, defined as having had sexual intercourse with a male partner at least twice in the past 30 days prior to screening, and is considered by the site staff to be at...",No,2022-12-05,FDA-98129,4.41,0.98,21.0,26.39,2026-07-01,2027-06-24,2048-06-23,17,Gilead,25,South Africa,54.5,38,88,75,44,0,82,55,0,4,2,False,False,True,True,True,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Clade C gp140,AltName A,Biological,hiv,hiv,Phase 2,2022-02-02,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Sexually active, defined as having had sexual intercourse with a male partner at least twice in the past 30 days prior to screening, and is considered by the site staff to be at...",Yes,2022-08-30,FDA-81617,4.41,0.98,21.0,26.39,2026-07-01,2027-06-24,2048-06-23,98,GSK,37,Overall,47.66666666666666,96,15,67,72,15,21,73,2,3,3,True,True,True,False,True,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Pentoxifylline,Comp Beta,Drug,hiv,hiv,Phase 2,2011-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documentation of HIV infection with a positive HIV enzyme-linked immunosorbent assay (ELISA) test and confirmatory western blot test
* CD4 cell count greater than 350/µL at the ...",No,2012-08-10,FDA-56103,4.41,0.98,21.0,26.39,2016-02-27,2017-02-19,2038-02-19,74,Bayer,33,Overall,57.5,86,58,13,34,54,100,55,2,2,2,True,True,False,True,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Levonorgestrel (LNG),AltName A,Drug,hiv,hiv,Phase 2,2020-11-30,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

* Postmenarcheal female.

  * Note: Participant report and clinician's opinion were acceptable.
* The following laboratory values obtained within 30 days prior to study entry by a...",No,2021-08-10,FDA-42299,4.41,0.98,21.0,26.39,2025-04-28,2026-04-21,2047-04-21,28,Bayer,75,Overall,43.66666666666666,13,47,13,49,53,87,45,1,2,2,True,False,True,False,False,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Simtuzumab,AltName B,Biological,hiv,hiv,Phase 2,2014-10-17,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* HIV-infected individuals must have positive serologies with viral load suppressed below 400 copies/mL
* HCV-infected individuals must have:

  * Chronic HCV infection with H...",Yes,2015-09-26,FDA-95151,4.41,0.98,21.0,26.39,2019-03-15,2020-03-07,2041-03-07,80,Sanofi,70,Senegal,66.66666666666667,49,78,87,67,39,80,45,2,2,1,True,True,False,True,False,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
PegIFN/RBV,Comp Beta,Drug,hiv,hiv,Phase 3,2014-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

1. Chronic hepatitis C (HCV) genotype 1 infection
2. Chronic Human Immunodeficiency Virus (HIV) -1 infection
3. HCV treatment naive or HCV treatment experienced but only relapsers...",Yes,2014-07-24,FDA-25831,2.62,0.32,5.0,7.94,2017-01-12,2017-05-09,2022-05-10,42,Novartis,71,South Africa,47.0,68,19,62,77,32,24,55,2,2,2,True,True,True,False,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PegIFN/RBV,TradeName X,Drug,hiv,hiv,Phase 3,2014-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

1. Chronic hepatitis C (HCV) genotype 1 infection
2. Chronic Human Immunodeficiency Virus (HIV) -1 infection
3. HCV treatment naive or HCV treatment experienced but only relapsers...",Yes,2015-02-02,FDA-70250,2.62,0.32,5.0,7.94,2017-01-12,2017-05-09,2022-05-10,24,Gilead,53,Kenya,46.16666666666666,66,20,87,96,3,5,55,1,3,2,False,True,True,False,False,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
BI201335,AltName B,Drug,hiv,hiv,Phase 3,2014-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

1. Chronic hepatitis C (HCV) genotype 1 infection
2. Chronic Human Immunodeficiency Virus (HIV) -1 infection
3. HCV treatment naive or HCV treatment experienced but only relapsers...",Yes,2014-08-16,FDA-70925,2.62,0.32,5.0,7.94,2017-01-12,2017-05-09,2022-05-10,95,AstraZeneca,8,Kenya,58.0,7,84,12,73,77,95,45,2,2,1,True,True,False,True,False,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
BI201335 24W,Comp Beta,Drug,hiv,hiv,Phase 3,2014-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

1. Chronic hepatitis C (HCV) genotype 1 infection
2. Chronic Human Immunodeficiency Virus (HIV) -1 infection
3. HCV treatment naive or HCV treatment experienced but only relapsers...",No,2014-09-27,FDA-92162,2.62,0.32,5.0,7.94,2017-01-12,2017-05-09,2022-05-10,24,Pfizer,72,Overall,66.5,74,88,26,96,69,46,55,1,3,2,False,True,True,True,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PegIFN/RBV,AltName B,Drug,hiv,hiv,Phase 3,2014-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

1. Chronic hepatitis C (HCV) genotype 1 infection
2. Chronic Human Immunodeficiency Virus (HIV) -1 infection
3. HCV treatment naive or HCV treatment experienced but only relapsers...",No,2014-10-02,FDA-41860,2.62,0.32,5.0,7.94,2017-01-12,2017-05-09,2022-05-10,91,J&J,10,Senegal,66.0,99,47,96,44,30,80,45,2,2,1,True,True,True,False,False,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Bi 201335,AltName B,Drug,hiv,hiv,Phase 3,2014-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

1. Chronic hepatitis C (HCV) genotype 1 infection
2. Chronic Human Immunodeficiency Virus (HIV) -1 infection
3. HCV treatment naive or HCV treatment experienced but only relapsers...",No,2015-05-30,FDA-49037,2.62,0.32,5.0,7.94,2017-01-12,2017-05-09,2022-05-10,58,Sanofi,88,South Africa,34.0,36,35,48,5,45,35,55,0,4,2,False,False,True,True,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Escitalopram,Product Alpha,Drug,hiv,hiv,Phase 3,2010-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* age 18 to 65 years,
* DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) criteria for Generalized Anxiety Disorder
* confirmed stable HIV disease and attending a HIV...",No,2011-04-17,FDA-61253,2.62,0.32,5.0,7.94,2013-04-14,2013-08-09,2018-08-10,50,GSK,74,Kenya,59.83333333333334,99,61,9,95,76,19,55,1,3,2,False,True,False,False,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Vacc-4x,Product Alpha,Drug,hiv,hiv,Phase 2,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Age 18-55
* HIV positive at least one year
* Clinically stable on ART for at least six months
* Documented viral load less than 50 copies/mL for the last six months
* Documented...",No,2011-09-14,FDA-44805,4.41,0.98,21.0,26.39,2015-10-28,2016-10-20,2037-10-20,56,GSK,58,Overall,29.33333333333333,31,26,82,17,5,15,73,2,3,3,True,True,True,True,True,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Sterile water,Product Alpha,Drug,hiv,hiv,Phase 2,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Age 18-55
* HIV positive at least one year
* Clinically stable on ART for at least six months
* Documented viral load less than 50 copies/mL for the last six months
* Documented...",No,2011-10-11,FDA-81461,4.41,0.98,21.0,26.39,2015-10-28,2016-10-20,2037-10-20,19,AstraZeneca,23,South Africa,54.16666666666666,19,66,31,55,66,88,64,2,3,2,True,True,False,True,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Losartan 100mg daily,TradeName X,Drug,hiv,hiv,Phase 2,2018-12-14,"Sex: ALL; Age: >50 Years; Criteria: Inclusion Criteria:

* HIV infection (verified by previous positive antibody or detectable HIV RNA level)
* Age \> 50 years
* Receiving continuous ART for \>= 2 years (regimen changes \> 6 months prio...",Yes,2019-04-12,FDA-10687,4.41,0.98,21.0,26.39,2023-05-12,2024-05-04,2045-05-04,61,Sanofi,84,Kenya,41.66666666666666,8,26,90,93,16,17,27,1,1,1,True,False,False,False,True,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
13-valent Pneumococcal Conjugate Vaccine (13vPnC),Molecule Z,Biological,hiv,hiv,Phase 3,2013-04-01,"Sex: ALL; Age: >6 Years; Criteria: Inclusion Criteria:

* Human immunodeficiency virus (HIV)-infected subjects aged 6 years or older
* Viral load \< 50,000 copies/mL and CD4+ T cell count \>= 200/uL within 6 months before study vaccina...",Yes,2013-09-18,FDA-25458,2.62,0.32,5.0,7.94,2015-11-13,2016-03-09,2021-03-10,46,GSK,25,Senegal,58.66666666666666,72,22,88,71,12,87,73,2,4,2,True,True,True,True,False,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
23-valent Pneumococcal Polysaccharide Vaccine (23vPS),Comp Beta,Biological,hiv,hiv,Phase 3,2013-04-01,"Sex: ALL; Age: >6 Years; Criteria: Inclusion Criteria:

* Human immunodeficiency virus (HIV)-infected subjects aged 6 years or older
* Viral load \< 50,000 copies/mL and CD4+ T cell count \>= 200/uL within 6 months before study vaccina...",Yes,2013-12-16,FDA-62990,2.62,0.32,5.0,7.94,2015-11-13,2016-03-09,2021-03-10,18,Sanofi,84,South Africa,23.66666666666667,3,18,28,31,36,26,55,1,2,3,False,True,False,False,True,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lovaza,Molecule Z,Drug,hiv,hiv,Phase 2,2010-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV+
* Ages 18-70
* HIV-1 RNA \<400 copies/ml.
* On stable ART (antiretroviral therapy) regimen for 12 weeks with no intent of modifying regimen, and cumulative ART before study...",No,2010-08-24,FDA-61148,4.41,0.98,21.0,26.39,2014-10-28,2015-10-21,2036-10-20,93,AstraZeneca,49,Senegal,68.66666666666667,64,13,58,88,93,96,64,2,2,3,True,True,False,True,False,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
rosuvastatin,Comp Beta,Drug,hiv,hiv,Phase 3,,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* HIV infection
* Age \> 18 years old
* On stable antiretroviral therapy for \> 6 months with no plans to change therapy during the treatment phase of the study
* Plasma HIV RNA \...",Yes,2026-09-14,FDA-16934,2.62,0.32,5.0,7.94,,,,5,Novartis,3,Senegal,46.0,0,77,97,57,44,1,45,1,3,1,False,True,False,True,True,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
13-valent pneumococcal conjugate vaccine,Molecule Z,Biological,hiv,hiv,Phase 3,2012-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male or female subjects aged 18 years or older at the time of enrollment.
* All female and male subjects who are biologically capable of having children must agree and commit to...",No,2012-07-19,FDA-53622,2.62,0.32,5.0,7.94,2014-12-13,2015-04-09,2020-04-09,68,Sanofi,95,South Africa,57.66666666666666,4,66,97,54,44,81,27,0,2,1,False,False,False,True,False,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Etravirine,GenName Y,Drug,hiv,hiv,Phase 3,2032-01-01,"Sex: ALL; Age: >2 Years; Criteria: Inclusion Criteria:

* Participants who meet all of the following criteria are eligible for this trial: Documented HIV-1 infection
* Male or female participants, aged 2 years and older
* Successfully ...",No,2032-04-11,FDA-50999,2.62,0.32,5.0,7.94,2034-08-14,2034-12-09,2039-12-10,22,Novartis,15,Kenya,35.66666666666666,1,63,9,95,13,33,36,2,1,1,True,True,False,False,False,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Influenza A (H1N1) monovalent vaccine,TradeName X,Biological,hiv,hiv,Phase 2,2010-11-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria for Step I:

* Confirmed diagnosis of HIV-1 infection
* Pregnant
* Between 14 and 35 weeks of gestation
* Documented platelet count of greater than 50,000 mm3 and an absolute neutro...",No,2011-02-22,FDA-22315,4.41,0.98,21.0,26.39,2015-03-30,2016-03-22,2037-03-22,91,J&J,50,Senegal,62.33333333333334,18,40,98,66,64,88,55,0,3,3,False,False,True,True,True,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
pregabalin (Lyrica),Comp Beta,Drug,hiv,hiv,Phase 3,2012-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects who participated in the preceding A0081244 double-blind trial and completed at least through Visit 9 of that trial.

Subjects with painful distal sensory polyneuropathy...",Yes,2013-02-26,FDA-69501,2.62,0.32,5.0,7.94,2014-12-13,2015-04-09,2020-04-09,22,Novartis,25,Senegal,62.0,54,83,50,43,78,64,64,1,3,3,True,False,True,False,False,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Depot medroxyprogesterone acetate,Molecule Z,Drug,hiv,hiv,Phase 2,2017-06-15,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection.
* Current tuberculosis infection, confirmed or probable diagnosis.
* Currently stable on EFV-based cART for at least 28 days with no intention to change the reg...",Yes,2018-04-19,FDA-16354,4.41,0.98,21.0,26.39,2021-11-11,2022-11-04,2043-11-04,69,J&J,81,South Africa,49.16666666666666,2,36,41,98,62,56,36,1,2,1,True,False,True,False,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
fosamprenavir/ritonavir,AltName A,Drug,hiv,hiv,Phase 3,2008-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subject is ≥18 years of age.
* Subject is antiretroviral-naïve (defined as having ≤14 days of prior therapy with any antiretroviral agent).
* Subject has plasma HIV-1 RNA ≥1,000...",Yes,2009-01-08,FDA-54453,2.62,0.32,5.0,7.94,2011-03-15,2011-07-10,2016-07-10,98,GSK,42,Senegal,53.5,98,40,94,49,38,2,55,1,3,2,False,True,True,False,False,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL,GenName Y,Drug,hiv,hiv,Phase 2,2005-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Capable of and willing to provide informed consent
* Evidence of HIV infection (either HIV-seropositive, CD4+ T-cell count of ≤350/mm3 or other clinically accepted indicator)
* ...",No,2005-10-01,FDA-44486,4.41,0.98,21.0,26.39,2009-10-28,2010-10-21,2031-10-21,43,Gilead,44,South Africa,47.83333333333334,53,68,32,86,34,14,27,0,1,2,False,False,False,True,False,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Megestrol acetate oral suspension 40 mg/mL,Comp Beta,Drug,hiv,hiv,Phase 2,2005-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Capable of and willing to provide informed consent
* Evidence of HIV infection (either HIV-seropositive, CD4+ T-cell count of ≤350/mm3 or other clinically accepted indicator)
* ...",Yes,2006-02-27,FDA-15349,4.41,0.98,21.0,26.39,2009-10-28,2010-10-21,2031-10-21,60,Merck,40,Senegal,45.33333333333334,49,3,85,14,100,21,45,0,4,1,False,False,True,True,False,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ABX464 150mg,GenName Y,Drug,hiv,hiv,Phase 2,2019-10-21,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion criteria:

* Males aged 18-65 years;
* Subjects with adequate hematological and biochemical laboratory parameters
* Subjects should be able and willing to comply with study visits and proced...",Yes,2020-06-02,FDA-86336,4.41,0.98,21.0,26.39,2024-03-18,2025-03-11,2046-03-11,30,AstraZeneca,45,Kenya,51.33333333333334,78,7,82,34,81,26,55,1,4,1,True,False,False,True,True,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ABX464 50mg,Comp Beta,Drug,hiv,hiv,Phase 2,2019-10-21,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion criteria:

* Males aged 18-65 years;
* Subjects with adequate hematological and biochemical laboratory parameters
* Subjects should be able and willing to comply with study visits and proced...",Yes,2020-01-20,FDA-89841,4.41,0.98,21.0,26.39,2024-03-18,2025-03-11,2046-03-11,35,Bayer,97,Kenya,60.16666666666666,78,91,3,63,100,26,36,0,2,2,False,False,True,False,False,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ABX464 50mg,GenName Y,Drug,hiv,hiv,Phase 2,2019-10-21,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion criteria:

* Males aged 18-65 years;
* Subjects with adequate hematological and biochemical laboratory parameters
* Subjects should be able and willing to comply with study visits and proced...",Yes,2020-04-18,FDA-75827,4.41,0.98,21.0,26.39,2024-03-18,2025-03-11,2046-03-11,38,Sanofi,14,South Africa,56.5,50,23,45,93,61,67,55,1,3,2,True,False,True,False,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Romidepsin,Comp Beta,Drug,hiv,hiv,Phase 2,2015-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Age \>18 years
2. Currently receiving cART and having received cART for a minimum of 1 year
3. HIV-1 plasma RNA \<50 copies/mL for at least 1 year (excluding viral load blips)
...",Yes,2016-02-07,FDA-56880,4.41,0.98,21.0,26.39,2020-04-28,2021-04-21,2042-04-21,21,J&J,70,South Africa,47.33333333333334,39,25,50,72,54,44,27,1,1,1,False,True,False,False,True,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Vacc-4x,GenName Y,Biological,hiv,hiv,Phase 2,2015-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Age \>18 years
2. Currently receiving cART and having received cART for a minimum of 1 year
3. HIV-1 plasma RNA \<50 copies/mL for at least 1 year (excluding viral load blips)
...",No,2016-07-05,FDA-54371,4.41,0.98,21.0,26.39,2020-04-28,2021-04-21,2042-04-21,35,Merck,38,South Africa,46.16666666666666,24,26,39,79,23,86,36,1,1,2,False,True,False,False,False,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
rhuGM-CSF,TradeName X,Biological,hiv,hiv,Phase 2,2015-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Age \>18 years
2. Currently receiving cART and having received cART for a minimum of 1 year
3. HIV-1 plasma RNA \<50 copies/mL for at least 1 year (excluding viral load blips)
...",No,2016-09-28,FDA-34842,4.41,0.98,21.0,26.39,2020-04-28,2021-04-21,2042-04-21,61,Gilead,45,Kenya,44.0,23,44,44,31,82,40,82,2,3,4,True,True,True,False,True,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Harvoni,AltName A,Drug,hiv,hiv,Phase 4,2019-12-31,"Sex: ALL; Age: >18 Years; Criteria: RETROSPECTIVE ARM INCLUSION CRITERIA

The intent of the Retrospective Arm is to capture all HIV/HCV coinfected patients exposed to sofosbuvir based DAA therapy since 2014, to mirror the population enr...",No,2020-10-18,FDA-22819,0.56,0.15,3.5,4.21,2020-07-22,2020-09-15,2024-03-16,42,AstraZeneca,17,South Africa,53.5,46,44,72,82,60,17,27,0,2,1,False,False,True,False,False,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Galantamine,AltName B,Drug,hiv,hiv,Phase 2,2022-05-31,"Sex: ALL; Age: >30 Years; Criteria: Inclusion Criteria:

Eligible subjects will be males and females:

1. At least 30 years old
2. Diagnosed with HIV-1 infection
3. On stable ART regimens (no changes to treatment within 4 weeks of Intak...",Yes,2023-04-03,FDA-18206,4.41,0.98,21.0,26.39,2026-10-27,2027-10-20,2048-10-19,94,AstraZeneca,67,Kenya,43.16666666666666,96,30,86,16,26,5,27,0,3,0,False,False,True,True,False,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Peginterferon alfa-2b (SCH 054031),TradeName X,Biological,hiv,hiv,Phase 4,2008-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Previously untreated chronic hepatitis C with HCV-RNA positive in plasma.
* Must have finished the detoxification phase of a drug rehabilitation program and abstained for at lea...",Yes,2009-04-04,FDA-74102,0.56,0.15,3.5,4.21,2009-03-24,2009-05-18,2012-11-16,30,Bayer,34,Senegal,57.5,43,81,32,41,62,86,45,1,1,3,True,False,False,True,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ribavirin (SCH 018908),AltName A,Drug,hiv,hiv,Phase 4,2008-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Previously untreated chronic hepatitis C with HCV-RNA positive in plasma.
* Must have finished the detoxification phase of a drug rehabilitation program and abstained for at lea...",Yes,2008-12-17,FDA-86028,0.56,0.15,3.5,4.21,2009-03-24,2009-05-18,2012-11-16,4,Pfizer,55,Overall,54.16666666666666,42,83,98,12,50,40,45,0,2,3,False,False,False,False,False,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PegIFN-2b,AltName A,Drug,hiv,hiv,Phase 2,2012-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* \>=18 and \<=65 years of age
* Body weight \>=40 and \<=125 kg
* Documented history of HIV infection for greater than 6 months prior to Day 1
* On an optimized anti-retroviral t...",No,2013-06-06,FDA-78298,4.41,0.98,21.0,26.39,2017-02-27,2018-02-20,2039-02-20,76,Sanofi,77,Kenya,43.33333333333334,6,38,40,20,62,94,45,0,2,3,False,False,False,True,True,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
RBV,GenName Y,Drug,hiv,hiv,Phase 2,2012-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* \>=18 and \<=65 years of age
* Body weight \>=40 and \<=125 kg
* Documented history of HIV infection for greater than 6 months prior to Day 1
* On an optimized anti-retroviral t...",Yes,2013-06-01,FDA-40518,4.41,0.98,21.0,26.39,2017-02-27,2018-02-20,2039-02-20,50,Sanofi,12,Kenya,40.83333333333334,27,15,38,67,41,57,27,0,3,0,False,False,True,False,True,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Boceprevir,GenName Y,Drug,hiv,hiv,Phase 2,2012-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* \>=18 and \<=65 years of age
* Body weight \>=40 and \<=125 kg
* Documented history of HIV infection for greater than 6 months prior to Day 1
* On an optimized anti-retroviral t...",No,2013-04-09,FDA-10118,4.41,0.98,21.0,26.39,2017-02-27,2018-02-20,2039-02-20,71,GSK,60,Overall,52.83333333333334,45,82,44,12,41,93,27,1,1,1,False,True,True,False,False,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rosiglitazone,TradeName X,Drug,hiv,hiv,Phase 2,2010-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-infected
* On stable Food and Drug Administration (FDA)-approved antiretrovirals for at least 8 weeks
* Excess abdominal fat based on waist and hip measurements done at the ...",Yes,2011-05-31,FDA-28173,4.41,0.98,21.0,26.39,2014-12-28,2015-12-21,2036-12-20,2,J&J,75,South Africa,61.5,58,95,51,69,54,42,36,0,3,1,False,False,True,True,False,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Recombinant human growth hormone + rosiglitazone,TradeName X,Drug,hiv,hiv,Phase 2,2010-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-infected
* On stable Food and Drug Administration (FDA)-approved antiretrovirals for at least 8 weeks
* Excess abdominal fat based on waist and hip measurements done at the ...",No,2010-10-04,FDA-36869,4.41,0.98,21.0,26.39,2014-12-28,2015-12-21,2036-12-20,50,Novartis,6,Senegal,44.66666666666666,2,54,89,78,40,5,36,1,1,2,False,True,False,False,False,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Pioglitazone,AltName B,Drug,hiv,hiv,Phase 4,2013-01-01,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

Men and women, 18 years of age or greater

Confirmed HIV infection by ELISA and Western blot

No changes in antiretroviral regimen within the prior 3 months--Individuals not cur...",Yes,2013-06-21,FDA-79925,0.56,0.15,3.5,4.21,2013-07-24,2013-09-17,2017-03-18,78,Bayer,70,Senegal,59.0,82,95,29,72,3,73,27,2,1,0,True,True,False,True,False,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir / Lamivudine Pill,GenName Y,Drug,hiv,hiv,Phase 4,2023-08-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria -

1. Aged 18 years or older at the time of signing the informed consent

   TYPE OF SUBJECT AND DIAGNOSIS INCLUDING DISEASE SEVERITY
2. HIV-1 infected men or women.
3. Must have a ...",No,2023-10-10,FDA-56159,0.56,0.15,3.5,4.21,2024-03-01,2024-04-25,2027-10-25,1,Novartis,18,South Africa,57.66666666666666,3,77,90,78,82,16,82,2,4,3,True,True,False,True,True,True,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill,Molecule Z,Drug,hiv,hiv,Phase 4,2023-08-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria -

1. Aged 18 years or older at the time of signing the informed consent

   TYPE OF SUBJECT AND DIAGNOSIS INCLUDING DISEASE SEVERITY
2. HIV-1 infected men or women.
3. Must have a ...",No,2024-08-01,FDA-78433,0.56,0.15,3.5,4.21,2024-03-01,2024-04-25,2027-10-25,33,Gilead,4,Overall,35.66666666666666,29,11,32,58,79,5,55,0,3,3,False,False,True,False,True,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Saroglitazar Magnesium 4 mg,GenName Y,Drug,hiv,hiv,Phase 2,2023-10-02,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Adults (≥18 years of age) with documented HIV.
2. Documented diagnosis of NAFLD established by imaging (ultrasound, CT scan or MRI) or liver biopsy within 6 months before scree...",No,2024-07-22,FDA-95262,4.41,0.98,21.0,26.39,2028-02-28,2029-02-20,2050-02-20,15,Novartis,30,South Africa,32.16666666666666,54,12,35,15,33,44,64,2,3,2,True,True,True,False,False,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
pregabalin,Product Alpha,Drug,hiv,hiv,Phase 3,2007-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects with confirmed diagnosis of HIV infection
* HIV-associated neuropathic pain (nerve pain) for at least 3 months prior to study start
* subjects with moderate to severe p...",No,2008-05-25,FDA-21812,2.62,0.32,5.0,7.94,2010-06-14,2010-10-09,2015-10-10,85,AstraZeneca,55,South Africa,23.16666666666667,40,6,4,45,16,28,64,1,2,4,False,True,False,False,False,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lisinopril,AltName A,Drug,hiv,hiv,Phase 2,2025-02-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion criteria:

* Participated in Study Aim 1
* 18-70 years of age
* HIV-positive (as documented by HIV-1 ELISA testing)
* On ART for a minimum of six (6) months AND having a suppressed plasma vi...",Yes,2025-08-04,FDA-74243,4.41,0.98,21.0,26.39,2029-06-30,2030-06-23,2051-06-23,65,AstraZeneca,95,South Africa,66.66666666666667,88,16,55,53,98,90,64,2,4,1,True,True,True,True,True,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Cannabis,AltName A,Drug,hiv,hiv,Phase 2,2022-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. the ability to provide informed consent
2. age 18 or older
3. HIV infection documented at the HNRP or assessed by an HIV test at screening;
4. a diagnosis of HIV sensory neurop...",No,2023-09-06,FDA-33122,4.41,0.98,21.0,26.39,2027-05-29,2028-05-21,2049-05-21,67,AstraZeneca,13,Senegal,44.83333333333334,0,46,96,40,8,79,64,2,4,1,True,True,False,True,True,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Carmustine,TradeName X,Drug,hiv,hiv,Phase 2,2036-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

* Inclusion criteria associated with type and status of lymphoma, one of the following must be applicable:

  * Biopsy-proven intermediate or high-grade non-Hodgkin's lymphoma, mee...",Yes,2036-06-13,FDA-67304,4.41,0.98,21.0,26.39,2040-07-28,2041-07-21,2062-07-21,20,Pfizer,6,Overall,57.16666666666666,67,52,18,86,48,72,45,0,2,3,False,False,False,True,True,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Cytarabine,Product Alpha,Drug,hiv,hiv,Phase 2,2036-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

* Inclusion criteria associated with type and status of lymphoma, one of the following must be applicable:

  * Biopsy-proven intermediate or high-grade non-Hodgkin's lymphoma, mee...",No,2036-05-09,FDA-88942,4.41,0.98,21.0,26.39,2040-07-28,2041-07-21,2062-07-21,66,Merck,1,Kenya,63.16666666666666,92,76,67,68,56,20,45,0,3,2,False,False,True,False,False,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Etoposide,GenName Y,Drug,hiv,hiv,Phase 2,2036-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

* Inclusion criteria associated with type and status of lymphoma, one of the following must be applicable:

  * Biopsy-proven intermediate or high-grade non-Hodgkin's lymphoma, mee...",Yes,2036-08-15,FDA-77420,4.41,0.98,21.0,26.39,2040-07-28,2041-07-21,2062-07-21,68,Merck,50,Senegal,56.66666666666666,2,88,94,82,70,4,82,2,4,3,True,True,True,True,True,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells,TradeName X,Biological,hiv,hiv,Phase 2,2036-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

* Inclusion criteria associated with type and status of lymphoma, one of the following must be applicable:

  * Biopsy-proven intermediate or high-grade non-Hodgkin's lymphoma, mee...",No,2037-02-28,FDA-62473,4.41,0.98,21.0,26.39,2040-07-28,2041-07-21,2062-07-21,38,Merck,68,Kenya,46.83333333333334,46,16,39,92,30,58,36,0,3,1,False,False,True,True,False,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Melphalan,Molecule Z,Drug,hiv,hiv,Phase 2,2036-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

* Inclusion criteria associated with type and status of lymphoma, one of the following must be applicable:

  * Biopsy-proven intermediate or high-grade non-Hodgkin's lymphoma, mee...",Yes,2036-06-03,FDA-39406,4.41,0.98,21.0,26.39,2040-07-28,2041-07-21,2062-07-21,2,Merck,56,Senegal,48.66666666666666,18,35,44,62,92,41,55,2,2,2,True,True,True,False,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
TDF with a boosted protease inhibitor,GenName Y,Drug,hiv,hiv,Phase 4,2019-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Between 18-70 years of age
* Have been taking TDF and a ritonavir- or cobicistat-boosted protease inhibitor as part of standard care for treatment of HIV

Exclusion Criteria:

*...",No,2020-07-19,FDA-23805,0.56,0.15,3.5,4.21,2020-04-22,2020-06-16,2023-12-16,41,Novartis,70,Senegal,52.33333333333334,0,59,66,77,40,72,45,1,3,1,True,False,True,True,True,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
TAF with a boosted protease inhibitor,Molecule Z,Drug,hiv,hiv,Phase 4,2019-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Between 18-70 years of age
* Have been taking TDF and a ritonavir- or cobicistat-boosted protease inhibitor as part of standard care for treatment of HIV

Exclusion Criteria:

*...",No,2020-01-01,FDA-62069,0.56,0.15,3.5,4.21,2020-04-22,2020-06-16,2023-12-16,68,AstraZeneca,38,South Africa,32.83333333333334,65,29,2,23,59,19,36,1,3,0,True,False,False,True,True,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
TAF with a boosted protease inhibitor and LDV/SOF,AltName A,Drug,hiv,hiv,Phase 4,2019-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Between 18-70 years of age
* Have been taking TDF and a ritonavir- or cobicistat-boosted protease inhibitor as part of standard care for treatment of HIV

Exclusion Criteria:

*...",No,2020-02-25,FDA-44208,0.56,0.15,3.5,4.21,2020-04-22,2020-06-16,2023-12-16,56,Pfizer,29,Kenya,54.0,3,51,76,89,62,43,73,2,4,2,True,True,True,True,True,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Fluconazole,AltName A,Drug,hiv,hiv,Phase 2,2016-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV+ based on ELISA and confirmed by either Western blot or plasma HIV RNA
* capable of providing informed consent
* age range: 18-65 years
* presence of neuropsychological test...",No,2016-07-05,FDA-33227,4.41,0.98,21.0,26.39,2020-07-28,2021-07-21,2042-07-21,87,GSK,33,Kenya,58.5,34,95,77,11,66,68,55,1,3,2,True,False,True,True,False,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Paroxetine,AltName A,Drug,hiv,hiv,Phase 2,2016-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV+ based on ELISA and confirmed by either Western blot or plasma HIV RNA
* capable of providing informed consent
* age range: 18-65 years
* presence of neuropsychological test...",Yes,2016-07-28,FDA-37774,4.41,0.98,21.0,26.39,2020-07-28,2021-07-21,2042-07-21,84,Novartis,78,Senegal,60.66666666666666,51,83,60,17,94,59,55,0,2,4,False,False,False,True,False,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Paroxetine and Fluconazole,AltName B,Drug,hiv,hiv,Phase 2,2016-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV+ based on ELISA and confirmed by either Western blot or plasma HIV RNA
* capable of providing informed consent
* age range: 18-65 years
* presence of neuropsychological test...",No,2016-06-13,FDA-64229,4.41,0.98,21.0,26.39,2020-07-28,2021-07-21,2042-07-21,23,AstraZeneca,87,South Africa,38.66666666666666,7,44,84,56,1,40,55,1,3,2,False,True,True,True,False,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Estradiol Vaginal Insert,AltName A,Drug,hiv,hiv,Phase 4,2023-08-09,"Sex: FEMALE; Age: >45 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* HIV infection
* Females aged 45-70
* Menopause defined by having no menstrual periods for 12 consecutive months, confirmed with serum follicle-stimulating hormone (FSH) level \>...",No,2023-09-19,FDA-59560,0.56,0.15,3.5,4.21,2024-02-29,2024-04-24,2027-10-24,13,Pfizer,19,Senegal,52.0,64,68,37,19,65,59,45,1,2,2,False,True,True,True,False,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Etonogestrel (ETG) implant,GenName Y,Drug,hiv,hiv,Phase 4,2024-02-05,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-positive
* Currently on 1st line ART (namely EFV- or DTG-containing ART),
* Have documented or confirmed viral suppression for HIV (defined as \<40 copies/mL) within 3 month...",No,2024-11-06,FDA-39973,0.56,0.15,3.5,4.21,2024-08-27,2024-10-21,2028-04-21,36,Bayer,11,Kenya,87.66666666666667,98,95,98,90,94,51,36,1,1,2,True,False,False,False,False,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Intramuscular depo-medroxyprogesterone acetate (IM DMPA),TradeName X,Drug,hiv,hiv,Phase 4,2024-02-05,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-positive
* Currently on 1st line ART (namely EFV- or DTG-containing ART),
* Have documented or confirmed viral suppression for HIV (defined as \<40 copies/mL) within 3 month...",No,2024-03-31,FDA-71760,0.56,0.15,3.5,4.21,2024-08-27,2024-10-21,2028-04-21,42,Gilead,84,Overall,27.83333333333333,48,52,17,2,32,16,45,2,2,1,True,True,False,False,True,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Sub-cutaneous medroxyprogesterone acetate (SC MPA),GenName Y,Drug,hiv,hiv,Phase 4,2024-02-05,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-positive
* Currently on 1st line ART (namely EFV- or DTG-containing ART),
* Have documented or confirmed viral suppression for HIV (defined as \<40 copies/mL) within 3 month...",Yes,2024-04-30,FDA-56132,0.56,0.15,3.5,4.21,2024-08-27,2024-10-21,2028-04-21,30,Pfizer,23,South Africa,46.5,78,4,83,39,9,66,45,1,2,2,True,False,True,False,True,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Non-hormonal intrauterine device (IUD),Molecule Z,Device,hiv,hiv,Phase 4,2024-02-05,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-positive
* Currently on 1st line ART (namely EFV- or DTG-containing ART),
* Have documented or confirmed viral suppression for HIV (defined as \<40 copies/mL) within 3 month...",No,2024-07-21,FDA-59578,0.56,0.15,3.5,4.21,2024-08-27,2024-10-21,2028-04-21,8,Bayer,79,Kenya,42.5,69,37,22,8,22,97,55,1,2,3,False,True,True,True,False,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
valacyclovir,Comp Beta,Drug,hiv,hiv,Phase 2,2010-08-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 seropositive
* HSV-2 seropositive
* Plans to deliver in Nairobi
* Resides and plans to remain in Nairobi for 12 months postpartum
* 18 years of age or older
* CD4 count\>2...",Yes,2011-02-28,FDA-28812,4.41,0.98,21.0,26.39,2014-12-28,2015-12-21,2036-12-20,0,Pfizer,13,Overall,53.83333333333334,74,40,33,71,83,22,55,2,1,3,True,True,False,False,False,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
V114,AltName A,Biological,hiv,hiv,Phase 3,2020-01-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) \<50,000 c...",Yes,2020-02-24,FDA-73408,2.62,0.32,5.0,7.94,2022-08-30,2022-12-25,2027-12-26,41,Merck,18,Kenya,60.5,41,73,61,76,81,31,45,1,3,1,True,False,True,True,False,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Prevnar 13™,Product Alpha,Biological,hiv,hiv,Phase 3,2020-01-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) \<50,000 c...",Yes,2021-01-11,FDA-76785,2.62,0.32,5.0,7.94,2022-08-30,2022-12-25,2027-12-26,92,AstraZeneca,28,Senegal,60.5,52,95,42,16,86,72,64,2,3,2,True,True,True,True,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PNEUMOVAX™23,AltName A,Biological,hiv,hiv,Phase 3,2020-01-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male or female infected with human immunodeficiency virus (HIV) and Cluster of Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid (RNA) \<50,000 c...",Yes,2020-07-22,FDA-25388,2.62,0.32,5.0,7.94,2022-08-30,2022-12-25,2027-12-26,62,GSK,47,Kenya,45.5,16,60,50,81,33,33,55,1,2,3,True,False,False,False,True,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Sitagliptin,Molecule Z,Drug,hiv,hiv,Phase 3,2014-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* 18-65 yr old HIV infected men and women.
* Stable (at least the past 6 months) on combined antiretroviral therapy (cART).
* Stable immune (\> 300 CD4+ T-cells/µL) and virologic ...",No,2015-10-10,FDA-12897,2.62,0.32,5.0,7.94,2017-07-14,2017-11-08,2022-11-09,61,Sanofi,56,South Africa,78.0,90,51,85,61,97,84,45,1,2,2,False,True,False,True,True,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Quadrivalent HPV vaccine,Comp Beta,Biological,hiv,hiv,Phase 2,2012-11-01,"Sex: FEMALE; Age: >13 Years; Criteria: Inclusion Criteria:

* HIV infection
* CD4 count obtained within 45 days prior to study entry
* Karnofsky performance score \>=70 on at least one occasion within 45 days prior to study entry
* The fol...",No,2013-06-22,FDA-51678,4.41,0.98,21.0,26.39,2017-03-30,2018-03-23,2039-03-23,73,Novartis,30,Senegal,37.66666666666666,28,5,100,54,3,36,64,2,3,2,True,True,True,True,False,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ad26.Mos.HIV,Comp Beta,Biological,hiv,hiv,Phase 2,2022-04-25,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Are negative for human immunodeficiency virus (HIV) infection at screening
* Is healthy on the basis of physical examination, medical history, electrocardiogram (ECG), and vital...",Yes,2022-08-07,FDA-62939,4.41,0.98,21.0,26.39,2026-09-21,2027-09-14,2048-09-13,20,Pfizer,57,Kenya,25.83333333333333,26,1,90,19,11,8,45,1,3,1,False,True,True,True,False,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ad26.Mos4.HIV,GenName Y,Biological,hiv,hiv,Phase 2,2022-04-25,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Are negative for human immunodeficiency virus (HIV) infection at screening
* Is healthy on the basis of physical examination, medical history, electrocardiogram (ECG), and vital...",No,2022-12-29,FDA-92136,4.41,0.98,21.0,26.39,2026-09-21,2027-09-14,2048-09-13,73,Sanofi,73,Senegal,64.0,77,44,60,79,30,94,45,1,2,2,False,True,False,False,True,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Clade C gp140,Comp Beta,Biological,hiv,hiv,Phase 2,2022-04-25,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Are negative for human immunodeficiency virus (HIV) infection at screening
* Is healthy on the basis of physical examination, medical history, electrocardiogram (ECG), and vital...",No,2022-06-28,FDA-68587,4.41,0.98,21.0,26.39,2026-09-21,2027-09-14,2048-09-13,24,Gilead,10,Senegal,53.16666666666666,98,59,29,53,41,39,55,2,1,3,True,True,False,False,False,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ISL,Molecule Z,Drug,hiv,hiv,Phase 3,2023-11-01,"Sex: ALL; Criteria: Inclusion Criteria:

* Is HIV-1 positive.
* Has been receiving the same baseline ART for ≥3 months prior to signing the Informed Consent Form/Assent Form.
* Weighs ≥35 kg.
* Has at least triple-class ...",Yes,2024-01-22,FDA-58128,2.62,0.32,5.0,7.94,2026-06-14,2026-10-09,2031-10-10,95,Bayer,88,Senegal,58.83333333333334,46,30,44,72,77,84,18,0,1,1,False,False,False,False,True,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DOR,GenName Y,Drug,hiv,hiv,Phase 3,2023-11-01,"Sex: ALL; Criteria: Inclusion Criteria:

* Is HIV-1 positive.
* Has been receiving the same baseline ART for ≥3 months prior to signing the Informed Consent Form/Assent Form.
* Weighs ≥35 kg.
* Has at least triple-class ...",Yes,2024-02-16,FDA-40573,2.62,0.32,5.0,7.94,2026-06-14,2026-10-09,2031-10-10,8,GSK,61,Overall,66.16666666666667,62,97,79,80,11,68,55,1,2,3,True,False,False,False,True,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
DOR/ISL,Product Alpha,Drug,hiv,hiv,Phase 3,2023-11-01,"Sex: ALL; Criteria: Inclusion Criteria:

* Is HIV-1 positive.
* Has been receiving the same baseline ART for ≥3 months prior to signing the Informed Consent Form/Assent Form.
* Weighs ≥35 kg.
* Has at least triple-class ...",Yes,2024-10-12,FDA-77008,2.62,0.32,5.0,7.94,2026-06-14,2026-10-09,2031-10-10,56,Novartis,97,Overall,37.83333333333334,13,34,34,64,29,53,45,0,3,2,False,False,True,True,True,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Valganciclovir,Comp Beta,Drug,hiv,hiv,Phase 2,2019-08-26,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients will be included with AIDS naïve to antiretroviral therapy and severe KS, who accept to participate and who sign the letter of informed consent.
* The following are the...",No,2020-01-04,FDA-37560,4.41,0.98,21.0,26.39,2024-01-22,2025-01-14,2046-01-14,56,Merck,76,Kenya,48.0,63,18,69,13,43,82,64,1,2,4,True,False,True,False,False,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Antiretroviral Combinations,Comp Beta,Drug,hiv,hiv,Phase 2,2019-08-26,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients will be included with AIDS naïve to antiretroviral therapy and severe KS, who accept to participate and who sign the letter of informed consent.
* The following are the...",Yes,2020-08-22,FDA-92032,4.41,0.98,21.0,26.39,2024-01-22,2025-01-14,2046-01-14,40,Novartis,90,Senegal,39.66666666666666,81,90,5,2,9,51,82,1,5,3,True,False,True,True,True,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ad26.Mos.HIV,AltName B,Biological,hiv,hiv,Phase 2,2022-03-28,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Participant must be healthy on the basis of physical examination, medical history, electrocardiogram (ECG) and laboratory criteria, and vital signs measurement performed at Scre...",No,2023-01-14,FDA-13730,4.41,0.98,21.0,26.39,2026-08-24,2027-08-17,2048-08-16,42,Bayer,34,Kenya,65.83333333333333,64,72,99,50,18,92,55,0,2,4,False,False,False,False,True,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
MVA-Mosaic,Product Alpha,Biological,hiv,hiv,Phase 2,2022-03-28,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Participant must be healthy on the basis of physical examination, medical history, electrocardiogram (ECG) and laboratory criteria, and vital signs measurement performed at Scre...",Yes,2023-03-10,FDA-73902,4.41,0.98,21.0,26.39,2026-08-24,2027-08-17,2048-08-16,4,Sanofi,92,Kenya,49.5,53,91,40,47,44,22,64,1,3,3,True,False,False,True,True,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
gp140 DP Low-dose,Product Alpha,Biological,hiv,hiv,Phase 2,2022-03-28,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Participant must be healthy on the basis of physical examination, medical history, electrocardiogram (ECG) and laboratory criteria, and vital signs measurement performed at Scre...",No,2022-05-28,FDA-84241,4.41,0.98,21.0,26.39,2026-08-24,2027-08-17,2048-08-16,38,GSK,28,South Africa,73.83333333333333,19,61,100,96,74,93,64,1,4,2,False,True,True,False,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
gp140 DP High-dose,AltName B,Biological,hiv,hiv,Phase 2,2022-03-28,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Participant must be healthy on the basis of physical examination, medical history, electrocardiogram (ECG) and laboratory criteria, and vital signs measurement performed at Scre...",No,2023-02-08,FDA-93361,4.41,0.98,21.0,26.39,2026-08-24,2027-08-17,2048-08-16,50,J&J,47,South Africa,73.0,96,100,95,96,50,1,45,0,3,2,False,False,False,True,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Anti-D,Molecule Z,Drug,hiv,hiv,Phase 4,2010-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria for All Participants:

* HCV-infected
* Currently on treatment for HCV OR plan to begin treatment for HCV at the start of this study
* Platelet count less than 50,000 cells/microl
*...",No,2010-05-06,FDA-48387,0.56,0.15,3.5,4.21,2010-08-24,2010-10-18,2014-04-18,37,AstraZeneca,46,South Africa,24.16666666666667,41,6,24,26,20,28,36,1,2,1,True,False,False,True,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
PPV-23,AltName B,Biological,hiv,hiv,Phase 2,2019-05-01,"Sex: FEMALE; Criteria: Step 1 Inclusion Criteria for Pregnant Women:

1. Pregnant women ≥ 18 years old who provided written informed consent prior to study initiation.
2. Pregnant women \< 18 years old with parent or legal ...",No,2019-08-26,FDA-35704,4.41,0.98,21.0,26.39,2023-09-27,2024-09-19,2045-09-19,66,Pfizer,88,Senegal,70.16666666666667,78,51,90,79,41,82,64,1,2,4,False,True,False,False,True,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PCV-10,Molecule Z,Biological,hiv,hiv,Phase 2,2019-05-01,"Sex: FEMALE; Criteria: Step 1 Inclusion Criteria for Pregnant Women:

1. Pregnant women ≥ 18 years old who provided written informed consent prior to study initiation.
2. Pregnant women \< 18 years old with parent or legal ...",No,2020-04-27,FDA-83238,4.41,0.98,21.0,26.39,2023-09-27,2024-09-19,2045-09-19,47,Novartis,75,Overall,28.83333333333333,25,59,12,26,4,47,73,2,3,3,True,True,True,True,False,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Bococizumab,Product Alpha,Drug,hiv,hiv,Phase 3,2017-11-01,"Sex: ALL; Age: >40 Years; Criteria: Inclusion Criteria:

1. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the st...",No,2018-02-10,FDA-56330,2.62,0.32,5.0,7.94,2020-06-14,2020-10-09,2025-10-10,23,AstraZeneca,95,Kenya,34.5,12,90,4,18,66,17,73,1,4,3,False,True,False,True,True,True,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"NGX-4010, 8% capsaicin patch",TradeName X,Drug,hiv,hiv,Phase 3,2007-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented evidence of HIV-1 infection
* Documented diagnosis of painful HIV-associated distal symmetric polyneuropathy resulting from HIV disease and/or antiretroviral drug exp...",Yes,2008-03-27,FDA-56006,2.62,0.32,5.0,7.94,2010-07-14,2010-11-08,2015-11-09,24,GSK,97,Overall,57.33333333333334,76,76,3,3,97,89,64,1,4,2,False,True,False,True,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
0.04% capsaicin patch,Product Alpha,Drug,hiv,hiv,Phase 3,2007-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented evidence of HIV-1 infection
* Documented diagnosis of painful HIV-associated distal symmetric polyneuropathy resulting from HIV disease and/or antiretroviral drug exp...",Yes,2008-03-17,FDA-24339,2.62,0.32,5.0,7.94,2010-07-14,2010-11-08,2015-11-09,35,Pfizer,35,Overall,41.5,27,60,40,41,22,59,55,2,1,3,True,True,True,False,False,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"NGX-4010, 8% capsaicin patch",AltName A,Drug,hiv,hiv,Phase 3,2007-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented evidence of HIV-1 infection
* Documented diagnosis of painful HIV-associated distal symmetric polyneuropathy resulting from HIV disease and/or antiretroviral drug exp...",No,2008-04-16,FDA-62542,2.62,0.32,5.0,7.94,2010-07-14,2010-11-08,2015-11-09,68,Merck,11,Overall,65.16666666666667,19,94,87,69,87,35,55,1,3,2,True,False,False,True,True,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
0.04% capsaicin patch,GenName Y,Drug,hiv,hiv,Phase 3,2007-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented evidence of HIV-1 infection
* Documented diagnosis of painful HIV-associated distal symmetric polyneuropathy resulting from HIV disease and/or antiretroviral drug exp...",Yes,2008-06-13,FDA-47246,2.62,0.32,5.0,7.94,2010-07-14,2010-11-08,2015-11-09,40,AstraZeneca,37,South Africa,29.0,35,49,24,50,14,2,73,0,4,4,False,False,False,True,True,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Low-dose naltrexone,GenName Y,Drug,hiv,hiv,Phase 2,2021-12-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* 18 years or older
* HIV-positive
* Chronic pain (present ≥3 mo) of moderate to severe intensity
* Heavy drinking past year (Based on NIAAA criteria: \> 14 standard drinks per we...",Yes,2022-11-15,FDA-29166,4.41,0.98,21.0,26.39,2026-05-13,2027-05-06,2048-05-05,56,Bayer,78,Kenya,20.66666666666667,0,4,47,37,26,10,45,1,2,2,True,False,True,False,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Gabapentin,AltName B,Drug,hiv,hiv,Phase 2,2021-12-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* 18 years or older
* HIV-positive
* Chronic pain (present ≥3 mo) of moderate to severe intensity
* Heavy drinking past year (Based on NIAAA criteria: \> 14 standard drinks per we...",No,2022-07-18,FDA-20458,4.41,0.98,21.0,26.39,2026-05-13,2027-05-06,2048-05-05,67,GSK,23,South Africa,25.16666666666667,3,39,13,61,24,11,55,0,4,2,False,False,False,True,True,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lenalidomide,Molecule Z,Drug,hiv,hiv,Phase 2,2014-08-04,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Biopsy-proven KS involving skin with or without visceral involvement either newly diagnosed or refractory to or intolerant of one or more prior therapies
* Patients must have cu...",Yes,2015-07-13,FDA-40732,4.41,0.98,21.0,26.39,2018-12-31,2019-12-24,2040-12-23,85,J&J,7,Overall,52.5,77,50,94,3,40,51,55,1,3,2,False,True,False,True,True,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Vorinostat,AltName B,Drug,hiv,hiv,Phase 2,2016-03-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. HIV-1 infection
2. Men, women age ≥18 years.
3. Ability, willingness to give written informed consent.
4. Able, willing to provide adequate locator information.
5. Karnofsky pe...",Yes,2017-02-19,FDA-21012,4.41,0.98,21.0,26.39,2020-08-27,2021-08-20,2042-08-20,6,J&J,24,Kenya,65.5,68,86,94,69,57,19,73,0,4,4,False,False,True,True,False,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Nicoderm C-Q Transdermal Product,GenName Y,Drug,hiv,hiv,Phase 4,2020-10-14,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* ≥ 18 years old
* Diagnosed with HIV
* Have been prescribed ART medication in the prior 6 months
* Have smoked ≥ 5 cigarettes/day in the past year
* Be interested in making a qui...",Yes,2020-12-15,FDA-95418,0.56,0.15,3.5,4.21,2021-05-06,2021-06-30,2024-12-29,94,AstraZeneca,77,South Africa,39.33333333333334,99,51,8,56,22,0,73,1,3,4,True,False,True,True,True,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
SOF/VEL,AltName B,Drug,hiv,hiv,Phase 3,2016-06-22,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* HCV RNA ≥ 10\^4 IU/mL at screening
* HCV genotype 1, 2, 3, 4, 5, 6
* Cirrhosis determination, a fibroscan or liver biopsy may be required
* HIV-1 infection
* Use of protocol...",No,2017-01-27,FDA-64626,2.62,0.32,5.0,7.94,2019-02-03,2019-05-31,2024-05-31,23,GSK,64,Overall,48.16666666666666,90,59,62,44,0,34,55,1,3,2,True,False,False,False,True,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Peginterferon alfa-2a,Molecule Z,Drug,hiv,hiv,Phase 2,2009-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria for Step 1:

* HIV infected
* Stable antiretroviral therapy for at least 8 weeks prior to study entry OR have not received any antiretroviral therapy for at least 4 weeks prior to e...",No,2009-03-21,FDA-74787,4.41,0.98,21.0,26.39,2013-06-30,2014-06-23,2035-06-23,36,Gilead,24,South Africa,49.5,55,39,31,59,20,93,64,1,4,2,True,False,True,False,True,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ribavirin,GenName Y,Drug,hiv,hiv,Phase 2,2009-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria for Step 1:

* HIV infected
* Stable antiretroviral therapy for at least 8 weeks prior to study entry OR have not received any antiretroviral therapy for at least 4 weeks prior to e...",No,2009-12-18,FDA-94317,4.41,0.98,21.0,26.39,2013-06-30,2014-06-23,2035-06-23,46,Novartis,42,Kenya,29.5,31,39,51,26,10,20,55,0,3,3,False,False,True,False,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
mRNA-transfected autologous dendritic cells,AltName B,Biological,hiv,hiv,Phase 2,2013-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 positive
* CD4+ T Cell count \>200
* Undetectable HIV viral load for 6 months prior to screening
* On antiretroviral treatment for 12 months prior to screening

Exclusion ...",No,2014-03-25,FDA-33179,4.41,0.98,21.0,26.39,2018-04-29,2019-04-22,2040-04-21,91,Novartis,28,Senegal,59.5,80,39,85,24,43,86,36,1,2,1,False,True,False,True,False,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
autologous dendritic cells with no mRNA transfection,GenName Y,Biological,hiv,hiv,Phase 2,2013-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 positive
* CD4+ T Cell count \>200
* Undetectable HIV viral load for 6 months prior to screening
* On antiretroviral treatment for 12 months prior to screening

Exclusion ...",Yes,2014-04-04,FDA-70124,4.41,0.98,21.0,26.39,2018-04-29,2019-04-22,2040-04-21,19,AstraZeneca,3,Kenya,62.16666666666666,65,22,76,66,63,81,64,1,4,2,False,True,True,True,True,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Atazanavir,Molecule Z,Drug,hiv,hiv,Phase 4,2014-02-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria

* Current treatment regimen of 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus any third agent for at least 3 months immediately prior to screening
* Virologic suppr...",Yes,2014-10-31,FDA-97132,0.56,0.15,3.5,4.21,2014-08-24,2014-10-18,2018-04-18,88,J&J,33,Kenya,34.33333333333334,58,40,19,69,11,9,73,1,5,2,False,True,True,True,True,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir (heat-stable),AltName B,Drug,hiv,hiv,Phase 4,2014-02-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria

* Current treatment regimen of 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus any third agent for at least 3 months immediately prior to screening
* Virologic suppr...",No,2015-01-19,FDA-96903,0.56,0.15,3.5,4.21,2014-08-24,2014-10-18,2018-04-18,8,GSK,14,Overall,46.33333333333334,54,21,16,93,72,22,64,2,2,3,True,True,False,False,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,AltName B,Drug,hiv,hiv,Phase 4,2014-02-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria

* Current treatment regimen of 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus any third agent for at least 3 months immediately prior to screening
* Virologic suppr...",Yes,2014-11-01,FDA-60584,0.56,0.15,3.5,4.21,2014-08-24,2014-10-18,2018-04-18,5,Pfizer,71,Kenya,44.66666666666666,20,69,76,35,2,66,18,0,1,1,False,False,False,False,False,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir/Emtricitabine,AltName A,Drug,hiv,hiv,Phase 4,2014-02-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria

* Current treatment regimen of 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus any third agent for at least 3 months immediately prior to screening
* Virologic suppr...",No,2014-03-12,FDA-68473,0.56,0.15,3.5,4.21,2014-08-24,2014-10-18,2018-04-18,36,J&J,25,South Africa,55.16666666666666,72,4,8,92,74,81,64,1,3,3,True,False,False,True,False,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Doxycycline,Comp Beta,Drug,hiv,hiv,Phase 4,2022-10-30,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Willing and able to give written informed consent
* Age ≥18 years and ≤30 years old
* Female sex at birth
* HIV-seronegative at the time of last test within the past month and a...",Yes,2023-04-08,FDA-74978,0.56,0.15,3.5,4.21,2023-05-22,2023-07-16,2027-01-14,65,Sanofi,16,South Africa,60.83333333333334,75,64,22,69,53,82,55,2,1,3,True,True,False,False,True,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Bupropion,Molecule Z,Drug,hiv,hiv,Phase 2,2007-11-01,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* HIV-negative by rapid test or able to document HIV infection through healthcare provider's note or documentation of laboratory test;
* Reports anal sex with men in prior 3 month...",Yes,2008-08-15,FDA-18993,4.41,0.98,21.0,26.39,2012-03-29,2013-03-22,2034-03-22,42,Novartis,33,South Africa,52.66666666666666,49,68,43,6,67,83,64,0,4,3,False,False,True,True,True,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
pregabalin,TradeName X,Drug,hiv,hiv,Phase 3,2012-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Men and women, ages of 18 or greater
* Documented evidence of HIV-1 infection
* Documented diagnosis of HIV-associated Distal Symmetrical Polyneuropathy (DSP) with subjective se...",No,2012-06-18,FDA-11422,2.62,0.32,5.0,7.94,2014-12-13,2015-04-09,2020-04-09,25,GSK,61,Senegal,44.33333333333334,2,15,61,76,60,52,36,1,1,2,False,True,False,False,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
VEGF inhibitor PTC299,Molecule Z,Drug,hiv,hiv,Phase 2,2010-12-01,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Biopsy-proven Kaposi sarcoma (KS) involving the skin (with or without lymph node), oral cavity, gastrointestinal (GI) tract, and/or lung

  * Patients with GI and/or pulmon...",No,2011-07-03,FDA-28420,4.41,0.98,21.0,26.39,2015-04-29,2016-04-21,2037-04-21,91,AstraZeneca,73,South Africa,55.0,56,91,5,87,82,9,55,1,3,2,False,True,True,False,False,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ISL,Molecule Z,Drug,hiv,hiv,Phase 3,2023-08-04,"Sex: MALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Has confirmed Human Immunodeficiency Virus (HIV) uninfected based on negative HIV-1/HIV-2 test result before randomization
* Is sexually active with male or transgender women (T...",No,2023-11-26,FDA-77553,2.62,0.32,5.0,7.94,2026-03-17,2026-07-12,2031-07-13,22,Pfizer,46,Senegal,35.5,37,43,11,47,46,29,64,1,3,3,False,True,False,True,False,True,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TDF,AltName A,Drug,hiv,hiv,Phase 3,2023-08-04,"Sex: MALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Has confirmed Human Immunodeficiency Virus (HIV) uninfected based on negative HIV-1/HIV-2 test result before randomization
* Is sexually active with male or transgender women (T...",Yes,2024-07-21,FDA-19882,2.62,0.32,5.0,7.94,2026-03-17,2026-07-12,2031-07-13,33,Novartis,61,Senegal,48.33333333333334,48,5,95,99,41,2,73,2,5,1,True,True,True,True,True,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TAF,Molecule Z,Drug,hiv,hiv,Phase 3,2023-08-04,"Sex: MALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Has confirmed Human Immunodeficiency Virus (HIV) uninfected based on negative HIV-1/HIV-2 test result before randomization
* Is sexually active with male or transgender women (T...",No,2024-07-27,FDA-58904,2.62,0.32,5.0,7.94,2026-03-17,2026-07-12,2031-07-13,72,Gilead,83,Senegal,47.5,88,8,50,29,86,24,45,1,2,2,False,True,True,False,False,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Sitagliptin,TradeName X,Drug,hiv,hiv,Phase 3,2012-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Thirty 18-65 yr old HIV-infected men and women (with source documentation of HIV status) who are stable on any antiretroviral therapy (cART) regimen
2. Have stable (at least th...",No,2012-07-14,FDA-24755,2.62,0.32,5.0,7.94,2015-01-13,2015-05-10,2020-05-10,80,J&J,11,Overall,32.33333333333334,29,84,0,7,0,74,45,1,3,1,False,True,True,False,True,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Naltrexone,GenName Y,Drug,hiv,hiv,Phase 2,2021-01-01,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* (1) Male gender (2) self-reported anal sex with men in the prior three months while under the influence of alcohol (3) at least one binge drinking (five or more drinks on a sing...",Yes,2021-10-20,FDA-57152,4.41,0.98,21.0,26.39,2025-05-30,2026-05-23,2047-05-23,15,Bayer,10,Senegal,42.33333333333334,80,17,42,38,67,10,45,1,0,4,False,True,False,False,False,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ondansetron,GenName Y,Drug,hiv,hiv,Phase 2,2017-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects will be at least 18 years old and HIV-infected
* All subjects will be actively drinking at hazardous levels (1) AUDIT score =\> 4 for women or =\>8 for men, or 2) =\> 2...",Yes,2017-10-04,FDA-67962,4.41,0.98,21.0,26.39,2021-05-30,2022-05-23,2043-05-23,47,J&J,92,Overall,57.0,51,52,25,48,83,83,45,1,3,1,False,True,True,True,False,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ondansetron,AltName A,Drug,hiv,hiv,Phase 2,2017-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects will be at least 18 years old and HIV-infected
* All subjects will be actively drinking at hazardous levels (1) AUDIT score =\> 4 for women or =\>8 for men, or 2) =\> 2...",Yes,2017-08-02,FDA-89600,4.41,0.98,21.0,26.39,2021-05-30,2022-05-23,2043-05-23,57,Sanofi,85,Overall,42.33333333333334,43,50,75,11,24,51,55,0,4,2,False,False,True,True,True,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Varenicline,AltName A,Drug,hiv,hiv,Phase 3,2018-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

1. 18 years of age or older who self-report smoking at least 5 cigarettes (menthol and non-menthol) per day, on average.
2. Diagnosed with HIV infection and exhibiting viral load o...",No,2018-11-28,FDA-21873,2.62,0.32,5.0,7.94,2021-04-14,2021-08-09,2026-08-10,1,AstraZeneca,42,South Africa,41.33333333333334,53,12,23,14,63,83,82,1,4,4,False,True,True,False,True,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Aripiprazole,AltName B,Drug,hiv,hiv,Phase 2,2012-03-01,Sex: ALL; Age: >18 Years; Criteria: A total of 90 high-risk individuals with methamphetamine dependence will be enrolled in the study. Subjects will be San Francisco Bay Area residents between 18-60 years of age and in good health. The ...,No,2013-01-07,FDA-76817,4.41,0.98,21.0,26.39,2016-07-28,2017-07-21,2038-07-21,56,J&J,55,South Africa,86.66666666666667,98,92,100,73,63,94,55,0,4,2,False,False,True,False,True,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Moderna mRNA-1273,Product Alpha,Biological,hiv,hiv,Phase 3,2024-04-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

General and Demographic Criteria

1. Age ≥ 18 years if participant self-reports living with HIV or another comorbidity known to be associated with severe COVID-19, for example (CD...",No,2024-07-03,FDA-19603,2.62,0.32,5.0,7.94,2026-12-01,2027-03-28,2032-03-28,11,Merck,8,South Africa,41.0,18,48,17,70,67,26,55,1,3,2,False,True,True,False,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Moderna mRNA-1273.222,AltName A,Biological,hiv,hiv,Phase 3,2024-04-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

General and Demographic Criteria

1. Age ≥ 18 years if participant self-reports living with HIV or another comorbidity known to be associated with severe COVID-19, for example (CD...",No,2024-12-25,FDA-38473,2.62,0.32,5.0,7.94,2026-12-01,2027-03-28,2032-03-28,72,Pfizer,34,Senegal,57.83333333333334,80,99,100,29,8,31,27,0,1,2,False,False,True,False,False,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Vaccine 3 Dose,AltName A,Biological,hiv,hiv,Phase 3,2024-04-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

General and Demographic Criteria

1. Age ≥ 18 years if participant self-reports living with HIV or another comorbidity known to be associated with severe COVID-19, for example (CD...",Yes,2024-06-21,FDA-56173,2.62,0.32,5.0,7.94,2026-12-01,2027-03-28,2032-03-28,33,Bayer,31,South Africa,57.66666666666666,25,50,99,79,13,80,45,1,2,2,False,True,True,False,True,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Vaccine 2 Dose,GenName Y,Biological,hiv,hiv,Phase 3,2024-04-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

General and Demographic Criteria

1. Age ≥ 18 years if participant self-reports living with HIV or another comorbidity known to be associated with severe COVID-19, for example (CD...",No,2024-06-19,FDA-58946,2.62,0.32,5.0,7.94,2026-12-01,2027-03-28,2032-03-28,60,J&J,11,Senegal,50.83333333333334,72,4,86,83,25,35,45,1,2,2,False,True,False,True,False,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Daclatasvir,TradeName X,Drug,hiv,hiv,Phase 3,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Key Inclusion Criteria:

* Males and females, 18 to 70 years of age
* Hepatitis C virus (HCV) gen...",Yes,2015-01-07,FDA-24435,2.62,0.32,5.0,7.94,2017-04-14,2017-08-09,2022-08-10,16,Gilead,44,Senegal,58.66666666666666,68,30,23,63,99,69,64,1,3,3,True,False,True,True,False,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ribavirin,AltName A,Drug,hiv,hiv,Phase 3,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Key Inclusion Criteria:

* Males and females, 18 to 70 years of age
* Hepatitis C virus (HCV) gen...",No,2015-04-20,FDA-86202,2.62,0.32,5.0,7.94,2017-04-14,2017-08-09,2022-08-10,37,AstraZeneca,73,Overall,56.5,64,34,55,66,72,48,64,1,2,4,True,False,False,False,True,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PEG-Interferon alfa 2a,Comp Beta,Drug,hiv,hiv,Phase 3,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Key Inclusion Criteria:

* Males and females, 18 to 70 years of age
* Hepatitis C virus (HCV) gen...",Yes,2015-08-22,FDA-14329,2.62,0.32,5.0,7.94,2017-04-14,2017-08-09,2022-08-10,52,Pfizer,61,Senegal,48.0,64,21,1,44,88,70,36,1,3,0,False,True,True,False,True,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Isoniazid,Molecule Z,Drug,hiv,hiv,Phase 2,2020-12-01,"Sex: ALL; Age: >6 Weeks; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* HIV exposed infants
* Aged 6 weeks within (+ 4 weeks)
* Born to HIV-infected mothers
* Not premature and over 2.5 kg

Exclusion Criteria:

* Infants with known exposure to activ...",No,2021-08-18,FDA-16450,4.41,0.98,21.0,26.39,2025-04-29,2026-04-22,2047-04-22,57,Gilead,99,South Africa,79.83333333333333,84,84,73,69,72,97,55,0,4,2,False,False,False,True,True,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
MTZ 500 mg twice daily x 7 days,AltName A,Drug,hiv,hiv,Phase 3,2017-06-05,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* female
* English speaking
* \>= 18 years old

Exclusion Criteria:

* HIV-infected
* unable to provide informed consent
* pregnant
* breast feeding
* treated by their provider fo...",No,2018-03-20,FDA-76440,2.62,0.32,5.0,7.94,2020-01-17,2020-05-13,2025-05-14,99,Merck,0,Senegal,26.5,0,21,65,49,5,19,36,0,3,1,False,False,True,False,True,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
MTZ 2 g,Comp Beta,Drug,hiv,hiv,Phase 3,2017-06-05,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* female
* English speaking
* \>= 18 years old

Exclusion Criteria:

* HIV-infected
* unable to provide informed consent
* pregnant
* breast feeding
* treated by their provider fo...",No,2017-12-30,FDA-74010,2.62,0.32,5.0,7.94,2020-01-17,2020-05-13,2025-05-14,60,Bayer,29,Overall,32.0,0,6,88,43,42,13,55,2,3,1,True,True,True,True,False,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Canakinumab,AltName A,Drug,hiv,hiv,Phase 2,2021-12-01,"Sex: ALL; Age: >40 Years; Criteria: Inclusion Criteria:

1. HIV infection,
2. Age ≥ 40 years \< 60 years
3. On continuous ART for at least 12 months with no change in regimen in 12 weeks prior to study entry
4. CD4+ T cell count ≥ 400 c...",Yes,2022-02-11,FDA-35370,4.41,0.98,21.0,26.39,2026-04-29,2027-04-22,2048-04-21,37,Gilead,80,South Africa,60.83333333333334,78,77,21,55,78,56,64,1,3,3,False,True,False,True,True,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
VGX-3100,AltName B,Biological,hiv,hiv,Phase 2,2021-05-26,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Negative screening test for HIV-1/2 within 30 days of Dose 1;
* Confirmed anal or anal/peri-anal HPV-16/18 infection at Screening by polymerase chain reaction (PCR) from HSIL sp...",Yes,2021-07-04,FDA-56371,4.41,0.98,21.0,26.39,2025-10-22,2026-10-15,2047-10-15,45,Sanofi,28,South Africa,75.16666666666667,72,67,66,53,99,94,73,2,4,2,True,True,True,True,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
CELLECTRA™ 5PSP,Product Alpha,Device,hiv,hiv,Phase 2,2021-05-26,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Negative screening test for HIV-1/2 within 30 days of Dose 1;
* Confirmed anal or anal/peri-anal HPV-16/18 infection at Screening by polymerase chain reaction (PCR) from HSIL sp...",No,2022-01-04,FDA-75119,4.41,0.98,21.0,26.39,2025-10-22,2026-10-15,2047-10-15,71,GSK,63,Overall,58.16666666666666,61,68,82,38,26,74,55,2,3,1,True,True,True,False,False,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK Biologicals' HIV vaccine (732461),Comp Beta,Biological,hiv,hiv,Phase 2,2010-10-04,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* A male or female between, and including, 18 to 52 years of age at the time of vaccination.
* Written informed consent prior to any study related procedure on the subject.
* Subj...",Yes,2011-02-26,FDA-21871,4.41,0.98,21.0,26.39,2015-03-02,2016-02-23,2037-02-22,94,Pfizer,81,South Africa,53.33333333333334,5,43,100,11,76,85,36,1,2,1,True,False,True,False,False,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Chloroquine,GenName Y,Drug,hiv,hiv,Phase 2,2010-10-04,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* A male or female between, and including, 18 to 52 years of age at the time of vaccination.
* Written informed consent prior to any study related procedure on the subject.
* Subj...",Yes,2010-11-19,FDA-87185,4.41,0.98,21.0,26.39,2015-03-02,2016-02-23,2037-02-22,46,Novartis,70,South Africa,56.0,80,25,45,90,75,21,27,0,2,1,False,False,False,False,False,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Naltrexone,Comp Beta,Drug,hiv,hiv,Phase 3,2017-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Be HIV-infected.
2. Currently be prescribed HAART medication or be eligible to receive HAART medication.
3. Report less than 95% adherence to their HAART medication.
4. Report ...",No,2018-06-17,FDA-50798,2.62,0.32,5.0,7.94,2020-03-14,2020-07-09,2025-07-10,64,GSK,97,Kenya,69.33333333333333,93,32,78,65,74,74,36,0,1,3,False,False,True,False,False,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"UK-453,061",Product Alpha,Drug,hiv,hiv,Phase 2,2007-02-01,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Asymptomatic HIV-1 infected male and patients aged 18-55 years inclusive.
* Patients with virus not containing NNRTI resistant mutations as determined by the VircoGEN virtual ph...",No,2007-05-06,FDA-84230,4.41,0.98,21.0,26.39,2011-06-30,2012-06-22,2033-06-22,59,J&J,98,Kenya,52.83333333333334,56,84,60,16,47,54,27,1,1,1,False,True,False,False,False,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"UK-453,061",TradeName X,Drug,hiv,hiv,Phase 2,2007-02-01,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Asymptomatic HIV-1 infected male and patients aged 18-55 years inclusive.
* Patients with virus not containing NNRTI resistant mutations as determined by the VircoGEN virtual ph...",Yes,2007-08-13,FDA-20919,4.41,0.98,21.0,26.39,2011-06-30,2012-06-22,2033-06-22,10,Novartis,16,Overall,37.0,58,56,30,11,33,34,45,0,5,0,False,False,True,True,True,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Islatravir,Comp Beta,Drug,hiv,hiv,Phase 2,2022-03-09,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Has HIV-1 infection
* Is naïve to anti-retroviral therapy (ART).
* Is clinically stable, with no signs or symptoms of acute infection, at the time of entry into the study
* Fema...",No,2023-03-05,FDA-37378,4.41,0.98,21.0,26.39,2026-08-05,2027-07-29,2048-07-28,75,GSK,7,Kenya,38.5,7,21,75,45,54,29,73,1,4,3,False,True,True,True,True,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Doravirine,GenName Y,Drug,hiv,hiv,Phase 2,2022-03-09,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Has HIV-1 infection
* Is naïve to anti-retroviral therapy (ART).
* Is clinically stable, with no signs or symptoms of acute infection, at the time of entry into the study
* Fema...",Yes,2022-06-13,FDA-99045,4.41,0.98,21.0,26.39,2026-08-05,2027-07-29,2048-07-28,29,AstraZeneca,47,South Africa,42.83333333333334,65,41,46,50,2,53,55,2,3,1,True,True,True,False,True,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine,TradeName X,Drug,hiv,hiv,Phase 2,2022-03-09,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Has HIV-1 infection
* Is naïve to anti-retroviral therapy (ART).
* Is clinically stable, with no signs or symptoms of acute infection, at the time of entry into the study
* Fema...",No,2022-05-29,FDA-83352,4.41,0.98,21.0,26.39,2026-08-05,2027-07-29,2048-07-28,30,Novartis,7,Overall,68.83333333333333,71,58,100,77,79,28,64,1,4,2,True,False,True,True,True,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate,AltName A,Drug,hiv,hiv,Phase 2,2022-03-09,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Has HIV-1 infection
* Is naïve to anti-retroviral therapy (ART).
* Is clinically stable, with no signs or symptoms of acute infection, at the time of entry into the study
* Fema...",No,2022-08-05,FDA-43112,4.41,0.98,21.0,26.39,2026-08-05,2027-07-29,2048-07-28,2,Sanofi,52,Kenya,36.66666666666666,43,10,68,25,46,28,55,2,2,2,True,True,False,True,False,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Doravirine/Islatravir,AltName B,Drug,hiv,hiv,Phase 2,2022-03-09,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Has HIV-1 infection
* Is naïve to anti-retroviral therapy (ART).
* Is clinically stable, with no signs or symptoms of acute infection, at the time of entry into the study
* Fema...",Yes,2022-11-25,FDA-45772,4.41,0.98,21.0,26.39,2026-08-05,2027-07-29,2048-07-28,58,Novartis,49,South Africa,49.83333333333334,18,8,50,89,64,70,45,1,2,2,False,True,False,False,False,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
imiquimod,GenName Y,Drug,hiv,hiv,Phase 3,2024-03-31,"Sex: ALL; Age: >35 Years; Criteria: Inclusion Criteria:

* HIV positive. Documentation of HIV-1 infection by means of any one of the following: 1) Documentation of HIV diagnosis in the medical record by a licensed health care provider; ...",Yes,2024-12-20,FDA-64537,2.62,0.32,5.0,7.94,2026-11-12,2027-03-09,2032-03-09,92,Bayer,75,Senegal,62.66666666666666,59,26,76,54,93,68,64,1,4,2,False,True,True,False,True,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
fluorouracil,AltName B,Drug,hiv,hiv,Phase 3,2024-03-31,"Sex: ALL; Age: >35 Years; Criteria: Inclusion Criteria:

* HIV positive. Documentation of HIV-1 infection by means of any one of the following: 1) Documentation of HIV diagnosis in the medical record by a licensed health care provider; ...",Yes,2024-11-14,FDA-10044,2.62,0.32,5.0,7.94,2026-11-12,2027-03-09,2032-03-09,51,Gilead,40,Senegal,50.16666666666666,33,31,72,68,17,80,73,2,3,3,True,True,True,False,False,True,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
infrared photocoagulation therapy,Product Alpha,Device,hiv,hiv,Phase 3,2024-03-31,"Sex: ALL; Age: >35 Years; Criteria: Inclusion Criteria:

* HIV positive. Documentation of HIV-1 infection by means of any one of the following: 1) Documentation of HIV diagnosis in the medical record by a licensed health care provider; ...",No,2024-11-09,FDA-35894,2.62,0.32,5.0,7.94,2026-11-12,2027-03-09,2032-03-09,86,Pfizer,33,Overall,38.16666666666666,33,72,0,24,60,40,36,1,1,2,False,True,True,False,False,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
thermal ablation therapy,Molecule Z,Device,hiv,hiv,Phase 3,2024-03-31,"Sex: ALL; Age: >35 Years; Criteria: Inclusion Criteria:

* HIV positive. Documentation of HIV-1 infection by means of any one of the following: 1) Documentation of HIV diagnosis in the medical record by a licensed health care provider; ...",No,2024-11-23,FDA-13440,2.62,0.32,5.0,7.94,2026-11-12,2027-03-09,2032-03-09,65,Pfizer,60,Overall,57.66666666666666,27,87,88,75,54,15,27,0,1,2,False,False,False,False,False,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
laser therapy,Product Alpha,Device,hiv,hiv,Phase 3,2024-03-31,"Sex: ALL; Age: >35 Years; Criteria: Inclusion Criteria:

* HIV positive. Documentation of HIV-1 infection by means of any one of the following: 1) Documentation of HIV diagnosis in the medical record by a licensed health care provider; ...",No,2024-09-22,FDA-52037,2.62,0.32,5.0,7.94,2026-11-12,2027-03-09,2032-03-09,97,Pfizer,19,Senegal,43.66666666666666,13,1,80,51,82,35,55,1,3,2,False,True,False,True,False,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Intervention Arm: dolutegravir/lamivudine,Molecule Z,Drug,hiv,hiv,Phase 4,2024-05-07,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Subject has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board (IRB) / Independent Ethics Committee (IEC), after the nature of the...",Yes,2024-12-05,FDA-36216,0.56,0.15,3.5,4.21,2024-11-27,2025-01-21,2028-07-22,58,J&J,48,Senegal,46.33333333333334,17,26,77,5,80,73,27,0,2,1,False,False,False,True,False,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Comparator ARM: TDF/XTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine),Molecule Z,Drug,hiv,hiv,Phase 4,2024-05-07,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Subject has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board (IRB) / Independent Ethics Committee (IEC), after the nature of the...",No,2025-01-31,FDA-26450,0.56,0.15,3.5,4.21,2024-11-27,2025-01-21,2028-07-22,41,GSK,46,Overall,65.83333333333333,89,19,99,27,76,85,55,2,2,2,True,True,True,False,False,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
maraviroc,GenName Y,Drug,hiv,hiv,Phase 2,2013-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection, as documented by any licensed HIV test kit and confirmed by Western blot, HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method ...",Yes,2013-08-06,FDA-61542,4.41,0.98,21.0,26.39,2017-08-28,2018-08-21,2039-08-21,91,AstraZeneca,64,Senegal,47.33333333333334,66,21,73,55,59,10,55,1,2,3,True,False,True,False,False,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
darunavir,AltName A,Drug,hiv,hiv,Phase 2,2013-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection, as documented by any licensed HIV test kit and confirmed by Western blot, HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method ...",Yes,2013-12-08,FDA-61458,4.41,0.98,21.0,26.39,2017-08-28,2018-08-21,2039-08-21,55,J&J,96,Senegal,58.33333333333334,90,10,79,78,62,31,45,0,1,4,False,False,False,True,False,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ritonavir,AltName A,Drug,hiv,hiv,Phase 2,2013-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection, as documented by any licensed HIV test kit and confirmed by Western blot, HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method ...",Yes,2013-11-07,FDA-86154,4.41,0.98,21.0,26.39,2017-08-28,2018-08-21,2039-08-21,89,Bayer,6,Senegal,66.83333333333333,22,61,96,64,74,84,64,2,3,2,True,True,False,True,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Algeron,GenName Y,Drug,hiv,hiv,Phase 3,2015-08-26,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Signed Informed Consent Form.
* Chronic hepatitis C (genotypes 1а, 1b, 2, 3, 4) confirmed by positive result of hepatitis C virus ribonucleic acid during \> 6 months before scre...",No,2016-04-20,FDA-96847,2.62,0.32,5.0,7.94,2018-04-08,2018-08-03,2023-08-04,50,Merck,95,Senegal,33.0,93,26,40,5,29,5,64,1,5,1,False,True,True,True,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
PegIntron,AltName A,Drug,hiv,hiv,Phase 3,2015-08-26,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Signed Informed Consent Form.
* Chronic hepatitis C (genotypes 1а, 1b, 2, 3, 4) confirmed by positive result of hepatitis C virus ribonucleic acid during \> 6 months before scre...",No,2016-04-30,FDA-22509,2.62,0.32,5.0,7.94,2018-04-08,2018-08-03,2023-08-04,41,Novartis,17,Overall,39.0,49,5,3,78,44,55,73,1,5,2,False,True,True,True,True,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Azithromycin/TMPS,Comp Beta,Drug,hiv,hiv,Phase 2,2022-01-01,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

* Confirmed HIV-infection (documented in medical record)
* Age ≥16 years
* Confirmed pregnancy, \<28 weeks estimated gestational age (by best obstetric estimate which may include ...",No,2022-11-16,FDA-53034,4.41,0.98,21.0,26.39,2026-05-30,2027-05-23,2048-05-22,1,Pfizer,91,Senegal,27.66666666666667,19,2,21,9,46,69,73,1,4,3,False,True,True,True,True,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate,GenName Y,Drug,hiv,hiv,Phase 4,2018-05-23,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

All subjects:

* HIV antibody seronegative (negative HIV rapid test),
* 18 years or older,
* Has a smart phone with access to two-way video call capability,
* Willingness to be co...",No,2018-11-13,FDA-25320,0.56,0.15,3.5,4.21,2018-12-13,2019-02-06,2022-08-07,88,Pfizer,57,Kenya,38.66666666666666,53,13,32,35,62,37,64,1,5,1,False,True,True,True,True,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
MSL-109,GenName Y,Drug,hiv,hiv,Phase 3,1996-08-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion criteria:

* 13 years or older at entry
* Diagnosis of AIDS according to the Centers for Disease Control and Prevention (CDC) definition
* Diagnosis of active CMV retinitis as determined by ...",Yes,1997-06-14,FDA-61888,2.62,0.32,5.0,7.94,1999-03-15,1999-07-10,2004-07-10,84,Merck,11,Senegal,38.66666666666666,47,0,0,43,43,99,55,0,3,3,False,False,True,False,False,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ganciclovir implant and oral ganciclovir,AltName A,Device,hiv,hiv,Phase 3,2000-06-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion criteria:

* Age 13 years or older
* Diagnosis of AIDS according to current Centers for Disease Control and Prevention (CDC) definition
* Diagnosis of active CMV retinitis by a SOCA-certifie...",Yes,2001-01-12,FDA-41304,2.62,0.32,5.0,7.94,2003-01-13,2003-05-10,2008-05-10,95,Gilead,50,South Africa,58.66666666666666,76,89,19,68,47,53,45,1,2,2,False,True,False,True,False,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Cidofovir intravenous,AltName A,Drug,hiv,hiv,Phase 3,2000-06-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion criteria:

* Age 13 years or older
* Diagnosis of AIDS according to current Centers for Disease Control and Prevention (CDC) definition
* Diagnosis of active CMV retinitis by a SOCA-certifie...",Yes,2001-03-17,FDA-22751,2.62,0.32,5.0,7.94,2003-01-13,2003-05-10,2008-05-10,69,AstraZeneca,9,Kenya,52.0,72,41,0,36,80,83,64,2,2,3,True,True,False,True,False,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Foscarnet,Comp Beta,Drug,hiv,hiv,Phase 3,1991-10-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion criteria:

* CMV retinitis in one or both eyes
* At least 1/4 disk are of one CMV lesion photographable
* Diagnosis of AIDS as defined by Center for Disease Control criteria or documented HI...",Yes,1991-12-08,FDA-65070,2.62,0.32,5.0,7.94,1994-05-14,1994-09-08,1999-09-09,93,Merck,90,Kenya,44.33333333333334,96,74,16,11,31,38,91,2,5,3,True,True,True,True,True,True,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ganciclovir,Molecule Z,Drug,hiv,hiv,Phase 3,1991-10-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion criteria:

* CMV retinitis in one or both eyes
* At least 1/4 disk are of one CMV lesion photographable
* Diagnosis of AIDS as defined by Center for Disease Control criteria or documented HI...",No,1992-04-06,FDA-92353,2.62,0.32,5.0,7.94,1994-05-14,1994-09-08,1999-09-09,53,J&J,34,Senegal,84.16666666666667,100,83,83,99,89,51,55,1,2,3,False,True,False,False,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Grazoprevir/Elbasvir,AltName B,Drug,hiv,hiv,Phase 2,2019-09-16,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Adult ≥18 years.
2. A recent acute HCV infection \[defined by (i) detectable HCV RNA within 6 months after a negative HCV RNA or HCV serology test OR (ii) detectable HCV RNA an...",Yes,2019-11-06,FDA-52516,4.41,0.98,21.0,26.39,2024-02-12,2025-02-04,2046-02-04,81,J&J,42,South Africa,48.66666666666666,75,65,8,27,43,74,45,2,2,1,True,True,True,False,False,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Doravirine,Comp Beta,Drug,hiv,hiv,Phase 4,2021-06-14,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Males and females\* aging ≥ 18 years.
2. Documented HIV infection).
3. Stable antiretroviral treatment for at least 2 weeks prior to enrolment.
4. Optimal adherence to antiretr...",No,2022-06-09,FDA-40320,0.56,0.15,3.5,4.21,2022-01-04,2022-02-28,2025-08-29,5,GSK,46,South Africa,46.0,19,41,30,67,99,20,55,1,3,2,False,True,False,False,True,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
9-valent HPV vaccine,Molecule Z,Biological,hiv,hiv,Phase 3,2020-07-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Independent Ethics Committee (IEC)-approved written informed consent form (ICF) must be obtained from the subject prior to any study-related procedures (including discontinuati...",No,2020-09-20,FDA-77959,2.62,0.32,5.0,7.94,2023-02-26,2023-06-23,2028-06-23,69,Bayer,42,Kenya,53.66666666666666,61,27,34,36,89,75,64,1,4,2,True,False,False,True,True,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Salsalate,GenName Y,Drug,hiv,hiv,Phase 2,2009-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. 18 years of age or older
2. HIV-infected
3. Evidence of durable virologic suppression, i.e., must have HIV-1 RNA \< 400 copies/ml at study entry and for at least 12 weeks prior...",Yes,2010-03-03,FDA-32984,4.41,0.98,21.0,26.39,2013-11-27,2014-11-20,2035-11-20,40,Sanofi,35,Senegal,40.66666666666666,27,51,34,73,34,25,36,1,2,1,True,False,False,False,False,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Doravirine,TradeName X,Drug,hiv,hiv,Phase 3,2023-03-06,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Is HIV-1 positive and has HIV treatment indicated based on physician assessment.
* Has received no (0 days of) antiretroviral therapy (ART), including investigational antiretrov...",No,2023-06-10,FDA-97809,2.62,0.32,5.0,7.94,2025-10-17,2026-02-11,2031-02-12,23,GSK,12,South Africa,38.5,88,23,8,67,31,14,45,0,3,2,False,False,True,True,False,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Darunavir,Product Alpha,Drug,hiv,hiv,Phase 3,2023-03-06,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Is HIV-1 positive and has HIV treatment indicated based on physician assessment.
* Has received no (0 days of) antiretroviral therapy (ART), including investigational antiretrov...",Yes,2023-05-30,FDA-12077,2.62,0.32,5.0,7.94,2025-10-17,2026-02-11,2031-02-12,74,GSK,66,Senegal,73.83333333333333,97,4,97,90,73,82,45,2,2,1,True,True,False,True,False,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,Molecule Z,Drug,hiv,hiv,Phase 3,2023-03-06,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Is HIV-1 positive and has HIV treatment indicated based on physician assessment.
* Has received no (0 days of) antiretroviral therapy (ART), including investigational antiretrov...",No,2023-10-19,FDA-31658,2.62,0.32,5.0,7.94,2025-10-17,2026-02-11,2031-02-12,14,AstraZeneca,99,South Africa,45.33333333333334,8,54,88,34,74,14,45,0,3,2,False,False,True,True,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
TRUVADA™ or EPZICOM™/KIVEXA™,Molecule Z,Drug,hiv,hiv,Phase 3,2023-03-06,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Is HIV-1 positive and has HIV treatment indicated based on physician assessment.
* Has received no (0 days of) antiretroviral therapy (ART), including investigational antiretrov...",Yes,2023-10-21,FDA-22789,2.62,0.32,5.0,7.94,2025-10-17,2026-02-11,2031-02-12,51,Pfizer,77,South Africa,60.66666666666666,42,80,97,40,31,74,36,1,2,1,True,False,True,False,False,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy,Molecule Z,Drug,hiv,hiv,Phase 3,2018-12-04,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Pregnancy confirmed by positive urine pregnancy test or intrauterine pregnancy by ultrasound
* Estimated gestational age between 12-20 weeks
* Confirmed to be HIV uninfected by ...",Yes,2019-05-01,FDA-15076,2.62,0.32,5.0,7.94,2021-07-17,2021-11-11,2026-11-12,55,AstraZeneca,6,Senegal,56.33333333333334,90,71,62,5,72,38,45,2,2,1,True,True,True,False,True,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy,TradeName X,Drug,hiv,hiv,Phase 3,2018-12-04,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Pregnancy confirmed by positive urine pregnancy test or intrauterine pregnancy by ultrasound
* Estimated gestational age between 12-20 weeks
* Confirmed to be HIV uninfected by ...",No,2019-03-06,FDA-75941,2.62,0.32,5.0,7.94,2021-07-17,2021-11-11,2026-11-12,41,Merck,79,Kenya,49.0,11,34,5,98,69,77,45,2,2,1,True,True,False,True,False,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Digital pill,AltName A,Device,hiv,hiv,Phase 3,2024-04-10,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Cisgender MSM
* Moderate to severe non-alcohol substance use disorder
* Self-reported missed PrEP doses (\> or equal to 2 doses in 1 week over past 3 months)
* HIV negative
* On...",Yes,2024-07-05,FDA-90509,2.62,0.32,5.0,7.94,2026-11-22,2027-03-19,2032-03-19,41,Merck,57,South Africa,42.33333333333334,25,54,47,53,71,4,64,2,3,2,True,True,False,True,True,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada,TradeName X,Drug,hiv,hiv,Phase 3,2024-04-10,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Cisgender MSM
* Moderate to severe non-alcohol substance use disorder
* Self-reported missed PrEP doses (\> or equal to 2 doses in 1 week over past 3 months)
* HIV negative
* On...",Yes,2025-01-20,FDA-19751,2.62,0.32,5.0,7.94,2026-11-22,2027-03-19,2032-03-19,2,Pfizer,50,Senegal,46.16666666666666,59,87,30,27,48,26,55,0,3,3,False,False,True,True,False,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Peg-Interferon Alpha-2A,TradeName X,Drug,hiv,hiv,Phase 4,2008-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Serological evidence of chronic hepatitis C infection by anti-hepatitis C virus (HCV) test
* Detectable HCV-ribonucleic acid (RNA) plasma level testing by Roche AMPLICOR HCV (\<...",Yes,2008-09-28,FDA-30602,0.56,0.15,3.5,4.21,2008-11-21,2009-01-15,2012-07-16,94,Novartis,35,South Africa,34.16666666666666,57,35,42,55,7,9,64,1,3,3,False,True,True,False,False,True,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Ribavirin,TradeName X,Drug,hiv,hiv,Phase 4,2008-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Serological evidence of chronic hepatitis C infection by anti-hepatitis C virus (HCV) test
* Detectable HCV-ribonucleic acid (RNA) plasma level testing by Roche AMPLICOR HCV (\<...",No,2008-12-23,FDA-26742,0.56,0.15,3.5,4.21,2008-11-21,2009-01-15,2012-07-16,86,Novartis,3,South Africa,61.33333333333334,46,71,87,6,86,72,55,1,3,2,True,False,False,False,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,TradeName X,Drug,hiv,hiv,Phase 2,2015-04-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infected, as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry. HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a...",Yes,2015-12-13,FDA-40030,4.41,0.98,21.0,26.39,2019-09-26,2020-09-18,2041-09-18,73,Novartis,40,Senegal,56.83333333333334,43,54,69,43,67,65,36,0,1,3,False,False,False,True,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Semaglutide,TradeName X,Drug,hiv,hiv,Phase 2,2023-09-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a li...",No,2024-01-28,FDA-63531,4.41,0.98,21.0,26.39,2028-02-11,2029-02-03,2050-02-03,84,Pfizer,62,Kenya,48.66666666666666,14,95,70,28,25,60,91,2,4,4,True,True,True,True,True,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Modafinil,Molecule Z,Drug,hiv,hiv,Phase 2,2013-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. 18 - 60 years;
2. Current DSM-IV diagnosis of cocaine dependence;
3. Using cocaine at least 8 days in a consecutive 30 day period over the 60 day period immediately preceding s...",No,2013-05-03,FDA-24678,4.41,0.98,21.0,26.39,2017-05-30,2018-05-23,2039-05-23,67,J&J,98,Senegal,58.33333333333334,95,11,64,91,63,26,36,2,1,1,True,True,False,True,False,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Doravirine/lamivudine/tenofovir disoproxil fumarate,AltName A,Drug,hiv,hiv,Phase 2,2020-10-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Is HIV-1 positive within 45 days prior to the treatment phase of this study, and have HIV treatment indicated based on physician assessment.
* Is naïve to antiretroviral therapy...",No,2020-12-24,FDA-59479,4.41,0.98,21.0,26.39,2025-03-26,2026-03-19,2047-03-19,57,Sanofi,87,Kenya,62.33333333333334,75,12,94,50,48,95,82,2,4,3,True,True,False,True,True,True,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Sertraline,Molecule Z,Drug,hiv,hiv,Phase 3,2017-09-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Cryptococcal meningitis diagnosed by CSF cryptococcal antigen (CRAG)
* HIV-1 infection
* Ability and willingness of the participant or legal guardian/representative to provide i...",No,2018-02-23,FDA-10625,2.62,0.32,5.0,7.94,2020-05-10,2020-09-04,2025-09-05,63,GSK,18,South Africa,37.5,66,18,80,2,30,29,45,0,3,2,False,False,True,True,False,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Isoniazid 300 Mg ORAL TABLET,AltName B,Drug,hiv,hiv,Phase 4,2021-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Age \> 18 years old
2. Patient of the MRRH ISS Clinic
3. HIV-infected
4. Consume alcohol (self-reported consumption in the prior 3 months) (2/3) OR prior year non-drinker (1/3)...",Yes,2022-03-10,FDA-94084,0.56,0.15,3.5,4.21,2021-10-22,2021-12-16,2025-06-16,27,Bayer,49,Overall,47.33333333333334,81,29,68,0,68,38,73,1,3,4,False,True,True,True,False,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Pyridoxine 25 Mg Oral Tablet,AltName A,Drug,hiv,hiv,Phase 4,2021-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Age \> 18 years old
2. Patient of the MRRH ISS Clinic
3. HIV-infected
4. Consume alcohol (self-reported consumption in the prior 3 months) (2/3) OR prior year non-drinker (1/3)...",Yes,2022-01-22,FDA-94630,0.56,0.15,3.5,4.21,2021-10-22,2021-12-16,2025-06-16,11,Merck,14,Senegal,42.83333333333334,87,4,75,18,2,71,55,1,2,3,False,True,False,True,False,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
B/F/TAF,Molecule Z,Drug,hiv,hiv,Phase 4,2023-05-05,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Age 18 years or older at enrollment.
2. Documented HIV-1 infection and currently on a stable regimen for at least 3 months if on an INSTI-based regimen (6 months if on a non-IN...",Yes,2023-12-16,FDA-91698,0.56,0.15,3.5,4.21,2023-11-25,2024-01-19,2027-07-20,54,Pfizer,39,Overall,40.66666666666666,12,50,25,14,94,49,18,0,0,2,False,False,False,False,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Pregabalin,Comp Beta,Drug,hiv,hiv,Phase 4,2008-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients who are diagnosed with neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, human immunodeficiency virus related peripheral neuropa...",No,2009-01-13,FDA-99206,0.56,0.15,3.5,4.21,2009-01-21,2009-03-17,2012-09-15,90,Merck,7,Overall,29.33333333333333,19,53,46,19,18,21,64,1,2,4,False,True,True,True,False,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Brentuximab Vedotin,Comp Beta,Drug,hiv,hiv,Phase 2,2024-03-21,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV positive; documentation of HIV-1 infection by means of any one of the following:

  * Documentation of HIV diagnosis in the medical record by a licensed health care provider...",No,2024-12-04,FDA-50309,4.41,0.98,21.0,26.39,2028-08-17,2029-08-10,2050-08-10,14,AstraZeneca,61,Kenya,44.16666666666666,95,26,45,76,7,16,45,0,1,4,False,False,False,True,False,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Dacarbazine,AltName B,Drug,hiv,hiv,Phase 2,2024-03-21,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV positive; documentation of HIV-1 infection by means of any one of the following:

  * Documentation of HIV diagnosis in the medical record by a licensed health care provider...",No,2024-05-24,FDA-10980,4.41,0.98,21.0,26.39,2028-08-17,2029-08-10,2050-08-10,24,Bayer,34,Senegal,37.33333333333334,92,39,34,42,7,10,55,2,1,3,True,True,True,False,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Doxorubicin Hydrochloride,Comp Beta,Drug,hiv,hiv,Phase 2,2024-03-21,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV positive; documentation of HIV-1 infection by means of any one of the following:

  * Documentation of HIV diagnosis in the medical record by a licensed health care provider...",Yes,2024-10-28,FDA-27128,4.41,0.98,21.0,26.39,2028-08-17,2029-08-10,2050-08-10,17,GSK,59,Overall,36.16666666666666,25,3,23,54,52,60,45,1,1,3,False,True,False,False,False,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Vinblastine,Molecule Z,Drug,hiv,hiv,Phase 2,2024-03-21,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV positive; documentation of HIV-1 infection by means of any one of the following:

  * Documentation of HIV diagnosis in the medical record by a licensed health care provider...",No,2024-08-28,FDA-19624,4.41,0.98,21.0,26.39,2028-08-17,2029-08-10,2050-08-10,28,AstraZeneca,79,Overall,50.0,43,66,10,61,27,93,45,0,3,2,False,False,True,True,True,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler",Molecule Z,Drug,hiv,hiv,Phase 4,2025-10-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV positive;
* \>= 18 years old
* Receiving HIV care at Yale-New Haven Hospital, Bridgeport Hospital, Mount Sinai Hospital, or SUNY Downstate STAR clinic;
* Have smoked \>= 100...",Yes,2026-08-04,FDA-26501,0.56,0.15,3.5,4.21,2026-05-16,2026-07-10,2030-01-08,96,Gilead,21,Senegal,62.5,97,56,75,14,87,46,36,1,1,2,False,True,False,False,False,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Varenicline or bupropion,Molecule Z,Drug,hiv,hiv,Phase 4,2025-10-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV positive;
* \>= 18 years old
* Receiving HIV care at Yale-New Haven Hospital, Bridgeport Hospital, Mount Sinai Hospital, or SUNY Downstate STAR clinic;
* Have smoked \>= 100...",Yes,2026-09-25,FDA-38641,0.56,0.15,3.5,4.21,2026-05-16,2026-07-10,2030-01-08,57,AstraZeneca,77,Kenya,37.5,14,53,14,48,21,75,36,0,1,3,False,False,False,False,True,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DOR/ISL,AltName B,Drug,hiv,hiv,Phase 2,2023-01-25,"Sex: ALL; Criteria: Inclusion Criteria:

* Is HIV-1 positive, is \<18 years of age, and weighs ≥35 kg at screening.
* VS Participants: Is HIV-1 positive at Screening with plasma HIV-1 RNA \<50 copies/mL and has been rece...",Yes,2024-01-08,FDA-78666,4.41,0.98,21.0,26.39,2027-06-23,2028-06-15,2049-06-15,51,Sanofi,55,Overall,50.33333333333334,92,82,17,49,51,11,36,0,3,1,False,False,False,True,True,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Stribild,AltName B,Drug,hiv,hiv,Phase 4,2016-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV+ subjects 18 years of age or older
* estimated Glomerular Filtration Rate \> 70 mL/min
* must currently be on Atripla and taking it for at least 3 months with a HIV-1 Viral ...",Yes,2016-02-02,FDA-96702,0.56,0.15,3.5,4.21,2016-07-23,2016-09-16,2020-03-17,53,Bayer,25,Senegal,55.0,87,92,6,22,25,98,27,1,1,1,False,True,False,True,False,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Telaprevir,GenName Y,Drug,hiv,hiv,Phase 3,2014-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants must have chronic, genotype 1a or 1b, hepatitis C with HCV RNA greater than (\>) 1000 international units per milliliter (IU/mL)
* Population A: HCV Pegylated inter...",No,2014-06-07,FDA-71869,2.62,0.32,5.0,7.94,2016-09-14,2017-01-09,2022-01-10,24,GSK,82,South Africa,29.16666666666667,2,41,8,11,25,88,27,1,2,0,False,True,True,False,True,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ribavirin,Comp Beta,Drug,hiv,hiv,Phase 3,2014-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants must have chronic, genotype 1a or 1b, hepatitis C with HCV RNA greater than (\>) 1000 international units per milliliter (IU/mL)
* Population A: HCV Pegylated inter...",No,2014-05-19,FDA-46364,2.62,0.32,5.0,7.94,2016-09-14,2017-01-09,2022-01-10,80,Novartis,28,South Africa,56.5,21,41,91,78,95,13,64,1,4,2,True,False,True,False,True,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Pegylated Interferon Alfa-2a,Product Alpha,Biological,hiv,hiv,Phase 3,2014-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants must have chronic, genotype 1a or 1b, hepatitis C with HCV RNA greater than (\>) 1000 international units per milliliter (IU/mL)
* Population A: HCV Pegylated inter...",No,2014-07-23,FDA-39724,2.62,0.32,5.0,7.94,2016-09-14,2017-01-09,2022-01-10,98,Gilead,44,South Africa,71.33333333333333,33,92,71,95,79,58,55,0,2,4,False,False,False,True,False,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Highly Active Antiretroviral Therapy (HAART),GenName Y,Drug,hiv,hiv,Phase 3,2014-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants must have chronic, genotype 1a or 1b, hepatitis C with HCV RNA greater than (\>) 1000 international units per milliliter (IU/mL)
* Population A: HCV Pegylated inter...",Yes,2015-01-18,FDA-42904,2.62,0.32,5.0,7.94,2016-09-14,2017-01-09,2022-01-10,86,J&J,69,Senegal,39.33333333333334,18,18,52,46,45,57,64,2,3,2,True,True,False,False,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
TMC435,AltName B,Drug,hiv,hiv,Phase 3,2013-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* A liver biopsy required within 3 years prior to screening unless the patient has a contraindication for a liver biopsy
* Patients with bridging fibrosis or cirrhosis and without...",Yes,2014-06-16,FDA-54732,2.62,0.32,5.0,7.94,2016-03-14,2016-07-09,2021-07-10,42,J&J,45,Senegal,37.33333333333334,7,31,38,51,74,23,36,1,0,3,True,False,False,False,False,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Pegylated interferon alpha-2a,Comp Beta,Drug,hiv,hiv,Phase 3,2013-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* A liver biopsy required within 3 years prior to screening unless the patient has a contraindication for a liver biopsy
* Patients with bridging fibrosis or cirrhosis and without...",Yes,2014-05-12,FDA-80708,2.62,0.32,5.0,7.94,2016-03-14,2016-07-09,2021-07-10,49,Novartis,81,South Africa,60.83333333333334,87,95,12,72,99,0,36,2,1,1,True,True,True,False,False,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ribavirin,Product Alpha,Drug,hiv,hiv,Phase 3,2013-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* A liver biopsy required within 3 years prior to screening unless the patient has a contraindication for a liver biopsy
* Patients with bridging fibrosis or cirrhosis and without...",No,2014-04-22,FDA-40782,2.62,0.32,5.0,7.94,2016-03-14,2016-07-09,2021-07-10,4,Gilead,19,Kenya,39.5,22,38,79,74,22,2,36,1,3,0,True,False,False,True,True,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Pegylated Interferon alpha 2b,AltName B,Drug,hiv,hiv,Phase 2,2016-05-02,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* 18-65 years of age
* Body weight between 125 and 299 lbs
* Confirmed diagnosis of HIV-1 infection by western blot or by a documented HIV-1 viral load
* Currently receiving ART a...",No,2017-04-02,FDA-70462,4.41,0.98,21.0,26.39,2020-09-28,2021-09-21,2042-09-21,60,Pfizer,58,Overall,62.33333333333334,32,100,96,27,90,29,45,0,3,2,False,False,True,False,False,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ad26.Mos4.HIV,GenName Y,Biological,hiv,hiv,Phase 2,2023-11-22,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Participant must be healthy on the basis of medical history, physical examination, and vital signs measurement performed at screening
* Participants are negative for human immun...",No,2024-01-06,FDA-83475,4.41,0.98,21.0,26.39,2028-04-19,2029-04-12,2050-04-12,8,AstraZeneca,94,Kenya,65.16666666666667,64,81,36,87,79,44,55,1,3,2,True,False,True,True,False,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Clade C gp140 plus adjuvant,Molecule Z,Biological,hiv,hiv,Phase 2,2023-11-22,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Participant must be healthy on the basis of medical history, physical examination, and vital signs measurement performed at screening
* Participants are negative for human immun...",Yes,2024-02-17,FDA-63052,4.41,0.98,21.0,26.39,2028-04-19,2029-04-12,2050-04-12,98,Sanofi,97,Senegal,60.33333333333334,49,90,84,57,38,44,36,0,2,2,False,False,True,False,False,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Clade C gp140/Mosaic gp140 plus adjuvant,Molecule Z,Biological,hiv,hiv,Phase 2,2023-11-22,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Participant must be healthy on the basis of medical history, physical examination, and vital signs measurement performed at screening
* Participants are negative for human immun...",No,2024-10-14,FDA-59967,4.41,0.98,21.0,26.39,2028-04-19,2029-04-12,2050-04-12,38,GSK,68,South Africa,43.83333333333334,8,52,22,58,55,68,64,2,3,2,True,True,True,True,True,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
gp140 HIV Bivalent Vaccine,Comp Beta,Biological,hiv,hiv,Phase 2,2023-11-22,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Participant must be healthy on the basis of medical history, physical examination, and vital signs measurement performed at screening
* Participants are negative for human immun...",Yes,2024-10-04,FDA-55732,4.41,0.98,21.0,26.39,2028-04-19,2029-04-12,2050-04-12,95,Merck,78,Kenya,57.0,43,60,28,56,93,62,45,1,3,1,True,False,True,True,False,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Benzathine penicillin G intramuscular 7.2 million units,TradeName X,Drug,hiv,hiv,Phase 4,2012-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Diagnosed with HIV by ELISA and confirmed by Western blot
* Positive Rapid Plasma Reagin and treponema pallidum particle agglutination tests

Exclusion Criteria:

* History of p...",No,2013-02-27,FDA-88721,0.56,0.15,3.5,4.21,2012-10-22,2012-12-16,2016-06-16,99,Pfizer,79,South Africa,19.16666666666667,35,22,3,22,0,33,36,1,2,1,True,False,False,True,False,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Benzathine penicillin G intramuscular 2.4 million units,Comp Beta,Drug,hiv,hiv,Phase 4,2012-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Diagnosed with HIV by ELISA and confirmed by Western blot
* Positive Rapid Plasma Reagin and treponema pallidum particle agglutination tests

Exclusion Criteria:

* History of p...",No,2012-05-04,FDA-61458,0.56,0.15,3.5,4.21,2012-10-22,2012-12-16,2016-06-16,20,Merck,13,South Africa,44.83333333333334,27,51,16,73,70,32,55,1,2,3,True,False,False,True,True,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Buprenorphine,AltName A,Drug,hiv,hiv,Phase 2,2024-03-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. age ≥ 18 years
2. opioid use disorder
3. interest in buprenorphine treatment
4. motivation for opioid use disorder treatment
5. willingness to accept community health center re...",Yes,2024-07-11,FDA-68884,4.41,0.98,21.0,26.39,2028-08-27,2029-08-20,2050-08-20,0,Novartis,8,South Africa,42.16666666666666,21,38,9,66,57,62,36,0,2,2,False,False,False,True,False,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Extended Release Naltrexone,AltName B,Drug,hiv,hiv,Phase 3,2015-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Meet Diagnostic and Statistical Manual (DSM-5) criteria for moderate or severe opioid use disorder and/or alcohol use disorder.
2. Be willing to be randomized to antagonist-bas...",Yes,2015-09-06,FDA-11791,2.62,0.32,5.0,7.94,2017-10-12,2018-02-06,2023-02-07,40,AstraZeneca,28,Senegal,41.0,45,13,68,34,72,14,55,2,1,3,True,True,False,False,False,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Dolutegravir 50 mg,AltName B,Drug,hiv,hiv,Phase 3,2021-09-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients with confirmed HIV-1 infection (positive Western blot or plasma HIV-1 RNA \>1,000 copies/ml)
* No previous use of any ARV drug (drug-naïve patients)
* Presence of clini...",Yes,2022-09-19,FDA-63884,2.62,0.32,5.0,7.94,2024-05-13,2024-09-07,2029-09-08,67,Gilead,97,Kenya,57.0,83,97,36,46,66,14,64,1,4,2,True,False,True,True,False,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz-based regimens,Molecule Z,Drug,hiv,hiv,Phase 3,2021-09-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients with confirmed HIV-1 infection (positive Western blot or plasma HIV-1 RNA \>1,000 copies/ml)
* No previous use of any ARV drug (drug-naïve patients)
* Presence of clini...",No,2022-01-02,FDA-88790,2.62,0.32,5.0,7.94,2024-05-13,2024-09-07,2029-09-08,21,Sanofi,95,Overall,67.33333333333333,58,97,94,75,40,40,55,2,3,1,True,True,False,False,True,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Sertraline,Product Alpha,Drug,hiv,hiv,Phase 4,2020-10-30,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion criteria:

* 18 years of age or older
* Documentation of confirmed HIV-1 infection
* Six to eight weeks postpartum
* Currently taking ART treatment
* Able and willing to provide written info...",No,2021-03-28,FDA-95237,0.56,0.15,3.5,4.21,2021-05-22,2021-07-16,2025-01-14,68,Bayer,37,Kenya,62.83333333333334,81,5,68,81,42,100,55,1,3,2,True,False,True,True,False,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Pitavastatin,Comp Beta,Drug,hiv,hiv,Phase 3,2023-08-21,"Sex: ALL; Age: >40 Years; Criteria: Inclusion Criteria:

* Ambulatory participants enrolled in both REPRIEVE (A5332) and its Mechanistic Substudy (A5333s) or ambulatory participants who are newly enrolling into REPRIEVE (A5332) at A5333...",Yes,2024-05-22,FDA-24056,2.62,0.32,5.0,7.94,2026-04-03,2026-07-29,2031-07-30,25,Pfizer,80,Overall,45.5,56,54,54,79,5,25,55,1,3,2,True,False,True,True,False,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Recombivax,Molecule Z,Biological,hiv,hiv,Phase 2,2008-07-01,"Sex: ALL; Age: >12 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* HIV negative youth age 12-17 years (No serologic evidence of HIV infection).
* Negative hepatitis B serology. (No serologic evidence of hepatitis B surface antigen (HBSAg), hepa...",No,2009-01-06,FDA-50291,4.41,0.98,21.0,26.39,2012-11-27,2013-11-20,2034-11-20,45,Gilead,88,Overall,58.33333333333334,69,69,69,96,46,1,36,0,2,2,False,False,False,False,False,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Twinrix,Comp Beta,Biological,hiv,hiv,Phase 2,2008-07-01,"Sex: ALL; Age: >12 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* HIV negative youth age 12-17 years (No serologic evidence of HIV infection).
* Negative hepatitis B serology. (No serologic evidence of hepatitis B surface antigen (HBSAg), hepa...",Yes,2008-11-08,FDA-82341,4.41,0.98,21.0,26.39,2012-11-27,2013-11-20,2034-11-20,4,Merck,50,Senegal,51.33333333333334,83,32,63,2,76,52,73,1,4,3,False,True,True,True,False,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
DOR/ISL,TradeName X,Drug,hiv,hiv,Phase 3,2028-08-04,"Sex: ALL; Age: >18 Years; Criteria: The key inclusion and exclusion criteria include but are not limited to the following:

Inclusion Criteria:

* Is HIV-1 positive with plasma HIV-1 RNA \<50 copies/mL
* Has been receiving BIC/FTC/TAF t...",No,2028-09-22,FDA-93618,2.62,0.32,5.0,7.94,2031-03-18,2031-07-13,2036-07-13,65,Bayer,95,Senegal,79.5,66,93,85,64,84,85,82,1,5,3,False,True,True,True,True,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
BIC/FTC/TAF,AltName A,Drug,hiv,hiv,Phase 3,2028-08-04,"Sex: ALL; Age: >18 Years; Criteria: The key inclusion and exclusion criteria include but are not limited to the following:

Inclusion Criteria:

* Is HIV-1 positive with plasma HIV-1 RNA \<50 copies/mL
* Has been receiving BIC/FTC/TAF t...",Yes,2029-03-22,FDA-74857,2.62,0.32,5.0,7.94,2031-03-18,2031-07-13,2036-07-13,22,Novartis,16,Senegal,53.0,71,49,40,31,35,92,36,0,1,3,False,False,False,False,True,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
IMVAMUNE®,Comp Beta,Biological,hiv,hiv,Phase 2,2017-05-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Male and female subjects aged between 18-45 years, vaccinia-naïve.
2. HIV-1 infection documented by ELISA and confirmed by Western blot at any time prior to study entry. HIV-1 ...",Yes,2017-07-31,FDA-29619,4.41,0.98,21.0,26.39,2021-10-06,2022-09-29,2043-09-29,37,Merck,17,Overall,69.83333333333333,41,75,47,97,72,87,55,1,2,3,True,False,False,True,False,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Cidofovir,Product Alpha,Drug,hiv,hiv,Phase 3,1996-02-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion criteria:

* diagnosis of AIDS according to the Centers for Disease Control and Prevention (CDC)
* 13 years or older
* Diagnosis of CMV (cytomegalovirus) retinitis as determined by a SOCA-ce...",Yes,1996-03-17,FDA-99428,2.62,0.32,5.0,7.94,1998-09-14,1999-01-09,2004-01-10,77,J&J,46,Senegal,51.66666666666666,25,20,95,61,79,30,55,2,3,1,True,True,True,False,False,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Vaginal Progesterone,Product Alpha,Drug,hiv,hiv,Phase 4,2018-11-13,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

1. 18 years of age or older
2. viable intrauterine pregnancy confirmed by ultrasound
3. presentation to antenatal care prior to 24 weeks gestation
4. antibody-confirmed HIV-1 infe...",No,2019-01-18,FDA-48782,0.56,0.15,3.5,4.21,2019-06-05,2019-07-30,2023-01-28,19,AstraZeneca,29,South Africa,48.83333333333334,27,60,36,75,78,17,45,1,3,1,True,False,True,False,True,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Glecaprevir/Pibrentasvir,TradeName X,Drug,hiv,hiv,Phase 3,2019-02-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Must be of Asian descent
* Screening laboratory result indicating hepatitis C virus (HCV) genotype (GT) 1, 2, 3, 4, 5 or 6 infection.
* Positive anti-HCV antibody (Ab) and HCV r...",Yes,2019-12-07,FDA-85151,2.62,0.32,5.0,7.94,2021-09-28,2022-01-23,2027-01-24,39,AstraZeneca,41,South Africa,56.33333333333334,59,69,90,69,26,25,45,1,2,2,False,True,False,True,False,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,Molecule Z,Drug,hiv,hiv,Phase 4,2018-06-04,"Sex: ALL; Age: >60 Years; Criteria: Inclusion Criteria:

* Patient having a diagnosis of HIV-1 infection.
* Age 45 years old.
* Current highly active antiretroviral therapy including Truvada or Kivexa plus a ritonavir boosted PI started...",Yes,2018-07-08,FDA-74781,0.56,0.15,3.5,4.21,2018-12-25,2019-02-18,2022-08-19,73,J&J,96,Senegal,39.66666666666666,0,34,59,62,67,16,45,1,2,2,False,True,False,True,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
PI-based regimen,AltName B,Drug,hiv,hiv,Phase 4,2018-06-04,"Sex: ALL; Age: >60 Years; Criteria: Inclusion Criteria:

* Patient having a diagnosis of HIV-1 infection.
* Age 45 years old.
* Current highly active antiretroviral therapy including Truvada or Kivexa plus a ritonavir boosted PI started...",No,2019-01-21,FDA-42613,0.56,0.15,3.5,4.21,2018-12-25,2019-02-18,2022-08-19,90,AstraZeneca,34,Kenya,25.83333333333333,56,22,12,23,41,1,36,0,1,3,False,False,True,False,False,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Atorvastatin,AltName A,Drug,hiv,hiv,Phase 4,2018-06-04,"Sex: ALL; Age: >60 Years; Criteria: Inclusion Criteria:

* Patient having a diagnosis of HIV-1 infection.
* Age 45 years old.
* Current highly active antiretroviral therapy including Truvada or Kivexa plus a ritonavir boosted PI started...",Yes,2018-10-05,FDA-75053,0.56,0.15,3.5,4.21,2018-12-25,2019-02-18,2022-08-19,6,Pfizer,12,Senegal,49.0,52,100,26,12,39,65,64,2,2,3,True,True,True,False,False,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Regimen A,AltName B,Drug,hiv,hiv,Phase 2,2013-05-28,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed Burkitt's or Burkitt-like non-Hodgkin's lymphoma meeting 1 of the following risk criteria:

  * Low-risk disease meeting all of the following crite...",No,2014-04-22,FDA-64209,4.41,0.98,21.0,26.39,2017-10-24,2018-10-17,2039-10-17,4,AstraZeneca,6,Overall,40.33333333333334,26,19,33,47,57,60,45,1,2,2,False,True,False,True,False,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Regimen B,Product Alpha,Drug,hiv,hiv,Phase 2,2013-05-28,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed Burkitt's or Burkitt-like non-Hodgkin's lymphoma meeting 1 of the following risk criteria:

  * Low-risk disease meeting all of the following crite...",Yes,2014-03-06,FDA-88153,4.41,0.98,21.0,26.39,2017-10-24,2018-10-17,2039-10-17,88,Pfizer,12,Overall,76.0,62,97,51,63,85,98,73,2,4,2,True,True,False,True,True,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Glecaprevir/Pibrentasvir,AltName B,Drug,hiv,hiv,Phase 3,2019-02-25,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Must be of Asian descent.
* Screening laboratory result indicating hepatitis C virus (HCV) genotype (GT) 1, 2, 3, 4, 5 or 6 infection.
* Positive anti-HCV antibody (Ab) and HCV ...",Yes,2019-08-20,FDA-71570,2.62,0.32,5.0,7.94,2021-10-08,2022-02-02,2027-02-03,35,AstraZeneca,38,Senegal,56.16666666666666,30,87,47,98,6,69,64,1,3,3,True,False,False,False,True,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
3BNC117,TradeName X,Drug,hiv,hiv,Phase 2,2017-03-25,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Age 18 to 65
* HIV-1 infection confirmed by ELISA and immunoblot.
* Plasma HIV-1 RNA \< 50 copies/ml for at least 12 months while on combination ART and \< 20 copies/ml at the s...",No,2017-07-23,FDA-26843,4.41,0.98,21.0,26.39,2021-08-21,2022-08-14,2043-08-14,32,AstraZeneca,13,Kenya,47.0,41,64,6,20,91,60,73,2,2,4,True,True,True,False,False,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Sirolimus,Product Alpha,Drug,hiv,hiv,Phase 2,2018-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* On continuous ART for ≥24 months prior to study entry.
* CD4+ cell count ≥350 cells/mm\^3
* Plasma HIV-1 RNA below the level of quantification for ≥24 months.
...",Yes,2018-09-19,FDA-10195,4.41,0.98,21.0,26.39,2022-06-30,2023-06-23,2044-06-22,31,Pfizer,80,South Africa,61.0,94,61,99,38,45,29,45,1,2,2,True,False,True,False,False,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Oral Lenacapavir,TradeName X,Drug,hiv,hiv,Phase 2,2023-09-19,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Antiretroviral (ARV) naive with no use of any ARV within one month of screening. Use of pre-exposure prophylaxis (PrEP) (any duration), post-exposure prophylaxis (PEP) (any ...",No,2024-03-03,FDA-25791,4.41,0.98,21.0,26.39,2028-02-15,2029-02-07,2050-02-07,86,Bayer,90,Senegal,34.16666666666666,40,29,27,22,11,76,64,1,3,3,True,False,True,False,False,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
F/TAF,TradeName X,Drug,hiv,hiv,Phase 2,2023-09-19,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Antiretroviral (ARV) naive with no use of any ARV within one month of screening. Use of pre-exposure prophylaxis (PrEP) (any duration), post-exposure prophylaxis (PEP) (any ...",Yes,2023-10-23,FDA-25188,4.41,0.98,21.0,26.39,2028-02-15,2029-02-07,2050-02-07,30,Sanofi,78,Senegal,28.83333333333333,72,6,47,6,29,13,36,1,1,2,False,True,False,False,True,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Subcutaneous Lenacapavir,AltName A,Drug,hiv,hiv,Phase 2,2023-09-19,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Antiretroviral (ARV) naive with no use of any ARV within one month of screening. Use of pre-exposure prophylaxis (PrEP) (any duration), post-exposure prophylaxis (PEP) (any ...",Yes,2024-07-09,FDA-99585,4.41,0.98,21.0,26.39,2028-02-15,2029-02-07,2050-02-07,39,Bayer,85,Overall,64.16666666666667,30,84,94,80,23,74,45,1,1,3,False,True,False,False,False,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
TAF,Comp Beta,Drug,hiv,hiv,Phase 2,2023-09-19,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Antiretroviral (ARV) naive with no use of any ARV within one month of screening. Use of pre-exposure prophylaxis (PrEP) (any duration), post-exposure prophylaxis (PEP) (any ...",No,2024-04-30,FDA-42213,4.41,0.98,21.0,26.39,2028-02-15,2029-02-07,2050-02-07,28,Pfizer,50,Kenya,56.83333333333334,52,97,37,36,88,31,45,1,2,2,True,False,False,True,True,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
BIC,Comp Beta,Drug,hiv,hiv,Phase 2,2023-09-19,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Antiretroviral (ARV) naive with no use of any ARV within one month of screening. Use of pre-exposure prophylaxis (PrEP) (any duration), post-exposure prophylaxis (PEP) (any ...",Yes,2024-01-15,FDA-89186,4.41,0.98,21.0,26.39,2028-02-15,2029-02-07,2050-02-07,27,Gilead,4,Kenya,59.16666666666666,26,39,70,67,91,62,45,0,4,1,False,False,False,True,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
B/F/TAF,AltName B,Drug,hiv,hiv,Phase 2,2023-09-19,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Antiretroviral (ARV) naive with no use of any ARV within one month of screening. Use of pre-exposure prophylaxis (PrEP) (any duration), post-exposure prophylaxis (PEP) (any ...",No,2024-06-02,FDA-72794,4.41,0.98,21.0,26.39,2028-02-15,2029-02-07,2050-02-07,95,Sanofi,6,Senegal,57.66666666666666,50,53,71,66,86,20,55,2,3,1,True,True,False,True,False,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Etravirine (TMC125),AltName B,Drug,hiv,hiv,Phase 2,2011-08-01,"Sex: ALL; Age: >6 Years; Criteria: Inclusion Criteria:

* HIV-1 infected
* Body weight according to age within the 10-90th percentile of CDC growth chart
* On steady antiretroviral therapy regimen for at least 8 weeks at screening and ...",Yes,2012-03-25,FDA-51480,4.41,0.98,21.0,26.39,2015-12-28,2016-12-20,2037-12-20,44,Bayer,29,Kenya,50.66666666666666,42,33,71,66,24,68,45,1,3,1,True,False,True,True,True,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Optimized background regimen (OBR),Product Alpha,Drug,hiv,hiv,Phase 2,2011-08-01,"Sex: ALL; Age: >6 Years; Criteria: Inclusion Criteria:

* HIV-1 infected
* Body weight according to age within the 10-90th percentile of CDC growth chart
* On steady antiretroviral therapy regimen for at least 8 weeks at screening and ...",Yes,2012-02-22,FDA-89820,4.41,0.98,21.0,26.39,2015-12-28,2016-12-20,2037-12-20,13,Merck,41,Overall,38.66666666666666,25,94,3,36,69,5,45,1,3,1,False,True,True,False,False,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose,Molecule Z,Drug,hiv,hiv,Phase 2,2013-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* documented HIV infection
* age of at least 18 years old
* HIV viral load \<400 on the most recent test

Exclusion Criteria:

* current acute moderate to severe illness (demonstr...",Yes,2014-04-07,FDA-91550,4.41,0.98,21.0,26.39,2017-12-28,2018-12-21,2039-12-21,78,Merck,93,South Africa,64.0,79,94,93,4,60,54,73,0,4,4,False,False,True,False,True,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Buprenorphine,Comp Beta,Drug,hiv,hiv,Phase 3,2019-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Currently receiving BMT at Montefiore community health center (CHC).
2. Received BMT for 12 or more weeks.
3. Persistent opioid abuse (positive toxicology for an unprescribed o...",No,2019-11-12,FDA-90966,2.62,0.32,5.0,7.94,2021-12-12,2022-04-08,2027-04-09,65,GSK,23,Overall,44.66666666666666,74,14,47,31,40,62,9,0,0,1,False,False,False,False,False,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
depo-medroxyprogesterone acetate,AltName A,Drug,hiv,hiv,Phase 2,2012-10-01,"Sex: FEMALE; Age: >13 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Documentation of plasma HIV-1 RNA \</= 400 copies/mL within 30 days prior to study entry.
* Last menstrual period \</= 35 days prior to study entry.
* If last ...",No,2013-07-27,FDA-55493,4.41,0.98,21.0,26.39,2017-02-27,2018-02-20,2039-02-20,12,Sanofi,29,Senegal,59.16666666666666,22,27,69,81,99,57,55,0,2,4,False,False,False,False,True,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ART,Comp Beta,Drug,hiv,hiv,Phase 3,2028-07-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Is Human Immunodeficiency Virus-1 (HIV-1) positive with plasma HIV-1 Ribonucleic Acid (RNA) \<50 copies/mL at screening
* Has been receiving continuous, stable oral 2-drug or 3-...",Yes,2028-08-14,FDA-90202,2.62,0.32,5.0,7.94,2031-02-22,2031-06-19,2036-06-19,54,Sanofi,55,Overall,74.0,32,83,93,97,86,53,55,1,3,2,True,False,False,False,True,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
DOR/ISL,Product Alpha,Drug,hiv,hiv,Phase 3,2028-07-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Is Human Immunodeficiency Virus-1 (HIV-1) positive with plasma HIV-1 Ribonucleic Acid (RNA) \<50 copies/mL at screening
* Has been receiving continuous, stable oral 2-drug or 3-...",Yes,2029-05-09,FDA-93636,2.62,0.32,5.0,7.94,2031-02-22,2031-06-19,2036-06-19,10,J&J,12,Overall,51.0,2,40,88,87,25,64,45,1,2,2,False,True,True,False,False,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Cyclophosphamide,Comp Beta,Drug,hiv,hiv,Phase 2,2022-05-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants with histologically or cytologically documented diffuse large B-cell lymphoma (DLBCL) must meet at least 1 of the following risk criteria:

  * Age-adjusted Interna...",Yes,2022-07-01,FDA-58833,4.41,0.98,21.0,26.39,2026-10-15,2027-10-08,2048-10-07,2,Bayer,30,South Africa,46.0,5,60,60,89,59,3,36,1,2,1,False,True,False,True,False,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Doxorubicin Hydrochloride,Product Alpha,Drug,hiv,hiv,Phase 2,2022-05-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants with histologically or cytologically documented diffuse large B-cell lymphoma (DLBCL) must meet at least 1 of the following risk criteria:

  * Age-adjusted Interna...",No,2022-06-28,FDA-99740,4.41,0.98,21.0,26.39,2026-10-15,2027-10-08,2048-10-07,13,Novartis,59,Overall,27.83333333333333,87,2,43,9,19,7,64,1,3,3,False,True,True,True,True,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Etoposide,TradeName X,Drug,hiv,hiv,Phase 2,2022-05-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants with histologically or cytologically documented diffuse large B-cell lymphoma (DLBCL) must meet at least 1 of the following risk criteria:

  * Age-adjusted Interna...",No,2022-08-05,FDA-61803,4.41,0.98,21.0,26.39,2026-10-15,2027-10-08,2048-10-07,4,Merck,29,Overall,27.5,49,6,36,25,29,20,55,2,1,3,True,True,True,False,False,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Prednisone,AltName B,Drug,hiv,hiv,Phase 2,2022-05-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants with histologically or cytologically documented diffuse large B-cell lymphoma (DLBCL) must meet at least 1 of the following risk criteria:

  * Age-adjusted Interna...",Yes,2022-07-24,FDA-66084,4.41,0.98,21.0,26.39,2026-10-15,2027-10-08,2048-10-07,86,Merck,98,Senegal,47.16666666666666,63,35,51,27,56,51,36,1,2,1,True,False,False,False,False,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rituximab,Molecule Z,Biological,hiv,hiv,Phase 2,2022-05-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants with histologically or cytologically documented diffuse large B-cell lymphoma (DLBCL) must meet at least 1 of the following risk criteria:

  * Age-adjusted Interna...",No,2023-03-21,FDA-15302,4.41,0.98,21.0,26.39,2026-10-15,2027-10-08,2048-10-07,61,Bayer,23,South Africa,43.83333333333334,62,13,47,88,46,7,55,1,3,2,False,True,False,True,False,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Vincristine Sulfate,AltName B,Drug,hiv,hiv,Phase 2,2022-05-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants with histologically or cytologically documented diffuse large B-cell lymphoma (DLBCL) must meet at least 1 of the following risk criteria:

  * Age-adjusted Interna...",Yes,2022-11-08,FDA-97711,4.41,0.98,21.0,26.39,2026-10-15,2027-10-08,2048-10-07,42,Bayer,0,Kenya,61.33333333333334,19,29,84,88,76,72,36,2,0,2,True,True,False,False,False,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Vorinostat,AltName A,Drug,hiv,hiv,Phase 2,2022-05-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants with histologically or cytologically documented diffuse large B-cell lymphoma (DLBCL) must meet at least 1 of the following risk criteria:

  * Age-adjusted Interna...",No,2022-10-21,FDA-21726,4.41,0.98,21.0,26.39,2026-10-15,2027-10-08,2048-10-07,71,Pfizer,81,Overall,52.16666666666666,41,83,58,79,35,17,64,2,3,2,True,True,False,True,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Fluzone High Dose,Product Alpha,Biological,hiv,hiv,Phase 2,2017-09-01,"Sex: ALL; Age: >5 Years; Criteria: Inclusion Criteria:

* Age ≥ 5 years and ≤ 35 years
* Receiving influenza vaccination in Children's Hospital Colorado (CHC) clinic as part of routine clinical care
* Only supposed to receive one dose ...",Yes,2018-03-05,FDA-65312,4.41,0.98,21.0,26.39,2022-01-28,2023-01-21,2044-01-21,48,Sanofi,10,Overall,28.66666666666667,7,5,25,11,93,31,18,0,2,0,False,False,False,False,False,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Fluzone,GenName Y,Biological,hiv,hiv,Phase 2,2017-09-01,"Sex: ALL; Age: >5 Years; Criteria: Inclusion Criteria:

* Age ≥ 5 years and ≤ 35 years
* Receiving influenza vaccination in Children's Hospital Colorado (CHC) clinic as part of routine clinical care
* Only supposed to receive one dose ...",Yes,2017-12-30,FDA-53990,4.41,0.98,21.0,26.39,2022-01-28,2023-01-21,2044-01-21,90,Pfizer,43,South Africa,47.83333333333334,33,1,75,95,55,28,45,0,4,1,False,False,True,True,True,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Islatravir,Comp Beta,Drug,hiv,hiv,Phase 2,2022-11-24,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Is in general good health with acceptable laboratory values at screening
* Is confirmed HIV-uninfected based on negative HIV-1/HIV-2 test result before randomization
* Has low r...",No,2023-04-01,FDA-72200,4.41,0.98,21.0,26.39,2027-04-22,2028-04-14,2049-04-14,5,AstraZeneca,41,South Africa,53.66666666666666,33,79,33,89,23,65,45,1,2,2,True,False,True,False,False,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
imatinib mesylate,GenName Y,Drug,hiv,hiv,Phase 2,2009-12-01,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed Kaposi's sarcoma (KS) involving at least 1 of the following areas:

  * Skin
  * Lymph nodes
  * Oral cavity
  * Gastrointestinal tract\*
  * Lungs...",Yes,2010-09-17,FDA-27786,4.41,0.98,21.0,26.39,2014-04-29,2015-04-22,2036-04-21,66,Pfizer,95,Overall,29.33333333333333,36,52,19,43,22,4,36,0,2,2,False,False,False,True,False,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ciprofloxacin,Comp Beta,Drug,hiv,hiv,Phase 3,2016-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV positive with Salivary Gland Disease
* Ability to read and understand English

Exclusion Criteria:

* Allergy to the family of fluoroquinolones (including ciprofloxacin)
* C...",Yes,2016-04-01,FDA-65722,2.62,0.32,5.0,7.94,2018-08-14,2018-12-09,2023-12-10,98,Sanofi,58,South Africa,58.5,59,75,83,25,24,85,36,0,2,2,False,False,False,False,True,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Moxifloxacin,AltName B,Drug,hiv,hiv,Phase 2,2008-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Presumptive diagnosis of smear-positive pulmonary TB within 2 weeks of study entry. Patients with both pulmonary and extrapulmonary disease are eligible.
* Documentation of HIV ...",Yes,2009-07-17,FDA-94776,4.41,0.98,21.0,26.39,2013-01-28,2014-01-21,2035-01-21,35,AstraZeneca,31,Kenya,46.83333333333334,96,94,12,32,8,39,36,1,2,1,False,True,False,False,True,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
B/F/TAF,Molecule Z,Drug,hiv,hiv,Phase 3,2021-02-10,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Currently receiving an ARV regimen of DTG+F/TAF or DTG+F/TDF for the following minimum time periods:

  * ≥ 6 months (if there is documented or suspected nucleoside/nucleoti...",No,2021-05-11,FDA-57557,2.62,0.32,5.0,7.94,2023-09-24,2024-01-19,2029-01-19,53,Gilead,19,Senegal,57.5,66,32,85,29,81,52,45,1,1,3,False,True,False,True,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
F/TAF,AltName B,Drug,hiv,hiv,Phase 3,2021-02-10,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Currently receiving an ARV regimen of DTG+F/TAF or DTG+F/TDF for the following minimum time periods:

  * ≥ 6 months (if there is documented or suspected nucleoside/nucleoti...",Yes,2021-12-14,FDA-62394,2.62,0.32,5.0,7.94,2023-09-24,2024-01-19,2029-01-19,7,Novartis,84,Overall,48.66666666666666,45,64,61,66,8,48,55,0,3,3,False,False,False,True,True,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
DTG,GenName Y,Drug,hiv,hiv,Phase 3,2021-02-10,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Currently receiving an ARV regimen of DTG+F/TAF or DTG+F/TDF for the following minimum time periods:

  * ≥ 6 months (if there is documented or suspected nucleoside/nucleoti...",Yes,2021-04-04,FDA-24869,2.62,0.32,5.0,7.94,2023-09-24,2024-01-19,2029-01-19,33,Bayer,81,Kenya,52.16666666666666,58,8,89,65,33,60,18,0,1,1,False,False,False,False,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Proflavine Hemisulfate,AltName A,Drug,hiv,hiv,Phase 2,2025-03-28,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Consentable patients with documented HIV disease
* Either: 1) previously documented HSIL or 2) abnormal anal cytology within the past 2 years
* Ages 18 years and older
* Seen at...",No,2026-01-12,FDA-77085,4.41,0.98,21.0,26.39,2029-08-24,2030-08-17,2051-08-17,78,Bayer,59,Kenya,28.66666666666667,94,14,3,51,10,0,36,2,2,0,True,True,False,True,False,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Telmisartan,Molecule Z,Drug,hiv,hiv,Phase 2,2013-03-01,"Sex: ALL; Age: >50 Years; Criteria: Inclusion Criteria:

* HIV positive men and women \> 50 years of age.
* HIV-1 RNA documented to be \< 50 copies/mL at screening and undetectable by assay of choice (\< 50 or \< 400 copies/mL) for at l...",No,2013-04-25,FDA-82063,4.41,0.98,21.0,26.39,2017-07-28,2018-07-21,2039-07-21,1,Sanofi,15,Overall,56.5,83,16,97,5,86,52,73,1,3,4,True,False,False,False,True,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Switch to E/C/FTC/TAF daily,Comp Beta,Drug,hiv,hiv,Phase 2,2021-07-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Inclusion criteria for HIV negative participants

All HIV negative participants must meet the following criteria:

1. 18 years of age or older
2. Understands and agrees to local...",No,2021-09-29,FDA-88906,4.41,0.98,21.0,26.39,2025-11-27,2026-11-20,2047-11-20,12,Novartis,4,Kenya,55.5,41,100,64,26,61,41,55,1,2,3,True,False,False,True,False,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
No drug will be administered,AltName A,Drug,hiv,hiv,Phase 2,2013-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Previous participation in a qualifying study.
* Male or female at least 18 years of age available for a follow-up period of at least 96 weeks.

Exclusion Criteria:

* Concurrent...",No,2014-01-21,FDA-44806,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,63,Novartis,16,South Africa,50.5,29,89,61,18,70,36,45,2,2,1,True,True,True,False,False,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
darunavir,TradeName X,Drug,hiv,hiv,Phase 2,2011-03-01,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria:

* Patients with a documented HIV-1 infection
* Body weight from at least 40 kg at screening
* Screening plasma HIV-1 RNA \>= 1000 copies/mL
* Parents or legal representative and t...",No,2011-11-10,FDA-10534,4.41,0.98,21.0,26.39,2015-07-28,2016-07-20,2037-07-20,90,Pfizer,41,Overall,30.33333333333333,49,32,2,74,17,8,82,2,4,3,True,True,True,True,True,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ritonavir,Product Alpha,Drug,hiv,hiv,Phase 2,2011-03-01,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria:

* Patients with a documented HIV-1 infection
* Body weight from at least 40 kg at screening
* Screening plasma HIV-1 RNA \>= 1000 copies/mL
* Parents or legal representative and t...",Yes,2011-12-16,FDA-50330,4.41,0.98,21.0,26.39,2015-07-28,2016-07-20,2037-07-20,100,Novartis,53,South Africa,46.83333333333334,68,7,22,89,71,24,36,0,1,3,False,False,False,True,False,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
zidovudine,Product Alpha,Drug,hiv,hiv,Phase 2,2011-03-01,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria:

* Patients with a documented HIV-1 infection
* Body weight from at least 40 kg at screening
* Screening plasma HIV-1 RNA \>= 1000 copies/mL
* Parents or legal representative and t...",Yes,2011-08-04,FDA-82332,4.41,0.98,21.0,26.39,2015-07-28,2016-07-20,2037-07-20,100,Pfizer,96,Senegal,48.66666666666666,29,12,33,78,97,43,55,1,2,3,True,False,True,False,False,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
lamivudine,TradeName X,Drug,hiv,hiv,Phase 2,2011-03-01,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria:

* Patients with a documented HIV-1 infection
* Body weight from at least 40 kg at screening
* Screening plasma HIV-1 RNA \>= 1000 copies/mL
* Parents or legal representative and t...",Yes,2011-06-22,FDA-98945,4.41,0.98,21.0,26.39,2015-07-28,2016-07-20,2037-07-20,25,J&J,32,Senegal,44.16666666666666,47,2,31,68,22,95,45,1,3,1,False,True,False,False,True,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
abacavir,TradeName X,Drug,hiv,hiv,Phase 2,2011-03-01,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria:

* Patients with a documented HIV-1 infection
* Body weight from at least 40 kg at screening
* Screening plasma HIV-1 RNA \>= 1000 copies/mL
* Parents or legal representative and t...",No,2011-10-05,FDA-93424,4.41,0.98,21.0,26.39,2015-07-28,2016-07-20,2037-07-20,8,J&J,98,Kenya,68.83333333333333,63,100,90,84,72,4,55,1,3,2,False,True,True,False,False,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
CBD oil,AltName B,Drug,hiv,hiv,Phase 4,2022-12-12,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

* Willingness to take CBD and to participate in follow up for two months
* Older than 21 and younger than 60
* Under antiretroviral therapy for 5+ years and suppressed viral load ...",Yes,2023-01-23,FDA-42800,0.56,0.15,3.5,4.21,2023-07-04,2023-08-28,2027-02-26,17,Merck,58,Overall,44.0,50,73,10,40,19,72,36,0,3,1,False,False,True,False,True,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC,Comp Beta,Drug,hiv,hiv,Phase 3,2019-09-04,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Newly diagnosed with human immunodeficiency virus type 1 (HIV-1) evidenced by any of the following within 2 weeks of the screening/baseline visit: a) HIV Rapid Antibody positive...",No,2020-01-12,FDA-14306,2.62,0.32,5.0,7.94,2022-04-17,2022-08-12,2027-08-13,13,Bayer,94,Senegal,36.5,12,54,1,45,64,43,55,2,2,2,True,True,False,True,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX],Comp Beta,Drug,hiv,hiv,Phase 4,2020-09-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria Participants must meet all of the following inclusion criteria to be eligible for participation

1. Ability and willingness of participant to provide written informed consent.
2. Me...",Yes,2021-09-28,FDA-15178,0.56,0.15,3.5,4.21,2021-04-22,2021-06-16,2024-12-15,40,AstraZeneca,48,South Africa,61.66666666666666,26,97,71,89,64,23,27,0,1,2,False,False,False,False,False,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Sofosbuvir/Velpatasvir (SOF/VEL),AltName B,Drug,hiv,hiv,Phase 4,2020-09-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria Participants must meet all of the following inclusion criteria to be eligible for participation

1. Ability and willingness of participant to provide written informed consent.
2. Me...",No,2020-11-08,FDA-17745,0.56,0.15,3.5,4.21,2021-04-22,2021-06-16,2024-12-15,88,Pfizer,86,Kenya,46.16666666666666,79,79,78,2,9,30,73,1,4,3,False,True,True,True,True,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
cetuximab,AltName A,Biological,hiv,hiv,Phase 2,2016-05-01,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed stage I-IIIB invasive anal canal or perianal (anal margin) squamous cell carcinoma, including tumors with any of the following nonkeratinizing hist...",No,2016-12-05,FDA-57186,4.41,0.98,21.0,26.39,2020-09-27,2021-09-20,2042-09-20,61,Pfizer,9,South Africa,34.66666666666666,51,10,39,5,22,81,45,0,3,2,False,False,True,False,True,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
cisplatin,AltName A,Drug,hiv,hiv,Phase 2,2016-05-01,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed stage I-IIIB invasive anal canal or perianal (anal margin) squamous cell carcinoma, including tumors with any of the following nonkeratinizing hist...",Yes,2016-06-22,FDA-63594,4.41,0.98,21.0,26.39,2020-09-27,2021-09-20,2042-09-20,35,Sanofi,33,Senegal,54.83333333333334,40,64,22,69,88,46,27,2,0,1,True,True,False,False,False,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
fluorouracil,AltName A,Drug,hiv,hiv,Phase 2,2016-05-01,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed stage I-IIIB invasive anal canal or perianal (anal margin) squamous cell carcinoma, including tumors with any of the following nonkeratinizing hist...",No,2017-04-28,FDA-52751,4.41,0.98,21.0,26.39,2020-09-27,2021-09-20,2042-09-20,9,Gilead,22,Senegal,57.16666666666666,48,58,38,45,76,78,55,1,2,3,False,True,False,False,True,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Amphotericin B,Molecule Z,Drug,hiv,hiv,Phase 2,2008-04-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* First episode of cryptococcal meningitis as evidenced by a positive cerebrospinal fluid (CSF) stain or cryptococcal antigen, CSF culture pending
* Documentation of proven diagno...",No,2009-01-12,FDA-40894,4.41,0.98,21.0,26.39,2012-08-28,2013-08-21,2034-08-21,93,Bayer,97,South Africa,61.0,93,87,11,37,61,77,45,1,2,2,True,False,False,False,False,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Fluconazole,AltName B,Drug,hiv,hiv,Phase 2,2008-04-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* First episode of cryptococcal meningitis as evidenced by a positive cerebrospinal fluid (CSF) stain or cryptococcal antigen, CSF culture pending
* Documentation of proven diagno...",Yes,2009-01-13,FDA-59962,4.41,0.98,21.0,26.39,2012-08-28,2013-08-21,2034-08-21,15,Pfizer,22,Kenya,71.16666666666667,55,90,65,86,100,31,55,2,2,2,True,True,False,True,False,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ibalizumab-uiyk,Comp Beta,Drug,hiv,hiv,Phase 3,2022-10-31,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria - HIV-infected participants (all groups):

1. Are capable of understanding and have voluntarily signed the informed consent document
2. Currently receiving a stable Trogarzo-contain...",No,2023-02-03,FDA-54147,2.62,0.32,5.0,7.94,2025-06-13,2025-10-08,2030-10-09,6,Novartis,100,Senegal,50.16666666666666,6,48,76,99,29,43,55,1,2,3,False,True,True,False,True,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy,Molecule Z,Drug,hiv,hiv,Phase 3,2018-05-14,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Pregnancy confirmed by positive urine pregnancy test or intrauterine pregnancy by ultrasound
2. Estimated gestational age between 12-20 weeks
3. Confirmed to be HIV uninfected ...",No,2018-07-20,FDA-33128,2.62,0.32,5.0,7.94,2020-12-25,2021-04-21,2026-04-22,7,Pfizer,18,Kenya,32.66666666666666,77,21,15,18,43,22,55,1,2,3,True,False,True,False,False,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy,AltName B,Drug,hiv,hiv,Phase 3,2018-05-14,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Pregnancy confirmed by positive urine pregnancy test or intrauterine pregnancy by ultrasound
2. Estimated gestational age between 12-20 weeks
3. Confirmed to be HIV uninfected ...",No,2018-12-06,FDA-40874,2.62,0.32,5.0,7.94,2020-12-25,2021-04-21,2026-04-22,1,Gilead,39,South Africa,27.5,18,3,56,70,1,17,45,2,1,2,True,True,True,False,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy,Product Alpha,Drug,hiv,hiv,Phase 3,2018-05-14,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Pregnancy confirmed by positive urine pregnancy test or intrauterine pregnancy by ultrasound
2. Estimated gestational age between 12-20 weeks
3. Confirmed to be HIV uninfected ...",Yes,2018-09-14,FDA-50651,2.62,0.32,5.0,7.94,2020-12-25,2021-04-21,2026-04-22,94,J&J,26,South Africa,61.5,80,89,13,52,41,94,55,1,3,2,True,False,True,True,True,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Monthly dihydroartemisinin-piperaquine (DP) for infants,Product Alpha,Drug,hiv,hiv,Phase 3,2018-05-14,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Pregnancy confirmed by positive urine pregnancy test or intrauterine pregnancy by ultrasound
2. Estimated gestational age between 12-20 weeks
3. Confirmed to be HIV uninfected ...",Yes,2019-01-15,FDA-71697,2.62,0.32,5.0,7.94,2020-12-25,2021-04-21,2026-04-22,93,GSK,48,Kenya,57.33333333333334,82,37,30,16,89,90,45,1,3,1,False,True,False,False,True,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
3-monthly dihydroartemisinin-piperaquine (DP) for infants,TradeName X,Drug,hiv,hiv,Phase 3,2018-05-14,"Sex: FEMALE; Age: >16 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Pregnancy confirmed by positive urine pregnancy test or intrauterine pregnancy by ultrasound
2. Estimated gestational age between 12-20 weeks
3. Confirmed to be HIV uninfected ...",Yes,2018-10-21,FDA-46985,2.62,0.32,5.0,7.94,2020-12-25,2021-04-21,2026-04-22,48,GSK,39,Senegal,69.66666666666667,23,71,90,76,68,90,45,1,2,2,True,False,True,False,False,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
EFV/FTC/TDF,TradeName X,Drug,hiv,hiv,Phase 2,2013-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* No evidence of any exclusionary resistance mutations based on results from any genotype assay from any laboratory that has a CLIA (Clinical Laboratory Improvem...",No,2013-11-12,FDA-86926,4.41,0.98,21.0,26.39,2017-06-30,2018-06-23,2039-06-23,5,AstraZeneca,10,Overall,63.0,78,91,71,63,33,42,45,0,1,4,False,False,False,False,True,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Calcium Carbonate,Molecule Z,Drug,hiv,hiv,Phase 2,2013-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* No evidence of any exclusionary resistance mutations based on results from any genotype assay from any laboratory that has a CLIA (Clinical Laboratory Improvem...",No,2013-10-05,FDA-95002,4.41,0.98,21.0,26.39,2017-06-30,2018-06-23,2039-06-23,11,J&J,20,Kenya,48.66666666666666,24,92,51,5,75,45,45,1,2,2,False,True,False,True,False,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Vitamin D3,GenName Y,Drug,hiv,hiv,Phase 2,2013-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* No evidence of any exclusionary resistance mutations based on results from any genotype assay from any laboratory that has a CLIA (Clinical Laboratory Improvem...",No,2013-03-24,FDA-23038,4.41,0.98,21.0,26.39,2017-06-30,2018-06-23,2039-06-23,78,Gilead,19,Overall,46.5,55,77,86,8,20,33,64,1,4,2,True,False,True,True,True,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK Biological's Investigational Malaria Vaccine 257049,Product Alpha,Biological,hiv,hiv,Phase 3,2013-05-24,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

All subjects must satisfy ALL the following criteria at study entry:

* A male or female infant or child between and including 6 weeks to 17 months of age, at the time of first va...",No,2013-09-20,FDA-68530,2.62,0.32,5.0,7.94,2016-01-05,2016-05-01,2021-05-02,34,AstraZeneca,89,Senegal,62.16666666666666,63,39,6,77,91,97,45,1,2,2,False,True,False,False,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);",TradeName X,Biological,hiv,hiv,Phase 3,2013-05-24,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

All subjects must satisfy ALL the following criteria at study entry:

* A male or female infant or child between and including 6 weeks to 17 months of age, at the time of first va...",Yes,2013-09-19,FDA-61814,2.62,0.32,5.0,7.94,2016-01-05,2016-05-01,2021-05-02,26,Gilead,56,Kenya,33.66666666666666,44,18,74,7,31,28,36,1,1,2,False,True,False,False,False,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).,Comp Beta,Biological,hiv,hiv,Phase 3,2013-05-24,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

All subjects must satisfy ALL the following criteria at study entry:

* A male or female infant or child between and including 6 weeks to 17 months of age, at the time of first va...",No,2014-01-10,FDA-77585,2.62,0.32,5.0,7.94,2016-01-05,2016-05-01,2021-05-02,20,Bayer,28,Overall,48.83333333333334,39,94,73,0,39,48,64,0,4,3,False,False,False,True,True,True,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Arm A: Poly-ICLC,Comp Beta,Drug,hiv,hiv,Phase 2,2016-07-26,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection documented by previous HIV-1 serology or rapid test, or documented plasma HIV-1 RNA of \>2000 copies/ml
* On stable cART regimen in accordance with the DHHS ""Gui...",Yes,2016-11-19,FDA-55636,4.41,0.98,21.0,26.39,2020-12-22,2021-12-15,2042-12-15,30,Merck,20,Kenya,47.16666666666666,57,65,53,48,19,41,36,0,1,3,False,False,False,False,False,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Arm B: Normal Saline,AltName A,Drug,hiv,hiv,Phase 2,2016-07-26,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection documented by previous HIV-1 serology or rapid test, or documented plasma HIV-1 RNA of \>2000 copies/ml
* On stable cART regimen in accordance with the DHHS ""Gui...",No,2017-07-09,FDA-55429,4.41,0.98,21.0,26.39,2020-12-22,2021-12-15,2042-12-15,61,AstraZeneca,69,South Africa,36.33333333333334,67,43,14,16,15,63,64,1,4,2,True,False,True,True,True,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine / Tenofovir Disoproxil Oral Tablet,Product Alpha,Drug,hiv,hiv,Phase 4,2020-04-21,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Self-identifies as a man
* Age 18-35 at enrollment
* Reports having insertive or receptive anal sex with a man or trans woman in the past 12 months and one or more of the follow...",Yes,2020-11-24,FDA-77971,0.56,0.15,3.5,4.21,2020-11-11,2021-01-05,2024-07-06,71,Novartis,34,Senegal,44.16666666666666,2,42,49,56,44,72,55,1,4,1,False,True,True,True,True,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine / Tenofovir Disoproxil Oral Tablet,Molecule Z,Drug,hiv,hiv,Phase 4,2018-08-30,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Self-identifies as a man
* Age 18-35 at enrollment
* Reports having anal sex with a man or trans woman in the past 12 months and one or more of the following criteria in the pas...",No,2019-01-09,FDA-74077,0.56,0.15,3.5,4.21,2019-03-22,2019-05-16,2022-11-14,62,Novartis,18,South Africa,42.83333333333334,28,27,6,47,84,65,55,1,3,2,False,True,True,True,True,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DOR/ISL,GenName Y,Drug,hiv,hiv,Phase 3,2025-01-29,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Is human immunodeficiency virus type 1 (HIV-1) positive
* Is naïve to antiretroviral therapy (ART) defined as having received ≤10 days of prior therapy with any antiretroviral a...",No,2025-06-28,FDA-53390,2.62,0.32,5.0,7.94,2027-09-12,2028-01-07,2033-01-07,5,AstraZeneca,25,Overall,41.5,7,32,78,79,2,51,64,1,4,2,False,True,True,True,True,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
BIC/FTC/TAF,Comp Beta,Drug,hiv,hiv,Phase 3,2025-01-29,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Is human immunodeficiency virus type 1 (HIV-1) positive
* Is naïve to antiretroviral therapy (ART) defined as having received ≤10 days of prior therapy with any antiretroviral a...",No,2025-09-24,FDA-33579,2.62,0.32,5.0,7.94,2027-09-12,2028-01-07,2033-01-07,29,Novartis,17,Overall,61.83333333333334,15,90,98,8,83,77,45,1,2,2,True,False,False,False,True,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"UK-453, 061",Molecule Z,Drug,hiv,hiv,Phase 2,2011-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male or female at least 18 years of age available for a follow-up period of at least 96 weeks.
* HIV 1 RNA viral load of greater then 1,000 copies/mL
* Negative urine pregnancy ...",Yes,2011-12-22,FDA-47785,4.41,0.98,21.0,26.39,2016-02-27,2017-02-19,2038-02-19,3,Merck,74,Kenya,39.0,44,77,24,72,6,11,64,1,3,3,False,True,True,True,True,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"UK-453, 061",Molecule Z,Drug,hiv,hiv,Phase 2,2011-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male or female at least 18 years of age available for a follow-up period of at least 96 weeks.
* HIV 1 RNA viral load of greater then 1,000 copies/mL
* Negative urine pregnancy ...",Yes,2011-11-11,FDA-13911,4.41,0.98,21.0,26.39,2016-02-27,2017-02-19,2038-02-19,65,GSK,57,South Africa,44.33333333333334,30,22,9,77,45,83,55,0,4,2,False,False,True,True,False,True,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
EFV +TVA,Molecule Z,Drug,hiv,hiv,Phase 2,2011-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male or female at least 18 years of age available for a follow-up period of at least 96 weeks.
* HIV 1 RNA viral load of greater then 1,000 copies/mL
* Negative urine pregnancy ...",No,2011-11-12,FDA-50119,4.41,0.98,21.0,26.39,2016-02-27,2017-02-19,2038-02-19,92,GSK,53,South Africa,65.66666666666667,59,35,81,96,74,49,27,1,1,1,False,True,False,False,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
GS-9131,Product Alpha,Drug,hiv,hiv,Phase 2,2019-12-09,"Sex: FEMALE; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Plasma HIV-1 RNA ≥ 500 copies/mL at screening Visit
* Currently taking a failing ARV regimen that contains 2 NRTIs and a NNRTI
* No prior or current ARV regimens containing ...",No,2020-02-16,FDA-91111,4.41,0.98,21.0,26.39,2024-05-06,2025-04-29,2046-04-29,75,J&J,22,Senegal,49.16666666666666,67,69,33,26,66,34,36,0,3,1,False,False,True,True,False,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
BIC,TradeName X,Drug,hiv,hiv,Phase 2,2019-12-09,"Sex: FEMALE; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Plasma HIV-1 RNA ≥ 500 copies/mL at screening Visit
* Currently taking a failing ARV regimen that contains 2 NRTIs and a NNRTI
* No prior or current ARV regimens containing ...",Yes,2020-04-03,FDA-10113,4.41,0.98,21.0,26.39,2024-05-06,2025-04-29,2046-04-29,87,J&J,78,South Africa,54.33333333333334,44,74,98,52,41,17,45,1,3,1,True,False,False,False,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
TAF,Product Alpha,Drug,hiv,hiv,Phase 2,2019-12-09,"Sex: FEMALE; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Plasma HIV-1 RNA ≥ 500 copies/mL at screening Visit
* Currently taking a failing ARV regimen that contains 2 NRTIs and a NNRTI
* No prior or current ARV regimens containing ...",Yes,2020-04-07,FDA-23726,4.41,0.98,21.0,26.39,2024-05-06,2025-04-29,2046-04-29,67,Merck,73,Senegal,40.16666666666666,25,15,76,56,10,59,27,1,1,1,True,False,False,False,False,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ARV regimen,TradeName X,Drug,hiv,hiv,Phase 2,2019-12-09,"Sex: FEMALE; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Plasma HIV-1 RNA ≥ 500 copies/mL at screening Visit
* Currently taking a failing ARV regimen that contains 2 NRTIs and a NNRTI
* No prior or current ARV regimens containing ...",Yes,2020-04-13,FDA-66786,4.41,0.98,21.0,26.39,2024-05-06,2025-04-29,2046-04-29,30,Bayer,32,Senegal,64.0,53,93,11,87,92,48,55,2,2,2,True,True,False,False,True,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DRV,GenName Y,Drug,hiv,hiv,Phase 2,2019-12-09,"Sex: FEMALE; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Plasma HIV-1 RNA ≥ 500 copies/mL at screening Visit
* Currently taking a failing ARV regimen that contains 2 NRTIs and a NNRTI
* No prior or current ARV regimens containing ...",No,2020-03-17,FDA-50918,4.41,0.98,21.0,26.39,2024-05-06,2025-04-29,2046-04-29,45,Bayer,25,Overall,34.0,9,33,47,42,28,45,45,1,3,1,False,True,False,True,True,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
RTV,Product Alpha,Drug,hiv,hiv,Phase 2,2019-12-09,"Sex: FEMALE; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Plasma HIV-1 RNA ≥ 500 copies/mL at screening Visit
* Currently taking a failing ARV regimen that contains 2 NRTIs and a NNRTI
* No prior or current ARV regimens containing ...",No,2020-08-10,FDA-41695,4.41,0.98,21.0,26.39,2024-05-06,2025-04-29,2046-04-29,15,Pfizer,77,Senegal,38.33333333333334,6,89,74,13,36,12,36,0,2,2,False,False,True,False,True,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Liposomal Doxorubicin,GenName Y,Drug,hiv,hiv,Phase 2,2017-11-08,"Sex: ALL; Age: >18 Years; Criteria: -INCLUSION CRITERIA:

1. Age greater than or equal to 18 years
2. Kaposi s sarcoma pathologically confirmed by Center for Cancer Research (CCR) pathology
3. Evaluable Kaposi's sarcoma (KS) involving t...",No,2018-01-07,FDA-53926,4.41,0.98,21.0,26.39,2022-04-06,2023-03-30,2044-03-29,97,Gilead,32,Overall,60.83333333333334,17,64,85,57,90,52,45,1,2,2,True,False,True,False,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Bevacizumab,Comp Beta,Drug,hiv,hiv,Phase 2,2017-11-08,"Sex: ALL; Age: >18 Years; Criteria: -INCLUSION CRITERIA:

1. Age greater than or equal to 18 years
2. Kaposi s sarcoma pathologically confirmed by Center for Cancer Research (CCR) pathology
3. Evaluable Kaposi's sarcoma (KS) involving t...",Yes,2017-12-23,FDA-98023,4.41,0.98,21.0,26.39,2022-04-06,2023-03-30,2044-03-29,47,Merck,69,Kenya,50.33333333333334,67,49,51,48,48,39,45,0,4,1,False,False,True,False,True,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Rilpivirine,GenName Y,Drug,hiv,hiv,Phase 2,2022-08-01,"Sex: ALL; Age: >6 Years; Criteria: Inclusion Criteria:

* Has documented human immuno deficiency virus (HIV-1) infection
* Patients who meet the following criteria; a) Cohort 1: Patients Aged greater than or equal to (\>=) 12 to less t...",No,2023-02-15,FDA-42516,4.41,0.98,21.0,26.39,2026-12-28,2027-12-21,2048-12-20,2,Novartis,46,South Africa,44.5,60,30,58,52,31,36,36,1,3,0,True,False,True,False,False,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Zidovudine,Comp Beta,Drug,hiv,hiv,Phase 2,2022-08-01,"Sex: ALL; Age: >6 Years; Criteria: Inclusion Criteria:

* Has documented human immuno deficiency virus (HIV-1) infection
* Patients who meet the following criteria; a) Cohort 1: Patients Aged greater than or equal to (\>=) 12 to less t...",Yes,2023-01-01,FDA-57736,4.41,0.98,21.0,26.39,2026-12-28,2027-12-21,2048-12-20,66,Sanofi,43,South Africa,76.16666666666667,82,76,64,41,95,99,55,2,3,1,True,True,False,False,True,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Abacavir,AltName B,Drug,hiv,hiv,Phase 2,2022-08-01,"Sex: ALL; Age: >6 Years; Criteria: Inclusion Criteria:

* Has documented human immuno deficiency virus (HIV-1) infection
* Patients who meet the following criteria; a) Cohort 1: Patients Aged greater than or equal to (\>=) 12 to less t...",No,2023-04-26,FDA-93388,4.41,0.98,21.0,26.39,2026-12-28,2027-12-21,2048-12-20,0,AstraZeneca,31,South Africa,65.66666666666667,70,68,69,90,85,12,45,1,2,2,False,True,False,True,False,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tenofovir disoproxil fumarate,AltName A,Drug,hiv,hiv,Phase 2,2022-08-01,"Sex: ALL; Age: >6 Years; Criteria: Inclusion Criteria:

* Has documented human immuno deficiency virus (HIV-1) infection
* Patients who meet the following criteria; a) Cohort 1: Patients Aged greater than or equal to (\>=) 12 to less t...",No,2023-01-07,FDA-67557,4.41,0.98,21.0,26.39,2026-12-28,2027-12-21,2048-12-20,39,Novartis,12,Kenya,38.66666666666666,26,22,87,30,30,37,55,1,3,2,True,False,False,True,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lamivudine,Molecule Z,Drug,hiv,hiv,Phase 2,2022-08-01,"Sex: ALL; Age: >6 Years; Criteria: Inclusion Criteria:

* Has documented human immuno deficiency virus (HIV-1) infection
* Patients who meet the following criteria; a) Cohort 1: Patients Aged greater than or equal to (\>=) 12 to less t...",No,2023-06-30,FDA-91470,4.41,0.98,21.0,26.39,2026-12-28,2027-12-21,2048-12-20,86,AstraZeneca,33,Kenya,51.0,66,75,17,16,92,40,55,0,3,3,False,False,False,True,True,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine,TradeName X,Drug,hiv,hiv,Phase 2,2022-08-01,"Sex: ALL; Age: >6 Years; Criteria: Inclusion Criteria:

* Has documented human immuno deficiency virus (HIV-1) infection
* Patients who meet the following criteria; a) Cohort 1: Patients Aged greater than or equal to (\>=) 12 to less t...",Yes,2023-01-25,FDA-23896,4.41,0.98,21.0,26.39,2026-12-28,2027-12-21,2048-12-20,76,Pfizer,81,Senegal,42.16666666666666,41,96,58,4,24,30,55,1,2,3,True,False,True,False,True,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Rotarix,TradeName X,Biological,hiv,hiv,Phase 2,2008-02-13,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
* A male or female...",No,2009-02-08,FDA-50534,4.41,0.98,21.0,26.39,2012-07-11,2013-07-04,2034-07-04,38,J&J,12,Kenya,49.5,8,81,76,11,93,28,55,0,4,2,False,False,True,True,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Tritanrix-HB+Hib,AltName B,Biological,hiv,hiv,Phase 2,2008-02-13,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
* A male or female...",No,2008-07-14,FDA-72863,4.41,0.98,21.0,26.39,2012-07-11,2013-07-04,2034-07-04,32,GSK,31,Overall,60.0,84,73,16,50,86,51,45,0,2,3,False,False,False,False,True,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Polio Sabin,GenName Y,Biological,hiv,hiv,Phase 2,2008-02-13,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
* A male or female...",No,2008-06-05,FDA-19289,4.41,0.98,21.0,26.39,2012-07-11,2013-07-04,2034-07-04,6,Sanofi,33,Kenya,51.5,34,87,4,53,59,72,55,1,3,2,True,False,True,True,False,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
D/C/F/TAF FDC,GenName Y,Drug,hiv,hiv,Phase 4,2023-08-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Body Mass Index (BMI) of greater than or equal to (\>=) 18 kilogram per meter square (kg/m\^2) at time of starting an integrase (INI)-based regimen plus Tenofovir Alafenamide/Em...",Yes,2023-11-25,FDA-92342,0.56,0.15,3.5,4.21,2024-03-21,2024-05-15,2027-11-14,91,Pfizer,71,Senegal,58.5,95,50,72,67,62,5,55,1,2,3,False,True,False,True,False,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
TAF/FTC FDC,GenName Y,Drug,hiv,hiv,Phase 4,2023-08-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Body Mass Index (BMI) of greater than or equal to (\>=) 18 kilogram per meter square (kg/m\^2) at time of starting an integrase (INI)-based regimen plus Tenofovir Alafenamide/Em...",No,2024-05-19,FDA-14995,0.56,0.15,3.5,4.21,2024-03-21,2024-05-15,2027-11-14,4,Bayer,67,Senegal,48.16666666666666,7,43,87,58,28,66,55,0,2,4,False,False,False,True,False,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
INI Based Regimen,AltName B,Drug,hiv,hiv,Phase 4,2023-08-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Body Mass Index (BMI) of greater than or equal to (\>=) 18 kilogram per meter square (kg/m\^2) at time of starting an integrase (INI)-based regimen plus Tenofovir Alafenamide/Em...",No,2024-03-14,FDA-77672,0.56,0.15,3.5,4.21,2024-03-21,2024-05-15,2027-11-14,91,GSK,23,Senegal,28.66666666666667,15,27,16,16,26,72,55,1,2,3,False,True,False,False,True,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Twinrix,TradeName X,Drug,hiv,hiv,Phase 2,2012-08-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* DSM-IV diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or major depression
* Diagnosis of a substance use disorder
* Enrolled in clinical care at Creativ...",No,2013-05-24,FDA-25140,4.41,0.98,21.0,26.39,2016-12-28,2017-12-21,2038-12-21,81,Merck,89,Senegal,63.5,94,19,84,61,93,30,36,1,2,1,False,True,True,False,True,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
DTG,AltName A,Drug,hiv,hiv,Phase 3,2021-07-05,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Antiretroviral treatment naive (≤ 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection) except the use for pre-exposure prophylaxi...",No,2022-06-26,FDA-96569,2.62,0.32,5.0,7.94,2024-02-16,2024-06-12,2029-06-13,91,Bayer,74,Senegal,47.0,20,71,28,69,85,9,55,1,2,3,False,True,False,True,True,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
F/TAF,Molecule Z,Drug,hiv,hiv,Phase 3,2021-07-05,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Antiretroviral treatment naive (≤ 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection) except the use for pre-exposure prophylaxi...",No,2022-06-22,FDA-19836,2.62,0.32,5.0,7.94,2024-02-16,2024-06-12,2029-06-13,88,Novartis,84,South Africa,60.16666666666666,3,90,57,86,55,70,45,1,2,2,False,True,False,True,True,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
B/F/TAF,AltName A,Drug,hiv,hiv,Phase 3,2021-07-05,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Antiretroviral treatment naive (≤ 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection) except the use for pre-exposure prophylaxi...",No,2021-09-28,FDA-27419,2.62,0.32,5.0,7.94,2024-02-16,2024-06-12,2029-06-13,60,Merck,16,South Africa,58.33333333333334,44,49,100,37,88,32,73,0,4,4,False,False,True,False,True,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,AltName B,Drug,hiv,hiv,Phase 4,2014-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. 18 years of age or older
2. Negative ELISA for HIV-1 or HIV-2 at screening
3. Negative hepatitis B surface antigen at screening
4. Negative hepatitis C antibody at screening
5....",Yes,2015-04-18,FDA-18505,0.56,0.15,3.5,4.21,2015-05-24,2015-07-18,2019-01-16,21,Pfizer,90,Senegal,49.0,4,52,76,58,94,10,55,1,3,2,False,True,True,True,True,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Rilpivirine,AltName A,Drug,hiv,hiv,Phase 4,2014-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. 18 years of age or older
2. Negative ELISA for HIV-1 or HIV-2 at screening
3. Negative hepatitis B surface antigen at screening
4. Negative hepatitis C antibody at screening
5....",Yes,2015-02-05,FDA-93374,0.56,0.15,3.5,4.21,2015-05-24,2015-07-18,2019-01-16,22,Gilead,31,South Africa,62.83333333333334,69,77,32,89,61,49,45,2,2,1,True,True,True,False,False,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Niacin,Product Alpha,Drug,hiv,hiv,Phase 2,2013-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Currently on continuous ART for ≥48 weeks.
* CD4+ cell count ≥100/mm3 obtained within 60 days prior to study entry.
* Most recent HIV-1 RNA below the limit of ...",Yes,2014-08-14,FDA-99431,4.41,0.98,21.0,26.39,2018-02-27,2019-02-20,2040-02-20,13,GSK,12,Kenya,58.0,49,100,99,74,21,5,55,2,2,2,True,True,True,False,False,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Aspirin,Comp Beta,Drug,hiv,hiv,Phase 2,2013-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Currently on continuous ART for ≥48 weeks.
* CD4+ cell count ≥100/mm3 obtained within 60 days prior to study entry.
* Most recent HIV-1 RNA below the limit of ...",Yes,2013-11-19,FDA-83641,4.41,0.98,21.0,26.39,2018-02-27,2019-02-20,2040-02-20,43,Sanofi,61,Kenya,29.16666666666667,61,68,22,1,13,10,55,1,1,4,False,True,False,True,False,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Fenofibrate,TradeName X,Drug,hiv,hiv,Phase 2,2013-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Currently on continuous ART for ≥48 weeks.
* CD4+ cell count ≥100/mm3 obtained within 60 days prior to study entry.
* Most recent HIV-1 RNA below the limit of ...",No,2013-11-28,FDA-47841,4.41,0.98,21.0,26.39,2018-02-27,2019-02-20,2040-02-20,6,Bayer,89,South Africa,36.16666666666666,35,18,6,49,49,60,55,1,4,1,True,False,True,True,False,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rifapentine 600 mg and INH 300 mg,Product Alpha,Drug,hiv,hiv,Phase 4,2024-06-10,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

* Positive tuberculin skin test or interferon-gamma release assay (IGRA) test and
* Household contact of an infectious TB case within previous 90 days, defined as sleeping at leas...",Yes,2024-09-20,FDA-78153,0.56,0.15,3.5,4.21,2024-12-31,2025-02-24,2028-08-25,67,J&J,40,Senegal,47.83333333333334,22,3,81,40,62,79,18,2,0,0,True,True,False,False,False,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rifapentine 900 mg and INH 900 mg,Product Alpha,Drug,hiv,hiv,Phase 4,2024-06-10,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

* Positive tuberculin skin test or interferon-gamma release assay (IGRA) test and
* Household contact of an infectious TB case within previous 90 days, defined as sleeping at leas...",No,2024-11-08,FDA-97162,0.56,0.15,3.5,4.21,2024-12-31,2025-02-24,2028-08-25,27,Merck,11,Overall,35.16666666666666,61,29,0,53,33,35,55,0,4,2,False,False,True,True,True,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC,GenName Y,Drug,hiv,hiv,Phase 3,2020-09-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subject must be antiretroviral (ARV) treatment-naive (never treated with an ARV including post-exposure prophylaxis and pre-exposure prophylaxis); no prior use of any approved o...",No,2021-04-27,FDA-45753,2.62,0.32,5.0,7.94,2023-05-14,2023-09-08,2028-09-08,18,Sanofi,78,Kenya,44.66666666666666,63,85,59,38,19,4,45,1,4,0,True,False,True,False,True,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DRV/COBI FDC,GenName Y,Drug,hiv,hiv,Phase 3,2020-09-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subject must be antiretroviral (ARV) treatment-naive (never treated with an ARV including post-exposure prophylaxis and pre-exposure prophylaxis); no prior use of any approved o...",No,2021-04-01,FDA-67432,2.62,0.32,5.0,7.94,2023-05-14,2023-09-08,2028-09-08,75,Pfizer,41,Kenya,42.16666666666666,11,34,74,95,23,16,45,0,2,3,False,False,True,False,False,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TDF FDC,Product Alpha,Drug,hiv,hiv,Phase 3,2020-09-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subject must be antiretroviral (ARV) treatment-naive (never treated with an ARV including post-exposure prophylaxis and pre-exposure prophylaxis); no prior use of any approved o...",No,2021-05-16,FDA-51267,2.62,0.32,5.0,7.94,2023-05-14,2023-09-08,2028-09-08,39,Gilead,51,Senegal,43.66666666666666,37,51,46,31,77,20,64,1,4,2,False,True,True,True,False,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
r-metHuLeptin,Comp Beta,Drug,hiv,hiv,Phase 2,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* At least 18 years old
* Documented HIV infection
* Exposed to at least 6 months of cumulative highly active antiretroviral medications for HIV
* Developed fat depletion after st...",No,2011-07-18,FDA-59855,4.41,0.98,21.0,26.39,2015-10-28,2016-10-20,2037-10-20,14,Merck,12,Overall,62.83333333333334,72,86,39,34,62,84,45,0,3,2,False,False,True,False,False,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
filgrastim,Product Alpha,Biological,hiv,hiv,Phase 2,2013-07-01,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed Burkitt's lymphoma (BL) or new WHO 2009 criteria B-cell lymphoma unclassified (with features intermediated between difuse large B-cell lymphoma and...",No,2014-06-10,FDA-16158,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,84,J&J,39,Overall,50.0,58,34,92,19,36,61,36,1,1,2,True,False,False,True,False,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
pegfilgrastim,TradeName X,Biological,hiv,hiv,Phase 2,2013-07-01,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed Burkitt's lymphoma (BL) or new WHO 2009 criteria B-cell lymphoma unclassified (with features intermediated between difuse large B-cell lymphoma and...",Yes,2013-09-02,FDA-50243,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,91,Pfizer,83,Senegal,50.0,25,49,85,51,54,36,73,2,4,2,True,True,True,True,True,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
rituximab,GenName Y,Biological,hiv,hiv,Phase 2,2013-07-01,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed Burkitt's lymphoma (BL) or new WHO 2009 criteria B-cell lymphoma unclassified (with features intermediated between difuse large B-cell lymphoma and...",No,2014-03-11,FDA-96501,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,94,Gilead,85,Overall,41.83333333333334,31,40,48,17,85,30,64,1,5,1,False,True,True,True,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
cyclophosphamide,Molecule Z,Drug,hiv,hiv,Phase 2,2013-07-01,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed Burkitt's lymphoma (BL) or new WHO 2009 criteria B-cell lymphoma unclassified (with features intermediated between difuse large B-cell lymphoma and...",Yes,2014-01-18,FDA-36039,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,33,AstraZeneca,27,Kenya,36.16666666666666,13,65,66,30,35,8,55,1,2,3,False,True,False,True,False,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
cytarabine,Molecule Z,Drug,hiv,hiv,Phase 2,2013-07-01,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed Burkitt's lymphoma (BL) or new WHO 2009 criteria B-cell lymphoma unclassified (with features intermediated between difuse large B-cell lymphoma and...",No,2013-12-14,FDA-39804,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,40,Novartis,41,Overall,53.0,71,55,55,99,13,25,64,2,3,2,True,True,False,False,True,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
doxorubicin hydrochloride,GenName Y,Drug,hiv,hiv,Phase 2,2013-07-01,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed Burkitt's lymphoma (BL) or new WHO 2009 criteria B-cell lymphoma unclassified (with features intermediated between difuse large B-cell lymphoma and...",No,2014-01-30,FDA-98165,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,34,J&J,12,Overall,31.66666666666667,0,25,12,16,47,90,36,0,2,2,False,False,False,False,True,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
etoposide,TradeName X,Drug,hiv,hiv,Phase 2,2013-07-01,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed Burkitt's lymphoma (BL) or new WHO 2009 criteria B-cell lymphoma unclassified (with features intermediated between difuse large B-cell lymphoma and...",No,2013-08-15,FDA-69687,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,0,J&J,11,Overall,46.0,47,19,42,67,76,25,36,0,2,2,False,False,False,False,True,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ifosfamide,GenName Y,Drug,hiv,hiv,Phase 2,2013-07-01,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed Burkitt's lymphoma (BL) or new WHO 2009 criteria B-cell lymphoma unclassified (with features intermediated between difuse large B-cell lymphoma and...",Yes,2014-06-23,FDA-95782,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,38,Sanofi,56,Senegal,43.83333333333334,2,10,24,60,95,72,27,1,1,1,False,True,False,False,False,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
leucovorin calcium,TradeName X,Drug,hiv,hiv,Phase 2,2013-07-01,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed Burkitt's lymphoma (BL) or new WHO 2009 criteria B-cell lymphoma unclassified (with features intermediated between difuse large B-cell lymphoma and...",No,2014-01-27,FDA-43625,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,59,Novartis,59,South Africa,44.16666666666666,36,23,78,23,17,88,45,0,3,2,False,False,True,False,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
liposomal cytarabine,GenName Y,Drug,hiv,hiv,Phase 2,2013-07-01,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed Burkitt's lymphoma (BL) or new WHO 2009 criteria B-cell lymphoma unclassified (with features intermediated between difuse large B-cell lymphoma and...",Yes,2014-02-11,FDA-30703,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,55,GSK,45,Overall,78.66666666666667,58,81,86,100,52,95,55,1,4,1,False,True,True,False,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
methotrexate,GenName Y,Drug,hiv,hiv,Phase 2,2013-07-01,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed Burkitt's lymphoma (BL) or new WHO 2009 criteria B-cell lymphoma unclassified (with features intermediated between difuse large B-cell lymphoma and...",Yes,2014-04-03,FDA-79394,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,100,Merck,24,Senegal,43.33333333333334,18,27,87,15,15,98,73,2,4,2,True,True,True,True,True,False,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
therapeutic hydrocortisone,Comp Beta,Drug,hiv,hiv,Phase 2,2013-07-01,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed Burkitt's lymphoma (BL) or new WHO 2009 criteria B-cell lymphoma unclassified (with features intermediated between difuse large B-cell lymphoma and...",No,2014-06-07,FDA-42674,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,5,Sanofi,45,Kenya,42.16666666666666,24,52,7,22,84,64,27,0,1,2,False,False,False,False,False,False,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
vincristine sulfate,Comp Beta,Drug,hiv,hiv,Phase 2,2013-07-01,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed Burkitt's lymphoma (BL) or new WHO 2009 criteria B-cell lymphoma unclassified (with features intermediated between difuse large B-cell lymphoma and...",Yes,2014-01-21,FDA-37181,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,55,Sanofi,40,Overall,26.83333333333333,64,2,14,57,3,21,45,1,3,1,True,False,False,True,True,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
bleomycin sulfate,TradeName X,Biological,hiv,hiv,Phase 2,2022-06-30,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed classical Hodgkin lymphoma (HL) (i.e., nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted)

  * Previously untreated sta...",No,2023-05-31,FDA-57197,4.41,0.98,21.0,26.39,2026-11-26,2027-11-19,2048-11-18,14,Merck,72,Senegal,70.5,37,53,91,98,89,55,36,1,2,1,False,True,False,True,False,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
filgrastim,Comp Beta,Biological,hiv,hiv,Phase 2,2022-06-30,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed classical Hodgkin lymphoma (HL) (i.e., nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted)

  * Previously untreated sta...",Yes,2023-01-03,FDA-26365,4.41,0.98,21.0,26.39,2026-11-26,2027-11-19,2048-11-18,74,Pfizer,25,Overall,43.33333333333334,47,20,59,8,65,61,45,1,2,2,True,False,False,False,True,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ABVD regimen,Product Alpha,Drug,hiv,hiv,Phase 2,2022-06-30,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed classical Hodgkin lymphoma (HL) (i.e., nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted)

  * Previously untreated sta...",No,2022-09-23,FDA-83971,4.41,0.98,21.0,26.39,2026-11-26,2027-11-19,2048-11-18,98,Gilead,87,Overall,65.66666666666667,72,65,65,55,51,86,36,1,1,2,False,True,True,False,False,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
BEACOPP regimen,Comp Beta,Drug,hiv,hiv,Phase 2,2022-06-30,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed classical Hodgkin lymphoma (HL) (i.e., nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted)

  * Previously untreated sta...",No,2022-12-10,FDA-22101,4.41,0.98,21.0,26.39,2026-11-26,2027-11-19,2048-11-18,6,Bayer,82,Overall,64.5,58,99,94,52,64,20,36,1,1,2,False,True,False,False,False,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
cyclophosphamide,GenName Y,Drug,hiv,hiv,Phase 2,2022-06-30,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed classical Hodgkin lymphoma (HL) (i.e., nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted)

  * Previously untreated sta...",Yes,2022-10-18,FDA-84054,4.41,0.98,21.0,26.39,2026-11-26,2027-11-19,2048-11-18,30,AstraZeneca,74,Senegal,34.0,12,9,56,25,97,5,45,1,2,2,True,False,True,False,False,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
dacarbazine,Molecule Z,Drug,hiv,hiv,Phase 2,2022-06-30,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed classical Hodgkin lymphoma (HL) (i.e., nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted)

  * Previously untreated sta...",Yes,2023-05-26,FDA-20769,4.41,0.98,21.0,26.39,2026-11-26,2027-11-19,2048-11-18,71,Merck,77,Kenya,52.16666666666666,65,55,4,91,0,98,36,1,2,1,True,False,False,False,False,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
doxorubicin hydrochloride,AltName A,Drug,hiv,hiv,Phase 2,2022-06-30,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed classical Hodgkin lymphoma (HL) (i.e., nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted)

  * Previously untreated sta...",Yes,2023-04-28,FDA-30424,4.41,0.98,21.0,26.39,2026-11-26,2027-11-19,2048-11-18,98,AstraZeneca,31,Senegal,46.0,84,28,4,34,87,39,45,1,2,2,False,True,False,True,True,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
etoposide,Molecule Z,Drug,hiv,hiv,Phase 2,2022-06-30,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed classical Hodgkin lymphoma (HL) (i.e., nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted)

  * Previously untreated sta...",Yes,2023-05-29,FDA-67912,4.41,0.98,21.0,26.39,2026-11-26,2027-11-19,2048-11-18,3,Bayer,100,Kenya,48.83333333333334,40,96,50,22,42,43,27,0,2,1,False,False,True,False,True,False,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
prednisone,TradeName X,Drug,hiv,hiv,Phase 2,2022-06-30,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed classical Hodgkin lymphoma (HL) (i.e., nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted)

  * Previously untreated sta...",No,2022-10-07,FDA-85747,4.41,0.98,21.0,26.39,2026-11-26,2027-11-19,2048-11-18,92,Novartis,82,South Africa,46.16666666666666,63,38,49,55,37,35,45,1,2,2,True,False,False,True,False,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
procarbazine hydrochloride,AltName A,Drug,hiv,hiv,Phase 2,2022-06-30,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed classical Hodgkin lymphoma (HL) (i.e., nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted)

  * Previously untreated sta...",Yes,2023-02-26,FDA-69700,4.41,0.98,21.0,26.39,2026-11-26,2027-11-19,2048-11-18,86,J&J,74,Overall,46.0,15,59,85,8,34,75,36,0,2,2,False,False,False,False,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
vinblastine sulfate,Product Alpha,Drug,hiv,hiv,Phase 2,2022-06-30,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed classical Hodgkin lymphoma (HL) (i.e., nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted)

  * Previously untreated sta...",Yes,2022-08-12,FDA-39699,4.41,0.98,21.0,26.39,2026-11-26,2027-11-19,2048-11-18,64,Bayer,88,Kenya,33.16666666666666,39,67,17,2,55,19,64,1,3,3,False,True,True,False,False,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
vincristine sulfate,GenName Y,Drug,hiv,hiv,Phase 2,2022-06-30,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed classical Hodgkin lymphoma (HL) (i.e., nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted)

  * Previously untreated sta...",No,2023-02-12,FDA-32885,4.41,0.98,21.0,26.39,2026-11-26,2027-11-19,2048-11-18,41,GSK,56,Kenya,78.5,84,63,59,81,89,95,18,0,1,1,False,False,True,False,False,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Artemether-lumefantrine,TradeName X,Drug,hiv,hiv,Phase 4,2021-08-31,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

1, All participants:

1. Residency within 60 km of the study clinics either at TDH or at MGH
2. Agreement to come to clinic for all follow-up clinical and PK evaluations
3. Provis...",Yes,2022-05-07,FDA-19192,0.56,0.15,3.5,4.21,2022-03-23,2022-05-17,2025-11-15,38,Sanofi,11,Overall,53.83333333333334,44,36,75,57,69,42,64,1,4,2,False,True,True,True,True,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
F/TAF,GenName Y,Drug,hiv,hiv,Phase 3,2024-12-11,"Sex: ALL; Age: >1 Month; Criteria: Key Inclusion Criteria:

* Human immunodeficiency virus 1 (HIV-1) infected male and female adolescents and children aged 1 month to \< 18 years at baseline/Day 1 (according to requirements of the enro...",No,2025-08-23,FDA-85199,2.62,0.32,5.0,7.94,2027-07-25,2027-11-19,2032-11-19,46,Bayer,61,South Africa,48.83333333333334,64,53,81,20,53,22,36,1,3,0,False,True,True,False,True,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
3rd ARV agent,AltName A,Drug,hiv,hiv,Phase 3,2024-12-11,"Sex: ALL; Age: >1 Month; Criteria: Key Inclusion Criteria:

* Human immunodeficiency virus 1 (HIV-1) infected male and female adolescents and children aged 1 month to \< 18 years at baseline/Day 1 (according to requirements of the enro...",Yes,2025-09-24,FDA-63834,2.62,0.32,5.0,7.94,2027-07-25,2027-11-19,2032-11-19,39,Sanofi,75,Kenya,63.0,95,51,80,21,46,85,55,1,4,1,False,True,True,True,True,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Boosted PIs,GenName Y,Drug,hiv,hiv,Phase 3,2024-12-11,"Sex: ALL; Age: >1 Month; Criteria: Key Inclusion Criteria:

* Human immunodeficiency virus 1 (HIV-1) infected male and female adolescents and children aged 1 month to \< 18 years at baseline/Day 1 (according to requirements of the enro...",No,2025-04-12,FDA-55695,2.62,0.32,5.0,7.94,2027-07-25,2027-11-19,2032-11-19,21,Novartis,72,Kenya,40.66666666666666,27,8,19,20,87,83,55,0,2,4,False,False,True,False,False,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
H56ug/IC31nmol,Product Alpha,Biological,hiv,hiv,Phase 2,2015-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Subjects must meet all of the following criteria prior to Study Day 0 vaccination:

1. Has completed the written informed consent process prior to the start of screening evaluatio...",Yes,2016-03-08,FDA-67058,4.41,0.98,21.0,26.39,2020-03-29,2021-03-22,2042-03-22,65,Merck,76,South Africa,47.5,14,61,96,83,10,21,45,1,2,2,True,False,False,True,True,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Digital pill,TradeName X,Device,hiv,hiv,Phase 4,2020-04-22,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

1. MSM (cisgender male)
2. Self-reported use of non-alcohol substances of abuse in past 6 months
3. Currently taking PrEP
4. Has qualifying laboratory tests (Cr, hepatitis B immun...",No,2020-06-29,FDA-19672,0.56,0.15,3.5,4.21,2020-11-12,2021-01-06,2024-07-07,78,AstraZeneca,88,Senegal,42.0,57,37,6,31,81,40,18,1,1,0,False,True,False,False,False,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Truvada,Product Alpha,Drug,hiv,hiv,Phase 4,2020-04-22,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

1. MSM (cisgender male)
2. Self-reported use of non-alcohol substances of abuse in past 6 months
3. Currently taking PrEP
4. Has qualifying laboratory tests (Cr, hepatitis B immun...",No,2021-02-10,FDA-69971,0.56,0.15,3.5,4.21,2020-11-12,2021-01-06,2024-07-07,45,Bayer,84,Overall,40.5,32,86,9,53,61,2,45,1,2,2,True,False,False,True,False,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK's investigational vaccine 692342,Molecule Z,Biological,hiv,hiv,Phase 2,2010-09-30,"Sex: ALL; Age: >13 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that they and their parent(s)/ legal guardian(s) can and will comply with the requirements of the protocol.
* A male or female between, an...",No,2011-04-29,FDA-86747,4.41,0.98,21.0,26.39,2015-02-26,2016-02-19,2037-02-18,79,GSK,89,Overall,48.83333333333334,98,71,44,46,25,9,55,2,2,2,True,True,True,False,False,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
CVC 150 mg,GenName Y,Drug,hiv,hiv,Phase 2,2024-06-19,"Sex: ALL; Age: >45 Years; Criteria: Key Inclusion Criteria:

1. Documented to be living with HIV-1 infection.
2. Currently on a stable, continuous NNRTI-based or unboosted INSTI-based ART regimen for ≥48 weeks prior to study entry with ...",No,2024-09-01,FDA-72027,4.41,0.98,21.0,26.39,2028-11-15,2029-11-08,2050-11-08,80,Novartis,81,South Africa,60.16666666666666,70,49,94,39,21,88,36,1,1,2,False,True,False,False,False,False,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
CVC 300 mg,Molecule Z,Drug,hiv,hiv,Phase 2,2024-06-19,"Sex: ALL; Age: >45 Years; Criteria: Key Inclusion Criteria:

1. Documented to be living with HIV-1 infection.
2. Currently on a stable, continuous NNRTI-based or unboosted INSTI-based ART regimen for ≥48 weeks prior to study entry with ...",No,2024-10-06,FDA-29144,4.41,0.98,21.0,26.39,2028-11-15,2029-11-08,2050-11-08,60,Bayer,77,Kenya,66.0,67,18,91,65,90,65,45,0,1,4,False,False,False,False,False,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Telmisartan,GenName Y,Drug,hiv,hiv,Phase 2,2016-03-01,"Sex: ALL; Age: >18 Years; Criteria: Step 1 Inclusion Criteria:

* HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to Step 1 entry and confirmed...",Yes,2016-06-12,FDA-78296,4.41,0.98,21.0,26.39,2020-07-28,2021-07-21,2042-07-21,70,Pfizer,51,South Africa,52.83333333333334,76,28,80,40,46,47,55,2,2,2,True,True,False,False,True,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
cyclophosphamide,GenName Y,Drug,hiv,hiv,Phase 2,2021-07-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and the willingness to provide written informed consent to participate
* Adults, 18 years of age or older; date of birth should be determined based on the ...",No,2021-11-28,FDA-82951,4.41,0.98,21.0,26.39,2025-12-11,2026-12-04,2047-12-04,86,J&J,81,Overall,51.83333333333334,57,88,27,58,24,57,27,0,1,2,False,False,False,False,True,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
doxorubicin hydrochloride,TradeName X,Drug,hiv,hiv,Phase 2,2021-07-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and the willingness to provide written informed consent to participate
* Adults, 18 years of age or older; date of birth should be determined based on the ...",No,2022-05-22,FDA-19949,4.41,0.98,21.0,26.39,2025-12-11,2026-12-04,2047-12-04,67,Merck,86,South Africa,52.33333333333334,77,27,74,56,64,16,64,0,4,3,False,False,True,True,True,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
vincristine sulfate,AltName A,Drug,hiv,hiv,Phase 2,2021-07-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and the willingness to provide written informed consent to participate
* Adults, 18 years of age or older; date of birth should be determined based on the ...",No,2022-05-11,FDA-53014,4.41,0.98,21.0,26.39,2025-12-11,2026-12-04,2047-12-04,49,GSK,49,South Africa,40.0,22,1,68,10,90,49,36,0,2,2,False,False,True,True,False,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
prednisone,Comp Beta,Drug,hiv,hiv,Phase 2,2021-07-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and the willingness to provide written informed consent to participate
* Adults, 18 years of age or older; date of birth should be determined based on the ...",Yes,2022-03-25,FDA-81528,4.41,0.98,21.0,26.39,2025-12-11,2026-12-04,2047-12-04,90,Gilead,83,Kenya,57.33333333333334,90,31,62,66,3,92,73,2,3,3,True,True,False,True,False,True,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
lomustine,AltName A,Drug,hiv,hiv,Phase 2,2021-07-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and the willingness to provide written informed consent to participate
* Adults, 18 years of age or older; date of birth should be determined based on the ...",Yes,2021-12-23,FDA-45087,4.41,0.98,21.0,26.39,2025-12-11,2026-12-04,2047-12-04,35,Bayer,61,Overall,51.5,23,23,98,95,50,20,36,1,2,1,True,False,True,False,False,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
etoposide,TradeName X,Drug,hiv,hiv,Phase 2,2021-07-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and the willingness to provide written informed consent to participate
* Adults, 18 years of age or older; date of birth should be determined based on the ...",Yes,2022-03-12,FDA-22911,4.41,0.98,21.0,26.39,2025-12-11,2026-12-04,2047-12-04,39,Bayer,19,South Africa,63.83333333333334,57,94,45,48,62,77,64,2,3,2,True,True,False,True,False,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
cyclophosphamide,AltName B,Drug,hiv,hiv,Phase 2,2021-07-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and the willingness to provide written informed consent to participate
* Adults, 18 years of age or older; date of birth should be determined based on the ...",No,2022-02-04,FDA-24268,4.41,0.98,21.0,26.39,2025-12-11,2026-12-04,2047-12-04,28,Gilead,14,Kenya,55.66666666666666,29,4,98,81,53,69,55,1,4,1,False,True,True,True,True,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
procarbazine hydrochloride,AltName A,Drug,hiv,hiv,Phase 2,2021-07-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and the willingness to provide written informed consent to participate
* Adults, 18 years of age or older; date of birth should be determined based on the ...",No,2022-06-13,FDA-27735,4.41,0.98,21.0,26.39,2025-12-11,2026-12-04,2047-12-04,20,Bayer,33,Kenya,59.33333333333334,38,80,85,81,44,28,27,1,0,2,True,False,False,False,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rifaximin,Comp Beta,Drug,hiv,hiv,Phase 2,2012-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* On ART for at least 96 weeks prior to study entry with a regimen that includes three or more antiretroviral medications. (Ritonavir ≤ 400 mg/day will not be co...",No,2013-05-16,FDA-55210,4.41,0.98,21.0,26.39,2017-03-30,2018-03-23,2039-03-23,59,Sanofi,50,South Africa,57.0,44,45,63,72,81,37,27,1,2,0,False,True,True,False,True,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate),Comp Beta,Drug,hiv,hiv,Phase 2,2013-08-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Informed consent obtained and informed consent form (ICF) signed.
* Female, aged 18-45 years.
* Sexually active with greater than or equal to 4 episodes of sex with a male partn...",Yes,2014-01-12,FDA-24412,4.41,0.98,21.0,26.39,2017-12-28,2018-12-21,2039-12-21,16,Bayer,63,Kenya,33.0,8,9,51,18,67,45,55,1,3,2,True,False,True,False,True,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
pioglitazone,GenName Y,Drug,hiv,hiv,Phase 2,2011-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

For Step 1:

* HIV infected
* Exhibited no response to previous treatment with PEG-IFN alfa-2a 180 mcg/week or alfa-2b 1.5 mcg/kg/week and at least 1000 mg/day ribavirin given for...",No,2012-11-29,FDA-17531,4.41,0.98,21.0,26.39,2016-04-28,2017-04-21,2038-04-21,21,Pfizer,37,South Africa,53.5,98,11,41,81,48,42,55,2,3,1,True,True,True,True,True,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
peginterferon,TradeName X,Drug,hiv,hiv,Phase 2,2011-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

For Step 1:

* HIV infected
* Exhibited no response to previous treatment with PEG-IFN alfa-2a 180 mcg/week or alfa-2b 1.5 mcg/kg/week and at least 1000 mg/day ribavirin given for...",No,2012-01-22,FDA-93199,4.41,0.98,21.0,26.39,2016-04-28,2017-04-21,2038-04-21,24,J&J,79,Overall,68.5,44,95,65,87,22,98,82,2,4,3,True,True,False,True,True,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ribavirin,Comp Beta,Drug,hiv,hiv,Phase 2,2011-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

For Step 1:

* HIV infected
* Exhibited no response to previous treatment with PEG-IFN alfa-2a 180 mcg/week or alfa-2b 1.5 mcg/kg/week and at least 1000 mg/day ribavirin given for...",Yes,2012-05-23,FDA-89848,4.41,0.98,21.0,26.39,2016-04-28,2017-04-21,2038-04-21,23,GSK,42,Senegal,49.16666666666666,4,96,54,46,90,5,55,1,3,2,True,False,True,True,False,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir,Comp Beta,Drug,hiv,hiv,Phase 2,2010-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1-infected
* Plasma HIV-1 RNA of at least 5,000 copies/mL within 90 days prior to study entry
* HIV genotype (for reverse transcriptase and protease) performed at any time p...",No,2011-08-28,FDA-94428,4.41,0.98,21.0,26.39,2015-01-28,2016-01-21,2037-01-20,64,Merck,16,Overall,41.83333333333334,89,3,37,29,31,62,73,1,4,3,False,True,False,True,True,True,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Darunavir/Ritonavir,AltName B,Drug,hiv,hiv,Phase 2,2010-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1-infected
* Plasma HIV-1 RNA of at least 5,000 copies/mL within 90 days prior to study entry
* HIV genotype (for reverse transcriptase and protease) performed at any time p...",No,2011-07-05,FDA-27852,4.41,0.98,21.0,26.39,2015-01-28,2016-01-21,2037-01-20,86,Bayer,65,Overall,70.16666666666667,51,75,89,74,75,57,9,0,1,0,False,False,False,True,False,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
EPOCH-R,TradeName X,Drug,hiv,hiv,Phase 2,2023-02-16,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

Patients must have one of the following histologic diagnoses:

-Patients must have Burkitt Lymphoma. Effective with Amendment J (version date: 06/24/2014), the following histolo...",Yes,2023-08-13,FDA-93853,4.41,0.98,21.0,26.39,2027-07-15,2028-07-07,2049-07-07,81,Merck,82,Kenya,31.83333333333333,21,40,57,19,18,36,55,1,3,2,False,True,True,True,False,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
EPOCH-RR,TradeName X,Drug,hiv,hiv,Phase 2,2023-02-16,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

Patients must have one of the following histologic diagnoses:

-Patients must have Burkitt Lymphoma. Effective with Amendment J (version date: 06/24/2014), the following histolo...",Yes,2023-11-11,FDA-89193,4.41,0.98,21.0,26.39,2027-07-15,2028-07-07,2049-07-07,34,Pfizer,5,South Africa,62.16666666666666,94,34,21,76,64,84,45,0,2,3,False,False,True,False,False,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Doxycycline Hyclate Delayed-Release 200 mg,AltName A,Drug,hiv,hiv,Phase 4,2023-06-12,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Willing and able to give written informed consent
* Age ≥ 18 years
* Male sex at birth
* Previously HIV-diagnosed OR HIV-seronegative at the time of last test within the past mo...",No,2024-04-04,FDA-41616,0.56,0.15,3.5,4.21,2024-01-02,2024-02-26,2027-08-27,95,Sanofi,38,South Africa,31.16666666666667,24,38,20,99,2,4,45,0,3,2,False,False,True,True,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,Product Alpha,Drug,hiv,hiv,Phase 3,2014-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Plasma HIV-1 RNA equal to or greater than 1,000 copies/mL measured at the Screening Visit.
* CD4 count equal to or greater than 100 cells/mm3 at Screening.
* Have only R5 HIV 1 ...",No,2014-12-21,FDA-65265,2.62,0.32,5.0,7.94,2016-08-14,2016-12-09,2021-12-10,3,GSK,23,Overall,34.33333333333334,7,43,84,1,10,61,55,1,2,3,False,True,True,False,False,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine/tenofovir,AltName B,Drug,hiv,hiv,Phase 3,2014-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Plasma HIV-1 RNA equal to or greater than 1,000 copies/mL measured at the Screening Visit.
* CD4 count equal to or greater than 100 cells/mm3 at Screening.
* Have only R5 HIV 1 ...",No,2014-09-08,FDA-99658,2.62,0.32,5.0,7.94,2016-08-14,2016-12-09,2021-12-10,15,AstraZeneca,71,Kenya,41.83333333333334,37,84,3,52,13,62,45,0,2,3,False,False,False,True,True,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
darunavir/ritonavir 800/100 mg,AltName A,Drug,hiv,hiv,Phase 3,2014-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Plasma HIV-1 RNA equal to or greater than 1,000 copies/mL measured at the Screening Visit.
* CD4 count equal to or greater than 100 cells/mm3 at Screening.
* Have only R5 HIV 1 ...",No,2014-07-16,FDA-78095,2.62,0.32,5.0,7.94,2016-08-14,2016-12-09,2021-12-10,74,AstraZeneca,1,South Africa,55.33333333333334,52,84,62,37,67,30,64,1,3,3,False,True,True,False,True,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
TDF,TradeName X,Drug,hiv,hiv,Phase 4,2016-08-23,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Chronic hepatitis B, hepatitis B e-antigen negative, hepatitis B e-antibody positive, and hepatitis B surface antigen-positive
* Hepatitis B e Antigen (HBeAg)-negative at th...",Yes,2017-04-08,FDA-87377,0.56,0.15,3.5,4.21,2017-03-15,2017-05-09,2020-11-07,60,J&J,50,Senegal,34.0,57,53,5,41,10,38,45,1,2,2,True,False,True,False,True,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
SOF/VEL for 6 weeks,TradeName X,Drug,hiv,hiv,Phase 3,2020-03-23,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects must meet all of the following inclusion criteria to be eligible to participate in this study:

  1. Participants have voluntarily signed the informed consent form.
  2...",Yes,2020-05-09,FDA-68190,2.62,0.32,5.0,7.94,2022-11-04,2023-03-01,2028-03-01,10,Pfizer,27,South Africa,28.5,37,60,2,17,29,26,18,0,2,0,False,False,False,False,True,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
SOF/VEL for 12 weeks,Product Alpha,Drug,hiv,hiv,Phase 3,2020-03-23,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects must meet all of the following inclusion criteria to be eligible to participate in this study:

  1. Participants have voluntarily signed the informed consent form.
  2...",Yes,2020-07-13,FDA-75893,2.62,0.32,5.0,7.94,2022-11-04,2023-03-01,2028-03-01,75,Novartis,40,Senegal,55.66666666666666,14,65,55,56,72,72,55,2,2,2,True,True,True,False,False,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ISL,Product Alpha,Drug,hiv,hiv,Phase 2,2027-11-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Received bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for ≥ 24 weeks at screening.
* Documented plasma human immunodeficiency virus type 1 (HIV-1) ribonucleic a...",No,2028-02-29,FDA-45096,4.41,0.98,21.0,26.39,2032-03-29,2033-03-22,2054-03-22,86,GSK,28,Kenya,34.66666666666666,61,5,20,44,78,0,9,0,1,0,False,False,False,False,True,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
LEN,Molecule Z,Drug,hiv,hiv,Phase 2,2027-11-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Received bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for ≥ 24 weeks at screening.
* Documented plasma human immunodeficiency virus type 1 (HIV-1) ribonucleic a...",Yes,2028-02-18,FDA-71183,4.41,0.98,21.0,26.39,2032-03-29,2033-03-22,2054-03-22,67,Bayer,23,Kenya,64.16666666666667,48,34,51,87,96,69,18,0,2,0,False,False,True,False,True,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
B/F/TAF,Comp Beta,Drug,hiv,hiv,Phase 2,2027-11-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Received bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for ≥ 24 weeks at screening.
* Documented plasma human immunodeficiency virus type 1 (HIV-1) ribonucleic a...",No,2028-02-18,FDA-69411,4.41,0.98,21.0,26.39,2032-03-29,2033-03-22,2054-03-22,37,AstraZeneca,57,Overall,52.16666666666666,98,41,49,32,3,90,73,1,4,3,True,False,True,True,True,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ISL/LEN FDC,Product Alpha,Drug,hiv,hiv,Phase 2,2027-11-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Received bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for ≥ 24 weeks at screening.
* Documented plasma human immunodeficiency virus type 1 (HIV-1) ribonucleic a...",Yes,2027-12-13,FDA-40994,4.41,0.98,21.0,26.39,2032-03-29,2033-03-22,2054-03-22,34,Gilead,67,Overall,77.66666666666667,85,96,44,99,67,75,45,2,1,2,True,True,False,False,False,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Raltegravir/3TC,Product Alpha,Drug,hiv,hiv,Phase 3,2017-02-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Eligible patients will be males or females at least 18 years of age. Women of childbearing potential must have a negative pregnancy test within 10 days prior to randomization i...",No,2017-06-29,FDA-24249,2.62,0.32,5.0,7.94,2019-10-12,2020-02-06,2025-02-06,80,Gilead,17,Senegal,59.83333333333334,42,35,40,88,85,69,55,0,4,2,False,False,True,True,False,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
EFV/TDF/FTC,Product Alpha,Drug,hiv,hiv,Phase 3,2017-02-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Eligible patients will be males or females at least 18 years of age. Women of childbearing potential must have a negative pregnancy test within 10 days prior to randomization i...",Yes,2017-12-13,FDA-83061,2.62,0.32,5.0,7.94,2019-10-12,2020-02-06,2025-02-06,17,Gilead,67,Senegal,25.33333333333333,9,18,6,54,52,13,45,2,1,2,True,True,False,True,False,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ATV/r + TDF/FTC or DRV/r + TDF/FTC,Comp Beta,Drug,hiv,hiv,Phase 3,2017-02-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Eligible patients will be males or females at least 18 years of age. Women of childbearing potential must have a negative pregnancy test within 10 days prior to randomization i...",No,2018-01-12,FDA-68735,2.62,0.32,5.0,7.94,2019-10-12,2020-02-06,2025-02-06,5,Merck,54,Kenya,46.66666666666666,34,82,10,19,85,50,36,0,3,1,False,False,True,False,True,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC,TradeName X,Drug,hiv,hiv,Phase 3,2017-02-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Eligible patients will be males or females at least 18 years of age. Women of childbearing potential must have a negative pregnancy test within 10 days prior to randomization i...",Yes,2017-09-11,FDA-69759,2.62,0.32,5.0,7.94,2019-10-12,2020-02-06,2025-02-06,46,Bayer,31,Senegal,33.5,54,57,45,18,27,0,45,0,3,2,False,False,True,True,False,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
EFV plus ABC/3TC or RPV/TDF/FTC,AltName B,Drug,hiv,hiv,Phase 3,2017-02-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Eligible patients will be males or females at least 18 years of age. Women of childbearing potential must have a negative pregnancy test within 10 days prior to randomization i...",Yes,2017-11-06,FDA-89791,2.62,0.32,5.0,7.94,2019-10-12,2020-02-06,2025-02-06,48,Merck,22,Overall,43.5,11,60,3,60,77,50,55,0,4,2,False,False,True,True,True,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ATV/r plus ABC/3TC,Molecule Z,Drug,hiv,hiv,Phase 3,2017-02-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Eligible patients will be males or females at least 18 years of age. Women of childbearing potential must have a negative pregnancy test within 10 days prior to randomization i...",No,2017-12-09,FDA-28219,2.62,0.32,5.0,7.94,2019-10-12,2020-02-06,2025-02-06,13,GSK,76,South Africa,59.66666666666666,55,82,18,91,50,62,45,0,2,3,False,False,False,False,False,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC,GenName Y,Drug,hiv,hiv,Phase 3,2017-02-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Eligible patients will be males or females at least 18 years of age. Women of childbearing potential must have a negative pregnancy test within 10 days prior to randomization i...",No,2018-01-19,FDA-70657,2.62,0.32,5.0,7.94,2019-10-12,2020-02-06,2025-02-06,90,Merck,100,South Africa,56.16666666666666,7,64,78,17,80,91,36,0,3,1,False,False,False,True,True,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
RAL plus ABC/3TC,GenName Y,Drug,hiv,hiv,Phase 3,2017-02-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Eligible patients will be males or females at least 18 years of age. Women of childbearing potential must have a negative pregnancy test within 10 days prior to randomization i...",Yes,2017-05-15,FDA-87765,2.62,0.32,5.0,7.94,2019-10-12,2020-02-06,2025-02-06,27,Gilead,8,Kenya,45.33333333333334,57,46,94,16,29,30,45,1,3,1,True,False,True,False,True,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Other ART regimens,Molecule Z,Drug,hiv,hiv,Phase 3,2017-02-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Eligible patients will be males or females at least 18 years of age. Women of childbearing potential must have a negative pregnancy test within 10 days prior to randomization i...",No,2017-09-25,FDA-73149,2.62,0.32,5.0,7.94,2019-10-12,2020-02-06,2025-02-06,7,J&J,99,Senegal,71.5,48,76,96,53,67,89,36,0,3,1,False,False,True,True,False,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
cidofovir,GenName Y,Drug,hiv,hiv,Phase 2,2010-02-01,"Sex: ALL; Age: >18 Years; Criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed perianal high-grade squamous intraepithelial lesions (HSIL) within the past 12 weeks

  * The perianal skin (i.e., perianus) is defined as extendin...",No,2010-10-01,FDA-47843,4.41,0.98,21.0,26.39,2014-06-30,2015-06-23,2036-06-22,1,Novartis,66,Overall,58.16666666666666,31,50,72,69,28,99,45,1,2,2,True,False,False,True,False,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
MVA85A/AERAS-485,Product Alpha,Biological,hiv,hiv,Phase 2,,"Sex: ALL; Age: >126 Days; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Age of 126 through 182 days on the day of randomization (Study Day 0)
2. Written informed consent obtained from the parents/guardian
3. Weight: by chart \>3rd percentile on Stu...",No,2026-03-13,FDA-39847,4.41,0.98,21.0,26.39,,,,8,Pfizer,98,Senegal,46.66666666666666,67,28,67,44,56,18,64,2,4,1,True,True,True,True,True,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Candida Skin Test Antigen,AltName A,Biological,hiv,hiv,Phase 2,,"Sex: ALL; Age: >126 Days; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Age of 126 through 182 days on the day of randomization (Study Day 0)
2. Written informed consent obtained from the parents/guardian
3. Weight: by chart \>3rd percentile on Stu...",Yes,2026-10-08,FDA-93354,4.41,0.98,21.0,26.39,,,,19,Gilead,39,Overall,53.5,76,25,7,62,85,66,73,1,5,2,False,True,True,True,True,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
maraviroc,AltName B,Drug,hiv,hiv,Phase 2,2011-07-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* HIV-1 RNA viral load of ≥1,000 copies/mL measured at the Screening Visit.
* CD4 count ≥100 cells/mm3 at Screening.
* Have only R5 HIV-1 at Screening as verified by the Monogram ...",Yes,2012-06-15,FDA-98167,4.41,0.98,21.0,26.39,2015-11-27,2016-11-19,2037-11-19,82,Merck,82,Kenya,37.5,20,92,4,38,62,9,64,2,2,3,True,True,True,True,False,False,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
maraviroc,AltName A,Drug,hiv,hiv,Phase 2,2011-07-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* HIV-1 RNA viral load of ≥1,000 copies/mL measured at the Screening Visit.
* CD4 count ≥100 cells/mm3 at Screening.
* Have only R5 HIV-1 at Screening as verified by the Monogram ...",Yes,2011-08-16,FDA-79822,4.41,0.98,21.0,26.39,2015-11-27,2016-11-19,2037-11-19,44,Bayer,22,South Africa,67.83333333333333,96,96,50,15,73,77,73,2,2,4,True,True,True,True,False,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Pitavastatin,Product Alpha,Drug,hiv,hiv,Phase 4,2013-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Males and females (non-pregnant, non-lactating females) 18-70 years of age, inclusive, at time of consent.
* Both men and women of child bearing potential (i.e., not surgically ...",No,2014-01-31,FDA-19650,0.56,0.15,3.5,4.21,2013-09-21,2013-11-15,2017-05-16,19,Pfizer,77,South Africa,53.83333333333334,42,22,95,74,0,90,64,0,4,3,False,False,True,True,False,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Pravastatin,TradeName X,Drug,hiv,hiv,Phase 4,2013-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Males and females (non-pregnant, non-lactating females) 18-70 years of age, inclusive, at time of consent.
* Both men and women of child bearing potential (i.e., not surgically ...",No,2013-09-30,FDA-98432,0.56,0.15,3.5,4.21,2013-09-21,2013-11-15,2017-05-16,8,Novartis,97,Senegal,53.5,45,89,85,4,32,66,55,1,3,2,True,False,True,True,True,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
3BNC117,Comp Beta,Drug,hiv,hiv,Phase 2,2018-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Informed consent obtained and signed.
* Males and females, age 18 to 65.
* HIV-1 infection confirmed by two independent methods.
* Plasma HIV-1 RNA \< 50 copies/ml for at least ...",No,2018-08-20,FDA-52632,4.41,0.98,21.0,26.39,2022-08-28,2023-08-21,2044-08-20,21,J&J,23,Kenya,49.5,68,60,53,91,0,25,18,1,1,0,False,True,False,False,False,True,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Visbiome Extra Strength,Product Alpha,Drug,hiv,hiv,Phase 2,2017-08-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

\- HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a l...",Yes,2017-10-10,FDA-52726,4.41,0.98,21.0,26.39,2022-01-24,2023-01-17,2044-01-17,75,Bayer,26,Overall,52.33333333333334,44,42,72,24,75,57,55,1,3,2,True,False,False,False,True,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Lopinavir/ritonavir,TradeName X,Drug,hiv,hiv,Phase 2,2016-06-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+ count \> 200 and \< 500 cells/mm\^3 obtained within 30 days prior to study entry at a DAIDS-approved laboratory.
* Pf SCP confirmed in a laboratory approv...",No,2016-10-15,FDA-97349,4.41,0.98,21.0,26.39,2020-11-15,2021-11-08,2042-11-08,67,Bayer,62,Kenya,59.16666666666666,24,63,50,100,57,61,9,0,0,1,False,False,False,False,False,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Emtricitabine/tenofovir disoproxil fumarate,GenName Y,Drug,hiv,hiv,Phase 2,2016-06-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+ count \> 200 and \< 500 cells/mm\^3 obtained within 30 days prior to study entry at a DAIDS-approved laboratory.
* Pf SCP confirmed in a laboratory approv...",No,2016-10-31,FDA-32607,4.41,0.98,21.0,26.39,2020-11-15,2021-11-08,2042-11-08,63,AstraZeneca,83,South Africa,29.5,38,24,13,87,11,4,73,1,3,4,True,False,True,True,False,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,Product Alpha,Drug,hiv,hiv,Phase 2,2016-06-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+ count \> 200 and \< 500 cells/mm\^3 obtained within 30 days prior to study entry at a DAIDS-approved laboratory.
* Pf SCP confirmed in a laboratory approv...",Yes,2016-11-08,FDA-31504,4.41,0.98,21.0,26.39,2020-11-15,2021-11-08,2042-11-08,66,J&J,90,Overall,31.66666666666667,32,0,23,3,60,72,45,1,4,0,True,False,True,True,True,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Nevirapine,Product Alpha,Drug,hiv,hiv,Phase 2,2016-06-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+ count \> 200 and \< 500 cells/mm\^3 obtained within 30 days prior to study entry at a DAIDS-approved laboratory.
* Pf SCP confirmed in a laboratory approv...",No,2017-03-24,FDA-39670,4.41,0.98,21.0,26.39,2020-11-15,2021-11-08,2042-11-08,69,AstraZeneca,45,Kenya,45.83333333333334,50,29,40,48,35,73,18,1,0,1,False,True,False,False,False,False,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Trimethoprim/sulfamethoxazole,AltName A,Drug,hiv,hiv,Phase 2,2016-06-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+ count \> 200 and \< 500 cells/mm\^3 obtained within 30 days prior to study entry at a DAIDS-approved laboratory.
* Pf SCP confirmed in a laboratory approv...",Yes,2017-01-30,FDA-32427,4.41,0.98,21.0,26.39,2020-11-15,2021-11-08,2042-11-08,6,GSK,55,South Africa,57.16666666666666,56,74,73,28,79,33,27,1,0,2,False,True,False,False,False,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"Doravirine, Tenofovir, Lamivudine",GenName Y,Drug,hiv,hiv,Phase 3,2023-09-05,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Inclusion Criteria include, but are not limited to:

* Have plasma Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) levels below the limit of quantification (BLoQ) (\<4...",Yes,2024-08-18,FDA-55396,2.62,0.32,5.0,7.94,2026-04-18,2026-08-13,2031-08-14,29,Sanofi,21,Overall,62.33333333333334,59,37,97,56,95,30,55,1,2,3,True,False,True,True,False,False,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor,Product Alpha,Drug,hiv,hiv,Phase 3,2023-09-05,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Inclusion Criteria include, but are not limited to:

* Have plasma Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) levels below the limit of quantification (BLoQ) (\<4...",Yes,2024-04-11,FDA-25164,2.62,0.32,5.0,7.94,2026-04-18,2026-08-13,2031-08-14,45,AstraZeneca,92,South Africa,45.16666666666666,60,85,37,25,0,64,64,1,3,3,True,False,True,False,True,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Baseline regimen of cobicistat-boosted elvitegravir,Product Alpha,Drug,hiv,hiv,Phase 3,2023-09-05,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Inclusion Criteria include, but are not limited to:

* Have plasma Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) levels below the limit of quantification (BLoQ) (\<4...",Yes,2024-05-25,FDA-25658,2.62,0.32,5.0,7.94,2026-04-18,2026-08-13,2031-08-14,76,J&J,16,Overall,41.16666666666666,26,72,6,13,100,30,55,1,3,2,True,False,True,False,True,True,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Baseline regimen of a non-nucleoside reverse transcriptase inhibitor,Molecule Z,Drug,hiv,hiv,Phase 3,2023-09-05,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Inclusion Criteria include, but are not limited to:

* Have plasma Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) levels below the limit of quantification (BLoQ) (\<4...",Yes,2024-07-25,FDA-62337,2.62,0.32,5.0,7.94,2026-04-18,2026-08-13,2031-08-14,8,Pfizer,27,South Africa,31.0,53,7,51,5,61,9,45,1,3,1,False,True,False,True,False,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Baseline regimen of two nucleoside reverse transcriptase inhibitors,AltName B,Drug,hiv,hiv,Phase 3,2023-09-05,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Inclusion Criteria include, but are not limited to:

* Have plasma Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) levels below the limit of quantification (BLoQ) (\<4...",Yes,2024-07-02,FDA-78753,2.62,0.32,5.0,7.94,2026-04-18,2026-08-13,2031-08-14,67,AstraZeneca,86,Kenya,64.0,99,66,12,88,82,37,55,1,3,2,True,False,False,True,True,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets,Comp Beta,Drug,hiv,hiv,Phase 3,2015-05-22,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented chronic HCV genotype (GT) 1, GT4, or GT6 infection with no evidence of non-typeable or mixed GT infection (positive for anti-HCV antibody, HCV RNA, or any of the list...",No,2015-12-11,FDA-48442,2.62,0.32,5.0,7.94,2018-01-02,2018-04-29,2023-04-30,14,AstraZeneca,3,Overall,47.5,61,97,14,12,53,48,55,1,2,3,True,False,False,True,False,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Human Papillomavirus vaccine,AltName A,Biological,hiv,hiv,Phase 2,2018-03-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

1. HIV infection
2. Women aged ≥ 18 years.
3. Cervical HSIL on biopsy (i.e. CIN2 and/or CIN3)
4. For participants of reproductive potential, negative serum or urine pregnancy test...",No,2018-05-16,FDA-14937,4.41,0.98,21.0,26.39,2022-07-28,2023-07-21,2044-07-20,30,Gilead,4,South Africa,75.0,91,68,78,44,73,96,64,1,4,2,False,True,True,True,True,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Lenalidomide,Comp Beta,Drug,hiv,hiv,Phase 2,2014-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Men, age ≥ 18 and ≤ 55 years at the time of screening.
2. Women, age ≥ 50 and ≤ 55 years at the time of screening, who are not of childbearing potential (see Exclusion criteria...",Yes,2015-05-05,FDA-72610,4.41,0.98,21.0,26.39,2018-12-28,2019-12-21,2040-12-20,32,J&J,55,Kenya,61.16666666666666,40,51,97,22,68,89,64,1,4,2,True,False,True,False,True,True,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Vacc-4X,AltName A,Drug,hiv,hiv,Phase 2,2014-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Men, age ≥ 18 and ≤ 55 years at the time of screening.
2. Women, age ≥ 50 and ≤ 55 years at the time of screening, who are not of childbearing potential (see Exclusion criteria...",No,2014-09-29,FDA-43663,4.41,0.98,21.0,26.39,2018-12-28,2019-12-21,2040-12-20,77,Merck,77,South Africa,49.33333333333334,19,79,17,30,60,91,55,1,1,4,False,True,True,False,False,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
rhuGM-CSF,Molecule Z,Drug,hiv,hiv,Phase 2,2014-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Men, age ≥ 18 and ≤ 55 years at the time of screening.
2. Women, age ≥ 50 and ≤ 55 years at the time of screening, who are not of childbearing potential (see Exclusion criteria...",Yes,2015-03-02,FDA-66530,4.41,0.98,21.0,26.39,2018-12-28,2019-12-21,2040-12-20,2,Bayer,71,Senegal,68.33333333333333,48,76,68,55,98,65,55,2,1,3,True,True,False,False,False,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Nelfinavir,Comp Beta,Drug,hiv,hiv,Phase 2,2017-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Histological diagnosis of adenoid cystic carcinoma.
* Cancer should be staged recurrent or end-stage with/without metastases who have failed all other therapy.
* Age ≥ 18 years
...",Yes,2018-02-06,FDA-82013,4.41,0.98,21.0,26.39,2022-03-30,2023-03-23,2044-03-22,96,AstraZeneca,14,South Africa,62.83333333333334,0,83,82,96,23,93,64,0,4,3,False,False,True,True,True,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
E/C/F/TAF,TradeName X,Drug,hiv,hiv,Phase 3,2018-01-24,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

HIV-infected adult participants who meet the following criteria will be given the option to participate in the study:

* Currently receiving ABC/3TC plus a third antiretrovira...",Yes,2019-01-08,FDA-57615,2.62,0.32,5.0,7.94,2020-09-06,2021-01-01,2026-01-02,97,Bayer,47,Senegal,69.0,25,71,80,75,84,79,64,2,2,3,True,True,False,True,False,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ABC/3TC,AltName B,Drug,hiv,hiv,Phase 3,2018-01-24,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

HIV-infected adult participants who meet the following criteria will be given the option to participate in the study:

* Currently receiving ABC/3TC plus a third antiretrovira...",No,2018-04-19,FDA-17665,2.62,0.32,5.0,7.94,2020-09-06,2021-01-01,2026-01-02,88,Novartis,57,Overall,62.0,63,54,63,100,45,47,64,1,3,3,True,False,True,False,True,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Third Antiretroviral Agent,Product Alpha,Drug,hiv,hiv,Phase 3,2018-01-24,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

HIV-infected adult participants who meet the following criteria will be given the option to participate in the study:

* Currently receiving ABC/3TC plus a third antiretrovira...",Yes,2018-06-15,FDA-98689,2.62,0.32,5.0,7.94,2020-09-06,2021-01-01,2026-01-02,17,Gilead,4,Overall,60.0,50,96,85,100,15,14,18,0,1,1,False,False,True,False,False,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Sitagliptin,TradeName X,Drug,hiv,hiv,Phase 2,2017-01-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented HIV-1 infection.
* Currently on an antiretroviral regimen consisting of at least 2 NRTIs and either a protease inhibitor boosted with low dose ritonavir, an integrase...",No,2017-10-19,FDA-95946,4.41,0.98,21.0,26.39,2021-06-08,2022-06-01,2043-06-01,78,Gilead,44,Overall,54.33333333333334,91,51,20,20,74,70,73,2,4,2,True,True,True,True,True,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc + Zidovudine/Lamivudine,Comp Beta,Drug,hiv,hiv,Phase 3,2012-12-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Men or women at least 16 years of age (or minimum age as determined by local regulatory authorities)
* HIV-1 RNA viral load of greater than or equal to 2, 000 copies/mL
* A nega...",Yes,2013-09-07,FDA-95290,2.62,0.32,5.0,7.94,2015-07-15,2015-11-09,2020-11-09,40,Bayer,35,Overall,39.0,12,56,75,51,9,31,64,1,3,3,True,False,True,True,False,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz + Zidovudine/Lamivudine,Comp Beta,Drug,hiv,hiv,Phase 3,2012-12-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Men or women at least 16 years of age (or minimum age as determined by local regulatory authorities)
* HIV-1 RNA viral load of greater than or equal to 2, 000 copies/mL
* A nega...",No,2013-01-29,FDA-80790,2.62,0.32,5.0,7.94,2015-07-15,2015-11-09,2020-11-09,5,J&J,13,Senegal,62.83333333333334,92,97,60,69,4,55,45,1,2,2,False,True,False,True,True,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
"Maraviroc (UK-427,857) + Zidovudine/Lamivudine",Product Alpha,Drug,hiv,hiv,Phase 3,2012-12-01,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Men or women at least 16 years of age (or minimum age as determined by local regulatory authorities)
* HIV-1 RNA viral load of greater than or equal to 2, 000 copies/mL
* A nega...",Yes,2013-07-16,FDA-79609,2.62,0.32,5.0,7.94,2015-07-15,2015-11-09,2020-11-09,17,Sanofi,60,Overall,38.16666666666666,25,40,15,20,34,95,9,0,1,0,False,False,False,False,True,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
F/TAF,Molecule Z,Drug,hiv,hiv,Phase 3,2019-03-13,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* The ability to understand and sign a written informed consent form
* On antiretroviral regimen containing ABC/3TC FDC in combination with one 3rd agent for ≥ 6 consecutive m...",Yes,2019-10-28,FDA-58270,2.62,0.32,5.0,7.94,2021-10-24,2022-02-18,2027-02-19,25,Pfizer,25,South Africa,54.16666666666666,15,69,47,76,32,86,36,1,2,1,False,True,True,False,False,True,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ABC/3TC,AltName B,Drug,hiv,hiv,Phase 3,2019-03-13,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* The ability to understand and sign a written informed consent form
* On antiretroviral regimen containing ABC/3TC FDC in combination with one 3rd agent for ≥ 6 consecutive m...",Yes,2019-11-09,FDA-25342,2.62,0.32,5.0,7.94,2021-10-24,2022-02-18,2027-02-19,61,Bayer,7,Kenya,42.5,37,49,18,18,57,76,64,2,4,1,True,True,True,True,True,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
3rd ARV agent,AltName A,Drug,hiv,hiv,Phase 3,2019-03-13,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* The ability to understand and sign a written informed consent form
* On antiretroviral regimen containing ABC/3TC FDC in combination with one 3rd agent for ≥ 6 consecutive m...",Yes,2019-07-11,FDA-43628,2.62,0.32,5.0,7.94,2021-10-24,2022-02-18,2027-02-19,57,Sanofi,42,South Africa,39.0,48,41,45,36,30,34,45,1,2,2,True,False,False,True,False,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK Biologicals' investigational TB vaccine GSK 692342,AltName B,Biological,hiv,hiv,Phase 2,2014-04-10,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes can and will comply with the requirements of the protocol.
* A male or female between, and including, 18 and 59 years of age at the time o...",Yes,2014-11-11,FDA-50789,4.41,0.98,21.0,26.39,2018-09-06,2019-08-30,2040-08-29,51,GSK,96,Kenya,33.66666666666666,42,15,59,7,68,11,82,2,4,3,True,True,True,True,False,True,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
rituximab,AltName A,Biological,hiv,hiv,Phase 2,2009-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Previously untreated histologically or cytologically documented B-cell non-Hodgkin's lymphoma; the following histologies are eligible: diffuse large B-cell lymphoma, high-grade ...",No,2010-04-06,FDA-38368,4.41,0.98,21.0,26.39,2013-09-27,2014-09-20,2035-09-20,67,GSK,8,Senegal,71.33333333333333,89,71,69,57,75,67,36,0,2,2,False,False,False,False,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
etoposide,GenName Y,Drug,hiv,hiv,Phase 2,2009-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Previously untreated histologically or cytologically documented B-cell non-Hodgkin's lymphoma; the following histologies are eligible: diffuse large B-cell lymphoma, high-grade ...",No,2010-02-26,FDA-11406,4.41,0.98,21.0,26.39,2013-09-27,2014-09-20,2035-09-20,25,Pfizer,55,South Africa,41.5,18,38,76,12,17,88,64,1,4,2,False,True,False,True,True,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
doxorubicin hydrochloride,Comp Beta,Drug,hiv,hiv,Phase 2,2009-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Previously untreated histologically or cytologically documented B-cell non-Hodgkin's lymphoma; the following histologies are eligible: diffuse large B-cell lymphoma, high-grade ...",Yes,2009-12-14,FDA-99119,4.41,0.98,21.0,26.39,2013-09-27,2014-09-20,2035-09-20,55,GSK,33,South Africa,34.5,32,2,65,11,31,66,36,1,0,3,False,True,False,False,False,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
vincristine sulfate,TradeName X,Drug,hiv,hiv,Phase 2,2009-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Previously untreated histologically or cytologically documented B-cell non-Hodgkin's lymphoma; the following histologies are eligible: diffuse large B-cell lymphoma, high-grade ...",Yes,2009-10-26,FDA-69162,4.41,0.98,21.0,26.39,2013-09-27,2014-09-20,2035-09-20,1,Pfizer,66,South Africa,58.0,15,97,79,32,61,64,36,1,2,1,False,True,False,True,False,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
prednisone,TradeName X,Drug,hiv,hiv,Phase 2,2009-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Previously untreated histologically or cytologically documented B-cell non-Hodgkin's lymphoma; the following histologies are eligible: diffuse large B-cell lymphoma, high-grade ...",Yes,2009-07-04,FDA-60895,4.41,0.98,21.0,26.39,2013-09-27,2014-09-20,2035-09-20,74,Gilead,20,Senegal,45.33333333333334,64,77,8,63,20,40,55,1,3,2,True,False,True,False,True,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
cyclophosphamide,AltName B,Drug,hiv,hiv,Phase 2,2009-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Previously untreated histologically or cytologically documented B-cell non-Hodgkin's lymphoma; the following histologies are eligible: diffuse large B-cell lymphoma, high-grade ...",No,2009-07-26,FDA-71446,4.41,0.98,21.0,26.39,2013-09-27,2014-09-20,2035-09-20,3,GSK,13,South Africa,34.0,26,30,63,54,21,10,73,2,3,3,True,True,False,True,True,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
E/C/F/TAF,Molecule Z,Drug,hiv,hiv,Phase 3,2017-09-29,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Chronic genotype (GT) 1, HCV infected, male and non-pregnant/ non-lactating female individuals, without cirrhosis, treatment-naive or treatment-experienced with interferon (...",Yes,2018-08-11,FDA-95482,2.62,0.32,5.0,7.94,2020-05-12,2020-09-06,2025-09-07,53,Bayer,59,Kenya,59.83333333333334,52,21,99,75,43,69,45,1,3,1,True,False,False,True,False,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
F/R/TAF,AltName B,Drug,hiv,hiv,Phase 3,2017-09-29,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Chronic genotype (GT) 1, HCV infected, male and non-pregnant/ non-lactating female individuals, without cirrhosis, treatment-naive or treatment-experienced with interferon (...",No,2018-04-06,FDA-97066,2.62,0.32,5.0,7.94,2020-05-12,2020-09-06,2025-09-07,8,J&J,71,South Africa,56.5,97,48,19,83,17,75,27,0,2,1,False,False,True,True,False,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
LDV/SOF,AltName A,Drug,hiv,hiv,Phase 3,2017-09-29,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Chronic genotype (GT) 1, HCV infected, male and non-pregnant/ non-lactating female individuals, without cirrhosis, treatment-naive or treatment-experienced with interferon (...",Yes,2017-12-27,FDA-74670,2.62,0.32,5.0,7.94,2020-05-12,2020-09-06,2025-09-07,36,Gilead,87,Senegal,49.83333333333334,20,18,92,41,55,73,36,0,1,3,False,False,False,False,False,True,False,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
E/C/F/TAF,Molecule Z,Drug,hiv,hiv,Phase 3,2018-03-21,"Sex: ALL; Age: >60 Years; Criteria: Key Inclusion Criteria:

* Currently receiving a TDF and FTC or 3TC-containing 'backbone' (maximum 2 NRTIs) regimen plus a third agent for ≥ 6 consecutive months prior to screening visit. For individu...",Yes,2018-06-10,FDA-81421,2.62,0.32,5.0,7.94,2020-11-01,2021-02-26,2026-02-27,77,Bayer,98,South Africa,31.33333333333333,33,4,14,70,11,56,73,0,4,4,False,False,True,True,True,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
TDF,Product Alpha,Drug,hiv,hiv,Phase 3,2018-03-21,"Sex: ALL; Age: >60 Years; Criteria: Key Inclusion Criteria:

* Currently receiving a TDF and FTC or 3TC-containing 'backbone' (maximum 2 NRTIs) regimen plus a third agent for ≥ 6 consecutive months prior to screening visit. For individu...",No,2018-08-20,FDA-97774,2.62,0.32,5.0,7.94,2020-11-01,2021-02-26,2026-02-27,48,Pfizer,45,Kenya,42.33333333333334,30,20,47,75,34,48,64,2,2,3,True,True,False,False,False,True,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC,AltName A,Drug,hiv,hiv,Phase 3,2018-03-21,"Sex: ALL; Age: >60 Years; Criteria: Key Inclusion Criteria:

* Currently receiving a TDF and FTC or 3TC-containing 'backbone' (maximum 2 NRTIs) regimen plus a third agent for ≥ 6 consecutive months prior to screening visit. For individu...",Yes,2018-07-21,FDA-47504,2.62,0.32,5.0,7.94,2020-11-01,2021-02-26,2026-02-27,26,AstraZeneca,18,Kenya,69.5,92,44,75,21,93,92,45,1,3,1,False,True,True,False,True,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TDF,AltName B,Drug,hiv,hiv,Phase 3,2018-03-21,"Sex: ALL; Age: >60 Years; Criteria: Key Inclusion Criteria:

* Currently receiving a TDF and FTC or 3TC-containing 'backbone' (maximum 2 NRTIs) regimen plus a third agent for ≥ 6 consecutive months prior to screening visit. For individu...",Yes,2018-10-09,FDA-19433,2.62,0.32,5.0,7.94,2020-11-01,2021-02-26,2026-02-27,80,Gilead,76,South Africa,37.5,19,55,54,20,47,30,55,1,3,2,False,True,True,True,False,True,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
3TC,GenName Y,Drug,hiv,hiv,Phase 3,2018-03-21,"Sex: ALL; Age: >60 Years; Criteria: Key Inclusion Criteria:

* Currently receiving a TDF and FTC or 3TC-containing 'backbone' (maximum 2 NRTIs) regimen plus a third agent for ≥ 6 consecutive months prior to screening visit. For individu...",Yes,2018-12-31,FDA-64341,2.62,0.32,5.0,7.94,2020-11-01,2021-02-26,2026-02-27,5,Gilead,26,South Africa,40.83333333333334,33,50,93,46,8,15,36,0,1,3,False,False,False,False,False,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Third agent,AltName B,Drug,hiv,hiv,Phase 3,2018-03-21,"Sex: ALL; Age: >60 Years; Criteria: Key Inclusion Criteria:

* Currently receiving a TDF and FTC or 3TC-containing 'backbone' (maximum 2 NRTIs) regimen plus a third agent for ≥ 6 consecutive months prior to screening visit. For individu...",No,2018-08-25,FDA-65106,2.62,0.32,5.0,7.94,2020-11-01,2021-02-26,2026-02-27,57,GSK,5,Senegal,65.33333333333333,74,96,34,98,35,55,36,0,2,2,False,False,False,True,False,False,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Nelfinavir,TradeName X,Drug,hiv,hiv,Phase 2,2011-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Histological diagnosis of non-small cell lung cancer that is Stage III (T1-3, pN2, M0) NSCLC in whom neoadjuvant therapy is recommended.
* Must have had a mediastinoscopy to det...",Yes,2012-02-05,FDA-91979,4.41,0.98,21.0,26.39,2015-07-28,2016-07-20,2037-07-20,0,Novartis,10,South Africa,61.16666666666666,85,67,70,8,56,81,45,2,2,1,True,True,True,False,False,True,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Gatifloxacin,AltName B,Drug,hiv,hiv,Phase 2,2007-12-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

-Adults, male or female, age 18 to 65 years. -Women with child-bearing potential (not surgically sterilized or postmenopausal for less than 1 year) must be using or agree to use a...",Yes,2008-04-23,FDA-18065,4.41,0.98,21.0,26.39,2012-05-25,2013-05-18,2034-05-18,30,Merck,83,Kenya,50.83333333333334,31,48,78,45,45,58,64,1,4,2,True,False,False,True,True,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Isoniazid,Comp Beta,Drug,hiv,hiv,Phase 2,2007-12-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

-Adults, male or female, age 18 to 65 years. -Women with child-bearing potential (not surgically sterilized or postmenopausal for less than 1 year) must be using or agree to use a...",No,2008-02-15,FDA-36711,4.41,0.98,21.0,26.39,2012-05-25,2013-05-18,2034-05-18,23,J&J,100,Senegal,38.5,25,29,29,50,4,94,45,2,1,2,True,True,False,True,False,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Levofloxacin,TradeName X,Drug,hiv,hiv,Phase 2,2007-12-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

-Adults, male or female, age 18 to 65 years. -Women with child-bearing potential (not surgically sterilized or postmenopausal for less than 1 year) must be using or agree to use a...",No,2008-10-19,FDA-91255,4.41,0.98,21.0,26.39,2012-05-25,2013-05-18,2034-05-18,18,AstraZeneca,100,Overall,53.83333333333334,79,81,4,35,61,63,64,2,3,2,True,True,True,False,True,False,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Linezolid,Molecule Z,Drug,hiv,hiv,Phase 2,2007-12-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

-Adults, male or female, age 18 to 65 years. -Women with child-bearing potential (not surgically sterilized or postmenopausal for less than 1 year) must be using or agree to use a...",Yes,2008-02-09,FDA-71653,4.41,0.98,21.0,26.39,2012-05-25,2013-05-18,2034-05-18,73,Novartis,58,South Africa,49.0,39,49,100,0,84,22,36,1,1,2,True,False,False,True,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Moxifloxacin,Comp Beta,Drug,hiv,hiv,Phase 2,2007-12-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

-Adults, male or female, age 18 to 65 years. -Women with child-bearing potential (not surgically sterilized or postmenopausal for less than 1 year) must be using or agree to use a...",No,2008-08-03,FDA-93024,4.41,0.98,21.0,26.39,2012-05-25,2013-05-18,2034-05-18,30,Bayer,46,Senegal,29.66666666666667,18,26,29,40,3,62,64,1,4,2,False,True,True,True,True,True,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Flucytosine and fluconazole,GenName Y,Drug,hiv,hiv,Phase 2,2014-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Able and willing to give informed consent
* Age \> 18 years
* HIV infection as confirmed by HIV-antibody test as per Kenyan guidelines
* CD4+ T-cell count ≤100 cells/µl
* Serum ...",Yes,2014-09-30,FDA-17330,4.41,0.98,21.0,26.39,2018-11-27,2019-11-20,2040-11-19,46,Merck,97,Senegal,54.16666666666666,87,57,62,1,61,57,55,2,2,2,True,True,False,False,True,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Fluconazole,Molecule Z,Drug,hiv,hiv,Phase 2,2014-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Able and willing to give informed consent
* Age \> 18 years
* HIV infection as confirmed by HIV-antibody test as per Kenyan guidelines
* CD4+ T-cell count ≤100 cells/µl
* Serum ...",No,2015-02-10,FDA-79114,4.41,0.98,21.0,26.39,2018-11-27,2019-11-20,2040-11-19,48,Merck,20,South Africa,64.83333333333333,82,94,70,85,49,9,36,2,1,1,True,True,False,False,False,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/RPV/TAF,Comp Beta,Drug,hiv,hiv,Phase 3,2019-01-02,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Currently receiving EFV/FTC/TDF FDC for ...",Yes,2019-08-22,FDA-59042,2.62,0.32,5.0,7.94,2021-08-15,2021-12-10,2026-12-11,87,Gilead,25,Senegal,48.5,62,25,45,68,51,40,55,2,2,2,True,True,False,False,True,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
EFV/FTC/TDF,TradeName X,Drug,hiv,hiv,Phase 3,2019-01-02,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Currently receiving EFV/FTC/TDF FDC for ...",Yes,2019-03-22,FDA-87895,2.62,0.32,5.0,7.94,2021-08-15,2021-12-10,2026-12-11,81,J&J,63,South Africa,56.66666666666666,65,58,2,80,75,60,45,1,2,2,False,True,True,False,False,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Vacc-4x,Comp Beta,Biological,hiv,hiv,Phase 2,2014-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Completed immunization regimen with Vacc-4x active and stopped ART (at Week 28) in the CT-BI Vacc-4x 2007/1 study. (No re-start of ART is required).
2. Documented pre-study CD4...",Yes,2014-11-06,FDA-20030,4.41,0.98,21.0,26.39,2018-05-30,2019-05-23,2040-05-22,23,Bayer,81,South Africa,51.66666666666666,86,87,53,12,26,46,36,2,0,2,True,True,False,False,False,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
AERAS-402 1.5 x 10^10 vp,GenName Y,Biological,hiv,hiv,Phase 2,2014-04-01,"Sex: ALL; Age: >112 Days; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Parent/legal guardian has completed the written informed consent process
2. Is age greater than or equal to 112 days (16 weeks) and less than or equal 182 days (26 weeks) on St...",Yes,2014-06-30,FDA-12789,4.41,0.98,21.0,26.39,2018-08-28,2019-08-21,2040-08-20,47,Novartis,64,Kenya,62.5,80,59,78,77,24,57,45,0,2,3,False,False,True,True,False,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
AERAS-402 3.0 x 10^10 vp,TradeName X,Biological,hiv,hiv,Phase 2,2014-04-01,"Sex: ALL; Age: >112 Days; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Parent/legal guardian has completed the written informed consent process
2. Is age greater than or equal to 112 days (16 weeks) and less than or equal 182 days (26 weeks) on St...",Yes,2014-10-03,FDA-68392,4.41,0.98,21.0,26.39,2018-08-28,2019-08-21,2040-08-20,97,Gilead,71,Overall,54.66666666666666,70,28,87,34,67,42,27,1,1,1,True,False,True,False,False,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
AERAS-402 1.0 x 10^11 vp,Molecule Z,Biological,hiv,hiv,Phase 2,2014-04-01,"Sex: ALL; Age: >112 Days; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Parent/legal guardian has completed the written informed consent process
2. Is age greater than or equal to 112 days (16 weeks) and less than or equal 182 days (26 weeks) on St...",Yes,2014-10-22,FDA-99548,4.41,0.98,21.0,26.39,2018-08-28,2019-08-21,2040-08-20,13,GSK,34,Kenya,55.66666666666666,79,11,93,22,69,60,64,0,3,4,False,False,True,True,False,True,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Bevacizumab,AltName B,Drug,hiv,hiv,Phase 2,2013-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV infected
* KS of the oral cavity, pharynx and larynx, histopathologically confirmed
* HIV treatment-naïve

Exclusion Criteria:

* Airway obstructive lesions
* Actively bleed...",Yes,2014-11-10,FDA-35193,4.41,0.98,21.0,26.39,2018-04-29,2019-04-22,2040-04-21,46,GSK,39,South Africa,47.33333333333334,15,75,13,70,36,75,64,2,2,3,True,True,True,True,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
carmustine,Comp Beta,Drug,hiv,hiv,Phase 2,2019-06-28,"Sex: ALL; Criteria: Inclusion Criteria:

* Karnofsky performance status: \>80% (\>60% if poor performance status is related to lymphoma)
* No evidence of serious organ dysfunction that is not attributable to tumor

  * C...",No,2020-03-02,FDA-71383,4.41,0.98,21.0,26.39,2023-11-24,2024-11-16,2045-11-16,54,AstraZeneca,57,Senegal,33.83333333333334,25,20,80,66,11,1,45,0,3,2,False,False,False,True,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
cyclophosphamide,Molecule Z,Drug,hiv,hiv,Phase 2,2019-06-28,"Sex: ALL; Criteria: Inclusion Criteria:

* Karnofsky performance status: \>80% (\>60% if poor performance status is related to lymphoma)
* No evidence of serious organ dysfunction that is not attributable to tumor

  * C...",No,2019-11-20,FDA-17526,4.41,0.98,21.0,26.39,2023-11-24,2024-11-16,2045-11-16,17,Pfizer,30,Kenya,58.16666666666666,43,87,1,61,87,70,36,1,2,1,False,True,True,False,False,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
etoposide,Product Alpha,Drug,hiv,hiv,Phase 2,2019-06-28,"Sex: ALL; Criteria: Inclusion Criteria:

* Karnofsky performance status: \>80% (\>60% if poor performance status is related to lymphoma)
* No evidence of serious organ dysfunction that is not attributable to tumor

  * C...",Yes,2020-06-20,FDA-38479,4.41,0.98,21.0,26.39,2023-11-24,2024-11-16,2045-11-16,73,Sanofi,70,Overall,61.83333333333334,53,53,45,73,72,75,45,2,2,1,True,True,False,True,True,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
G-CSF,AltName A,Biological,hiv,hiv,Phase 2,2019-06-28,"Sex: ALL; Criteria: Inclusion Criteria:

* Karnofsky performance status: \>80% (\>60% if poor performance status is related to lymphoma)
* No evidence of serious organ dysfunction that is not attributable to tumor

  * C...",Yes,2020-04-01,FDA-37762,4.41,0.98,21.0,26.39,2023-11-24,2024-11-16,2045-11-16,33,GSK,73,Senegal,46.66666666666666,12,89,46,27,39,67,64,2,3,2,True,True,True,True,False,False,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Cytarabine,Product Alpha,Drug,hiv,hiv,Phase 2,2019-06-28,"Sex: ALL; Criteria: Inclusion Criteria:

* Karnofsky performance status: \>80% (\>60% if poor performance status is related to lymphoma)
* No evidence of serious organ dysfunction that is not attributable to tumor

  * C...",Yes,2020-01-21,FDA-24780,4.41,0.98,21.0,26.39,2023-11-24,2024-11-16,2045-11-16,14,Novartis,70,Kenya,62.83333333333334,51,76,94,35,65,56,45,1,2,2,True,False,False,True,True,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Sertraline,Product Alpha,Drug,hiv,hiv,Phase 3,2018-03-13,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-infected
* Cryptococcal antigen (CrAg) positive in blood
* Age \>=18 years
* Written informed consent
* Women of childbearing potential who are participating in sexual activ...",No,2019-01-20,FDA-22827,2.62,0.32,5.0,7.94,2020-10-24,2021-02-18,2026-02-19,30,AstraZeneca,27,Overall,54.5,44,69,93,82,32,7,73,1,3,4,True,False,True,False,False,True,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Fluconazole,TradeName X,Drug,hiv,hiv,Phase 3,2018-03-13,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-infected
* Cryptococcal antigen (CrAg) positive in blood
* Age \>=18 years
* Written informed consent
* Women of childbearing potential who are participating in sexual activ...",Yes,2018-07-20,FDA-88233,2.62,0.32,5.0,7.94,2020-10-24,2021-02-18,2026-02-19,1,Novartis,68,Overall,56.16666666666666,96,35,14,52,90,50,27,0,3,0,False,False,False,True,False,True,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
dapivirine 4789,Comp Beta,Drug,hiv,hiv,Phase 2,2011-01-08,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Women 18 to 40 years of age inclusive who can give written informed consent
2. Available for all visits and consent to follow all procedures scheduled for the trial
3. Healthy ...",Yes,2011-11-01,FDA-69773,4.41,0.98,21.0,26.39,2015-06-06,2016-05-29,2037-05-29,99,Novartis,12,Kenya,57.83333333333334,62,37,67,73,56,52,45,1,2,2,True,False,True,False,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
dapivirine gel 4759,Comp Beta,Drug,hiv,hiv,Phase 2,2011-01-08,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Women 18 to 40 years of age inclusive who can give written informed consent
2. Available for all visits and consent to follow all procedures scheduled for the trial
3. Healthy ...",No,2011-09-02,FDA-29359,4.41,0.98,21.0,26.39,2015-06-06,2016-05-29,2037-05-29,35,Sanofi,12,Senegal,49.16666666666666,43,99,10,44,22,77,64,1,2,4,True,False,True,False,True,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Fluorouracil,AltName B,Drug,hiv,hiv,Phase 2,2018-12-01,"Sex: ALL; Age: >19 Years; Criteria: Inclusion Criteria:

* Pathologically confirmed adenocarcinoma of the pancreas; patients have resectable borderline resectable disease, or unresectable disease with no evidence of distant metastases o...",No,2019-09-16,FDA-12922,4.41,0.98,21.0,26.39,2023-04-29,2024-04-21,2045-04-21,86,Gilead,67,Kenya,55.83333333333334,81,32,46,40,98,38,91,2,5,3,True,True,True,True,True,True,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Gemcitabine Hydrochloride,GenName Y,Drug,hiv,hiv,Phase 2,2018-12-01,"Sex: ALL; Age: >19 Years; Criteria: Inclusion Criteria:

* Pathologically confirmed adenocarcinoma of the pancreas; patients have resectable borderline resectable disease, or unresectable disease with no evidence of distant metastases o...",Yes,2019-08-24,FDA-54874,4.41,0.98,21.0,26.39,2023-04-29,2024-04-21,2045-04-21,61,Bayer,37,Senegal,55.83333333333334,83,17,100,9,80,46,27,1,1,1,True,False,False,True,False,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Leucovorin Calcium,GenName Y,Drug,hiv,hiv,Phase 2,2018-12-01,"Sex: ALL; Age: >19 Years; Criteria: Inclusion Criteria:

* Pathologically confirmed adenocarcinoma of the pancreas; patients have resectable borderline resectable disease, or unresectable disease with no evidence of distant metastases o...",No,2019-01-18,FDA-76665,4.41,0.98,21.0,26.39,2023-04-29,2024-04-21,2045-04-21,57,Gilead,13,Senegal,60.0,80,34,67,27,67,85,64,1,4,2,False,True,False,True,True,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Nelfinavir Mesylate,TradeName X,Drug,hiv,hiv,Phase 2,2018-12-01,"Sex: ALL; Age: >19 Years; Criteria: Inclusion Criteria:

* Pathologically confirmed adenocarcinoma of the pancreas; patients have resectable borderline resectable disease, or unresectable disease with no evidence of distant metastases o...",No,2019-05-10,FDA-24215,4.41,0.98,21.0,26.39,2023-04-29,2024-04-21,2045-04-21,100,Sanofi,37,Kenya,27.16666666666667,11,8,11,7,99,27,64,1,3,3,True,False,True,False,True,True,False,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Oregovomab,TradeName X,Biological,hiv,hiv,Phase 2,2018-12-01,"Sex: ALL; Age: >19 Years; Criteria: Inclusion Criteria:

* Pathologically confirmed adenocarcinoma of the pancreas; patients have resectable borderline resectable disease, or unresectable disease with no evidence of distant metastases o...",No,2019-10-19,FDA-33771,4.41,0.98,21.0,26.39,2023-04-29,2024-04-21,2045-04-21,73,J&J,72,Kenya,25.0,15,32,1,23,48,31,18,1,1,0,True,False,True,False,False,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Zidovudine,TradeName X,Drug,hiv,hiv,Phase 2,2020-10-05,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:
* Pathologically confirmed Kaposi sarcoma (KS)-associated herpes virus multi-centric Castleman disease (KSHV-MCD)
* Age greater than or equal to 18
* At least one clinical sympto...",Yes,2021-02-17,FDA-99554,4.41,0.98,21.0,26.39,2025-03-03,2026-02-24,2047-02-24,40,Novartis,55,South Africa,37.5,33,14,86,28,38,26,55,2,3,1,True,True,False,True,True,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Tocilizumab,AltName B,Drug,hiv,hiv,Phase 2,2020-10-05,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:
* Pathologically confirmed Kaposi sarcoma (KS)-associated herpes virus multi-centric Castleman disease (KSHV-MCD)
* Age greater than or equal to 18
* At least one clinical sympto...",Yes,2021-03-21,FDA-83201,4.41,0.98,21.0,26.39,2025-03-03,2026-02-24,2047-02-24,83,GSK,87,South Africa,41.5,65,80,59,21,7,17,55,1,2,3,False,True,True,True,False,False,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Valganciclovir (VGC),TradeName X,Drug,hiv,hiv,Phase 2,2020-10-05,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:
* Pathologically confirmed Kaposi sarcoma (KS)-associated herpes virus multi-centric Castleman disease (KSHV-MCD)
* Age greater than or equal to 18
* At least one clinical sympto...",Yes,2021-03-21,FDA-57321,4.41,0.98,21.0,26.39,2025-03-03,2026-02-24,2047-02-24,13,Bayer,97,Overall,53.33333333333334,73,9,48,23,84,83,27,1,1,1,False,True,True,False,False,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Methotrexate,Molecule Z,Drug,hiv,hiv,Phase 2,2019-09-19,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

Positive human immunodeficiency virus (HIV) serology (previous records acceptable)

* Diagnosis of Primary Central Nervous System Lymphoma
* Confirmed histopathologic diagnosis ...",No,2020-09-12,FDA-75951,4.41,0.98,21.0,26.39,2024-02-15,2025-02-07,2046-02-07,71,Sanofi,3,Senegal,56.83333333333334,82,37,5,82,61,74,64,2,2,3,True,True,True,False,False,True,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Rituximab,AltName A,Drug,hiv,hiv,Phase 2,2019-09-19,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

Positive human immunodeficiency virus (HIV) serology (previous records acceptable)

* Diagnosis of Primary Central Nervous System Lymphoma
* Confirmed histopathologic diagnosis ...",No,2020-02-29,FDA-73978,4.41,0.98,21.0,26.39,2024-02-15,2025-02-07,2046-02-07,83,Sanofi,84,South Africa,49.33333333333334,87,39,17,35,60,58,73,2,4,2,True,True,True,False,True,True,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Leucovorin,GenName Y,Drug,hiv,hiv,Phase 2,2019-09-19,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

Positive human immunodeficiency virus (HIV) serology (previous records acceptable)

* Diagnosis of Primary Central Nervous System Lymphoma
* Confirmed histopathologic diagnosis ...",Yes,2020-04-12,FDA-48029,4.41,0.98,21.0,26.39,2024-02-15,2025-02-07,2046-02-07,55,J&J,59,Senegal,48.16666666666666,88,4,9,34,89,65,45,1,2,2,False,True,False,True,True,False,False,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
ID93 + GLA-SE,GenName Y,Biological,hiv,hiv,Phase 2,2017-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Males and females 18 to 60 years of age.
2. Subjects must have been successfully treated, i.e., completed the scheduled course of TB treatment as per the prevailing South Afric...",No,2017-10-30,FDA-76050,4.41,0.98,21.0,26.39,2021-05-30,2022-05-23,2043-05-23,68,Sanofi,53,South Africa,58.5,10,75,55,34,90,87,36,1,2,1,True,False,False,True,True,False,False,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
TMC125; darunavir; ritonavir,Product Alpha,Drug,hiv,hiv,Phase 2,2009-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented HIV-1 infection
* Naive to antiretroviral therapy (never received antiretroviral therapy prior to study)
* In the opinion of the investigator, have an indication for ...",Yes,2009-07-16,FDA-36213,4.41,0.98,21.0,26.39,2013-07-28,2014-07-21,2035-07-21,15,AstraZeneca,23,Senegal,57.66666666666666,63,94,50,48,48,43,36,0,3,1,False,False,True,False,False,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
EFV/FTC/TDF + Losartan,Molecule Z,Drug,hiv,hiv,Phase 4,2016-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Patients older than 18 years.
2. Patients with HIV infection in antiretroviral treatment with EFV / FTC / TDF with undetectable viral load (VL \<37 copies) for at least 48 week...",No,2016-03-18,FDA-94061,0.56,0.15,3.5,4.21,2016-08-23,2016-10-17,2020-04-17,11,Novartis,93,Senegal,60.0,94,26,46,93,26,75,73,2,3,3,True,True,False,True,True,False,True,True,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
EFV/FTC/TDF,GenName Y,Drug,hiv,hiv,Phase 4,2016-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Patients older than 18 years.
2. Patients with HIV infection in antiretroviral treatment with EFV / FTC / TDF with undetectable viral load (VL \<37 copies) for at least 48 week...",No,2016-03-19,FDA-52878,0.56,0.15,3.5,4.21,2016-08-23,2016-10-17,2020-04-17,7,GSK,50,Overall,51.0,84,69,90,13,18,32,27,0,1,2,False,False,False,False,True,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TDF + MK-0518,GenName Y,Drug,hiv,hiv,Phase 4,2016-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Patients older than 18 years.
2. Patients with HIV infection in antiretroviral treatment with EFV / FTC / TDF with undetectable viral load (VL \<37 copies) for at least 48 week...",No,2016-06-01,FDA-47071,0.56,0.15,3.5,4.21,2016-08-23,2016-10-17,2020-04-17,18,Sanofi,99,Overall,52.83333333333334,29,98,80,11,10,89,55,2,2,2,True,True,True,False,True,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TDF+MK-0518+Losartan,GenName Y,Drug,hiv,hiv,Phase 4,2016-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Patients older than 18 years.
2. Patients with HIV infection in antiretroviral treatment with EFV / FTC / TDF with undetectable viral load (VL \<37 copies) for at least 48 week...",Yes,2016-05-30,FDA-71036,0.56,0.15,3.5,4.21,2016-08-23,2016-10-17,2020-04-17,55,Pfizer,24,South Africa,45.66666666666666,74,97,54,36,7,6,45,1,2,2,True,False,False,False,True,False,True,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Eltrombopag,Molecule Z,Drug,hiv,hiv,Phase 3,2009-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Male and female subjects, 18 years of age or more with chronic liver disease.
* Child-Pugh score of 12 or less.
* Model of End Stage Liver Disease (MELD) score of 24 or less.
* ...",Yes,2009-12-23,FDA-56313,2.62,0.32,5.0,7.94,2012-05-14,2012-09-08,2017-09-09,39,Novartis,90,South Africa,38.0,27,82,8,39,52,20,73,1,4,3,False,True,False,True,True,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/RPV/TDF,Product Alpha,Drug,hiv,hiv,Phase 2,2012-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* Receiving EFV/FTC/TDF continuously for ≥ 3 months preceding the screening visit
* Plasma HIV-1 RNA concentration...",No,2012-04-27,FDA-70603,4.41,0.98,21.0,26.39,2016-07-28,2017-07-21,2038-07-21,22,Novartis,21,Kenya,55.33333333333334,36,59,27,98,28,84,45,2,2,1,True,True,False,False,False,True,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Efavirenz,AltName B,Drug,hiv,hiv,Phase 4,2018-04-04,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Healthy women aged 18-40 years who have a Nexplanon®/Implanon® in place that is palpable on exam, had the device placed between 12 and 24 months prior to enrollment, and can pro...",No,2018-07-19,FDA-96228,0.56,0.15,3.5,4.21,2018-10-25,2018-12-19,2022-06-19,14,Pfizer,50,South Africa,50.5,74,80,50,9,46,44,45,1,3,1,False,True,False,False,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/RPV/TAF,AltName B,Drug,hiv,hiv,Phase 3,2019-01-09,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Currently receiving FTC/RPV/TDF FDC for ...",Yes,2019-07-07,FDA-57125,2.62,0.32,5.0,7.94,2021-08-22,2021-12-17,2026-12-18,80,Sanofi,32,Kenya,73.16666666666667,53,82,73,47,100,84,18,1,1,0,True,False,False,False,True,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/RPV/TDF,GenName Y,Drug,hiv,hiv,Phase 3,2019-01-09,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Currently receiving FTC/RPV/TDF FDC for ...",Yes,2019-10-22,FDA-12892,2.62,0.32,5.0,7.94,2021-08-22,2021-12-17,2026-12-18,22,Pfizer,88,South Africa,65.5,29,99,95,43,63,64,45,1,2,2,False,True,True,True,False,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ABC/DTG/3TC,AltName B,Drug,hiv,hiv,Phase 3,2021-07-02,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Antiretroviral treatment naive (≤ 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection) except the use for pre-exposure prophylaxi...",Yes,2021-08-28,FDA-49923,2.62,0.32,5.0,7.94,2024-02-13,2024-06-09,2029-06-10,42,Merck,49,Senegal,50.16666666666666,18,93,51,62,33,44,36,0,2,2,False,False,False,True,True,False,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
B/F/TAF,GenName Y,Drug,hiv,hiv,Phase 3,2021-07-02,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Antiretroviral treatment naive (≤ 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection) except the use for pre-exposure prophylaxi...",No,2021-12-27,FDA-69694,2.62,0.32,5.0,7.94,2024-02-13,2024-06-09,2029-06-10,19,Pfizer,90,Kenya,56.83333333333334,74,80,24,95,57,11,45,2,2,1,True,True,False,False,True,False,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ethambutol,AltName B,Drug,hiv,hiv,Phase 3,2008-11-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

-Adults, male or female, aged 18-60. -Newly diagnosed initial episodes of pulmonary tuberculosis. Sputum smear-positive and -negative patients are eligible for enrollment. The dia...",Yes,2009-05-19,FDA-73103,2.62,0.32,5.0,7.94,2011-07-12,2011-11-06,2016-11-06,94,Bayer,59,South Africa,63.16666666666666,43,97,91,34,55,59,73,1,4,3,False,True,True,True,True,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Isoniazid,AltName B,Drug,hiv,hiv,Phase 3,2008-11-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

-Adults, male or female, aged 18-60. -Newly diagnosed initial episodes of pulmonary tuberculosis. Sputum smear-positive and -negative patients are eligible for enrollment. The dia...",Yes,2009-11-14,FDA-72996,2.62,0.32,5.0,7.94,2011-07-12,2011-11-06,2016-11-06,82,Gilead,18,Overall,55.0,63,40,17,67,50,93,45,1,2,2,False,True,False,False,True,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Pyrazinamide,TradeName X,Drug,hiv,hiv,Phase 3,2008-11-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

-Adults, male or female, aged 18-60. -Newly diagnosed initial episodes of pulmonary tuberculosis. Sputum smear-positive and -negative patients are eligible for enrollment. The dia...",Yes,2009-11-08,FDA-21960,2.62,0.32,5.0,7.94,2011-07-12,2011-11-06,2016-11-06,37,Bayer,9,South Africa,38.0,69,15,6,34,55,49,55,0,5,1,False,False,True,True,True,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rifampin,Molecule Z,Drug,hiv,hiv,Phase 3,2008-11-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

-Adults, male or female, aged 18-60. -Newly diagnosed initial episodes of pulmonary tuberculosis. Sputum smear-positive and -negative patients are eligible for enrollment. The dia...",No,2009-04-22,FDA-32881,2.62,0.32,5.0,7.94,2011-07-12,2011-11-06,2016-11-06,74,AstraZeneca,19,Senegal,37.0,9,90,50,10,47,16,27,1,1,1,True,False,True,False,False,False,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Doxycycline,GenName Y,Drug,hiv,hiv,Phase 4,2022-05-09,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. HIV negative person, who was assigned male or female at birth, who reports sex with another man in the last year and is in good general health
2. Aged 18-59 years
3. Not curren...",Yes,2023-01-25,FDA-38748,0.56,0.15,3.5,4.21,2022-11-29,2023-01-23,2026-07-24,52,Novartis,74,Kenya,68.83333333333333,99,59,49,58,96,52,36,1,1,2,False,True,False,False,False,True,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Biktarvy,Comp Beta,Drug,hiv,hiv,Phase 4,2022-05-09,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. HIV negative person, who was assigned male or female at birth, who reports sex with another man in the last year and is in good general health
2. Aged 18-59 years
3. Not curren...",Yes,2023-03-19,FDA-40502,0.56,0.15,3.5,4.21,2022-11-29,2023-01-23,2026-07-24,57,Bayer,83,South Africa,33.66666666666666,89,49,15,33,2,14,45,0,3,2,False,False,False,True,False,True,True,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Pegylated Interferon Lambda-1a,Product Alpha,Biological,hiv,hiv,Phase 3,2015-08-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HCV Genotype-1, -2, -3 or -4 treatment naïve;
* HCV RNA ≥10,000 IU/mL at screening;
* HIV-1 infection \[(approximately 200 subjects receiving HAART, approximately 100 subjects n...",No,2015-10-22,FDA-13619,2.62,0.32,5.0,7.94,2018-04-09,2018-08-04,2023-08-05,76,J&J,34,Kenya,33.0,4,46,70,2,8,68,45,0,4,1,False,False,True,True,False,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Daclatasvir (DCV),Molecule Z,Drug,hiv,hiv,Phase 3,2015-08-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HCV Genotype-1, -2, -3 or -4 treatment naïve;
* HCV RNA ≥10,000 IU/mL at screening;
* HIV-1 infection \[(approximately 200 subjects receiving HAART, approximately 100 subjects n...",No,2015-12-12,FDA-76325,2.62,0.32,5.0,7.94,2018-04-09,2018-08-04,2023-08-05,52,J&J,79,Senegal,50.16666666666666,30,50,44,52,32,93,55,2,3,1,True,True,True,True,False,False,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ribasphere (RBV),GenName Y,Drug,hiv,hiv,Phase 3,2015-08-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HCV Genotype-1, -2, -3 or -4 treatment naïve;
* HCV RNA ≥10,000 IU/mL at screening;
* HIV-1 infection \[(approximately 200 subjects receiving HAART, approximately 100 subjects n...",Yes,2015-12-09,FDA-68240,2.62,0.32,5.0,7.94,2018-04-09,2018-08-04,2023-08-05,57,Bayer,9,Kenya,53.0,9,51,93,79,34,52,55,1,1,4,True,False,False,False,True,False,False,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch,Comp Beta,Drug,hiv,hiv,Phase 4,2021-11-11,"Sex: MALE; Age: >45 Years; Criteria: Inclusion Criteria:

* HIV positive Males, age 45 or older
* Any genotypic or phenotypic resistance except k65R, 69 insertion, integrase resistance, or resistance to rilpivarine or doravirine.
* Recei...",Yes,2022-02-28,FDA-30751,0.56,0.15,3.5,4.21,2022-06-03,2022-07-28,2026-01-26,39,AstraZeneca,8,South Africa,42.83333333333334,10,62,9,82,92,2,55,0,2,4,False,False,True,False,False,False,True,True,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
BIC,AltName A,Drug,hiv,hiv,Phase 2,2019-02-27,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Antiretroviral naive (≤ 10 days of prior therapy with any antiretroviral agent)
* Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening
* Screening genotype report provided...",No,2019-12-18,FDA-17495,4.41,0.98,21.0,26.39,2023-07-26,2024-07-18,2045-07-18,1,J&J,43,Senegal,46.66666666666666,40,65,41,11,39,84,36,1,1,2,True,False,False,False,True,False,False,False,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
F/TAF,TradeName X,Drug,hiv,hiv,Phase 2,2019-02-27,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Antiretroviral naive (≤ 10 days of prior therapy with any antiretroviral agent)
* Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening
* Screening genotype report provided...",No,2019-10-11,FDA-66384,4.41,0.98,21.0,26.39,2023-07-26,2024-07-18,2045-07-18,30,AstraZeneca,4,Senegal,48.66666666666666,69,58,90,21,54,0,36,0,2,2,False,False,False,True,False,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
DTG,AltName B,Drug,hiv,hiv,Phase 2,2019-02-27,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Antiretroviral naive (≤ 10 days of prior therapy with any antiretroviral agent)
* Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening
* Screening genotype report provided...",Yes,2019-09-20,FDA-99281,4.41,0.98,21.0,26.39,2023-07-26,2024-07-18,2045-07-18,53,Gilead,5,South Africa,45.5,4,75,59,88,38,9,45,1,3,1,True,False,False,False,True,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
B/F/TAF,Product Alpha,Drug,hiv,hiv,Phase 2,2019-02-27,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Antiretroviral naive (≤ 10 days of prior therapy with any antiretroviral agent)
* Plasma HIV-1 RNA levels ≥ 1,000 copies/mL at screening
* Screening genotype report provided...",Yes,2019-08-04,FDA-61527,4.41,0.98,21.0,26.39,2023-07-26,2024-07-18,2045-07-18,12,Bayer,44,Overall,63.0,9,96,88,24,72,89,27,1,1,1,True,False,False,False,True,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
single dose of L-AmB,AltName B,Drug,hiv,hiv,Phase 2,2022-03-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult (\> 18 years) HIV-infected hospitalized patients diagnosed with HD by the means of (i) urine Histoplasma positive antigen (IMMY® monoclonal antibody test); (ii) confirmati...",Yes,2022-09-10,FDA-97223,4.41,0.98,21.0,26.39,2026-08-26,2027-08-19,2048-08-18,95,Merck,97,Kenya,29.66666666666667,43,49,8,48,15,15,55,1,4,1,False,True,True,True,True,True,False,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
2 doses of L-AmB,Molecule Z,Drug,hiv,hiv,Phase 2,2022-03-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult (\> 18 years) HIV-infected hospitalized patients diagnosed with HD by the means of (i) urine Histoplasma positive antigen (IMMY® monoclonal antibody test); (ii) confirmati...",No,2022-12-21,FDA-68365,4.41,0.98,21.0,26.39,2026-08-26,2027-08-19,2048-08-18,46,Sanofi,63,Kenya,44.5,8,49,62,13,69,66,45,2,2,1,True,True,True,True,False,False,False,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
2 weeks of L-AmB,AltName A,Drug,hiv,hiv,Phase 2,2022-03-30,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult (\> 18 years) HIV-infected hospitalized patients diagnosed with HD by the means of (i) urine Histoplasma positive antigen (IMMY® monoclonal antibody test); (ii) confirmati...",Yes,2022-06-15,FDA-48872,4.41,0.98,21.0,26.39,2026-08-26,2027-08-19,2048-08-18,26,Pfizer,63,Overall,57.66666666666666,52,21,37,92,98,46,36,0,2,2,False,False,False,True,True,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
raltegravir and etravirine,TradeName X,Drug,hiv,hiv,Phase 2,2018-04-01,"Sex: ALL; Age: >45 Years; Criteria: Inclusion Criteria:

* Documented HIV-1 infection
* Age ≥ 45 years
* Naïve to integrase inhibitor and etravirine
* At least 6 months of stable antiretroviral therapy (ART) including a boosted protease...",Yes,2019-02-13,FDA-64714,4.41,0.98,21.0,26.39,2022-08-28,2023-08-21,2044-08-20,58,Merck,92,Senegal,40.66666666666666,76,0,31,42,81,14,27,0,0,3,False,False,False,False,False,False,False,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
COBI,TradeName X,Drug,hiv,hiv,Phase 2,2015-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* Plasma HIV-1 RNA levels ≥ 5,000 copies/mL
* No prior use of any approved or experimental anti-HIV drug
* Normal ...",Yes,2015-12-13,FDA-72395,4.41,0.98,21.0,26.39,2019-05-30,2020-05-22,2041-05-22,62,Pfizer,13,South Africa,47.16666666666666,62,73,99,22,5,22,55,2,1,3,True,True,False,False,False,True,False,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
RTV,Product Alpha,Drug,hiv,hiv,Phase 2,2015-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* Plasma HIV-1 RNA levels ≥ 5,000 copies/mL
* No prior use of any approved or experimental anti-HIV drug
* Normal ...",No,2015-07-17,FDA-55714,4.41,0.98,21.0,26.39,2019-05-30,2020-05-22,2041-05-22,17,Gilead,33,Senegal,25.66666666666667,7,24,19,70,20,14,45,1,2,2,True,False,False,False,True,False,True,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
ATV,TradeName X,Drug,hiv,hiv,Phase 2,2015-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* Plasma HIV-1 RNA levels ≥ 5,000 copies/mL
* No prior use of any approved or experimental anti-HIV drug
* Normal ...",Yes,2015-08-13,FDA-14683,4.41,0.98,21.0,26.39,2019-05-30,2020-05-22,2041-05-22,74,Sanofi,39,Overall,71.83333333333333,81,76,53,43,86,92,55,1,4,1,False,True,True,True,True,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TDF,Product Alpha,Drug,hiv,hiv,Phase 2,2015-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* Plasma HIV-1 RNA levels ≥ 5,000 copies/mL
* No prior use of any approved or experimental anti-HIV drug
* Normal ...",Yes,2015-12-30,FDA-37202,4.41,0.98,21.0,26.39,2019-05-30,2020-05-22,2041-05-22,38,Pfizer,2,Senegal,58.33333333333334,40,11,95,96,15,93,27,1,2,0,False,True,False,True,False,False,True,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/RPV/TDF,TradeName X,Drug,hiv,hiv,Phase 3,2014-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* Plasma HIV-1 RNA levels ≥ 2,500 copies/mL at screening
* No prior use of any approved or experimental anti-HIV d...",Yes,2014-12-14,FDA-84459,2.62,0.32,5.0,7.94,2016-09-14,2017-01-09,2022-01-10,77,GSK,47,Kenya,56.5,90,57,58,40,89,5,45,0,2,3,False,False,True,False,False,False,True,False,True,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
EFV/FTC/TDF,Product Alpha,Drug,hiv,hiv,Phase 3,2014-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* Plasma HIV-1 RNA levels ≥ 2,500 copies/mL at screening
* No prior use of any approved or experimental anti-HIV d...",No,2014-05-10,FDA-68568,2.62,0.32,5.0,7.94,2016-09-14,2017-01-09,2022-01-10,83,AstraZeneca,81,Overall,52.0,38,50,88,56,10,70,55,1,4,1,False,True,True,False,True,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/RPV/TDF,AltName B,Drug,hiv,hiv,Phase 3,2014-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* Receiving antiretroviral therapy with a ritonavir-boosted PI and two NRTIs continuously for ≥ 6 months preceding...",Yes,2015-06-11,FDA-87624,2.62,0.32,5.0,7.94,2017-05-14,2017-09-08,2022-09-09,51,J&J,25,Kenya,48.33333333333334,25,34,76,96,45,14,36,0,2,2,False,False,False,False,True,False,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
PI,AltName B,Drug,hiv,hiv,Phase 3,2014-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* Receiving antiretroviral therapy with a ritonavir-boosted PI and two NRTIs continuously for ≥ 6 months preceding...",No,2015-01-27,FDA-38371,2.62,0.32,5.0,7.94,2017-05-14,2017-09-08,2022-09-09,88,Merck,93,Kenya,40.83333333333334,11,1,99,60,46,28,27,1,1,1,False,True,False,False,False,False,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
RTV,AltName B,Drug,hiv,hiv,Phase 3,2014-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* Receiving antiretroviral therapy with a ritonavir-boosted PI and two NRTIs continuously for ≥ 6 months preceding...",No,2015-05-17,FDA-68427,2.62,0.32,5.0,7.94,2017-05-14,2017-09-08,2022-09-09,49,Novartis,23,Kenya,31.83333333333333,46,31,52,36,26,0,55,1,3,2,True,False,True,False,False,True,True,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
NRTIs,GenName Y,Drug,hiv,hiv,Phase 3,2014-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Ability to understand and sign a written informed consent form
* Receiving antiretroviral therapy with a ritonavir-boosted PI and two NRTIs continuously for ≥ 6 months preceding...",No,2015-08-28,FDA-98053,2.62,0.32,5.0,7.94,2017-05-14,2017-09-08,2022-09-09,99,Merck,66,Kenya,51.16666666666666,62,31,40,56,57,61,45,1,2,2,False,True,False,False,True,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Doxycycline,Comp Beta,Drug,hiv,hiv,Phase 4,2024-12-24,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Aged 18-59 years
* Assigned male sex or female sex at birth
* In good general health
* Not currently taking doxycycline or other tetracycline-derived antibiotics and no plans to...",No,2025-09-24,FDA-15120,0.56,0.15,3.5,4.21,2025-07-16,2025-09-09,2029-03-10,3,AstraZeneca,52,South Africa,44.66666666666666,12,72,59,26,50,49,55,1,4,1,True,False,True,False,True,True,True,False,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Grazoprevir + Elbasvir,Comp Beta,Drug,hiv,hiv,Phase 3,2016-06-14,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* has HCV GT1, GT4, or GT6 with sickle cell anemia, thalassemia, or hemophilia/von Willebrand disease
* has cirrhosis or is non-cirrhotic
* is human immunodeficiency virus (HIV) c...",No,2017-01-01,FDA-57732,2.62,0.32,5.0,7.94,2019-01-26,2019-05-23,2024-05-23,36,Bayer,7,Senegal,40.0,43,86,12,34,38,27,36,1,2,1,False,True,True,False,False,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
FTC/TDF,TradeName X,Drug,hiv,hiv,Phase 3,2019-03-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Currently receiving antiretroviral regimen c...",No,2019-04-03,FDA-47303,2.62,0.32,5.0,7.94,2021-10-12,2022-02-06,2027-02-07,13,Gilead,31,Overall,47.83333333333334,19,69,34,93,16,56,73,2,3,3,True,True,True,False,False,True,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
F/TAF,AltName B,Drug,hiv,hiv,Phase 3,2019-03-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Currently receiving antiretroviral regimen c...",No,2019-12-21,FDA-91598,2.62,0.32,5.0,7.94,2021-10-12,2022-02-06,2027-02-07,3,AstraZeneca,96,Overall,39.33333333333334,51,0,36,75,66,8,55,0,4,2,False,False,True,True,False,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Allowed third antiretroviral agent,Product Alpha,Drug,hiv,hiv,Phase 3,2019-03-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
* Currently receiving antiretroviral regimen c...",Yes,2019-11-15,FDA-48431,2.62,0.32,5.0,7.94,2021-10-12,2022-02-06,2027-02-07,18,GSK,95,Overall,44.16666666666666,72,16,41,11,76,49,18,0,0,2,False,False,False,False,False,False,False,True,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Intermittent Oral Naltrexone,TradeName X,Drug,hiv,hiv,Phase 2,2014-11-01,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. male gender or transgender male-to-female
2. self-reported anal sex with men in the prior six months while under the influence of meth and/or alcohol
3. self-reported meth use ...",No,2015-02-01,FDA-39247,4.41,0.98,21.0,26.39,2019-03-30,2020-03-22,2041-03-22,84,Novartis,42,Senegal,34.16666666666666,18,51,7,96,33,0,45,1,3,1,False,True,True,True,False,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,GenName Y,Drug,hiv,hiv,Phase 4,2008-05-01,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Healthy male subjects. no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurem...",No,2009-01-29,FDA-96971,0.56,0.15,3.5,4.21,2008-11-21,2009-01-15,2012-07-16,94,J&J,47,South Africa,44.83333333333334,80,8,96,52,18,15,27,1,2,0,True,False,False,True,True,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Vardenafil,AltName B,Drug,hiv,hiv,Phase 4,2008-05-01,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Healthy male subjects. no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurem...",Yes,2008-07-05,FDA-68905,0.56,0.15,3.5,4.21,2008-11-21,2009-01-15,2012-07-16,53,Gilead,22,Overall,44.5,18,54,66,22,70,37,55,1,3,2,False,True,False,True,True,True,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Maraviroc,TradeName X,Drug,hiv,hiv,Phase 4,2008-05-01,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Healthy male subjects. no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurem...",Yes,2008-07-26,FDA-62966,0.56,0.15,3.5,4.21,2008-11-21,2009-01-15,2012-07-16,40,GSK,11,Kenya,25.5,0,38,62,9,13,31,73,2,4,2,True,True,False,True,True,True,True,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Rituximab,Molecule Z,Drug,hiv,hiv,Phase 2,2026-06-07,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Newly diagnosed or previously treated subjects with KSHV-associated MCD that is pathologically confirmed by characteristic histologic features and latency-associated nuclear an...",No,2026-09-27,FDA-33641,4.41,0.98,21.0,26.39,2030-11-03,2031-10-27,2052-10-26,78,Merck,70,South Africa,52.33333333333334,85,9,51,93,46,30,45,1,3,1,True,False,True,False,True,True,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Etoposide,Comp Beta,Drug,hiv,hiv,Phase 2,2026-06-07,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Newly diagnosed or previously treated subjects with KSHV-associated MCD that is pathologically confirmed by characteristic histologic features and latency-associated nuclear an...",No,2026-09-25,FDA-49535,4.41,0.98,21.0,26.39,2030-11-03,2031-10-27,2052-10-26,3,J&J,39,Senegal,47.0,48,54,41,93,26,20,36,1,2,1,True,False,True,True,False,False,False,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Curcumin,Product Alpha,Drug,hiv,hiv,Phase 2,2018-10-30,"Sex: FEMALE; Age: >21 Years; Criteria: Inclusion Criteria:

* HIV positive women and HIV negative women
* HSIL cytology with no invasive features identified on colposcopy or the baseline biopsy
* Compliant on combined antiretrovirals (cART...",No,2019-09-21,FDA-44267,4.41,0.98,21.0,26.39,2023-03-28,2024-03-20,2045-03-20,51,J&J,27,Senegal,36.16666666666666,6,29,58,24,56,44,45,1,3,1,True,False,False,True,True,False,True,False,False,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Darunavir,GenName Y,Drug,hiv,hiv,Phase 3,2021-07-29,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

* Patients treated with DRV/rtv who have successfully completed the TMC114-C211, TMC114-C214, TMC114-TiDP31-C229 (parent) trial or the pediatric (parent) trial TMC114-TiDP29-C232 ...",No,2022-03-16,FDA-80784,2.62,0.32,5.0,7.94,2024-03-11,2024-07-06,2029-07-07,55,Pfizer,84,South Africa,55.5,30,71,78,58,56,40,45,2,2,1,True,True,False,False,False,True,True,True,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Ritonavir,GenName Y,Drug,hiv,hiv,Phase 3,2021-07-29,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

* Patients treated with DRV/rtv who have successfully completed the TMC114-C211, TMC114-C214, TMC114-TiDP31-C229 (parent) trial or the pediatric (parent) trial TMC114-TiDP29-C232 ...",Yes,2022-01-28,FDA-61965,2.62,0.32,5.0,7.94,2024-03-11,2024-07-06,2029-07-07,41,AstraZeneca,71,Kenya,36.33333333333334,80,10,87,28,3,10,55,2,2,2,True,True,False,False,True,False,True,False,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
Rilpivirine,AltName B,Drug,hiv,hiv,Phase 3,2020-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Patients are HIV-1 infected and were previously randomized to receive TMC278 in a TMC278 clinical trial and completed the protocol-defined treatment period.
* Patients continue ...",Yes,2020-06-15,FDA-72096,2.62,0.32,5.0,7.94,2022-09-14,2023-01-09,2028-01-10,16,Sanofi,56,Kenya,38.66666666666666,67,31,24,46,32,32,36,0,2,2,False,False,True,True,False,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"Rivaroxaban (Xarelto, BAY59-7939)",Comp Beta,Drug,hiv,hiv,Phase 2,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Confirmed acute symptomatic proximal deep- vein thrombosis and/or pulmonary embolism
* Concomitant use of a strong CYP 3A4 inducer, (i.e., carbamazepine, phenytoin, rifampicin/r...",No,2012-05-03,FDA-40247,4.41,0.98,21.0,26.39,2015-10-28,2016-10-20,2037-10-20,8,Pfizer,58,Senegal,43.33333333333334,38,35,28,92,34,33,45,0,3,2,False,False,True,False,True,True,False,True,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
LDV/SOF,AltName A,Drug,hiv,hiv,Phase 3,2016-06-30,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Participants who failed treatment in Study GS-US-334-0119 who meet relevant inclusion/exclusion criteria are eligible for retreatment in this study
* Chronic genotype 1 HCV ...",Yes,2016-11-03,FDA-77286,2.62,0.32,5.0,7.94,2019-02-11,2019-06-08,2024-06-08,37,Novartis,29,Kenya,45.83333333333334,83,68,34,1,36,53,36,2,2,0,True,True,True,True,False,False,False,False,False,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
RBV,Molecule Z,Drug,hiv,hiv,Phase 3,2016-06-30,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Participants who failed treatment in Study GS-US-334-0119 who meet relevant inclusion/exclusion criteria are eligible for retreatment in this study
* Chronic genotype 1 HCV ...",Yes,2016-10-12,FDA-72470,2.62,0.32,5.0,7.94,2019-02-11,2019-06-08,2024-06-08,47,Merck,5,Overall,65.16666666666667,72,57,39,57,87,79,73,1,4,3,True,False,True,True,True,False,True,True,False,True,True,HorizonScan_hiv_20251201_Harmonized.xlsx
lorcaserin,Product Alpha,Drug,hiv,hiv,Phase 2,2020-06-30,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Male gender assigned at birth and transgender men;
* self-reported anal intercourse with men in the prior six months while under the influence of cocaine;
* cocaine use disorder...",Yes,2021-05-20,FDA-46525,4.41,0.98,21.0,26.39,2024-11-26,2025-11-19,2046-11-19,4,Bayer,66,South Africa,50.83333333333334,8,99,75,10,44,69,45,1,3,1,False,True,False,True,False,True,True,False,True,False,False,HorizonScan_hiv_20251201_Harmonized.xlsx
mefloquine,Molecule Z,Drug,hiv,hiv,Phase 2,2010-11-01,"Sex: ALL; Age: >18 Years; Criteria: Key Inclusion Criteria:

* Diagnosis of PML confirmed by detection of JCV DNA in CSF.
* Onset of PML symptoms within 6 months prior to study.

Key Exclusion Criteria:

* Other opportunistic infection ...",Yes,2011-02-15,FDA-27118,4.41,0.98,21.0,26.39,2015-03-30,2016-03-22,2037-03-22,1,Novartis,69,Overall,52.33333333333334,62,53,17,75,21,86,55,1,2,3,False,True,False,False,True,False,True,True,True,False,True,HorizonScan_hiv_20251201_Harmonized.xlsx
GSK Biologicals' investigational TB vaccine GSK 692342,Product Alpha,Biological,hiv,hiv,Phase 2,2013-05-24,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* A male or female between, and including, 18 and 50 years of age at...",No,2014-04-15,FDA-24715,4.41,0.98,21.0,26.39,2017-10-20,2018-10-13,2039-10-13,97,AstraZeneca,81,Kenya,44.66666666666666,36,4,66,73,15,74,27,0,1,2,False,False,True,False,False,False,False,True,False,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs),Product Alpha,Biological,hiv,hiv,Phase 2,2019-07-01,"Sex: ALL; Criteria: Inclusion Criteria:

* Pathologically documented EBV antigen positive lymphoproliferative disease, lymphoma, or other EBV-associated malignancy OR
* Severely immunocompromised patients who develop blo...",No,2020-04-12,FDA-82304,4.41,0.98,21.0,26.39,2023-11-27,2024-11-19,2045-11-19,58,Pfizer,88,South Africa,44.5,52,74,94,18,28,1,36,1,1,2,False,True,False,True,False,False,False,False,True,True,False,HorizonScan_hiv_20251201_Harmonized.xlsx
"Malaria Vaccine RTS,S/AS01E",TradeName X,Biological,malaria,malaria,Phase 2,2022-08-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Provision of signed or thumb printed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Ma...",No,2023-01-17,FDA-25210,4.41,0.98,21.0,26.39,2027-01-13,2028-01-06,2049-01-05,51,J&J,66,South Africa,51.66666666666666,28,54,33,81,15,99,45,1,3,1,True,False,False,True,True,True,False,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Abhayrab rabies vaccine,TradeName X,Biological,malaria,malaria,Phase 2,2022-08-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Provision of signed or thumb printed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Ma...",Yes,2022-10-31,FDA-75285,4.41,0.98,21.0,26.39,2027-01-13,2028-01-06,2049-01-05,18,Sanofi,91,Senegal,48.16666666666666,0,42,0,93,57,97,45,1,3,1,False,True,True,True,True,False,False,False,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Dihydroartemisinin-piperaquine (DHA/Pip),Molecule Z,Drug,malaria,malaria,Phase 2,2022-08-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Provision of signed or thumb printed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Ma...",No,2022-09-19,FDA-54905,4.41,0.98,21.0,26.39,2027-01-13,2028-01-06,2049-01-05,67,Bayer,54,Overall,51.16666666666666,87,85,1,74,19,41,55,1,2,3,False,True,True,False,False,True,False,False,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Artemether / Lumefantrine,AltName A,Drug,malaria,malaria,Phase 2,2022-08-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Provision of signed or thumb printed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Ma...",Yes,2022-10-25,FDA-85591,4.41,0.98,21.0,26.39,2027-01-13,2028-01-06,2049-01-05,75,Sanofi,33,Senegal,45.66666666666666,16,48,45,58,17,90,64,2,3,2,True,True,True,False,False,True,True,True,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Primaquine,AltName B,Drug,malaria,malaria,Phase 2,2022-08-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Provision of signed or thumb printed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Ma...",No,2023-02-21,FDA-50037,4.41,0.98,21.0,26.39,2027-01-13,2028-01-06,2049-01-05,77,Novartis,3,Kenya,62.83333333333334,43,37,79,97,53,68,36,0,2,2,False,False,True,False,False,False,True,True,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Atovaquone Proguanil,Product Alpha,Drug,malaria,malaria,Phase 2,2010-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* A male or non-pregnant, non-lactating female 18 to 50 years of age (inclusive) at the time of screening
* Free of clinically significant health problems
* Baseline ECG before en...",No,2010-07-08,FDA-23313,4.41,0.98,21.0,26.39,2014-08-28,2015-08-21,2036-08-20,99,AstraZeneca,16,Overall,59.83333333333334,1,99,86,80,22,71,73,1,4,3,False,True,True,True,True,True,False,False,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
NMRC-M3V-Ad-PfCA,GenName Y,Biological,malaria,malaria,Phase 2,2017-09-25,"Sex: ALL; Age: >18 Years; Criteria: INCLUSION CRITERIA:

* Between the ages of 18-50 (inclusive)
* Negative results of HIV ELISA, HbSAg, anti-HCV antibody, and no other clinically significant abnormal laboratory results from screening.
...",Yes,2017-11-22,FDA-31383,4.41,0.98,21.0,26.39,2022-02-21,2023-02-14,2044-02-14,17,Sanofi,33,Kenya,43.33333333333334,60,19,17,33,33,98,64,2,2,3,True,True,True,True,False,False,False,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
"NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA",Molecule Z,Biological,malaria,malaria,Phase 2,2017-09-25,"Sex: ALL; Age: >18 Years; Criteria: INCLUSION CRITERIA:

* Between the ages of 18-50 (inclusive)
* Negative results of HIV ELISA, HbSAg, anti-HCV antibody, and no other clinically significant abnormal laboratory results from screening.
...",Yes,2018-07-06,FDA-77166,4.41,0.98,21.0,26.39,2022-02-21,2023-02-14,2044-02-14,24,J&J,70,South Africa,79.83333333333333,96,92,99,61,83,48,36,0,2,2,False,False,False,True,True,False,False,False,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Malaria Vaccine 257049 (MALARIA-055 PRI),Molecule Z,Biological,malaria,malaria,Phase 3,2017-01-31,"Sex: ALL; Age: >42 Months; Criteria: Inclusion Criteria:

* Subjects' parent(s)/ Legally Acceptable Representative (LARs) who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* Subjects who ...",No,2018-01-10,FDA-12870,2.62,0.32,5.0,7.94,2019-09-14,2020-01-09,2025-01-09,95,Novartis,3,Overall,35.66666666666666,52,30,63,44,2,23,55,0,3,3,False,False,True,True,False,True,False,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Meningococcal C Conjugate Vaccine (MALARIA-055 PRI),Comp Beta,Biological,malaria,malaria,Phase 3,2017-01-31,"Sex: ALL; Age: >42 Months; Criteria: Inclusion Criteria:

* Subjects' parent(s)/ Legally Acceptable Representative (LARs) who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* Subjects who ...",No,2017-03-06,FDA-40130,2.62,0.32,5.0,7.94,2019-09-14,2020-01-09,2025-01-09,25,Pfizer,68,South Africa,63.5,100,59,74,97,9,42,64,1,2,4,True,False,False,False,True,False,True,True,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Cell-culture rabies vaccine (MALARIA-055 PRI),Product Alpha,Biological,malaria,malaria,Phase 3,2017-01-31,"Sex: ALL; Age: >42 Months; Criteria: Inclusion Criteria:

* Subjects' parent(s)/ Legally Acceptable Representative (LARs) who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* Subjects who ...",Yes,2017-12-13,FDA-89812,2.62,0.32,5.0,7.94,2019-09-14,2020-01-09,2025-01-09,26,Pfizer,36,Kenya,36.0,4,7,82,38,58,27,55,0,4,2,False,False,True,False,True,True,True,True,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
TritanrixHepB/Hib (MALARIA-055 PRI),AltName A,Biological,malaria,malaria,Phase 3,2017-01-31,"Sex: ALL; Age: >42 Months; Criteria: Inclusion Criteria:

* Subjects' parent(s)/ Legally Acceptable Representative (LARs) who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* Subjects who ...",No,2018-01-24,FDA-48942,2.62,0.32,5.0,7.94,2019-09-14,2020-01-09,2025-01-09,10,Bayer,80,Kenya,59.16666666666666,95,24,83,75,8,70,55,1,2,3,True,False,False,True,False,False,True,True,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI),Product Alpha,Biological,malaria,malaria,Phase 3,2017-01-31,"Sex: ALL; Age: >42 Months; Criteria: Inclusion Criteria:

* Subjects' parent(s)/ Legally Acceptable Representative (LARs) who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* Subjects who ...",Yes,2017-07-04,FDA-70255,2.62,0.32,5.0,7.94,2019-09-14,2020-01-09,2025-01-09,34,J&J,40,Overall,43.0,66,39,30,81,35,7,36,1,1,2,False,True,False,True,False,False,False,True,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Sanaria® PfSPZ Vaccine,GenName Y,Biological,malaria,malaria,Phase 2,2022-12-10,"Sex: ALL; Age: >6 Years; Criteria: Inclusion Criteria:

1. Parent(s) or guardian(s) willing and able to provide consent prior to initiation of any study procedures
2. Stated willingness of parent(s) or guardian(s) to comply with all st...",No,2023-08-26,FDA-46004,4.41,0.98,21.0,26.39,2027-05-08,2028-04-30,2049-04-30,76,Sanofi,22,South Africa,37.66666666666666,21,45,42,37,74,7,36,1,2,1,True,False,False,False,True,True,False,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
KAE609,GenName Y,Drug,malaria,malaria,Phase 2,2019-11-23,"Sex: ALL; Age: >18 Years; Criteria: KEY Inclusion Criteria:

1. Male and female patients ≥ 18 years with a body weight ≥ 45 kg.
2. Microscopic confirmation of acute uncomplicated P. falciparum using by Giemsa-stained thick film.
3. P. f...",Yes,2020-06-28,FDA-34315,4.41,0.98,21.0,26.39,2024-04-20,2025-04-13,2046-04-13,57,GSK,91,Senegal,63.16666666666666,30,53,96,78,96,26,55,1,3,2,True,False,False,True,True,True,False,True,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Coartem,AltName B,Drug,malaria,malaria,Phase 2,2019-11-23,"Sex: ALL; Age: >18 Years; Criteria: KEY Inclusion Criteria:

1. Male and female patients ≥ 18 years with a body weight ≥ 45 kg.
2. Microscopic confirmation of acute uncomplicated P. falciparum using by Giemsa-stained thick film.
3. P. f...",Yes,2020-11-11,FDA-88671,4.41,0.98,21.0,26.39,2024-04-20,2025-04-13,2046-04-13,71,AstraZeneca,48,Senegal,58.5,42,59,50,14,95,91,64,1,3,3,False,True,True,True,True,False,False,False,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Chloroquine,Product Alpha,Drug,malaria,malaria,Phase 3,2015-01-01,"Sex: FEMALE; Criteria: Inclusion Criteria:

Women who present to the Ndirande Antenatal Clinic (ANC) and meet the following inclusion criteria will be enrolled in the study: -Before the end of 27th week of gestation -First ...",No,2015-03-07,FDA-24786,2.62,0.32,5.0,7.94,2017-08-14,2017-12-09,2022-12-10,93,Sanofi,54,South Africa,49.83333333333334,5,83,54,55,93,9,36,0,2,2,False,False,False,True,True,False,False,False,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Sulfadoxine-pyrimethamine,Comp Beta,Drug,malaria,malaria,Phase 3,2015-01-01,"Sex: FEMALE; Criteria: Inclusion Criteria:

Women who present to the Ndirande Antenatal Clinic (ANC) and meet the following inclusion criteria will be enrolled in the study: -Before the end of 27th week of gestation -First ...",Yes,2015-06-09,FDA-14537,2.62,0.32,5.0,7.94,2017-08-14,2017-12-09,2022-12-10,54,Bayer,53,Kenya,45.83333333333334,85,8,35,76,31,40,45,1,2,2,False,True,True,False,False,True,False,False,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Candidate Plasmodium falciparum malaria vaccine,TradeName X,Biological,malaria,malaria,Phase 3,2020-10-07,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* Subjects' parent(s)/Legally Acceptable Representative(s) (LAR\[s\]) who, in the opinion of the investigator, could and complied with the requirements of the protocol.
* A male o...",Yes,2020-12-28,FDA-73079,2.62,0.32,5.0,7.94,2023-05-21,2023-09-15,2028-09-15,63,Novartis,79,Overall,45.33333333333334,15,27,49,91,44,46,55,0,3,3,False,False,False,True,True,False,True,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
MR-Vac,AltName B,Biological,malaria,malaria,Phase 3,2020-10-07,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* Subjects' parent(s)/Legally Acceptable Representative(s) (LAR\[s\]) who, in the opinion of the investigator, could and complied with the requirements of the protocol.
* A male o...",No,2021-01-27,FDA-27899,2.62,0.32,5.0,7.94,2023-05-21,2023-09-15,2028-09-15,82,Gilead,0,Senegal,52.83333333333334,19,91,79,77,39,12,73,2,3,3,True,True,False,False,True,True,True,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Stamaril,AltName B,Biological,malaria,malaria,Phase 3,2020-10-07,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* Subjects' parent(s)/Legally Acceptable Representative(s) (LAR\[s\]) who, in the opinion of the investigator, could and complied with the requirements of the protocol.
* A male o...",No,2021-06-15,FDA-91310,2.62,0.32,5.0,7.94,2023-05-21,2023-09-15,2028-09-15,96,GSK,35,Overall,42.0,69,38,22,10,47,66,45,1,2,2,False,True,False,True,False,True,False,True,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01),Molecule Z,Biological,malaria,malaria,Phase 2,2012-07-03,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects who the investigator believes can and will comply with the requirements of the protocol.
* A male or non-pregnant female 18 to 50 years of age at the time of first vacc...",Yes,2013-03-24,FDA-34817,4.41,0.98,21.0,26.39,2016-11-29,2017-11-22,2038-11-22,76,Bayer,4,Senegal,39.0,14,49,44,0,32,95,55,1,4,1,False,True,True,True,True,True,False,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
GSK Biologicals' malaria vaccine 257049 (2 doses),GenName Y,Biological,malaria,malaria,Phase 2,2012-07-03,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects who the investigator believes can and will comply with the requirements of the protocol.
* A male or non-pregnant female 18 to 50 years of age at the time of first vacc...",Yes,2012-08-28,FDA-63250,4.41,0.98,21.0,26.39,2016-11-29,2017-11-22,2038-11-22,78,Novartis,16,South Africa,35.0,9,0,57,36,35,73,82,2,4,3,True,True,True,True,True,False,True,True,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
GSK Biologicals' malaria vaccine 257049 (3 doses),GenName Y,Biological,malaria,malaria,Phase 2,2012-07-03,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects who the investigator believes can and will comply with the requirements of the protocol.
* A male or non-pregnant female 18 to 50 years of age at the time of first vacc...",Yes,2013-05-23,FDA-61059,4.41,0.98,21.0,26.39,2016-11-29,2017-11-22,2038-11-22,74,AstraZeneca,100,Kenya,39.5,57,9,57,6,28,80,55,1,3,2,True,False,False,False,True,True,True,True,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
VMP001,AltName A,Biological,malaria,malaria,Phase 2,2012-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects who meet all of the following criteria may participate in this study:
* Healthy adults (male or non-pregnant, non-lactating female) 18 to 55 years of age (inclusive) at...",Yes,2012-05-31,FDA-13969,4.41,0.98,21.0,26.39,2016-05-29,2017-05-22,2038-05-22,37,AstraZeneca,48,South Africa,58.66666666666666,85,18,99,13,95,42,64,0,4,3,False,False,True,False,True,True,True,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Malaria Vaccine 257049,Product Alpha,Biological,malaria,malaria,Phase 3,2014-01-31,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

All subjects must satisfy the following criteria at study entry:

* A male or female child of:5-17 months (inclusive) of age at time of first vaccination,or between 6-12 weeks of ...",Yes,2015-01-03,FDA-31355,2.62,0.32,5.0,7.94,2016-09-13,2017-01-08,2022-01-09,68,Sanofi,73,Overall,41.83333333333334,9,29,67,81,7,58,27,1,0,2,True,False,False,False,False,False,False,True,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Meningococcal C Conjugate Vaccine,GenName Y,Biological,malaria,malaria,Phase 3,2014-01-31,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

All subjects must satisfy the following criteria at study entry:

* A male or female child of:5-17 months (inclusive) of age at time of first vaccination,or between 6-12 weeks of ...",No,2014-08-30,FDA-74158,2.62,0.32,5.0,7.94,2016-09-13,2017-01-08,2022-01-09,23,GSK,36,South Africa,67.0,32,57,86,63,85,79,27,0,1,2,False,False,True,False,False,False,False,False,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Cell-culture rabies vaccine,Comp Beta,Biological,malaria,malaria,Phase 3,2014-01-31,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

All subjects must satisfy the following criteria at study entry:

* A male or female child of:5-17 months (inclusive) of age at time of first vaccination,or between 6-12 weeks of ...",No,2014-11-08,FDA-40271,2.62,0.32,5.0,7.94,2016-09-13,2017-01-08,2022-01-09,2,Sanofi,100,Kenya,49.66666666666666,78,16,26,79,24,75,55,1,2,3,True,False,False,False,True,True,False,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
TritanrixHepB/Hib,TradeName X,Biological,malaria,malaria,Phase 3,2014-01-31,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

All subjects must satisfy the following criteria at study entry:

* A male or female child of:5-17 months (inclusive) of age at time of first vaccination,or between 6-12 weeks of ...",No,2014-07-01,FDA-30633,2.62,0.32,5.0,7.94,2016-09-13,2017-01-08,2022-01-09,36,J&J,5,Senegal,37.0,8,82,15,37,2,78,55,2,3,1,True,True,False,True,True,True,False,True,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Polio Sabin Oral Polio Vaccine (GSK),AltName B,Biological,malaria,malaria,Phase 3,2014-01-31,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

All subjects must satisfy the following criteria at study entry:

* A male or female child of:5-17 months (inclusive) of age at time of first vaccination,or between 6-12 weeks of ...",No,2014-10-24,FDA-28090,2.62,0.32,5.0,7.94,2016-09-13,2017-01-08,2022-01-09,10,Gilead,61,Senegal,68.5,74,86,98,10,50,93,82,1,4,4,True,False,True,True,True,True,False,True,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
"RTS, S/AS01B",Product Alpha,Biological,malaria,malaria,Phase 2,2006-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

* Healthy male or female volunteers aged between 18 and 35 years at the time of first vaccination who have given written consent for their participation in the study were included...",Yes,2007-02-06,FDA-24132,4.41,0.98,21.0,26.39,2011-01-28,2012-01-21,2033-01-20,49,J&J,83,Overall,46.33333333333334,38,74,67,19,37,43,91,2,4,4,True,True,True,False,True,True,True,True,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
"RTS, S/AS02A",AltName B,Biological,malaria,malaria,Phase 2,2006-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

* Healthy male or female volunteers aged between 18 and 35 years at the time of first vaccination who have given written consent for their participation in the study were included...",No,2006-10-24,FDA-11144,4.41,0.98,21.0,26.39,2011-01-28,2012-01-21,2033-01-20,6,Merck,51,Senegal,37.16666666666666,55,59,34,12,5,58,64,2,2,3,True,True,False,False,False,True,True,True,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Rabipur (Rabies) Vaccine,Molecule Z,Biological,malaria,malaria,Phase 2,2006-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion criteria:

* Healthy male or female volunteers aged between 18 and 35 years at the time of first vaccination who have given written consent for their participation in the study were included...",Yes,2006-11-08,FDA-78034,4.41,0.98,21.0,26.39,2011-01-28,2012-01-21,2033-01-20,8,J&J,50,Overall,30.83333333333333,6,10,14,19,71,65,36,0,2,2,False,False,False,True,False,False,True,True,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Ivermectin,Comp Beta,Drug,malaria,malaria,Phase 3,2024-08-01,"Sex: ALL; Criteria: Inclusion Criteria (for being enrolled in the study):

* Residence in selected study village
* Able to understand the information and willing to give consent or assent (age 12-18) and parent/guardian ...",Yes,2025-06-08,FDA-89308,2.62,0.32,5.0,7.94,2027-03-15,2027-07-10,2032-07-10,57,Bayer,5,Overall,54.83333333333334,82,85,31,37,66,28,45,1,2,2,True,False,False,True,False,True,False,True,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
GSK Biological's Investigational Malaria Vaccine 257049,Product Alpha,Biological,malaria,malaria,Phase 3,2013-05-24,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

All subjects must satisfy ALL the following criteria at study entry:

* A male or female infant or child between and including 6 weeks to 17 months of age, at the time of first va...",No,2014-02-22,FDA-29669,2.62,0.32,5.0,7.94,2016-01-05,2016-05-01,2021-05-02,34,Bayer,44,Overall,47.83333333333334,72,47,69,43,55,1,45,0,2,3,False,False,True,False,False,False,True,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
"Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);",AltName B,Biological,malaria,malaria,Phase 3,2013-05-24,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

All subjects must satisfy ALL the following criteria at study entry:

* A male or female infant or child between and including 6 weeks to 17 months of age, at the time of first va...",No,2013-10-17,FDA-59258,2.62,0.32,5.0,7.94,2016-01-05,2016-05-01,2021-05-02,10,Merck,84,Senegal,45.0,42,25,73,37,71,22,64,2,2,3,True,True,False,False,True,True,False,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).,Product Alpha,Biological,malaria,malaria,Phase 3,2013-05-24,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

All subjects must satisfy ALL the following criteria at study entry:

* A male or female infant or child between and including 6 weeks to 17 months of age, at the time of first va...",Yes,2014-02-22,FDA-72996,2.62,0.32,5.0,7.94,2016-01-05,2016-05-01,2021-05-02,7,AstraZeneca,3,Senegal,39.66666666666666,29,32,72,45,50,10,55,0,4,2,False,False,False,True,True,True,True,True,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049),GenName Y,Biological,malaria,malaria,Phase 3,2012-05-04,"Sex: ALL; Age: >5 Months; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol.
* A male or fem...",Yes,2012-11-18,FDA-46269,2.62,0.32,5.0,7.94,2014-12-16,2015-04-12,2020-04-12,73,Novartis,99,South Africa,55.33333333333334,22,51,49,51,67,92,45,1,1,3,True,False,False,False,False,False,True,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
KAF156,Product Alpha,Drug,malaria,malaria,Phase 2,2014-08-01,"Sex: ALL; Age: >20 Years; Criteria: Inclusion Criteria:

-Male and female patients aged 20 to 60 years;Presence of mono-infection of P. falciparum or P. vivax; Weight between 40 kg to 90 kg.

Exclusion Criteria:

* Patients with signs a...",Yes,2014-12-20,FDA-93375,4.41,0.98,21.0,26.39,2018-12-28,2019-12-21,2040-12-20,18,GSK,86,South Africa,52.0,63,1,71,26,92,59,73,2,3,3,True,True,True,True,True,False,False,False,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
"RTS,S/AS02D",TradeName X,Biological,malaria,malaria,Phase 2,2009-01-15,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion criteria:

* A male or female infant between 6 and 10 weeks of age at the time of first vaccination.
* Written or oral, signed or thumb-printed and witnessed informed consent obtained from t...",No,2009-07-30,FDA-84339,4.41,0.98,21.0,26.39,2013-06-13,2014-06-06,2035-06-06,23,J&J,61,Overall,64.33333333333333,93,38,53,90,99,13,55,2,1,3,True,True,True,False,False,False,False,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Engerix-B®,TradeName X,Biological,malaria,malaria,Phase 2,2009-01-15,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion criteria:

* A male or female infant between 6 and 10 weeks of age at the time of first vaccination.
* Written or oral, signed or thumb-printed and witnessed informed consent obtained from t...",No,2009-10-25,FDA-95782,4.41,0.98,21.0,26.39,2013-06-13,2014-06-06,2035-06-06,98,AstraZeneca,83,Senegal,44.66666666666666,56,42,95,25,40,10,36,0,1,3,False,False,False,False,True,False,False,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
TETRActHib™,Molecule Z,Biological,malaria,malaria,Phase 2,2009-01-15,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion criteria:

* A male or female infant between 6 and 10 weeks of age at the time of first vaccination.
* Written or oral, signed or thumb-printed and witnessed informed consent obtained from t...",No,2009-11-20,FDA-57698,4.41,0.98,21.0,26.39,2013-06-13,2014-06-06,2035-06-06,6,Sanofi,91,Senegal,40.16666666666666,63,2,5,85,85,1,73,1,3,4,False,True,True,True,False,False,True,True,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
L9LS (VRC-MALMAB0114-00-AB) Subcutaneous injection,Comp Beta,Biological,malaria,malaria,Phase 2,2024-04-20,"Sex: ALL; Age: >6 Years; Criteria: Inclusion Criteria:

* Is within the appropriate age range for the respective cohort:

  1. Children: Aged ≥6 years and \<11 years.
  2. Adults: Aged ≥18 years.
* Able to provide proof of identity to ...",No,2024-08-26,FDA-15457,4.41,0.98,21.0,26.39,2028-09-16,2029-09-09,2050-09-09,79,Merck,4,Senegal,35.0,70,12,77,37,8,6,27,0,0,3,False,False,False,False,False,False,False,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
L9LS (VRC-MALMAB0114-00-AB) intravenous injection,Molecule Z,Biological,malaria,malaria,Phase 2,2024-04-20,"Sex: ALL; Age: >6 Years; Criteria: Inclusion Criteria:

* Is within the appropriate age range for the respective cohort:

  1. Children: Aged ≥6 years and \<11 years.
  2. Adults: Aged ≥18 years.
* Able to provide proof of identity to ...",No,2024-08-11,FDA-64542,4.41,0.98,21.0,26.39,2028-09-16,2029-09-09,2050-09-09,21,Gilead,4,Kenya,59.83333333333334,21,0,76,97,67,98,73,1,5,2,False,True,True,True,True,True,True,False,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
GSK malaria vaccine 257049 Vaccine,TradeName X,Biological,malaria,malaria,Phase 2,2008-11-11,"Sex: ALL; Age: >5 Months; Criteria: Inclusion Criteria:

* A male or female child of between 5 months and 17 months of age at the time of first vaccination.
* Written or oral, signed or thumb-printed and witnessed informed consent obtai...",No,2009-03-17,FDA-20937,4.41,0.98,21.0,26.39,2013-04-09,2014-04-02,2035-04-02,26,Gilead,10,Senegal,44.0,11,24,75,33,96,25,45,1,1,3,False,True,True,False,False,False,False,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine,TradeName X,Biological,malaria,malaria,Phase 2,2008-11-11,"Sex: ALL; Age: >5 Months; Criteria: Inclusion Criteria:

* A male or female child of between 5 months and 17 months of age at the time of first vaccination.
* Written or oral, signed or thumb-printed and witnessed informed consent obtai...",No,2009-02-03,FDA-55047,4.41,0.98,21.0,26.39,2013-04-09,2014-04-02,2035-04-02,66,AstraZeneca,35,Overall,44.66666666666666,9,3,92,32,79,53,36,1,2,1,False,True,False,False,False,True,True,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049,TradeName X,Biological,malaria,malaria,Phase 2,2008-05-30,"Sex: ALL; Age: >5 Months; Criteria: Inclusion Criteria:

* A male or female child between 5 months and 17 months of age at the time of first vaccination.
* Written or oral, signed or thumb-printed and witnessed informed consent obtained...",No,2009-02-07,FDA-45012,4.41,0.98,21.0,26.39,2012-10-26,2013-10-19,2034-10-19,84,Merck,8,Senegal,59.5,83,59,16,57,93,49,55,1,2,3,True,False,True,False,True,False,False,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Rabipur,Comp Beta,Biological,malaria,malaria,Phase 2,2008-05-30,"Sex: ALL; Age: >5 Months; Criteria: Inclusion Criteria:

* A male or female child between 5 months and 17 months of age at the time of first vaccination.
* Written or oral, signed or thumb-printed and witnessed informed consent obtained...",Yes,2008-12-03,FDA-79998,4.41,0.98,21.0,26.39,2012-10-26,2013-10-19,2034-10-19,27,GSK,79,Senegal,48.66666666666666,43,50,88,55,54,2,36,1,0,3,True,False,False,False,False,False,False,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Atovaquone-proguanil,Molecule Z,Drug,malaria,malaria,Phase 3,2012-09-01,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* Subjects aged greater than or equal to 6 months to 5 years presenting to Ndirande Health Centre with signs or symptoms consistent with malaria including, but not limited to, one...",No,2012-11-14,FDA-80184,2.62,0.32,5.0,7.94,2015-04-15,2015-08-10,2020-08-10,11,Sanofi,95,South Africa,51.0,0,64,72,2,89,79,36,0,2,2,False,False,False,False,False,True,True,True,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Artesunate,AltName B,Drug,malaria,malaria,Phase 3,2012-09-01,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* Subjects aged greater than or equal to 6 months to 5 years presenting to Ndirande Health Centre with signs or symptoms consistent with malaria including, but not limited to, one...",Yes,2012-12-12,FDA-97268,2.62,0.32,5.0,7.94,2015-04-15,2015-08-10,2020-08-10,91,J&J,43,Kenya,62.33333333333334,65,49,7,99,76,78,45,0,4,1,False,False,False,True,True,True,True,False,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Azithromycin,AltName A,Drug,malaria,malaria,Phase 3,2012-09-01,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* Subjects aged greater than or equal to 6 months to 5 years presenting to Ndirande Health Centre with signs or symptoms consistent with malaria including, but not limited to, one...",Yes,2013-07-11,FDA-76174,2.62,0.32,5.0,7.94,2015-04-15,2015-08-10,2020-08-10,33,Novartis,3,Overall,63.0,74,85,34,89,40,56,27,0,2,1,False,False,True,True,False,False,False,True,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Chloroquine,TradeName X,Drug,malaria,malaria,Phase 3,2012-09-01,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* Subjects aged greater than or equal to 6 months to 5 years presenting to Ndirande Health Centre with signs or symptoms consistent with malaria including, but not limited to, one...",Yes,2013-02-13,FDA-42066,2.62,0.32,5.0,7.94,2015-04-15,2015-08-10,2020-08-10,96,Pfizer,38,Overall,61.33333333333334,64,89,100,41,1,73,55,0,3,3,False,False,True,False,True,True,False,False,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
GSK257049 Dosage 1,Comp Beta,Biological,malaria,malaria,Phase 2,2014-12-16,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Inclusion criteria for enrolment to the primary phase:

* Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* A male or ...",No,2015-12-11,FDA-36728,4.41,0.98,21.0,26.39,2019-05-14,2020-05-06,2041-05-06,83,Gilead,87,South Africa,72.5,82,55,96,64,69,69,45,1,2,2,True,False,False,True,False,True,False,False,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
GSK257049 Dosage 2,Molecule Z,Biological,malaria,malaria,Phase 2,2014-12-16,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Inclusion criteria for enrolment to the primary phase:

* Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* A male or ...",Yes,2015-07-04,FDA-88849,4.41,0.98,21.0,26.39,2019-05-14,2020-05-06,2041-05-06,43,Merck,44,South Africa,55.5,0,80,51,58,88,56,73,1,5,2,False,True,True,True,True,True,True,True,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Actidose Aqua,TradeName X,Drug,malaria,malaria,Phase 2,2015-07-01,"Sex: ALL; Age: >2 Years; Criteria: * INCLUSION CRITERIA

  1. Age 2 to 10 years, inclusive
  2. Resident of Kenieroba
  3. Uncomplicated malaria\*
  4. P. falciparum density 10,000 70,000/micro L, inclusive
  5. Willingness to particip...",Yes,2015-11-14,FDA-58099,4.41,0.98,21.0,26.39,2019-11-27,2020-11-19,2041-11-19,1,Merck,61,South Africa,51.33333333333334,0,4,55,94,70,85,36,1,3,0,False,True,True,True,True,False,False,False,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Artesunate,TradeName X,Drug,malaria,malaria,Phase 2,2015-07-01,"Sex: ALL; Age: >2 Years; Criteria: * INCLUSION CRITERIA

  1. Age 2 to 10 years, inclusive
  2. Resident of Kenieroba
  3. Uncomplicated malaria\*
  4. P. falciparum density 10,000 70,000/micro L, inclusive
  5. Willingness to particip...",No,2015-09-14,FDA-87257,4.41,0.98,21.0,26.39,2019-11-27,2020-11-19,2041-11-19,14,Bayer,45,South Africa,51.0,94,42,11,34,83,42,45,0,4,1,False,False,True,False,True,True,True,True,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Amodiaquine,Molecule Z,Drug,malaria,malaria,Phase 2,2015-07-01,"Sex: ALL; Age: >2 Years; Criteria: * INCLUSION CRITERIA

  1. Age 2 to 10 years, inclusive
  2. Resident of Kenieroba
  3. Uncomplicated malaria\*
  4. P. falciparum density 10,000 70,000/micro L, inclusive
  5. Willingness to particip...",Yes,2016-03-19,FDA-46167,4.41,0.98,21.0,26.39,2019-11-27,2020-11-19,2041-11-19,68,Gilead,13,Overall,60.83333333333334,21,47,80,69,81,67,82,2,4,3,True,True,True,True,True,True,False,True,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
OZ439,Product Alpha,Drug,malaria,malaria,Phase 2,2015-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Male or female patients between the age of 18 and 60 years, inclusive
2. Body weight between 45 kg and 90 kg inclusive
3. Presence of mono-infection of P. falciparum confirmed ...",Yes,2015-05-08,FDA-73411,4.41,0.98,21.0,26.39,2019-08-28,2020-08-20,2041-08-20,59,J&J,61,South Africa,43.16666666666666,39,32,42,56,12,78,45,1,3,1,True,False,True,True,True,False,False,False,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Falciparum Malaria Protein 11 with AS02A adjuvant,AltName B,Biological,malaria,malaria,Phase 2,2007-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* A male or non-pregnant female 18 to 50 years of age (inclusive) at the time of screening.
* Written informed consent obtained from the subject before screening procedures.
* Fre...",Yes,2007-08-01,FDA-54261,4.41,0.98,21.0,26.39,2011-08-28,2012-08-20,2033-08-20,6,J&J,88,Senegal,29.16666666666667,29,22,24,6,70,24,45,0,1,4,False,False,False,False,False,False,True,True,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
(+)-SJ000557733 (SJ733),AltName A,Drug,malaria,malaria,Phase 2,2022-04-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Male or female, aged 18 to 70 years of age (inclusive) at screening.
2. Body weight between 45 kg and 90 kg inclusive
3. Presence of mono-infection of P. falciparum or P. vivax...",No,2023-02-12,FDA-18450,4.41,0.98,21.0,26.39,2026-09-11,2027-09-04,2048-09-03,13,Bayer,83,Senegal,39.33333333333334,17,48,39,81,33,18,27,2,0,1,True,True,False,False,False,False,False,True,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
"RTS,S/AS01E",GenName Y,Biological,malaria,malaria,Phase 2,2018-09-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* Written informed consent obtained from the subject prior to perfor...",Yes,2018-11-14,FDA-37502,4.41,0.98,21.0,26.39,2023-02-20,2024-02-13,2045-02-12,5,Novartis,88,Overall,41.5,49,19,11,47,43,80,55,1,3,2,False,True,True,False,True,False,True,False,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
"RTS,S/AS01B",TradeName X,Biological,malaria,malaria,Phase 2,2018-09-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* Written informed consent obtained from the subject prior to perfor...",Yes,2019-02-15,FDA-24217,4.41,0.98,21.0,26.39,2023-02-20,2024-02-13,2045-02-12,40,Pfizer,75,Kenya,31.66666666666667,34,8,66,30,16,36,55,1,2,3,False,True,False,True,True,False,False,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
GSK Biological's Investigational Malaria Vaccine 257049,AltName B,Biological,malaria,malaria,Phase 2,2014-12-23,"Sex: ALL; Age: >1 Day; Criteria: Inclusion Criteria:

All subjects must satisfy the following criteria at study entry:

* A male or female infant between 1 and 7 days (inclusive) of age (where day 1 is day of birth).
* Signed or thum...",Yes,2015-12-09,FDA-89656,4.41,0.98,21.0,26.39,2019-05-21,2020-05-13,2041-05-13,96,Novartis,4,South Africa,49.83333333333334,0,50,64,34,67,84,64,2,2,3,True,True,True,False,False,False,True,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Engerix-B,Molecule Z,Biological,malaria,malaria,Phase 2,2014-12-23,"Sex: ALL; Age: >1 Day; Criteria: Inclusion Criteria:

All subjects must satisfy the following criteria at study entry:

* A male or female infant between 1 and 7 days (inclusive) of age (where day 1 is day of birth).
* Signed or thum...",Yes,2015-11-05,FDA-77888,4.41,0.98,21.0,26.39,2019-05-21,2020-05-13,2041-05-13,34,Novartis,58,Senegal,47.83333333333334,88,65,4,49,65,16,64,2,2,3,True,True,False,False,True,True,False,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Tritanrix HepB Hib,Comp Beta,Biological,malaria,malaria,Phase 2,2014-12-23,"Sex: ALL; Age: >1 Day; Criteria: Inclusion Criteria:

All subjects must satisfy the following criteria at study entry:

* A male or female infant between 1 and 7 days (inclusive) of age (where day 1 is day of birth).
* Signed or thum...",No,2015-05-11,FDA-56218,4.41,0.98,21.0,26.39,2019-05-21,2020-05-13,2041-05-13,30,J&J,79,Overall,67.0,64,96,80,64,41,57,55,0,3,3,False,False,False,True,True,False,True,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
BCG,Product Alpha,Biological,malaria,malaria,Phase 2,2014-12-23,"Sex: ALL; Age: >1 Day; Criteria: Inclusion Criteria:

All subjects must satisfy the following criteria at study entry:

* A male or female infant between 1 and 7 days (inclusive) of age (where day 1 is day of birth).
* Signed or thum...",No,2015-02-16,FDA-37277,4.41,0.98,21.0,26.39,2019-05-21,2020-05-13,2041-05-13,55,AstraZeneca,73,Overall,67.5,37,93,74,23,95,83,45,2,1,2,True,True,True,False,False,False,False,False,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
OPV,Molecule Z,Biological,malaria,malaria,Phase 2,2014-12-23,"Sex: ALL; Age: >1 Day; Criteria: Inclusion Criteria:

All subjects must satisfy the following criteria at study entry:

* A male or female infant between 1 and 7 days (inclusive) of age (where day 1 is day of birth).
* Signed or thum...",No,2015-08-25,FDA-48357,4.41,0.98,21.0,26.39,2019-05-21,2020-05-13,2041-05-13,30,Pfizer,27,South Africa,49.0,83,71,36,6,42,56,64,1,3,3,False,True,True,True,False,False,True,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Rouvax,Product Alpha,Biological,malaria,malaria,Phase 2,2014-12-23,"Sex: ALL; Age: >1 Day; Criteria: Inclusion Criteria:

All subjects must satisfy the following criteria at study entry:

* A male or female infant between 1 and 7 days (inclusive) of age (where day 1 is day of birth).
* Signed or thum...",Yes,2015-10-06,FDA-98343,4.41,0.98,21.0,26.39,2019-05-21,2020-05-13,2041-05-13,40,J&J,38,Senegal,69.5,84,78,10,79,87,79,45,1,2,2,True,False,False,True,True,False,False,False,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049,TradeName X,Biological,malaria,malaria,Phase 3,2017-02-09,"Sex: ALL; Age: >8 Weeks; Criteria: Inclusion Criteria:

All subjects must satisfy ALL the following criteria at study entry:

* A male or female infant aged between 8 and 12 weeks inclusive at the time of first vaccination
* Signed or ...",Yes,2018-01-23,FDA-50736,2.62,0.32,5.0,7.94,2019-09-23,2020-01-18,2025-01-18,25,Bayer,75,Kenya,48.66666666666666,47,96,62,41,42,4,55,1,2,3,True,False,False,False,True,False,True,True,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Engerix-B™ vaccine,GenName Y,Biological,malaria,malaria,Phase 3,2017-02-09,"Sex: ALL; Age: >8 Weeks; Criteria: Inclusion Criteria:

All subjects must satisfy ALL the following criteria at study entry:

* A male or female infant aged between 8 and 12 weeks inclusive at the time of first vaccination
* Signed or ...",No,2017-05-12,FDA-94715,2.62,0.32,5.0,7.94,2019-09-23,2020-01-18,2025-01-18,67,Sanofi,54,Kenya,57.0,61,78,73,19,67,44,73,1,4,3,False,True,True,True,False,True,True,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Infanrix/Hib™ vaccine,Comp Beta,Biological,malaria,malaria,Phase 3,2017-02-09,"Sex: ALL; Age: >8 Weeks; Criteria: Inclusion Criteria:

All subjects must satisfy ALL the following criteria at study entry:

* A male or female infant aged between 8 and 12 weeks inclusive at the time of first vaccination
* Signed or ...",Yes,2017-04-09,FDA-39741,2.62,0.32,5.0,7.94,2019-09-23,2020-01-18,2025-01-18,74,GSK,26,Senegal,55.0,36,59,64,31,87,53,64,1,4,2,False,True,True,False,True,True,True,True,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Polio Sabin™ vaccine,GenName Y,Biological,malaria,malaria,Phase 3,2017-02-09,"Sex: ALL; Age: >8 Weeks; Criteria: Inclusion Criteria:

All subjects must satisfy ALL the following criteria at study entry:

* A male or female infant aged between 8 and 12 weeks inclusive at the time of first vaccination
* Signed or ...",No,2017-08-19,FDA-92769,2.62,0.32,5.0,7.94,2019-09-23,2020-01-18,2025-01-18,68,J&J,51,Overall,46.33333333333334,46,72,18,81,40,21,45,1,3,1,False,True,False,True,True,True,False,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Rotarix™ vaccine,AltName A,Biological,malaria,malaria,Phase 3,2017-02-09,"Sex: ALL; Age: >8 Weeks; Criteria: Inclusion Criteria:

All subjects must satisfy ALL the following criteria at study entry:

* A male or female infant aged between 8 and 12 weeks inclusive at the time of first vaccination
* Signed or ...",No,2017-07-27,FDA-60477,2.62,0.32,5.0,7.94,2019-09-23,2020-01-18,2025-01-18,62,Novartis,71,Overall,57.0,59,82,3,89,36,73,55,0,4,2,False,False,True,True,False,True,True,True,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Synflorix™ vaccine,Comp Beta,Biological,malaria,malaria,Phase 3,2017-02-09,"Sex: ALL; Age: >8 Weeks; Criteria: Inclusion Criteria:

All subjects must satisfy ALL the following criteria at study entry:

* A male or female infant aged between 8 and 12 weeks inclusive at the time of first vaccination
* Signed or ...",No,2017-05-28,FDA-37232,2.62,0.32,5.0,7.94,2019-09-23,2020-01-18,2025-01-18,54,Novartis,21,Overall,66.16666666666667,87,38,98,13,76,85,73,2,4,2,True,True,False,True,True,True,True,False,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Measles vaccine,AltName A,Biological,malaria,malaria,Phase 3,2017-02-09,"Sex: ALL; Age: >8 Weeks; Criteria: Inclusion Criteria:

All subjects must satisfy ALL the following criteria at study entry:

* A male or female infant aged between 8 and 12 weeks inclusive at the time of first vaccination
* Signed or ...",No,2018-01-13,FDA-73935,2.62,0.32,5.0,7.94,2019-09-23,2020-01-18,2025-01-18,82,GSK,60,Overall,73.5,92,55,69,95,82,48,45,2,3,0,True,True,False,True,True,True,False,False,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Yellow fever vaccine,GenName Y,Biological,malaria,malaria,Phase 3,2017-02-09,"Sex: ALL; Age: >8 Weeks; Criteria: Inclusion Criteria:

All subjects must satisfy ALL the following criteria at study entry:

* A male or female infant aged between 8 and 12 weeks inclusive at the time of first vaccination
* Signed or ...",No,2017-07-17,FDA-25988,2.62,0.32,5.0,7.94,2019-09-23,2020-01-18,2025-01-18,0,Merck,65,Senegal,37.33333333333334,48,74,32,49,15,6,55,0,3,3,False,False,True,True,False,True,False,False,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy,GenName Y,Drug,malaria,malaria,Phase 3,2018-05-14,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

1. Pregnancy confirmed by positive urine pregnancy test or intrauterine pregnancy by ultrasound
2. Estimated gestational age between 12-20 weeks
3. Confirmed to be HIV uninfected ...",No,2019-05-06,FDA-71479,2.62,0.32,5.0,7.94,2020-12-25,2021-04-21,2026-04-22,68,Merck,81,Senegal,50.0,34,30,89,30,52,65,36,0,2,2,False,False,False,False,True,False,True,False,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy,Product Alpha,Drug,malaria,malaria,Phase 3,2018-05-14,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

1. Pregnancy confirmed by positive urine pregnancy test or intrauterine pregnancy by ultrasound
2. Estimated gestational age between 12-20 weeks
3. Confirmed to be HIV uninfected ...",No,2018-08-01,FDA-31558,2.62,0.32,5.0,7.94,2020-12-25,2021-04-21,2026-04-22,46,Pfizer,95,South Africa,71.66666666666667,60,92,65,97,21,95,55,1,2,3,True,False,False,False,True,True,False,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy,GenName Y,Drug,malaria,malaria,Phase 3,2018-05-14,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

1. Pregnancy confirmed by positive urine pregnancy test or intrauterine pregnancy by ultrasound
2. Estimated gestational age between 12-20 weeks
3. Confirmed to be HIV uninfected ...",No,2018-06-15,FDA-24665,2.62,0.32,5.0,7.94,2020-12-25,2021-04-21,2026-04-22,17,Sanofi,5,South Africa,48.0,18,85,69,37,10,69,45,1,2,2,True,False,False,False,False,True,True,True,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Monthly dihydroartemisinin-piperaquine (DP) for infants,Product Alpha,Drug,malaria,malaria,Phase 3,2018-05-14,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

1. Pregnancy confirmed by positive urine pregnancy test or intrauterine pregnancy by ultrasound
2. Estimated gestational age between 12-20 weeks
3. Confirmed to be HIV uninfected ...",No,2019-02-13,FDA-54000,2.62,0.32,5.0,7.94,2020-12-25,2021-04-21,2026-04-22,37,Pfizer,96,Overall,48.33333333333334,22,81,18,22,88,59,55,1,2,3,False,True,True,True,False,False,False,False,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
3-monthly dihydroartemisinin-piperaquine (DP) for infants,Comp Beta,Drug,malaria,malaria,Phase 3,2018-05-14,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

1. Pregnancy confirmed by positive urine pregnancy test or intrauterine pregnancy by ultrasound
2. Estimated gestational age between 12-20 weeks
3. Confirmed to be HIV uninfected ...",Yes,2018-10-26,FDA-73467,2.62,0.32,5.0,7.94,2020-12-25,2021-04-21,2026-04-22,38,Merck,28,Senegal,43.16666666666666,35,76,47,11,2,88,27,0,3,0,False,False,False,True,True,True,False,False,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
MMV390048,TradeName X,Drug,malaria,malaria,Phase 2,2018-09-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Body weight between 40 kg and 90 kg inclusive
* Presence of P. vivax or P. falciparum monoinfection confirmed by:
* Fever, as defined by axillary temperature ≥37.5°C or oral/rec...",Yes,2019-01-16,FDA-23317,4.41,0.98,21.0,26.39,2023-02-20,2024-02-13,2045-02-12,13,Merck,65,Senegal,68.16666666666667,49,76,93,77,39,75,36,1,2,1,False,True,True,False,True,False,False,True,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy,GenName Y,Drug,malaria,malaria,Phase 3,2018-12-04,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

* Pregnancy confirmed by positive urine pregnancy test or intrauterine pregnancy by ultrasound
* Estimated gestational age between 12-20 weeks
* Confirmed to be HIV uninfected by ...",No,2019-05-18,FDA-54503,2.62,0.32,5.0,7.94,2021-07-17,2021-11-11,2026-11-12,69,GSK,34,South Africa,30.83333333333333,2,11,48,18,7,99,45,1,2,2,False,True,False,True,False,False,True,True,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy,Product Alpha,Drug,malaria,malaria,Phase 3,2018-12-04,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

* Pregnancy confirmed by positive urine pregnancy test or intrauterine pregnancy by ultrasound
* Estimated gestational age between 12-20 weeks
* Confirmed to be HIV uninfected by ...",Yes,2019-10-22,FDA-24122,2.62,0.32,5.0,7.94,2021-07-17,2021-11-11,2026-11-12,59,Sanofi,37,Senegal,29.0,16,94,0,16,39,9,64,1,5,1,True,False,True,True,True,True,True,False,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
trimethoprim-sulfamethoxazole (TS; TMP/SMX),GenName Y,Drug,malaria,malaria,Phase 3,2014-04-01,"Sex: ALL; Age: >4 Months; Criteria: Inclusion Criteria:

1. Age 4 -5 months
2. Confirmed HIV status of biological mother
3. Negative HIV DNA PCR test at time of enrollment for infants born to HIV-infected mothers
4. Infants born to HIV-...",Yes,2014-08-13,FDA-57443,2.62,0.32,5.0,7.94,2016-11-12,2017-03-09,2022-03-10,56,GSK,88,Kenya,58.66666666666666,36,82,82,29,92,31,36,1,0,3,True,False,False,False,False,False,False,True,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
sulfadoxine-pyrimethamine (SP),AltName B,Drug,malaria,malaria,Phase 3,2014-04-01,"Sex: ALL; Age: >4 Months; Criteria: Inclusion Criteria:

1. Age 4 -5 months
2. Confirmed HIV status of biological mother
3. Negative HIV DNA PCR test at time of enrollment for infants born to HIV-infected mothers
4. Infants born to HIV-...",No,2014-10-24,FDA-95418,2.62,0.32,5.0,7.94,2016-11-12,2017-03-09,2022-03-10,12,AstraZeneca,28,South Africa,44.83333333333334,6,40,64,70,28,61,27,1,1,1,False,True,True,False,False,False,False,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
dihydroartemisinin-piperaquine (DP),Comp Beta,Drug,malaria,malaria,Phase 3,2014-04-01,"Sex: ALL; Age: >4 Months; Criteria: Inclusion Criteria:

1. Age 4 -5 months
2. Confirmed HIV status of biological mother
3. Negative HIV DNA PCR test at time of enrollment for infants born to HIV-infected mothers
4. Infants born to HIV-...",Yes,2014-07-21,FDA-15127,2.62,0.32,5.0,7.94,2016-11-12,2017-03-09,2022-03-10,34,Bayer,4,Senegal,46.33333333333334,33,6,54,48,59,78,27,0,1,2,False,False,True,False,False,False,False,True,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Pyronaridine artesunate,GenName Y,Drug,malaria,malaria,Phase 3,2008-09-01,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

1. Male or female patients between the age of 3 and 60 years, inclusive.
2. Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.
3. Presence of ac...",Yes,2008-12-29,FDA-53059,2.62,0.32,5.0,7.94,2011-04-15,2011-08-10,2016-08-10,47,Bayer,2,South Africa,23.5,25,43,4,11,5,53,36,1,2,1,False,True,True,True,False,False,False,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Chloroquine,GenName Y,Drug,malaria,malaria,Phase 3,2008-09-01,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

1. Male or female patients between the age of 3 and 60 years, inclusive.
2. Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.
3. Presence of ac...",No,2008-10-13,FDA-98938,2.62,0.32,5.0,7.94,2011-04-15,2011-08-10,2016-08-10,52,Bayer,78,South Africa,52.33333333333334,61,61,14,24,87,67,64,2,4,1,True,True,True,False,True,True,True,False,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Tafenoquine,AltName B,Drug,malaria,malaria,Phase 2,2005-01-10,"Sex: ALL; Age: >20 Years; Criteria: Inclusion Criteria:

1. Positive smear for P. vivax.
2. Parasite density \> 500 and \< 200,000/μl
3. Age: 20-60 years old
4. Willing to sign consent form
5. Willing to be hospitalized for 29 days and ...",Yes,2005-04-26,FDA-78652,4.41,0.98,21.0,26.39,2009-06-08,2010-06-01,2031-06-01,100,Bayer,63,Overall,59.66666666666666,64,95,8,91,97,3,55,2,1,3,True,True,False,True,False,False,False,False,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Chloroquine + Primaquine,Comp Beta,Drug,malaria,malaria,Phase 2,2005-01-10,"Sex: ALL; Age: >20 Years; Criteria: Inclusion Criteria:

1. Positive smear for P. vivax.
2. Parasite density \> 500 and \< 200,000/μl
3. Age: 20-60 years old
4. Willing to sign consent form
5. Willing to be hospitalized for 29 days and ...",No,2006-01-09,FDA-43083,4.41,0.98,21.0,26.39,2009-06-08,2010-06-01,2031-06-01,90,Novartis,61,South Africa,44.83333333333334,43,100,3,43,71,9,36,2,1,1,True,True,False,False,True,False,False,False,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
tafenoquine,Molecule Z,Drug,malaria,malaria,Phase 2,2005-01-10,"Sex: ALL; Age: >20 Years; Criteria: Inclusion Criteria:

1. Positive smear for P. vivax.
2. Parasite density \> 500 and \< 200,000/μl
3. Age: 20-60 years old
4. Willing to sign consent form
5. Willing to be hospitalized for 29 days and ...",Yes,2005-09-13,FDA-42915,4.41,0.98,21.0,26.39,2009-06-08,2010-06-01,2031-06-01,57,Bayer,29,Kenya,57.0,0,86,47,23,95,91,36,2,0,2,True,True,False,False,False,False,False,False,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Chloroquine + Primaquine,Comp Beta,Drug,malaria,malaria,Phase 2,2005-01-10,"Sex: ALL; Age: >20 Years; Criteria: Inclusion Criteria:

1. Positive smear for P. vivax.
2. Parasite density \> 500 and \< 200,000/μl
3. Age: 20-60 years old
4. Willing to sign consent form
5. Willing to be hospitalized for 29 days and ...",No,2005-06-05,FDA-32720,4.41,0.98,21.0,26.39,2009-06-08,2010-06-01,2031-06-01,93,Sanofi,7,Senegal,26.0,59,28,15,15,1,38,64,0,5,2,False,False,True,True,True,True,True,False,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Pyronaridine - artesunate,AltName A,Drug,malaria,malaria,Phase 3,2010-11-15,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

1. Male or female patients between the age of 3 and 60 years, inclusive.
2. Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.
3. Presence of ac...",No,2011-09-07,FDA-87110,2.62,0.32,5.0,7.94,2013-06-28,2013-10-23,2018-10-24,24,Pfizer,9,Overall,38.33333333333334,84,29,4,21,36,56,64,1,3,3,False,True,True,True,False,True,False,True,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Chloroquine,Comp Beta,Drug,malaria,malaria,Phase 3,2010-11-15,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

1. Male or female patients between the age of 3 and 60 years, inclusive.
2. Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.
3. Presence of ac...",Yes,2011-09-13,FDA-31683,2.62,0.32,5.0,7.94,2013-06-28,2013-10-23,2018-10-24,40,GSK,89,Overall,60.16666666666666,53,18,91,68,59,72,36,2,1,1,True,True,False,False,False,False,True,False,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
OZ439,AltName B,Drug,malaria,malaria,Phase 2,2012-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Male or female patients between the age of 18 and 60 years, inclusive
2. Body weight between 40 kg and 90 kg inclusive
3. Presence of mono-infection of P. falciparum or P. viva...",Yes,2012-08-28,FDA-36791,4.41,0.98,21.0,26.39,2016-09-27,2017-09-20,2038-09-20,94,Pfizer,88,Senegal,40.33333333333334,81,16,17,0,47,81,64,0,4,3,False,False,True,True,False,True,True,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
artemether:lumefantrine (2.5 mg:30 mg),AltName A,Drug,malaria,malaria,Phase 3,2024-05-10,"Sex: ALL; Criteria: Inclusion Criteria:

1. Male or female neonates/infants
2. Body weight \<5 kg but ≥ 2 kg
3. In Cohort 1, infants aged \>28 days; in Cohort 2, neonates aged 1 to ≤28 days (3 subgroups: 1-7 days; 8-14 d...",Yes,2025-01-07,FDA-70724,2.62,0.32,5.0,7.94,2026-12-22,2027-04-18,2032-04-18,40,GSK,43,South Africa,46.5,21,53,30,79,62,34,45,1,3,1,False,True,True,False,True,False,True,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
"RTS,S/AS01E (SB257049)",AltName A,Biological,malaria,malaria,Phase 2,2019-09-26,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Only for subjects from MALARIA-092 study (NCT03162614):

• Subjects vaccinated and having undergone sporozoite challenge during the primary study (MALARIA-092 \[NCT03162614\]).

F...",Yes,2019-12-30,FDA-84525,4.41,0.98,21.0,26.39,2024-02-22,2025-02-14,2046-02-14,9,GSK,5,Overall,62.0,98,52,70,51,42,59,64,1,3,3,True,False,False,True,True,True,False,False,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049,TradeName X,Biological,malaria,malaria,Phase 2,2007-05-01,"Sex: ALL; Age: >33 Months; Criteria: Inclusion criteria:

* Completion of Visit 7, Month 21 of 104297 (NCT= NCT00197041).
* Written informed consent obtained from the parent(s) or guardian(s) of the subject

Exclusion criteria:

* Planne...",Yes,2008-03-13,FDA-21681,4.41,0.98,21.0,26.39,2011-09-27,2012-09-19,2033-09-19,55,Sanofi,77,South Africa,44.0,46,49,41,80,15,33,45,0,4,1,False,False,False,True,True,True,True,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Engerix™-B,Product Alpha,Biological,malaria,malaria,Phase 2,2007-05-01,"Sex: ALL; Age: >33 Months; Criteria: Inclusion criteria:

* Completion of Visit 7, Month 21 of 104297 (NCT= NCT00197041).
* Written informed consent obtained from the parent(s) or guardian(s) of the subject

Exclusion criteria:

* Planne...",Yes,2007-11-16,FDA-71516,4.41,0.98,21.0,26.39,2011-09-27,2012-09-19,2033-09-19,69,GSK,12,Overall,77.83333333333333,85,42,75,75,92,98,36,0,3,1,False,False,False,False,True,True,True,False,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Hiberix®,GenName Y,Biological,malaria,malaria,Phase 2,2007-05-01,"Sex: ALL; Age: >33 Months; Criteria: Inclusion criteria:

* Completion of Visit 7, Month 21 of 104297 (NCT= NCT00197041).
* Written informed consent obtained from the parent(s) or guardian(s) of the subject

Exclusion criteria:

* Planne...",No,2007-11-17,FDA-76914,4.41,0.98,21.0,26.39,2011-09-27,2012-09-19,2033-09-19,3,J&J,34,South Africa,51.16666666666666,70,99,1,100,6,31,55,2,3,1,True,True,True,True,False,False,True,False,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Prevnar™,TradeName X,Biological,malaria,malaria,Phase 2,2007-05-01,"Sex: ALL; Age: >33 Months; Criteria: Inclusion criteria:

* Completion of Visit 7, Month 21 of 104297 (NCT= NCT00197041).
* Written informed consent obtained from the parent(s) or guardian(s) of the subject

Exclusion criteria:

* Planne...",Yes,2008-04-26,FDA-92088,4.41,0.98,21.0,26.39,2011-09-27,2012-09-19,2033-09-19,82,Bayer,39,Senegal,56.5,24,100,52,93,37,33,55,0,5,1,False,False,True,True,True,True,True,False,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
sulfadoxine-pyrimethamine,AltName B,Drug,malaria,malaria,Phase 2,2007-05-01,"Sex: ALL; Age: >33 Months; Criteria: Inclusion criteria:

* Completion of Visit 7, Month 21 of 104297 (NCT= NCT00197041).
* Written informed consent obtained from the parent(s) or guardian(s) of the subject

Exclusion criteria:

* Planne...",No,2007-07-29,FDA-71469,4.41,0.98,21.0,26.39,2011-09-27,2012-09-19,2033-09-19,71,Merck,60,South Africa,55.33333333333334,49,15,84,64,41,79,45,0,3,2,False,False,True,False,True,False,True,True,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
amodiaquine,AltName B,Drug,malaria,malaria,Phase 2,2007-05-01,"Sex: ALL; Age: >33 Months; Criteria: Inclusion criteria:

* Completion of Visit 7, Month 21 of 104297 (NCT= NCT00197041).
* Written informed consent obtained from the parent(s) or guardian(s) of the subject

Exclusion criteria:

* Planne...",No,2008-01-20,FDA-45357,4.41,0.98,21.0,26.39,2011-09-27,2012-09-19,2033-09-19,40,Pfizer,69,Kenya,53.66666666666666,70,71,74,6,40,61,27,0,1,2,False,False,False,True,False,False,False,False,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
PfSPZ Vaccine,AltName A,Biological,malaria,malaria,Phase 2,2023-03-17,"Sex: ALL; Criteria: * INCLUSION CRITERIA:

  1. Females of child bearing potential aged greater than or equal to 18 and less than or equal to 38 years
  2. Able to provide proof of identity to the satisfaction of the stu...",No,2023-06-24,FDA-61805,4.41,0.98,21.0,26.39,2027-08-13,2028-08-05,2049-08-05,84,Sanofi,31,Overall,64.66666666666667,85,25,96,78,20,84,82,2,4,3,True,True,True,True,True,False,True,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
RH5.1/ ASO1,GenName Y,Biological,malaria,malaria,Phase 2,2019-06-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Healthy adults aged 18 to 45 years.
* Able and willing (in the Investigator's opinion) to comply with all study requirements.
* Willing to allow the Investigators to discuss the...",Yes,2020-05-05,FDA-45188,4.41,0.98,21.0,26.39,2023-11-23,2024-11-15,2045-11-15,97,J&J,21,Senegal,38.83333333333334,16,61,50,19,20,67,55,1,2,3,True,False,True,False,True,False,False,False,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
"RTS,S/AS02D",Product Alpha,Biological,malaria,malaria,Phase 2,2007-12-27,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

* A male or female infant of between 6 and 12 weeks of age at the time of first vaccination.
* Written informed consent obtained from the parent(s) or guardian(s) of the subject
*...",Yes,2008-05-17,FDA-62572,4.41,0.98,21.0,26.39,2012-05-24,2013-05-17,2034-05-17,87,GSK,20,Senegal,52.16666666666666,50,52,50,34,98,29,73,1,4,3,False,True,True,False,True,True,True,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
TETRActHib™,Comp Beta,Biological,malaria,malaria,Phase 2,2007-12-27,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

* A male or female infant of between 6 and 12 weeks of age at the time of first vaccination.
* Written informed consent obtained from the parent(s) or guardian(s) of the subject
*...",No,2008-06-20,FDA-38379,4.41,0.98,21.0,26.39,2012-05-24,2013-05-17,2034-05-17,14,Pfizer,100,Kenya,44.5,45,87,23,57,18,37,45,1,2,2,True,False,True,False,False,False,True,False,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Engerix-B®,GenName Y,Biological,malaria,malaria,Phase 2,2007-12-27,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

* A male or female infant of between 6 and 12 weeks of age at the time of first vaccination.
* Written informed consent obtained from the parent(s) or guardian(s) of the subject
*...",Yes,2008-11-20,FDA-33659,4.41,0.98,21.0,26.39,2012-05-24,2013-05-17,2034-05-17,78,J&J,59,Kenya,37.83333333333334,76,22,0,10,89,30,55,0,3,3,False,False,True,False,True,False,True,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
COA566,Molecule Z,Drug,malaria,malaria,Phase 4,2012-07-01,"Sex: ALL; Criteria: Inclusion:

* Subjects who were diagnosed as Asymptomatic Carrier (AC) by Rapid Diagnostic Test (RDT).
* Subjects who were diagnosed with a Symptomatic malaria episode, RDT-confirmed (SMRC)

Exclusion...",Yes,2012-08-09,FDA-14390,0.56,0.15,3.5,4.21,2013-01-21,2013-03-17,2016-09-15,48,AstraZeneca,35,South Africa,82.33333333333333,94,45,91,92,93,79,45,0,2,3,False,False,False,True,False,False,True,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
"RTS,S/AS01E (Full dose)",AltName A,Biological,malaria,malaria,Phase 2,2022-11-14,"Sex: ALL; Age: >5 Months; Criteria: Inclusion Criteria:

* Participants' parent(s)/LAR(s) who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. return for follow-up visits).
* Signed or...",No,2023-06-26,FDA-92158,4.41,0.98,21.0,26.39,2027-04-12,2028-04-04,2049-04-04,95,Sanofi,25,Kenya,36.83333333333334,7,73,81,26,9,25,36,1,2,1,False,True,True,True,False,False,False,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
"RTS,S/AS01E (1/5th dose)",AltName A,Biological,malaria,malaria,Phase 2,2022-11-14,"Sex: ALL; Age: >5 Months; Criteria: Inclusion Criteria:

* Participants' parent(s)/LAR(s) who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. return for follow-up visits).
* Signed or...",No,2023-09-28,FDA-17475,4.41,0.98,21.0,26.39,2027-04-12,2028-04-04,2049-04-04,55,Gilead,51,Kenya,52.16666666666666,76,18,3,34,83,99,64,1,2,4,True,False,False,False,True,True,False,True,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Rabies vaccine,Comp Beta,Biological,malaria,malaria,Phase 2,2022-11-14,"Sex: ALL; Age: >5 Months; Criteria: Inclusion Criteria:

* Participants' parent(s)/LAR(s) who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. return for follow-up visits).
* Signed or...",Yes,2023-10-10,FDA-88628,4.41,0.98,21.0,26.39,2027-04-12,2028-04-04,2049-04-04,38,Pfizer,2,Overall,45.16666666666666,100,32,51,45,34,9,55,1,4,1,False,True,True,True,True,True,False,False,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Chloroquine Phosphate,Comp Beta,Drug,malaria,malaria,Phase 2,2021-02-10,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:
* Age greater than or equal to 18 and less than or equal to 50 years (for booster phase, age greater than or equal to 18 and less than or equal to 52 years)
* Resident of Bancoum...",Yes,2022-01-30,FDA-66772,4.41,0.98,21.0,26.39,2025-07-09,2026-07-02,2047-07-02,87,AstraZeneca,26,Kenya,57.33333333333334,77,6,33,69,81,78,45,2,1,2,True,True,False,False,True,False,False,True,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
PfSPZ Challenge,GenName Y,Biological,malaria,malaria,Phase 2,2021-02-10,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:
* Age greater than or equal to 18 and less than or equal to 50 years (for booster phase, age greater than or equal to 18 and less than or equal to 52 years)
* Resident of Bancoum...",No,2021-03-14,FDA-55599,4.41,0.98,21.0,26.39,2025-07-09,2026-07-02,2047-07-02,15,AstraZeneca,74,South Africa,40.66666666666666,50,9,24,41,43,77,55,2,2,2,True,True,False,True,False,False,True,False,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Pyrimethamine,Product Alpha,Drug,malaria,malaria,Phase 2,2021-02-10,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:
* Age greater than or equal to 18 and less than or equal to 50 years (for booster phase, age greater than or equal to 18 and less than or equal to 52 years)
* Resident of Bancoum...",No,2021-09-30,FDA-91369,4.41,0.98,21.0,26.39,2025-07-09,2026-07-02,2047-07-02,43,AstraZeneca,98,Senegal,48.16666666666666,68,85,9,30,49,48,45,0,2,3,False,False,False,True,True,False,False,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Coartem,Molecule Z,Drug,malaria,malaria,Phase 2,2021-02-10,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:
* Age greater than or equal to 18 and less than or equal to 50 years (for booster phase, age greater than or equal to 18 and less than or equal to 52 years)
* Resident of Bancoum...",No,2021-04-21,FDA-86983,4.41,0.98,21.0,26.39,2025-07-09,2026-07-02,2047-07-02,9,J&J,78,Senegal,21.5,8,26,63,4,16,12,45,1,2,2,False,True,False,False,False,True,True,False,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
ibuprofen,GenName Y,Drug,malaria,malaria,Phase 2,2021-02-10,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:
* Age greater than or equal to 18 and less than or equal to 50 years (for booster phase, age greater than or equal to 18 and less than or equal to 52 years)
* Resident of Bancoum...",No,2021-06-15,FDA-77512,4.41,0.98,21.0,26.39,2025-07-09,2026-07-02,2047-07-02,44,Merck,28,South Africa,59.0,95,35,16,17,97,94,36,1,2,1,False,True,True,True,False,False,False,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
p52-/p36- GAP Vaccine,AltName B,Biological,malaria,malaria,Phase 2,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* A male or non-pregnant, non-lactating female 18 to 50 years of age (inclusive) at the time of enrollment
* Free of significant health problems as established by medical history,...",Yes,2012-05-14,FDA-46004,4.41,0.98,21.0,26.39,2015-10-28,2016-10-20,2037-10-20,24,Pfizer,12,Senegal,46.66666666666666,71,35,45,22,35,72,73,1,3,4,False,True,False,True,True,True,False,True,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
p52-p36- GAP Vaccine,Product Alpha,Biological,malaria,malaria,Phase 2,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* A male or non-pregnant, non-lactating female 18 to 50 years of age (inclusive) at the time of enrollment
* Free of significant health problems as established by medical history,...",Yes,2012-02-02,FDA-93413,4.41,0.98,21.0,26.39,2015-10-28,2016-10-20,2037-10-20,84,Merck,43,South Africa,42.83333333333334,13,83,93,4,61,3,27,0,1,2,False,False,False,False,True,False,False,True,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
p52-/p36- GAP Vaccine,AltName B,Biological,malaria,malaria,Phase 2,2011-06-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* A male or non-pregnant, non-lactating female 18 to 50 years of age (inclusive) at the time of enrollment
* Free of significant health problems as established by medical history,...",No,2012-02-21,FDA-13737,4.41,0.98,21.0,26.39,2015-10-28,2016-10-20,2037-10-20,91,Bayer,87,South Africa,61.0,93,78,27,85,66,17,45,2,2,1,True,True,True,False,False,False,True,False,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
GSK 257049,AltName B,Biological,malaria,malaria,Phase 2,2009-10-07,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

* A male or female infant between 6 and 10 weeks of age at the time of first vaccination.
* Signed or thumb-printed informed consent obtained from the parent(s)/guardian(s) of the...",Yes,2010-08-16,FDA-10960,4.41,0.98,21.0,26.39,2014-03-05,2015-02-26,2036-02-26,5,Sanofi,33,Senegal,27.0,15,3,7,37,13,87,55,0,3,3,False,False,True,True,True,False,False,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Tritanrix™ HepB/Hib,AltName B,Biological,malaria,malaria,Phase 2,2009-10-07,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

* A male or female infant between 6 and 10 weeks of age at the time of first vaccination.
* Signed or thumb-printed informed consent obtained from the parent(s)/guardian(s) of the...",Yes,2010-03-23,FDA-89288,4.41,0.98,21.0,26.39,2014-03-05,2015-02-26,2036-02-26,46,Novartis,37,Senegal,81.33333333333333,99,78,33,88,92,98,82,1,4,4,False,True,True,True,True,False,True,True,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Rouvax™,AltName B,Biological,malaria,malaria,Phase 2,2009-10-07,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

* A male or female infant between 6 and 10 weeks of age at the time of first vaccination.
* Signed or thumb-printed informed consent obtained from the parent(s)/guardian(s) of the...",No,2009-11-24,FDA-16995,4.41,0.98,21.0,26.39,2014-03-05,2015-02-26,2036-02-26,66,Merck,58,Senegal,61.33333333333334,76,30,35,65,87,75,45,1,3,1,True,False,True,False,True,True,False,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Stamaril™,Comp Beta,Biological,malaria,malaria,Phase 2,2009-10-07,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

* A male or female infant between 6 and 10 weeks of age at the time of first vaccination.
* Signed or thumb-printed informed consent obtained from the parent(s)/guardian(s) of the...",Yes,2010-08-03,FDA-14957,4.41,0.98,21.0,26.39,2014-03-05,2015-02-26,2036-02-26,94,Merck,40,Overall,47.16666666666666,78,82,0,19,37,67,45,1,1,3,False,True,True,False,False,False,False,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Polio Sabin™,AltName B,Biological,malaria,malaria,Phase 2,2009-10-07,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

* A male or female infant between 6 and 10 weeks of age at the time of first vaccination.
* Signed or thumb-printed informed consent obtained from the parent(s)/guardian(s) of the...",No,2010-09-16,FDA-72732,4.41,0.98,21.0,26.39,2014-03-05,2015-02-26,2036-02-26,74,Pfizer,81,Kenya,32.16666666666666,20,77,11,51,31,3,73,2,4,2,True,True,True,True,True,True,False,True,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Artesunate,TradeName X,Drug,malaria,malaria,Phase 2,2007-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult male \& non-pregnant females, 18-65 years
* Fever, defined as \>37.5ºC, during the current illness, or history (within the last 48 hours) of fever.
* Diagnosis of falcipar...",Yes,2008-08-19,FDA-34069,4.41,0.98,21.0,26.39,2012-02-27,2013-02-19,2034-02-19,70,AstraZeneca,22,South Africa,54.83333333333334,65,66,61,21,83,33,55,1,3,2,True,False,False,True,False,True,True,False,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Malarone,GenName Y,Drug,malaria,malaria,Phase 2,2007-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adult male \& non-pregnant females, 18-65 years
* Fever, defined as \>37.5ºC, during the current illness, or history (within the last 48 hours) of fever.
* Diagnosis of falcipar...",Yes,2008-02-04,FDA-94042,4.41,0.98,21.0,26.39,2012-02-27,2013-02-19,2034-02-19,34,Gilead,42,South Africa,38.5,38,5,17,67,100,4,55,2,2,2,True,True,True,False,True,False,False,False,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Azithromycin,Product Alpha,Drug,malaria,malaria,Phase 4,2022-06-01,"Sex: ALL; Age: >8 Days; Criteria: Inclusion Criteria:

* Between 8 days and 59 months old
* Primary residence within catchment area of study site
* Available for full 6 month study
* No known allergy to macrolides/azalides
* Appropria...",No,2023-04-16,FDA-57888,0.56,0.15,3.5,4.21,2022-12-22,2023-02-15,2026-08-16,26,AstraZeneca,13,South Africa,40.5,26,3,72,66,20,56,55,1,3,2,True,False,True,True,True,False,False,False,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Artemether Sublingual Spray,GenName Y,Drug,malaria,malaria,Phase 3,2012-09-01,"Sex: ALL; Criteria: Inclusion Criteria:

1. The patient's legally acceptable representative has provided informed consent and the patient has assented (where relevant) to participation in the trial
2. The patient is a ch...",Yes,2012-10-18,FDA-69999,2.62,0.32,5.0,7.94,2015-04-15,2015-08-10,2020-08-10,67,Merck,26,Senegal,44.33333333333334,0,77,78,12,88,11,45,0,2,3,False,False,False,True,False,True,False,False,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Quinine,AltName B,Drug,malaria,malaria,Phase 3,2012-09-01,"Sex: ALL; Criteria: Inclusion Criteria:

1. The patient's legally acceptable representative has provided informed consent and the patient has assented (where relevant) to participation in the trial
2. The patient is a ch...",Yes,2013-04-19,FDA-89090,2.62,0.32,5.0,7.94,2015-04-15,2015-08-10,2020-08-10,54,Bayer,20,Kenya,43.83333333333334,4,0,93,32,54,80,45,1,1,3,False,True,False,False,False,True,False,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
DSM265,GenName Y,Drug,malaria,malaria,Phase 2,2016-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Health status:

* Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
* Normal vital signs after 5 minutes re...",No,2016-12-14,FDA-77893,4.41,0.98,21.0,26.39,2020-09-27,2021-09-20,2042-09-20,49,Bayer,58,Kenya,60.0,88,54,32,74,56,56,73,1,3,4,True,False,True,False,False,True,True,True,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
OZ439,TradeName X,Drug,malaria,malaria,Phase 2,2016-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Health status:

* Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
* Normal vital signs after 5 minutes re...",No,2017-04-22,FDA-37349,4.41,0.98,21.0,26.39,2020-09-27,2021-09-20,2042-09-20,5,Novartis,30,Senegal,48.66666666666666,66,23,44,93,10,56,55,0,5,1,False,False,True,True,True,True,True,False,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Ferroquine SSR97193,Molecule Z,Drug,malaria,malaria,Phase 2,2019-09-23,"Sex: ALL; Age: >6 Months; Criteria: Inclusion criteria:

Male or female participant aged greater than (\>) 6 months old and \<70 years old:

* Cohort 1 = 14 years \< age \<70 years and body weight greater than or equal to (\>=) 35 kilog...",No,2020-02-15,FDA-87303,4.41,0.98,21.0,26.39,2024-02-19,2025-02-11,2046-02-11,69,J&J,65,Senegal,53.66666666666666,84,5,16,87,57,73,64,2,3,2,True,True,False,True,True,False,True,True,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Artefenomel,Product Alpha,Drug,malaria,malaria,Phase 2,2019-09-23,"Sex: ALL; Age: >6 Months; Criteria: Inclusion criteria:

Male or female participant aged greater than (\>) 6 months old and \<70 years old:

* Cohort 1 = 14 years \< age \<70 years and body weight greater than or equal to (\>=) 35 kilog...",No,2020-06-23,FDA-54625,4.41,0.98,21.0,26.39,2024-02-19,2025-02-11,2046-02-11,81,GSK,85,Senegal,27.16666666666667,13,58,4,46,14,28,55,0,3,3,False,False,False,True,True,False,True,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
L9LS,Comp Beta,Drug,malaria,malaria,Phase 2,2024-06-02,"Sex: ALL; Age: >5 Months; Criteria: Inclusion Criteria

Healthy children aged 5 months to 10 years (Part 1) or 5-59 months (Part 2). Weight ≥5 kg and weight ≤30 kg (Part 1) or weight ≥5 kg and ≤22.5 kg (Part 2) or weight ≥5 kg and ≤20 k...",No,2025-02-23,FDA-71378,4.41,0.98,21.0,26.39,2028-10-29,2029-10-22,2050-10-22,52,Merck,21,Senegal,71.83333333333333,98,90,55,73,68,47,64,1,4,2,True,False,True,True,True,False,True,True,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
chloroquine,AltName A,Drug,malaria,malaria,Phase 4,2015-03-01,"Sex: ALL; Age: >12 Months; Criteria: Inclusion Criteria:

* Age ≥ 12 months
* P. vivax or P. falciparum monoinfection or P.v. / P.f. mixed infection
* Presence of axillary temperature ≥ 37.5°C or history of fever during the past 24 hrs
*...",Yes,2015-06-04,FDA-57474,0.56,0.15,3.5,4.21,2015-09-21,2015-11-15,2019-05-16,48,Gilead,75,Senegal,50.0,14,28,66,71,94,27,36,2,0,2,True,True,False,False,False,False,False,False,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Artemether-lumefantrine combination,AltName B,Drug,malaria,malaria,Phase 4,2015-03-01,"Sex: ALL; Age: >12 Months; Criteria: Inclusion Criteria:

* Age ≥ 12 months
* P. vivax or P. falciparum monoinfection or P.v. / P.f. mixed infection
* Presence of axillary temperature ≥ 37.5°C or history of fever during the past 24 hrs
*...",No,2015-11-03,FDA-73528,0.56,0.15,3.5,4.21,2015-09-21,2015-11-15,2019-05-16,65,Sanofi,67,Overall,33.66666666666666,32,14,1,36,58,61,55,1,3,2,True,False,True,True,False,False,True,False,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Primaquine,Molecule Z,Drug,malaria,malaria,Phase 4,2015-03-01,"Sex: ALL; Age: >12 Months; Criteria: Inclusion Criteria:

* Age ≥ 12 months
* P. vivax or P. falciparum monoinfection or P.v. / P.f. mixed infection
* Presence of axillary temperature ≥ 37.5°C or history of fever during the past 24 hrs
*...",No,2015-05-09,FDA-37447,0.56,0.15,3.5,4.21,2015-09-21,2015-11-15,2019-05-16,39,GSK,60,Overall,42.0,10,98,31,52,44,17,36,1,2,1,False,True,True,False,True,False,False,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Primaquine,AltName A,Drug,malaria,malaria,Phase 4,2015-03-01,"Sex: ALL; Age: >12 Months; Criteria: Inclusion Criteria:

* Age ≥ 12 months
* P. vivax or P. falciparum monoinfection or P.v. / P.f. mixed infection
* Presence of axillary temperature ≥ 37.5°C or history of fever during the past 24 hrs
*...",Yes,2016-01-07,FDA-29826,0.56,0.15,3.5,4.21,2015-09-21,2015-11-15,2019-05-16,12,Sanofi,15,Overall,53.0,97,60,46,69,27,19,55,1,3,2,True,False,False,True,True,False,True,True,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
pyronaridine artesunate,AltName A,Drug,malaria,malaria,Phase 3,2008-11-01,"Sex: ALL; Criteria: Inclusion Criteria:

1. Male or female patients ≤12 years of age.
2. Body weight ≥ 5 kg and \< 25 kg with no clinical evidence of severe malnutrition (defined as a child whose weight-for-height is bel...",No,2009-07-10,FDA-45245,2.62,0.32,5.0,7.94,2011-06-15,2011-10-10,2016-10-10,57,Bayer,21,Senegal,42.83333333333334,59,46,27,25,84,16,64,2,2,3,True,True,True,False,False,True,False,True,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
arthemeter lumefantrine,AltName B,Drug,malaria,malaria,Phase 3,2008-11-01,"Sex: ALL; Criteria: Inclusion Criteria:

1. Male or female patients ≤12 years of age.
2. Body weight ≥ 5 kg and \< 25 kg with no clinical evidence of severe malnutrition (defined as a child whose weight-for-height is bel...",No,2009-09-18,FDA-61100,2.62,0.32,5.0,7.94,2011-06-15,2011-10-10,2016-10-10,40,Gilead,28,Kenya,53.83333333333334,46,96,37,45,31,68,45,1,2,2,True,False,False,True,True,False,False,False,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Sulfadoxine-pyrimethamine (SP),Product Alpha,Drug,malaria,malaria,Phase 3,2024-07-28,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

1. Viable singleton pregnancy confirmed by ultrasound
2. Estimated gestational age between 12-20 weeks
3. Confirmed to be HIV- uninfected by rapid test
4. 16 years of age or older...",Yes,2024-12-28,FDA-94951,2.62,0.32,5.0,7.94,2027-03-11,2027-07-06,2032-07-06,2,GSK,95,South Africa,75.5,86,55,74,93,80,65,55,1,2,3,False,True,False,True,True,False,False,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Dihydroartemisinin-piperaquine (DP),TradeName X,Drug,malaria,malaria,Phase 3,2024-07-28,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

1. Viable singleton pregnancy confirmed by ultrasound
2. Estimated gestational age between 12-20 weeks
3. Confirmed to be HIV- uninfected by rapid test
4. 16 years of age or older...",Yes,2024-12-16,FDA-22209,2.62,0.32,5.0,7.94,2027-03-11,2027-07-06,2032-07-06,97,Pfizer,29,Senegal,38.66666666666666,33,34,79,3,25,58,36,1,2,1,True,False,True,True,False,False,False,False,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
RABIPUR®,AltName B,Biological,malaria,malaria,Phase 3,2020-03-31,"Sex: ALL; Age: >5 Months; Criteria: Inclusion Criteria:

* The child is a permanent resident of the study area and likely to remain a resident for the duration of the trial
* The child is 5 - 17 months of age at the time of first vaccin...",Yes,2020-07-14,FDA-96116,2.62,0.32,5.0,7.94,2022-11-12,2023-03-09,2028-03-09,62,Pfizer,2,Overall,54.0,90,63,28,39,14,90,64,1,4,2,True,False,True,True,True,False,True,True,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
"RTS,S/AS01",AltName B,Biological,malaria,malaria,Phase 3,2020-03-31,"Sex: ALL; Age: >5 Months; Criteria: Inclusion Criteria:

* The child is a permanent resident of the study area and likely to remain a resident for the duration of the trial
* The child is 5 - 17 months of age at the time of first vaccin...",No,2021-01-31,FDA-41633,2.62,0.32,5.0,7.94,2022-11-12,2023-03-09,2028-03-09,52,Gilead,15,Senegal,62.5,60,39,70,62,78,66,73,1,3,4,True,False,True,True,False,True,False,True,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
SMC with SP+AQ,AltName A,Drug,malaria,malaria,Phase 3,2020-03-31,"Sex: ALL; Age: >5 Months; Criteria: Inclusion Criteria:

* The child is a permanent resident of the study area and likely to remain a resident for the duration of the trial
* The child is 5 - 17 months of age at the time of first vaccin...",Yes,2020-07-06,FDA-32795,2.62,0.32,5.0,7.94,2022-11-12,2023-03-09,2028-03-09,43,AstraZeneca,94,Kenya,63.5,88,72,37,28,66,90,64,1,3,3,False,True,True,True,True,False,False,False,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
KAE609,Molecule Z,Drug,malaria,malaria,Phase 2,2015-03-01,"Sex: ALL; Age: >20 Years; Criteria: Key Inclusion Criteria:

* Monoinfection with P. falciparum confirmed by microscopy
* Asexual P. falciparum parasitemia count of 5,000 to 50,000/µL
* Axillary temperature ≥37.5 ºC or oral/tympanic/rec...",Yes,2015-12-10,FDA-76724,4.41,0.98,21.0,26.39,2019-07-28,2020-07-20,2041-07-20,15,Bayer,73,Kenya,46.66666666666666,68,5,70,7,93,37,36,1,2,1,True,False,True,False,False,True,False,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
AQ-13 Treatment,Comp Beta,Drug,malaria,malaria,Phase 2,2017-02-01,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria

1. Adult Malian males ≥ 18 years of age,
2. Uncomplicated malaria with ≥ 2,000 asexual P. falciparum parasites per ul, and
3. Informed consent obtained and signed.

Exclusion Crite...",No,2017-06-29,FDA-53652,4.41,0.98,21.0,26.39,2021-06-30,2022-06-23,2043-06-23,32,Sanofi,43,Kenya,59.16666666666666,12,48,98,49,91,57,55,0,4,2,False,False,True,False,True,True,True,True,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Coartem Treatment,GenName Y,Drug,malaria,malaria,Phase 2,2017-02-01,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria

1. Adult Malian males ≥ 18 years of age,
2. Uncomplicated malaria with ≥ 2,000 asexual P. falciparum parasites per ul, and
3. Informed consent obtained and signed.

Exclusion Crite...",No,2017-05-05,FDA-14588,4.41,0.98,21.0,26.39,2021-06-30,2022-06-23,2043-06-23,28,Merck,59,Senegal,36.16666666666666,3,50,23,17,87,37,64,0,5,2,False,False,True,True,True,True,True,True,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Pyronaridine artesunate,TradeName X,Drug,malaria,malaria,Phase 3,2008-05-01,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

* Male or female patients between the age of 3 and 60 years, inclusive.
* Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.
* Presence of acute...",Yes,2008-12-29,FDA-15274,2.62,0.32,5.0,7.94,2010-12-13,2011-04-09,2016-04-09,43,Novartis,85,Senegal,65.66666666666667,67,60,96,73,52,46,64,2,2,3,True,True,True,False,False,True,False,False,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Coartem® (artemether lumefantrine),Comp Beta,Drug,malaria,malaria,Phase 3,2008-05-01,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

* Male or female patients between the age of 3 and 60 years, inclusive.
* Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.
* Presence of acute...",Yes,2008-12-08,FDA-61761,2.62,0.32,5.0,7.94,2010-12-13,2011-04-09,2016-04-09,71,GSK,58,Senegal,43.66666666666666,5,13,69,21,94,60,55,1,3,2,False,True,False,True,False,True,True,True,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
M5717 330 mg,AltName A,Drug,malaria,malaria,Phase 2,2024-05-28,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria:

* Participants with microscopic confirmation of acute uncomplicated Plasmodium falciparum using Giemsa-stained thick and thin film
* P. falciparum parasitemia of 1,000 to 50,000 a...",No,2024-11-15,FDA-74688,4.41,0.98,21.0,26.39,2028-10-24,2029-10-17,2050-10-17,77,Gilead,74,Senegal,45.0,44,38,4,50,97,37,64,1,4,2,False,True,True,False,True,True,True,False,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
M5717 500 mg,AltName B,Drug,malaria,malaria,Phase 2,2024-05-28,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria:

* Participants with microscopic confirmation of acute uncomplicated Plasmodium falciparum using Giemsa-stained thick and thin film
* P. falciparum parasitemia of 1,000 to 50,000 a...",Yes,2024-07-02,FDA-26608,4.41,0.98,21.0,26.39,2028-10-24,2029-10-17,2050-10-17,24,Bayer,88,Kenya,36.66666666666666,99,18,14,17,35,37,73,1,5,2,True,False,True,True,True,True,True,False,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
M5717 660 mg,Comp Beta,Drug,malaria,malaria,Phase 2,2024-05-28,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria:

* Participants with microscopic confirmation of acute uncomplicated Plasmodium falciparum using Giemsa-stained thick and thin film
* P. falciparum parasitemia of 1,000 to 50,000 a...",Yes,2024-11-22,FDA-21985,4.41,0.98,21.0,26.39,2028-10-24,2029-10-17,2050-10-17,38,Merck,4,Overall,60.33333333333334,38,58,50,64,77,75,36,1,1,2,True,False,False,False,True,False,False,True,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Pyronaridine 360 mg,AltName B,Drug,malaria,malaria,Phase 2,2024-05-28,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria:

* Participants with microscopic confirmation of acute uncomplicated Plasmodium falciparum using Giemsa-stained thick and thin film
* P. falciparum parasitemia of 1,000 to 50,000 a...",No,2024-10-13,FDA-90729,4.41,0.98,21.0,26.39,2028-10-24,2029-10-17,2050-10-17,50,Merck,87,Senegal,57.16666666666666,85,42,47,91,44,34,64,2,4,1,True,True,False,True,True,True,True,True,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Pyronaridine 360 mg,Product Alpha,Drug,malaria,malaria,Phase 2,2024-05-28,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria:

* Participants with microscopic confirmation of acute uncomplicated Plasmodium falciparum using Giemsa-stained thick and thin film
* P. falciparum parasitemia of 1,000 to 50,000 a...",Yes,2024-11-01,FDA-54623,4.41,0.98,21.0,26.39,2028-10-24,2029-10-17,2050-10-17,6,Bayer,75,Overall,71.16666666666667,82,69,53,72,78,73,55,1,2,3,True,False,False,True,False,True,False,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Pyronaridine 540 mg,AltName B,Drug,malaria,malaria,Phase 2,2024-05-28,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria:

* Participants with microscopic confirmation of acute uncomplicated Plasmodium falciparum using Giemsa-stained thick and thin film
* P. falciparum parasitemia of 1,000 to 50,000 a...",Yes,2024-09-01,FDA-35057,4.41,0.98,21.0,26.39,2028-10-24,2029-10-17,2050-10-17,30,Sanofi,18,Senegal,66.33333333333333,93,51,96,28,86,44,64,1,2,4,True,False,False,False,True,True,False,True,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Pyronaridine 720 mg,Comp Beta,Drug,malaria,malaria,Phase 2,2024-05-28,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria:

* Participants with microscopic confirmation of acute uncomplicated Plasmodium falciparum using Giemsa-stained thick and thin film
* P. falciparum parasitemia of 1,000 to 50,000 a...",Yes,2025-03-26,FDA-43299,4.41,0.98,21.0,26.39,2028-10-24,2029-10-17,2050-10-17,14,Pfizer,74,Senegal,60.16666666666666,32,86,75,75,78,15,45,2,1,2,True,True,False,False,False,False,True,True,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
PvDBPII/Matrix-M1,Product Alpha,Biological,malaria,malaria,Phase 2,2022-07-14,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Healthy adult aged 18 to 45 years.
* Red blood cells positive for the Duffy antigen/chemokine receptor (DARC).
* Normal serum levels of Glucose-6-phosphate dehydrogenase (G6PD)....",No,2022-10-22,FDA-31736,4.41,0.98,21.0,26.39,2026-12-10,2027-12-03,2048-12-02,43,Pfizer,46,Overall,60.5,8,80,63,34,88,90,18,0,1,1,False,False,True,False,False,False,False,True,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Pb(PfCS@UIS4)-infected mosquitoes,TradeName X,Biological,malaria,malaria,Phase 2,2018-10-03,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Subject is aged ≥ 18 and ≤ 35 years and in good health.
2. Subject has adequate understanding of the procedures of the study and is able and willing (in the investigator's opin...",Yes,2019-04-24,FDA-85952,4.41,0.98,21.0,26.39,2023-03-01,2024-02-22,2045-02-21,47,Sanofi,63,South Africa,74.0,64,92,94,73,54,67,64,1,3,3,True,False,False,True,False,True,True,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Tetanus/diphtheria toxoids,AltName A,Biological,malaria,malaria,Phase 3,2022-03-31,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

* The child had been enrolled in the initial phase of the trial of seasonal vaccination with the RTS,S/AS01 vaccine
* A parent or legally recognised guardian provides informed con...",Yes,2023-02-10,FDA-24129,2.62,0.32,5.0,7.94,2024-11-11,2025-03-08,2030-03-09,54,Bayer,79,Overall,31.16666666666667,48,21,69,11,11,27,64,1,3,3,True,False,True,True,False,True,False,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
SMC with SP+AQ,Molecule Z,Drug,malaria,malaria,Phase 3,2022-03-31,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

* The child had been enrolled in the initial phase of the trial of seasonal vaccination with the RTS,S/AS01 vaccine
* A parent or legally recognised guardian provides informed con...",Yes,2022-05-09,FDA-50366,2.62,0.32,5.0,7.94,2024-11-11,2025-03-08,2030-03-09,86,Gilead,7,South Africa,41.83333333333334,55,21,24,66,61,24,36,2,1,1,True,True,True,False,False,False,False,False,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
"RTS,S/AS01",Product Alpha,Biological,malaria,malaria,Phase 3,2022-03-31,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

* The child had been enrolled in the initial phase of the trial of seasonal vaccination with the RTS,S/AS01 vaccine
* A parent or legally recognised guardian provides informed con...",Yes,2022-11-16,FDA-60689,2.62,0.32,5.0,7.94,2024-11-11,2025-03-08,2030-03-09,67,Sanofi,55,Senegal,56.5,36,52,31,53,74,93,64,1,4,2,False,True,True,False,True,True,True,False,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Pfs230D1M-EPA/AS01,AltName B,Biological,malaria,malaria,Phase 2,2022-10-31,"Sex: ALL; Age: >1 Year; Criteria: * INCLUSION CRITERIA FOR GROUPS 1,2,3:

All of the following criteria must be fulfilled for a volunteer to participate in this trial:

1. Meets age requirements for Arm currently being enrolled.
2. Av...",No,2023-10-15,FDA-58427,4.41,0.98,21.0,26.39,2027-03-29,2028-03-21,2049-03-21,95,Sanofi,74,Overall,53.16666666666666,68,44,27,85,86,9,36,1,1,2,False,True,False,False,False,True,False,False,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
HAVRIX,AltName A,Biological,malaria,malaria,Phase 2,2022-10-31,"Sex: ALL; Age: >1 Year; Criteria: * INCLUSION CRITERIA FOR GROUPS 1,2,3:

All of the following criteria must be fulfilled for a volunteer to participate in this trial:

1. Meets age requirements for Arm currently being enrolled.
2. Av...",No,2023-02-28,FDA-94268,4.41,0.98,21.0,26.39,2027-03-29,2028-03-21,2049-03-21,86,GSK,4,Kenya,52.0,85,2,94,57,28,46,36,1,2,1,False,True,False,True,False,False,True,False,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
TYPHIM Vi (Salmonella typhi vaccine),AltName B,Biological,malaria,malaria,Phase 2,2022-10-31,"Sex: ALL; Age: >1 Year; Criteria: * INCLUSION CRITERIA FOR GROUPS 1,2,3:

All of the following criteria must be fulfilled for a volunteer to participate in this trial:

1. Meets age requirements for Arm currently being enrolled.
2. Av...",No,2023-06-24,FDA-69939,4.41,0.98,21.0,26.39,2027-03-29,2028-03-21,2049-03-21,92,J&J,26,Senegal,33.66666666666666,3,4,30,29,61,75,45,1,3,1,True,False,True,False,True,False,True,False,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Menactra,AltName A,Biological,malaria,malaria,Phase 2,2022-10-31,"Sex: ALL; Age: >1 Year; Criteria: * INCLUSION CRITERIA FOR GROUPS 1,2,3:

All of the following criteria must be fulfilled for a volunteer to participate in this trial:

1. Meets age requirements for Arm currently being enrolled.
2. Av...",No,2023-07-17,FDA-77822,4.41,0.98,21.0,26.39,2027-03-29,2028-03-21,2049-03-21,33,Bayer,94,Kenya,47.5,49,4,46,45,84,57,55,0,4,2,False,False,False,True,True,True,True,True,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
AVAXIM,AltName A,Biological,malaria,malaria,Phase 2,2022-10-31,"Sex: ALL; Age: >1 Year; Criteria: * INCLUSION CRITERIA FOR GROUPS 1,2,3:

All of the following criteria must be fulfilled for a volunteer to participate in this trial:

1. Meets age requirements for Arm currently being enrolled.
2. Av...",No,2023-04-01,FDA-25230,4.41,0.98,21.0,26.39,2027-03-29,2028-03-21,2049-03-21,39,Merck,32,South Africa,46.16666666666666,21,38,56,36,52,74,36,0,3,1,False,False,False,False,True,True,True,False,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Artesunate-mefloquine,Product Alpha,Drug,malaria,malaria,Phase 4,2008-11-01,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria

* 12 years of age or older
* Accepts Healthy Volunteers
* P. falciparum parasitemia between 1,000 and 100,000 parasites/μl
* History of fever or presence of fever (temperature ≥ 37...",Yes,2009-02-26,FDA-78815,0.56,0.15,3.5,4.21,2009-05-24,2009-07-18,2013-01-16,63,Pfizer,31,South Africa,45.83333333333334,68,55,43,17,44,48,73,2,3,3,True,True,False,True,True,False,True,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Atovaquone-proguanil,AltName A,Drug,malaria,malaria,Phase 4,2008-11-01,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria

* 12 years of age or older
* Accepts Healthy Volunteers
* P. falciparum parasitemia between 1,000 and 100,000 parasites/μl
* History of fever or presence of fever (temperature ≥ 37...",No,2009-09-05,FDA-64008,0.56,0.15,3.5,4.21,2009-05-24,2009-07-18,2013-01-16,42,J&J,50,South Africa,45.5,62,58,0,96,52,5,27,0,1,2,False,False,False,True,False,False,False,True,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Artemether-lumefantrine,GenName Y,Drug,malaria,malaria,Phase 4,2008-11-01,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria

* 12 years of age or older
* Accepts Healthy Volunteers
* P. falciparum parasitemia between 1,000 and 100,000 parasites/μl
* History of fever or presence of fever (temperature ≥ 37...",No,2009-08-07,FDA-75433,0.56,0.15,3.5,4.21,2009-05-24,2009-07-18,2013-01-16,80,Gilead,13,Kenya,70.83333333333333,98,74,70,40,61,82,36,1,2,1,True,False,False,True,True,False,False,True,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
L9LS (VRC-MALMAB0114-00-AB),Comp Beta,Biological,malaria,malaria,Phase 2,2024-02-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Females aged ≥18 and ≤49 years and weighing ≥ 45.0 and ≤ 90.0 kg.
2. Males aged ≥18 and ≤55 years and weighing ≥ 50.0 and ≤ 100.0 kg.
3. Able to provide proof of identity to th...",No,2024-07-13,FDA-69147,4.41,0.98,21.0,26.39,2028-07-09,2029-07-02,2050-07-02,59,Bayer,75,Kenya,66.16666666666667,78,71,64,54,36,94,36,1,2,1,False,True,True,True,False,False,False,True,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Artefenomel (OZ439),AltName B,Drug,malaria,malaria,Phase 2,2019-11-06,"Sex: ALL; Age: >14 Years; Criteria: Inclusion criteria :

Participants (14-69 years old inclusive) with body weight within 35 and 90 kilograms (kg), with uncomplicated Plasmodium falciparum (P. falciparum) malaria, with a fever as defin...",No,2020-02-09,FDA-55841,4.41,0.98,21.0,26.39,2024-04-03,2025-03-27,2046-03-27,39,Bayer,63,Overall,56.33333333333334,50,15,83,88,27,75,73,1,5,2,False,True,True,True,True,True,True,False,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Ferroquine (SSR97193),Molecule Z,Drug,malaria,malaria,Phase 2,2019-11-06,"Sex: ALL; Age: >14 Years; Criteria: Inclusion criteria :

Participants (14-69 years old inclusive) with body weight within 35 and 90 kilograms (kg), with uncomplicated Plasmodium falciparum (P. falciparum) malaria, with a fever as defin...",No,2020-03-18,FDA-76592,4.41,0.98,21.0,26.39,2024-04-03,2025-03-27,2046-03-27,43,Novartis,19,Kenya,52.5,28,90,8,80,31,78,18,1,1,0,True,False,False,False,True,False,False,False,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Artefenomel 800mg: piperaquine 640mg,AltName B,Drug,malaria,malaria,Phase 3,2015-11-01,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

1. Male or female patient age \>6 months \<70 years.
2. Body weight \>5 kg \<90 kg.
3. Presence of mono-infection of P. falciparum with:

   1. Fever, as defined by axillary tempe...",Yes,2016-03-14,FDA-64501,2.62,0.32,5.0,7.94,2018-06-14,2018-10-09,2023-10-10,33,Sanofi,97,Kenya,82.0,69,90,77,71,100,85,64,2,4,1,True,True,True,False,True,True,True,False,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Artefenomel 800mg: piperaquine 960mg,Comp Beta,Drug,malaria,malaria,Phase 3,2015-11-01,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

1. Male or female patient age \>6 months \<70 years.
2. Body weight \>5 kg \<90 kg.
3. Presence of mono-infection of P. falciparum with:

   1. Fever, as defined by axillary tempe...",No,2016-06-09,FDA-15792,2.62,0.32,5.0,7.94,2018-06-14,2018-10-09,2023-10-10,71,Novartis,84,Senegal,27.33333333333333,17,59,18,19,32,19,55,1,4,1,False,True,True,False,True,True,True,False,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Artefenomel 800mg: piperaquine 1440mg,Comp Beta,Drug,malaria,malaria,Phase 3,2015-11-01,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

1. Male or female patient age \>6 months \<70 years.
2. Body weight \>5 kg \<90 kg.
3. Presence of mono-infection of P. falciparum with:

   1. Fever, as defined by axillary tempe...",Yes,2016-07-14,FDA-67853,2.62,0.32,5.0,7.94,2018-06-14,2018-10-09,2023-10-10,45,Gilead,97,Overall,64.66666666666667,64,48,88,54,41,93,64,1,4,2,False,True,True,True,False,True,True,True,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Artemether-lumefantrine,Product Alpha,Drug,malaria,malaria,Phase 4,2021-08-31,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

1, All participants:

1. Residency within 60 km of the study clinics either at TDH or at MGH
2. Agreement to come to clinic for all follow-up clinical and PK evaluations
3. Provis...",Yes,2021-12-24,FDA-34178,0.56,0.15,3.5,4.21,2022-03-23,2022-05-17,2025-11-15,2,Merck,25,Senegal,32.83333333333334,39,36,49,33,24,16,64,1,4,2,False,True,True,True,True,True,False,False,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
pyronaridine/artesunate,TradeName X,Drug,malaria,malaria,Phase 2,2006-04-01,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

1. Male or female patients between the age of 15 and 60 years of age inclusive
2. Written informed consent, in accordance with local practice, provided by patient and/or parent/gu...",Yes,2007-01-29,FDA-16359,4.41,0.98,21.0,26.39,2010-08-28,2011-08-21,2032-08-20,86,Merck,43,South Africa,50.0,82,50,30,31,7,100,64,1,3,3,False,True,False,False,True,True,True,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
R21/Matrix-M1,GenName Y,Biological,malaria,malaria,Phase 2,2017-02-15,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

The volunteer must satisfy all the following criteria to be eligible for the study:

* Healthy adults ages 18 to 45 years.
* Willingness to remain in study area for the period of ...",No,2017-11-19,FDA-12732,4.41,0.98,21.0,26.39,2021-07-14,2022-07-07,2043-07-07,52,GSK,74,Senegal,55.5,0,87,79,92,51,24,45,1,3,1,True,False,False,True,True,True,False,False,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Falciparum Malaria Protein 11 with AS01B adjuvant.,GenName Y,Biological,malaria,malaria,Phase 2,2007-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* A male or non-pregnant female 18 to 50 years of age (inclusive) at the time of screening.
* Written informed consent obtained from the subject before screening procedures.
* Fre...",Yes,2007-05-13,FDA-22164,4.41,0.98,21.0,26.39,2011-08-28,2012-08-20,2033-08-20,14,Gilead,34,Overall,40.0,88,12,8,19,83,30,27,0,0,3,False,False,False,False,False,False,False,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
FMP2.1/AS02A,Molecule Z,Biological,malaria,malaria,Phase 2,2009-07-01,"Sex: ALL; Age: >1 Year; Criteria: Inclusion Criteria:

* Age 1-6 years inclusive at the time of screening
* Residing in Bandiagara town
* Appear to be in generally good health based on clinical and laboratory investigation
* Separate ...",No,2010-03-05,FDA-57788,4.41,0.98,21.0,26.39,2013-11-27,2014-11-20,2035-11-20,23,Pfizer,97,Kenya,57.83333333333334,76,35,30,84,84,38,36,1,1,2,False,True,False,False,True,False,False,False,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Rabies Vaccine,TradeName X,Biological,malaria,malaria,Phase 2,2009-07-01,"Sex: ALL; Age: >1 Year; Criteria: Inclusion Criteria:

* Age 1-6 years inclusive at the time of screening
* Residing in Bandiagara town
* Appear to be in generally good health based on clinical and laboratory investigation
* Separate ...",No,2010-03-18,FDA-34626,4.41,0.98,21.0,26.39,2013-11-27,2014-11-20,2035-11-20,54,Gilead,6,Overall,55.66666666666666,89,51,78,18,83,15,27,0,2,1,False,False,True,False,False,True,False,False,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
FMP1/AS02A,AltName B,Biological,malaria,malaria,Phase 2,2007-06-01,"Sex: ALL; Age: >12 Months; Criteria: Inclusion Criteria:

All subjects must satisfy the following criteria at study entry:

* A healthy male or female child, 12 to 47 months of age on the day of screening
* Written informed consent obtai...",Yes,2008-02-16,FDA-48778,4.41,0.98,21.0,26.39,2011-10-28,2012-10-20,2033-10-20,5,Sanofi,38,South Africa,49.33333333333334,84,39,14,35,64,60,45,1,1,3,True,False,True,False,False,False,False,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
RabAvert,GenName Y,Biological,malaria,malaria,Phase 2,2007-06-01,"Sex: ALL; Age: >12 Months; Criteria: Inclusion Criteria:

All subjects must satisfy the following criteria at study entry:

* A healthy male or female child, 12 to 47 months of age on the day of screening
* Written informed consent obtai...",No,2008-05-24,FDA-18838,4.41,0.98,21.0,26.39,2011-10-28,2012-10-20,2033-10-20,17,J&J,96,South Africa,33.0,4,0,23,86,20,65,73,2,3,3,True,True,False,True,True,False,True,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
VRC-MALMAB0100-00-AB (CIS43LS),TradeName X,Biological,malaria,malaria,Phase 2,2023-07-05,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Aged ≥18 and ≤55 years.
* Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
* In good general health and without cl...",Yes,2023-08-21,FDA-99737,4.41,0.98,21.0,26.39,2027-12-01,2028-11-23,2049-11-23,64,GSK,94,Kenya,49.83333333333334,6,83,89,20,6,95,27,1,1,1,True,False,False,False,False,False,True,False,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Proguanil Oral Tablet,Product Alpha,Drug,malaria,malaria,Phase 4,2020-12-16,"Sex: ALL; Age: >1 Year; Criteria: Inclusion Criteria:

* Age greater than 12 months and less than 10 years at enrollment;
* Current attendance at or willingness to attend the study SCA clinic at HBCH;
* Residence in either Homa Bay Co...",Yes,2021-08-15,FDA-12875,0.56,0.15,3.5,4.21,2021-07-08,2021-09-01,2025-03-02,16,Pfizer,69,Senegal,41.33333333333334,85,17,29,38,15,64,27,1,1,1,False,True,True,False,False,False,False,False,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ),Product Alpha,Drug,malaria,malaria,Phase 4,2020-12-16,"Sex: ALL; Age: >1 Year; Criteria: Inclusion Criteria:

* Age greater than 12 months and less than 10 years at enrollment;
* Current attendance at or willingness to attend the study SCA clinic at HBCH;
* Residence in either Homa Bay Co...",Yes,2021-10-17,FDA-39513,0.56,0.15,3.5,4.21,2021-07-08,2021-09-01,2025-03-02,39,AstraZeneca,90,Senegal,54.16666666666666,83,48,29,84,12,69,64,1,2,4,False,True,True,False,True,False,False,True,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Dihydroartemisinin-Piperaquine (DP),GenName Y,Drug,malaria,malaria,Phase 4,2020-12-16,"Sex: ALL; Age: >1 Year; Criteria: Inclusion Criteria:

* Age greater than 12 months and less than 10 years at enrollment;
* Current attendance at or willingness to attend the study SCA clinic at HBCH;
* Residence in either Homa Bay Co...",No,2021-10-20,FDA-43922,0.56,0.15,3.5,4.21,2021-07-08,2021-09-01,2025-03-02,46,GSK,62,Kenya,50.66666666666666,59,33,56,20,51,85,55,1,3,2,False,True,True,False,False,True,True,False,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
OZ439,Comp Beta,Drug,malaria,malaria,Phase 2,2016-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Demography:

* Adult (male and females) participants between 18 and 55 years of age, inclusive who do not live alone (from Day 0 until at least the end of the anti-malarial drug t...",No,2017-03-15,FDA-70461,4.41,0.98,21.0,26.39,2021-01-28,2022-01-21,2043-01-21,29,Bayer,86,Overall,53.5,30,91,10,70,72,48,64,2,3,2,True,True,False,True,False,True,True,False,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Primaquine,GenName Y,Drug,malaria,malaria,Phase 2,2016-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Demography:

* Adult (male and females) participants between 18 and 55 years of age, inclusive who do not live alone (from Day 0 until at least the end of the anti-malarial drug t...",No,2016-10-07,FDA-45866,4.41,0.98,21.0,26.39,2021-01-28,2022-01-21,2043-01-21,5,Merck,61,Senegal,45.5,92,22,68,36,45,10,45,0,3,2,False,False,True,False,True,True,False,True,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Tafenoquine,AltName A,Drug,malaria,malaria,Phase 2,2020-02-17,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* Subject is \>=2 years to \<16 years of age at the time of signing of the assent and/or informed consent. An additional cohort of subjects aged \>=6 months to \<2 years may be re...",Yes,2021-01-17,FDA-40949,4.41,0.98,21.0,26.39,2024-07-15,2025-07-08,2046-07-08,97,Merck,27,Kenya,50.5,46,4,70,87,57,39,45,1,2,2,False,True,False,True,False,True,False,False,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Chloroquine,TradeName X,Drug,malaria,malaria,Phase 2,2020-02-17,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* Subject is \>=2 years to \<16 years of age at the time of signing of the assent and/or informed consent. An additional cohort of subjects aged \>=6 months to \<2 years may be re...",No,2020-08-07,FDA-36679,4.41,0.98,21.0,26.39,2024-07-15,2025-07-08,2046-07-08,34,AstraZeneca,52,Overall,45.83333333333334,88,33,10,84,11,49,45,0,4,1,False,False,False,True,True,True,True,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Tafenoquine,Molecule Z,Drug,malaria,malaria,Phase 3,2019-08-19,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Male subjects \>=18 years at the time of signing the informed consent.
* The subject has a positive Giemsa smear for P. vivax (mixed infection with P.falciparum is acceptable).
...",No,2019-09-18,FDA-90337,2.62,0.32,5.0,7.94,2022-04-01,2022-07-27,2027-07-28,32,Pfizer,11,Kenya,62.0,36,73,21,68,84,90,55,1,2,3,True,False,True,False,False,False,True,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Primaquine,Comp Beta,Drug,malaria,malaria,Phase 3,2019-08-19,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Male subjects \>=18 years at the time of signing the informed consent.
* The subject has a positive Giemsa smear for P. vivax (mixed infection with P.falciparum is acceptable).
...",No,2020-08-08,FDA-78607,2.62,0.32,5.0,7.94,2022-04-01,2022-07-27,2027-07-28,15,Bayer,70,Senegal,38.5,44,50,43,2,52,40,64,1,2,4,False,True,False,True,False,False,True,True,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Dihydroartemisinin-piperaquine (DHA-PQP),TradeName X,Drug,malaria,malaria,Phase 3,2019-08-19,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Male subjects \>=18 years at the time of signing the informed consent.
* The subject has a positive Giemsa smear for P. vivax (mixed infection with P.falciparum is acceptable).
...",Yes,2020-01-22,FDA-63737,2.62,0.32,5.0,7.94,2022-04-01,2022-07-27,2027-07-28,26,AstraZeneca,63,Overall,44.0,36,39,74,70,36,9,18,0,0,2,False,False,False,False,False,False,False,False,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
ACT plus PQ (Rescue medication),Comp Beta,Drug,malaria,malaria,Phase 3,2019-08-19,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Male subjects \>=18 years at the time of signing the informed consent.
* The subject has a positive Giemsa smear for P. vivax (mixed infection with P.falciparum is acceptable).
...",No,2020-08-01,FDA-25325,2.62,0.32,5.0,7.94,2022-04-01,2022-07-27,2027-07-28,43,Pfizer,62,South Africa,46.83333333333334,19,33,55,71,15,88,45,2,1,2,True,True,False,False,False,False,True,False,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
PQ (End of study treatment),GenName Y,Drug,malaria,malaria,Phase 3,2019-08-19,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Male subjects \>=18 years at the time of signing the informed consent.
* The subject has a positive Giemsa smear for P. vivax (mixed infection with P.falciparum is acceptable).
...",Yes,2020-07-11,FDA-86027,2.62,0.32,5.0,7.94,2022-04-01,2022-07-27,2027-07-28,14,AstraZeneca,57,Kenya,50.0,92,39,61,67,39,2,64,2,4,1,True,True,False,True,True,True,True,True,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Pyronaridine-Artesunate,Product Alpha,Drug,malaria,malaria,Phase 2,2006-12-01,"Sex: ALL; Age: >2 Years; Criteria: Inclusion Criteria:

Patients presenting with symptoms of acute uncomplicated falciparum malaria with the following inclusion criteria:

* Male or female children, being between 2 and 14 years of age ...",Yes,2007-01-03,FDA-38667,4.41,0.98,21.0,26.39,2011-04-29,2012-04-21,2033-04-21,71,Gilead,27,Senegal,50.16666666666666,72,74,9,71,56,19,55,2,2,2,True,True,False,True,False,False,True,True,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Hypertonic saline,Molecule Z,Drug,malaria,malaria,Phase 3,2023-12-31,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* Peripheral P. falciparum parasitemia of any density
* Blantyre Coma Score ≤2
* No evidence of meningitis on lumbar puncture
* Consciousness not regained after correction of hypo...",Yes,2024-03-01,FDA-21850,2.62,0.32,5.0,7.94,2026-08-13,2026-12-08,2031-12-09,68,Novartis,12,Overall,38.83333333333334,15,71,53,33,34,27,45,0,4,1,False,False,False,True,True,True,True,True,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Tafenoquine,AltName A,Drug,malaria,malaria,Phase 3,2016-11-04,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* A female is eligible to enter and participate in the study if she is non-pregnant, nonlactating and if she is of: a. Non-childbearing potential defined as: post-menopausal (12 m...",Yes,2017-04-10,FDA-57575,2.62,0.32,5.0,7.94,2019-06-18,2019-10-13,2024-10-13,46,Pfizer,36,Senegal,45.66666666666666,72,27,46,52,2,75,36,2,1,1,True,True,False,True,False,False,False,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Chloroquine,Molecule Z,Drug,malaria,malaria,Phase 3,2016-11-04,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* A female is eligible to enter and participate in the study if she is non-pregnant, nonlactating and if she is of: a. Non-childbearing potential defined as: post-menopausal (12 m...",Yes,2016-12-13,FDA-53714,2.62,0.32,5.0,7.94,2019-06-18,2019-10-13,2024-10-13,87,Pfizer,86,South Africa,56.33333333333334,18,29,59,99,70,63,36,1,3,0,True,False,True,False,False,True,True,False,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Primaquine,Product Alpha,Drug,malaria,malaria,Phase 3,2016-11-04,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* A female is eligible to enter and participate in the study if she is non-pregnant, nonlactating and if she is of: a. Non-childbearing potential defined as: post-menopausal (12 m...",Yes,2017-03-28,FDA-19696,2.62,0.32,5.0,7.94,2019-06-18,2019-10-13,2024-10-13,26,AstraZeneca,53,Kenya,33.66666666666666,18,48,22,42,14,58,55,1,3,2,False,True,False,True,False,True,True,False,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Azithromycin plus chloroquine,Molecule Z,Drug,malaria,malaria,Phase 2,2008-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Males and females greater then or equal to the age of 18 with uncomplicated, symptomatic malaria as indicated by the presence of blood smears positive for P. falciparum asexual ...",No,2008-06-21,FDA-52883,4.41,0.98,21.0,26.39,2012-06-29,2013-06-22,2034-06-22,13,Pfizer,70,Overall,45.5,85,51,46,21,46,24,55,1,3,2,True,False,False,True,False,True,True,True,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Methylene Blue,Comp Beta,Drug,malaria,malaria,Phase 2,2017-02-01,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* Weight ≥ 6 kg
* Uncomplicated malaria caused by P. falciparum
* Asexual parasites ≥ 2 000/µl and ≤ 100 000/µl
* Axillary temperature ≥ 37.5°C or a history of fever during the la...",No,2017-07-29,FDA-86579,4.41,0.98,21.0,26.39,2021-06-30,2022-06-23,2043-06-23,6,Bayer,5,Overall,29.0,41,21,15,7,0,90,36,0,4,0,False,False,True,True,True,True,False,False,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Primaquine,Product Alpha,Drug,malaria,malaria,Phase 2,2017-02-01,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* Weight ≥ 6 kg
* Uncomplicated malaria caused by P. falciparum
* Asexual parasites ≥ 2 000/µl and ≤ 100 000/µl
* Axillary temperature ≥ 37.5°C or a history of fever during the la...",No,2017-11-15,FDA-77097,4.41,0.98,21.0,26.39,2021-06-30,2022-06-23,2043-06-23,93,Pfizer,45,Overall,66.83333333333333,71,92,15,84,97,42,36,1,1,2,True,False,False,True,False,False,False,False,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Azithromycin plus Chloroquine,AltName B,Drug,malaria,malaria,Phase 3,2010-09-01,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* Girls and boys ≥5 years to ≤12 years (Cohort 1); and ≥6 to ≤59 months of age (Cohort 2) with uncomplicated, symptomatic malaria as indicated by the presence of the following:
* ...",No,2011-03-16,FDA-42430,2.62,0.32,5.0,7.94,2013-04-14,2013-08-09,2018-08-10,49,AstraZeneca,74,South Africa,33.66666666666666,60,46,6,10,17,63,55,1,2,3,False,True,True,False,False,True,False,True,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Artemether-lumefantrine,Product Alpha,Drug,malaria,malaria,Phase 3,2010-09-01,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* Girls and boys ≥5 years to ≤12 years (Cohort 1); and ≥6 to ≤59 months of age (Cohort 2) with uncomplicated, symptomatic malaria as indicated by the presence of the following:
* ...",Yes,2010-10-29,FDA-62322,2.62,0.32,5.0,7.94,2013-04-14,2013-08-09,2018-08-10,2,Merck,3,Senegal,53.83333333333334,5,45,72,89,25,87,45,2,2,1,True,True,True,True,False,False,False,True,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
R21/Matrix-M vaccination,Molecule Z,Biological,malaria,malaria,Phase 2,2023-09-18,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

The participant is eligible to enter the study if all of the following apply:

1. Participant is a healthy adult, aged 18 to 55 years (inclusive), of Thai origin.
2. Participant is...",No,2024-01-15,FDA-21753,4.41,0.98,21.0,26.39,2028-02-14,2029-02-06,2050-02-06,28,Gilead,25,Senegal,46.33333333333334,90,28,52,85,16,7,73,2,3,3,True,True,True,True,False,True,False,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
DHA-PIP,Comp Beta,Drug,malaria,malaria,Phase 2,2023-09-18,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

The participant is eligible to enter the study if all of the following apply:

1. Participant is a healthy adult, aged 18 to 55 years (inclusive), of Thai origin.
2. Participant is...",No,2024-08-09,FDA-43825,4.41,0.98,21.0,26.39,2028-02-14,2029-02-06,2050-02-06,51,AstraZeneca,53,Kenya,38.66666666666666,69,40,45,7,19,52,55,1,2,3,True,False,True,True,False,False,False,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
PQ,Molecule Z,Drug,malaria,malaria,Phase 2,2023-09-18,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

The participant is eligible to enter the study if all of the following apply:

1. Participant is a healthy adult, aged 18 to 55 years (inclusive), of Thai origin.
2. Participant is...",Yes,2024-07-12,FDA-55064,4.41,0.98,21.0,26.39,2028-02-14,2029-02-06,2050-02-06,57,Merck,92,Overall,44.83333333333334,31,81,68,71,12,6,45,1,2,2,False,True,False,False,False,True,True,True,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Chloroquine 600mg,Molecule Z,Drug,malaria,malaria,Phase 2,2016-11-18,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria: - Positive Giemsa smear for P. vivax

* Parasite density \>100 and \<200,000/μL
* ≥16 years
* A female is eligible if she is non-pregnant, nonlactating and if she is of: - non-chil...",Yes,2017-08-04,FDA-84804,4.41,0.98,21.0,26.39,2021-04-16,2022-04-09,2043-04-09,41,AstraZeneca,19,South Africa,49.83333333333334,100,21,40,77,48,13,36,1,2,1,False,True,True,False,False,True,False,False,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Chloroquine 300mg,GenName Y,Drug,malaria,malaria,Phase 2,2016-11-18,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria: - Positive Giemsa smear for P. vivax

* Parasite density \>100 and \<200,000/μL
* ≥16 years
* A female is eligible if she is non-pregnant, nonlactating and if she is of: - non-chil...",Yes,2017-04-14,FDA-84598,4.41,0.98,21.0,26.39,2021-04-16,2022-04-09,2043-04-09,41,Pfizer,47,South Africa,40.0,57,48,24,14,50,47,55,1,3,2,True,False,True,True,True,False,False,True,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Tafenoquine 50mg,GenName Y,Drug,malaria,malaria,Phase 2,2016-11-18,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria: - Positive Giemsa smear for P. vivax

* Parasite density \>100 and \<200,000/μL
* ≥16 years
* A female is eligible if she is non-pregnant, nonlactating and if she is of: - non-chil...",Yes,2017-03-08,FDA-33947,4.41,0.98,21.0,26.39,2021-04-16,2022-04-09,2043-04-09,97,GSK,23,Kenya,59.0,16,32,52,69,89,96,36,0,2,2,False,False,True,False,True,False,False,False,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Tafenoquine 100mg,GenName Y,Drug,malaria,malaria,Phase 2,2016-11-18,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria: - Positive Giemsa smear for P. vivax

* Parasite density \>100 and \<200,000/μL
* ≥16 years
* A female is eligible if she is non-pregnant, nonlactating and if she is of: - non-chil...",No,2017-05-17,FDA-32439,4.41,0.98,21.0,26.39,2021-04-16,2022-04-09,2043-04-09,87,Gilead,37,Senegal,53.66666666666666,62,11,77,64,65,43,27,0,3,0,False,False,True,True,True,False,False,False,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Tafenoquine 300mg,TradeName X,Drug,malaria,malaria,Phase 2,2016-11-18,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria: - Positive Giemsa smear for P. vivax

* Parasite density \>100 and \<200,000/μL
* ≥16 years
* A female is eligible if she is non-pregnant, nonlactating and if she is of: - non-chil...",No,2017-07-18,FDA-63269,4.41,0.98,21.0,26.39,2021-04-16,2022-04-09,2043-04-09,49,Gilead,54,South Africa,27.0,16,29,46,22,7,42,64,1,4,2,True,False,True,False,True,True,True,False,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Tafenoquine 600mg,AltName B,Drug,malaria,malaria,Phase 2,2016-11-18,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria: - Positive Giemsa smear for P. vivax

* Parasite density \>100 and \<200,000/μL
* ≥16 years
* A female is eligible if she is non-pregnant, nonlactating and if she is of: - non-chil...",No,2017-08-30,FDA-15191,4.41,0.98,21.0,26.39,2021-04-16,2022-04-09,2043-04-09,54,AstraZeneca,2,Overall,50.0,89,15,93,1,45,57,27,1,0,2,False,True,False,False,False,False,False,False,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Primaquine 15mg,AltName A,Drug,malaria,malaria,Phase 2,2016-11-18,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria: - Positive Giemsa smear for P. vivax

* Parasite density \>100 and \<200,000/μL
* ≥16 years
* A female is eligible if she is non-pregnant, nonlactating and if she is of: - non-chil...",Yes,2017-11-13,FDA-23964,4.41,0.98,21.0,26.39,2021-04-16,2022-04-09,2043-04-09,55,Sanofi,69,Overall,52.33333333333334,53,42,79,0,92,48,36,2,2,0,True,True,False,False,True,True,False,False,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Chloroquine 600mg (Part 2 ),AltName B,Drug,malaria,malaria,Phase 2,2016-11-18,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria: - Positive Giemsa smear for P. vivax

* Parasite density \>100 and \<200,000/μL
* ≥16 years
* A female is eligible if she is non-pregnant, nonlactating and if she is of: - non-chil...",No,2017-06-10,FDA-38437,4.41,0.98,21.0,26.39,2021-04-16,2022-04-09,2043-04-09,71,Sanofi,33,Overall,41.5,9,82,96,30,18,14,73,1,5,2,True,False,True,True,True,True,True,True,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Chloroquine 300mg (Part 2 ),Molecule Z,Drug,malaria,malaria,Phase 2,2016-11-18,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria: - Positive Giemsa smear for P. vivax

* Parasite density \>100 and \<200,000/μL
* ≥16 years
* A female is eligible if she is non-pregnant, nonlactating and if she is of: - non-chil...",No,2017-08-13,FDA-10932,4.41,0.98,21.0,26.39,2021-04-16,2022-04-09,2043-04-09,24,J&J,5,Kenya,32.33333333333334,6,24,10,64,85,5,45,1,2,2,True,False,False,True,False,True,False,True,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Tafenoquine 300mg (Part 2),AltName A,Drug,malaria,malaria,Phase 2,2016-11-18,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria: - Positive Giemsa smear for P. vivax

* Parasite density \>100 and \<200,000/μL
* ≥16 years
* A female is eligible if she is non-pregnant, nonlactating and if she is of: - non-chil...",Yes,2017-06-28,FDA-24528,4.41,0.98,21.0,26.39,2021-04-16,2022-04-09,2043-04-09,8,Gilead,71,Senegal,28.33333333333333,23,41,51,43,10,2,27,0,1,2,False,False,False,False,False,False,True,True,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Primaquine 15mg (Part2 ),Product Alpha,Drug,malaria,malaria,Phase 2,2016-11-18,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria: - Positive Giemsa smear for P. vivax

* Parasite density \>100 and \<200,000/μL
* ≥16 years
* A female is eligible if she is non-pregnant, nonlactating and if she is of: - non-chil...",Yes,2017-11-02,FDA-29374,4.41,0.98,21.0,26.39,2021-04-16,2022-04-09,2043-04-09,20,Gilead,12,South Africa,62.66666666666666,74,6,64,89,90,53,64,2,3,2,True,True,True,True,False,True,False,False,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
ChAd63 PvDBP and MVA PvDBP,AltName B,Biological,malaria,malaria,Phase 2,2022-07-07,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Healthy adult aged 18 to 45 years.
* Red blood cells positive for the Duffy antigen/chemokine receptor (DARC).
* Normal serum levels of Glucose-6-phosphate dehydrogenase (G6PD)....",No,2022-12-09,FDA-67434,4.41,0.98,21.0,26.39,2026-12-03,2027-11-26,2048-11-25,51,J&J,65,South Africa,15.83333333333333,59,8,2,1,19,6,45,1,3,1,False,True,True,False,False,True,True,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Pyronaridine - artesunate,TradeName X,Drug,malaria,malaria,Phase 3,2008-12-01,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

* Male or female patients between the ages of 3 and 60 years, inclusive.
* Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.
* Presence of acut...",No,2009-02-21,FDA-19140,2.62,0.32,5.0,7.94,2011-07-15,2011-11-09,2016-11-09,51,J&J,22,Overall,37.0,57,1,42,31,39,52,55,1,3,2,False,True,True,False,True,False,True,False,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Mefloquine plus artesunate,Molecule Z,Drug,malaria,malaria,Phase 3,2008-12-01,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

* Male or female patients between the ages of 3 and 60 years, inclusive.
* Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.
* Presence of acut...",No,2009-06-09,FDA-13965,2.62,0.32,5.0,7.94,2011-07-15,2011-11-09,2016-11-09,1,Merck,62,South Africa,43.83333333333334,67,94,34,42,0,26,64,2,3,2,True,True,False,False,True,True,True,True,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
1. Artemether-Lumefantrine (AL),AltName A,Drug,malaria,malaria,Phase 3,2009-07-01,"Sex: ALL; Age: >6 Months; Criteria: Inclusion criteria:

* children aged 6-120 months;
* axillary temperature ≥ 37.5°C and/or history of fever within past 24 hours;
* P. falciparum asexual parasitemia between 1000 and 100000/µl;
* abili...",Yes,2009-10-07,FDA-52331,2.62,0.32,5.0,7.94,2012-02-12,2012-06-08,2017-06-09,56,J&J,11,South Africa,60.5,98,63,75,45,7,75,36,2,2,0,True,True,True,False,False,True,False,False,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
2. Amodiaquine-Artesunate (AQ-AS),Molecule Z,Drug,malaria,malaria,Phase 3,2009-07-01,"Sex: ALL; Age: >6 Months; Criteria: Inclusion criteria:

* children aged 6-120 months;
* axillary temperature ≥ 37.5°C and/or history of fever within past 24 hours;
* P. falciparum asexual parasitemia between 1000 and 100000/µl;
* abili...",No,2009-10-26,FDA-15123,2.62,0.32,5.0,7.94,2012-02-12,2012-06-08,2017-06-09,12,Gilead,34,Overall,55.33333333333334,73,14,82,99,64,0,45,2,2,1,True,True,True,False,True,False,False,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Lopinavir/ritonavir,GenName Y,Drug,malaria,malaria,Phase 3,2013-07-01,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

1. Age \> 16 years (if \<18 years old, living independently from parents)
2. Documentation of HIV status must come from two assays. Assays include DNA PCR, HIV RNA, Western blot, ...",No,2013-08-08,FDA-46640,2.62,0.32,5.0,7.94,2016-02-12,2016-06-08,2021-06-09,47,Gilead,62,Senegal,64.66666666666667,55,76,52,75,56,74,55,0,5,1,False,False,True,True,True,True,True,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Efavirenz,AltName A,Drug,malaria,malaria,Phase 3,2013-07-01,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

1. Age \> 16 years (if \<18 years old, living independently from parents)
2. Documentation of HIV status must come from two assays. Assays include DNA PCR, HIV RNA, Western blot, ...",Yes,2013-07-31,FDA-19464,2.62,0.32,5.0,7.94,2016-02-12,2016-06-08,2021-06-09,75,AstraZeneca,21,South Africa,31.33333333333333,63,27,15,1,46,36,36,0,3,1,False,False,True,True,True,False,False,False,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Zidovudine,AltName A,Drug,malaria,malaria,Phase 3,2013-07-01,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

1. Age \> 16 years (if \<18 years old, living independently from parents)
2. Documentation of HIV status must come from two assays. Assays include DNA PCR, HIV RNA, Western blot, ...",Yes,2013-11-10,FDA-40068,2.62,0.32,5.0,7.94,2016-02-12,2016-06-08,2021-06-09,32,Novartis,61,South Africa,64.16666666666667,54,90,88,40,70,43,55,1,2,3,True,False,True,False,True,False,False,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Lamivudine,Comp Beta,Drug,malaria,malaria,Phase 3,2013-07-01,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

1. Age \> 16 years (if \<18 years old, living independently from parents)
2. Documentation of HIV status must come from two assays. Assays include DNA PCR, HIV RNA, Western blot, ...",Yes,2014-05-22,FDA-75779,2.62,0.32,5.0,7.94,2016-02-12,2016-06-08,2021-06-09,38,GSK,40,Overall,43.5,72,54,7,35,55,38,64,1,3,3,True,False,False,False,True,True,True,False,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
KAF156,TradeName X,Drug,malaria,malaria,Phase 2,2021-06-28,"Sex: ALL; Age: >2 Years; Criteria: Inclusion Criteria:

* Part A: male and female patients ≥ 12 years and with a body weight ≥ 35.0 kg. Part B: after determining the effective/tolerated doses and regimens in adolescent and adult patien...",Yes,2021-09-01,FDA-61274,4.41,0.98,21.0,26.39,2025-11-24,2026-11-17,2047-11-17,12,GSK,14,South Africa,61.16666666666666,77,82,45,21,45,97,36,0,2,2,False,False,True,False,True,False,False,True,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Coartem,Comp Beta,Drug,malaria,malaria,Phase 2,2021-06-28,"Sex: ALL; Age: >2 Years; Criteria: Inclusion Criteria:

* Part A: male and female patients ≥ 12 years and with a body weight ≥ 35.0 kg. Part B: after determining the effective/tolerated doses and regimens in adolescent and adult patien...",No,2022-01-17,FDA-58251,4.41,0.98,21.0,26.39,2025-11-24,2026-11-17,2047-11-17,47,GSK,76,Senegal,68.33333333333333,42,3,99,94,85,87,55,2,2,2,True,True,False,True,True,False,False,True,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Lumefantrine Solid Dispersion Formulation,AltName A,Drug,malaria,malaria,Phase 2,2021-06-28,"Sex: ALL; Age: >2 Years; Criteria: Inclusion Criteria:

* Part A: male and female patients ≥ 12 years and with a body weight ≥ 35.0 kg. Part B: after determining the effective/tolerated doses and regimens in adolescent and adult patien...",No,2021-09-19,FDA-70684,4.41,0.98,21.0,26.39,2025-11-24,2026-11-17,2047-11-17,89,Novartis,93,Senegal,50.0,82,45,74,1,40,58,45,1,3,1,False,True,True,False,False,True,True,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Quinine,GenName Y,Drug,malaria,malaria,Phase 2,2010-01-01,"Sex: ALL; Criteria: Inclusion Criteria:

1. The patient's parent or attendant relative has provided informed consent and the patient has assented (where relevant) to participation in the trial
2. The patient is a child t...",No,2010-07-09,FDA-73728,4.41,0.98,21.0,26.39,2014-05-30,2015-05-23,2036-05-22,53,Sanofi,51,Senegal,56.5,45,98,47,62,67,20,45,0,3,2,False,False,False,True,True,True,False,True,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Artemether,AltName B,Drug,malaria,malaria,Phase 2,2010-01-01,"Sex: ALL; Criteria: Inclusion Criteria:

1. The patient's parent or attendant relative has provided informed consent and the patient has assented (where relevant) to participation in the trial
2. The patient is a child t...",Yes,2010-12-25,FDA-60951,4.41,0.98,21.0,26.39,2014-05-30,2015-05-23,2036-05-22,63,AstraZeneca,93,Overall,37.16666666666666,40,46,7,78,13,39,18,0,2,0,False,False,True,True,False,False,False,False,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
ACT,Comp Beta,Drug,malaria,malaria,Phase 3,2020-03-04,"Sex: ALL; Age: >2 Years; Criteria: Inclusion Criteria:

* Male or female, aged from 2 years to 65 years old
* Acute uncomplicated P. falciparum malaria, confirmed by positive blood smear with asexual forms of P. falciparum (or mixed wi...",Yes,2020-12-13,FDA-31144,2.62,0.32,5.0,7.94,2022-10-16,2023-02-10,2028-02-11,34,Pfizer,70,South Africa,38.66666666666666,25,61,5,36,65,40,18,0,1,1,False,False,False,False,True,False,False,False,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
TACT,TradeName X,Drug,malaria,malaria,Phase 3,2020-03-04,"Sex: ALL; Age: >2 Years; Criteria: Inclusion Criteria:

* Male or female, aged from 2 years to 65 years old
* Acute uncomplicated P. falciparum malaria, confirmed by positive blood smear with asexual forms of P. falciparum (or mixed wi...",Yes,2020-04-04,FDA-32429,2.62,0.32,5.0,7.94,2022-10-16,2023-02-10,2028-02-11,86,Gilead,11,Kenya,78.0,87,68,82,37,98,96,36,0,2,2,False,False,False,False,True,True,False,False,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Lopinavir/Ritonavir (LPV/r),Molecule Z,Drug,malaria,malaria,Phase 3,2013-01-01,"Sex: ALL; Age: >2 Months; Criteria: Inclusion criteria:

1. Age 2 months to \< 11 years
2. Confirmed HIV diagnosis. i. Children \> 18 months: Documentation of HIV status must come from two assays. Assays include DNA PCR, HIV RNA, Wester...",No,2013-06-27,FDA-78988,2.62,0.32,5.0,7.94,2015-08-15,2015-12-10,2020-12-10,65,Pfizer,83,Kenya,52.0,64,9,19,57,91,72,45,2,0,3,True,True,False,False,False,False,False,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Nevirapine (NVP),Product Alpha,Drug,malaria,malaria,Phase 3,2013-01-01,"Sex: ALL; Age: >2 Months; Criteria: Inclusion criteria:

1. Age 2 months to \< 11 years
2. Confirmed HIV diagnosis. i. Children \> 18 months: Documentation of HIV status must come from two assays. Assays include DNA PCR, HIV RNA, Wester...",No,2013-11-20,FDA-28536,2.62,0.32,5.0,7.94,2015-08-15,2015-12-10,2020-12-10,21,J&J,28,South Africa,42.0,32,10,69,93,6,42,27,0,2,1,False,False,False,True,False,False,True,False,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Efavirenz (EFV),AltName B,Drug,malaria,malaria,Phase 3,2013-01-01,"Sex: ALL; Age: >2 Months; Criteria: Inclusion criteria:

1. Age 2 months to \< 11 years
2. Confirmed HIV diagnosis. i. Children \> 18 months: Documentation of HIV status must come from two assays. Assays include DNA PCR, HIV RNA, Wester...",Yes,2013-05-06,FDA-53836,2.62,0.32,5.0,7.94,2015-08-15,2015-12-10,2020-12-10,94,Bayer,60,Kenya,61.33333333333334,74,87,32,88,38,49,55,0,3,3,False,False,True,True,False,True,False,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
2 nucleoside reverse transcriptase inhibitor (NRTI),AltName B,Drug,malaria,malaria,Phase 3,2013-01-01,"Sex: ALL; Age: >2 Months; Criteria: Inclusion criteria:

1. Age 2 months to \< 11 years
2. Confirmed HIV diagnosis. i. Children \> 18 months: Documentation of HIV status must come from two assays. Assays include DNA PCR, HIV RNA, Wester...",No,2013-04-04,FDA-15558,2.62,0.32,5.0,7.94,2015-08-15,2015-12-10,2020-12-10,16,Sanofi,74,Senegal,40.66666666666666,29,47,63,3,72,30,36,0,1,3,False,False,False,False,True,False,False,True,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
"RTS,S/AS01B Fractional dose",AltName A,Biological,malaria,malaria,Phase 2,2018-02-20,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participant is a healthy male or non-pregnant female, aged 18 to 55 years (inclusive), of Thai origin.
* Participant is willing and able to give informed consent to participate ...",Yes,2018-10-26,FDA-29257,4.41,0.98,21.0,26.39,2022-07-19,2023-07-12,2044-07-11,90,J&J,28,Senegal,56.16666666666666,23,83,74,51,28,78,36,1,2,1,True,False,False,False,False,True,True,True,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
"Double RTS,S/AS01E Fractional dose",GenName Y,Biological,malaria,malaria,Phase 2,2018-02-20,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participant is a healthy male or non-pregnant female, aged 18 to 55 years (inclusive), of Thai origin.
* Participant is willing and able to give informed consent to participate ...",No,2018-12-29,FDA-73299,4.41,0.98,21.0,26.39,2022-07-19,2023-07-12,2044-07-11,38,Pfizer,61,Kenya,43.5,85,82,7,8,26,53,45,0,3,2,False,False,False,False,True,True,True,True,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
"RTS,S/AS01E Standard dose",Comp Beta,Biological,malaria,malaria,Phase 2,2018-02-20,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participant is a healthy male or non-pregnant female, aged 18 to 55 years (inclusive), of Thai origin.
* Participant is willing and able to give informed consent to participate ...",Yes,2018-07-29,FDA-58361,4.41,0.98,21.0,26.39,2022-07-19,2023-07-12,2044-07-11,48,AstraZeneca,10,Kenya,37.0,74,21,44,48,6,29,55,1,3,2,False,True,True,True,False,True,False,True,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
"RTS,S/AS01E + DHA-PIP+PQ Standard dose",Comp Beta,Biological,malaria,malaria,Phase 2,2018-02-20,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participant is a healthy male or non-pregnant female, aged 18 to 55 years (inclusive), of Thai origin.
* Participant is willing and able to give informed consent to participate ...",No,2018-07-05,FDA-86848,4.41,0.98,21.0,26.39,2022-07-19,2023-07-12,2044-07-11,26,Novartis,49,South Africa,30.83333333333333,23,79,32,0,35,16,82,2,4,3,True,True,True,True,True,True,False,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
"RTS,S/AS01E Fractional dose",Molecule Z,Biological,malaria,malaria,Phase 2,2018-02-20,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participant is a healthy male or non-pregnant female, aged 18 to 55 years (inclusive), of Thai origin.
* Participant is willing and able to give informed consent to participate ...",Yes,2018-12-27,FDA-38137,4.41,0.98,21.0,26.39,2022-07-19,2023-07-12,2044-07-11,76,Bayer,100,Kenya,53.16666666666666,56,37,91,12,60,63,45,1,2,2,True,False,False,False,True,False,True,True,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
"RTS,S/AS01E + DHA-PIP+PQ Fractional dose",AltName B,Biological,malaria,malaria,Phase 2,2018-02-20,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participant is a healthy male or non-pregnant female, aged 18 to 55 years (inclusive), of Thai origin.
* Participant is willing and able to give informed consent to participate ...",Yes,2018-06-14,FDA-27923,4.41,0.98,21.0,26.39,2022-07-19,2023-07-12,2044-07-11,54,AstraZeneca,73,Kenya,37.5,42,15,52,35,37,44,36,1,1,2,False,True,False,False,True,False,False,False,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
"RTS,S/AS01E + DHA-PIP+PQ Fractional two-dose",TradeName X,Biological,malaria,malaria,Phase 2,2018-02-20,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participant is a healthy male or non-pregnant female, aged 18 to 55 years (inclusive), of Thai origin.
* Participant is willing and able to give informed consent to participate ...",No,2018-11-01,FDA-59876,4.41,0.98,21.0,26.39,2022-07-19,2023-07-12,2044-07-11,52,GSK,85,South Africa,43.33333333333334,73,2,2,92,22,69,27,1,1,1,True,False,False,False,False,True,False,True,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Ivermectin,Comp Beta,Drug,malaria,malaria,Phase 3,2015-12-01,"Sex: ALL; Criteria: Inclusion Criteria:

* Residence in the study site
* Able to understand the information and willing to give consent and assent (parent or guardian consent if study participant age is \< 18 years)

Exc...",No,2016-04-10,FDA-13162,2.62,0.32,5.0,7.94,2018-07-14,2018-11-08,2023-11-09,81,Bayer,32,Overall,35.5,48,30,36,36,51,12,36,2,2,0,True,True,True,False,False,True,False,False,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Albendazole,GenName Y,Drug,malaria,malaria,Phase 3,2015-12-01,"Sex: ALL; Criteria: Inclusion Criteria:

* Residence in the study site
* Able to understand the information and willing to give consent and assent (parent or guardian consent if study participant age is \< 18 years)

Exc...",No,2016-11-29,FDA-28181,2.62,0.32,5.0,7.94,2018-07-14,2018-11-08,2023-11-09,74,Sanofi,81,Senegal,39.83333333333334,20,7,46,63,22,81,73,2,3,3,True,True,False,False,True,True,True,True,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS),AltName A,Drug,malaria,malaria,Phase 3,2016-05-26,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

1. Intrauterine pregnancy confirmed by ultrasound
2. Estimated gestational age between 12-28 weeks
3. Confirmed to be HIV-infected by Uganda country standard rapid HIV test
4. 16 ...",Yes,2016-08-04,FDA-29868,2.62,0.32,5.0,7.94,2019-01-07,2019-05-04,2024-05-04,13,Gilead,2,South Africa,60.66666666666666,89,40,54,36,68,77,55,0,5,1,False,False,True,True,True,True,True,False,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
sulfadoxine-pyrimethamine,GenName Y,Drug,malaria,malaria,Phase 3,2008-06-01,"Sex: ALL; Age: >8 Years; Criteria: Inclusion Criteria:

* Age ≥ 8 to \< 14 years (boys), ≥ 8 to \< 12 years (girls)
* Student enrolled at participating school in classes 3-7
* Provision of informed consent from parent or guardian
* Pro...",Yes,2009-04-05,FDA-71369,2.62,0.32,5.0,7.94,2011-01-13,2011-05-10,2016-05-10,77,AstraZeneca,89,Kenya,70.5,94,61,29,88,80,71,55,0,2,4,False,False,False,True,True,False,False,True,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
amodiaquine + sulfadoxine-pyrimethamine,TradeName X,Drug,malaria,malaria,Phase 3,2008-06-01,"Sex: ALL; Age: >8 Years; Criteria: Inclusion Criteria:

* Age ≥ 8 to \< 14 years (boys), ≥ 8 to \< 12 years (girls)
* Student enrolled at participating school in classes 3-7
* Provision of informed consent from parent or guardian
* Pro...",Yes,2008-11-27,FDA-18122,2.62,0.32,5.0,7.94,2011-01-13,2011-05-10,2016-05-10,96,AstraZeneca,66,Kenya,80.66666666666667,95,90,83,65,80,71,73,0,4,4,False,False,True,False,True,True,True,True,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
dihydroartemisinin-piperaquine,AltName B,Drug,malaria,malaria,Phase 3,2008-06-01,"Sex: ALL; Age: >8 Years; Criteria: Inclusion Criteria:

* Age ≥ 8 to \< 14 years (boys), ≥ 8 to \< 12 years (girls)
* Student enrolled at participating school in classes 3-7
* Provision of informed consent from parent or guardian
* Pro...",No,2008-12-08,FDA-16855,2.62,0.32,5.0,7.94,2011-01-13,2011-05-10,2016-05-10,12,Pfizer,65,Senegal,46.66666666666666,27,39,22,78,72,42,64,1,3,3,True,False,False,True,True,True,False,True,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
LEVETIRACETAM,Comp Beta,Drug,malaria,malaria,Phase 2,2013-07-01,"Sex: ALL; Age: >2 Years; Criteria: Inclusion Criteria:

* Comatose with Blantyre Comas Score ≤ 3
* P. falciparum parasitemia
* Active seizure

Exclusion Criteria:

* Serum creatinine \> 2mg/dL
* Pre-admission/concomitant treatment with...",Yes,2013-10-08,FDA-82103,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,19,J&J,65,South Africa,38.83333333333334,27,51,76,16,14,49,64,1,3,3,True,False,True,True,False,True,False,True,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Artemether-lumefantrine (COA566),Molecule Z,Drug,malaria,malaria,Phase 3,2014-07-01,"Sex: ALL; Criteria: Inclusion Criteria:

* Neonates / infants
* Body weight \< 5 kg
* In cohort 1, infants aged \> 28 days; in cohort 2, neonates of a term age 0 to ≤ 28 days
* Microscopically confirmed diagnosis of acut...",No,2014-08-07,FDA-58426,2.62,0.32,5.0,7.94,2017-02-11,2017-06-08,2022-06-09,84,Sanofi,0,Kenya,49.5,24,35,34,90,99,15,55,2,3,1,True,True,False,True,False,True,True,True,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Hydroxyurea,Product Alpha,Drug,malaria,malaria,Phase 3,2017-11-01,"Sex: ALL; Age: >12 Months; Criteria: Inclusion Criteria:

* Pediatric subjects with documented sickle cell anemia (HbSS supported by hemoglobin electrophoresis or by peripheral blood smear showing sickled red blood cells)
* Age range of ...",No,2017-12-21,FDA-81869,2.62,0.32,5.0,7.94,2020-06-14,2020-10-09,2025-10-10,50,Bayer,89,South Africa,52.16666666666666,42,61,93,17,42,58,18,0,1,1,False,False,False,False,False,False,True,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Acetaminophen,Product Alpha,Drug,malaria,malaria,Phase 2,2022-12-02,"Sex: ALL; Age: >2 Years; Criteria: Inclusion Criteria:

* Evidence of Plasmodium falciparum malaria infection by peripheral blood smear or rapid diagnostic test
* Central nervous system (CNS) symptoms associated with malaria. CEREBRAL ...",Yes,2023-03-18,FDA-37974,4.41,0.98,21.0,26.39,2027-04-30,2028-04-22,2049-04-22,68,Sanofi,86,Kenya,58.0,81,83,25,98,55,6,45,1,3,1,False,True,True,False,True,False,True,True,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Ibuprofen,TradeName X,Drug,malaria,malaria,Phase 2,2022-12-02,"Sex: ALL; Age: >2 Years; Criteria: Inclusion Criteria:

* Evidence of Plasmodium falciparum malaria infection by peripheral blood smear or rapid diagnostic test
* Central nervous system (CNS) symptoms associated with malaria. CEREBRAL ...",No,2023-04-30,FDA-97147,4.41,0.98,21.0,26.39,2027-04-30,2028-04-22,2049-04-22,42,AstraZeneca,88,Overall,69.66666666666667,42,99,54,91,68,64,64,2,4,1,True,True,True,True,False,True,True,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Azithromycin/TMPS,Molecule Z,Drug,malaria,malaria,Phase 2,2022-01-01,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

* Confirmed HIV-infection (documented in medical record)
* Age ≥16 years
* Confirmed pregnancy, \<28 weeks estimated gestational age (by best obstetric estimate which may include ...",No,2022-09-25,FDA-11445,4.41,0.98,21.0,26.39,2026-05-30,2027-05-23,2048-05-22,52,Pfizer,57,Senegal,50.5,17,30,39,50,100,67,55,1,4,1,False,True,False,True,True,True,True,True,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Oral Levetiracetam,Molecule Z,Drug,malaria,malaria,Phase 2,2015-06-01,"Sex: ALL; Age: >24 Months; Criteria: Inclusion Criteria:

* Comatose with Blantyre Comas Score ≤ 2
* P. falciparum parasitemia via thick blood film or rapid diagnostic test
* Active seizure in past 24 hours

Exclusion Criteria:

* Serum ...",No,2016-03-31,FDA-14954,4.41,0.98,21.0,26.39,2019-10-28,2020-10-20,2041-10-20,90,AstraZeneca,31,Kenya,43.5,48,64,5,94,15,35,27,1,1,1,True,False,False,True,False,False,False,False,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Standard AED,GenName Y,Drug,malaria,malaria,Phase 2,2015-06-01,"Sex: ALL; Age: >24 Months; Criteria: Inclusion Criteria:

* Comatose with Blantyre Comas Score ≤ 2
* P. falciparum parasitemia via thick blood film or rapid diagnostic test
* Active seizure in past 24 hours

Exclusion Criteria:

* Serum ...",Yes,2016-02-01,FDA-44998,4.41,0.98,21.0,26.39,2019-10-28,2020-10-20,2041-10-20,31,GSK,24,Overall,39.83333333333334,51,12,41,8,32,95,18,1,1,0,False,True,False,False,False,True,False,False,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
primaquine,GenName Y,Drug,malaria,malaria,Phase 4,2018-10-21,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Previous G6PD test at Shoklo Malaria Research Unit (SMRU) clinic with one of following results: 1) G6PD homozygous wildtype females (G6PD genotype normal) 2) G6PD heterozygous f...",No,2019-06-07,FDA-61206,0.56,0.15,3.5,4.21,2019-05-13,2019-07-07,2023-01-05,23,Novartis,78,Senegal,35.66666666666666,59,48,29,32,44,2,64,1,3,3,True,False,True,False,True,True,False,False,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
chloroquine + primaquine,GenName Y,Drug,malaria,malaria,Phase 4,2018-10-21,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Previous G6PD test at Shoklo Malaria Research Unit (SMRU) clinic with one of following results: 1) G6PD homozygous wildtype females (G6PD genotype normal) 2) G6PD heterozygous f...",Yes,2019-04-02,FDA-27144,0.56,0.15,3.5,4.21,2019-05-13,2019-07-07,2023-01-05,29,Gilead,100,Senegal,51.66666666666666,29,22,9,96,85,69,45,0,2,3,False,False,False,False,False,True,True,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Lopinavir/ritonavir,Product Alpha,Drug,malaria,malaria,Phase 2,2016-06-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+ count \> 200 and \< 500 cells/mm\^3 obtained within 30 days prior to study entry at a DAIDS-approved laboratory.
* Pf SCP confirmed in a laboratory approv...",No,2017-05-27,FDA-51295,4.41,0.98,21.0,26.39,2020-11-15,2021-11-08,2042-11-08,5,Pfizer,11,Senegal,52.66666666666666,76,36,41,90,47,26,55,1,2,3,True,False,True,False,False,False,True,True,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Emtricitabine/tenofovir disoproxil fumarate,AltName B,Drug,malaria,malaria,Phase 2,2016-06-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+ count \> 200 and \< 500 cells/mm\^3 obtained within 30 days prior to study entry at a DAIDS-approved laboratory.
* Pf SCP confirmed in a laboratory approv...",Yes,2016-11-06,FDA-12873,4.41,0.98,21.0,26.39,2020-11-15,2021-11-08,2042-11-08,66,Sanofi,53,Overall,47.0,6,69,76,61,62,8,64,2,2,3,True,True,False,False,True,False,True,True,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Efavirenz,GenName Y,Drug,malaria,malaria,Phase 2,2016-06-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+ count \> 200 and \< 500 cells/mm\^3 obtained within 30 days prior to study entry at a DAIDS-approved laboratory.
* Pf SCP confirmed in a laboratory approv...",No,2016-12-05,FDA-72553,4.41,0.98,21.0,26.39,2020-11-15,2021-11-08,2042-11-08,47,GSK,58,South Africa,56.16666666666666,27,55,34,90,50,81,45,1,3,1,True,False,False,True,True,True,False,True,False,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Nevirapine,Comp Beta,Drug,malaria,malaria,Phase 2,2016-06-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+ count \> 200 and \< 500 cells/mm\^3 obtained within 30 days prior to study entry at a DAIDS-approved laboratory.
* Pf SCP confirmed in a laboratory approv...",No,2017-01-31,FDA-18882,4.41,0.98,21.0,26.39,2020-11-15,2021-11-08,2042-11-08,93,Sanofi,97,Kenya,48.83333333333334,80,10,94,28,80,1,64,1,4,2,False,True,True,True,True,True,False,False,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Trimethoprim/sulfamethoxazole,GenName Y,Drug,malaria,malaria,Phase 2,2016-06-19,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+ count \> 200 and \< 500 cells/mm\^3 obtained within 30 days prior to study entry at a DAIDS-approved laboratory.
* Pf SCP confirmed in a laboratory approv...",Yes,2017-04-13,FDA-26237,4.41,0.98,21.0,26.39,2020-11-15,2021-11-08,2042-11-08,73,AstraZeneca,99,Senegal,58.83333333333334,72,91,26,45,57,62,55,2,1,3,True,True,True,False,False,False,False,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
KAE609,AltName A,Drug,malaria,malaria,Phase 2,2014-08-01,"Sex: ALL; Age: >20 Years; Criteria: Inclusion Criteria:

* Male and female patients aged 20 to 60 years
* Presence of mono-infection of P. falciparum
* Weight between 40 kg to 90 kg

Exclusion Criteria:

* Patients with signs and sympto...",Yes,2015-03-10,FDA-37473,4.41,0.98,21.0,26.39,2018-12-28,2019-12-21,2040-12-20,43,Bayer,47,Kenya,46.0,83,25,50,8,17,93,45,1,2,2,True,False,False,False,True,True,False,True,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
KAE609,AltName A,Drug,malaria,malaria,Phase 2,2014-08-01,"Sex: ALL; Age: >20 Years; Criteria: Inclusion Criteria:

* Male and female patients aged 20 to 60 years
* Presence of mono-infection of P. falciparum
* Weight between 40 kg to 90 kg

Exclusion Criteria:

* Patients with signs and sympto...",Yes,2014-11-23,FDA-63183,4.41,0.98,21.0,26.39,2018-12-28,2019-12-21,2040-12-20,87,Bayer,40,Senegal,44.83333333333334,15,32,10,60,97,55,64,1,3,3,False,True,True,True,False,True,False,True,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
KAE609,Product Alpha,Drug,malaria,malaria,Phase 2,2014-08-01,"Sex: ALL; Age: >20 Years; Criteria: Inclusion Criteria:

* Male and female patients aged 20 to 60 years
* Presence of mono-infection of P. falciparum
* Weight between 40 kg to 90 kg

Exclusion Criteria:

* Patients with signs and sympto...",No,2015-01-30,FDA-39541,4.41,0.98,21.0,26.39,2018-12-28,2019-12-21,2040-12-20,29,Pfizer,30,Senegal,41.83333333333334,16,95,27,91,11,11,36,1,1,2,True,False,False,False,True,False,False,False,False,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
KAE609,Molecule Z,Drug,malaria,malaria,Phase 2,2014-08-01,"Sex: ALL; Age: >20 Years; Criteria: Inclusion Criteria:

* Male and female patients aged 20 to 60 years
* Presence of mono-infection of P. falciparum
* Weight between 40 kg to 90 kg

Exclusion Criteria:

* Patients with signs and sympto...",No,2015-04-27,FDA-12025,4.41,0.98,21.0,26.39,2018-12-28,2019-12-21,2040-12-20,40,Novartis,12,Senegal,56.16666666666666,65,79,44,54,50,45,36,1,2,1,False,True,False,False,True,True,False,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Tafenoquine,Product Alpha,Drug,malaria,malaria,Phase 2,2003-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Healthy male or female volunteers who provided informed consent (a healthy volunteer was defined as one who was free of ailments that might cause difficulty in evaluating drug e...",No,2003-08-11,FDA-48590,4.41,0.98,21.0,26.39,2007-07-28,2008-07-20,2029-07-20,63,Bayer,83,South Africa,45.66666666666666,55,4,74,20,30,91,55,0,4,2,False,False,True,True,False,True,True,False,True,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Mefloquine,Molecule Z,Drug,malaria,malaria,Phase 2,2003-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Healthy male or female volunteers who provided informed consent (a healthy volunteer was defined as one who was free of ailments that might cause difficulty in evaluating drug e...",Yes,2003-09-30,FDA-75994,4.41,0.98,21.0,26.39,2007-07-28,2008-07-20,2029-07-20,61,AstraZeneca,19,Overall,42.0,97,6,94,8,22,25,55,2,3,1,True,True,True,False,True,False,True,False,False,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Azithromycin,TradeName X,Drug,malaria,malaria,Phase 4,2025-12-28,"Sex: ALL; Age: >1 Month; Criteria: Inclusion Criteria:

* Age 1-59 months,
* Plan to remain in study area greater than 6 months
* Discharged from hospital following non-trauma related admission

Exclusion Criteria:

* Contraindication ...",Yes,2026-06-11,FDA-15582,0.56,0.15,3.5,4.21,2026-07-20,2026-09-13,2030-03-14,64,Sanofi,93,Overall,27.5,43,26,49,21,17,9,45,1,2,2,True,False,False,True,True,False,False,True,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Azithromycin plus chloroquine,TradeName X,Drug,malaria,malaria,Phase 3,2013-11-01,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

* Pregnant women (all gravidae) with ≥14 and ≤26 weeks of gestational age (by ultrasound).
* Evidence of a personally signed and dated informed consent/assent document. Assent wil...",No,2014-10-03,FDA-46813,2.62,0.32,5.0,7.94,2016-06-14,2016-10-09,2021-10-10,77,Novartis,12,Overall,43.16666666666666,1,30,13,97,54,64,55,1,3,2,True,False,True,False,True,False,True,True,False,True,False,HorizonScan_malaria_20251201_Harmonized.xlsx
sulfadoxine-pyrimethamine,TradeName X,Drug,malaria,malaria,Phase 3,2013-11-01,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

* Pregnant women (all gravidae) with ≥14 and ≤26 weeks of gestational age (by ultrasound).
* Evidence of a personally signed and dated informed consent/assent document. Assent wil...",Yes,2014-08-31,FDA-54369,2.62,0.32,5.0,7.94,2016-06-14,2016-10-09,2021-10-10,13,Bayer,82,Senegal,37.66666666666666,18,4,11,61,60,72,45,1,1,3,True,False,False,False,False,True,False,True,True,False,True,HorizonScan_malaria_20251201_Harmonized.xlsx
Dihydroartemisinin-piperaquine,TradeName X,Drug,malaria,malaria,Phase 4,2022-04-11,"Sex: ALL; Age: >3 Years; Criteria: Inclusion Criteria:

All participants:

* Agreement to come to clinic for all follow-up PK and safety evaluations
* Provision of informed consent.

HIV-infected participants:

* Residency within 30km ...",No,2022-09-11,FDA-10232,0.56,0.15,3.5,4.21,2022-11-01,2022-12-26,2026-06-26,91,AstraZeneca,55,Senegal,62.66666666666666,99,71,11,53,47,95,73,1,5,2,True,False,True,True,True,True,True,True,True,False,False,HorizonScan_malaria_20251201_Harmonized.xlsx
Azithromycin plus chloroquine,TradeName X,Drug,malaria,malaria,Phase 3,2013-10-01,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

* Primigravidae and secundigravidae pregnant women at \>=14 and \<=30 weeks of gestational age (confirmed by ultrasound examination).
* Evidence of asymptomatic parasitemia with P...",Yes,2014-05-01,FDA-45851,2.62,0.32,5.0,7.94,2016-05-14,2016-09-08,2021-09-09,60,GSK,41,Senegal,42.83333333333334,7,21,90,11,99,29,64,1,3,3,True,False,True,True,False,True,False,False,True,True,True,HorizonScan_malaria_20251201_Harmonized.xlsx
"Malaria Vaccine RTS,S/AS01E",AltName A,Biological,malaria_copy,Vaccine,Phase 2,2022-08-17,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Provision of signed or thumb printed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Ma...",Yes,2023-04-27,FDA-25909,4.41,0.98,21.0,26.39,2027-01-13,2028-01-06,2049-01-05,50,AstraZeneca,21,Kenya,37.16666666666666,46,25,30,60,1,61,45,1,2,2,False,True,False,True,False,False,True,False,True,True,False,HorizonScan_malaria_copy_Harmonized.xlsx
Abhayrab rabies vaccine,Molecule Z,Biological,malaria_copy,Vaccine,Phase 2,2022-08-17,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Provision of signed or thumb printed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Ma...",Yes,2023-02-06,FDA-91401,4.41,0.98,21.0,26.39,2027-01-13,2028-01-06,2049-01-05,61,AstraZeneca,98,South Africa,42.5,81,81,4,42,33,14,45,1,2,2,False,True,True,True,False,False,False,True,False,True,False,HorizonScan_malaria_copy_Harmonized.xlsx
Dihydroartemisinin-piperaquine (DHA/Pip),Product Alpha,Drug,malaria_copy,Vaccine,Phase 2,2022-08-17,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Provision of signed or thumb printed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Ma...",No,2023-04-03,FDA-38234,4.41,0.98,21.0,26.39,2027-01-13,2028-01-06,2049-01-05,63,J&J,84,Kenya,47.16666666666666,65,76,23,31,73,15,82,2,3,4,True,True,False,True,True,False,True,True,True,True,True,HorizonScan_malaria_copy_Harmonized.xlsx
Artemether / Lumefantrine,AltName B,Drug,malaria_copy,Vaccine,Phase 2,2022-08-17,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Provision of signed or thumb printed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Ma...",Yes,2023-01-06,FDA-21566,4.41,0.98,21.0,26.39,2027-01-13,2028-01-06,2049-01-05,31,GSK,17,Senegal,61.33333333333334,31,29,88,51,73,96,45,1,3,1,False,True,False,False,True,True,True,False,False,False,True,HorizonScan_malaria_copy_Harmonized.xlsx
Primaquine,Molecule Z,Drug,malaria_copy,Vaccine,Phase 2,2022-08-17,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Provision of signed or thumb printed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Ma...",No,2022-10-31,FDA-93334,4.41,0.98,21.0,26.39,2027-01-13,2028-01-06,2049-01-05,77,Bayer,86,Senegal,39.66666666666666,20,67,54,1,42,54,55,2,2,2,True,True,True,False,False,False,True,False,False,True,True,HorizonScan_malaria_copy_Harmonized.xlsx
Atovaquone Proguanil,AltName A,Drug,malaria_copy,Prevention,Phase 2,2010-04-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* A male or non-pregnant, non-lactating female 18 to 50 years of age (inclusive) at the time of screening
* Free of clinically significant health problems
* Baseline ECG before en...",Yes,2010-06-19,FDA-52899,4.41,0.98,21.0,26.39,2014-08-28,2015-08-21,2036-08-20,77,Merck,40,Kenya,27.66666666666667,24,27,57,44,4,10,64,0,4,3,False,False,True,True,True,True,False,True,False,True,True,HorizonScan_malaria_copy_Harmonized.xlsx
NMRC-M3V-Ad-PfCA,GenName Y,Biological,malaria_copy,Vaccine,Phase 2,2017-09-25,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: INCLUSION CRITERIA:

* Between the ages of 18-50 (inclusive)
* Negative results of HIV ELISA, HbSAg, anti-HCV antibody, and no other clinically significant abnormal laboratory results from screening.
...",No,2018-06-01,FDA-27443,4.41,0.98,21.0,26.39,2022-02-21,2023-02-14,2044-02-14,59,Gilead,66,Kenya,43.0,22,81,1,4,67,83,82,2,5,2,True,True,True,True,True,True,True,True,False,True,False,HorizonScan_malaria_copy_Harmonized.xlsx
"NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA",AltName A,Biological,malaria_copy,Vaccine,Phase 2,2017-09-25,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: INCLUSION CRITERIA:

* Between the ages of 18-50 (inclusive)
* Negative results of HIV ELISA, HbSAg, anti-HCV antibody, and no other clinically significant abnormal laboratory results from screening.
...",No,2018-08-01,FDA-36087,4.41,0.98,21.0,26.39,2022-02-21,2023-02-14,2044-02-14,21,AstraZeneca,62,Kenya,52.66666666666666,90,18,67,69,11,61,45,0,2,3,False,False,False,True,False,True,False,True,False,True,True,HorizonScan_malaria_copy_Harmonized.xlsx
Zidovudine (ZDV),Molecule Z,Drug,MCNH,MCNH,Phase 3,2016-09-30,"Sex: ALL; Criteria: Antepartum Component Inclusion Criteria:

* Confirmed HIV-1 infection, defined as documented positive results from two samples collected at different time points prior to study entry. More information...",Yes,2017-03-02,FDA-59028,2.62,0.32,5.0,7.94,2019-05-14,2019-09-08,2024-09-08,54,AstraZeneca,29,Senegal,69.5,75,95,67,6,95,79,45,1,3,1,False,True,False,True,False,True,True,True,False,False,False,HorizonScan_maternal_and_child_health_20251124_Harmonized.xlsx
Nevirapine (NVP): Antepartum Mothers,TradeName X,Drug,MCNH,MCNH,Phase 3,2016-09-30,"Sex: ALL; Criteria: Antepartum Component Inclusion Criteria:

* Confirmed HIV-1 infection, defined as documented positive results from two samples collected at different time points prior to study entry. More information...",No,2017-09-04,FDA-20164,2.62,0.32,5.0,7.94,2019-05-14,2019-09-08,2024-09-08,83,Bayer,72,South Africa,54.0,31,80,30,68,81,34,73,2,4,2,True,True,False,True,True,True,True,True,False,True,False,HorizonScan_maternal_and_child_health_20251124_Harmonized.xlsx
Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail,Molecule Z,Drug,MCNH,MCNH,Phase 3,2016-09-30,"Sex: ALL; Criteria: Antepartum Component Inclusion Criteria:

* Confirmed HIV-1 infection, defined as documented positive results from two samples collected at different time points prior to study entry. More information...",Yes,2017-03-25,FDA-20457,2.62,0.32,5.0,7.94,2019-05-14,2019-09-08,2024-09-08,13,Pfizer,36,Senegal,76.66666666666667,40,52,96,88,97,87,64,2,2,3,True,True,True,False,False,True,False,True,True,True,False,HorizonScan_maternal_and_child_health_20251124_Harmonized.xlsx
Lamivudine-Zidovudine (3TC-ZDV),TradeName X,Drug,MCNH,MCNH,Phase 3,2016-09-30,"Sex: ALL; Criteria: Antepartum Component Inclusion Criteria:

* Confirmed HIV-1 infection, defined as documented positive results from two samples collected at different time points prior to study entry. More information...",No,2017-01-01,FDA-66805,2.62,0.32,5.0,7.94,2019-05-14,2019-09-08,2024-09-08,61,Bayer,34,South Africa,45.0,91,16,10,83,66,4,55,2,2,2,True,True,False,False,True,False,True,True,False,True,False,HorizonScan_maternal_and_child_health_20251124_Harmonized.xlsx
Lopinavir-ritonavir (LPV-RTV),Molecule Z,Drug,MCNH,MCNH,Phase 3,2016-09-30,"Sex: ALL; Criteria: Antepartum Component Inclusion Criteria:

* Confirmed HIV-1 infection, defined as documented positive results from two samples collected at different time points prior to study entry. More information...",Yes,2017-07-07,FDA-64229,2.62,0.32,5.0,7.94,2019-05-14,2019-09-08,2024-09-08,81,Merck,60,South Africa,41.5,0,10,57,52,50,80,45,0,3,2,False,False,False,True,True,False,True,True,False,False,True,HorizonScan_maternal_and_child_health_20251124_Harmonized.xlsx
Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]),AltName A,Drug,MCNH,MCNH,Phase 3,2016-09-30,"Sex: ALL; Criteria: Antepartum Component Inclusion Criteria:

* Confirmed HIV-1 infection, defined as documented positive results from two samples collected at different time points prior to study entry. More information...",Yes,2017-09-04,FDA-86193,2.62,0.32,5.0,7.94,2019-05-14,2019-09-08,2024-09-08,33,Pfizer,94,Kenya,63.33333333333334,88,83,87,27,9,86,27,1,2,0,True,False,False,False,True,False,True,False,False,False,False,HorizonScan_maternal_and_child_health_20251124_Harmonized.xlsx
Nevirapine (NVP): Infant short-course,GenName Y,Drug,MCNH,MCNH,Phase 3,2016-09-30,"Sex: ALL; Criteria: Antepartum Component Inclusion Criteria:

* Confirmed HIV-1 infection, defined as documented positive results from two samples collected at different time points prior to study entry. More information...",Yes,2017-01-14,FDA-37878,2.62,0.32,5.0,7.94,2019-05-14,2019-09-08,2024-09-08,94,J&J,75,Kenya,50.66666666666666,28,82,17,86,80,11,64,0,5,2,False,False,True,True,True,True,True,False,True,False,True,HorizonScan_maternal_and_child_health_20251124_Harmonized.xlsx
Nevirapine (NVP): Infant extended,Comp Beta,Drug,MCNH,MCNH,Phase 3,2016-09-30,"Sex: ALL; Criteria: Antepartum Component Inclusion Criteria:

* Confirmed HIV-1 infection, defined as documented positive results from two samples collected at different time points prior to study entry. More information...",No,2017-07-24,FDA-37784,2.62,0.32,5.0,7.94,2019-05-14,2019-09-08,2024-09-08,35,Bayer,28,Kenya,65.5,32,82,86,88,81,24,36,0,1,3,False,False,False,False,False,True,False,False,True,True,True,HorizonScan_maternal_and_child_health_20251124_Harmonized.xlsx
"Hydroxyprogesterone Caproate Injection (HPC), 250mg/mL",Molecule Z,Drug,MCNH,MCNH,Phase 3,2018-10-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

Each subject must meet the following criteria to be enrolled in this study:

1. Age ≥ 18 years.
2. Singleton gestation.
3. Project gestational age 16 weeks 0 days of gestation or ...",No,2019-04-03,FDA-51409,2.62,0.32,5.0,7.94,2021-05-14,2021-09-08,2026-09-09,62,Gilead,54,Kenya,68.0,37,67,65,70,87,82,45,2,2,1,True,True,False,False,True,True,False,True,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Vehicle,Molecule Z,Drug,MCNH,MCNH,Phase 3,2018-10-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

Each subject must meet the following criteria to be enrolled in this study:

1. Age ≥ 18 years.
2. Singleton gestation.
3. Project gestational age 16 weeks 0 days of gestation or ...",No,2019-06-13,FDA-49657,2.62,0.32,5.0,7.94,2021-05-14,2021-09-08,2026-09-09,49,Gilead,22,South Africa,29.5,34,29,20,33,6,55,45,1,2,2,True,False,False,True,False,True,False,True,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
17-Hydroxyprogesterone caproate 250mg or 500 mg.,Comp Beta,Drug,MCNH,MCNH,Phase 2,2021-09-02,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: 1. Randomized Clinical Trial Eligibility Criteria:

   Inclusion Criteria:
   * pregnant with a prior preterm birth 16 0/7-35 6/7 weeks from spontaneous labor or preterm premature rupture of membranes...",Yes,2021-12-22,FDA-66726,4.41,0.98,21.0,26.39,2026-01-29,2027-01-22,2048-01-22,23,Sanofi,83,Overall,51.66666666666666,77,39,98,3,39,54,45,0,1,4,False,False,False,False,False,False,True,True,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Safety study of 500 mg dose.,AltName A,Drug,MCNH,MCNH,Phase 2,2021-09-02,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: 1. Randomized Clinical Trial Eligibility Criteria:

   Inclusion Criteria:
   * pregnant with a prior preterm birth 16 0/7-35 6/7 weeks from spontaneous labor or preterm premature rupture of membranes...",No,2022-05-29,FDA-47561,4.41,0.98,21.0,26.39,2026-01-29,2027-01-22,2048-01-22,93,Gilead,13,Overall,40.16666666666666,0,33,95,17,93,3,64,2,3,2,True,True,False,True,False,True,True,True,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
oral micronized progesterone,Comp Beta,Drug,MCNH,MCNH,Phase 3,2009-01-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* pregnant women less than 20 weeks' gestation who had at least one prior spontaneous preterm birth of a liveborn baby between 20 \& 0/7 weeks' and 36 \& 6/7 weeks' gestation.

Ex...",Yes,2009-04-06,FDA-84256,2.62,0.32,5.0,7.94,2011-08-15,2011-12-10,2016-12-10,75,Pfizer,89,Overall,38.5,55,6,64,36,52,18,45,0,3,2,False,False,True,False,True,True,False,True,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Progesterone Cervical Pessary 6.3 g,TradeName X,Drug,MCNH,MCNH,Phase 2,2017-03-13,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Women with a single pregnancy and a cervical length of 10 mm - 25 mm between 16 and 24 weeks of gestation, without any previous factors.
* Women with a single pregnancy with 10 ...",No,2018-02-18,FDA-60787,4.41,0.98,21.0,26.39,2021-08-09,2022-08-02,2043-08-02,69,Gilead,56,South Africa,65.83333333333333,71,58,60,60,91,55,36,1,1,2,True,False,False,True,False,False,False,True,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Progesterone 200 mg vaginal capsules,GenName Y,Drug,MCNH,MCNH,Phase 2,2017-03-13,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Women with a single pregnancy and a cervical length of 10 mm - 25 mm between 16 and 24 weeks of gestation, without any previous factors.
* Women with a single pregnancy with 10 ...",No,2018-02-07,FDA-13432,4.41,0.98,21.0,26.39,2021-08-09,2022-08-02,2043-08-02,10,Merck,3,Overall,61.5,47,90,85,10,78,59,55,1,2,3,False,True,False,True,False,True,False,True,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Progesterone Cervical Pessary 7.7 g,Comp Beta,Drug,MCNH,MCNH,Phase 2,2017-03-13,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Women with a single pregnancy and a cervical length of 10 mm - 25 mm between 16 and 24 weeks of gestation, without any previous factors.
* Women with a single pregnancy with 10 ...",Yes,2018-02-23,FDA-46700,4.41,0.98,21.0,26.39,2021-08-09,2022-08-02,2043-08-02,52,Novartis,76,Kenya,71.66666666666667,80,52,90,60,68,80,55,1,2,3,True,False,False,True,False,False,True,True,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Vaginal Progesterone,Product Alpha,Drug,MCNH,MCNH,Phase 4,2018-11-13,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

1. 18 years of age or older
2. viable intrauterine pregnancy confirmed by ultrasound
3. presentation to antenatal care prior to 24 weeks gestation
4. antibody-confirmed HIV-1 infe...",Yes,2019-06-20,FDA-17945,0.56,0.15,3.5,4.21,2019-06-05,2019-07-30,2023-01-28,32,Pfizer,68,South Africa,47.0,66,3,97,22,39,55,36,1,1,2,True,False,False,False,False,False,True,False,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
"17-alpha-hydroxy-progesterone caproate, Makena®",AltName A,Drug,MCNH,MCNH,Phase 3,2014-10-01,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Participant is 18 years old or older
2. Gestational Age (GA) 23w0d and 30w6d @ time of enrollment
3. Singleton pregnancy
4. PROM defined as either (a) or (b) or (c) below (a) D...",No,2014-11-08,FDA-29388,2.62,0.32,5.0,7.94,2017-05-14,2017-09-08,2022-09-09,71,GSK,39,Kenya,55.16666666666666,56,30,62,86,68,29,64,2,4,1,True,True,True,True,False,True,True,True,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
17-alpha-hydroxyprogesterone caproate injectable,GenName Y,Drug,MCNH,MCNH,Phase 3,2009-08-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

1. Gestational age (GA) 15-23w0d gestational age at the time of recruitment
2. GA 16w0dk to 23w6d at the time of randomization and initiation of injections
3. Maternal age 18 year...",No,2010-03-23,FDA-33615,2.62,0.32,5.0,7.94,2012-03-14,2012-07-09,2017-07-10,79,Sanofi,18,Kenya,47.0,19,57,49,86,45,26,73,1,4,3,True,False,True,True,False,True,True,False,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Betamethasone or Dexamethasone (2nd course of ACS),AltName A,Drug,MCNH,MCNH,Phase 4,2008-02-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* 25 to 32 6/7 weeks gestation
* Singleton or twin gestation
* Received 1st course of betamethasone prior to 30 weeks' gestation
* Began 1st course of betamethasone at least 14 da...",No,2009-01-20,FDA-37851,0.56,0.15,3.5,4.21,2008-08-23,2008-10-17,2012-04-17,41,GSK,9,Kenya,66.83333333333333,68,70,20,94,71,78,45,0,3,2,False,False,True,True,False,True,False,True,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
17 alpha-hydroxyprogesterone caproate,GenName Y,Drug,MCNH,MCNH,Phase 3,2011-12-01,"Sex: FEMALE; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Nulliparous
* Cervical length as measured on transvaginal examination \< 30mm between gestational ages of 16 weeks 0 days to 22 weeks 3 days
* Gestational age 16 weeks 3 days to...",Yes,2012-11-27,FDA-18485,2.62,0.32,5.0,7.94,2014-07-14,2014-11-08,2019-11-09,59,Pfizer,98,Senegal,68.0,69,74,32,49,99,85,36,1,1,2,False,True,False,False,False,False,True,False,True,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Arabin Cervical Pessary,GenName Y,Device,MCNH,MCNH,Phase 3,2022-05-10,"Sex: FEMALE; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Singleton gestation. Twin gestation reduced to singleton either spontaneously or therapeutically, is not eligible unless the reduction occurred before 13 weeks 6 days project ge...",No,2023-03-17,FDA-34454,2.62,0.32,5.0,7.94,2024-12-21,2025-04-17,2030-04-18,53,Sanofi,21,South Africa,45.16666666666666,2,63,2,94,61,49,36,1,3,0,True,False,True,False,False,True,True,False,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
17P,GenName Y,Drug,MCNH,MCNH,Phase 3,2020-08-06,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* 18 years of age or older
* less than 24 0/7 weeks of gestation
* viable intrauterine singleton pregnancy confirmed by ultrasound
* antibody-confirmed HIV-1 infection
* currently...",Yes,2021-01-06,FDA-84285,2.62,0.32,5.0,7.94,2023-03-20,2023-07-15,2028-07-15,22,J&J,0,Senegal,37.0,46,53,15,49,11,48,45,1,1,3,False,True,False,False,False,False,True,True,True,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Melatonin injection,AltName A,Drug,MCNH,MCNH,Phase 2,2011-02-01,"Sex: ALL; Age: >23 Weeks; Criteria: Inclusion Criteria:

* Infants born less than 31 weeks gestation who are less than 7 days old, after parental consent for participation will be included in the study.

Exclusion Criteria:

* Those wit...",No,2011-09-10,FDA-11929,4.41,0.98,21.0,26.39,2015-06-30,2016-06-22,2037-06-22,48,J&J,50,Overall,42.0,31,100,40,31,43,7,36,0,3,1,False,False,True,False,False,True,True,True,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Merotocin,GenName Y,Drug,MCNH,MCNH,Phase 2,2022-11-11,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Delivered at the hospital system associated with the trial center
* Delivered preterm singleton gestational age 24 weeks + 0 days to 34 weeks + 2 days
* Willing to express milk ...",No,2023-11-01,FDA-38408,4.41,0.98,21.0,26.39,2027-04-09,2028-04-01,2049-04-01,75,Novartis,49,Kenya,43.5,4,99,4,29,53,72,36,0,2,2,False,False,False,True,False,False,True,False,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Metoprolol,Product Alpha,Drug,MCNH,MCNH,Phase 2,2020-02-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Provision of signed and dated informed consent form
2. Male or female aged 18-35
3. History of preterm birth (either a or b):

   1. Participant in the Newborn Lung Project (bi...",Yes,2020-12-08,FDA-95795,4.41,0.98,21.0,26.39,2024-07-22,2025-07-15,2046-07-15,73,J&J,43,Kenya,46.16666666666666,11,83,87,27,44,25,27,1,0,2,False,True,False,False,False,False,False,True,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Sildenafil,TradeName X,Drug,MCNH,MCNH,Phase 2,2020-02-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Provision of signed and dated informed consent form
2. Male or female aged 18-35
3. History of preterm birth (either a or b):

   1. Participant in the Newborn Lung Project (bi...",No,2021-01-02,FDA-14467,4.41,0.98,21.0,26.39,2024-07-22,2025-07-15,2046-07-15,75,GSK,42,South Africa,46.83333333333334,22,0,73,12,92,82,55,2,2,2,True,True,False,True,True,False,False,False,True,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
progesterone,AltName B,Drug,MCNH,MCNH,Phase 3,2010-11-01,"Sex: FEMALE; Age: >15 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. The subject has a short cervical length by transvaginal ultrasound (TVU) defined as 10-20mm. In cases of ""dynamic cervix"", the shortest observed/documented cervical length by T...",No,2011-02-15,FDA-93224,2.62,0.32,5.0,7.94,2013-06-14,2013-10-09,2018-10-10,42,Merck,20,Overall,41.66666666666666,9,70,12,59,18,82,45,0,3,2,False,False,True,True,False,True,False,True,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
LCPUFA oil supplement,AltName B,Drug,MCNH,MCNH,Phase 4,2017-01-01,"Sex: ALL; Age: >18 Months; Criteria: Inclusion Criteria:

1. Child born at less than or equal to 29 completed weeks' gestation;
2. Child between 18 months, 0 days and 38 months, 30 days old chronological age;
3. Child admitted to NICU an...",No,2017-03-18,FDA-45817,0.56,0.15,3.5,4.21,2017-07-24,2017-09-17,2021-03-18,89,Novartis,51,South Africa,53.66666666666666,45,76,85,44,59,13,36,1,1,2,True,False,True,False,False,False,False,True,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Docosahexaenoic Acid + Arachidonic Acid (DHA+AA),Molecule Z,Drug,MCNH,MCNH,Phase 4,2017-04-06,"Sex: ALL; Age: >10 Months; Criteria: Inclusion Criteria:

1. Age 10-16 completed months (age corrected for prematurity) at baseline
2. Discontinued regular breastfeeding and formula feeding at the time of randomization
3. Gestational age...",No,2017-11-29,FDA-69970,0.56,0.15,3.5,4.21,2017-10-27,2017-12-21,2021-06-21,54,J&J,73,South Africa,42.83333333333334,62,89,29,27,9,41,82,2,3,4,True,True,True,True,False,True,False,True,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Donor Milk,GenName Y,Biological,MCNH,MCNH,Phase 3,2021-11-30,"Sex: ALL; Criteria: Inclusion Criteria:

* Gestational age less than 29 weeks.
* Admitted to the NICU at less than or equal to 72 hours of life
* Survived at least 12 hours

Exclusion Criteria:

* Chromosomal anomalies
*...",Yes,2022-02-27,FDA-14525,2.62,0.32,5.0,7.94,2024-07-13,2024-11-07,2029-11-08,90,Gilead,0,Overall,48.16666666666666,34,50,53,74,59,19,45,1,2,2,False,True,False,True,False,False,True,True,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Ranibizumab,AltName B,Drug,MCNH,MCNH,Phase 3,2017-12-14,"Sex: ALL; Criteria: Inclusion Criteria:

* preterm infants with a birth weight of less than 1500 g
* bilateral ROP with one of the following retinal findings in each eye: Zone I, stage 1+, 2+, 3 or 3+ disease, or Zone II...",No,2018-05-01,FDA-63769,2.62,0.32,5.0,7.94,2020-07-27,2020-11-21,2025-11-22,11,J&J,57,South Africa,62.5,98,93,66,46,21,51,27,0,2,1,False,False,False,False,True,False,True,False,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
17-Hydroxyprogesterone Capronate,AltName A,Drug,MCNH,MCNH,Phase 3,2021-07-14,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* \- Pregnant women, with a singleton gestation
* Ages 18 - 55
* Able to read and write in English and / or Spanish
* History of spontaneous PTB
* Obesity (≥ 30 kg / m2 ) vs non-o...",No,2022-06-27,FDA-84298,2.62,0.32,5.0,7.94,2024-02-25,2024-06-21,2029-06-22,60,Sanofi,97,Senegal,36.0,18,34,22,43,37,62,36,0,3,1,False,False,True,False,True,False,True,False,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Hydrocortisone,Product Alpha,Drug,MCNH,MCNH,Phase 2,2012-11-01,"Sex: ALL; Age: >1 Week; Criteria: Inclusion Criteria:

* Patient in the Memorial Hermann Children's Hospital (MHCH) neonatal intensive care unit with a birth weight ≤ 1000 grams.
* Ventilator-dependent between 10 and 21 days of age.
*...",No,2013-07-22,FDA-89221,4.41,0.98,21.0,26.39,2017-03-30,2018-03-23,2039-03-23,79,Gilead,13,Senegal,60.16666666666666,58,47,71,63,77,45,36,0,2,2,False,False,True,True,False,False,False,False,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Nifedipine,AltName B,Drug,MCNH,MCNH,Phase 3,2018-10-29,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

* Between 16 and 44 years of age inclusive
* Singleton pregnancy
* Intact membranes
* Between 28-0/7 weeks and 33-6/7 weeks' gestation inclusive
* Reported or documented uterine a...",No,2019-10-28,FDA-80474,2.62,0.32,5.0,7.94,2021-06-11,2021-10-06,2026-10-07,97,J&J,6,Senegal,37.16666666666666,60,48,39,23,29,24,55,2,2,2,True,True,False,False,False,True,True,False,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Varied albuterol dose response,TradeName X,Drug,MCNH,MCNH,Phase 4,2014-12-30,"Sex: ALL; Age: >14 Days; Criteria: Inclusion Criteria:

* very low birthweight infant (\<1500g)
* gestational age at birth \<32 weeks
* age 14 or more days and corrected to 28w0d to 33w6d gestational age
* continuing to require respira...",Yes,2015-02-20,FDA-43891,0.56,0.15,3.5,4.21,2015-07-22,2015-09-15,2019-03-16,21,Novartis,47,Kenya,65.16666666666667,78,87,5,71,82,68,36,1,1,2,True,False,False,False,False,True,False,False,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Omegaven,AltName A,Drug,MCNH,MCNH,Phase 2,2019-12-01,"Sex: ALL; Criteria: Inclusion Criteria:

* Infants born less than or equal to 30 weeks gestation or less than 1500 g at birth

Exclusion Criteria:

* Patients with liver disease as tested by liver function tests (LFTs)
*...",Yes,2020-03-18,FDA-61512,4.41,0.98,21.0,26.39,2024-04-28,2025-04-21,2046-04-21,80,Bayer,85,Overall,72.66666666666667,62,91,97,82,23,81,27,0,1,2,False,False,False,False,False,True,False,False,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Retosiban,AltName B,Drug,MCNH,MCNH,Phase 3,2017-08-25,"Sex: FEMALE; Age: >12 Years; Criteria: Inclusion Criteria:

* Signed and dated written informed consent is required prior to a subject's participation in the study and the performance of any protocol specific procedures. Adolescents aged 1...",No,2017-11-20,FDA-36112,2.62,0.32,5.0,7.94,2020-04-07,2020-08-02,2025-08-03,20,GSK,73,South Africa,55.83333333333334,88,80,1,60,100,6,64,1,4,2,True,False,True,True,True,True,False,False,True,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Atosiban,Molecule Z,Drug,MCNH,MCNH,Phase 3,2017-08-25,"Sex: FEMALE; Age: >12 Years; Criteria: Inclusion Criteria:

* Signed and dated written informed consent is required prior to a subject's participation in the study and the performance of any protocol specific procedures. Adolescents aged 1...",No,2018-06-19,FDA-89493,2.62,0.32,5.0,7.94,2020-04-07,2020-08-02,2025-08-03,85,Gilead,45,Overall,39.16666666666666,16,47,24,62,55,31,45,2,2,1,True,True,True,False,False,False,True,False,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Retosiban IV infusion,Product Alpha,Drug,MCNH,MCNH,Phase 3,2017-07-24,"Sex: FEMALE; Age: >12 Years; Criteria: Inclusion Criteria:

* Signed and dated written informed consent is required prior to a subject's participation in the study and the performance of any protocol specific procedures. Adolescents aged 1...",No,2017-12-04,FDA-34308,2.62,0.32,5.0,7.94,2020-03-06,2020-07-01,2025-07-02,37,GSK,17,Senegal,53.66666666666666,77,35,27,3,94,86,36,2,0,2,True,True,False,False,False,False,False,True,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
NTRA-2112,Molecule Z,Drug,MCNH,MCNH,Phase 3,2018-04-25,"Sex: ALL; Age: >1 Day; Criteria: Inclusion Criteria

1. Male or female pre-term infant 26 and up to 32 weeks gestation. Gestational age matching (±2 weeks) between maternal dates and/or early antenatal ultrasound
2. Birth weight ≥ 50...",No,2018-09-02,FDA-90670,2.62,0.32,5.0,7.94,2020-12-06,2021-04-02,2026-04-03,91,Novartis,17,South Africa,42.0,11,60,33,78,30,40,45,0,3,2,False,False,False,True,True,True,False,True,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Betamethasone,AltName B,Drug,MCNH,MCNH,Phase 3,2022-08-31,"Sex: FEMALE; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

Singleton Pregnancy. A twin pregnancy reduced to singleton (either spontaneously or therapeutically) before 14,0 weeks by project gestational age is acceptable

Gestational age at...",No,2023-02-12,FDA-58574,2.62,0.32,5.0,7.94,2025-04-13,2025-08-08,2030-08-09,34,Sanofi,9,Senegal,72.33333333333333,73,64,61,93,47,96,64,0,4,3,False,False,False,True,True,True,True,True,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Caffeine citrate 6 mg/kg/day,Product Alpha,Drug,MCNH,MCNH,Phase 3,2011-12-01,"Sex: ALL; Age: >33 Weeks; Criteria: Inclusion Criteria:

1. Gestational age of 25 + 0 to 32 + 0 weeks PMA at birth, and 34 + 0 to 375 + 6 weeks PMA at randomization
2. Prior treatment with caffeine based on routine clinical indications,...",No,2012-05-29,FDA-13615,2.62,0.32,5.0,7.94,2014-07-14,2014-11-08,2019-11-09,73,Novartis,13,Overall,43.66666666666666,83,28,45,32,71,3,73,1,4,3,True,False,True,True,True,True,False,False,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Retosiban,Product Alpha,Drug,MCNH,MCNH,Phase 3,2019-09-02,"Sex: ALL; Age: >10 Weeks; Criteria: Inclusion Criteria:

* Mother is randomly assigned and dosed (retosiban or comparator) in 1 of the Phase III SPTL retosiban clinical studies.
* Infant is alive at 28 days post EDD.
* Written informed ...",Yes,2020-04-26,FDA-16507,2.62,0.32,5.0,7.94,2022-04-15,2022-08-10,2027-08-11,83,Novartis,23,Senegal,64.83333333333333,33,97,50,60,53,96,64,0,3,4,False,False,True,False,True,False,True,True,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Atosiban,GenName Y,Drug,MCNH,MCNH,Phase 3,2019-09-02,"Sex: ALL; Age: >10 Weeks; Criteria: Inclusion Criteria:

* Mother is randomly assigned and dosed (retosiban or comparator) in 1 of the Phase III SPTL retosiban clinical studies.
* Infant is alive at 28 days post EDD.
* Written informed ...",Yes,2019-12-01,FDA-12245,2.62,0.32,5.0,7.94,2022-04-15,2022-08-10,2027-08-11,44,Bayer,75,Kenya,39.83333333333334,29,27,5,35,77,66,45,0,2,3,False,False,False,True,False,False,True,True,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
low dose remifentanil,AltName A,Drug,MCNH,MCNH,Phase 2,2012-04-01,"Sex: ALL; Criteria: Inclusion Criteria:

* preterm infants mechanically ventilated
* requiring peripherally induced central catheterization
* with informed consent of their parents

Exclusion Criteria:

* major congenita...",No,2012-06-24,FDA-51718,4.41,0.98,21.0,26.39,2016-08-28,2017-08-21,2038-08-21,25,Novartis,100,Senegal,62.5,72,56,53,44,85,65,18,0,1,1,False,False,False,False,False,False,True,False,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
three times weekly Epo,Product Alpha,Drug,MCNH,MCNH,Phase 2,2009-12-01,"Sex: ALL; Age: >7 Days; Criteria: Inclusion Criteria:

* \< or = 1,500 grams
* \< or = 32 weeks gestation
* \> or = 7 days of age
* informed consent obtained

Exclusion Criteria:

* hemolytic disease
* hypertension
* seizures
* thromb...",Yes,2010-04-21,FDA-16283,4.41,0.98,21.0,26.39,2014-04-29,2015-04-22,2036-04-21,4,Pfizer,50,Senegal,33.5,85,5,2,9,70,30,55,1,3,2,False,True,False,True,False,True,True,True,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
weekly Epo,AltName A,Drug,MCNH,MCNH,Phase 2,2009-12-01,"Sex: ALL; Age: >7 Days; Criteria: Inclusion Criteria:

* \< or = 1,500 grams
* \< or = 32 weeks gestation
* \> or = 7 days of age
* informed consent obtained

Exclusion Criteria:

* hemolytic disease
* hypertension
* seizures
* thromb...",Yes,2010-02-05,FDA-10133,4.41,0.98,21.0,26.39,2014-04-29,2015-04-22,2036-04-21,38,Gilead,74,South Africa,55.5,88,63,77,38,42,25,55,0,4,2,False,False,True,True,True,True,False,True,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Epo,Product Alpha,Drug,MCNH,MCNH,Phase 3,2020-02-28,"Sex: ALL; Age: >24 Weeks; Criteria: Inclusion Criteria:

1. NICU inpatients between 24-0/7 and 27-6/7 weeks of gestation
2. Less than twenty four hours of age
3. Parental informed consent

Exclusion Criteria:

1. Major life-threatening ...",Yes,2020-07-07,FDA-52291,2.62,0.32,5.0,7.94,2022-10-11,2023-02-05,2028-02-06,12,Merck,64,Kenya,63.66666666666666,5,41,89,74,95,78,64,2,2,3,True,True,True,False,False,True,False,True,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
myo-Inositol 5% Injection,AltName B,Drug,MCNH,MCNH,Phase 3,2016-12-31,"Sex: ALL; Age: >12 Hours; Criteria: Inclusion Criteria:

* Inborn or out born infants of either gender or any race with best obstetrical estimate of gestation \<28 weeks (27 6/7 weeks and younger). Gestational age will be determined by ...",Yes,2017-04-05,FDA-99577,2.62,0.32,5.0,7.94,2019-08-14,2019-12-09,2024-12-09,99,Gilead,20,Senegal,36.33333333333334,18,46,10,30,49,65,73,1,4,3,True,False,True,True,False,True,True,True,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Ranibizumab,Comp Beta,Drug,MCNH,MCNH,Phase 3,2022-04-21,"Sex: ALL; Age: >6 Months; Criteria: Inclusion Criteria:

* Signed informed consent from parent(s) or legal guardian(s), in compliance with local requirements
* The patient successfully completed the core study H2301, as defined by provi...",Yes,2023-02-02,FDA-40230,2.62,0.32,5.0,7.94,2024-12-02,2025-03-29,2030-03-30,0,Bayer,62,Kenya,36.33333333333334,18,33,37,62,36,32,64,2,4,1,True,True,True,True,True,False,True,False,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
13-valent pneumococcal conjugate vaccine,Comp Beta,Biological,MCNH,MCNH,Phase 4,2014-01-01,"Sex: ALL; Age: >42 Days; Criteria: Inclusion Criteria:

* Healthy Infants between 42 and 98 days of age (approximately 2 months) at the time of enrollment.

Exclusion Criteria:

* Previous vaccination with pneumococcal vaccine,Haemophi...",Yes,2014-10-17,FDA-45169,0.56,0.15,3.5,4.21,2014-07-24,2014-09-17,2018-03-18,62,Gilead,37,Kenya,57.16666666666666,76,23,93,46,80,25,64,0,3,4,False,False,False,True,False,True,True,True,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
13-valent pneumococcal conjugate vaccine,TradeName X,Biological,MCNH,MCNH,Phase 4,2014-01-01,"Sex: ALL; Age: >42 Days; Criteria: Inclusion Criteria:

* Healthy Infants between 42 and 98 days of age (approximately 2 months) at the time of enrollment.

Exclusion Criteria:

* Previous vaccination with pneumococcal vaccine,Haemophi...",No,2014-12-30,FDA-23982,0.56,0.15,3.5,4.21,2014-07-24,2014-09-17,2018-03-18,98,Novartis,88,Kenya,35.66666666666666,42,13,14,39,100,6,36,1,1,2,True,False,False,False,True,False,False,True,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
GSK221149A,AltName B,Drug,MCNH,MCNH,Phase 2,2011-07-07,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion criteria:

* Healthy pregnant females, 30 -36 weeks pregnant, without ruptured membranes
* 18-45 inclusive
* Symptoms of pre-term labor, (greater than or equal to 6 uterine contractions per ...",Yes,2012-01-23,FDA-30431,4.41,0.98,21.0,26.39,2015-12-03,2016-11-25,2037-11-25,22,Bayer,63,Kenya,34.33333333333334,0,0,50,83,39,34,82,2,3,4,True,True,True,False,True,True,False,True,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Lucinactant 175 mg/kg,GenName Y,Drug,MCNH,MCNH,Phase 2,2006-07-01,"Sex: ALL; Age: >3 Days; Criteria: Inclusion Criteria:

* Premature infants between 600 and 900 grams birth weight
* Intubated and on mechanical ventilation
* Sustained (\>= 30 minutes) fraction of inspired oxygen (FiO₂) \>= 0.30 withi...",No,2007-05-24,FDA-62343,4.41,0.98,21.0,26.39,2010-11-27,2011-11-20,2032-11-19,33,J&J,72,Senegal,54.0,12,53,78,86,19,76,55,2,3,1,True,True,False,True,True,False,True,False,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Lucinactant 90 mg/kg,Molecule Z,Drug,MCNH,MCNH,Phase 2,2006-07-01,"Sex: ALL; Age: >3 Days; Criteria: Inclusion Criteria:

* Premature infants between 600 and 900 grams birth weight
* Intubated and on mechanical ventilation
* Sustained (\>= 30 minutes) fraction of inspired oxygen (FiO₂) \>= 0.30 withi...",Yes,2007-03-18,FDA-52297,4.41,0.98,21.0,26.39,2010-11-27,2011-11-20,2032-11-19,39,Merck,53,Senegal,64.5,89,51,54,18,89,86,55,1,3,2,False,True,False,True,False,True,True,True,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
propranolol,TradeName X,Drug,MCNH,MCNH,Phase 2,2012-07-01,"Sex: ALL; Age: >4 Weeks; Criteria: Inclusion Criteria:

Evidence for ROP that might progress and that includes any one of the following:

* Stage 1 (zone I)
* Stage 2 or higher (zones I, II or III), or Plus disease. The classification ...",Yes,2012-11-13,FDA-20853,4.41,0.98,21.0,26.39,2016-11-27,2017-11-20,2038-11-20,97,Bayer,37,Kenya,40.66666666666666,98,8,54,7,62,15,36,1,0,3,False,True,False,False,False,False,False,True,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
sucrose 5%,AltName B,Drug,MCNH,MCNH,Phase 2,2012-07-01,"Sex: ALL; Age: >4 Weeks; Criteria: Inclusion Criteria:

Evidence for ROP that might progress and that includes any one of the following:

* Stage 1 (zone I)
* Stage 2 or higher (zones I, II or III), or Plus disease. The classification ...",No,2013-02-27,FDA-14916,4.41,0.98,21.0,26.39,2016-11-27,2017-11-20,2038-11-20,6,AstraZeneca,83,Kenya,38.0,79,18,50,36,6,39,55,1,3,2,True,False,True,True,False,False,True,False,True,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
"Intralipid, 20% Intravenous Emulsion",TradeName X,Drug,MCNH,MCNH,Phase 4,2020-06-11,"Sex: ALL; Age: >0 Days; Criteria: Inclusion Criteria:

* premature newborns (\<32 weeks gestation, stratified \<28 weeks versus \>28 weeks) \<8 days of age
* receiving lipid infusions \<1 g/kg/day at enrollment
* anticipated to be tre...",No,2020-12-27,FDA-35953,0.56,0.15,3.5,4.21,2021-01-01,2021-02-25,2024-08-26,20,Sanofi,61,Kenya,27.16666666666667,20,3,11,23,52,54,27,1,2,0,True,False,False,True,False,False,True,False,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Soybean oil Medium-chain triglycerides Olive oil Fish Oil (SMOF) lipid,AltName A,Drug,MCNH,MCNH,Phase 4,2020-06-11,"Sex: ALL; Age: >0 Days; Criteria: Inclusion Criteria:

* premature newborns (\<32 weeks gestation, stratified \<28 weeks versus \>28 weeks) \<8 days of age
* receiving lipid infusions \<1 g/kg/day at enrollment
* anticipated to be tre...",No,2020-07-24,FDA-50230,0.56,0.15,3.5,4.21,2021-01-01,2021-02-25,2024-08-26,55,Sanofi,2,Senegal,48.5,46,53,44,48,96,4,27,1,2,0,True,False,False,True,True,False,False,False,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Somatropin,GenName Y,Drug,MCNH,MCNH,Phase 2,2010-03-01,"Sex: ALL; Age: >4 Years; Criteria: Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:

* Prepubertal caucasian boys between 4 and 10 years of age and girls betw...",No,2010-04-07,FDA-39878,4.41,0.98,21.0,26.39,2014-07-28,2015-07-21,2036-07-20,40,Bayer,31,Senegal,68.5,88,70,81,24,57,91,55,1,3,2,True,False,True,True,True,False,False,True,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Sodium < 1mEq/kg/day,Product Alpha,Drug,MCNH,MCNH,Phase 4,2020-03-20,"Sex: ALL; Criteria: Inclusion Criteria:

* Preterm infants \<35 Weeks gestation

Exclusion Criteria:

* Urinary malformations
* Congenital abdominal wall defect
* Intestinal atresia / obstruction
* Congenital heart defec...",Yes,2021-03-12,FDA-29799,0.56,0.15,3.5,4.21,2020-10-10,2020-12-04,2024-06-04,79,J&J,29,Overall,44.66666666666666,32,40,38,20,38,100,36,1,3,0,False,True,True,True,False,True,False,False,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Sodium 5mEq/kg/day,Product Alpha,Drug,MCNH,MCNH,Phase 4,2020-03-20,"Sex: ALL; Criteria: Inclusion Criteria:

* Preterm infants \<35 Weeks gestation

Exclusion Criteria:

* Urinary malformations
* Congenital abdominal wall defect
* Intestinal atresia / obstruction
* Congenital heart defec...",No,2020-09-17,FDA-35002,0.56,0.15,3.5,4.21,2020-10-10,2020-12-04,2024-06-04,98,Gilead,42,Senegal,46.33333333333334,83,40,63,26,40,26,36,0,2,2,False,False,True,False,True,False,False,False,True,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Nifedipine,Molecule Z,Drug,MCNH,MCNH,Phase 4,2019-10-10,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* We will include pregnant women between 22 0/7 to 31 6/7 weeks gestation who present with regular uterine contractions defined as at least one contraction every 10 minutes for 30...",Yes,2019-11-11,FDA-39533,0.56,0.15,3.5,4.21,2020-05-01,2020-06-25,2023-12-25,34,Novartis,18,Senegal,30.83333333333333,25,2,56,49,7,46,73,2,3,3,True,True,True,True,False,True,False,True,True,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Indomethacin,Comp Beta,Drug,MCNH,MCNH,Phase 4,2019-10-10,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* We will include pregnant women between 22 0/7 to 31 6/7 weeks gestation who present with regular uterine contractions defined as at least one contraction every 10 minutes for 30...",Yes,2020-05-07,FDA-15102,0.56,0.15,3.5,4.21,2020-05-01,2020-06-25,2023-12-25,93,Gilead,2,Overall,44.16666666666666,17,56,5,83,15,89,45,1,3,1,True,False,True,False,False,True,True,True,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Bevacizumab,AltName B,Drug,MCNH,MCNH,Phase 2,2020-08-01,"Sex: ALL; Age: >4 Weeks; Criteria: Inclusion Criteria:

1. Infants who have been screened by the American Academy of Ophthalmology, the American Academy of Pediatrics, and the American Association for Pediatric Ophthalmology and Strabi...",No,2021-01-13,FDA-58203,4.41,0.98,21.0,26.39,2024-12-28,2025-12-21,2046-12-21,67,Sanofi,22,Overall,33.66666666666666,46,46,33,42,31,4,45,0,3,2,False,False,False,True,True,True,False,True,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Surfactant,Product Alpha,Drug,MCNH,MCNH,Phase 3,2016-08-01,"Sex: ALL; Age: >24 Weeks; Criteria: Inclusion Criteria:

* Infants with a minimal gestational age of 24 weeks 0 days to 27 completed weeks (up to 27 6/7ths) by best obstetrical estimate
* Infants who will receive full resuscitation as n...",Yes,2017-07-06,FDA-14054,2.62,0.32,5.0,7.94,2019-03-15,2019-07-10,2024-07-10,43,Pfizer,93,Kenya,62.16666666666666,80,52,92,41,38,70,64,1,2,4,True,False,True,False,True,False,False,True,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Continuous Positive Airway Pressure (CPAP),AltName A,Device,MCNH,MCNH,Phase 3,2016-08-01,"Sex: ALL; Age: >24 Weeks; Criteria: Inclusion Criteria:

* Infants with a minimal gestational age of 24 weeks 0 days to 27 completed weeks (up to 27 6/7ths) by best obstetrical estimate
* Infants who will receive full resuscitation as n...",Yes,2017-02-23,FDA-44551,2.62,0.32,5.0,7.94,2019-03-15,2019-07-10,2024-07-10,20,Gilead,54,Overall,49.33333333333334,100,25,23,23,94,31,36,1,1,2,False,True,False,False,False,True,False,False,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Supplemental oxygen with target saturation of 85 to 89%,Molecule Z,Drug,MCNH,MCNH,Phase 3,2016-08-01,"Sex: ALL; Age: >24 Weeks; Criteria: Inclusion Criteria:

* Infants with a minimal gestational age of 24 weeks 0 days to 27 completed weeks (up to 27 6/7ths) by best obstetrical estimate
* Infants who will receive full resuscitation as n...",No,2017-06-10,FDA-78930,2.62,0.32,5.0,7.94,2019-03-15,2019-07-10,2024-07-10,62,GSK,74,Kenya,52.0,13,3,99,61,83,53,27,0,2,1,False,False,False,True,True,False,False,True,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Supplemental oxygen with target saturation of 91 to 95%,Product Alpha,Drug,MCNH,MCNH,Phase 3,2016-08-01,"Sex: ALL; Age: >24 Weeks; Criteria: Inclusion Criteria:

* Infants with a minimal gestational age of 24 weeks 0 days to 27 completed weeks (up to 27 6/7ths) by best obstetrical estimate
* Infants who will receive full resuscitation as n...",Yes,2016-10-11,FDA-39387,2.62,0.32,5.0,7.94,2019-03-15,2019-07-10,2024-07-10,46,Sanofi,100,South Africa,56.16666666666666,71,4,62,99,67,34,27,1,2,0,True,False,True,False,False,True,False,False,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
ACULAR,AltName B,Drug,MCNH,MCNH,Phase 4,2008-08-01,"Sex: ALL; Age: >10 Days; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* All preterm infants of gestational age less or equal to 28 weeks completed gestational age and 10 to 15 days of postnatal age admitted to our regional NICU...",Yes,2008-09-05,FDA-90352,0.56,0.15,3.5,4.21,2009-02-21,2009-04-17,2012-10-16,86,Merck,26,Senegal,51.83333333333334,73,8,88,23,93,26,82,2,4,3,True,True,True,True,True,False,True,True,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
REFRESH TEARS,GenName Y,Drug,MCNH,MCNH,Phase 4,2008-08-01,"Sex: ALL; Age: >10 Days; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* All preterm infants of gestational age less or equal to 28 weeks completed gestational age and 10 to 15 days of postnatal age admitted to our regional NICU...",No,2008-10-23,FDA-11064,0.56,0.15,3.5,4.21,2009-02-21,2009-04-17,2012-10-16,68,Gilead,21,Senegal,57.66666666666666,33,92,77,89,52,3,64,2,3,2,True,True,False,True,True,True,False,False,True,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Indomethacin,GenName Y,Drug,MCNH,MCNH,Phase 2,2021-08-28,"Sex: ALL; Age: >24 Weeks; Criteria: Inclusion Criteria:

* pregnant women admitted \>24weeks and \<30weeks gestational age,
* in-hospital birth (allowing for cord clamp randomization)

Exclusion Criteria:

* preterm infant \<24weeks or ...",No,2021-10-22,FDA-94351,4.41,0.98,21.0,26.39,2026-01-24,2027-01-17,2048-01-17,98,Novartis,18,South Africa,42.0,85,30,42,9,77,9,36,0,2,2,False,False,True,True,False,False,False,False,True,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A),Comp Beta,Biological,MCNH,MCNH,Phase 3,2009-03-30,"Sex: ALL; Age: >16 Months; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
* A male or female...",No,2009-05-19,FDA-83530,2.62,0.32,5.0,7.94,2011-11-11,2012-03-07,2017-03-08,98,AstraZeneca,45,Kenya,46.0,14,63,73,94,0,32,55,1,3,2,True,False,True,False,True,False,True,False,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Infanrix™-IPV/Hib,Comp Beta,Biological,MCNH,MCNH,Phase 3,2009-03-30,"Sex: ALL; Age: >16 Months; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
* A male or female...",No,2009-11-15,FDA-66046,2.62,0.32,5.0,7.94,2011-11-11,2012-03-07,2017-03-08,43,Pfizer,83,Kenya,39.33333333333334,71,39,51,32,13,30,73,1,4,3,True,False,True,True,True,True,False,True,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
indomethacin,AltName B,Drug,MCNH,MCNH,Phase 3,2012-03-01,"Sex: ALL; Healthy Volunteers: Yes; Criteria: * Preterm infants \< 1250 g birth weight
* Admitted to participating institution \< 6 hrs of age
* No evidence for congenital malformations
* Cranial US at 6 postnatal hours without evidence of Grades...",No,2012-04-13,FDA-38782,2.62,0.32,5.0,7.94,2014-10-13,2015-02-07,2020-02-08,87,Sanofi,87,Kenya,53.5,52,56,24,55,48,86,36,0,2,2,False,False,False,False,True,True,False,False,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Live attenuated influenza vaccine,Comp Beta,Biological,MCNH,MCNH,Phase 4,2012-05-01,"Sex: ALL; Age: >24 Months; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

Subjects must meet all relevant criteria (by time of influenza vaccination) to participate.

1. (a) Former premature (\<32 weeks' gestation at birth), VLBW (\<1500 grams' birth we...",No,2012-08-30,FDA-32963,0.56,0.15,3.5,4.21,2012-11-21,2013-01-15,2016-07-16,19,Sanofi,56,Senegal,56.16666666666666,98,28,11,17,99,84,36,1,1,2,False,True,False,False,False,True,False,False,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Inactivated influenza vaccine,Product Alpha,Biological,MCNH,MCNH,Phase 4,2012-05-01,"Sex: ALL; Age: >24 Months; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

Subjects must meet all relevant criteria (by time of influenza vaccination) to participate.

1. (a) Former premature (\<32 weeks' gestation at birth), VLBW (\<1500 grams' birth we...",Yes,2012-07-25,FDA-42702,0.56,0.15,3.5,4.21,2012-11-21,2013-01-15,2016-07-16,3,AstraZeneca,79,South Africa,41.5,43,99,22,13,31,41,45,0,3,2,False,False,True,True,False,False,True,False,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
L-carnitine,AltName B,Drug,MCNH,MCNH,Phase 3,2021-12-28,"Sex: ALL; Age: >1 Day; Criteria: Inclusion Criteria:

* Infants born at equal to or less than 30 weeks gestation and with birth weight \< 1250 grams
* Less than 72 hours of age
* Signed parental consent

Exclusion Criteria:

* Critic...",No,2022-07-02,FDA-32543,2.62,0.32,5.0,7.94,2024-08-10,2024-12-05,2029-12-06,49,Merck,35,Senegal,48.66666666666666,53,86,44,62,23,24,73,2,3,3,True,True,True,False,True,True,False,True,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
5% Dextrose,Molecule Z,Drug,MCNH,MCNH,Phase 3,2021-12-28,"Sex: ALL; Age: >1 Day; Criteria: Inclusion Criteria:

* Infants born at equal to or less than 30 weeks gestation and with birth weight \< 1250 grams
* Less than 72 hours of age
* Signed parental consent

Exclusion Criteria:

* Critic...",No,2022-02-09,FDA-86032,2.62,0.32,5.0,7.94,2024-08-10,2024-12-05,2029-12-06,18,GSK,14,Kenya,71.33333333333333,99,45,89,24,99,72,64,1,4,2,False,True,True,True,False,True,True,False,True,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
noninvasive respiratory support with NAVA mode and PSV,GenName Y,Device,MCNH,MCNH,Phase 3,2014-04-01,"Sex: ALL; Age: >3 Days; Criteria: Inclusion Criteria:

* preterm infants less than 32 weeks of gestational age
* intubated more than 48 hours after birth
* subjected to extubation with minimal ventilator setting (mean airway pressure ...",No,2015-03-12,FDA-93145,2.62,0.32,5.0,7.94,2016-11-12,2017-03-09,2022-03-10,71,AstraZeneca,80,Overall,33.83333333333334,75,3,3,36,47,39,18,0,1,1,False,False,False,True,False,False,False,True,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Azithromycin,AltName B,Drug,MCNH,MCNH,Phase 3,2023-12-08,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Maternal age ≥ 18 years and \<50 years
* Pregnant women between the gestational age 23 6/7 and 32 6/7 weeks
* Singleton pregnancy
* Preterm premature rupture of membranes, deter...",No,2024-02-06,FDA-91635,2.62,0.32,5.0,7.94,2026-07-21,2026-11-15,2031-11-16,77,AstraZeneca,22,Kenya,33.0,48,13,0,79,2,56,45,0,3,2,False,False,False,True,False,True,True,True,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Erythromycin,Product Alpha,Drug,MCNH,MCNH,Phase 3,2023-12-08,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Maternal age ≥ 18 years and \<50 years
* Pregnant women between the gestational age 23 6/7 and 32 6/7 weeks
* Singleton pregnancy
* Preterm premature rupture of membranes, deter...",No,2024-08-07,FDA-80445,2.62,0.32,5.0,7.94,2026-07-21,2026-11-15,2031-11-16,86,Sanofi,12,Overall,52.83333333333334,9,72,78,3,71,84,55,0,2,4,False,False,False,False,False,True,True,True,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Ampicillin,GenName Y,Drug,MCNH,MCNH,Phase 3,2023-12-08,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Maternal age ≥ 18 years and \<50 years
* Pregnant women between the gestational age 23 6/7 and 32 6/7 weeks
* Singleton pregnancy
* Preterm premature rupture of membranes, deter...",Yes,2024-07-31,FDA-46913,2.62,0.32,5.0,7.94,2026-07-21,2026-11-15,2031-11-16,84,Bayer,96,Kenya,38.66666666666666,14,73,43,57,28,17,55,1,2,3,True,False,False,False,True,False,True,True,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Amoxicillin,AltName B,Drug,MCNH,MCNH,Phase 3,2023-12-08,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Maternal age ≥ 18 years and \<50 years
* Pregnant women between the gestational age 23 6/7 and 32 6/7 weeks
* Singleton pregnancy
* Preterm premature rupture of membranes, deter...",Yes,2024-01-16,FDA-19540,2.62,0.32,5.0,7.94,2026-07-21,2026-11-15,2031-11-16,55,Merck,27,Overall,51.0,94,39,44,22,92,15,36,0,2,2,False,False,True,False,False,True,False,True,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
multicomponent lipid emulsion,AltName A,Drug,MCNH,MCNH,Phase 3,2016-01-01,"Sex: ALL; Age: >24 Weeks; Criteria: Inclusion Criteria:

* Inborn infants with a gestational age of less than 30 weeks
* Who required parenteral nutrition for at least 7 days

Exclusion Criteria:

* Evidence of congenital infection
* Pe...",No,2016-05-09,FDA-92159,2.62,0.32,5.0,7.94,2018-08-14,2018-12-09,2023-12-10,87,AstraZeneca,86,Senegal,46.16666666666666,62,57,9,29,100,20,55,1,2,3,False,True,False,False,True,True,False,True,True,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
pure soybean oil lipid emulsion,Comp Beta,Drug,MCNH,MCNH,Phase 3,2016-01-01,"Sex: ALL; Age: >24 Weeks; Criteria: Inclusion Criteria:

* Inborn infants with a gestational age of less than 30 weeks
* Who required parenteral nutrition for at least 7 days

Exclusion Criteria:

* Evidence of congenital infection
* Pe...",Yes,2016-04-09,FDA-41801,2.62,0.32,5.0,7.94,2018-08-14,2018-12-09,2023-12-10,74,GSK,65,Kenya,47.66666666666666,58,44,48,15,66,55,45,1,2,2,False,True,False,True,False,True,False,True,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
PS Group,AltName B,Drug,MCNH,MCNH,Phase 3,2011-06-01,"Sex: ALL; Age: >26 Weeks; Criteria: Inclusion Criteria:

Infants likely to be delivered to women presenting to a participating Vermont Oxford Network Center at high risk of premature delivery at gestational age 26 + 0 to 29 + 6 weeks wi...",Yes,2011-07-07,FDA-38675,2.62,0.32,5.0,7.94,2014-01-12,2014-05-09,2019-05-10,1,AstraZeneca,59,Kenya,38.83333333333334,26,50,64,7,61,25,64,1,3,3,False,True,True,False,True,False,True,False,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
NCPAP Group,AltName B,Device,MCNH,MCNH,Phase 3,2011-06-01,"Sex: ALL; Age: >26 Weeks; Criteria: Inclusion Criteria:

Infants likely to be delivered to women presenting to a participating Vermont Oxford Network Center at high risk of premature delivery at gestational age 26 + 0 to 29 + 6 weeks wi...",No,2011-10-28,FDA-48089,2.62,0.32,5.0,7.94,2014-01-12,2014-05-09,2019-05-10,26,Bayer,80,Overall,48.66666666666666,48,88,59,37,7,53,64,1,4,2,True,False,True,True,True,True,False,False,True,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
ISX Group,GenName Y,Drug,MCNH,MCNH,Phase 3,2011-06-01,"Sex: ALL; Age: >26 Weeks; Criteria: Inclusion Criteria:

Infants likely to be delivered to women presenting to a participating Vermont Oxford Network Center at high risk of premature delivery at gestational age 26 + 0 to 29 + 6 weeks wi...",Yes,2011-12-15,FDA-12128,2.62,0.32,5.0,7.94,2014-01-12,2014-05-09,2019-05-10,51,Merck,74,Senegal,41.16666666666666,28,61,53,21,1,83,45,0,3,2,False,False,False,True,False,True,True,True,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Azithromycin,Comp Beta,Drug,MCNH,MCNH,Phase 2,2009-08-01,"Sex: ALL; Age: >1 Day; Criteria: Inclusion Criteria:

* Infants weighing \<1250 grams at birth with respiratory distress syndrome who have respiratory infection with Ureaplasma sp organisms.

Exclusion Criteria:

* Severe respiratory...",Yes,2010-07-27,FDA-11715,4.41,0.98,21.0,26.39,2013-12-28,2014-12-21,2035-12-21,55,Pfizer,82,Overall,66.16666666666667,39,88,50,72,51,97,45,0,4,1,False,False,True,False,True,True,True,False,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
PCV13,AltName B,Biological,MCNH,MCNH,Phase 4,2021-11-01,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

1. \<33 and 0 days weeks gestational age at birth
2. ≥6 weeks and 0 days and ≤12 weeks and 0 days postnatal age at randomization
3. Remains hospitalized after birth (has never bee...",Yes,2022-08-07,FDA-92928,0.56,0.15,3.5,4.21,2022-05-24,2022-07-18,2026-01-16,8,Sanofi,20,Overall,52.0,96,83,21,1,77,34,18,0,0,2,False,False,False,False,False,False,False,True,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
DTaP,Molecule Z,Biological,MCNH,MCNH,Phase 4,2021-11-01,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

1. \<33 and 0 days weeks gestational age at birth
2. ≥6 weeks and 0 days and ≤12 weeks and 0 days postnatal age at randomization
3. Remains hospitalized after birth (has never bee...",No,2022-01-12,FDA-15545,0.56,0.15,3.5,4.21,2022-05-24,2022-07-18,2026-01-16,22,Merck,72,Kenya,30.83333333333333,10,40,33,26,23,53,45,1,4,0,True,False,True,True,True,True,False,False,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
HBV,TradeName X,Biological,MCNH,MCNH,Phase 4,2021-11-01,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

1. \<33 and 0 days weeks gestational age at birth
2. ≥6 weeks and 0 days and ≤12 weeks and 0 days postnatal age at randomization
3. Remains hospitalized after birth (has never bee...",Yes,2022-02-24,FDA-23649,0.56,0.15,3.5,4.21,2022-05-24,2022-07-18,2026-01-16,98,Gilead,59,South Africa,63.66666666666666,84,64,42,62,61,69,73,1,3,4,True,False,True,False,True,False,True,True,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
IPV,Comp Beta,Biological,MCNH,MCNH,Phase 4,2021-11-01,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

1. \<33 and 0 days weeks gestational age at birth
2. ≥6 weeks and 0 days and ≤12 weeks and 0 days postnatal age at randomization
3. Remains hospitalized after birth (has never bee...",No,2022-04-05,FDA-31479,0.56,0.15,3.5,4.21,2022-05-24,2022-07-18,2026-01-16,0,Novartis,85,South Africa,45.66666666666666,2,70,31,99,53,19,73,1,3,4,False,True,True,True,True,False,False,True,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Hib,GenName Y,Biological,MCNH,MCNH,Phase 4,2021-11-01,"Sex: ALL; Age: >6 Weeks; Criteria: Inclusion Criteria:

1. \<33 and 0 days weeks gestational age at birth
2. ≥6 weeks and 0 days and ≤12 weeks and 0 days postnatal age at randomization
3. Remains hospitalized after birth (has never bee...",No,2022-09-12,FDA-15910,0.56,0.15,3.5,4.21,2022-05-24,2022-07-18,2026-01-16,61,GSK,98,South Africa,55.66666666666666,19,65,57,65,41,87,45,1,2,2,True,False,True,True,False,False,False,False,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Inhaled Nitric Oxide,GenName Y,Drug,MCNH,MCNH,Phase 3,2014-05-01,"Sex: ALL; Age: >5 Days; Criteria: Inclusion Criteria:

* Preterm infants who are:

  1. 500 to 1250 grams at birth
  2. \< 30 weeks gestational age
  3. 5 to 14 days of age (inclusive) at the time of entry
  4. Requiring mechanical ve...",No,2015-02-07,FDA-77728,2.62,0.32,5.0,7.94,2016-12-12,2017-04-08,2022-04-09,100,Gilead,62,South Africa,39.0,74,45,37,14,7,57,45,0,2,3,False,False,False,True,False,False,True,True,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Lipofundin MCT/LCT 20 %,Product Alpha,Drug,MCNH,MCNH,Phase 2,2008-02-01,"Sex: ALL; Age: >5 Hours; Criteria: Inclusion Criteria:

* prematurity (birth weight 500 - 1500 g)
* postnatal age \<= 72 h
* need for cumulative parenteral energy supply of at least 70% during study duration
* signed informed consent f...",Yes,2009-01-30,FDA-60965,4.41,0.98,21.0,26.39,2012-06-29,2013-06-22,2034-06-22,93,Novartis,34,Senegal,47.16666666666666,46,62,13,90,29,43,18,1,1,0,True,False,False,False,False,True,False,False,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Lipidem 20%,Product Alpha,Drug,MCNH,MCNH,Phase 2,2008-02-01,"Sex: ALL; Age: >5 Hours; Criteria: Inclusion Criteria:

* prematurity (birth weight 500 - 1500 g)
* postnatal age \<= 72 h
* need for cumulative parenteral energy supply of at least 70% during study duration
* signed informed consent f...",No,2008-11-17,FDA-73139,4.41,0.98,21.0,26.39,2012-06-29,2013-06-22,2034-06-22,33,Sanofi,24,Senegal,46.5,18,83,40,18,61,59,55,0,3,3,False,False,False,True,True,True,False,True,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Inositol lower volume,Comp Beta,Drug,MCNH,MCNH,Phase 2,2013-09-01,"Sex: ALL; Age: >12 Hours; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* 23 0/7 to 26 6/7 weeks gestational age (48 infants) or
* 27 0/7 to 29 6/7 weeks gestational age (48 infants)
* 401 grams birth weight or larger
* 12-72 hours of age

Exclusion C...",No,2013-11-24,FDA-10057,4.41,0.98,21.0,26.39,2018-01-28,2019-01-21,2040-01-21,57,Gilead,35,Overall,54.5,55,79,79,42,11,61,45,1,2,2,False,True,False,False,False,True,True,True,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Inositol mid-level volume,Comp Beta,Drug,MCNH,MCNH,Phase 2,2013-09-01,"Sex: ALL; Age: >12 Hours; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* 23 0/7 to 26 6/7 weeks gestational age (48 infants) or
* 27 0/7 to 29 6/7 weeks gestational age (48 infants)
* 401 grams birth weight or larger
* 12-72 hours of age

Exclusion C...",Yes,2014-02-19,FDA-73514,4.41,0.98,21.0,26.39,2018-01-28,2019-01-21,2040-01-21,35,Merck,87,Kenya,60.66666666666666,94,30,49,58,72,61,55,1,3,2,True,False,False,True,True,True,False,True,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Inositol high volume,Comp Beta,Drug,MCNH,MCNH,Phase 2,2013-09-01,"Sex: ALL; Age: >12 Hours; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* 23 0/7 to 26 6/7 weeks gestational age (48 infants) or
* 27 0/7 to 29 6/7 weeks gestational age (48 infants)
* 401 grams birth weight or larger
* 12-72 hours of age

Exclusion C...",Yes,2014-07-27,FDA-18062,4.41,0.98,21.0,26.39,2018-01-28,2019-01-21,2040-01-21,4,Pfizer,37,South Africa,49.5,45,37,13,75,57,70,64,1,4,2,True,False,True,True,True,True,False,False,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
budesonide (Pulmicort nebulizing suspension).,AltName A,Drug,MCNH,MCNH,Phase 3,2026-12-17,"Sex: ALL; Criteria: Inclusion Criteria:

* Liveborn infants 22 0/7 - 28 6/7 weeks gestation or 401 - 1000 grams (inclusive) birth weight
* Clinical decision to give surfactant
* Less than or equal to 48 hours postnatal a...",No,2027-10-30,FDA-22658,2.62,0.32,5.0,7.94,2029-07-30,2029-11-24,2034-11-25,89,AstraZeneca,41,Overall,45.5,35,40,74,20,69,35,36,1,2,1,True,False,False,False,True,False,True,False,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
surfactant (poractant alfa;Curosurf),Product Alpha,Drug,MCNH,MCNH,Phase 3,2026-12-17,"Sex: ALL; Criteria: Inclusion Criteria:

* Liveborn infants 22 0/7 - 28 6/7 weeks gestation or 401 - 1000 grams (inclusive) birth weight
* Clinical decision to give surfactant
* Less than or equal to 48 hours postnatal a...",Yes,2027-05-15,FDA-61894,2.62,0.32,5.0,7.94,2029-07-30,2029-11-24,2034-11-25,85,GSK,41,Senegal,42.5,96,90,43,11,8,7,64,2,3,2,True,True,True,False,False,True,True,True,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Expecta 200 mg,Product Alpha,Drug,MCNH,MCNH,Phase 2,2018-07-16,"Sex: FEMALE; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

•Lactating mothers at Cincinnati University Hospital with infants born at \< 29 weeks gestation.

Exclusion Criteria:

* the presence of congenital anomalies (trisomy 13, 18, 21, ...",Yes,2019-02-19,FDA-28690,4.41,0.98,21.0,26.39,2022-12-12,2023-12-05,2044-12-04,8,AstraZeneca,16,Overall,60.16666666666666,81,42,84,61,52,41,82,1,4,4,True,False,True,True,True,True,False,True,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Expecta 1 gram,AltName B,Drug,MCNH,MCNH,Phase 2,2018-07-16,"Sex: FEMALE; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

•Lactating mothers at Cincinnati University Hospital with infants born at \< 29 weeks gestation.

Exclusion Criteria:

* the presence of congenital anomalies (trisomy 13, 18, 21, ...",Yes,2018-11-02,FDA-82672,4.41,0.98,21.0,26.39,2022-12-12,2023-12-05,2044-12-04,93,GSK,79,Kenya,42.66666666666666,65,3,77,30,35,46,64,2,2,3,True,True,True,False,False,False,True,True,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Azithromycin,Comp Beta,Drug,MCNH,MCNH,Phase 2,2020-11-03,"Sex: ALL; Age: >2 Hours; Criteria: Inclusion Criteria:

* Gestational age 24 weeks 0 days-28weeks 6 days by best obstetrical estimate
* \<72 h age
* Positive pressure ventilation for at least 1 hour duration during the first 72 hours o...",Yes,2021-09-20,FDA-37946,4.41,0.98,21.0,26.39,2025-04-01,2026-03-25,2047-03-25,73,Gilead,51,Senegal,53.66666666666666,34,79,12,94,57,46,45,2,2,1,True,True,True,True,False,False,False,True,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
inhaled nitric oxide,GenName Y,Drug,MCNH,MCNH,Phase 3,2023-11-28,"Sex: ALL; Age: >2 Hours; Criteria: Inclusion Criteria:

* Prematurity (birthweight ≤ 1500g, \< 31 weeks gestation)
* Requiring respiratory support
* Admitted to the NICU at the University of Chicago

Exclusion Criteria:

* Severe conge...",No,2024-01-22,FDA-81052,2.62,0.32,5.0,7.94,2026-07-11,2026-11-05,2031-11-06,46,GSK,10,Kenya,51.33333333333334,32,14,87,61,89,25,64,1,3,3,False,True,True,True,False,True,False,True,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
oxygen,AltName A,Drug,MCNH,MCNH,Phase 3,2023-11-28,"Sex: ALL; Age: >2 Hours; Criteria: Inclusion Criteria:

* Prematurity (birthweight ≤ 1500g, \< 31 weeks gestation)
* Requiring respiratory support
* Admitted to the NICU at the University of Chicago

Exclusion Criteria:

* Severe conge...",Yes,2024-07-25,FDA-21995,2.62,0.32,5.0,7.94,2026-07-11,2026-11-05,2031-11-06,28,Bayer,59,South Africa,53.66666666666666,93,71,26,21,17,94,45,1,2,2,False,True,True,False,False,True,False,True,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Indomethacin,Product Alpha,Drug,MCNH,MCNH,Phase 2,2012-12-08,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Singleton and twin gestations
* Intact amniotic membranes
* No contra-indications to tocolysis
* 24-34 weeks gestation by last menstrual period and/or ultrasound
* Documented ce...",No,2013-05-07,FDA-93875,4.41,0.98,21.0,26.39,2017-05-06,2018-04-29,2039-04-29,79,Pfizer,96,Kenya,44.66666666666666,24,36,65,0,67,76,9,0,0,1,False,False,False,False,False,False,False,False,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Nifedipine,AltName A,Drug,MCNH,MCNH,Phase 2,2012-12-08,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Singleton and twin gestations
* Intact amniotic membranes
* No contra-indications to tocolysis
* 24-34 weeks gestation by last menstrual period and/or ultrasound
* Documented ce...",Yes,2013-04-02,FDA-34606,4.41,0.98,21.0,26.39,2017-05-06,2018-04-29,2039-04-29,41,AstraZeneca,95,Senegal,47.5,64,32,44,17,98,30,27,1,1,1,False,True,False,False,False,False,True,False,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Survanta (beractant),AltName A,Drug,MCNH,MCNH,Phase 4,2009-01-01,"Sex: ALL; Criteria: Inclusion Criteria:

* \<29 6/7 and \>24 0/7 weeks gestational age
* Inborn at the participating institution enrolling the patient
* FIO2 \>25% and Intubated with mean airway pressure \> 5 cm H20
* \<...",No,2009-02-14,FDA-30359,0.56,0.15,3.5,4.21,2009-07-24,2009-09-17,2013-03-18,36,GSK,15,Kenya,39.5,34,45,1,90,65,2,55,1,4,1,False,True,True,False,True,True,True,False,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Curosurf (poractant),Product Alpha,Drug,MCNH,MCNH,Phase 4,2009-01-01,"Sex: ALL; Criteria: Inclusion Criteria:

* \<29 6/7 and \>24 0/7 weeks gestational age
* Inborn at the participating institution enrolling the patient
* FIO2 \>25% and Intubated with mean airway pressure \> 5 cm H20
* \<...",No,2009-10-04,FDA-54532,0.56,0.15,3.5,4.21,2009-07-24,2009-09-17,2013-03-18,35,Gilead,53,Kenya,55.16666666666666,50,57,54,75,23,72,45,1,2,2,True,False,False,False,True,True,False,True,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
palivizumab,Comp Beta,Biological,MCNH,MCNH,Phase 3,2010-07-01,"Sex: ALL; Criteria: Inclusion Criteria:

Subjects must meet all of the following criteria to be enrolled into the study:

1. Infants at high risk of severe RSV infection defined as fulfilling at least one of the followin...",Yes,2011-06-11,FDA-70513,2.62,0.32,5.0,7.94,2013-02-11,2013-06-08,2018-06-09,31,Gilead,72,Overall,55.16666666666666,1,70,100,27,41,92,36,1,2,1,True,False,False,True,False,False,True,False,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Domperidone maleate,Molecule Z,Drug,MCNH,MCNH,Phase 2,2016-03-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* mothers of a preterm infant born \< 30 completed weeks gestation (23 0/7-29 6/7 weeks)
* postpartum period of 7-21 days
* mechanically pumping a minimum average of 6 times a day...",No,2016-12-09,FDA-14853,4.41,0.98,21.0,26.39,2020-07-28,2021-07-21,2042-07-21,77,GSK,69,Kenya,45.5,12,48,61,45,31,76,55,0,3,3,False,False,False,True,False,True,True,True,True,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Domperidone maleate,Comp Beta,Drug,MCNH,MCNH,Phase 2,2016-03-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* mothers of a preterm infant born \< 30 completed weeks gestation (23 0/7-29 6/7 weeks)
* postpartum period of 7-21 days
* mechanically pumping a minimum average of 6 times a day...",No,2016-07-20,FDA-71454,4.41,0.98,21.0,26.39,2020-07-28,2021-07-21,2042-07-21,20,Sanofi,10,South Africa,66.5,50,54,69,88,72,66,27,1,1,1,False,True,False,True,False,False,False,True,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
17-Hydroxyprogesterone Caproate,Molecule Z,Drug,MCNH,MCNH,Phase 2,2015-12-01,"Sex: FEMALE; Criteria: Inclusion Criteria:

1. 18yr of age
2. Singleton pregnancy
3. PPROM confirmed on clinical exam
4. GA between 24+0 and 33+5 wk
5. Ability to understand consent in either English or Spanish

Exclusion C...",Yes,2016-09-25,FDA-74819,4.41,0.98,21.0,26.39,2020-04-28,2021-04-21,2042-04-21,80,Merck,88,Overall,58.0,49,5,80,52,78,84,45,0,3,2,False,False,True,False,True,True,False,False,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Antibiotic,Product Alpha,Drug,MCNH,MCNH,Phase 2,2019-09-11,"Sex: ALL; Age: >23 Weeks; Criteria: Inclusion Criteria:

* All infants less than 33 weeks gestation.

Exclusion Criteria:

* Infants who are non-viable at birth....",Yes,2020-04-21,FDA-15157,4.41,0.98,21.0,26.39,2024-02-07,2025-01-30,2046-01-30,78,Bayer,4,Overall,50.83333333333334,58,41,27,39,72,68,45,2,2,1,True,True,True,False,False,True,False,False,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Antibiotics,GenName Y,Drug,MCNH,MCNH,Phase 2,2019-09-11,"Sex: ALL; Age: >23 Weeks; Criteria: Inclusion Criteria:

* All infants less than 33 weeks gestation.

Exclusion Criteria:

* Infants who are non-viable at birth....",Yes,2020-06-06,FDA-77726,4.41,0.98,21.0,26.39,2024-02-07,2025-01-30,2046-01-30,10,GSK,57,South Africa,48.0,61,26,33,86,82,0,45,2,1,2,True,True,True,False,False,False,False,False,True,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Cholecalciferol,GenName Y,Drug,MCNH,MCNH,Phase 4,2017-03-12,"Sex: ALL; Criteria: Inclusion criteria:

1. 28 0/7-36 6/7 weeks gestational age (GA) at birth;
2. family identifies the child as black or African American;
3. \< 28 days of supplemental oxygen (subsequent oxygen therapy ...",Yes,2017-12-26,FDA-59988,0.56,0.15,3.5,4.21,2017-10-02,2017-11-26,2021-05-27,42,GSK,76,Overall,57.16666666666666,80,31,75,7,80,70,55,1,4,1,False,True,True,True,False,True,True,False,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Darbepoetin Alfa Injection,TradeName X,Drug,MCNH,MCNH,Phase 2,2014-06-01,"Sex: ALL; Age: >1 Hour; Criteria: Inclusion Criteria:

* 500-1250 grams birth weight
* less than or equal to 32 weeks gestation
* less than 2 days of age

Exclusion Criteria:

* severe hemorrhagic disease
* severe hemolytic disease
* ...",Yes,2014-08-01,FDA-74371,4.41,0.98,21.0,26.39,2018-10-28,2019-10-21,2040-10-20,24,AstraZeneca,84,Kenya,54.66666666666666,35,87,42,1,93,70,64,1,3,3,False,True,True,True,False,False,True,True,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
erythropoietin alfa injection,AltName B,Drug,MCNH,MCNH,Phase 2,2014-06-01,"Sex: ALL; Age: >1 Hour; Criteria: Inclusion Criteria:

* 500-1250 grams birth weight
* less than or equal to 32 weeks gestation
* less than 2 days of age

Exclusion Criteria:

* severe hemorrhagic disease
* severe hemolytic disease
* ...",Yes,2014-12-24,FDA-90564,4.41,0.98,21.0,26.39,2018-10-28,2019-10-21,2040-10-20,45,GSK,4,Kenya,36.33333333333334,8,25,86,13,69,17,55,1,2,3,True,False,False,True,False,False,True,False,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
sham injection,AltName A,Drug,MCNH,MCNH,Phase 2,2014-06-01,"Sex: ALL; Age: >1 Hour; Criteria: Inclusion Criteria:

* 500-1250 grams birth weight
* less than or equal to 32 weeks gestation
* less than 2 days of age

Exclusion Criteria:

* severe hemorrhagic disease
* severe hemolytic disease
* ...",Yes,2015-01-16,FDA-47562,4.41,0.98,21.0,26.39,2018-10-28,2019-10-21,2040-10-20,1,GSK,40,Senegal,67.16666666666667,98,72,61,66,90,16,27,0,1,2,False,False,False,False,False,False,True,False,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Pneumococcal conjugate vaccine GSK1024850A,Comp Beta,Biological,MCNH,MCNH,Phase 3,2008-05-02,"Sex: ALL; Age: >8 Weeks; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol
* A male or female between, and including, 8-16 wee...",Yes,2009-01-25,FDA-71005,2.62,0.32,5.0,7.94,2010-12-14,2011-04-10,2016-04-10,63,Pfizer,95,Overall,56.5,17,48,82,42,77,73,55,1,4,1,False,True,True,False,True,True,True,False,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Infanrix hexa,Comp Beta,Biological,MCNH,MCNH,Phase 3,2008-05-02,"Sex: ALL; Age: >8 Weeks; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol
* A male or female between, and including, 8-16 wee...",No,2008-12-09,FDA-89622,2.62,0.32,5.0,7.94,2010-12-14,2011-04-10,2016-04-10,74,Merck,22,Senegal,64.0,81,23,52,98,74,56,45,1,2,2,True,False,False,False,False,True,True,False,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
AeroFact,AltName B,Drug,MCNH,MCNH,Phase 2,2024-08-05,"Sex: ALL; Age: >26 Weeks; Criteria: Inclusion Criteria:

1. Parental consent obtained prior to study procedures being performed (pre-natal consent is allowed)
2. 26 0/7 to 30 6/7 weeks of gestational age
3. Weight \<2.0 Kg
4. Respirator...",No,2025-01-01,FDA-34293,4.41,0.98,21.0,26.39,2029-01-01,2029-12-25,2050-12-25,56,J&J,63,Senegal,31.66666666666667,87,27,23,13,22,18,73,1,3,4,False,True,False,True,True,True,False,True,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Azithromycin,Molecule Z,Drug,MCNH,MCNH,Phase 2,2012-06-01,"Sex: ALL; Criteria: Inclusion Criteria:

* birthweight less than 1250 grams admitted to UK NICU
* mechanical ventilation within the first 72 hours of life

Exclusion Criteria:

* confirmed sepsis by blood culture
* multi...",Yes,2012-08-04,FDA-90795,4.41,0.98,21.0,26.39,2016-10-28,2017-10-21,2038-10-21,75,GSK,17,Overall,24.83333333333333,28,7,25,54,0,35,64,1,3,3,False,True,False,False,True,True,True,True,True,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Endotracheal intubation,Molecule Z,Device,MCNH,MCNH,Phase 4,2020-12-31,"Sex: ALL; Age: >2 Hours; Criteria: Inclusion Criteria:

* Mild-to-moderate RDS;
* Postnatal age 2 to 48 hours;
* Gestational age 27 0/7 to 36 6/7 weeks;
* Treated with nasal CPAP modalities ≥ 5 cm H2O and FiO2 between 0.30 and 0.60 for...",Yes,2021-04-23,FDA-25894,0.56,0.15,3.5,4.21,2021-07-23,2021-09-16,2025-03-17,35,AstraZeneca,75,Kenya,36.5,91,4,28,25,32,39,73,1,3,4,True,False,False,True,False,True,True,True,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Laryngeal mask airway,TradeName X,Device,MCNH,MCNH,Phase 4,2020-12-31,"Sex: ALL; Age: >2 Hours; Criteria: Inclusion Criteria:

* Mild-to-moderate RDS;
* Postnatal age 2 to 48 hours;
* Gestational age 27 0/7 to 36 6/7 weeks;
* Treated with nasal CPAP modalities ≥ 5 cm H2O and FiO2 between 0.30 and 0.60 for...",Yes,2021-11-03,FDA-86617,0.56,0.15,3.5,4.21,2021-07-23,2021-09-16,2025-03-17,67,Gilead,51,Overall,26.83333333333333,26,38,12,8,59,18,64,0,3,4,False,False,False,False,True,True,True,True,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
remifentanil,Comp Beta,Drug,MCNH,MCNH,Phase 4,2020-12-31,"Sex: ALL; Age: >2 Hours; Criteria: Inclusion Criteria:

* Mild-to-moderate RDS;
* Postnatal age 2 to 48 hours;
* Gestational age 27 0/7 to 36 6/7 weeks;
* Treated with nasal CPAP modalities ≥ 5 cm H2O and FiO2 between 0.30 and 0.60 for...",Yes,2021-09-02,FDA-52805,0.56,0.15,3.5,4.21,2021-07-23,2021-09-16,2025-03-17,56,Pfizer,69,South Africa,48.5,86,23,11,6,97,68,73,2,3,3,True,True,False,True,False,True,True,True,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Ibuprofen and acetaminophen,AltName A,Drug,MCNH,MCNH,Phase 2,2020-12-02,"Sex: ALL; Age: >5 Days; Criteria: Inclusion Criteria:

1. Preterm infant ≤27 6/7
2. Written parental consent is obtained
3. Infant requires respiratory support
4. diagnosis of a persistent patent ductus arteriosus after 5 days of age,...",No,2021-10-08,FDA-17529,4.41,0.98,21.0,26.39,2025-04-30,2026-04-23,2047-04-23,80,J&J,65,Senegal,31.5,55,63,16,20,6,29,64,1,4,2,True,False,True,False,True,True,True,False,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Advil® Pediatric drops for infants,AltName B,Drug,MCNH,MCNH,Phase 2,2012-04-01,"Sex: ALL; Age: >7 Weeks; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* preterm infants less than 32 weeks of gestational age
* Postnatal age more than 7 weeks
* Informed parental consent

Exclusion Criteria:

* anomalies in cardiac conduction
* con...",No,2012-08-12,FDA-63214,4.41,0.98,21.0,26.39,2016-08-28,2017-08-21,2038-08-21,62,Pfizer,36,South Africa,68.0,84,65,68,62,88,41,45,1,3,1,False,True,False,True,True,False,True,False,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Hydrocortisone,AltName B,Drug,MCNH,MCNH,Phase 3,2024-09-12,"Sex: ALL; Criteria: Inclusion Criteria:

* infants \<30 weeks estimated gestational age
* inborn at an NRN site or were admitted to an NRN site before 72 hours postnatal age
* have received at least 7days of mechanical v...",No,2024-12-13,FDA-15486,2.62,0.32,5.0,7.94,2027-04-26,2027-08-21,2032-08-21,65,GSK,30,South Africa,33.83333333333334,11,35,12,66,30,49,64,1,3,3,True,False,True,False,True,False,True,False,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Infasurf (ONY Inc.),Product Alpha,Drug,MCNH,MCNH,Phase 3,2012-12-01,"Sex: ALL; Age: >7 Days; Criteria: Inclusion Criteria:

* Less than or equal to 1000 gm. birth weight
* Less than or equal to 30 weeks gestational age
* Day 7-14 of life
* Intubated and mechanically ventilated at any time days 7-14 of ...",No,2013-02-04,FDA-23756,2.62,0.32,5.0,7.94,2015-07-15,2015-11-09,2020-11-09,73,GSK,14,Overall,49.33333333333334,7,91,54,88,45,11,64,2,4,1,True,True,False,True,True,True,True,False,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Sham,AltName B,Drug,MCNH,MCNH,Phase 3,2012-12-01,"Sex: ALL; Age: >7 Days; Criteria: Inclusion Criteria:

* Less than or equal to 1000 gm. birth weight
* Less than or equal to 30 weeks gestational age
* Day 7-14 of life
* Intubated and mechanically ventilated at any time days 7-14 of ...",No,2013-11-08,FDA-48504,2.62,0.32,5.0,7.94,2015-07-15,2015-11-09,2020-11-09,80,Novartis,71,Overall,45.0,25,69,64,35,1,76,64,1,4,2,False,True,False,True,True,True,True,False,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Caffeine citrate,AltName B,Drug,MCNH,MCNH,Phase 4,2015-12-01,"Sex: ALL; Age: >24 Weeks; Criteria: Inclusion Criteria:

* Preterm infants from 24 to 30 weeks completed PMA admitted to the neonatal intensive care unit (NICU) at St. Louis Children's Hospital. The estimated post menstrual age will be ...",No,2016-09-24,FDA-18901,0.56,0.15,3.5,4.21,2016-06-22,2016-08-16,2020-02-15,18,Bayer,11,Senegal,64.0,72,95,8,53,58,98,27,1,1,1,False,True,False,False,False,False,True,False,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
usual prescribed intralipid (UL) regimen,Comp Beta,Drug,MCNH,MCNH,Phase 2,2026-06-14,"Sex: ALL; Criteria: Inclusion Criteria:

* no major congenital anomaly or overt nonbacterial infection
* mother has consented to inclusion of the infant for the Neonatal Research Network (NRN) Cycled Phototherapy Trial

...",Yes,2026-10-22,FDA-74275,4.41,0.98,21.0,26.39,2030-11-10,2031-11-03,2052-11-02,53,AstraZeneca,59,Senegal,44.5,44,91,42,46,4,40,55,1,2,3,True,False,True,False,True,False,False,True,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
restricted prescribed intralipid (RL) regimen,GenName Y,Drug,MCNH,MCNH,Phase 2,2026-06-14,"Sex: ALL; Criteria: Inclusion Criteria:

* no major congenital anomaly or overt nonbacterial infection
* mother has consented to inclusion of the infant for the Neonatal Research Network (NRN) Cycled Phototherapy Trial

...",No,2027-05-08,FDA-72961,4.41,0.98,21.0,26.39,2030-11-10,2031-11-03,2052-11-02,52,GSK,30,Senegal,29.0,20,11,4,90,33,16,45,1,3,1,True,False,True,True,False,True,False,False,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Aerosolized Calfactant,Product Alpha,Drug,MCNH,MCNH,Phase 3,2018-07-31,"Sex: ALL; Age: >1 Hour; Criteria: Inclusion Criteria:

RDS Patients

1. NICU patient, ≥1hour of age and \<24 hours of age.
2. Clinical diagnosis of RDS, with or without chest X-ray data.
3. Inspired oxygen ≥21% to maintain adequate ox...",No,2018-12-10,FDA-88561,2.62,0.32,5.0,7.94,2021-03-13,2021-07-08,2026-07-09,55,Bayer,28,Overall,40.66666666666666,16,72,40,12,47,57,27,0,0,3,False,False,False,False,False,False,False,True,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Solarys,AltName B,Device,MCNH,MCNH,Phase 3,2018-07-31,"Sex: ALL; Age: >1 Hour; Criteria: Inclusion Criteria:

RDS Patients

1. NICU patient, ≥1hour of age and \<24 hours of age.
2. Clinical diagnosis of RDS, with or without chest X-ray data.
3. Inspired oxygen ≥21% to maintain adequate ox...",No,2019-02-16,FDA-29850,2.62,0.32,5.0,7.94,2021-03-13,2021-07-08,2026-07-09,92,Sanofi,59,South Africa,61.5,13,91,75,65,80,45,55,2,3,1,True,True,False,True,True,False,True,False,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
inhaled nitric oxide,TradeName X,Drug,MCNH,MCNH,Phase 3,2014-07-01,"Sex: ALL; Age: >30 Weeks; Criteria: Inclusion Criteria:

* \<48 hours of age,
* 30 - 36 weeks gestational age at birth based on best estimate using obstetrical sonography (first or second trimester), solid dating criteria, or Ballard ex...",No,2015-03-11,FDA-71490,2.62,0.32,5.0,7.94,2017-02-11,2017-06-08,2022-06-09,31,Novartis,82,Overall,62.83333333333334,57,83,77,43,80,37,27,1,1,1,False,True,False,True,False,False,False,False,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Aerosolized lucinactant,AltName B,Drug,MCNH,MCNH,Phase 2,2005-09-01,"Sex: ALL; Age: >15 Minutes; Criteria: Inclusion Criteria:

* Gestational age 28-32 completed weeks, inclusive
* Placement of arterial line
* Successful initiation of nCPAP
* Informed Consent

Exclusion Criteria:

* Heart rate that cannot ...",Yes,2005-11-14,FDA-71043,4.41,0.98,21.0,26.39,2010-01-28,2011-01-21,2032-01-21,65,Novartis,92,Kenya,62.5,50,24,91,72,99,39,36,1,2,1,False,True,False,False,True,False,True,False,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Aerosolized lucinactant,AltName B,Drug,MCNH,MCNH,Phase 2,2005-09-01,"Sex: ALL; Age: >15 Minutes; Criteria: Inclusion Criteria:

* Gestational age 28-32 completed weeks, inclusive
* Placement of arterial line
* Successful initiation of nCPAP
* Informed Consent

Exclusion Criteria:

* Heart rate that cannot ...",No,2006-08-09,FDA-32790,4.41,0.98,21.0,26.39,2010-01-28,2011-01-21,2032-01-21,61,Merck,44,Senegal,55.33333333333334,10,82,34,61,73,72,55,0,3,3,False,False,True,True,True,False,False,False,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Recombinant Human Prolactin,AltName A,Drug,MCNH,MCNH,Phase 2,2010-09-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Healthy women, aged 18-45 years
* Lactation insufficiency postpartum
* Subjects will be women with children in the neonatal Intensive Care Unit (ICU) who are pumping breast milk...",Yes,2011-06-04,FDA-43277,4.41,0.98,21.0,26.39,2015-01-28,2016-01-21,2037-01-20,46,Pfizer,84,Senegal,52.66666666666666,23,95,31,10,93,64,45,0,3,2,False,False,False,True,True,True,False,False,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Recombinant human prolactin,GenName Y,Biological,MCNH,MCNH,Phase 2,2010-09-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Healthy women, aged 18-45 years
* Lactation insufficiency postpartum
* Subjects will be women with children in the neonatal Intensive Care Unit (ICU) who are pumping breast milk...",No,2011-06-14,FDA-98721,4.41,0.98,21.0,26.39,2015-01-28,2016-01-21,2037-01-20,31,Bayer,53,South Africa,50.5,55,37,57,44,19,91,27,0,1,2,False,False,False,False,False,False,True,False,True,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Normal Saline,AltName B,Biological,MCNH,MCNH,Phase 2,2010-09-01,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* Healthy women, aged 18-45 years
* Lactation insufficiency postpartum
* Subjects will be women with children in the neonatal Intensive Care Unit (ICU) who are pumping breast milk...",Yes,2011-02-16,FDA-80361,4.41,0.98,21.0,26.39,2015-01-28,2016-01-21,2037-01-20,87,Novartis,85,Overall,49.5,53,29,42,93,9,71,45,1,3,1,False,True,True,True,False,False,True,False,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Endotracheal tube insertion,Product Alpha,Device,MCNH,MCNH,Phase 4,2012-11-01,"Sex: ALL; Age: >4 Hours; Criteria: Inclusion Criteria:

* Mild-to-moderate RDS
* Postnatal age 4 to 48 hours
* Gestational age 29 0/7 to 36 6/7 weeks
* Treated with nasal CPAP ≥ 5 cm H2O and FiO2 between 0.30 and 0.60 for at least 2 ho...",No,2013-03-12,FDA-20320,0.56,0.15,3.5,4.21,2013-05-24,2013-07-18,2017-01-16,0,Merck,30,South Africa,49.5,27,37,95,40,37,61,27,1,2,0,True,False,False,False,True,True,False,False,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Laryngeal mask airway insertion,TradeName X,Device,MCNH,MCNH,Phase 4,2012-11-01,"Sex: ALL; Age: >4 Hours; Criteria: Inclusion Criteria:

* Mild-to-moderate RDS
* Postnatal age 4 to 48 hours
* Gestational age 29 0/7 to 36 6/7 weeks
* Treated with nasal CPAP ≥ 5 cm H2O and FiO2 between 0.30 and 0.60 for at least 2 ho...",No,2013-07-30,FDA-98179,0.56,0.15,3.5,4.21,2013-05-24,2013-07-18,2017-01-16,62,Pfizer,71,South Africa,61.66666666666666,79,19,82,39,84,67,64,2,2,3,True,True,False,True,True,False,False,False,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Curosurf-Group1,AltName B,Drug,MCNH,MCNH,Phase 3,2016-08-01,"Sex: ALL; Age: >24 Weeks; Criteria: Inclusion Criteria:

1. Infants born between 24+0 and 31+6 weeks gestational age, admitted to the study centers
2. Infants with RDS requiring intubation and surfactant therapy within 48 hours after bi...",No,2017-01-02,FDA-47359,2.62,0.32,5.0,7.94,2019-03-15,2019-07-10,2024-07-10,13,J&J,39,Kenya,57.83333333333334,19,17,99,59,53,100,27,1,2,0,True,False,False,False,True,True,False,False,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
BLES-group 2,GenName Y,Drug,MCNH,MCNH,Phase 3,2016-08-01,"Sex: ALL; Age: >24 Weeks; Criteria: Inclusion Criteria:

1. Infants born between 24+0 and 31+6 weeks gestational age, admitted to the study centers
2. Infants with RDS requiring intubation and surfactant therapy within 48 hours after bi...",Yes,2016-09-17,FDA-91809,2.62,0.32,5.0,7.94,2019-03-15,2019-07-10,2024-07-10,37,Gilead,10,Overall,42.83333333333334,39,24,79,59,55,1,36,0,2,2,False,False,False,True,False,False,True,False,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Recombinant human antithrombin (ATryn),Molecule Z,Biological,MCNH,MCNH,Phase 3,2016-11-01,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

1. Hospitalized female pregnant patients of gestational age of ≥23 0/7 weeks to ≤30 0/7 weeks (for subjects at gestational age 23 0/7 to 23 6/7 all standard interventions includin...",Yes,2017-05-11,FDA-69280,2.62,0.32,5.0,7.94,2019-06-15,2019-10-10,2024-10-10,40,AstraZeneca,14,Senegal,48.66666666666666,75,92,42,16,12,55,64,1,5,1,False,True,True,True,True,True,True,False,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
High dose Cholecalciferol,Molecule Z,Drug,MCNH,MCNH,Phase 4,2022-04-01,"Sex: ALL; Age: >0 Days; Criteria: Inclusion Criteria:

* Women with documentation of fully breastfeeding who present within one month of delivery, who are 18-45 years old and in good general health will be eligible for participation.
...",No,2022-05-03,FDA-60488,0.56,0.15,3.5,4.21,2022-10-22,2022-12-16,2026-06-16,29,J&J,30,South Africa,53.83333333333334,16,85,40,67,64,51,36,0,2,2,False,False,False,True,False,False,True,True,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Cholecalciferol,TradeName X,Drug,MCNH,MCNH,Phase 4,2022-04-01,"Sex: ALL; Age: >0 Days; Criteria: Inclusion Criteria:

* Women with documentation of fully breastfeeding who present within one month of delivery, who are 18-45 years old and in good general health will be eligible for participation.
...",No,2022-05-24,FDA-39467,0.56,0.15,3.5,4.21,2022-10-22,2022-12-16,2026-06-16,4,Bayer,29,South Africa,59.66666666666666,88,40,31,100,46,53,45,2,3,0,True,True,False,True,False,True,True,False,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Lucinactant delivered via investigational delivery device,GenName Y,Drug,MCNH,MCNH,Phase 2,2019-08-06,"Sex: ALL; Age: >26 Weeks; Criteria: Inclusion Criteria:

1. Signed informed consent form (ICF) from legally authorized representative
2. 26 0/7 to 32 6/7 completed weeks gestation PMA
3. Successful implementation of non-invasive support...",Yes,2019-12-02,FDA-89602,4.41,0.98,21.0,26.39,2024-01-02,2024-12-25,2045-12-25,43,Merck,29,South Africa,38.33333333333334,32,36,55,38,4,65,45,2,2,1,True,True,True,False,False,False,True,False,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
nCPAP,AltName B,Drug,MCNH,MCNH,Phase 2,2019-08-06,"Sex: ALL; Age: >26 Weeks; Criteria: Inclusion Criteria:

1. Signed informed consent form (ICF) from legally authorized representative
2. 26 0/7 to 32 6/7 completed weeks gestation PMA
3. Successful implementation of non-invasive support...",No,2019-11-17,FDA-98662,4.41,0.98,21.0,26.39,2024-01-02,2024-12-25,2045-12-25,91,J&J,13,Kenya,49.66666666666666,45,42,35,28,61,87,36,0,3,1,False,False,False,True,False,True,True,True,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Menitorix™,GenName Y,Biological,MCNH,MCNH,Phase 3,2008-12-30,"Sex: ALL; Age: >8 Weeks; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

All subjects must satisfy the following criteria at study entry:

* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements o...",Yes,2009-03-03,FDA-92784,2.62,0.32,5.0,7.94,2011-08-13,2011-12-08,2016-12-08,45,GSK,97,Overall,42.5,52,5,25,62,31,80,64,0,4,3,False,False,True,True,True,True,False,True,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Infanrix™ penta,Molecule Z,Biological,MCNH,MCNH,Phase 3,2008-12-30,"Sex: ALL; Age: >8 Weeks; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

All subjects must satisfy the following criteria at study entry:

* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements o...",Yes,2009-07-16,FDA-51577,2.62,0.32,5.0,7.94,2011-08-13,2011-12-08,2016-12-08,46,AstraZeneca,98,South Africa,54.16666666666666,89,81,43,32,4,76,27,0,0,3,False,False,False,False,False,False,False,True,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Prevenar™,AltName B,Biological,MCNH,MCNH,Phase 3,2008-12-30,"Sex: ALL; Age: >8 Weeks; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

All subjects must satisfy the following criteria at study entry:

* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements o...",Yes,2009-07-20,FDA-74681,2.62,0.32,5.0,7.94,2011-08-13,2011-12-08,2016-12-08,81,J&J,31,Kenya,54.83333333333334,77,43,92,18,81,18,64,1,3,3,True,False,False,False,True,True,True,True,True,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Infanrix™ IPV,AltName B,Biological,MCNH,MCNH,Phase 3,2008-12-30,"Sex: ALL; Age: >8 Weeks; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

All subjects must satisfy the following criteria at study entry:

* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements o...",No,2009-05-12,FDA-53620,2.62,0.32,5.0,7.94,2011-08-13,2011-12-08,2016-12-08,0,J&J,12,Overall,57.33333333333334,62,74,24,91,58,35,55,1,3,2,False,True,False,True,False,True,True,False,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
"Infasurf surfactant (ONY, Inc.)",GenName Y,Drug,MCNH,MCNH,Phase 3,2016-01-01,"Sex: ALL; Age: >7 Days; Criteria: Inclusion Criteria:

* \<=28 0/7 weeks gestational age
* Day of life 7-14
* Intubated and mechanically ventilated
* Plan to treat with inhaled nitric oxide

Exclusion Criteria:

* Serious congenital m...",Yes,2016-02-25,FDA-95297,2.62,0.32,5.0,7.94,2018-08-14,2018-12-09,2023-12-10,17,GSK,53,South Africa,58.83333333333334,21,29,69,99,36,99,55,1,2,3,True,False,True,False,False,True,False,True,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Sham (No Treatment),Comp Beta,Drug,MCNH,MCNH,Phase 3,2016-01-01,"Sex: ALL; Age: >7 Days; Criteria: Inclusion Criteria:

* \<=28 0/7 weeks gestational age
* Day of life 7-14
* Intubated and mechanically ventilated
* Plan to treat with inhaled nitric oxide

Exclusion Criteria:

* Serious congenital m...",No,2016-02-08,FDA-65738,2.62,0.32,5.0,7.94,2018-08-14,2018-12-09,2023-12-10,47,Merck,31,Kenya,32.83333333333334,26,36,57,77,1,0,45,1,2,2,False,True,False,True,False,True,False,False,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Caffeine,GenName Y,Drug,MCNH,MCNH,Phase 4,2014-05-01,"Sex: ALL; Criteria: Inclusion Criteria:

* Any infant delivered at Sharp Mary Birch Hospital between 23 and 28 6/7 weeks; gestation

Exclusion Criteria:

* Any infant with a major congenital anomaly including airway anom...",Yes,2014-09-16,FDA-13650,0.56,0.15,3.5,4.21,2014-11-21,2015-01-15,2018-07-16,98,AstraZeneca,98,South Africa,62.66666666666666,55,89,69,68,37,58,55,1,2,3,True,False,False,True,False,False,True,True,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Hydrocortisone,Comp Beta,Drug,MCNH,MCNH,Phase 3,2018-03-20,"Sex: ALL; Age: >34 Weeks; Criteria: Inclusion Criteria:

* Gestational age greater than or equal to 34 weeks at birth
* Admitted to the center NICU by 48 hours of age
* Intubated and mechanically ventilated for a minimum of 2 hours befo...",Yes,2018-05-28,FDA-21052,2.62,0.32,5.0,7.94,2020-10-31,2021-02-25,2026-02-26,56,J&J,55,Overall,53.0,26,49,46,53,68,76,36,0,2,2,False,False,True,False,False,True,False,False,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Darbepoetin,Molecule Z,Drug,MCNH,MCNH,Phase 3,2025-05-12,"Sex: ALL; Age: >1 Hour; Criteria: Inclusion Criteria:

* Inborn and outborn preterm infants
* 23 0/7-28 6/7 weeks gestational age
* ≤24 hours postnatal age

Exclusion Criteria:

* Hematocrit \> 60%
* Infants with known congenital or c...",No,2025-06-16,FDA-49127,2.62,0.32,5.0,7.94,2027-12-24,2028-04-19,2033-04-20,24,GSK,99,South Africa,22.16666666666667,13,3,32,12,44,29,45,1,2,2,True,False,False,True,False,True,False,False,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Aerosolized Normal Saline,GenName Y,Drug,MCNH,MCNH,Phase 2,2012-06-01,"Sex: ALL; Criteria: Inclusion Criteria:

* Gestational age less than or equal to 34 weeks
* Postnatal age less than or equal to 7 days (168 hours).
* Assisted ventilation for hypoxemic respiratory failure.
* Diagnosis of...",Yes,2013-01-10,FDA-68858,4.41,0.98,21.0,26.39,2016-10-28,2017-10-21,2038-10-21,49,Novartis,19,Overall,38.5,21,74,0,95,14,27,55,1,2,3,False,True,False,True,True,False,False,False,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Inhaled PGE1,GenName Y,Drug,MCNH,MCNH,Phase 2,2012-06-01,"Sex: ALL; Criteria: Inclusion Criteria:

* Gestational age less than or equal to 34 weeks
* Postnatal age less than or equal to 7 days (168 hours).
* Assisted ventilation for hypoxemic respiratory failure.
* Diagnosis of...",Yes,2013-01-13,FDA-10586,4.41,0.98,21.0,26.39,2016-10-28,2017-10-21,2038-10-21,93,AstraZeneca,66,Senegal,52.83333333333334,99,23,30,43,24,98,55,1,2,3,False,True,False,True,False,True,False,True,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Fenoldopam,Product Alpha,Drug,MCNH,MCNH,Phase 3,2020-01-31,"Sex: ALL; Age: >0 Days; Criteria: Inclusion Criteria:

1. Gestational age at birth 23 0/7 to 27 6/7 weeks by best obstetrical dating
2. No previous exposure to indomethacin
3. Clinical determination to use indomethacin to attempt clos...",Yes,2020-05-12,FDA-26234,2.62,0.32,5.0,7.94,2022-09-13,2023-01-08,2028-01-09,45,J&J,1,South Africa,55.83333333333334,24,6,93,81,78,53,45,1,1,3,True,False,True,False,False,False,False,False,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
0.9%NS,Comp Beta,Drug,MCNH,MCNH,Phase 3,2020-01-31,"Sex: ALL; Age: >0 Days; Criteria: Inclusion Criteria:

1. Gestational age at birth 23 0/7 to 27 6/7 weeks by best obstetrical dating
2. No previous exposure to indomethacin
3. Clinical determination to use indomethacin to attempt clos...",No,2020-05-17,FDA-25804,2.62,0.32,5.0,7.94,2022-09-13,2023-01-08,2028-01-09,57,Novartis,36,Kenya,45.66666666666666,19,23,55,15,79,83,36,0,2,2,False,False,False,False,True,False,True,True,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
NSIPPV,Product Alpha,Device,MCNH,MCNH,Phase 3,2012-12-01,"Sex: ALL; Criteria: Inclusion Criteria:

* All inborn VLBW infants (birthweight less than 1500 g and Gestational Age \< 32 wks) with signs of RDS, spontaneously breathing and only supported by N-CPAP, will be randomized ...",Yes,2013-02-16,FDA-85112,2.62,0.32,5.0,7.94,2015-07-15,2015-11-09,2020-11-09,58,GSK,18,South Africa,56.33333333333334,87,65,77,47,37,25,27,1,1,1,True,False,True,False,False,False,False,False,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
BiPAP,Comp Beta,Device,MCNH,MCNH,Phase 3,2012-12-01,"Sex: ALL; Criteria: Inclusion Criteria:

* All inborn VLBW infants (birthweight less than 1500 g and Gestational Age \< 32 wks) with signs of RDS, spontaneously breathing and only supported by N-CPAP, will be randomized ...",No,2013-02-14,FDA-60621,2.62,0.32,5.0,7.94,2015-07-15,2015-11-09,2020-11-09,85,Gilead,55,South Africa,48.16666666666666,100,26,39,37,24,63,55,1,3,2,False,True,True,False,True,False,True,True,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Dornase alfa,TradeName X,Drug,MCNH,MCNH,Phase 4,2017-04-30,"Sex: ALL; Age: >7 Days; Criteria: Inclusion Criteria:

* infants less than 38 weeks gestation and over 7 days of age
* infants with a ventilator associated pulmonary infection, defined as intubated infants who have moderate to heavy W...",Yes,2017-06-29,FDA-94166,0.56,0.15,3.5,4.21,2017-11-20,2018-01-14,2021-07-15,63,Novartis,87,Senegal,45.66666666666666,15,42,24,84,58,51,55,1,2,3,False,True,True,True,False,False,False,True,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Metaclopramide,Product Alpha,Drug,MCNH,MCNH,Phase 3,2008-03-01,"Sex: ALL; Age: >1 Month; Criteria: Inclusion Criteria:

* Premature infants \< 37 weeks gestation at birth; currently less than 44 weeks postmenstrual age.
* Not currently receiving mechanical ventilation
* Clinical diagnosis of GER an...",No,2008-09-05,FDA-55452,2.62,0.32,5.0,7.94,2010-10-13,2011-02-07,2016-02-08,34,Bayer,61,Kenya,38.16666666666666,93,47,34,21,8,26,45,1,3,1,True,False,False,False,True,True,True,False,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Ranitidine,AltName B,Drug,MCNH,MCNH,Phase 3,2008-03-01,"Sex: ALL; Age: >1 Month; Criteria: Inclusion Criteria:

* Premature infants \< 37 weeks gestation at birth; currently less than 44 weeks postmenstrual age.
* Not currently receiving mechanical ventilation
* Clinical diagnosis of GER an...",No,2009-01-28,FDA-52690,2.62,0.32,5.0,7.94,2010-10-13,2011-02-07,2016-02-08,87,Pfizer,67,Senegal,51.33333333333334,85,23,4,96,11,89,27,1,1,1,False,True,False,False,True,False,False,False,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
CHF5633,GenName Y,Drug,MCNH,MCNH,Phase 2,2018-05-24,"Sex: ALL; Age: >1 Hour; Criteria: Inclusion Criteria:

1. Written informed consent obtained by parents/legal representative (according to local regulation) prior to any study-related procedures
2. Inborn preterm neonates of either sex...",No,2018-07-20,FDA-92059,4.41,0.98,21.0,26.39,2022-10-20,2023-10-13,2044-10-12,41,AstraZeneca,36,South Africa,52.83333333333334,94,26,8,77,54,58,45,1,2,2,False,True,True,False,False,True,False,False,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Poractant alfa,AltName B,Drug,MCNH,MCNH,Phase 2,2018-05-24,"Sex: ALL; Age: >1 Hour; Criteria: Inclusion Criteria:

1. Written informed consent obtained by parents/legal representative (according to local regulation) prior to any study-related procedures
2. Inborn preterm neonates of either sex...",Yes,2018-11-03,FDA-67891,4.41,0.98,21.0,26.39,2022-10-20,2023-10-13,2044-10-12,20,Sanofi,99,Kenya,62.33333333333334,9,82,99,99,32,53,45,1,2,2,True,False,False,False,True,False,True,False,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
NSAID,Product Alpha,Drug,MCNH,MCNH,Phase 2,2017-06-01,"Sex: ALL; Age: >5 Days; Criteria: Inclusion Criteria:

This will be a prospective randomized, multi-center, controlled trial that will enroll infants delivered between 23 \& 0/7 - 27 \& 6/7 weeks gestation:

1. infants must be between...",Yes,2018-03-09,FDA-21657,4.41,0.98,21.0,26.39,2021-10-28,2022-10-21,2043-10-21,11,Pfizer,93,Senegal,56.83333333333334,92,10,92,69,78,0,36,2,0,2,True,True,False,False,False,False,False,True,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
pantoprazole,Product Alpha,Drug,MCNH,MCNH,Phase 3,2007-12-01,"Sex: ALL; Age: >1 Day; Criteria: Inclusion Criteria:

* Hospitalized patients
* Presumed diagnosis of GERD
* Term or post-term infants within the neonatal period less than 28 days or preterm infants with a corrected gestational age o...",Yes,2008-07-09,FDA-90429,2.62,0.32,5.0,7.94,2010-07-14,2010-11-08,2015-11-09,16,Bayer,36,Overall,80.33333333333333,76,36,91,95,99,85,45,1,2,2,False,True,True,False,True,False,False,False,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Caffeine Citrate,Product Alpha,Drug,MCNH,MCNH,Phase 3,2023-03-20,"Sex: ALL; Age: >29 Weeks; Criteria: Inclusion Criteria:

* Inborn and outborn infants of 29 0/7 to 33 6/7 weeks gestational age at birth
* admitted to hospitals of the NICHD NRN who, are at time of enrollment:
* ≤35 6/7 weeks post-menst...",No,2023-09-14,FDA-65124,2.62,0.32,5.0,7.94,2025-10-31,2026-02-25,2031-02-26,81,GSK,82,South Africa,45.83333333333334,6,33,3,60,80,93,45,2,1,2,True,True,False,False,False,False,True,False,True,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Suptavumab 30 mg/kg,Product Alpha,Drug,MCNH,MCNH,Phase 3,2017-09-26,"Sex: ALL; Healthy Volunteers: Yes; Criteria: Key Inclusion Criteria:

1. Preterm, otherwise healthy male or female infant who is ≤6 months of age at the time of the first dose (i.e., infant must be treated on or before their 6 month birthday)
2....",No,2018-08-17,FDA-27525,2.62,0.32,5.0,7.94,2020-05-09,2020-09-03,2025-09-04,55,AstraZeneca,38,Senegal,57.83333333333334,45,43,45,89,51,74,55,2,2,2,True,True,False,True,False,False,True,True,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Suptavumab 30 mg/kg- 1 Dose,AltName B,Drug,MCNH,MCNH,Phase 3,2017-09-26,"Sex: ALL; Healthy Volunteers: Yes; Criteria: Key Inclusion Criteria:

1. Preterm, otherwise healthy male or female infant who is ≤6 months of age at the time of the first dose (i.e., infant must be treated on or before their 6 month birthday)
2....",Yes,2018-05-23,FDA-10709,2.62,0.32,5.0,7.94,2020-05-09,2020-09-03,2025-09-04,9,Pfizer,31,Senegal,58.0,52,95,43,51,59,48,45,1,4,0,False,True,True,True,True,False,True,False,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Suptavumab 30 mg/kg - 2 Doses,AltName B,Drug,MCNH,MCNH,Phase 3,2017-09-26,"Sex: ALL; Healthy Volunteers: Yes; Criteria: Key Inclusion Criteria:

1. Preterm, otherwise healthy male or female infant who is ≤6 months of age at the time of the first dose (i.e., infant must be treated on or before their 6 month birthday)
2....",No,2018-07-10,FDA-61083,2.62,0.32,5.0,7.94,2020-05-09,2020-09-03,2025-09-04,82,GSK,63,Overall,36.83333333333334,72,4,9,72,2,62,36,1,1,2,False,True,False,False,False,True,False,True,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
inhaled nitric oxide,AltName A,Drug,MCNH,MCNH,Phase 2,2023-10-09,"Sex: ALL; Age: >23 Weeks; Criteria: Inclusion Criteria:

Step 1:

* Birth between 23 weeks and 0 days and 29 weeks and 6 days.
* Positive pressure ventilation at 72-96 hours of age

Step 2:

* Early pulmonary hypertension

Exclusion Cri...",No,2024-04-09,FDA-70984,4.41,0.98,21.0,26.39,2028-03-06,2029-02-27,2050-02-27,77,J&J,81,Senegal,52.16666666666666,91,10,66,15,55,76,27,1,1,1,True,False,False,False,True,False,False,False,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
MEDI8897,Product Alpha,Drug,MCNH,MCNH,Phase 2,2018-12-06,"Sex: ALL; Healthy Volunteers: Yes; Criteria: Key Inclusion Criteria:

1. Healthy infants born between 29 weeks 0 days and 34 weeks 6 days GA.
2. Infants who are entering their first full RSV season at the time of screening.

Key Exclusion Criter...",Yes,2019-10-31,FDA-38994,4.41,0.98,21.0,26.39,2023-05-04,2024-04-26,2045-04-26,53,GSK,0,Overall,38.33333333333334,48,22,40,29,74,17,64,1,5,1,False,True,True,True,True,True,True,False,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
nCPAP alone,GenName Y,Device,MCNH,MCNH,Phase 2,2017-08-11,"Sex: ALL; Age: >26 Weeks; Criteria: Inclusion Criteria:

1. Informed consent from a legally authorized representative.
2. Gestational age 26 to 28 completed weeks post menstrual age (PMA).
3. Successful implementation of controlled nCPA...",No,2018-04-03,FDA-98116,4.41,0.98,21.0,26.39,2022-01-07,2022-12-31,2043-12-31,61,Sanofi,83,Kenya,66.83333333333333,86,32,93,72,26,92,55,1,2,3,False,True,False,True,False,True,False,False,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
levetiracetam,Molecule Z,Drug,MCNH,MCNH,Phase 2,2011-07-01,"Sex: ALL; Age: >1 Day; Criteria: Inclusion Criteria:

* Gestational age ≥ 32 weeks
* Postnatal age ≤ 30 days
* Birth weight ≥ 2000 grams
* Admitted to the Neonatal Intensive Care Unit at Cincinnati Children's Hospital
* Clinical or e...",Yes,2011-10-17,FDA-48985,4.41,0.98,21.0,26.39,2015-11-27,2016-11-19,2037-11-19,14,Merck,67,Senegal,45.66666666666666,64,33,31,62,55,29,82,2,3,4,True,True,True,True,False,False,True,True,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Lucinactant for Inhalation,AltName B,Drug,MCNH,MCNH,Phase 2,2015-11-01,"Sex: ALL; Age: >29 Weeks; Criteria: Inclusion Criteria:

* Informed consent from a legally authorized representative
* Gestational age 29 to 34 completed weeks (34 weeks 6 days) post menstrual age (PMA)
* Successful implementation of co...",Yes,2015-12-19,FDA-32107,4.41,0.98,21.0,26.39,2020-03-29,2021-03-22,2042-03-22,73,Merck,74,Kenya,43.16666666666666,71,79,3,40,58,8,64,2,2,3,True,True,False,True,True,False,False,True,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
nCPAP alone,AltName B,Device,MCNH,MCNH,Phase 2,2015-11-01,"Sex: ALL; Age: >29 Weeks; Criteria: Inclusion Criteria:

* Informed consent from a legally authorized representative
* Gestational age 29 to 34 completed weeks (34 weeks 6 days) post menstrual age (PMA)
* Successful implementation of co...",Yes,2016-10-09,FDA-63738,4.41,0.98,21.0,26.39,2020-03-29,2021-03-22,2042-03-22,54,Bayer,63,South Africa,49.66666666666666,26,54,0,76,53,89,27,0,3,0,False,False,False,True,True,True,False,False,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Dexmedetomidine,Comp Beta,Drug,MCNH,MCNH,Phase 3,2012-05-01,"Sex: ALL; Age: >28 Weeks; Criteria: Inclusion Criteria:

1. Initially intubated and mechanically ventilated pediatric subjects in an intensive care setting anticipated to require at least 6 hours of continuous IV sedation.
2. Age: subje...",No,2012-08-13,FDA-57520,2.62,0.32,5.0,7.94,2014-12-13,2015-04-09,2020-04-09,62,Sanofi,93,South Africa,19.83333333333333,24,16,4,41,27,7,45,1,2,2,True,False,False,False,True,False,True,True,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Midazolam,AltName B,Drug,MCNH,MCNH,Phase 3,2012-05-01,"Sex: ALL; Age: >28 Weeks; Criteria: Inclusion Criteria:

1. Initially intubated and mechanically ventilated pediatric subjects in an intensive care setting anticipated to require at least 6 hours of continuous IV sedation.
2. Age: subje...",No,2013-01-19,FDA-60788,2.62,0.32,5.0,7.94,2014-12-13,2015-04-09,2020-04-09,81,Novartis,52,Kenya,56.0,61,39,89,14,41,92,45,0,2,3,False,False,False,True,False,False,True,True,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Fentanyl,AltName B,Drug,MCNH,MCNH,Phase 3,2012-05-01,"Sex: ALL; Age: >28 Weeks; Criteria: Inclusion Criteria:

1. Initially intubated and mechanically ventilated pediatric subjects in an intensive care setting anticipated to require at least 6 hours of continuous IV sedation.
2. Age: subje...",Yes,2012-08-28,FDA-89486,2.62,0.32,5.0,7.94,2014-12-13,2015-04-09,2020-04-09,32,Gilead,14,Kenya,49.16666666666666,88,20,64,37,69,17,73,0,5,3,False,False,True,True,True,True,True,True,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Morphine,Molecule Z,Drug,MCNH,MCNH,Phase 3,2012-05-01,"Sex: ALL; Age: >28 Weeks; Criteria: Inclusion Criteria:

1. Initially intubated and mechanically ventilated pediatric subjects in an intensive care setting anticipated to require at least 6 hours of continuous IV sedation.
2. Age: subje...",No,2012-08-17,FDA-70385,2.62,0.32,5.0,7.94,2014-12-13,2015-04-09,2020-04-09,98,J&J,85,Kenya,64.16666666666667,55,24,87,40,97,82,64,2,2,3,True,True,True,False,True,False,False,True,False,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
intravenous lipid,Product Alpha,Drug,MCNH,MCNH,Phase 3,2019-01-31,"Sex: ALL; Criteria: Inclusion Criteria:

All neonates ≥ 34 weeks gestational age with major GI surgical disorders (Gastroschisis, omphalocele, volvulus, trachea-esophageal fistula, duodenal atresia, jejunal atresia, ilea...",Yes,2019-12-01,FDA-94306,2.62,0.32,5.0,7.94,2021-09-13,2022-01-08,2027-01-09,70,Pfizer,46,Senegal,62.5,99,13,77,59,72,55,82,1,4,4,False,True,True,True,True,True,False,True,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
"Motavizumab, palivizumab",TradeName X,Biological,MCNH,MCNH,Phase 2,2007-02-01,"Sex: ALL; Criteria: Inclusion Criteria:

* The child must have been born at less than or equal to 35 weeks gestation and be less than or equal to 6 months of age at the time of entry into the study (child must be entered...",No,2007-12-16,FDA-14988,4.41,0.98,21.0,26.39,2011-06-30,2012-06-22,2033-06-22,26,Bayer,61,Senegal,37.0,28,38,26,38,58,34,36,1,2,1,True,False,True,True,False,False,False,False,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
"Palivizumab, motavizumab",Comp Beta,Biological,MCNH,MCNH,Phase 2,2007-02-01,"Sex: ALL; Criteria: Inclusion Criteria:

* The child must have been born at less than or equal to 35 weeks gestation and be less than or equal to 6 months of age at the time of entry into the study (child must be entered...",Yes,2007-07-26,FDA-87560,4.41,0.98,21.0,26.39,2011-06-30,2012-06-22,2033-06-22,11,Novartis,62,Kenya,52.16666666666666,46,41,67,20,93,46,64,1,4,2,True,False,True,True,True,False,True,True,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Motavizumab,TradeName X,Biological,MCNH,MCNH,Phase 2,2007-02-01,"Sex: ALL; Criteria: Inclusion Criteria:

* The child must have been born at less than or equal to 35 weeks gestation and be less than or equal to 6 months of age at the time of entry into the study (child must be entered...",No,2007-04-01,FDA-65073,4.41,0.98,21.0,26.39,2011-06-30,2012-06-22,2033-06-22,93,AstraZeneca,12,Overall,60.33333333333334,27,73,88,33,44,97,45,2,2,1,True,True,False,True,False,True,False,False,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
MEDI8897,AltName A,Drug,MCNH,MCNH,Phase 3,2023-03-21,"Sex: ALL; Age: >0 Years; Healthy Volunteers: Yes; Criteria: Key Inclusion Criteria:

* Healthy infants in their first year of life and born at or after 35 weeks 0 days GA
* Infants who are entering their first RSV season at the time of screening

Key Exclusion...",Yes,2023-05-03,FDA-31481,2.62,0.32,5.0,7.94,2025-11-01,2026-02-26,2031-02-27,99,Novartis,46,South Africa,36.66666666666666,33,29,22,63,72,1,64,1,4,2,True,False,False,True,True,True,True,True,False,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
acetylsalicylic acid,AltName A,Drug,MCNH,MCNH,Phase 3,2025-01-23,"Sex: FEMALE; Age: >18 Years; Criteria: Patients are currently only being enrolled at the New York Presbyterian Weill Cornell Medicine and at the New York Presbyterian Queens campuses.

Inclusion Criteria:

Pregnant patients, ≥18 years old,...",No,2025-09-11,FDA-18910,2.62,0.32,5.0,7.94,2027-09-06,2028-01-01,2033-01-01,17,Pfizer,97,Senegal,64.66666666666667,46,61,77,69,97,38,45,1,3,1,False,True,False,True,True,False,True,False,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
"Bupivacaine, Dexmedetomidine, Caffeine, Tylenol",Comp Beta,Drug,MCNH,MCNH,Phase 4,2018-03-08,"Sex: ALL; Age: >23 Weeks; Criteria: Inclusion Criteria:

* Preterm infants less than 60 weeks post gestational age born at less than 37 weeks gestational age.
* Patients in the NICU will meet discharge criteria with or without supplemen...",No,2018-10-30,FDA-24699,0.56,0.15,3.5,4.21,2018-09-28,2018-11-22,2022-05-23,75,Gilead,78,South Africa,50.66666666666666,10,46,80,87,74,7,45,1,3,1,False,True,True,False,False,True,True,False,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
"Propofol, rocuronium, caffeine, Tylenol, bupivacaine",Product Alpha,Drug,MCNH,MCNH,Phase 4,2018-03-08,"Sex: ALL; Age: >23 Weeks; Criteria: Inclusion Criteria:

* Preterm infants less than 60 weeks post gestational age born at less than 37 weeks gestational age.
* Patients in the NICU will meet discharge criteria with or without supplemen...",Yes,2018-05-19,FDA-62354,0.56,0.15,3.5,4.21,2018-09-28,2018-11-22,2022-05-23,30,Bayer,66,Senegal,41.33333333333334,19,26,26,27,51,99,91,2,5,3,True,True,True,True,True,True,True,True,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Curosurf through conventional administration (endotracheal tube),Molecule Z,Drug,MCNH,MCNH,Phase 3,2022-08-13,"Sex: ALL; Age: >30 Minutes; Criteria: Inclusion Criteria:

1. Written informed consent obtained by parents/legal representative (according to local regulation) prior to or after birth
2. Preterm neonates of either sex aged ≥30 minutes and...",No,2022-10-05,FDA-34032,2.62,0.32,5.0,7.94,2025-03-26,2025-07-21,2030-07-22,19,GSK,61,Kenya,35.5,65,66,11,7,23,41,55,1,2,3,False,True,False,True,False,False,True,True,True,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
atropine+ propofol,AltName B,Drug,MCNH,MCNH,Phase 3,2020-04-15,"Sex: ALL; Criteria: Inclusion Criteria:

* Corrected age \< 45 weeks of gestational age
* Currently hospitalized in a neonatal intensive care unit
* Requiring semi-urgent or elective intubation
* Equipped with a reliable...",No,2021-03-13,FDA-90497,2.62,0.32,5.0,7.94,2022-11-27,2023-03-24,2028-03-24,51,Gilead,19,South Africa,44.33333333333334,33,39,22,63,42,67,45,1,3,1,True,False,True,True,False,False,True,False,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
atropine + atracurium + sufentanil,AltName A,Drug,MCNH,MCNH,Phase 3,2020-04-15,"Sex: ALL; Criteria: Inclusion Criteria:

* Corrected age \< 45 weeks of gestational age
* Currently hospitalized in a neonatal intensive care unit
* Requiring semi-urgent or elective intubation
* Equipped with a reliable...",Yes,2020-11-18,FDA-51167,2.62,0.32,5.0,7.94,2022-11-27,2023-03-24,2028-03-24,22,Merck,28,Kenya,68.0,85,76,27,92,76,52,36,1,2,1,False,True,False,False,True,False,True,True,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Nirsevimab,AltName B,Biological,MCNH,MCNH,Phase 3,2025-04-09,"Sex: ALL; Age: >0 Days; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Born at ≥ 29 weeks gestational age and aged 0 to 12 months (calendar age), who entered their first RSV season on the day of inclusion in the study (D01)
* Informed consent form ...",Yes,2025-09-01,FDA-92402,2.62,0.32,5.0,7.94,2027-11-21,2028-03-17,2033-03-18,7,J&J,19,Senegal,46.5,85,18,80,14,17,65,64,2,3,2,True,True,False,False,True,True,True,True,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
MEDI8897,AltName B,Drug,MCNH,MCNH,Phase 3,2023-01-20,"Sex: ALL; Age: >0 Years; Criteria: Inclusion criteria

1. For the preterm cohort (excluding subjects with CLD or hemodynamically significant CHD): preterm infants in their first year of life and born ≤ 35 weeks 0 days GA eligible to re...",Yes,2023-08-14,FDA-91517,2.62,0.32,5.0,7.94,2025-09-02,2025-12-28,2030-12-29,64,Novartis,72,South Africa,61.66666666666666,11,25,92,55,87,100,45,2,2,1,True,True,True,False,True,False,False,True,False,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Palivizumab,Product Alpha,Drug,MCNH,MCNH,Phase 3,2023-01-20,"Sex: ALL; Age: >0 Years; Criteria: Inclusion criteria

1. For the preterm cohort (excluding subjects with CLD or hemodynamically significant CHD): preterm infants in their first year of life and born ≤ 35 weeks 0 days GA eligible to re...",Yes,2023-08-13,FDA-60947,2.62,0.32,5.0,7.94,2025-09-02,2025-12-28,2030-12-29,66,GSK,91,Overall,44.0,58,59,24,64,22,37,55,0,4,2,False,False,True,True,True,True,False,False,True,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Clinolipid,GenName Y,Drug,MCNH,MCNH,Phase 4,2022-11-16,"Sex: ALL; Age: >0 Years; Criteria: Inclusion Criteria:

1. Patients and/or their legal representative must be able to understand the study and voluntarily sign the informed consent form (ICF) per 21 CFR Part 50.55(e)
2. Patients and/or...",No,2023-02-16,FDA-59393,0.56,0.15,3.5,4.21,2023-06-08,2023-08-02,2027-01-31,35,J&J,74,Overall,45.66666666666666,21,92,10,27,82,42,55,2,2,2,True,True,True,False,True,False,False,True,False,False,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Intralipid,AltName A,Drug,MCNH,MCNH,Phase 4,2022-11-16,"Sex: ALL; Age: >0 Years; Criteria: Inclusion Criteria:

1. Patients and/or their legal representative must be able to understand the study and voluntarily sign the informed consent form (ICF) per 21 CFR Part 50.55(e)
2. Patients and/or...",No,2023-07-26,FDA-90566,0.56,0.15,3.5,4.21,2023-06-08,2023-08-02,2027-01-31,22,GSK,84,South Africa,59.0,91,59,29,43,34,98,73,2,4,2,True,True,True,True,True,False,True,True,True,False,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Clinolipid,Comp Beta,Drug,MCNH,MCNH,Phase 4,2016-10-01,"Sex: ALL; Criteria: Inclusion Criteria:

1. Patients and/or their legal representative must be able to understand the study and voluntarily sign the ICF
2. Patients age \<18 years
3. Patients who are able to adhere to pr...",No,2017-04-27,FDA-51952,0.56,0.15,3.5,4.21,2017-04-23,2017-06-17,2020-12-16,1,J&J,38,Overall,37.16666666666666,4,90,16,12,7,94,73,1,3,4,False,True,False,True,True,False,True,True,True,True,True,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Intralipid,AltName B,Drug,MCNH,MCNH,Phase 4,2016-10-01,"Sex: ALL; Criteria: Inclusion Criteria:

1. Patients and/or their legal representative must be able to understand the study and voluntarily sign the ICF
2. Patients age \<18 years
3. Patients who are able to adhere to pr...",Yes,2017-01-27,FDA-79364,0.56,0.15,3.5,4.21,2017-04-23,2017-06-17,2020-12-16,1,Novartis,21,Kenya,35.83333333333334,65,59,21,3,43,24,64,1,3,3,True,False,False,True,True,False,True,True,True,True,False,HorizonScan_preterm_birth_20251207_Harmonized.xlsx
Ceftobiprole medocaril,AltName A,Drug,MCNH,MCNH,Phase 3,2024-12-18,"Sex: ALL; Age: >3 Days; Criteria: Key Inclusion Criteria:

* Informed consent from parent(s) or other legally acceptable representative (LAR) to participate in the study
* Male or female, with a gestational age of ≥ 24 weeks and a pos...",Yes,2025-08-13,FDA-65074,2.62,0.32,5.0,7.94,2027-08-01,2027-11-26,2032-11-26,90,GSK,17,Senegal,31.66666666666667,88,18,17,42,19,6,36,1,1,2,False,True,False,False,False,True,False,True,True,False,False,HorizonScan_sepsis__neonatal_20251207_Harmonized.xlsx
Chlorhexidine gluconate (4%),Molecule Z,Drug,MCNH,MCNH,Phase 3,2013-09-01,"Sex: ALL; Age: >15 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Pregnant women in the 2nd or 3rd trimester
* Age 15 years and above
* Pregnant women who plan to stay in the study area (catchment area of the health facility) for delivery and ...",No,2014-05-11,FDA-85520,2.62,0.32,5.0,7.94,2016-04-14,2016-08-09,2021-08-10,96,AstraZeneca,90,Senegal,59.66666666666666,84,92,47,30,85,20,27,1,2,0,False,True,True,True,False,False,False,False,False,False,False,HorizonScan_sepsis__neonatal_20251207_Harmonized.xlsx
Azithromycin,AltName B,Drug,MCNH,MCNH,Phase 3,2022-09-30,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Pregnant women in labor ≥28 weeks Gestational Age (GA) (by best estimate) with a pregnancy with one or more live fetuses who plan to deliver vaginally in a facility.
* Admitted ...",No,2023-05-02,FDA-64686,2.62,0.32,5.0,7.94,2025-05-13,2025-09-07,2030-09-08,50,Novartis,60,Kenya,60.16666666666666,63,48,50,55,66,79,64,2,4,1,True,True,True,True,True,True,False,False,True,False,False,HorizonScan_sepsis__neonatal_20251207_Harmonized.xlsx
Pagibaximab 50 mg/mL,AltName A,Drug,MCNH,MCNH,Phase 3,2011-05-01,"Sex: ALL; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. In-patient at a Neonatal Intensive Care Unit (NICU)
2. Informed consent obtained from the legally authorized representative
3. Less than 48 hours old at the time of first infus...",Yes,2011-11-18,FDA-76430,2.62,0.32,5.0,7.94,2013-12-12,2014-04-08,2019-04-09,26,Gilead,93,Senegal,49.66666666666666,53,69,63,14,65,34,73,2,4,2,True,True,True,True,True,False,True,False,True,True,False,HorizonScan_sepsis__neonatal_20251207_Harmonized.xlsx
Ceftaroline Fosamil,AltName B,Drug,MCNH,MCNH,Phase 2,2017-12-26,"Sex: ALL; Age: >7 Days; Criteria: Inclusion Criteria:

* Informed consent in writing from parent(s) or other legally-acceptable representative(s);
* Male or female, gestational age ≥34 weeks, and chronological age 7 to \<60 days at th...",No,2018-10-18,FDA-32391,4.41,0.98,21.0,26.39,2022-05-24,2023-05-17,2044-05-16,11,J&J,52,Overall,26.83333333333333,12,35,74,18,9,13,82,1,4,4,True,False,True,False,True,True,True,True,True,True,True,HorizonScan_sepsis__neonatal_20251207_Harmonized.xlsx
Ampicillin,Molecule Z,Drug,MCNH,MCNH,Phase 2,2017-12-26,"Sex: ALL; Age: >7 Days; Criteria: Inclusion Criteria:

* Informed consent in writing from parent(s) or other legally-acceptable representative(s);
* Male or female, gestational age ≥34 weeks, and chronological age 7 to \<60 days at th...",Yes,2018-10-01,FDA-79523,4.41,0.98,21.0,26.39,2022-05-24,2023-05-17,2044-05-16,35,Gilead,87,Senegal,52.5,23,22,59,71,75,65,45,1,3,1,False,True,False,True,False,True,True,False,False,True,False,HorizonScan_sepsis__neonatal_20251207_Harmonized.xlsx
Aminoglycoside,Molecule Z,Drug,MCNH,MCNH,Phase 2,2017-12-26,"Sex: ALL; Age: >7 Days; Criteria: Inclusion Criteria:

* Informed consent in writing from parent(s) or other legally-acceptable representative(s);
* Male or female, gestational age ≥34 weeks, and chronological age 7 to \<60 days at th...",Yes,2018-05-05,FDA-41626,4.41,0.98,21.0,26.39,2022-05-24,2023-05-17,2044-05-16,15,Merck,11,South Africa,40.66666666666666,67,36,24,34,72,11,45,0,2,3,False,False,False,False,True,True,False,True,True,False,True,HorizonScan_sepsis__neonatal_20251207_Harmonized.xlsx
Antibiotic,Comp Beta,Drug,MCNH,MCNH,Phase 2,2019-09-11,"Sex: ALL; Age: >23 Weeks; Criteria: Inclusion Criteria:

* All infants less than 33 weeks gestation.

Exclusion Criteria:

* Infants who are non-viable at birth....",Yes,2020-07-13,FDA-85523,4.41,0.98,21.0,26.39,2024-02-07,2025-01-30,2046-01-30,45,Pfizer,93,Kenya,58.16666666666666,52,15,61,99,92,30,18,0,1,1,False,False,False,False,False,True,False,False,False,True,False,HorizonScan_sepsis__neonatal_20251207_Harmonized.xlsx
Antibiotics,Comp Beta,Drug,MCNH,MCNH,Phase 2,2019-09-11,"Sex: ALL; Age: >23 Weeks; Criteria: Inclusion Criteria:

* All infants less than 33 weeks gestation.

Exclusion Criteria:

* Infants who are non-viable at birth....",No,2020-02-19,FDA-59569,4.41,0.98,21.0,26.39,2024-02-07,2025-01-30,2046-01-30,94,GSK,6,Overall,47.83333333333334,27,57,26,51,49,77,36,0,2,2,False,False,True,False,False,False,True,False,False,True,True,HorizonScan_sepsis__neonatal_20251207_Harmonized.xlsx
micafungin,GenName Y,Drug,MCNH,MCNH,Phase 3,2014-12-01,"Sex: ALL; Age: >48 Hours; Criteria: Inclusion Criteria:

* Infant greater than 48 hours of life after birth up to day of life 120 at the time of culture acquisition
* Diagnosis of proven invasive candidiasis within 4 days prior to study...",Yes,2015-11-09,FDA-34825,2.62,0.32,5.0,7.94,2017-07-14,2017-11-08,2022-11-09,37,Novartis,80,Overall,69.33333333333333,91,60,78,47,78,62,55,2,3,1,True,True,True,True,True,False,False,False,True,False,False,HorizonScan_sepsis__neonatal_20251207_Harmonized.xlsx
amphotericin B deoxycholate,TradeName X,Drug,MCNH,MCNH,Phase 3,2014-12-01,"Sex: ALL; Age: >48 Hours; Criteria: Inclusion Criteria:

* Infant greater than 48 hours of life after birth up to day of life 120 at the time of culture acquisition
* Diagnosis of proven invasive candidiasis within 4 days prior to study...",Yes,2015-09-15,FDA-37473,2.62,0.32,5.0,7.94,2017-07-14,2017-11-08,2022-11-09,30,GSK,72,Overall,69.83333333333333,63,100,27,63,97,69,73,2,3,3,True,True,True,False,True,True,False,True,True,True,False,HorizonScan_sepsis__neonatal_20251207_Harmonized.xlsx
Isoniazid,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 2,2020-12-01,"Sex: ALL; Age: >6 Weeks; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* HIV exposed infants
* Aged 6 weeks within (+ 4 weeks)
* Born to HIV-infected mothers
* Not premature and over 2.5 kg

Exclusion Criteria:

* Infants with known exposure to activ...",No,2021-03-28,FDA-24673,4.41,0.98,21.0,26.39,2025-04-29,2026-04-22,2047-04-22,70,AstraZeneca,28,South Africa,20.5,1,5,46,45,4,22,36,0,1,3,False,False,True,False,False,False,False,False,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
isoniazid and rifapentine,GenName Y,Drug,tuberculosis,tuberculosis,Phase 3,2014-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Males and non-pregnant, non-nursing females
* Age \> 18 years
* Weight \> 45kg and considered appropriate to receive RPT 900mg and INH 900mg once weekly by the local site invest...",Yes,2015-05-22,FDA-34161,2.62,0.32,5.0,7.94,2017-05-14,2017-09-08,2022-09-09,67,Gilead,11,Senegal,36.83333333333334,11,18,95,17,27,53,45,1,1,3,True,False,False,False,True,False,False,True,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
BCG vaccine SSI,GenName Y,Biological,tuberculosis,tuberculosis,Phase 2,2024-05-14,"Sex: ALL; Age: >10 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Participant between ≥ 10 years and ≤ 18 years on Study Day 1
* General good health, confirmed by medical history and physical examination
* Vaccinated with Bacille Calmette Guer...",No,2024-09-28,FDA-25399,4.41,0.98,21.0,26.39,2028-10-10,2029-10-03,2050-10-03,51,J&J,8,Kenya,43.5,65,42,47,20,10,77,73,1,4,3,False,True,True,True,True,False,True,True,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative,AltName B,Biological,tuberculosis,tuberculosis,Phase 2,2014-08-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria of healthy subjects:

1. 18 to 65 years old
2. Consent and signed ICF(informed consent forms)
3. Comply with follow-up
4. No history or family history of TB(tuberculosis)
5. Without...",Yes,2014-11-29,FDA-19218,4.41,0.98,21.0,26.39,2018-12-28,2019-12-21,2040-12-20,87,AstraZeneca,7,Kenya,59.33333333333334,50,19,20,81,90,96,36,2,1,1,True,True,False,False,False,True,False,False,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative,Product Alpha,Biological,tuberculosis,tuberculosis,Phase 2,2014-08-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria of healthy subjects:

1. 18 to 65 years old
2. Consent and signed ICF(informed consent forms)
3. Comply with follow-up
4. No history or family history of TB(tuberculosis)
5. Without...",Yes,2015-03-17,FDA-63723,4.41,0.98,21.0,26.39,2018-12-28,2019-12-21,2040-12-20,19,AstraZeneca,73,Overall,41.33333333333334,71,10,2,50,88,27,36,2,0,2,True,True,False,False,False,False,False,True,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative,Molecule Z,Biological,tuberculosis,tuberculosis,Phase 2,2014-08-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria of healthy subjects:

1. 18 to 65 years old
2. Consent and signed ICF(informed consent forms)
3. Comply with follow-up
4. No history or family history of TB(tuberculosis)
5. Without...",No,2014-11-25,FDA-26846,4.41,0.98,21.0,26.39,2018-12-28,2019-12-21,2040-12-20,75,Bayer,31,Overall,47.5,37,69,44,32,50,53,45,2,1,2,True,True,False,False,False,True,False,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative,GenName Y,Biological,tuberculosis,tuberculosis,Phase 2,2014-08-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria of healthy subjects:

1. 18 to 65 years old
2. Consent and signed ICF(informed consent forms)
3. Comply with follow-up
4. No history or family history of TB(tuberculosis)
5. Without...",Yes,2015-06-25,FDA-19316,4.41,0.98,21.0,26.39,2018-12-28,2019-12-21,2040-12-20,3,J&J,83,Kenya,56.0,91,95,23,72,6,49,64,2,3,2,True,True,True,False,True,True,False,False,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Ethambutol,AltName B,Drug,tuberculosis,tuberculosis,Phase 3,2008-11-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

-Adults, male or female, aged 18-60. -Newly diagnosed initial episodes of pulmonary tuberculosis. Sputum smear-positive and -negative patients are eligible for enrollment. The dia...",No,2009-10-10,FDA-90242,2.62,0.32,5.0,7.94,2011-07-12,2011-11-06,2016-11-06,1,Bayer,59,Overall,56.5,25,43,95,81,74,21,64,2,3,2,True,True,False,False,True,True,True,True,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Isoniazid,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 3,2008-11-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

-Adults, male or female, aged 18-60. -Newly diagnosed initial episodes of pulmonary tuberculosis. Sputum smear-positive and -negative patients are eligible for enrollment. The dia...",No,2009-05-06,FDA-36234,2.62,0.32,5.0,7.94,2011-07-12,2011-11-06,2016-11-06,29,Bayer,33,Kenya,53.33333333333334,47,38,100,44,24,67,27,0,2,1,False,False,False,True,False,False,True,False,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Pyrazinamide,AltName B,Drug,tuberculosis,tuberculosis,Phase 3,2008-11-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

-Adults, male or female, aged 18-60. -Newly diagnosed initial episodes of pulmonary tuberculosis. Sputum smear-positive and -negative patients are eligible for enrollment. The dia...",Yes,2009-06-18,FDA-50694,2.62,0.32,5.0,7.94,2011-07-12,2011-11-06,2016-11-06,86,Sanofi,66,Overall,68.0,97,91,66,42,95,17,27,0,2,1,False,False,False,False,True,True,False,False,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifampin,AltName B,Drug,tuberculosis,tuberculosis,Phase 3,2008-11-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

-Adults, male or female, aged 18-60. -Newly diagnosed initial episodes of pulmonary tuberculosis. Sputum smear-positive and -negative patients are eligible for enrollment. The dia...",No,2009-02-04,FDA-64603,2.62,0.32,5.0,7.94,2011-07-12,2011-11-06,2016-11-06,75,Gilead,75,South Africa,50.66666666666666,78,97,38,6,18,67,64,1,2,4,True,False,True,False,False,True,False,True,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Pravastatin,TradeName X,Drug,tuberculosis,tuberculosis,Phase 2,2022-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* 18 years of age or older
* Clinical signs and symptoms of pulmonary tuberculosis
* Abnormal chest radiograph consistent with pulmonary tuberculosis
* At least one sputum positiv...",No,2023-12-12,FDA-49180,4.41,0.98,21.0,26.39,2027-05-29,2028-05-21,2049-05-21,52,Novartis,11,Senegal,45.16666666666666,90,10,68,34,62,7,82,2,3,4,True,True,True,False,False,True,True,True,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifafour,AltName B,Drug,tuberculosis,tuberculosis,Phase 2,2022-12-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* 18 years of age or older
* Clinical signs and symptoms of pulmonary tuberculosis
* Abnormal chest radiograph consistent with pulmonary tuberculosis
* At least one sputum positiv...",Yes,2023-07-09,FDA-43499,4.41,0.98,21.0,26.39,2027-05-29,2028-05-21,2049-05-21,20,Bayer,84,South Africa,40.0,2,92,43,83,11,9,45,1,2,2,True,False,False,False,True,False,True,False,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
GSK Biologicals' investigational TB vaccine (GSK692342),TradeName X,Biological,tuberculosis,tuberculosis,Phase 2,2018-11-16,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* A male or female between, and including, 18 and 50 years of age at...",No,2019-04-11,FDA-13449,4.41,0.98,21.0,26.39,2023-04-14,2024-04-06,2045-04-06,4,Sanofi,39,Senegal,36.16666666666666,53,31,12,53,68,0,55,2,3,1,True,True,False,True,True,True,False,False,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
RPT + INH once weekly for 3 months given by DOT,AltName A,Drug,tuberculosis,tuberculosis,Phase 3,2013-09-01,"Sex: ALL; Age: >2 Years; Criteria: INCLUSION criteria:

* Males or nonpregnant, non-nursing females \> 2 years old.
* Tuberculin (PPD) skin test reactors at high risk for developing TB but without evidence of active TB. High-risk react...",No,2014-01-13,FDA-53769,2.62,0.32,5.0,7.94,2016-04-14,2016-08-09,2021-08-10,55,AstraZeneca,31,Senegal,50.5,60,28,78,41,10,86,64,2,2,3,True,True,False,True,True,False,False,False,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Isoniazid (INH) daily for 9 months,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 3,2013-09-01,"Sex: ALL; Age: >2 Years; Criteria: INCLUSION criteria:

* Males or nonpregnant, non-nursing females \> 2 years old.
* Tuberculin (PPD) skin test reactors at high risk for developing TB but without evidence of active TB. High-risk react...",No,2014-03-01,FDA-46825,2.62,0.32,5.0,7.94,2016-04-14,2016-08-09,2021-08-10,21,Sanofi,75,Overall,54.33333333333334,76,6,51,99,76,18,64,1,3,3,False,True,True,False,True,False,True,True,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
GSK3036656,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2021-12-14,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects must be 18 to 65 years of age inclusive, at the time of signing the informed consent.
* In addition, subjects recruited into cohorts that are planned to undergo fluorod...",No,2022-08-29,FDA-27854,4.41,0.98,21.0,26.39,2026-05-12,2027-05-05,2048-05-04,93,Novartis,27,Kenya,42.5,47,59,14,73,51,11,36,0,3,1,False,False,True,True,True,False,False,True,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifafour e-275,TradeName X,Drug,tuberculosis,tuberculosis,Phase 2,2021-12-14,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects must be 18 to 65 years of age inclusive, at the time of signing the informed consent.
* In addition, subjects recruited into cohorts that are planned to undergo fluorod...",Yes,2022-04-18,FDA-63248,4.41,0.98,21.0,26.39,2026-05-12,2027-05-05,2048-05-04,33,Merck,15,Senegal,49.33333333333334,50,100,4,58,39,45,55,1,3,2,False,True,False,True,True,False,True,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
GSK's candidate Mycobacterium tuberculosis vaccine 692342,AltName A,Biological,tuberculosis,tuberculosis,Phase 2,2009-12-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that they can and will comply with the requirements of the protocol
* A male or female between, and including, 18 and 50 years of age at t...",Yes,2010-10-27,FDA-65589,4.41,0.98,21.0,26.39,2014-04-29,2015-04-22,2036-04-21,87,Pfizer,17,Kenya,37.0,36,20,91,10,23,42,55,1,4,1,True,False,True,True,False,True,True,False,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system,Molecule Z,Biological,tuberculosis,tuberculosis,Phase 2,2009-12-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that they can and will comply with the requirements of the protocol
* A male or female between, and including, 18 and 50 years of age at t...",No,2010-02-20,FDA-72104,4.41,0.98,21.0,26.39,2014-04-29,2015-04-22,2036-04-21,44,Merck,27,South Africa,57.33333333333334,60,69,19,89,77,30,36,1,1,2,True,False,False,False,False,True,False,True,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline,Comp Beta,Biological,tuberculosis,tuberculosis,Phase 2,2009-12-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that they can and will comply with the requirements of the protocol
* A male or female between, and including, 18 and 50 years of age at t...",Yes,2010-03-19,FDA-67346,4.41,0.98,21.0,26.39,2014-04-29,2015-04-22,2036-04-21,82,Gilead,38,Senegal,30.83333333333333,45,4,26,19,71,20,45,0,3,2,False,False,True,False,True,True,False,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
rifapentine,AltName A,Drug,tuberculosis,tuberculosis,Phase 3,2021-05-01,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria:

* Suspected pulmonary tuberculosis plus one or both of the following: a) at least one sputum specimen positive for acid-fast bacilli on smear microscopy OR b) at least one sputum ...",No,2021-12-06,FDA-51119,2.62,0.32,5.0,7.94,2023-12-13,2024-04-08,2029-04-09,61,AstraZeneca,24,Senegal,51.0,26,34,61,58,45,82,27,1,0,2,True,False,False,False,False,False,False,False,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
rifapentine and moxifloxacin,AltName A,Drug,tuberculosis,tuberculosis,Phase 3,2021-05-01,"Sex: ALL; Age: >12 Years; Criteria: Inclusion Criteria:

* Suspected pulmonary tuberculosis plus one or both of the following: a) at least one sputum specimen positive for acid-fast bacilli on smear microscopy OR b) at least one sputum ...",Yes,2022-03-22,FDA-88850,2.62,0.32,5.0,7.94,2023-12-13,2024-04-08,2029-04-09,63,GSK,38,Kenya,47.33333333333334,59,6,49,5,84,81,55,1,3,2,False,True,False,True,True,False,True,True,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
GSK Biologicals' AS01B adjuvant,Molecule Z,Biological,tuberculosis,tuberculosis,Phase 2,2009-04-03,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.
* A male or female between, and inclu...",Yes,2009-09-16,FDA-49425,4.41,0.98,21.0,26.39,2013-08-30,2014-08-23,2035-08-23,54,Bayer,41,South Africa,28.0,44,29,31,20,34,10,36,0,2,2,False,False,True,True,False,False,False,True,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 1,Molecule Z,Biological,tuberculosis,tuberculosis,Phase 2,2009-04-03,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.
* A male or female between, and inclu...",Yes,2009-12-25,FDA-30982,4.41,0.98,21.0,26.39,2013-08-30,2014-08-23,2035-08-23,13,Sanofi,27,Overall,50.66666666666666,54,69,15,81,24,61,64,1,3,3,False,True,True,False,True,True,False,True,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 2,AltName B,Biological,tuberculosis,tuberculosis,Phase 2,2009-04-03,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.
* A male or female between, and inclu...",No,2009-11-25,FDA-88395,4.41,0.98,21.0,26.39,2013-08-30,2014-08-23,2035-08-23,15,Gilead,14,Senegal,54.83333333333334,39,0,75,100,48,67,64,2,3,2,True,True,True,True,True,False,False,False,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 3,Molecule Z,Biological,tuberculosis,tuberculosis,Phase 2,2009-04-03,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.
* A male or female between, and inclu...",Yes,2009-10-28,FDA-33237,4.41,0.98,21.0,26.39,2013-08-30,2014-08-23,2035-08-23,25,Pfizer,31,Senegal,64.66666666666667,89,51,35,66,59,88,45,1,3,1,False,True,False,True,True,True,False,True,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 1,Molecule Z,Biological,tuberculosis,tuberculosis,Phase 2,2009-04-03,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.
* A male or female between, and inclu...",Yes,2010-03-14,FDA-72555,4.41,0.98,21.0,26.39,2013-08-30,2014-08-23,2035-08-23,29,Sanofi,36,Kenya,54.0,93,78,62,10,31,50,64,0,3,4,False,False,True,True,False,False,True,True,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 2,AltName A,Biological,tuberculosis,tuberculosis,Phase 2,2009-04-03,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.
* A male or female between, and inclu...",No,2009-11-21,FDA-14423,4.41,0.98,21.0,26.39,2013-08-30,2014-08-23,2035-08-23,57,GSK,37,South Africa,44.83333333333334,76,83,16,60,6,28,45,0,3,2,False,False,False,True,True,True,False,False,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Pretomanid,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 2,2024-07-17,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

1. Understands study procedures and voluntarily provides written informed consent prior to the start of any study-specific procedures.
2. Male gender 18 years or over
3. Body weig...",Yes,2024-10-06,FDA-81445,4.41,0.98,21.0,26.39,2028-12-13,2029-12-06,2050-12-06,74,Sanofi,1,South Africa,42.0,14,55,66,97,19,1,64,1,2,4,True,False,False,False,False,True,True,True,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Bedaquiline,TradeName X,Drug,tuberculosis,tuberculosis,Phase 2,2024-07-17,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

1. Understands study procedures and voluntarily provides written informed consent prior to the start of any study-specific procedures.
2. Male gender 18 years or over
3. Body weig...",Yes,2024-09-19,FDA-68667,4.41,0.98,21.0,26.39,2028-12-13,2029-12-06,2050-12-06,47,Pfizer,52,South Africa,55.83333333333334,24,36,99,85,56,35,73,1,5,2,False,True,True,True,True,True,True,False,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
moxifloxacin,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2024-07-17,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

1. Understands study procedures and voluntarily provides written informed consent prior to the start of any study-specific procedures.
2. Male gender 18 years or over
3. Body weig...",No,2024-11-29,FDA-41493,4.41,0.98,21.0,26.39,2028-12-13,2029-12-06,2050-12-06,92,J&J,46,Senegal,66.33333333333333,88,85,75,69,39,42,27,0,2,1,False,False,False,True,True,False,False,False,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
pyrazinamide,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2024-07-17,"Sex: MALE; Age: >18 Years; Criteria: Inclusion Criteria:

1. Understands study procedures and voluntarily provides written informed consent prior to the start of any study-specific procedures.
2. Male gender 18 years or over
3. Body weig...",Yes,2025-07-01,FDA-21052,4.41,0.98,21.0,26.39,2028-12-13,2029-12-06,2050-12-06,17,GSK,39,Senegal,44.16666666666666,21,87,77,12,36,32,55,1,2,3,True,False,False,True,True,False,False,True,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Delamanid,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2011-05-12,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Provide written, informed consent prior to all trial-related procedures
2. Male or female participants aged between 18 and 64 years, inclusive.
3. Able to produce sputum for my...",Yes,2012-04-17,FDA-23250,4.41,0.98,21.0,26.39,2015-10-08,2016-09-30,2037-09-30,99,J&J,74,Kenya,39.83333333333334,18,62,5,6,62,86,73,2,2,4,True,True,True,False,False,True,False,True,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Optimized Background Regimen (OBR),Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2011-05-12,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Provide written, informed consent prior to all trial-related procedures
2. Male or female participants aged between 18 and 64 years, inclusive.
3. Able to produce sputum for my...",No,2011-06-19,FDA-89392,4.41,0.98,21.0,26.39,2015-10-08,2016-09-30,2037-09-30,88,Gilead,48,South Africa,61.83333333333334,4,70,57,75,98,67,55,1,4,1,False,True,True,True,True,False,True,False,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
GSK's investigational vaccine 692342,TradeName X,Biological,tuberculosis,tuberculosis,Phase 2,2015-06-04,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
* A male or female between, and including, 18 and 59 years of age at ...",Yes,2015-07-11,FDA-82971,4.41,0.98,21.0,26.39,2019-10-31,2020-10-23,2041-10-23,67,Novartis,1,South Africa,45.16666666666666,64,5,32,58,44,68,36,0,1,3,False,False,True,False,False,False,False,False,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Physiological saline,Comp Beta,Biological,tuberculosis,tuberculosis,Phase 2,2015-06-04,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
* A male or female between, and including, 18 and 59 years of age at ...",Yes,2016-05-21,FDA-46986,4.41,0.98,21.0,26.39,2019-10-31,2020-10-23,2041-10-23,65,Gilead,60,Senegal,54.0,93,50,35,54,46,46,55,1,1,4,True,False,True,False,False,False,False,True,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
GSK's investigational vaccine 692342,GenName Y,Biological,tuberculosis,tuberculosis,Phase 2,2012-03-16,"Sex: ALL; Age: >2 Months; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Male and female subjects who the investigator believes that their parent(s)/ Legally Acceptable Representative (LAR(s)) can and will comply with the requirements of the protocol...",No,2013-01-12,FDA-31346,4.41,0.98,21.0,26.39,2016-08-12,2017-08-05,2038-08-05,86,AstraZeneca,47,Senegal,59.0,42,29,73,83,99,28,45,1,2,2,False,True,False,False,True,True,False,False,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Tritanrix™ HB+Hib,Comp Beta,Biological,tuberculosis,tuberculosis,Phase 2,2012-03-16,"Sex: ALL; Age: >2 Months; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Male and female subjects who the investigator believes that their parent(s)/ Legally Acceptable Representative (LAR(s)) can and will comply with the requirements of the protocol...",Yes,2012-07-01,FDA-34612,4.41,0.98,21.0,26.39,2016-08-12,2017-08-05,2038-08-05,39,Pfizer,44,South Africa,49.16666666666666,49,54,49,45,2,96,64,2,3,2,True,True,True,False,False,True,True,True,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Prevnar™,AltName B,Biological,tuberculosis,tuberculosis,Phase 2,2012-03-16,"Sex: ALL; Age: >2 Months; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Male and female subjects who the investigator believes that their parent(s)/ Legally Acceptable Representative (LAR(s)) can and will comply with the requirements of the protocol...",Yes,2012-12-02,FDA-81531,4.41,0.98,21.0,26.39,2016-08-12,2017-08-05,2038-08-05,19,Pfizer,66,Kenya,51.66666666666666,66,55,12,48,87,42,27,0,2,1,False,False,False,True,False,True,False,True,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Polio Sabin™,AltName B,Biological,tuberculosis,tuberculosis,Phase 2,2012-03-16,"Sex: ALL; Age: >2 Months; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Male and female subjects who the investigator believes that their parent(s)/ Legally Acceptable Representative (LAR(s)) can and will comply with the requirements of the protocol...",Yes,2012-06-24,FDA-68584,4.41,0.98,21.0,26.39,2016-08-12,2017-08-05,2038-08-05,40,Novartis,38,South Africa,46.16666666666666,23,99,9,73,38,35,27,0,2,1,False,False,True,False,False,False,True,False,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Menjugate™,AltName B,Biological,tuberculosis,tuberculosis,Phase 2,2012-03-16,"Sex: ALL; Age: >2 Months; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Male and female subjects who the investigator believes that their parent(s)/ Legally Acceptable Representative (LAR(s)) can and will comply with the requirements of the protocol...",No,2012-11-05,FDA-70002,4.41,0.98,21.0,26.39,2016-08-12,2017-08-05,2038-08-05,20,AstraZeneca,45,Kenya,22.83333333333333,45,8,3,0,67,14,45,1,2,2,False,True,True,False,False,False,True,True,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Isoniazid,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2021-10-06,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria for Step 1:

* New or recurrent pulmonary TB with sputum positive for acid-fast bacilli on direct microscopy of at least grade 1+ (International Union Against Tuberculosis and Lung ...",Yes,2022-05-04,FDA-38522,4.41,0.98,21.0,26.39,2026-03-04,2027-02-25,2048-02-25,60,Sanofi,30,Senegal,64.83333333333333,77,29,43,61,88,91,45,1,2,2,False,True,True,False,False,True,False,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
LZD,AltName B,Drug,tuberculosis,tuberculosis,Phase 2,2023-12-04,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

1. Age \> 18 years
2. Written informed consent from participant or proxy
3. Definite, probable, possible, or suspected TBM diagnosis wherein the patient is being committed to a ful...",No,2024-02-14,FDA-50587,4.41,0.98,21.0,26.39,2028-05-01,2029-04-24,2050-04-24,35,GSK,16,South Africa,60.33333333333334,50,9,92,86,54,71,36,1,1,2,True,False,False,True,False,False,False,True,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
High dose RIF,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 2,2023-12-04,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

1. Age \> 18 years
2. Written informed consent from participant or proxy
3. Definite, probable, possible, or suspected TBM diagnosis wherein the patient is being committed to a ful...",No,2024-05-02,FDA-55455,4.41,0.98,21.0,26.39,2028-05-01,2029-04-24,2050-04-24,13,Gilead,39,Senegal,49.5,51,59,42,36,29,80,64,0,4,3,False,False,True,True,True,True,False,True,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Standard dose RIF,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2023-12-04,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

1. Age \> 18 years
2. Written informed consent from participant or proxy
3. Definite, probable, possible, or suspected TBM diagnosis wherein the patient is being committed to a ful...",No,2024-01-07,FDA-33504,4.41,0.98,21.0,26.39,2028-05-01,2029-04-24,2050-04-24,93,Novartis,16,South Africa,63.83333333333334,44,84,78,28,68,81,64,2,2,3,True,True,False,False,True,True,False,True,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
GSK Biologicals' investigational TB vaccine GSK 692342,Molecule Z,Biological,tuberculosis,tuberculosis,Phase 2,2014-04-10,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes can and will comply with the requirements of the protocol.
* A male or female between, and including, 18 and 59 years of age at the time o...",No,2014-10-04,FDA-35316,4.41,0.98,21.0,26.39,2018-09-06,2019-08-30,2040-08-29,81,Pfizer,11,South Africa,52.83333333333334,57,52,37,70,94,7,45,1,1,3,True,False,False,False,False,True,False,True,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifapentine 450,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Suspected pulmonary tuberculosis with acid-fast bacilli in a stained smear of expectorated sputum. Patients having extra-pulmonary manifestations of tuberculosis, in addition t...",Yes,2015-04-13,FDA-97550,4.41,0.98,21.0,26.39,2019-01-28,2020-01-21,2041-01-20,35,AstraZeneca,4,Kenya,27.0,20,0,70,31,35,6,27,1,2,0,False,True,False,True,False,True,False,False,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifapentine 600,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 2,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Suspected pulmonary tuberculosis with acid-fast bacilli in a stained smear of expectorated sputum. Patients having extra-pulmonary manifestations of tuberculosis, in addition t...",No,2015-03-01,FDA-16316,4.41,0.98,21.0,26.39,2019-01-28,2020-01-21,2041-01-20,46,Sanofi,80,South Africa,51.66666666666666,4,90,8,99,83,26,64,1,3,3,True,False,True,False,False,True,True,True,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifampin,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Suspected pulmonary tuberculosis with acid-fast bacilli in a stained smear of expectorated sputum. Patients having extra-pulmonary manifestations of tuberculosis, in addition t...",Yes,2015-03-25,FDA-25344,4.41,0.98,21.0,26.39,2019-01-28,2020-01-21,2041-01-20,12,J&J,48,Senegal,27.33333333333333,33,5,3,87,26,10,36,0,3,1,False,False,True,True,False,False,True,True,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
GSK's candidate Mycobacterium tuberculosis vaccine 692342,Product Alpha,Biological,tuberculosis,tuberculosis,Phase 2,2009-05-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subjects who the Investigator believes that they can and will comply with the requirements of the protocol.
* A male or female between, and including, 18 and 50 years of age at ...",Yes,2009-10-20,FDA-33858,4.41,0.98,21.0,26.39,2013-10-23,2014-10-16,2035-10-16,73,Novartis,48,Overall,47.66666666666666,98,22,10,99,47,10,55,1,2,3,False,True,True,False,True,False,False,True,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
TMC207,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 2,2013-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Females of child-bearing potential must be using and are willing to continue using effective birth control methods, or be willing to practice sexual abstinence throughout treatm...",No,2013-05-21,FDA-10982,4.41,0.98,21.0,26.39,2017-05-30,2018-05-23,2039-05-23,96,Merck,55,South Africa,51.83333333333334,98,37,14,64,26,72,45,1,1,3,True,False,False,True,False,False,False,True,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Background Regimen (BR) for MDR-TB,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2013-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Females of child-bearing potential must be using and are willing to continue using effective birth control methods, or be willing to practice sexual abstinence throughout treatm...",No,2013-08-03,FDA-13587,4.41,0.98,21.0,26.39,2017-05-30,2018-05-23,2039-05-23,13,Gilead,32,Kenya,40.66666666666666,7,97,34,87,19,0,64,2,3,2,True,True,True,False,False,True,True,False,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Pretomanid,TradeName X,Drug,tuberculosis,tuberculosis,Phase 3,2022-06-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Sputum positive for tubercule bacilli (at least 1+ on the International Union Against Tuberculosis and Lung Disease \[IUATLD\]/WHO scale (Appendix 1) on smear microscopy) at the...",No,2022-12-01,FDA-68859,2.62,0.32,5.0,7.94,2025-01-21,2025-05-18,2030-05-19,0,AstraZeneca,83,South Africa,52.5,18,10,75,59,75,78,64,2,3,2,True,True,False,True,True,False,True,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Bedaquiline,TradeName X,Drug,tuberculosis,tuberculosis,Phase 3,2022-06-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Sputum positive for tubercule bacilli (at least 1+ on the International Union Against Tuberculosis and Lung Disease \[IUATLD\]/WHO scale (Appendix 1) on smear microscopy) at the...",No,2022-08-13,FDA-29937,2.62,0.32,5.0,7.94,2025-01-21,2025-05-18,2030-05-19,72,GSK,80,Senegal,49.83333333333334,77,38,19,33,97,35,64,2,2,3,True,True,True,False,False,True,False,True,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Moxifloxacin,AltName B,Drug,tuberculosis,tuberculosis,Phase 3,2022-06-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Sputum positive for tubercule bacilli (at least 1+ on the International Union Against Tuberculosis and Lung Disease \[IUATLD\]/WHO scale (Appendix 1) on smear microscopy) at the...",No,2022-10-07,FDA-56788,2.62,0.32,5.0,7.94,2025-01-21,2025-05-18,2030-05-19,43,Gilead,77,South Africa,24.5,12,55,19,4,40,17,36,2,1,1,True,True,True,False,False,False,False,False,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Pyrazinamide,AltName B,Drug,tuberculosis,tuberculosis,Phase 3,2022-06-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Sputum positive for tubercule bacilli (at least 1+ on the International Union Against Tuberculosis and Lung Disease \[IUATLD\]/WHO scale (Appendix 1) on smear microscopy) at the...",Yes,2022-08-05,FDA-56680,2.62,0.32,5.0,7.94,2025-01-21,2025-05-18,2030-05-19,37,Novartis,47,Senegal,48.0,91,37,29,31,54,46,55,1,2,3,False,True,False,False,True,True,False,False,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
HRZE,TradeName X,Drug,tuberculosis,tuberculosis,Phase 3,2022-06-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Sputum positive for tubercule bacilli (at least 1+ on the International Union Against Tuberculosis and Lung Disease \[IUATLD\]/WHO scale (Appendix 1) on smear microscopy) at the...",No,2023-01-10,FDA-64159,2.62,0.32,5.0,7.94,2025-01-21,2025-05-18,2030-05-19,76,Gilead,74,Overall,52.83333333333334,43,6,74,36,97,61,27,1,1,1,False,True,False,False,True,False,False,False,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
HR,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 3,2022-06-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Sputum positive for tubercule bacilli (at least 1+ on the International Union Against Tuberculosis and Lung Disease \[IUATLD\]/WHO scale (Appendix 1) on smear microscopy) at the...",Yes,2023-03-03,FDA-35221,2.62,0.32,5.0,7.94,2025-01-21,2025-05-18,2030-05-19,79,GSK,28,South Africa,29.66666666666667,29,39,59,15,0,36,18,0,0,2,False,False,False,False,False,False,False,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
"Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid",Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2013-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Presumptive diagnosis of sputum smear-positive pulmonary TB.
* Age: ≥18 years
* Seven (7) or fewer days of multidrug therapy for TB disease in the preceding 6 months.
* Seven (7...",Yes,2013-07-10,FDA-47506,4.41,0.98,21.0,26.39,2017-08-28,2018-08-21,2039-08-21,32,Merck,42,Kenya,55.16666666666666,57,2,95,52,89,36,55,1,3,2,False,True,True,False,False,True,True,False,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
"Isoniazid, Rifampin, Pyrazinamide, Ethambutol",Product Alpha,Drug,tuberculosis,tuberculosis,Phase 2,2013-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Presumptive diagnosis of sputum smear-positive pulmonary TB.
* Age: ≥18 years
* Seven (7) or fewer days of multidrug therapy for TB disease in the preceding 6 months.
* Seven (7...",No,2014-02-08,FDA-76919,4.41,0.98,21.0,26.39,2017-08-28,2018-08-21,2039-08-21,9,GSK,52,Senegal,54.0,95,44,19,70,88,8,55,1,4,1,False,True,False,True,True,True,True,False,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Digital Health Feedback System,Molecule Z,Device,tuberculosis,tuberculosis,Phase 4,2017-01-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

* Basic competency in understanding written and verbal information as it applies to DHFS use.
* Persons undergoing treatment for TB that includes at least isoniazid and rifampin at...",No,2017-09-10,FDA-73730,0.56,0.15,3.5,4.21,2017-08-23,2017-10-17,2021-04-17,22,Bayer,50,Senegal,49.33333333333334,53,63,48,25,24,83,64,1,2,4,False,True,True,True,False,False,False,True,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
MVA85A/AERAS-485,Comp Beta,Biological,tuberculosis,tuberculosis,Phase 2,,"Sex: ALL; Age: >126 Days; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Age of 126 through 182 days on the day of randomization (Study Day 0)
2. Written informed consent obtained from the parents/guardian
3. Weight: by chart \>3rd percentile on Stu...",No,2026-11-01,FDA-37321,4.41,0.98,21.0,26.39,,,,80,Merck,81,Overall,50.66666666666666,30,46,69,79,45,35,27,1,2,0,False,True,True,False,False,True,False,False,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Candida Skin Test Antigen,AltName B,Biological,tuberculosis,tuberculosis,Phase 2,,"Sex: ALL; Age: >126 Days; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Age of 126 through 182 days on the day of randomization (Study Day 0)
2. Written informed consent obtained from the parents/guardian
3. Weight: by chart \>3rd percentile on Stu...",No,2026-10-17,FDA-45729,4.41,0.98,21.0,26.39,,,,38,Novartis,61,Overall,44.33333333333334,45,60,66,68,22,5,45,0,2,3,False,False,True,False,True,False,False,True,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
TMC207,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2012-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Females of non-childbearing potential
* Patients with newly diagnosed sputum smear-positive pulmonary MDR-TB infection
* Patients must consent to HIV-testing
* Patients must be ...",No,2013-04-02,FDA-38726,4.41,0.98,21.0,26.39,2017-02-27,2018-02-20,2039-02-20,71,Sanofi,30,Overall,45.83333333333334,4,42,100,76,45,8,55,2,2,2,True,True,False,True,False,True,False,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis),GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2012-10-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Females of non-childbearing potential
* Patients with newly diagnosed sputum smear-positive pulmonary MDR-TB infection
* Patients must consent to HIV-testing
* Patients must be ...",No,2013-03-12,FDA-32103,4.41,0.98,21.0,26.39,2017-02-27,2018-02-20,2039-02-20,46,Gilead,51,South Africa,62.5,0,57,86,70,78,84,36,2,2,0,True,True,True,False,True,False,False,False,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
GSK's investigational vaccine 692342,TradeName X,Biological,tuberculosis,tuberculosis,Phase 2,2010-09-30,"Sex: ALL; Age: >13 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who the investigator believes that they and their parent(s)/ legal guardian(s) can and will comply with the requirements of the protocol.
* A male or female between, an...",Yes,2011-07-09,FDA-33723,4.41,0.98,21.0,26.39,2015-02-26,2016-02-19,2037-02-18,66,Gilead,13,South Africa,58.33333333333334,58,69,59,77,15,72,73,1,4,3,True,False,True,True,True,False,True,True,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
GSK Biologicals' investigational TB vaccine GSK 692342,Comp Beta,Biological,tuberculosis,tuberculosis,Phase 2,2013-05-24,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* A male or female between, and including, 18 and 50 years of age at...",No,2013-12-22,FDA-70418,4.41,0.98,21.0,26.39,2017-10-20,2018-10-13,2039-10-13,97,Gilead,95,Overall,48.83333333333334,44,15,83,62,3,86,27,2,1,0,True,True,False,False,False,True,False,False,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
DAR-901,AltName A,Biological,tuberculosis,tuberculosis,Phase 2,2020-02-01,"Sex: ALL; Age: >13 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria: Negative IGRA at baseline -

Exclusion Criteria: Pregnancy, serious underlying disease

\-...",Yes,2020-07-22,FDA-59168,4.41,0.98,21.0,26.39,2024-06-29,2025-06-22,2046-06-22,79,J&J,77,South Africa,49.5,30,39,71,41,100,16,18,0,1,1,False,False,False,False,True,False,False,True,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
PA-824,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2018-02-07,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Provide written, informed consent prior to all trial-related procedures. Male or female, aged between 18 and 75 years inclusive.
2. Body weight (in light clothing and with no s...",Yes,2018-04-24,FDA-56618,4.41,0.98,21.0,26.39,2022-07-06,2023-06-29,2044-06-28,61,GSK,24,Senegal,51.33333333333334,39,43,92,69,54,11,45,0,2,3,False,False,True,False,True,False,False,True,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
bedaquiline,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2018-02-07,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Provide written, informed consent prior to all trial-related procedures. Male or female, aged between 18 and 75 years inclusive.
2. Body weight (in light clothing and with no s...",Yes,2018-12-21,FDA-58211,4.41,0.98,21.0,26.39,2022-07-06,2023-06-29,2044-06-28,57,Sanofi,2,Overall,51.5,60,52,80,14,42,61,55,1,2,3,False,True,False,True,False,True,False,True,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
moxifloxacin,TradeName X,Drug,tuberculosis,tuberculosis,Phase 2,2018-02-07,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Provide written, informed consent prior to all trial-related procedures. Male or female, aged between 18 and 75 years inclusive.
2. Body weight (in light clothing and with no s...",Yes,2018-07-31,FDA-66468,4.41,0.98,21.0,26.39,2022-07-06,2023-06-29,2044-06-28,73,Merck,90,Overall,58.33333333333334,93,47,61,39,53,57,64,2,2,3,True,True,True,True,False,False,False,True,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
pyrazinamide,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2018-02-07,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Provide written, informed consent prior to all trial-related procedures. Male or female, aged between 18 and 75 years inclusive.
2. Body weight (in light clothing and with no s...",Yes,2018-08-02,FDA-52402,4.41,0.98,21.0,26.39,2022-07-06,2023-06-29,2044-06-28,37,Pfizer,93,South Africa,67.0,94,90,56,92,43,27,45,2,2,1,True,True,True,False,True,False,False,False,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
"isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet",AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2018-02-07,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Provide written, informed consent prior to all trial-related procedures. Male or female, aged between 18 and 75 years inclusive.
2. Body weight (in light clothing and with no s...",Yes,2018-05-24,FDA-21448,4.41,0.98,21.0,26.39,2022-07-06,2023-06-29,2044-06-28,13,Sanofi,79,South Africa,64.5,84,86,53,58,20,86,27,0,1,2,False,False,True,False,False,False,False,False,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifampicin,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2016-02-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Absence of HIV-1 infection within 30 days prior to study entry OR
* HIV-1 infection
* Sputum positive for acid fast bacilli (AFB) by smear-microscopy ≥1+ on the WHO/IUALTD scale...",Yes,2016-04-14,FDA-57067,4.41,0.98,21.0,26.39,2020-07-08,2021-07-01,2042-07-01,55,Pfizer,62,Overall,39.83333333333334,26,14,12,64,33,90,55,2,1,3,True,True,False,True,False,False,False,True,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Isoniazid,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2016-02-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Absence of HIV-1 infection within 30 days prior to study entry OR
* HIV-1 infection
* Sputum positive for acid fast bacilli (AFB) by smear-microscopy ≥1+ on the WHO/IUALTD scale...",No,2016-06-03,FDA-26639,4.41,0.98,21.0,26.39,2020-07-08,2021-07-01,2042-07-01,18,Merck,31,Senegal,42.66666666666666,1,36,71,47,77,24,55,0,3,3,False,False,True,False,False,True,True,False,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Pyrazinamide,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2016-02-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Absence of HIV-1 infection within 30 days prior to study entry OR
* HIV-1 infection
* Sputum positive for acid fast bacilli (AFB) by smear-microscopy ≥1+ on the WHO/IUALTD scale...",No,2016-10-10,FDA-46553,4.41,0.98,21.0,26.39,2020-07-08,2021-07-01,2042-07-01,21,Pfizer,3,Overall,60.66666666666666,80,66,95,80,18,25,36,1,1,2,False,True,False,True,False,False,False,False,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Ethambutol,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2016-02-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Absence of HIV-1 infection within 30 days prior to study entry OR
* HIV-1 infection
* Sputum positive for acid fast bacilli (AFB) by smear-microscopy ≥1+ on the WHO/IUALTD scale...",Yes,2016-06-18,FDA-28819,4.41,0.98,21.0,26.39,2020-07-08,2021-07-01,2042-07-01,94,Merck,67,Overall,45.5,31,43,87,2,76,34,55,0,3,3,False,False,True,True,False,True,False,True,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Moxifloxacin,TradeName X,Drug,tuberculosis,tuberculosis,Phase 2,2016-02-10,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Absence of HIV-1 infection within 30 days prior to study entry OR
* HIV-1 infection
* Sputum positive for acid fast bacilli (AFB) by smear-microscopy ≥1+ on the WHO/IUALTD scale...",Yes,2016-11-24,FDA-25439,4.41,0.98,21.0,26.39,2020-07-08,2021-07-01,2042-07-01,43,Pfizer,100,Overall,45.16666666666666,5,71,71,57,42,25,27,0,1,2,False,False,False,False,True,False,False,True,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
PBTZ169,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2018-02-22,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Written informed consent received from a volunteer
* Men and women aged 18 to 65 years, inclusive
* The first-diagnosed active pulmonary tuberculosis, confirmed by characteristi...",Yes,2018-10-05,FDA-20094,4.41,0.98,21.0,26.39,2022-07-21,2023-07-14,2044-07-13,94,Pfizer,63,Kenya,52.33333333333334,30,23,41,79,92,49,36,1,2,1,False,True,False,False,False,True,True,False,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Isoniazid,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2018-02-22,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Written informed consent received from a volunteer
* Men and women aged 18 to 65 years, inclusive
* The first-diagnosed active pulmonary tuberculosis, confirmed by characteristi...",Yes,2018-05-11,FDA-94483,4.41,0.98,21.0,26.39,2022-07-21,2023-07-14,2044-07-13,21,Pfizer,23,South Africa,42.16666666666666,19,39,96,66,33,0,64,1,4,2,True,False,False,True,True,True,True,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifapentine (RPT),Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2019-04-10,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Age greater than or equal to 18 years, or minimum age of consent according to locally applicable laws or regulations at screening, verified per site standard operating procedure...",No,2019-06-26,FDA-98386,4.41,0.98,21.0,26.39,2023-09-06,2024-08-29,2045-08-29,74,J&J,67,South Africa,46.83333333333334,64,42,100,6,55,14,45,0,2,3,False,False,False,True,False,False,True,True,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Isoniazid (INH),TradeName X,Drug,tuberculosis,tuberculosis,Phase 2,2019-04-10,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Age greater than or equal to 18 years, or minimum age of consent according to locally applicable laws or regulations at screening, verified per site standard operating procedure...",Yes,2019-12-14,FDA-61653,4.41,0.98,21.0,26.39,2023-09-06,2024-08-29,2045-08-29,93,GSK,0,Senegal,55.16666666666666,56,16,46,68,64,81,27,0,1,2,False,False,False,False,True,False,False,True,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Metronidazole,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2013-02-01,"Sex: ALL; Age: >20 Years; Criteria: * INCLUSION CRITERIA:

  1. Male and females age 20 and above
  2. Signs or symptoms of tuberculosis (i.e., cough that has lasted 3 weeks or longer, hemoptysis, chest pain, fatigue, weight loss, night...",No,2013-04-11,FDA-30842,4.41,0.98,21.0,26.39,2017-06-30,2018-06-23,2039-06-23,69,Merck,17,Senegal,32.0,66,8,19,48,23,28,55,1,4,1,False,True,True,True,True,False,True,False,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
AERAS-402 1.5 x 10^10 vp,Product Alpha,Biological,tuberculosis,tuberculosis,Phase 2,2014-04-01,"Sex: ALL; Age: >112 Days; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Parent/legal guardian has completed the written informed consent process
2. Is age greater than or equal to 112 days (16 weeks) and less than or equal 182 days (26 weeks) on St...",Yes,2014-07-10,FDA-29137,4.41,0.98,21.0,26.39,2018-08-28,2019-08-21,2040-08-20,59,GSK,27,Overall,64.33333333333333,86,5,66,95,63,71,64,1,3,3,False,True,False,True,True,False,True,True,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
AERAS-402 3.0 x 10^10 vp,TradeName X,Biological,tuberculosis,tuberculosis,Phase 2,2014-04-01,"Sex: ALL; Age: >112 Days; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Parent/legal guardian has completed the written informed consent process
2. Is age greater than or equal to 112 days (16 weeks) and less than or equal 182 days (26 weeks) on St...",Yes,2014-11-30,FDA-99332,4.41,0.98,21.0,26.39,2018-08-28,2019-08-21,2040-08-20,55,Sanofi,5,Senegal,52.33333333333334,5,86,9,99,36,79,45,1,2,2,True,False,False,False,True,True,False,True,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
AERAS-402 1.0 x 10^11 vp,AltName B,Biological,tuberculosis,tuberculosis,Phase 2,2014-04-01,"Sex: ALL; Age: >112 Days; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Parent/legal guardian has completed the written informed consent process
2. Is age greater than or equal to 112 days (16 weeks) and less than or equal 182 days (26 weeks) on St...",No,2014-07-11,FDA-99731,4.41,0.98,21.0,26.39,2018-08-28,2019-08-21,2040-08-20,63,Sanofi,48,Overall,52.0,64,88,99,31,8,22,55,0,4,2,False,False,True,True,True,True,False,True,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifapentine (RPT),AltName B,Drug,tuberculosis,tuberculosis,Phase 3,2017-11-14,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Tuberculin skin test (TST) reactivity greater than or equal to 5 mm or a positive interferon gamma release assay (IGRA) at any time prior to study entry, OR li...",No,2018-10-23,FDA-57793,2.62,0.32,5.0,7.94,2020-06-27,2020-10-22,2025-10-23,99,AstraZeneca,46,South Africa,46.0,27,86,18,15,59,71,64,1,3,3,True,False,True,False,True,False,True,True,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Isoniazid (INH),GenName Y,Drug,tuberculosis,tuberculosis,Phase 3,2017-11-14,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Tuberculin skin test (TST) reactivity greater than or equal to 5 mm or a positive interferon gamma release assay (IGRA) at any time prior to study entry, OR li...",No,2018-06-29,FDA-22022,2.62,0.32,5.0,7.94,2020-06-27,2020-10-22,2025-10-23,9,AstraZeneca,76,Overall,66.83333333333333,49,1,97,82,96,76,55,1,3,2,False,True,True,True,True,False,False,False,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Gatifloxacin,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2007-12-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

-Adults, male or female, age 18 to 65 years. -Women with child-bearing potential (not surgically sterilized or postmenopausal for less than 1 year) must be using or agree to use a...",Yes,2008-09-09,FDA-44365,4.41,0.98,21.0,26.39,2012-05-25,2013-05-18,2034-05-18,53,AstraZeneca,27,Kenya,43.0,7,32,72,28,35,84,27,0,1,2,False,False,True,False,False,False,False,True,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Isoniazid,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2007-12-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

-Adults, male or female, age 18 to 65 years. -Women with child-bearing potential (not surgically sterilized or postmenopausal for less than 1 year) must be using or agree to use a...",No,2008-09-12,FDA-52014,4.41,0.98,21.0,26.39,2012-05-25,2013-05-18,2034-05-18,90,AstraZeneca,5,Overall,23.33333333333333,40,7,62,8,13,10,73,1,3,4,True,False,True,False,False,True,True,True,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Levofloxacin,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2007-12-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

-Adults, male or female, age 18 to 65 years. -Women with child-bearing potential (not surgically sterilized or postmenopausal for less than 1 year) must be using or agree to use a...",Yes,2008-12-19,FDA-58488,4.41,0.98,21.0,26.39,2012-05-25,2013-05-18,2034-05-18,18,Novartis,10,Kenya,48.33333333333334,39,21,19,64,83,64,73,2,2,4,True,True,False,False,True,False,True,True,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Linezolid,AltName B,Drug,tuberculosis,tuberculosis,Phase 2,2007-12-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

-Adults, male or female, age 18 to 65 years. -Women with child-bearing potential (not surgically sterilized or postmenopausal for less than 1 year) must be using or agree to use a...",Yes,2008-03-26,FDA-78461,4.41,0.98,21.0,26.39,2012-05-25,2013-05-18,2034-05-18,33,GSK,20,Kenya,49.66666666666666,96,70,22,79,14,17,45,1,2,2,False,True,False,False,True,False,True,True,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Moxifloxacin,TradeName X,Drug,tuberculosis,tuberculosis,Phase 2,2007-12-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

-Adults, male or female, age 18 to 65 years. -Women with child-bearing potential (not surgically sterilized or postmenopausal for less than 1 year) must be using or agree to use a...",No,2008-12-06,FDA-91282,4.41,0.98,21.0,26.39,2012-05-25,2013-05-18,2034-05-18,55,Novartis,59,Senegal,50.16666666666666,72,12,45,83,27,62,55,0,3,3,False,False,True,True,False,True,False,True,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Moxifloxacin,AltName B,Drug,tuberculosis,tuberculosis,Phase 2,2008-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Presumptive diagnosis of smear-positive pulmonary TB within 2 weeks of study entry. Patients with both pulmonary and extrapulmonary disease are eligible.
* Documentation of HIV ...",Yes,2009-04-19,FDA-48006,4.41,0.98,21.0,26.39,2013-01-28,2014-01-21,2035-01-21,87,Pfizer,23,Kenya,69.16666666666667,92,14,56,66,88,99,45,1,2,2,False,True,False,True,False,True,False,False,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
AERAS-404,AltName A,Biological,tuberculosis,tuberculosis,Phase 2,2017-10-06,"Sex: ALL; Age: >12 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Has completed the written informed consent and assent process
2. Is age ≥ 12 years and ≤ 17 years on Study Day 0
3. Agrees to stay in contact with the study site for the durati...",Yes,2018-01-06,FDA-98595,4.41,0.98,21.0,26.39,2022-03-04,2023-02-25,2044-02-25,6,Pfizer,70,South Africa,67.5,89,87,52,50,57,70,9,0,1,0,False,False,False,False,False,False,True,False,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Bacillus Calmette-Guérin (BCG),Comp Beta,Biological,tuberculosis,tuberculosis,Phase 2,2017-10-06,"Sex: ALL; Age: >12 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Has completed the written informed consent and assent process
2. Is age ≥ 12 years and ≤ 17 years on Study Day 0
3. Agrees to stay in contact with the study site for the durati...",No,2018-09-16,FDA-51701,4.41,0.98,21.0,26.39,2022-03-04,2023-02-25,2044-02-25,60,Bayer,12,Overall,32.33333333333334,12,12,87,16,5,62,64,2,4,1,True,True,False,True,True,True,True,False,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifapentine 600 mg and INH 300 mg,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 4,2024-06-10,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

* Positive tuberculin skin test or interferon-gamma release assay (IGRA) test and
* Household contact of an infectious TB case within previous 90 days, defined as sleeping at leas...",Yes,2024-07-11,FDA-12027,0.56,0.15,3.5,4.21,2024-12-31,2025-02-24,2028-08-25,16,Pfizer,90,South Africa,52.0,24,28,75,31,59,95,27,0,2,1,False,False,True,False,False,False,True,False,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifapentine 900 mg and INH 900 mg,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 4,2024-06-10,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

* Positive tuberculin skin test or interferon-gamma release assay (IGRA) test and
* Household contact of an infectious TB case within previous 90 days, defined as sleeping at leas...",No,2025-05-26,FDA-66819,0.56,0.15,3.5,4.21,2024-12-31,2025-02-24,2028-08-25,64,Gilead,56,Senegal,46.5,24,12,25,54,72,92,18,0,0,2,False,False,False,False,False,False,False,False,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
TBA-7371,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2022-10-05,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants between 18 to 60 years of age inclusive at the time of signing the informed consent.
* Body weight within 40 and 100 kilogram (inclusive).
* Untreated, rifampicin-s...",Yes,2023-04-17,FDA-67352,4.41,0.98,21.0,26.39,2027-03-03,2028-02-24,2049-02-23,28,Pfizer,7,Kenya,65.16666666666667,95,84,28,23,62,99,55,2,1,3,True,True,False,True,False,False,False,True,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
TBA-7371,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2022-10-05,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants between 18 to 60 years of age inclusive at the time of signing the informed consent.
* Body weight within 40 and 100 kilogram (inclusive).
* Untreated, rifampicin-s...",Yes,2022-12-13,FDA-15675,4.41,0.98,21.0,26.39,2027-03-03,2028-02-24,2049-02-23,15,Bayer,22,Kenya,31.66666666666667,28,38,7,17,52,48,45,0,4,1,False,False,False,True,True,True,True,True,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
TBA-7371,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2022-10-05,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants between 18 to 60 years of age inclusive at the time of signing the informed consent.
* Body weight within 40 and 100 kilogram (inclusive).
* Untreated, rifampicin-s...",Yes,2022-11-19,FDA-81946,4.41,0.98,21.0,26.39,2027-03-03,2028-02-24,2049-02-23,81,Bayer,3,Senegal,53.33333333333334,10,18,77,53,67,95,55,1,3,2,True,False,True,True,True,False,False,True,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
TBA-7371,AltName B,Drug,tuberculosis,tuberculosis,Phase 2,2022-10-05,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants between 18 to 60 years of age inclusive at the time of signing the informed consent.
* Body weight within 40 and 100 kilogram (inclusive).
* Untreated, rifampicin-s...",Yes,2023-03-19,FDA-41204,4.41,0.98,21.0,26.39,2027-03-03,2028-02-24,2049-02-23,37,GSK,15,South Africa,63.66666666666666,78,94,38,46,33,93,36,1,3,0,True,False,True,True,False,True,False,False,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
TBA-7371,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2022-10-05,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants between 18 to 60 years of age inclusive at the time of signing the informed consent.
* Body weight within 40 and 100 kilogram (inclusive).
* Untreated, rifampicin-s...",Yes,2023-06-02,FDA-95206,4.41,0.98,21.0,26.39,2027-03-03,2028-02-24,2049-02-23,18,GSK,0,Overall,51.66666666666666,96,74,48,56,26,10,55,0,4,2,False,False,False,True,True,True,True,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
HRZE,TradeName X,Drug,tuberculosis,tuberculosis,Phase 2,2022-10-05,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants between 18 to 60 years of age inclusive at the time of signing the informed consent.
* Body weight within 40 and 100 kilogram (inclusive).
* Untreated, rifampicin-s...",No,2023-09-21,FDA-89839,4.41,0.98,21.0,26.39,2027-03-03,2028-02-24,2049-02-23,74,AstraZeneca,77,South Africa,50.83333333333334,27,27,37,40,97,77,55,0,3,3,False,False,False,False,True,True,True,True,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Fixed dose combination zidovudine/lamivudine/abacavir,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 4,2007-09-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* HIV Infection is documented by rapid HIV test or any licensed enzyme-linked immunosorbent assay (ELISA) test kit and confirmed with a different sample.
* Men or women admitted t...",Yes,2007-12-13,FDA-32185,0.56,0.15,3.5,4.21,2008-03-23,2008-05-17,2011-11-16,0,Sanofi,36,South Africa,40.16666666666666,36,65,86,40,10,4,55,2,2,2,True,True,True,False,False,True,False,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
AERAS-402 3 x 10^8 vp,Molecule Z,Biological,tuberculosis,tuberculosis,Phase 2,2010-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Is male or female.
2. Is age 18 through 45 years on Study Day 0.
3. Has completed the written informed consent process.
4. Has a history of pulmonary tuberculosis diagnosed by ...",Yes,2011-05-29,FDA-22440,4.41,0.98,21.0,26.39,2015-03-30,2016-03-22,2037-03-22,45,Pfizer,70,Overall,67.0,47,75,96,86,69,29,73,2,2,4,True,True,True,True,False,False,False,True,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
AERAS-402 3 x 10^9 vp,AltName B,Biological,tuberculosis,tuberculosis,Phase 2,2010-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Is male or female.
2. Is age 18 through 45 years on Study Day 0.
3. Has completed the written informed consent process.
4. Has a history of pulmonary tuberculosis diagnosed by ...",No,2011-02-26,FDA-15341,4.41,0.98,21.0,26.39,2015-03-30,2016-03-22,2037-03-22,34,GSK,30,Overall,50.0,55,52,18,42,99,34,73,2,4,2,True,True,True,True,True,True,False,True,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
AERAS-402 3 x 10^10 vp,Molecule Z,Biological,tuberculosis,tuberculosis,Phase 2,2010-11-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

1. Is male or female.
2. Is age 18 through 45 years on Study Day 0.
3. Has completed the written informed consent process.
4. Has a history of pulmonary tuberculosis diagnosed by ...",No,2010-12-09,FDA-62503,4.41,0.98,21.0,26.39,2015-03-30,2016-03-22,2037-03-22,43,Pfizer,71,Kenya,33.16666666666666,53,15,44,8,12,67,45,0,3,2,False,False,True,True,True,False,False,True,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Immediate Start Linezolid,AltName B,Drug,tuberculosis,tuberculosis,Phase 2,2014-11-01,"Sex: ALL; Age: >20 Years; Criteria: * INCLUSION CRITERIA:

Males and females age 20 and above

Documented pulmonary tuberculosis at screening

Radiographic evidence of tuberculous disease of the lung(s)

History of chronic, AFB positive...",Yes,2014-12-28,FDA-87828,4.41,0.98,21.0,26.39,2019-03-30,2020-03-22,2041-03-22,61,Gilead,40,Kenya,56.0,32,74,29,77,92,32,55,2,3,1,True,True,True,False,False,True,True,False,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Delayed Start Linezolid,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2014-11-01,"Sex: ALL; Age: >20 Years; Criteria: * INCLUSION CRITERIA:

Males and females age 20 and above

Documented pulmonary tuberculosis at screening

Radiographic evidence of tuberculous disease of the lung(s)

History of chronic, AFB positive...",Yes,2014-12-21,FDA-73190,4.41,0.98,21.0,26.39,2019-03-30,2020-03-22,2041-03-22,3,Gilead,52,Overall,66.33333333333333,55,93,65,80,55,50,36,0,3,1,False,False,True,True,False,True,False,False,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
PA-824,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 2,2022-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Suspected pulmonary tuberculosis with acid-fast bacilli in a stained smear of expectorated sputum or Gene Xpert positive sputum sample. Patients having extra-pulmonary manifest...",No,2022-06-24,FDA-84972,4.41,0.98,21.0,26.39,2026-09-27,2027-09-20,2048-09-19,95,GSK,44,Overall,51.83333333333334,75,49,24,84,73,6,45,0,1,4,False,False,True,False,False,False,False,True,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifampin,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2022-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Suspected pulmonary tuberculosis with acid-fast bacilli in a stained smear of expectorated sputum or Gene Xpert positive sputum sample. Patients having extra-pulmonary manifest...",Yes,2022-11-18,FDA-76099,4.41,0.98,21.0,26.39,2026-09-27,2027-09-20,2048-09-19,56,Novartis,24,South Africa,48.0,69,65,5,4,93,52,55,1,2,3,True,False,False,True,False,True,False,True,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifabutin,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2022-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Suspected pulmonary tuberculosis with acid-fast bacilli in a stained smear of expectorated sputum or Gene Xpert positive sputum sample. Patients having extra-pulmonary manifest...",Yes,2023-02-09,FDA-90439,4.41,0.98,21.0,26.39,2026-09-27,2027-09-20,2048-09-19,35,Sanofi,80,Senegal,76.83333333333333,63,89,100,31,79,99,45,1,1,3,False,True,False,True,False,False,False,True,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Pyrazinamide,AltName B,Drug,tuberculosis,tuberculosis,Phase 2,2022-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Suspected pulmonary tuberculosis with acid-fast bacilli in a stained smear of expectorated sputum or Gene Xpert positive sputum sample. Patients having extra-pulmonary manifest...",Yes,2022-11-28,FDA-99781,4.41,0.98,21.0,26.39,2026-09-27,2027-09-20,2048-09-19,37,Sanofi,64,Kenya,60.0,3,77,80,40,89,71,64,2,2,3,True,True,False,True,True,False,False,True,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Ethambutol,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 2,2022-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Suspected pulmonary tuberculosis with acid-fast bacilli in a stained smear of expectorated sputum or Gene Xpert positive sputum sample. Patients having extra-pulmonary manifest...",Yes,2022-09-25,FDA-51441,4.41,0.98,21.0,26.39,2026-09-27,2027-09-20,2048-09-19,35,J&J,53,Senegal,53.33333333333334,57,50,75,62,4,72,27,0,2,1,False,False,False,True,True,False,False,False,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Isoniazid,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2022-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Suspected pulmonary tuberculosis with acid-fast bacilli in a stained smear of expectorated sputum or Gene Xpert positive sputum sample. Patients having extra-pulmonary manifest...",No,2022-10-25,FDA-90020,4.41,0.98,21.0,26.39,2026-09-27,2027-09-20,2048-09-19,95,AstraZeneca,90,Kenya,73.0,66,35,95,81,100,61,45,1,3,1,True,False,True,False,True,True,False,False,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Pravastatin,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2022-08-31,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* 18 years of age or older
* Clinical signs and symptoms of pulmonary tuberculosis
* Abnormal chest radiograph consistent with pulmonary tuberculosis
* At least one sputum positiv...",No,2023-01-29,FDA-30581,4.41,0.98,21.0,26.39,2027-01-27,2028-01-20,2049-01-19,80,Gilead,20,South Africa,39.16666666666666,17,36,28,45,13,96,36,1,3,0,True,False,True,False,True,False,True,False,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
H56ug/IC31nmol,Product Alpha,Biological,tuberculosis,tuberculosis,Phase 2,2015-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Subjects must meet all of the following criteria prior to Study Day 0 vaccination:

1. Has completed the written informed consent process prior to the start of screening evaluatio...",No,2016-06-02,FDA-53268,4.41,0.98,21.0,26.39,2020-03-29,2021-03-22,2042-03-22,68,J&J,96,Senegal,54.66666666666666,64,13,96,46,30,79,55,1,3,2,True,False,True,False,False,True,True,True,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Isoniazid,AltName A,Drug,tuberculosis,tuberculosis,Phase 3,2009-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

The inclusion criteria for this study will be San Francisco Jail inmates, age 18 or older (the jail does not house juveniles) having evidence of M. tuberculosis infection by posit...",No,2010-07-31,FDA-45181,2.62,0.32,5.0,7.94,2012-04-14,2012-08-09,2017-08-10,87,Sanofi,40,South Africa,35.66666666666666,21,25,28,25,47,68,64,0,4,3,False,False,True,True,True,True,False,False,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifampin,AltName B,Drug,tuberculosis,tuberculosis,Phase 3,2009-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

The inclusion criteria for this study will be San Francisco Jail inmates, age 18 or older (the jail does not house juveniles) having evidence of M. tuberculosis infection by posit...",No,2010-05-12,FDA-92932,2.62,0.32,5.0,7.94,2012-04-14,2012-08-09,2017-08-10,1,Gilead,15,Kenya,49.5,25,61,25,43,90,53,55,0,4,2,False,False,True,True,False,True,True,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Imatinib,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2022-08-30,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Adult age between 18 years and 55 years
* Body mass index (BMI) greater than 18.5 kg/m\^2
* At least 8 years formal education, with appropriate reading and comprehension skills
...",Yes,2023-01-28,FDA-96589,4.41,0.98,21.0,26.39,2027-01-26,2028-01-19,2049-01-18,20,Bayer,21,Overall,44.66666666666666,96,12,56,31,47,26,55,1,3,2,False,True,True,True,False,True,False,True,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Isoniazid,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2022-08-30,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Adult age between 18 years and 55 years
* Body mass index (BMI) greater than 18.5 kg/m\^2
* At least 8 years formal education, with appropriate reading and comprehension skills
...",No,2023-03-30,FDA-96795,4.41,0.98,21.0,26.39,2027-01-26,2028-01-19,2049-01-18,78,J&J,15,Overall,60.5,100,64,82,48,54,15,36,0,2,2,False,False,False,True,False,False,True,True,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifabutin,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 2,2022-08-30,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Adult age between 18 years and 55 years
* Body mass index (BMI) greater than 18.5 kg/m\^2
* At least 8 years formal education, with appropriate reading and comprehension skills
...",No,2023-04-13,FDA-67546,4.41,0.98,21.0,26.39,2027-01-26,2028-01-19,2049-01-18,99,Gilead,87,Overall,48.5,30,57,49,9,100,46,36,1,2,1,True,False,True,False,False,True,False,False,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Higher-Dose Rifampin,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2016-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Newly diagnosed pulmonary TB with acid-fast bacilli (\>=2+) in a stained sputum smear, ultimately confirmed by culture.
* Susceptibility of isolate to INH and RIF by HAIN test.
...",No,2016-06-30,FDA-24326,4.41,0.98,21.0,26.39,2020-08-28,2021-08-21,2042-08-21,93,GSK,73,Overall,28.5,23,3,17,38,70,20,64,0,3,4,False,False,False,True,True,True,False,True,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
PA-824,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2010-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Informed Consent
* Body weight between 40 and 90 kg, inclusive.
* Newly diagnosed, previously untreated, uncomplicated, sputum smear-positive, pulmonary TB.
* A chest X-ray comp...",No,2010-07-27,FDA-35212,4.41,0.98,21.0,26.39,2014-09-27,2015-09-20,2036-09-19,73,J&J,98,South Africa,66.66666666666667,78,46,95,100,9,72,27,0,2,1,False,False,True,False,True,False,False,False,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
PA-824,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2010-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Informed Consent
* Body weight between 40 and 90 kg, inclusive.
* Newly diagnosed, previously untreated, uncomplicated, sputum smear-positive, pulmonary TB.
* A chest X-ray comp...",Yes,2010-11-01,FDA-53817,4.41,0.98,21.0,26.39,2014-09-27,2015-09-20,2036-09-19,74,Sanofi,20,South Africa,73.83333333333333,58,81,88,72,60,84,45,1,3,1,True,False,True,True,False,False,True,False,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
PA-824,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2010-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Informed Consent
* Body weight between 40 and 90 kg, inclusive.
* Newly diagnosed, previously untreated, uncomplicated, sputum smear-positive, pulmonary TB.
* A chest X-ray comp...",Yes,2010-11-22,FDA-24353,4.41,0.98,21.0,26.39,2014-09-27,2015-09-20,2036-09-19,65,GSK,67,Kenya,52.33333333333334,37,20,79,58,68,52,55,2,1,3,True,True,False,False,True,False,False,False,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifafour e-275 mg,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2010-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Informed Consent
* Body weight between 40 and 90 kg, inclusive.
* Newly diagnosed, previously untreated, uncomplicated, sputum smear-positive, pulmonary TB.
* A chest X-ray comp...",Yes,2010-12-03,FDA-98444,4.41,0.98,21.0,26.39,2014-09-27,2015-09-20,2036-09-19,35,Novartis,92,Kenya,42.5,16,30,82,70,51,6,27,1,1,1,True,False,True,False,False,False,False,False,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
PA-824,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2010-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Informed Consent
* Body weight between 40 and 90 kg, inclusive.
* Newly diagnosed, previously untreated, uncomplicated, sputum smear-positive, pulmonary TB.
* A chest X-ray comp...",No,2010-07-06,FDA-68682,4.41,0.98,21.0,26.39,2014-09-27,2015-09-20,2036-09-19,28,Bayer,55,Overall,39.66666666666666,37,3,74,40,16,68,36,1,1,2,False,True,True,False,False,False,False,False,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Standard-dose Lopinavir/Ritonavir,AltName B,Drug,tuberculosis,tuberculosis,Phase 2,2017-06-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+/CD8+ T-cell count obtained within 30 days prior to study entry
* Confirmed or probable pulmonary or extrapulmonary TB (more information on the criterion c...",No,2018-05-11,FDA-15588,4.41,0.98,21.0,26.39,2021-11-24,2022-11-17,2043-11-17,0,Novartis,37,Senegal,47.83333333333334,19,38,98,85,28,19,36,2,1,1,True,True,False,False,False,True,False,False,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Double-dose Lopinavir/Ritonavir,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 2,2017-06-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+/CD8+ T-cell count obtained within 30 days prior to study entry
* Confirmed or probable pulmonary or extrapulmonary TB (more information on the criterion c...",No,2017-09-20,FDA-67160,4.41,0.98,21.0,26.39,2021-11-24,2022-11-17,2043-11-17,21,Pfizer,37,Senegal,35.33333333333334,24,16,25,69,44,34,55,1,1,4,True,False,False,True,False,False,False,True,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Raltegravir,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 2,2017-06-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+/CD8+ T-cell count obtained within 30 days prior to study entry
* Confirmed or probable pulmonary or extrapulmonary TB (more information on the criterion c...",No,2018-05-18,FDA-95233,4.41,0.98,21.0,26.39,2021-11-24,2022-11-17,2043-11-17,0,Bayer,24,South Africa,68.83333333333333,82,93,76,95,54,13,45,1,3,1,False,True,False,True,True,True,False,True,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Isoniazid,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2017-06-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+/CD8+ T-cell count obtained within 30 days prior to study entry
* Confirmed or probable pulmonary or extrapulmonary TB (more information on the criterion c...",No,2017-08-20,FDA-69395,4.41,0.98,21.0,26.39,2021-11-24,2022-11-17,2043-11-17,79,AstraZeneca,16,Kenya,53.66666666666666,44,16,35,66,87,74,45,2,1,2,True,True,False,False,True,False,False,False,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Pyridoxine,AltName B,Drug,tuberculosis,tuberculosis,Phase 2,2017-06-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+/CD8+ T-cell count obtained within 30 days prior to study entry
* Confirmed or probable pulmonary or extrapulmonary TB (more information on the criterion c...",No,2018-01-11,FDA-71297,4.41,0.98,21.0,26.39,2021-11-24,2022-11-17,2043-11-17,74,Novartis,62,Kenya,60.5,91,90,54,33,64,31,36,1,3,0,True,False,True,True,True,False,False,False,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Pyrazinamide,TradeName X,Drug,tuberculosis,tuberculosis,Phase 2,2017-06-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+/CD8+ T-cell count obtained within 30 days prior to study entry
* Confirmed or probable pulmonary or extrapulmonary TB (more information on the criterion c...",No,2017-10-12,FDA-39419,4.41,0.98,21.0,26.39,2021-11-24,2022-11-17,2043-11-17,99,Gilead,54,Overall,53.16666666666666,94,36,65,54,52,18,55,2,2,2,True,True,False,False,False,True,True,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Ethambutol,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2017-06-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+/CD8+ T-cell count obtained within 30 days prior to study entry
* Confirmed or probable pulmonary or extrapulmonary TB (more information on the criterion c...",No,2017-10-26,FDA-74776,4.41,0.98,21.0,26.39,2021-11-24,2022-11-17,2043-11-17,46,Novartis,28,South Africa,54.16666666666666,30,26,75,95,11,88,27,0,1,2,False,False,False,False,False,False,True,True,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifabutin,AltName B,Drug,tuberculosis,tuberculosis,Phase 2,2017-06-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+/CD8+ T-cell count obtained within 30 days prior to study entry
* Confirmed or probable pulmonary or extrapulmonary TB (more information on the criterion c...",Yes,2018-04-22,FDA-80460,4.41,0.98,21.0,26.39,2021-11-24,2022-11-17,2043-11-17,56,AstraZeneca,7,Overall,47.0,34,51,25,23,76,73,64,1,4,2,False,True,False,True,True,True,True,False,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifampin,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2017-06-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* CD4+/CD8+ T-cell count obtained within 30 days prior to study entry
* Confirmed or probable pulmonary or extrapulmonary TB (more information on the criterion c...",No,2018-02-02,FDA-99770,4.41,0.98,21.0,26.39,2021-11-24,2022-11-17,2043-11-17,72,Bayer,41,Senegal,49.0,60,17,73,13,53,78,45,1,2,2,False,True,False,False,True,True,False,True,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
TMC207,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2010-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Provide written, informed consent prior to all trial-related procedures including HIV testing.
* Male or female, aged between 18 and 65 years inclusive.
* Body weight (in light ...",Yes,2010-12-22,FDA-91323,4.41,0.98,21.0,26.39,2015-01-28,2016-01-21,2037-01-20,61,Merck,82,Kenya,60.16666666666666,21,69,99,57,84,31,36,0,4,0,False,False,True,False,True,True,True,False,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifafour e-275 mg,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2010-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Provide written, informed consent prior to all trial-related procedures including HIV testing.
* Male or female, aged between 18 and 65 years inclusive.
* Body weight (in light ...",No,2011-07-02,FDA-78117,4.41,0.98,21.0,26.39,2015-01-28,2016-01-21,2037-01-20,80,Bayer,34,Senegal,54.33333333333334,75,51,33,63,83,21,55,2,3,1,True,True,True,True,False,False,True,False,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
PA-824,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2011-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Provide written, informed consent prior to all trial-related procedures including HIV testing.
2. Male or female, aged between 18 and 65 years inclusive.
3. Body weight (in lig...",No,2011-10-07,FDA-91538,4.41,0.98,21.0,26.39,2015-12-28,2016-12-20,2037-12-20,72,J&J,28,Kenya,58.83333333333334,24,75,90,59,98,7,45,1,3,1,True,False,True,True,False,True,False,False,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Pyrazinamide,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 2,2011-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Provide written, informed consent prior to all trial-related procedures including HIV testing.
2. Male or female, aged between 18 and 65 years inclusive.
3. Body weight (in lig...",No,2011-09-22,FDA-12530,4.41,0.98,21.0,26.39,2015-12-28,2016-12-20,2037-12-20,84,Bayer,25,South Africa,52.83333333333334,59,43,76,27,16,96,36,1,2,1,False,True,True,False,False,False,True,True,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
TMC207,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2011-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Provide written, informed consent prior to all trial-related procedures including HIV testing.
2. Male or female, aged between 18 and 65 years inclusive.
3. Body weight (in lig...",Yes,2011-12-27,FDA-89134,4.41,0.98,21.0,26.39,2015-12-28,2016-12-20,2037-12-20,80,Merck,78,Kenya,43.83333333333334,50,13,39,64,33,64,64,1,3,3,True,False,True,False,False,True,True,True,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifafour,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2011-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Provide written, informed consent prior to all trial-related procedures including HIV testing.
2. Male or female, aged between 18 and 65 years inclusive.
3. Body weight (in lig...",No,2011-11-01,FDA-22742,4.41,0.98,21.0,26.39,2015-12-28,2016-12-20,2037-12-20,13,Novartis,18,Senegal,46.83333333333334,13,57,79,100,1,31,55,2,3,1,True,True,False,True,True,False,True,False,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Moxifloxacin,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2011-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Provide written, informed consent prior to all trial-related procedures including HIV testing.
2. Male or female, aged between 18 and 65 years inclusive.
3. Body weight (in lig...",No,2011-10-15,FDA-88391,4.41,0.98,21.0,26.39,2015-12-28,2016-12-20,2037-12-20,40,GSK,22,Senegal,33.16666666666666,33,28,30,31,75,2,45,1,3,1,False,True,True,True,True,False,False,False,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
PA-824,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2007-12-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* informed consent
* M/F 18-64 yo
* newly diagnosed pulmonary TB
* sputum positive
* adequate contraception

Exclusion Criteria:

* poor health
* rifampicin resistance
* treatment...",No,2008-03-29,FDA-59303,4.41,0.98,21.0,26.39,2012-04-28,2013-04-21,2034-04-21,56,AstraZeneca,84,South Africa,52.16666666666666,77,46,71,49,22,48,45,0,3,2,False,False,True,False,True,False,True,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
TMC207 (J),AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2013-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* 1\. Provide written, informed consent prior to all trial-related procedures including HIV testing.

  2\. Male or female, aged between 18 and 65 years inclusive.

  3\. Body wei...",No,2014-03-14,FDA-46608,4.41,0.98,21.0,26.39,2017-09-27,2018-09-20,2039-09-20,98,Bayer,99,Senegal,42.66666666666666,4,81,56,8,20,87,36,2,2,0,True,True,False,False,False,True,True,False,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
PA-824 (PA),AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2013-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* 1\. Provide written, informed consent prior to all trial-related procedures including HIV testing.

  2\. Male or female, aged between 18 and 65 years inclusive.

  3\. Body wei...",Yes,2014-03-13,FDA-12514,4.41,0.98,21.0,26.39,2017-09-27,2018-09-20,2039-09-20,26,Novartis,70,Senegal,65.83333333333333,87,75,30,99,30,74,64,1,3,3,True,False,True,False,False,True,True,True,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
pyrazinamide (Z),GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2013-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* 1\. Provide written, informed consent prior to all trial-related procedures including HIV testing.

  2\. Male or female, aged between 18 and 65 years inclusive.

  3\. Body wei...",Yes,2013-06-20,FDA-75608,4.41,0.98,21.0,26.39,2017-09-27,2018-09-20,2039-09-20,21,Novartis,53,Overall,50.66666666666666,38,78,1,58,30,99,64,1,3,3,False,True,True,False,True,True,False,True,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
clofazimine (C),TradeName X,Drug,tuberculosis,tuberculosis,Phase 2,2013-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* 1\. Provide written, informed consent prior to all trial-related procedures including HIV testing.

  2\. Male or female, aged between 18 and 65 years inclusive.

  3\. Body wei...",Yes,2014-01-28,FDA-10715,4.41,0.98,21.0,26.39,2017-09-27,2018-09-20,2039-09-20,18,Merck,77,South Africa,31.0,46,49,13,24,3,51,36,0,2,2,False,False,False,True,True,False,False,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifafour,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2013-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* 1\. Provide written, informed consent prior to all trial-related procedures including HIV testing.

  2\. Male or female, aged between 18 and 65 years inclusive.

  3\. Body wei...",No,2014-02-15,FDA-53877,4.41,0.98,21.0,26.39,2017-09-27,2018-09-20,2039-09-20,12,AstraZeneca,13,Kenya,52.0,59,36,16,72,89,40,36,0,2,2,False,False,True,False,False,True,False,False,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifapentine,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2025-06-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Pulmonary TB (among participants with or without history of prior TB treatment) identified within 5 days prior to entry by:

  * At least one sputum specimen positive for M. tub...",Yes,2025-11-07,FDA-37223,4.41,0.98,21.0,26.39,2029-11-20,2030-11-13,2051-11-13,73,AstraZeneca,13,Overall,50.16666666666666,15,69,14,64,63,76,45,1,3,1,False,True,True,True,False,False,True,True,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifampicin,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2025-06-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Pulmonary TB (among participants with or without history of prior TB treatment) identified within 5 days prior to entry by:

  * At least one sputum specimen positive for M. tub...",Yes,2026-01-05,FDA-14876,4.41,0.98,21.0,26.39,2029-11-20,2030-11-13,2051-11-13,32,Novartis,12,Senegal,39.83333333333334,3,57,63,44,35,37,64,2,3,2,True,True,False,True,True,False,True,False,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Isoniazid,TradeName X,Drug,tuberculosis,tuberculosis,Phase 2,2025-06-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Pulmonary TB (among participants with or without history of prior TB treatment) identified within 5 days prior to entry by:

  * At least one sputum specimen positive for M. tub...",No,2025-10-16,FDA-44643,4.41,0.98,21.0,26.39,2029-11-20,2030-11-13,2051-11-13,32,Pfizer,48,Kenya,43.83333333333334,29,48,54,39,61,32,45,0,2,3,False,False,True,False,True,False,False,True,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Pyrazinamide,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 2,2025-06-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Pulmonary TB (among participants with or without history of prior TB treatment) identified within 5 days prior to entry by:

  * At least one sputum specimen positive for M. tub...",No,2025-11-01,FDA-80699,4.41,0.98,21.0,26.39,2029-11-20,2030-11-13,2051-11-13,77,Merck,15,Kenya,41.5,42,87,65,10,22,23,45,0,2,3,False,False,False,False,True,False,True,False,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Ethambutol,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2025-06-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Pulmonary TB (among participants with or without history of prior TB treatment) identified within 5 days prior to entry by:

  * At least one sputum specimen positive for M. tub...",Yes,2025-11-17,FDA-20769,4.41,0.98,21.0,26.39,2029-11-20,2030-11-13,2051-11-13,28,AstraZeneca,76,South Africa,41.0,1,72,36,67,20,50,45,1,2,2,True,False,True,False,False,False,True,False,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Clofazimine loading dose,AltName B,Drug,tuberculosis,tuberculosis,Phase 2,2025-06-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Pulmonary TB (among participants with or without history of prior TB treatment) identified within 5 days prior to entry by:

  * At least one sputum specimen positive for M. tub...",No,2026-05-28,FDA-86546,4.41,0.98,21.0,26.39,2029-11-20,2030-11-13,2051-11-13,21,Pfizer,28,Kenya,33.16666666666666,27,11,53,11,65,32,45,1,2,2,False,True,False,True,False,True,False,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Clofazimine 100 MG,TradeName X,Drug,tuberculosis,tuberculosis,Phase 2,2025-06-24,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Pulmonary TB (among participants with or without history of prior TB treatment) identified within 5 days prior to entry by:

  * At least one sputum specimen positive for M. tub...",No,2026-05-14,FDA-37879,4.41,0.98,21.0,26.39,2029-11-20,2030-11-13,2051-11-13,38,Novartis,16,South Africa,60.33333333333334,81,62,95,38,30,56,55,2,2,2,True,True,True,False,False,False,True,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Pretomanid,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 3,2022-02-08,"Sex: ALL; Age: >14 Years; Criteria: Inclusion Criteria:

* Male or female, aged 14 years or older.
* One of the following with documentation of culture positive or molecular test within 3 months of screening:

  * XDR-TB defined as resi...",Yes,2022-03-19,FDA-65797,2.62,0.32,5.0,7.94,2024-09-21,2025-01-16,2030-01-17,16,Bayer,65,South Africa,38.16666666666666,62,2,16,52,89,8,45,1,2,2,True,False,True,True,False,False,False,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Linezolid,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 3,2022-02-08,"Sex: ALL; Age: >14 Years; Criteria: Inclusion Criteria:

* Male or female, aged 14 years or older.
* One of the following with documentation of culture positive or molecular test within 3 months of screening:

  * XDR-TB defined as resi...",Yes,2022-03-28,FDA-93889,2.62,0.32,5.0,7.94,2024-09-21,2025-01-16,2030-01-17,71,Sanofi,63,South Africa,49.33333333333334,18,91,17,5,72,93,27,0,1,2,False,False,False,True,False,False,False,False,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Bedaquiline,AltName A,Drug,tuberculosis,tuberculosis,Phase 3,2022-02-08,"Sex: ALL; Age: >14 Years; Criteria: Inclusion Criteria:

* Male or female, aged 14 years or older.
* One of the following with documentation of culture positive or molecular test within 3 months of screening:

  * XDR-TB defined as resi...",Yes,2022-10-12,FDA-36859,2.62,0.32,5.0,7.94,2024-09-21,2025-01-16,2030-01-17,66,Sanofi,19,Senegal,73.66666666666667,66,96,41,99,60,80,55,2,2,2,True,True,False,True,False,False,True,False,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Delamanid,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 2,2010-06-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Provide written, informed consent prior to all trial-related procedures
* Male and female participants aged between 18 and 64 years, inclusive.
* Either mycobacterial culture of...",No,2011-03-15,FDA-73985,4.41,0.98,21.0,26.39,2014-11-07,2015-10-31,2036-10-30,14,GSK,87,Overall,37.66666666666666,11,52,60,10,78,15,55,2,2,2,True,True,True,True,False,False,False,False,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Optimized Background Regimen (OBR),Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2010-06-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Provide written, informed consent prior to all trial-related procedures
* Male and female participants aged between 18 and 64 years, inclusive.
* Either mycobacterial culture of...",Yes,2010-09-05,FDA-87263,4.41,0.98,21.0,26.39,2014-11-07,2015-10-31,2036-10-30,21,Pfizer,16,Senegal,60.16666666666666,22,90,9,83,76,81,45,1,2,2,True,False,True,True,False,False,False,True,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Moxifloxacin (M),Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2013-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Provide written, informed consent prior to all trial-related procedures including HIV testing (if an HIV test was performed within 1 month prior to trial start, it should not be...",No,2013-09-26,FDA-79287,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,90,Sanofi,28,South Africa,58.5,92,26,8,84,100,41,64,2,3,2,True,True,True,False,True,False,True,True,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Pretomid (Pa),Product Alpha,Drug,tuberculosis,tuberculosis,Phase 2,2013-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Provide written, informed consent prior to all trial-related procedures including HIV testing (if an HIV test was performed within 1 month prior to trial start, it should not be...",Yes,2014-05-31,FDA-90045,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,5,GSK,1,Senegal,46.66666666666666,27,51,99,10,81,12,55,1,2,3,False,True,True,False,False,False,True,False,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Pyrazinamide (Z),GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2013-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Provide written, informed consent prior to all trial-related procedures including HIV testing (if an HIV test was performed within 1 month prior to trial start, it should not be...",No,2014-06-15,FDA-54801,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,96,AstraZeneca,67,South Africa,34.16666666666666,0,62,79,39,12,13,55,2,3,1,True,True,False,False,True,True,True,True,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifafour,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2013-07-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Provide written, informed consent prior to all trial-related procedures including HIV testing (if an HIV test was performed within 1 month prior to trial start, it should not be...",No,2013-11-04,FDA-60688,4.41,0.98,21.0,26.39,2017-11-27,2018-11-20,2039-11-20,45,J&J,48,Overall,44.83333333333334,69,4,15,3,80,98,64,1,4,2,True,False,True,True,True,False,True,False,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
"Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin",AltName B,Drug,tuberculosis,tuberculosis,Phase 3,2014-02-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Signed written consent or witnessed oral consent in the case of illiteracy, before undertaking any trial related activity.
* Two sputum specimens positive for tubercle bacilli o...",Yes,2014-11-19,FDA-42246,2.62,0.32,5.0,7.94,2016-09-14,2017-01-09,2022-01-10,69,Merck,41,Senegal,69.16666666666667,61,74,79,88,81,32,45,1,2,2,False,True,True,False,False,False,True,True,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Addition of different doses of clarithromycin.,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 4,2012-11-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Age ≥18 years old
* Signed informed consent
* Diagnosis of MDR/XDR-TB confirmed with standard microbiological criteria (culture-based, molecular or both)
* Treatment with linezo...",Yes,2013-10-19,FDA-72940,0.56,0.15,3.5,4.21,2013-05-24,2013-07-18,2017-01-16,90,Merck,61,Senegal,55.5,90,45,83,23,70,22,55,1,4,1,True,False,False,True,True,True,True,True,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifampin,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2022-05-13,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* New or recurrent pulmonary TB with one or both of the following:
* sputum positive for acid-fast bacilli on direct microscopy of at least grade 1+ (International Union Against T...",No,2022-08-05,FDA-60841,4.41,0.98,21.0,26.39,2026-10-09,2027-10-02,2048-10-01,25,Merck,6,South Africa,46.33333333333334,32,18,84,25,88,31,45,1,2,2,False,True,True,False,False,True,False,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
MEROPENEM 2 grams TID,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2022-05-13,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* New or recurrent pulmonary TB with one or both of the following:
* sputum positive for acid-fast bacilli on direct microscopy of at least grade 1+ (International Union Against T...",No,2022-12-28,FDA-10062,4.41,0.98,21.0,26.39,2026-10-09,2027-10-02,2048-10-01,4,AstraZeneca,51,Overall,53.33333333333334,0,8,96,92,41,83,55,1,3,2,False,True,True,True,False,False,True,True,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
MEROPENEM 1 gram TID,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2022-05-13,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* New or recurrent pulmonary TB with one or both of the following:
* sputum positive for acid-fast bacilli on direct microscopy of at least grade 1+ (International Union Against T...",Yes,2023-02-03,FDA-39857,4.41,0.98,21.0,26.39,2026-10-09,2027-10-02,2048-10-01,91,Sanofi,42,South Africa,64.5,77,89,16,89,78,38,36,1,3,0,False,True,True,True,True,False,False,False,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
MEROPENEM 3 grams QD,TradeName X,Drug,tuberculosis,tuberculosis,Phase 2,2022-05-13,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* New or recurrent pulmonary TB with one or both of the following:
* sputum positive for acid-fast bacilli on direct microscopy of at least grade 1+ (International Union Against T...",Yes,2023-02-20,FDA-39037,4.41,0.98,21.0,26.39,2026-10-09,2027-10-02,2048-10-01,25,Pfizer,61,Kenya,59.0,62,77,73,58,37,47,36,0,3,1,False,False,True,True,False,True,False,False,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2022-05-13,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* New or recurrent pulmonary TB with one or both of the following:
* sputum positive for acid-fast bacilli on direct microscopy of at least grade 1+ (International Union Against T...",No,2023-04-13,FDA-12096,4.41,0.98,21.0,26.39,2026-10-09,2027-10-02,2048-10-01,36,GSK,17,South Africa,38.5,59,28,100,11,4,29,73,2,3,3,True,True,True,False,False,True,True,True,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2022-05-13,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* New or recurrent pulmonary TB with one or both of the following:
* sputum positive for acid-fast bacilli on direct microscopy of at least grade 1+ (International Union Against T...",Yes,2023-04-10,FDA-41838,4.41,0.98,21.0,26.39,2026-10-09,2027-10-02,2048-10-01,98,Gilead,29,Overall,34.66666666666666,29,22,42,47,43,25,36,0,1,3,False,False,True,False,False,False,False,True,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Isoniazid 900 milligrams,GenName Y,Drug,tuberculosis,tuberculosis,Phase 4,2019-08-10,"Sex: MALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion criteria:

* Age above 18 and under 45 at the time of inclusion;
* Sign the informed consent form.

Exclusion criteria:

* Be indigenous;
* Active TB or previous use of isoniazid;
* Score Al...",No,2019-12-18,FDA-44715,0.56,0.15,3.5,4.21,2020-03-01,2020-04-25,2023-10-25,58,Pfizer,81,Overall,47.16666666666666,41,55,90,31,60,6,55,1,3,2,True,False,False,True,True,True,False,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
SQ109,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2015-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

1. The patient has given free, signed written or witnessed oral informed consent for study participation prior to all trial-related procedures, including HIV testing if HIV serosta...",No,2015-04-21,FDA-15960,4.41,0.98,21.0,26.39,2019-07-28,2020-07-20,2041-07-20,29,Merck,75,Senegal,58.83333333333334,92,57,17,84,15,88,27,0,1,2,False,False,False,False,False,False,True,True,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifampicin,TradeName X,Drug,tuberculosis,tuberculosis,Phase 2,2015-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

1. The patient has given free, signed written or witnessed oral informed consent for study participation prior to all trial-related procedures, including HIV testing if HIV serosta...",Yes,2015-07-03,FDA-18803,4.41,0.98,21.0,26.39,2019-07-28,2020-07-20,2041-07-20,26,Pfizer,19,Kenya,46.5,12,78,60,3,82,44,55,1,1,4,True,False,False,True,False,False,False,True,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Moxifloxacin,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2015-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

1. The patient has given free, signed written or witnessed oral informed consent for study participation prior to all trial-related procedures, including HIV testing if HIV serosta...",No,2015-08-10,FDA-20074,4.41,0.98,21.0,26.39,2019-07-28,2020-07-20,2041-07-20,48,Pfizer,12,South Africa,35.66666666666666,43,16,62,8,62,23,36,1,2,1,True,False,True,False,True,False,False,True,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
isoniazid,TradeName X,Drug,tuberculosis,tuberculosis,Phase 2,2015-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

1. The patient has given free, signed written or witnessed oral informed consent for study participation prior to all trial-related procedures, including HIV testing if HIV serosta...",No,2015-09-01,FDA-93262,4.41,0.98,21.0,26.39,2019-07-28,2020-07-20,2041-07-20,98,Gilead,85,Overall,45.5,5,67,59,5,39,98,55,1,4,1,True,False,True,True,True,False,True,False,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
pyrazinamide,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2015-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

1. The patient has given free, signed written or witnessed oral informed consent for study participation prior to all trial-related procedures, including HIV testing if HIV serosta...",No,2015-12-23,FDA-52047,4.41,0.98,21.0,26.39,2019-07-28,2020-07-20,2041-07-20,16,Pfizer,51,Senegal,50.5,81,39,34,35,71,43,45,1,3,1,True,False,False,False,True,True,True,False,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
ethambutol,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2015-03-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria

1. The patient has given free, signed written or witnessed oral informed consent for study participation prior to all trial-related procedures, including HIV testing if HIV serosta...",No,2015-10-13,FDA-36818,4.41,0.98,21.0,26.39,2019-07-28,2020-07-20,2041-07-20,59,Bayer,91,Kenya,48.5,12,89,67,1,29,93,64,1,3,3,True,False,True,False,False,True,True,False,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Bedaquiline,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2025-04-30,"Sex: ALL; Age: >0 Months; Criteria: Inclusion Criteria:

* Parent/legal guardian willing and able to provide written informed consent for study participation; in addition, when applicable per local Institutional Review Board (IRB)/Ethic...",Yes,2025-12-07,FDA-56081,4.41,0.98,21.0,26.39,2029-09-26,2030-09-19,2051-09-19,15,AstraZeneca,88,Senegal,56.83333333333334,51,38,48,86,19,99,64,1,4,2,False,True,False,True,True,True,True,True,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
ID93 + GLA-SE,GenName Y,Biological,tuberculosis,tuberculosis,Phase 2,2017-01-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Males and females 18 to 60 years of age.
2. Subjects must have been successfully treated, i.e., completed the scheduled course of TB treatment as per the prevailing South Afric...",No,2017-09-02,FDA-34990,4.41,0.98,21.0,26.39,2021-05-30,2022-05-23,2043-05-23,100,Pfizer,36,Kenya,50.83333333333334,8,34,87,63,45,68,55,1,3,2,False,True,False,True,True,False,True,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Bedaquiline,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 3,2020-08-03,"Sex: ALL; Age: >14 Years; Criteria: Key Inclusion Criteria

1. Provide written, informed consent prior to all trial-related procedures (if under 18, include consent of legal guardian).
2. Body weight of ≥35 kg (in light clothing and no ...",Yes,2020-12-30,FDA-19316,2.62,0.32,5.0,7.94,2023-03-17,2023-07-12,2028-07-12,8,Pfizer,76,South Africa,26.0,36,14,11,6,6,83,64,1,5,1,True,False,True,True,True,True,True,False,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
PA-824,TradeName X,Drug,tuberculosis,tuberculosis,Phase 3,2020-08-03,"Sex: ALL; Age: >14 Years; Criteria: Key Inclusion Criteria

1. Provide written, informed consent prior to all trial-related procedures (if under 18, include consent of legal guardian).
2. Body weight of ≥35 kg (in light clothing and no ...",Yes,2020-09-27,FDA-23710,2.62,0.32,5.0,7.94,2023-03-17,2023-07-12,2028-07-12,83,Bayer,48,Kenya,74.5,87,77,82,96,31,74,55,2,4,0,True,True,True,True,True,True,False,False,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Linezolid,AltName A,Drug,tuberculosis,tuberculosis,Phase 3,2020-08-03,"Sex: ALL; Age: >14 Years; Criteria: Key Inclusion Criteria

1. Provide written, informed consent prior to all trial-related procedures (if under 18, include consent of legal guardian).
2. Body weight of ≥35 kg (in light clothing and no ...",Yes,2021-05-21,FDA-48852,2.62,0.32,5.0,7.94,2023-03-17,2023-07-12,2028-07-12,6,Novartis,62,Kenya,62.33333333333334,87,86,49,20,74,58,27,0,2,1,False,False,False,False,True,True,False,False,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
moxifloxacin,TradeName X,Drug,tuberculosis,tuberculosis,Phase 2,2017-07-17,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Adults ≥ 18 years of age
* Previous history of anti-TB chemotherapy
* HIV status: HIV infected and uninfected patients are allowed in the study:
* All patients must agree to HIV...",Yes,2017-11-06,FDA-51413,4.41,0.98,21.0,26.39,2021-12-13,2022-12-06,2043-12-06,1,GSK,35,South Africa,61.5,95,72,67,29,53,53,55,1,3,2,False,True,True,True,False,False,True,True,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Dolutegravir 50 mg,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2022-06-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection as documented by screening plasma HIV-1 RNA \>1000 c/mL
* ART-naïve (short-term antiretroviral use for prevention of mother-to-child transmission will be allowed...",No,2023-03-14,FDA-62443,4.41,0.98,21.0,26.39,2026-11-24,2027-11-17,2048-11-16,22,J&J,52,Kenya,44.0,16,31,80,64,32,41,73,2,4,2,True,True,True,True,False,True,True,True,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Aerosol Interferon-Gamma,AltName B,Drug,tuberculosis,tuberculosis,Phase 2,2007-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Positive acid-fast bacillus (AFB) smear within 14 days prior to randomization
* Cluster of Differentiation 4 greater than 200 if HIV positive
* Ability to sign consent
* Bilater...",Yes,2007-12-26,FDA-39312,4.41,0.98,21.0,26.39,2011-12-28,2012-12-20,2033-12-20,90,Merck,17,Overall,49.33333333333334,60,1,61,17,71,86,55,2,1,3,True,True,False,False,True,False,False,True,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Subcutaneous interferon-gamma,AltName B,Drug,tuberculosis,tuberculosis,Phase 2,2007-08-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Positive acid-fast bacillus (AFB) smear within 14 days prior to randomization
* Cluster of Differentiation 4 greater than 200 if HIV positive
* Ability to sign consent
* Bilater...",No,2007-11-17,FDA-39055,4.41,0.98,21.0,26.39,2011-12-28,2012-12-20,2033-12-20,66,J&J,16,Kenya,27.83333333333333,17,13,34,47,51,5,45,1,2,2,False,True,False,False,True,False,True,False,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
double rimfampicin,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 3,2017-08-01,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

* Diagnosed with smear-positive pulmonary TB
* 15 years or older
* Able and willing to provide written informed consent

Exclusion Criteria:

* contacts of MDR-TB patients and oth...",No,2018-03-22,FDA-45024,2.62,0.32,5.0,7.94,2020-03-14,2020-07-09,2025-07-10,36,Novartis,83,Kenya,36.16666666666666,24,7,70,77,30,9,55,1,3,2,True,False,True,True,False,False,True,False,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Standard TB treatment,TradeName X,Drug,tuberculosis,tuberculosis,Phase 3,2017-08-01,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

* Diagnosed with smear-positive pulmonary TB
* 15 years or older
* Able and willing to provide written informed consent

Exclusion Criteria:

* contacts of MDR-TB patients and oth...",Yes,2018-02-09,FDA-22087,2.62,0.32,5.0,7.94,2020-03-14,2020-07-09,2025-07-10,32,Merck,93,South Africa,43.33333333333334,17,34,87,36,66,20,55,2,3,1,True,True,False,True,True,True,False,True,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
"Isoniazid, Rifampicin, Pyrazinamide and Ethambutol",AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2022-02-28,"Sex: ALL; Age: >18 Years; Criteria: * INCLUSION CRITERIA:

  1. Age 18 to 75 years with body weight from 35 kg to 90 kg
  2. Has not been treated for active TB within the past 3 years
  3. Not yet on TB treatment
  4. Xpert positive for...",Yes,2022-05-21,FDA-56163,4.41,0.98,21.0,26.39,2026-07-27,2027-07-20,2048-07-19,40,Merck,3,South Africa,68.66666666666667,25,96,60,96,46,89,36,0,2,2,False,False,False,True,False,True,False,False,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifampin 600 MG,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 4,2022-02-22,"Sex: FEMALE; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Healthy women, who have had an ENG implant for 12-36 months at the time of enrollment and will maintain their implant during the study without modifications.

Exclusion Criteria...",Yes,2022-10-15,FDA-17930,0.56,0.15,3.5,4.21,2022-09-14,2022-11-08,2026-05-09,90,GSK,69,Overall,51.16666666666666,87,57,35,14,59,55,27,0,3,0,False,False,True,False,True,True,False,False,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Delamanid + OBR,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 3,2016-07-04,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Provide written, informed consent
* Current diagnosis of MDR TB
* Chest radiograph consistent with TB
* Able to produce sputum
* Negative urine pregnancy test and agree to use a...",Yes,2017-05-08,FDA-67381,2.62,0.32,5.0,7.94,2019-02-15,2019-06-12,2024-06-12,74,AstraZeneca,2,Overall,31.83333333333333,88,3,30,34,35,1,36,0,3,1,False,False,True,False,False,True,True,True,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Ethambutol,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 4,2010-12-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Male and female volunteers, age 18 years of age or older, of all racial and ethnic origins. English and/or Spanish speaking volunteers are eligible to participate.
* We are recr...",No,2011-09-04,FDA-27787,0.56,0.15,3.5,4.21,2011-06-23,2011-08-17,2015-02-15,100,Pfizer,6,Overall,55.66666666666666,89,70,37,68,52,18,73,2,2,4,True,True,False,False,False,True,True,True,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Delamanid,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2020-01-13,"Sex: ALL; Age: >0 Years; Criteria: Inclusion Criteria:

* Successfully completed Trial 242-12-232
* Confirmed diagnosis of MDR-TB OR
* Presumptive diagnosis of pulmonary or extrapulmonary MDR-TB including one of the following:

  * Cli...",No,2020-11-08,FDA-50126,4.41,0.98,21.0,26.39,2024-06-10,2025-06-03,2046-06-03,4,AstraZeneca,14,Kenya,29.16666666666667,50,55,14,14,4,38,18,0,0,2,False,False,False,False,False,False,False,False,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Delamanid Pediatric Formulation (DPF),Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2020-01-13,"Sex: ALL; Age: >0 Years; Criteria: Inclusion Criteria:

* Successfully completed Trial 242-12-232
* Confirmed diagnosis of MDR-TB OR
* Presumptive diagnosis of pulmonary or extrapulmonary MDR-TB including one of the following:

  * Cli...",No,2020-02-13,FDA-78504,4.41,0.98,21.0,26.39,2024-06-10,2025-06-03,2046-06-03,96,GSK,58,Overall,31.66666666666667,26,20,37,16,63,28,73,2,4,2,True,True,True,True,True,True,False,True,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Optimized Background Regimen (OBR),GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2020-01-13,"Sex: ALL; Age: >0 Years; Criteria: Inclusion Criteria:

* Successfully completed Trial 242-12-232
* Confirmed diagnosis of MDR-TB OR
* Presumptive diagnosis of pulmonary or extrapulmonary MDR-TB including one of the following:

  * Cli...",No,2020-02-22,FDA-97421,4.41,0.98,21.0,26.39,2024-06-10,2025-06-03,2046-06-03,25,Bayer,1,Senegal,40.33333333333334,14,88,30,33,32,45,64,1,4,2,True,False,True,False,True,True,True,True,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Isoniazid (INH),AltName B,Drug,tuberculosis,tuberculosis,Phase 3,2009-05-01,"Sex: ALL; Age: >91 Days; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Mother is HIV-infected. Hard copy documentation of the mother's HIV infection is unnecessary if a positive DNA PCR from her infant is available.
* Received Bacille Calmette-Guer...",Yes,2009-09-09,FDA-84812,2.62,0.32,5.0,7.94,2011-12-13,2012-04-08,2017-04-09,66,Merck,79,South Africa,55.0,11,25,93,31,77,93,45,0,3,2,False,False,False,False,True,True,True,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Trimethoprim/Sulfamethoxazole (TMP/SMX),AltName A,Drug,tuberculosis,tuberculosis,Phase 3,2009-05-01,"Sex: ALL; Age: >91 Days; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Mother is HIV-infected. Hard copy documentation of the mother's HIV infection is unnecessary if a positive DNA PCR from her infant is available.
* Received Bacille Calmette-Guer...",No,2010-02-20,FDA-63758,2.62,0.32,5.0,7.94,2011-12-13,2012-04-08,2017-04-09,75,Merck,9,Senegal,50.66666666666666,55,8,66,43,99,33,45,2,1,2,True,True,False,True,False,False,False,True,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Bedaquiline,TradeName X,Drug,tuberculosis,tuberculosis,Phase 2,2021-02-04,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented pulmonary infection due to strains of MTB with (a) resistance to isoniazid (INH) and rifampin (RIF) (MDR-TB) or (b) resistance to RIF but not INH (RR-TB) from a sputu...",No,2021-04-15,FDA-28494,4.41,0.98,21.0,26.39,2025-07-03,2026-06-26,2047-06-26,23,Novartis,21,Senegal,62.66666666666666,89,66,52,42,69,58,55,2,3,1,True,True,True,False,True,False,True,False,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Delamanid,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2021-02-04,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented pulmonary infection due to strains of MTB with (a) resistance to isoniazid (INH) and rifampin (RIF) (MDR-TB) or (b) resistance to RIF but not INH (RR-TB) from a sputu...",Yes,2021-10-01,FDA-91357,4.41,0.98,21.0,26.39,2025-07-03,2026-06-26,2047-06-26,39,Sanofi,100,South Africa,57.0,7,49,61,66,65,94,45,0,4,1,False,False,False,True,True,True,True,False,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Dolutegravir,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2021-02-04,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented pulmonary infection due to strains of MTB with (a) resistance to isoniazid (INH) and rifampin (RIF) (MDR-TB) or (b) resistance to RIF but not INH (RR-TB) from a sputu...",No,2021-09-17,FDA-43512,4.41,0.98,21.0,26.39,2025-07-03,2026-06-26,2047-06-26,82,Pfizer,84,Kenya,41.33333333333334,35,13,6,81,26,87,55,0,3,3,False,False,True,True,False,False,True,True,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Multidrug Background Treatment (MBT) for TB,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2021-02-04,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Documented pulmonary infection due to strains of MTB with (a) resistance to isoniazid (INH) and rifampin (RIF) (MDR-TB) or (b) resistance to RIF but not INH (RR-TB) from a sputu...",No,2021-09-14,FDA-77449,4.41,0.98,21.0,26.39,2025-07-03,2026-06-26,2047-06-26,50,Bayer,64,Kenya,58.16666666666666,32,70,87,16,72,72,45,1,2,2,True,False,False,False,True,False,True,False,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Inhaled molgramostim,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2020-01-13,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. History of chronic pulmonary infection with MAC or M. abscessus (defined as at least 2 documented positive sputum cultures in the prior 2 years, of which at least one was obtai...",Yes,2020-05-23,FDA-99842,4.41,0.98,21.0,26.39,2024-06-10,2025-06-03,2046-06-03,68,Gilead,24,Kenya,40.83333333333334,81,23,5,97,14,25,55,2,2,2,True,True,True,False,False,False,True,True,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Antimycobacterial regimen,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 2,2020-01-13,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. History of chronic pulmonary infection with MAC or M. abscessus (defined as at least 2 documented positive sputum cultures in the prior 2 years, of which at least one was obtai...",Yes,2020-02-19,FDA-38384,4.41,0.98,21.0,26.39,2024-06-10,2025-06-03,2046-06-03,52,Gilead,98,South Africa,57.33333333333334,1,60,72,64,68,79,36,0,3,1,False,False,False,True,True,False,True,True,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Levonorgestrel (LNG),Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2020-11-30,"Sex: FEMALE; Age: >16 Years; Criteria: Inclusion Criteria:

* Postmenarcheal female.

  * Note: Participant report and clinician's opinion were acceptable.
* The following laboratory values obtained within 30 days prior to study entry by a...",Yes,2021-07-09,FDA-85070,4.41,0.98,21.0,26.39,2025-04-28,2026-04-21,2047-04-21,8,J&J,29,Overall,45.83333333333334,38,81,72,30,15,39,73,2,4,2,True,True,True,True,True,True,False,True,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Delamanid,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2011-10-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Provide written, informed consent prior to all trial-related procedures
* Male or female participants aged between 18 and 64 years, inclusive, at the time of enrollment into the...",No,2011-12-28,FDA-71957,4.41,0.98,21.0,26.39,2016-03-24,2017-03-17,2038-03-17,92,Merck,94,Kenya,57.33333333333334,6,81,100,69,46,42,55,0,4,2,False,False,False,True,True,True,True,True,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
OBR,TradeName X,Drug,tuberculosis,tuberculosis,Phase 2,2011-10-27,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Provide written, informed consent prior to all trial-related procedures
* Male or female participants aged between 18 and 64 years, inclusive, at the time of enrollment into the...",No,2012-03-29,FDA-80104,4.41,0.98,21.0,26.39,2016-03-24,2017-03-17,2038-03-17,66,Bayer,78,Senegal,43.5,83,70,25,20,47,16,55,1,4,1,False,True,True,True,True,True,False,True,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
AERAS-402,Molecule Z,Biological,tuberculosis,tuberculosis,Phase 2,2012-05-01,"Sex: ALL; Age: >21 Years; Criteria: Inclusion Criteria:

1. Age 21 years through 45 years (i.e., subject had not yet reached his/her 46th birthday at day of randomization).
2. Had completed the written informed consent process prior to ...",No,2012-11-24,FDA-20050,4.41,0.98,21.0,26.39,2016-09-27,2017-09-20,2038-09-20,14,GSK,67,South Africa,62.0,28,64,90,99,78,13,55,2,3,1,True,True,True,False,True,False,True,False,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Linezolid,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2021-06-01,"Sex: ALL; Age: >19 Years; Criteria: Inclusion Criteria:

* Males and females aged from 19 to 85 years
* Confirmed MDR-TB or RR-TB
* On current TB therapy for ≤14 days at the time of enrollment.

Exclusion Criteria:

* Known any quinolon...",Yes,2021-07-16,FDA-88888,4.41,0.98,21.0,26.39,2025-10-28,2026-10-21,2047-10-21,94,GSK,24,Kenya,52.16666666666666,71,17,58,86,12,69,36,0,2,2,False,False,False,True,True,False,False,True,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Delamanid,AltName B,Drug,tuberculosis,tuberculosis,Phase 2,2021-06-01,"Sex: ALL; Age: >19 Years; Criteria: Inclusion Criteria:

* Males and females aged from 19 to 85 years
* Confirmed MDR-TB or RR-TB
* On current TB therapy for ≤14 days at the time of enrollment.

Exclusion Criteria:

* Known any quinolon...",No,2021-12-04,FDA-36994,4.41,0.98,21.0,26.39,2025-10-28,2026-10-21,2047-10-21,45,GSK,4,South Africa,53.83333333333334,65,21,61,61,45,70,27,0,1,2,False,False,False,False,False,True,False,False,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Levofloxacin,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2021-06-01,"Sex: ALL; Age: >19 Years; Criteria: Inclusion Criteria:

* Males and females aged from 19 to 85 years
* Confirmed MDR-TB or RR-TB
* On current TB therapy for ≤14 days at the time of enrollment.

Exclusion Criteria:

* Known any quinolon...",Yes,2022-03-18,FDA-83649,4.41,0.98,21.0,26.39,2025-10-28,2026-10-21,2047-10-21,30,AstraZeneca,56,Senegal,49.0,93,51,46,2,94,8,45,1,3,1,False,True,True,False,False,True,True,True,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Pyrazinamide,TradeName X,Drug,tuberculosis,tuberculosis,Phase 2,2021-06-01,"Sex: ALL; Age: >19 Years; Criteria: Inclusion Criteria:

* Males and females aged from 19 to 85 years
* Confirmed MDR-TB or RR-TB
* On current TB therapy for ≤14 days at the time of enrollment.

Exclusion Criteria:

* Known any quinolon...",No,2021-10-04,FDA-64238,4.41,0.98,21.0,26.39,2025-10-28,2026-10-21,2047-10-21,67,Bayer,98,Overall,35.16666666666666,23,62,3,16,71,36,45,2,2,1,True,True,False,False,False,True,True,True,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Locally-used WHO-approved MDR-TB regimen in Korea,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2021-06-01,"Sex: ALL; Age: >19 Years; Criteria: Inclusion Criteria:

* Males and females aged from 19 to 85 years
* Confirmed MDR-TB or RR-TB
* On current TB therapy for ≤14 days at the time of enrollment.

Exclusion Criteria:

* Known any quinolon...",Yes,2021-07-10,FDA-94567,4.41,0.98,21.0,26.39,2025-10-28,2026-10-21,2047-10-21,45,Sanofi,45,Kenya,70.83333333333333,90,56,82,55,48,94,36,1,1,2,False,True,False,False,False,False,True,True,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Isoniazid (INH),Comp Beta,Drug,tuberculosis,tuberculosis,Phase 4,2017-09-06,"Sex: FEMALE; Age: >13 Years; Criteria: Inclusion Criteria:

* Documented HIV-1 infection, defined as positive results from two samples collected at different time points. All samples tested must be whole blood, serum, or plasma. More infor...",Yes,2017-10-11,FDA-91409,0.56,0.15,3.5,4.21,2018-03-29,2018-05-23,2021-11-21,76,Bayer,13,South Africa,51.66666666666666,39,88,27,39,71,46,64,2,1,4,True,True,False,False,True,False,False,True,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Levofloxacin,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2022-03-29,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Patients with smear-positive, culture positive\* pulmonary TB
2. Sputum contains isoniazid\* and rifampin-resistant, Ofloxacin-susceptible MTB, all by MTBDR-sl
3. Previously tr...",Yes,2022-09-13,FDA-63529,4.41,0.98,21.0,26.39,2026-08-25,2027-08-18,2048-08-17,95,Pfizer,70,Senegal,72.83333333333333,67,79,65,90,43,93,45,1,1,3,False,True,False,False,False,False,True,True,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Optimized background regimen (OBR),Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2022-03-29,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Patients with smear-positive, culture positive\* pulmonary TB
2. Sputum contains isoniazid\* and rifampin-resistant, Ofloxacin-susceptible MTB, all by MTBDR-sl
3. Previously tr...",No,2023-01-29,FDA-65116,4.41,0.98,21.0,26.39,2026-08-25,2027-08-18,2048-08-17,66,Bayer,92,Kenya,47.0,10,45,93,38,55,41,36,0,3,1,False,False,False,True,False,True,True,False,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
MVA85A/AERAS-485,GenName Y,Biological,tuberculosis,tuberculosis,Phase 2,2014-09-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Has completed the written informed consent process prior to undergoing any screening evaluations.
* Either males or females aged 18-50 years (inclusive) on Study Day 0
* In gene...",No,2014-10-29,FDA-39349,4.41,0.98,21.0,26.39,2019-01-28,2020-01-21,2041-01-20,50,Novartis,30,Senegal,66.33333333333333,66,68,100,84,61,19,55,1,3,2,False,True,False,True,True,False,True,True,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Depot medroxyprogesterone acetate,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2017-06-15,"Sex: FEMALE; Age: >18 Years; Criteria: Inclusion Criteria:

* HIV-1 infection.
* Current tuberculosis infection, confirmed or probable diagnosis.
* Currently stable on EFV-based cART for at least 28 days with no intention to change the reg...",Yes,2018-05-09,FDA-46301,4.41,0.98,21.0,26.39,2021-11-11,2022-11-04,2043-11-04,75,Sanofi,53,South Africa,56.66666666666666,66,49,33,10,99,83,45,1,2,2,False,True,True,False,True,False,False,True,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Dapsone,AltName B,Drug,tuberculosis,tuberculosis,Phase 4,2012-05-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Male and female subjects, age \>18 years, of all racial and ethnic origins.
* Non-English speaking Spanish speakers will be included in the study.
* We are recruiting 12 normal ...",No,2013-01-26,FDA-89978,0.56,0.15,3.5,4.21,2012-11-21,2013-01-15,2016-07-16,33,Pfizer,85,Senegal,56.33333333333334,32,99,65,2,66,74,45,0,3,2,False,False,False,True,False,True,True,True,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
RESP301,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2025-03-06,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Provide written, informed consent prior to all study-related procedures and agree to undergo all study procedures
* Body weight (in light clothing and with no shoes) between 40 ...",No,2025-11-27,FDA-34258,4.41,0.98,21.0,26.39,2029-08-02,2030-07-26,2051-07-26,22,Bayer,43,South Africa,53.5,24,97,32,63,95,10,45,1,1,3,False,True,False,True,False,False,False,True,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
HRZE,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2025-03-06,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Provide written, informed consent prior to all study-related procedures and agree to undergo all study procedures
* Body weight (in light clothing and with no shoes) between 40 ...",No,2025-11-11,FDA-29802,4.41,0.98,21.0,26.39,2029-08-02,2030-07-26,2051-07-26,100,Novartis,13,South Africa,62.83333333333334,43,71,87,93,34,49,73,1,4,3,True,False,True,True,True,False,True,True,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
SPR720,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2021-01-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Has a diagnosis of NTM-PD due to MAC
* Had at least 1 prior positive culture (sputum or bronchoalveolar lavage) positive for MAC in the previous 6 months
* Has an induced sputum...",Yes,2021-10-06,FDA-51154,4.41,0.98,21.0,26.39,2025-06-26,2026-06-19,2047-06-19,95,Gilead,42,South Africa,49.0,82,92,2,1,47,70,36,1,2,1,True,False,False,True,False,False,True,False,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Open-label Standard of Care,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2021-01-28,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Has a diagnosis of NTM-PD due to MAC
* Had at least 1 prior positive culture (sputum or bronchoalveolar lavage) positive for MAC in the previous 6 months
* Has an induced sputum...",No,2021-10-02,FDA-64905,4.41,0.98,21.0,26.39,2025-06-26,2026-06-19,2047-06-19,54,GSK,21,Senegal,63.5,88,14,72,77,83,47,36,0,2,2,False,False,False,True,False,True,False,True,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Raltegravir,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 2,2019-11-27,"Sex: ALL; Age: >4 Weeks; Criteria: Inclusion Criteria:

* Weight greater than or equal to 3.5 kg at entry
* Confirmation of HIV-1 infection was defined as positive results from two samples collected at different time points. All sample...",No,2020-04-17,FDA-42777,4.41,0.98,21.0,26.39,2024-04-24,2025-04-17,2046-04-17,97,J&J,68,Overall,57.16666666666666,71,7,22,66,93,84,18,0,1,1,False,False,False,True,False,False,False,True,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Moxifloxacin,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 3,2018-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Signed written consent or witnessed oral consent in the case of illiteracy, prior to undertaking any trial-related procedures.
2. Male or female, aged 18 years or over.
3. Body...",Yes,2018-10-28,FDA-33829,2.62,0.32,5.0,7.94,2020-12-12,2021-04-08,2026-04-09,2,AstraZeneca,8,South Africa,69.0,79,70,69,48,80,68,73,1,4,3,False,True,False,True,True,True,True,True,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
PA-824,GenName Y,Drug,tuberculosis,tuberculosis,Phase 3,2018-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Signed written consent or witnessed oral consent in the case of illiteracy, prior to undertaking any trial-related procedures.
2. Male or female, aged 18 years or over.
3. Body...",No,2018-08-31,FDA-13666,2.62,0.32,5.0,7.94,2020-12-12,2021-04-08,2026-04-09,72,Merck,42,Overall,70.5,88,70,99,80,25,61,36,0,2,2,False,False,True,False,True,False,False,False,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Pyrazinamide,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 3,2018-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Signed written consent or witnessed oral consent in the case of illiteracy, prior to undertaking any trial-related procedures.
2. Male or female, aged 18 years or over.
3. Body...",Yes,2019-03-02,FDA-78423,2.62,0.32,5.0,7.94,2020-12-12,2021-04-08,2026-04-09,64,GSK,1,South Africa,48.16666666666666,49,37,73,5,51,74,27,1,1,1,False,True,False,False,False,True,False,False,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
"HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)",Molecule Z,Drug,tuberculosis,tuberculosis,Phase 3,2018-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Signed written consent or witnessed oral consent in the case of illiteracy, prior to undertaking any trial-related procedures.
2. Male or female, aged 18 years or over.
3. Body...",Yes,2019-02-25,FDA-93667,2.62,0.32,5.0,7.94,2020-12-12,2021-04-08,2026-04-09,95,Gilead,65,Overall,21.16666666666667,44,20,13,15,6,29,36,0,2,2,False,False,False,True,True,False,False,True,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
HR (rifampicin plus isoniazid combination tablets),AltName A,Drug,tuberculosis,tuberculosis,Phase 3,2018-05-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Signed written consent or witnessed oral consent in the case of illiteracy, prior to undertaking any trial-related procedures.
2. Male or female, aged 18 years or over.
3. Body...",No,2019-02-22,FDA-79329,2.62,0.32,5.0,7.94,2020-12-12,2021-04-08,2026-04-09,2,Gilead,26,South Africa,52.66666666666666,7,97,64,92,5,51,36,2,1,1,True,True,True,False,False,False,False,False,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Indacaterol,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 3,2014-09-01,"Sex: ALL; Age: >19 Years; Criteria: Inclusion Criteria:

* Male and female adults aged ≥ 19 years in international age
* Patients with a diagnosis of moderate-to-severe COPD as classified by the GOLD guidelines (2009)
* Patients with at...",Yes,2015-07-22,FDA-58957,2.62,0.32,5.0,7.94,2017-04-14,2017-08-09,2022-08-10,96,Novartis,92,Senegal,48.66666666666666,2,73,77,18,91,31,18,0,0,2,False,False,False,False,False,False,False,False,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
BCG TICE Vaccine,Molecule Z,Biological,tuberculosis,tuberculosis,Phase 2,2023-12-30,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria (CF and non-CF bronchiectasis):

* Confirmed diagnosis of either CF or non-CF bronchiectasis
* Forced expiratory volume over one second (FEV1) \> 40%
* Willingness to participate in...",No,2024-10-10,FDA-26974,4.41,0.98,21.0,26.39,2028-05-27,2029-05-20,2050-05-20,55,GSK,51,South Africa,42.66666666666666,79,24,62,15,69,7,27,0,1,2,False,False,False,False,False,True,False,True,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
M72/AS01E Mycobacterium tuberculosis vaccine,TradeName X,Biological,tuberculosis,tuberculosis,Phase 2,2022-08-12,"Sex: ALL; Age: >16 Years; Criteria: Inclusion Criteria:

* Participant with documented human immunodeficiency virus (HIV) infection who fulfill all of the following:

  * Has reactive anti-HIV antibody at screening
  * On antiretroviral...",Yes,2023-01-10,FDA-54448,4.41,0.98,21.0,26.39,2027-01-08,2028-01-01,2048-12-31,13,Merck,88,South Africa,47.83333333333334,76,2,59,91,0,59,36,2,1,1,True,True,False,False,True,False,False,False,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
gNO,AltName B,Drug,tuberculosis,tuberculosis,Phase 2,2020-03-26,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

Subjects are \>18 years of age and able to provide informed consent.

Subjects have NTM lung disease as defined by each of the following:

Sputum cultures positive for NTM (MAC or...",No,2020-06-17,FDA-93843,4.41,0.98,21.0,26.39,2024-08-22,2025-08-15,2046-08-15,31,Bayer,1,South Africa,49.66666666666666,13,98,16,51,54,66,36,1,0,3,False,True,False,False,False,False,False,True,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Atripla (r),Molecule Z,Drug,tuberculosis,tuberculosis,Phase 4,2016-04-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Willingness to start efavirenz-based ART as soon as possible and within no more than 3 days following randomization.
* CD4+ cell count \<50 cells/mm\^3 obtaine...",No,2016-08-12,FDA-67488,0.56,0.15,3.5,4.21,2016-10-22,2016-12-16,2020-06-16,98,J&J,95,Kenya,30.16666666666667,29,46,27,17,59,3,45,1,2,2,True,False,True,False,False,False,True,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Efavirenz,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 4,2016-04-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Willingness to start efavirenz-based ART as soon as possible and within no more than 3 days following randomization.
* CD4+ cell count \<50 cells/mm\^3 obtaine...",Yes,2016-05-03,FDA-49705,0.56,0.15,3.5,4.21,2016-10-22,2016-12-16,2020-06-16,48,Gilead,26,Senegal,39.83333333333334,73,32,74,3,29,28,55,1,3,2,True,False,True,True,False,True,False,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Truvada,TradeName X,Drug,tuberculosis,tuberculosis,Phase 4,2016-04-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Willingness to start efavirenz-based ART as soon as possible and within no more than 3 days following randomization.
* CD4+ cell count \<50 cells/mm\^3 obtaine...",No,2017-02-24,FDA-39312,0.56,0.15,3.5,4.21,2016-10-22,2016-12-16,2020-06-16,2,Novartis,90,Overall,53.33333333333334,82,78,42,12,6,100,55,1,3,2,True,False,True,True,False,True,False,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifampin/isoniazid/pyrazinamide/ethambutol FDC,AltName A,Drug,tuberculosis,tuberculosis,Phase 4,2016-04-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Willingness to start efavirenz-based ART as soon as possible and within no more than 3 days following randomization.
* CD4+ cell count \<50 cells/mm\^3 obtaine...",Yes,2016-12-19,FDA-59840,0.56,0.15,3.5,4.21,2016-10-22,2016-12-16,2020-06-16,93,Novartis,8,South Africa,58.33333333333334,73,75,40,71,6,85,45,1,1,3,True,False,False,True,False,False,False,True,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Rifampin/isoniazid FDC,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 4,2016-04-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Willingness to start efavirenz-based ART as soon as possible and within no more than 3 days following randomization.
* CD4+ cell count \<50 cells/mm\^3 obtaine...",Yes,2016-09-03,FDA-26842,0.56,0.15,3.5,4.21,2016-10-22,2016-12-16,2020-06-16,39,Bayer,84,Kenya,56.66666666666666,23,71,3,88,55,100,36,1,2,1,True,False,False,True,True,False,False,False,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Isoniazid,AltName B,Drug,tuberculosis,tuberculosis,Phase 4,2016-04-01,"Sex: ALL; Age: >13 Years; Criteria: Inclusion Criteria:

* HIV-1 infection
* Willingness to start efavirenz-based ART as soon as possible and within no more than 3 days following randomization.
* CD4+ cell count \<50 cells/mm\^3 obtaine...",Yes,2016-08-12,FDA-15319,0.56,0.15,3.5,4.21,2016-10-22,2016-12-16,2020-06-16,65,J&J,31,Kenya,59.5,82,34,49,91,32,69,36,2,2,0,True,True,True,False,True,False,False,False,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Delpazolid,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 2,2023-09-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Provide written, informed consent prior to all trial-related procedures including HIV testing.
2. Male or female, aged between 18 and 65 years, inclusive.
3. Body weight betwee...",No,2024-08-23,FDA-17011,4.41,0.98,21.0,26.39,2028-02-07,2029-01-30,2050-01-30,7,GSK,78,Senegal,55.83333333333334,14,93,100,12,64,52,64,1,4,2,False,True,True,False,True,True,True,True,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
"Bedaquiline, Delamanid, Moxifloxacin",GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2023-09-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Provide written, informed consent prior to all trial-related procedures including HIV testing.
2. Male or female, aged between 18 and 65 years, inclusive.
3. Body weight betwee...",Yes,2024-06-02,FDA-36025,4.41,0.98,21.0,26.39,2028-02-07,2029-01-30,2050-01-30,39,Gilead,47,Kenya,52.33333333333334,92,81,24,34,82,1,45,2,1,2,True,True,False,True,False,False,False,True,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Sulfamethoxazole/trimethoprim,TradeName X,Drug,tuberculosis,tuberculosis,Phase 4,2012-05-01,"Sex: ALL; Age: >18 Years; Healthy Volunteers: Yes; Criteria: Inclusion Criteria:

* Male and female subjects, age \>18 years, of all racial and ethnic origins.
* We are recruiting 12 normal or underweight (BMI \<25kg/m2), 12 overweight or obese (BMI 25-40 kg/m2...",No,2012-06-10,FDA-89068,0.56,0.15,3.5,4.21,2012-11-21,2013-01-15,2016-07-16,51,Novartis,6,Overall,51.0,57,1,29,68,100,51,64,1,4,2,False,True,False,True,True,True,True,True,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Interferon-Gamma,AltName A,Drug,tuberculosis,tuberculosis,Phase 2,2006-04-06,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Participants must sign the form of informed consent and agree to follow the protocol requirements
* Women willing to participate in the study must protect against possible pregn...",No,2006-09-15,FDA-71871,4.41,0.98,21.0,26.39,2010-09-02,2011-08-26,2032-08-25,12,Pfizer,90,Overall,45.33333333333334,62,57,15,21,88,29,45,1,1,3,False,True,False,True,False,False,False,False,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline),AltName A,Drug,tuberculosis,tuberculosis,Phase 3,2023-05-02,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

1. Consent: Is willing and able to give informed consent to participate in the trial treatment and follow-up (signed or witnessed consent if the patient is illiterate). If the pat...",No,2023-08-30,FDA-48593,2.62,0.32,5.0,7.94,2025-12-13,2026-04-09,2031-04-10,84,Sanofi,45,South Africa,50.0,67,52,15,73,20,73,45,2,0,3,True,True,False,False,False,False,False,True,True,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Moxifloxacin,TradeName X,Drug,tuberculosis,tuberculosis,Phase 3,2023-05-02,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

1. Consent: Is willing and able to give informed consent to participate in the trial treatment and follow-up (signed or witnessed consent if the patient is illiterate). If the pat...",Yes,2023-11-24,FDA-38504,2.62,0.32,5.0,7.94,2025-12-13,2026-04-09,2031-04-10,2,Bayer,85,Senegal,46.5,47,42,66,43,27,54,55,1,4,1,True,False,True,True,True,True,False,False,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Clofazimine,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 3,2023-05-02,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

1. Consent: Is willing and able to give informed consent to participate in the trial treatment and follow-up (signed or witnessed consent if the patient is illiterate). If the pat...",No,2024-02-28,FDA-15472,2.62,0.32,5.0,7.94,2025-12-13,2026-04-09,2031-04-10,31,Bayer,28,Kenya,39.33333333333334,20,6,46,19,85,60,36,1,2,1,False,True,True,False,True,False,False,False,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Ethambutol,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 3,2023-05-02,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

1. Consent: Is willing and able to give informed consent to participate in the trial treatment and follow-up (signed or witnessed consent if the patient is illiterate). If the pat...",No,2023-09-30,FDA-74066,2.62,0.32,5.0,7.94,2025-12-13,2026-04-09,2031-04-10,60,Sanofi,37,Overall,41.0,66,3,28,73,11,65,45,1,2,2,False,True,True,True,False,False,False,True,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Pyrazinamide,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 3,2023-05-02,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

1. Consent: Is willing and able to give informed consent to participate in the trial treatment and follow-up (signed or witnessed consent if the patient is illiterate). If the pat...",Yes,2024-04-03,FDA-93194,2.62,0.32,5.0,7.94,2025-12-13,2026-04-09,2031-04-10,5,AstraZeneca,61,Overall,68.0,72,17,95,94,97,33,36,0,3,1,False,False,False,True,True,False,True,False,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Isoniazid,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 3,2023-05-02,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

1. Consent: Is willing and able to give informed consent to participate in the trial treatment and follow-up (signed or witnessed consent if the patient is illiterate). If the pat...",No,2023-08-27,FDA-32184,2.62,0.32,5.0,7.94,2025-12-13,2026-04-09,2031-04-10,59,GSK,91,Senegal,51.83333333333334,12,72,61,25,94,47,64,1,5,1,False,True,True,True,True,True,True,False,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Prothionamide,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 3,2023-05-02,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

1. Consent: Is willing and able to give informed consent to participate in the trial treatment and follow-up (signed or witnessed consent if the patient is illiterate). If the pat...",No,2024-01-13,FDA-73618,2.62,0.32,5.0,7.94,2025-12-13,2026-04-09,2031-04-10,67,J&J,75,Overall,56.0,72,48,19,59,42,96,55,1,1,4,True,False,False,False,False,True,False,True,True,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Kanamycin,AltName B,Drug,tuberculosis,tuberculosis,Phase 3,2023-05-02,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

1. Consent: Is willing and able to give informed consent to participate in the trial treatment and follow-up (signed or witnessed consent if the patient is illiterate). If the pat...",Yes,2024-04-25,FDA-47367,2.62,0.32,5.0,7.94,2025-12-13,2026-04-09,2031-04-10,2,Gilead,96,Kenya,49.16666666666666,96,42,41,17,58,41,64,2,4,1,True,True,True,False,True,True,True,False,True,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Levofloxacin,TradeName X,Drug,tuberculosis,tuberculosis,Phase 3,2023-05-02,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

1. Consent: Is willing and able to give informed consent to participate in the trial treatment and follow-up (signed or witnessed consent if the patient is illiterate). If the pat...",No,2023-10-07,FDA-20819,2.62,0.32,5.0,7.94,2025-12-13,2026-04-09,2031-04-10,94,J&J,45,Overall,45.5,71,31,7,36,83,45,45,2,2,1,True,True,False,False,False,True,True,False,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Bedaquiline,AltName A,Drug,tuberculosis,tuberculosis,Phase 3,2023-05-02,"Sex: ALL; Age: >15 Years; Criteria: Inclusion Criteria:

1. Consent: Is willing and able to give informed consent to participate in the trial treatment and follow-up (signed or witnessed consent if the patient is illiterate). If the pat...",No,2023-12-04,FDA-81446,2.62,0.32,5.0,7.94,2025-12-13,2026-04-09,2031-04-10,76,GSK,69,Overall,44.83333333333334,61,0,50,52,75,31,55,1,4,1,False,True,False,True,True,True,True,False,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Isoniazid 300 Mg ORAL TABLET,Product Alpha,Drug,tuberculosis,tuberculosis,Phase 4,2021-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Age \> 18 years old
2. Patient of the MRRH ISS Clinic
3. HIV-infected
4. Consume alcohol (self-reported consumption in the prior 3 months) (2/3) OR prior year non-drinker (1/3)...",Yes,2021-09-28,FDA-79471,0.56,0.15,3.5,4.21,2021-10-22,2021-12-16,2025-06-16,70,AstraZeneca,8,Senegal,56.66666666666666,93,34,49,12,67,85,55,2,1,3,True,True,False,False,True,False,False,True,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
Pyridoxine 25 Mg Oral Tablet,GenName Y,Drug,tuberculosis,tuberculosis,Phase 4,2021-04-01,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

1. Age \> 18 years old
2. Patient of the MRRH ISS Clinic
3. HIV-infected
4. Consume alcohol (self-reported consumption in the prior 3 months) (2/3) OR prior year non-drinker (1/3)...",Yes,2021-09-14,FDA-58421,0.56,0.15,3.5,4.21,2021-10-22,2021-12-16,2025-06-16,95,AstraZeneca,75,Overall,46.83333333333334,70,58,0,87,4,62,9,0,1,0,False,False,False,False,False,False,True,False,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
10 mg OPC-167832,AltName B,Drug,tuberculosis,tuberculosis,Phase 2,2022-03-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Able to provide written, informed consent prior to initiation of any trial-related procedures, and able, in the opinion of the investigator, to comply with all the requirements ...",No,2022-06-02,FDA-73044,4.41,0.98,21.0,26.39,2026-08-07,2027-07-31,2048-07-30,10,Bayer,27,Overall,53.66666666666666,21,47,92,13,57,92,55,0,4,2,False,False,True,False,True,True,True,False,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
30 mg OPC-167832,AltName B,Drug,tuberculosis,tuberculosis,Phase 2,2022-03-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Able to provide written, informed consent prior to initiation of any trial-related procedures, and able, in the opinion of the investigator, to comply with all the requirements ...",No,2022-06-08,FDA-50578,4.41,0.98,21.0,26.39,2026-08-07,2027-07-31,2048-07-30,68,Sanofi,42,Senegal,27.33333333333333,38,9,39,30,2,46,64,1,4,2,True,False,True,True,True,False,True,True,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
90 mg OPC-167832,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 2,2022-03-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Able to provide written, informed consent prior to initiation of any trial-related procedures, and able, in the opinion of the investigator, to comply with all the requirements ...",Yes,2022-04-14,FDA-70997,4.41,0.98,21.0,26.39,2026-08-07,2027-07-31,2048-07-30,86,GSK,48,South Africa,63.66666666666666,85,98,74,60,47,18,55,0,3,3,False,False,True,True,False,False,True,True,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
3 mg OPC-167832,AltName B,Drug,tuberculosis,tuberculosis,Phase 2,2022-03-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Able to provide written, informed consent prior to initiation of any trial-related procedures, and able, in the opinion of the investigator, to comply with all the requirements ...",No,2022-05-03,FDA-56039,4.41,0.98,21.0,26.39,2026-08-07,2027-07-31,2048-07-30,25,Novartis,20,South Africa,41.16666666666666,65,75,21,9,42,35,45,1,2,2,False,True,False,False,True,True,False,False,True,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
RHEZ,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2022-03-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Able to provide written, informed consent prior to initiation of any trial-related procedures, and able, in the opinion of the investigator, to comply with all the requirements ...",Yes,2022-09-05,FDA-16900,4.41,0.98,21.0,26.39,2026-08-07,2027-07-31,2048-07-30,67,Bayer,93,Overall,55.83333333333334,83,21,97,81,8,45,36,1,3,0,False,True,False,True,True,True,False,False,False,False,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
30 mg OPC-167832 + 300 mg delamanid,GenName Y,Drug,tuberculosis,tuberculosis,Phase 2,2022-03-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Able to provide written, informed consent prior to initiation of any trial-related procedures, and able, in the opinion of the investigator, to comply with all the requirements ...",Yes,2023-02-20,FDA-40736,4.41,0.98,21.0,26.39,2026-08-07,2027-07-31,2048-07-30,63,Bayer,61,Overall,68.66666666666667,62,36,88,86,98,42,45,1,2,2,True,False,True,False,False,False,True,False,False,True,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
30 mg OPC-167832 + 400 mg BDQ,AltName B,Drug,tuberculosis,tuberculosis,Phase 2,2022-03-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Able to provide written, informed consent prior to initiation of any trial-related procedures, and able, in the opinion of the investigator, to comply with all the requirements ...",Yes,2023-03-04,FDA-28182,4.41,0.98,21.0,26.39,2026-08-07,2027-07-31,2048-07-30,41,Bayer,34,Overall,40.16666666666666,77,38,10,28,9,79,45,1,3,1,False,True,False,True,True,True,False,False,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
30 mg OPC-167832 + 300 mg delamanid + 400 mg BDQ,Comp Beta,Drug,tuberculosis,tuberculosis,Phase 2,2022-03-11,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Able to provide written, informed consent prior to initiation of any trial-related procedures, and able, in the opinion of the investigator, to comply with all the requirements ...",Yes,2023-03-11,FDA-35807,4.41,0.98,21.0,26.39,2026-08-07,2027-07-31,2048-07-30,29,GSK,18,South Africa,51.66666666666666,51,51,37,38,92,41,27,1,1,1,False,True,False,False,False,True,False,False,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
DTG 50 mg,AltName B,Drug,tuberculosis,tuberculosis,Phase 3,2020-03-06,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subject or the subject's legal representative is willing and able to understand and provide signed and dated written informed consent prior to Screening
* Adult subject (at leas...",No,2020-12-16,FDA-49653,2.62,0.32,5.0,7.94,2022-10-18,2023-02-12,2028-02-13,76,Merck,60,South Africa,36.16666666666666,2,12,24,85,16,78,45,2,2,1,True,True,True,False,True,False,False,False,False,True,False,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
EFV 600 mg,Molecule Z,Drug,tuberculosis,tuberculosis,Phase 3,2020-03-06,"Sex: ALL; Age: >18 Years; Criteria: Inclusion Criteria:

* Subject or the subject's legal representative is willing and able to understand and provide signed and dated written informed consent prior to Screening
* Adult subject (at leas...",Yes,2021-02-15,FDA-47928,2.62,0.32,5.0,7.94,2022-10-18,2023-02-12,2028-02-13,58,AstraZeneca,20,Kenya,63.5,97,56,22,61,87,58,73,2,4,2,True,True,False,True,True,True,True,True,False,False,True,HorizonScan_tuberculosis_20251201_Harmonized.xlsx
